<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000978.pub5" GROUP_ID="ORAL" ID="805199072110275943" MERGED_FROM="" MODIFIED="2013-01-31 15:35:34 +0000" MODIFIED_BY="Philip Riley" REVIEW_NO="10a" REVMAN_SUB_VERSION="5.2.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="13.0">
<COVER_SHEET MODIFIED="2013-01-31 15:20:31 +0000" MODIFIED_BY="Philip Riley">
<TITLE>Interventions for preventing oral mucositis for patients with cancer receiving treatment</TITLE>
<CONTACT>
<PERSON ID="8328" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Helen</FIRST_NAME>
<MIDDLE_INITIALS>V</MIDDLE_INITIALS>
<LAST_NAME>Worthington</LAST_NAME>
<SUFFIX/>
<POSITION>Co-ordinating Editor</POSITION>
<EMAIL_1>helen.worthington@manchester.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Oral Health Group</DEPARTMENT>
<ORGANISATION>School of Dentistry, The University of Manchester</ORGANISATION>
<ADDRESS_1>Coupland III Building, Oxford Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Manchester</CITY>
<ZIP>M13 9PL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 161 306 0237</PHONE_1>
<PHONE_2>+44 161 275 7819</PHONE_2>
<FAX_1>+44 161 275 7815</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2013-01-31 15:18:46 +0000" MODIFIED_BY="Philip Riley">
<PERSON ID="8328" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Helen</FIRST_NAME>
<MIDDLE_INITIALS>V</MIDDLE_INITIALS>
<LAST_NAME>Worthington</LAST_NAME>
<SUFFIX/>
<POSITION>Co-ordinating Editor</POSITION>
<EMAIL_1>helen.worthington@manchester.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Oral Health Group</DEPARTMENT>
<ORGANISATION>School of Dentistry, The University of Manchester</ORGANISATION>
<ADDRESS_1>Coupland III Building, Oxford Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Manchester</CITY>
<ZIP>M13 9PL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 161 306 0237</PHONE_1>
<PHONE_2>+44 161 275 7819</PHONE_2>
<FAX_1>+44 161 275 7815</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7294" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Jan</FIRST_NAME>
<MIDDLE_INITIALS>E</MIDDLE_INITIALS>
<LAST_NAME>Clarkson</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>j.e.clarkson@dundee.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Dental Health Services &amp; Research Unit, University of Dundee, Dundee</DEPARTMENT>
<ORGANISATION>Cochrane Oral Health Group, The University of Manchester</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Manchester</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="EE30404B82E26AA200CE015F25C2B508" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Gemma</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Bryan</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>gemmadbryan@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Oral Health Group</DEPARTMENT>
<ORGANISATION>School of Dentistry, The University of Manchester</ORGANISATION>
<ADDRESS_1>Coupland III Building, Oxford Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Manchester</CITY>
<ZIP>M13 9PL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="50BB1C5582E26AA20094E4F45CBA083C" ROLE="AUTHOR">
<PREFIX>Mrs</PREFIX>
<FIRST_NAME>Susan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Furness</LAST_NAME>
<SUFFIX/>
<POSITION>Research Fellow</POSITION>
<EMAIL_1>Susan.Furness@manchester.ac.uk</EMAIL_1>
<EMAIL_2>suefurness@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Oral Health Group</DEPARTMENT>
<ORGANISATION>School of Dentistry, The University of Manchester</ORGANISATION>
<ADDRESS_1>Coupland III Building, Oxford Rd</ADDRESS_1>
<ADDRESS_2/>
<CITY>Manchester</CITY>
<ZIP>M13 9PL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 161 275 6877</PHONE_1>
<PHONE_2/>
<FAX_1>+44 161 275 7815</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7514" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Anne-Marie</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Glenny</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Lecturer in Evidence Based Oral Health Care</POSITION>
<EMAIL_1>a.glenny@manchester.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Oral Health Group</DEPARTMENT>
<ORGANISATION>School of Dentistry, The University of Manchester</ORGANISATION>
<ADDRESS_1>Coupland III Building, Oxford Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Manchester</CITY>
<ZIP>M13 9PL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 161 275 7811</PHONE_1>
<PHONE_2/>
<FAX_1>+44 161 275 7815</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="BA70B13682E26AA2003F1F39B31F36B7" ROLE="AUTHOR">
<PREFIX>Miss</PREFIX>
<FIRST_NAME>Anne</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Littlewood</LAST_NAME>
<SUFFIX/>
<POSITION>Trials Search Co-ordinator</POSITION>
<EMAIL_1>a.littlewood@manchester.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Oral Health Group</DEPARTMENT>
<ORGANISATION>School of Dentistry, The University of Manchester</ORGANISATION>
<ADDRESS_1>Coupland III Building</ADDRESS_1>
<ADDRESS_2>Oxford Road</ADDRESS_2>
<CITY>Manchester</CITY>
<ZIP>M13 9PL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 161 275 7814</PHONE_1>
<PHONE_2/>
<FAX_1>+44 161 275 7815</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="36609597071280741395100423113520" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Martin</FIRST_NAME>
<MIDDLE_INITIALS>G</MIDDLE_INITIALS>
<LAST_NAME>McCabe</LAST_NAME>
<SUFFIX/>
<POSITION>Teenage Cancer Trust Senior Lecturer</POSITION>
<EMAIL_1>martin.mccabe@manchester.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Manchester Academic Health Science Centre, School of Cancer and Enabling Sciences</DEPARTMENT>
<ORGANISATION>University of Manchester</ORGANISATION>
<ADDRESS_1>Academic Unit of Paediatric and Adolescent Oncology, Young Oncology Unit</ADDRESS_1>
<ADDRESS_2>The Christie NHS Foundation Trust, Wilmslow Road</ADDRESS_2>
<CITY>Manchester</CITY>
<ZIP>M20 4BX</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 161 446 3090</PHONE_1>
<PHONE_2/>
<FAX_1>+44 161 446 3092</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="05247147787469840180100423115648" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Stefan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Meyer</LAST_NAME>
<SUFFIX/>
<POSITION>CRUK Clinician Scientist &amp; Honorary Consultant Paediatric Oncologist</POSITION>
<EMAIL_1>stefan.meyer@manchester.ac.uk</EMAIL_1>
<EMAIL_2>stefan.meyer-2@manchester.ac.uk</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Paediatric and Adolescent Oncology, Royal Manchester Children's and Christie Hospital, School of Cancer and Enabling Sciences, Manchester Academic Health Science Centre</DEPARTMENT>
<ORGANISATION>The University of Manchester</ORGANISATION>
<ADDRESS_1>Young Oncology Unit, Christie Hospital</ADDRESS_1>
<ADDRESS_2>Wilmslow Road</ADDRESS_2>
<CITY>Manchester</CITY>
<ZIP>M20 4BX</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 161 446 3090</PHONE_1>
<PHONE_2/>
<FAX_1>+44 161 446 3092</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="85870278412409877228100423113832" ROLE="AUTHOR">
<PREFIX>Mrs</PREFIX>
<FIRST_NAME>Tasneem</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Khalid</LAST_NAME>
<SUFFIX/>
<POSITION>Principal Pharmacist</POSITION>
<EMAIL_1>tasneem.khalid@cmft.nhs.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Haematology/Oncology</DEPARTMENT>
<ORGANISATION>Royal Manchester Children's Hospital</ORGANISATION>
<ADDRESS_1>Oxford Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Manchester</CITY>
<ZIP>M13 9WL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 161 701 5466</PHONE_1>
<PHONE_2/>
<FAX_1>+44 161 701 5233</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2011-07-21 15:01:20 +0100" MODIFIED_BY="Anne-Marie Glenny">
<UP_TO_DATE>
<DATE DAY="8" MONTH="3" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="16" MONTH="2" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="12" MONTH="12" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2011"/>
</DATES>
<WHATS_NEW MODIFIED="2013-01-31 15:20:31 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-01-31 15:20:31 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="31" MONTH="1" YEAR="2013"/>
<DESCRIPTION>
<P>Corrected error in summary of findings table 1</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-01-31 15:19:39 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-01-31 15:19:39 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="3" YEAR="2011"/>
<DESCRIPTION>
<P>Updated search.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2013-01-31 15:19:36 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="3" YEAR="2011"/>
<DESCRIPTION>
<P>Results and conclusions changed and five summary of findings tables added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2011-03-09 15:37:48 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="11" YEAR="2010"/>
<DESCRIPTION>
<P>Nine interventions found to be beneficial for the prevention of mucositis. Conclusions changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-03-09 15:37:45 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="11" YEAR="2010"/>
<DESCRIPTION>
<P>42 new studies and 14 new interventions added. Risk of bias assessments incorporated. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-11-09 09:04:36 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2008-06-16 16:23:44 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="8" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment. This substantial update with a search only 14 months after the previous one includes 18 new included studies, bringing the total of number of studies up to 89. There are four new interventions included, bringing the total number of interventions to 33.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2010-11-09 12:05:26 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2010-11-09 12:05:26 +0000" MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>The University of Manchester</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Chief Scientists Office, Scottish Executive</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>NHS Education for Scotland</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>University of Dundee</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2010-11-09 12:05:26 +0000" MODIFIED_BY="[Empty name]">
<NAME>Manchester Academic Health Sciences Centre (MAHSC) and NIHR Manchester Biomedical Research Centre</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2010-07-25 21:37:51 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-07-25 21:37:51 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt; Makkonen TA, Minn H, Jekunen A, Vilja P, Tuominen J, Joeensuu H. Granulocyte Macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: A prospective randomized study. International Journal of Radiation Oncology, Biology and Physics 2000;46(3):525-34. McAleese 2006 McAleese JJ, Bishop KM, A'Hern R, Henk JM. Randomized phase II study of GM-CSF to reduce mucositis caused by accelerated radiotherapy of laryngeal cancer. British Journal of Radiology 2006;79(943):608-13. Meropol 2003 Meropol NJ, Somer RA, Gutheil J, Pelley RJ, Modiano MR, Rowinsky EK et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. Journal of Clinical Oncology 2003;21(8):1452-8.Meropol NJ, Somer RA, Gutheil J, Pelley RJ, Modiano MR, Rowinsky EK, et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant.+AFs-comment+AF0-. Journal of Clinical Oncology 2003+ADs- 21(8):1452-8. Mills 1988 Mills EE. The modifying effect of beta-carotene on radiation and chemotherapy induced oral mucositis. British Journal of Cancer 1988;57(4):416-7. Motallebnejad 2008 Motallebnejad M, Akram S, Moghadamnia A, Moulana Z, Omidi S. The effect of topical application of pure honey on radiation-induced mucositis: a randomized clinical trial. Journal of Contemporary Dental Practice [Electronic Resource] 2008;9(3):40-7. Naidu 2005 Naidu MU, Ramana GV, Ratnam SV, Sudhavani T, Naidu KJ, Roy P et al. A randomised, double-blind, parallel, placebo-controlled study to evaluate the efficacy of MF 5232 (Mucotrol), a concentrated oral gel wafer, in the treatment of oral mucositis. Drugs in R&amp;amp;D 2005;6(5):291-8. Nemunaitis 1995 Nemunaitis J, Rosenfeld CS, Ash R, Freedman MH, Deeg HJ, Appelbaum F et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplantation 1995;15(6):949-54. Niibe 1985 Niibe H, Takahashi I, Mitsuhashi N, Miyaishi K, Itoh J, Maehara Y et al. An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study.1. Head and neck tumors. Nippon-gan-chiryo-gakkai-shi 1985;20(5):984-93. Nottage 2003 Nottage M, McLachlan SA, Brittain MA, Oza A, Hedley D, Feld R, et al. Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial. Supportive Care in Cancer 2003;11(1):41-7.Nottage M, McLachlan SA, Brittain MA, Oza A, Hedley D, Feld R, et al. Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial. Supportive Care in Cancer 2003+ADs- 11(1):41-7. Oberbaum 2001 Oberbaum M, Yaniv I, Ben-Gal Y, Stein J, Ben-Zvi N, Freedman LS et al. A randomized, controlled clinical trial of the homeopathic medication TRAUMEEL S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation. American Cancer Society 2001;92(3):684-90. Oberbaum M, Yaniv I, Ben-Gal Y, Stein J, Ben-Zvi N, Freedman LS et al. A randomized, controlled clinical trial of the homoeopathic medication Traumeel S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation. Biologische Medizin 2002;31(1):25-31.Oberbaum MYIB-GYSJZNFLBD. A randomized, controlled clinical trial of the homoeopathic medication Traumeel S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation. Biologische Medizin 2002+ADs- Vol 31(1): 25-31. Oberbaum MY. Randomized, controlled study to prove the effectiveness of traumeel (R)s in the management of chemotherapy-induced stomatitis in children and young adults undergoing bone-marrow transplantation. Biol Medizin 2002;31(1):26-31. Okuno 1999 Okuno SH, Woodhouse CO, Loprinzi CL, Sloan JA, LaVasseur BI, Clemens-Schutjer D et al. Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy. American Journal of Clinical Oncology 1999;22(3):258-61. Papas 2003Reconsider inclusion as patients received active mouthwash + active Fl plate versus placebo (Fl) mouthwash and placebo plate. Papas AS, Clark RE, Martuscelli G, O'Loughlin KT, Johansen E, Miller KB. A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplantation 2003;31(8):705-12.Papas AS, Clark RE, Martuscelli G, O'Loughlin KT, Johansen E, Miller KB. A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplantation 2003+ADs- 31(8):705-12. Peterson 2007 Peterson DE, Jones JB, Petit RG. Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer 2007;109(2):322-31. Pfeiffer 1990 Pfeiffer P, Madsen EL, Hansen O, May O. Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy. Acta Oncologica 1990;29(2):171-3. Pillsbury 1986 Pillsbury HC 3rd, Webster WP, Rosenman J. Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers. Archives of Otolaryngology - Head &amp;amp; Neck Surgery 1986;112(5):552-3.Pillsbury HC 3rd WW, Rosenman J. Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers. Archives of Otolaryngology -- Head &amp;amp; Neck Surgery 1986;112(5):552-3. Pitten 2003 Pitten FA, Kiefer T, Buth C, Doelken G, Kramer A. Do cancer patients with chemotherapy-induced leukopenia benefit from an antiseptic chlorhexidine-based oral rinse? A double-blind, block-randomized, controlled study. Journal of Hospital Infection 2003;53(4):283-91.Pitten FA, Kiefer T, Buth C, Doelken G, Kramer A. Do cancer patients with chemotherapy-induced leukopenia benefit from an antiseptic chlorhexidine-based oral rinse? A double-blind, block-randomized, controlled study. Journal of Hospital Infection 2003+ADs- 53(4):283-91. Prada 1987 Prada A, Chiesa F. Effects of benzydamine on the oral mucositis during antineoplastic radiotherapy and/or intra-arterial chemotherapy. International Journal of Tissue Reaction 1987;9(2):115-9. Rahn 1997 Adamietz IA, Rahn R, Bottcher HD, Schafer V, Reimer K, Fleischer W. Prophylaxis of radiochemotherapy-induced mucositis. Efficacy of prophylactic oral rinsing with povidone iodine solution [Pophylaxe der radiochemotherapeutisch bedingten mukositis]. Stranhlentherapie und Onkologie 1998;174(3):149-55. Adamietz IA, Rhan R, Bottcher HD, Schafer V, Reimer K, Fleischer W. Prophylaxis with povidone-iodine against induction of oral mucositis by radiochemotherapy. Supportive Care in Cancer 1998;6(4):373-7. Rahn R AI, Bottcher HD, Reimer K, and Fleischer W. PVP-iodine solution as a mucositis prophylaxis by radiotherapy. Deutsche Zeitschrift fur Mund-, Kiefer- und Gesichtschirurgie 1996;20(3):137-9. Rahn R, Adamietz IA, Boettcher HD, Schaefer V, Reimer K, Fleischer W. Povidone-iodine to prevent mucositis in patients during antineoplastic radiochemotherapy. Dermatology 1997;195(Suppl 2):57-61. Rashad 2008 Rashad UM, Al-Gezawy SM, El-Gezawy E, Azzaz AN. Honey as topical prophylaxis against radiochemotherapy-induced mucositis in head and neck cancer. Journal of Laryngology &amp;amp; Otology 2009;123(2):223-8. Rocke 1993 Rocke LK, Loprinzi CL, Lee JK, Kunselman SJ, Iverson RK, Finck G et al. A randomized clinical trial of two different durations or oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. Cancer 1993;72(7):2234-8. Rosen 2006 Rosen LS, Abdi E, Davis ID, Gutheil J, Schnell FM, Zalcberg J, et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.[see comment]. Journal of Clinical Oncology 2006;24(33):5194-200. Rothwell 1990 Rothwell BR. Palliation of radiation-related mucositis. Special Care in Dentistry 1990:21-25. Saarilahti 2002 Saarilahti K, Kajanti M, Joensuu T, Kouri M, Joensuu H. Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized phase III study. International Journal of Radiation Oncology Biology and Physics 2002;54(2):479-85.Saarilahti K KM, Joensuu T, Kouri M, Joensuu H. Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized phase III study. International Journal of Radiation Oncology, Biology, Physics 2002+ADs-54(2):479-85. Scarantino 2006 Scarantino C, LeVeque F, Swann RS, White R, Schulsinger A, Hodson DI et al. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients. The Journal of Supportive Oncology 2006;4(5):252-8.Scarantino C, LeVeque F, Swann RS, White R, Schulsinger A, Hodson DI, et al. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients. The Journal of Supportive Oncology. 2006;4(5):252-8. Scherlacher 1990 Scherlacher A, Beaufort-Spontin F. [Radiotherapy of head-neck neoplasms: prevention of inflammation of the mucosa by sucralfate treatment]. [German]. HNO 1990;38(1):24-8.Scherlacher A B-SF. [Radiotherapy of head-neck neoplasms: prevention of inflammation of the mucosa by sucralfate treatment]. [German]. HNO 1990;38(1):24-8. Schneider 1999 Schneider SB, Nishimura RD, Zimmerman RP, Tran L, Shiplacoff J, Tormey M et al. Filgrastim (r-metHuG-CSF) and its potential use in the reduction of radiation-induced oropharyngeal mucositis: An interim look at a randomized, double blind, placebo-controlled trial. Cytokines, Cellular and Molecular Therapy 1999;5(3):175-80. Schubert 2007 Schubert MM, Eduardo FP, Guthrie KA, Franquin JC, Bensadoun RJ, Migliorati CA, et al. A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Supportive Care in Cancer 2007;15(10):1145-54. Shenep 1988 Shenep JL, Kalwinsky DK, Hutson PR, George SL, Dodge RK, Blankenship KR et al. Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositis. Journal of Pediatrics 1988;113(4):758-63.Shenep JL, Kalwinsky DK, Hutson PR, George SL, Dodge RK, Blankenship KR et al. Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositis. J Pediatr 1988;113:758-63.[published erratum appears in J Paediatr 1989 May; 114(5):900] Shieh 1997 Shieh SH, Wang ST, Tsai ST, Tseng CC. Mouth care for nasopharyngeal cancer patients undergoing radiotherapy. Oral Oncology 1997;33(1):36-41. Sorensen 2008 Sorensen J, Skovsgaard T, Bork E, Damstrup L, Ingeberg S. Double blind, placebo-controlled randomized study of chlorhexidine prophylaxis for chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) [abstract] 2001. Journal of Clinical Oncology : ASCO annual meeting proceedings 2006;24(18S Part I):470. Sorensen JB, Skovsgaard T, Bork E, Damstrup L, Ingeberg S. Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies. Cancer 2008;112(7):1600-6. Sornsuvit 2008 Sornsuvit C, Komindr S, Chuncharunee S, Wanikiat P, Archararit N, Santanirand P. Pilot Study: effects of parenteral glutamine dipeptide supplementation on neutrophil functions and prevention of chemotherapy-induced side-effects in acute myeloid leukaemia patients. Journal of International Medical Research 2008;36(6):1383-91. Spencer 2005 Spencer A, Horvath N, Gibson J, Prince HM, Herrmann R, Bashford J et al. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplantation 2005;35(10):971-7.Spencer A, Horvath N, Gibson J, Prince HM, Herrmann R, Bashford J, et al. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplantation. 2005;35(10):971-7. Spielberger 2004 Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. The New England Journal of Medicine 2004;351(25):2590-8. Spijkervet 1989 Spijkervet FKL, van Saene HK, Panders AK, Vermey A, van Saene JJ, Mehta DM et al. Effects of chlorhexidine rinsing on the oropharyngeal ecology in patients with head and neck cancer who have irradiation mucositis. Oral Surgery, Oral Medicine, Oral Pathology 1989;67(2):154-61. Stokman 2003 Stokman MA, Spijkervet FK, Burlage FR, Dijkstra PU, Manson WL, de Vries EG et al. Oral mucositis and selective elimination of oral flora in head and neck cancer patients receiving radiotherapy: a double-blind randomised clinical trial. British Journal of Cancer 2003;88(7):1012-6. Su 2003 Su C, Mehta V, Ravikumar L, Shah R, Pinto H, Halpern J et al. Phase II double-blind randomized study comparing oral aloe vera (AV) versus placebo to prevent radiation (RT)-related mucositis in patients with head and neck (HN) neoplasms. International Journal of Radiation, Oncology, Biology and Physics 2004;60(1 Sept):171-7.Su C, Mehta, V, Ravikumar, L, Shah, R, Pinto, H, Halpern, J, Koong, A, Goffinet, D, and Le, Q-T. Phase II double-blind randomized study comparing oral aloe vera (AV) versus placebo to prevent radiation (RT)-related mucositis in patients with head and neck (HN) neoplasms. Proceedings of ASCO 2003. Su 2006 Su YB, Vickers AJ, Zelefsky MJ, Kraus DH, Shaha AR, Shah JP, et al. Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor during postoperative radiotherapy for squamous head and neck cancer.[see comment]. Cancer Journal 2006;12(3):182-8. Symonds 1996 Symonds RP, McIlroy P, Khorrami J, Pyper E, Alcock SR, McCallum I et al. The reduction of radiation mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial. British Journal of Cancer 1996;74(2):312-7. Trotti 2004 Trotti A, Garden A, Warde P, Symonds P, Langer C, Redman R et al. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. International Journal of Radiation Oncology, Biology and Physics 2004;58(3):674-81.Trotti A, Garden A, Warde P, Symonds P, Langer C, Redman R, et al. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. International Journal of Radiation Oncology, Biology, Physics 2004; 58(3):674-81. Trotti A, Garden AS, Warde P, Symonds P, Langer C, Fleming T et al. Phase III trial of iseganan HCL oral solution (iseganan) for reducing oral mucositis severity in patients receiving radiotherapy for head and neck malignancies (PROMPT-RT). In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 2002:(Abs No 908). van der Lelie 2001 van der Lelie H, Thomas BL, van Oers RH, Ek-Post M, Sjamsoedin SA, van Dijk-Overtoom ML et al. Effect of locally applied GM-CSF on oral mucositis after stem cell transplantation: a prospective placebo-controlled double-blind study. Annals of Hematology 2001;80(3):150-4. Veerasarn 2006 Veerasarn V, Phromratanapongse P, Suntornpong N, Lorvidhaya V, Sukthomya V, Chitapanarux I, et al. Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand 2006;89(12):2056-67. Veness 2006 Veness MJ, Foroudi F, Gebski V, Timms I, Sathiyaseelan Y, Cakir B, et al. Use of topical misoprostol to reduce radiation-induced mucositis: results of a randomized, double-blind, placebo-controlled trial. Australasian Radiology 2006;50(5):468-74. Vokurka 2005 Vokurka S, Bystricka E, Koza V, Scudlova J, Pavlicova V, Valentova D, et al. The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT--results of a randomized multicentre study. Supportive Care in Cancer 2005;13(7):554-8.Vokurka S, Bystricka E, Koza V, Scudlova J, Pavlicova V, Valentova D, et al. The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT--results of a randomized multicentre study. Supportive Care in Cancer. 2005;13(7):554-8. Wahlin 1989 Wahlin YB. Effects of chlorhexidine mouthrinse on the oral health in patients with acute leukemia. Oral Surgery, Oral Medicine, Oral Pathology 1989;68(3):279-87.Wahlin YD. Effects of chlorhexidine mouth rinse on the oral health in patients with acute leukemia. Oral Surg Oral Med Oral Path 1989;68:279-87. Wang 2002a Wang J. Effect on Chinese herbs decoction gargling to treat and to prevent chemotherapy caused stomatitis. Chinese Nursing Research 2002;16(10):578-9. Wijers 2001 Wijers OB, Levendag PC, Harms ER, Gan-Teng AM, Schmitz PI, Hendriks WD et al. Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: A placebo-controlled double-blind randomized study. International Journal of Radiation Oncology, Biology and Physics 2001;50(2):343-52. Wu 2009 Wu PA, Kim YH, Lavori PW, Hoppe RT, Stockerl-Goldstein KE. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome. Biology of Blood &amp;amp; Marrow Transplantation 2009;15(8):982-90. You 2009 You WC, Hsieh CC, Huang JT. Effect of extracts from indigowood root (Isatis indigotica Fort.) on immune responses in radiation-induced mucositis. Journal of Alternative &amp;amp; Complementary Medicine 2009;15(7):771-8. Yuen 2001 Yuen KY, Woo PCY, Tai JW, Lie AK, Luk J, Liang R. Effects of clarithromycin on oral mucositis in bone marrow transplant recipients. Haematologica 2001;86(5):554-5. Excluded studies Abramoff 2008 Abramoff MM, Lopes NN, Lopes LA, Dib LL, Guilherme A, Caran EM, et al. Low-level laser therapy in the prevention and treatment of chemotherapy-induced oral mucositis in young patients. Photomed Laser Surg 2008;26(4):393-400. Adamietz 1997 Adamietz IA, Rahn R, Bottcher HD, Reimer K, Fleischer W. Prophylaxis of radiation induced oral mucositis with povidone iodine. Supportive Care in Cancer 1997;5 Suppl:165 (Abs No 48).Adamietz IA, Rahn R, Bottcher HD, Reimer K, Fleischer W. Prophylaxis of radiation induced oral mucositis with povidone iodine. Supportive Care in Cancer. 1997;5 Suppl(Abstr 48):165. Ahn 2008 Ahn YWH, Song S, Kim Y, Oh Y, Lee C, and, et al. The therapeutic effect of recombinant human epidermal growth factor (rhEGF) on mucositis in patients with head and neck cancer undergoing radiotherapy with or without chemotherapy: a double-blind placebo-controlled prospective phase II multi-institutional study. J Clin Oncol 2008;26(suppl):Abstract no: 6021. Aisa 2005 Aisa Y, Mori T, Kudo M, Yashima T, Kondo S, Yokoyama A et al. Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients.. Supportive Care in Cancer 2005;13(4):266-9. Altmann 1999 Altmann S Hoffmanns H. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors]. [German]. Strahlentherapie und Onkologie 1999;175(Suppl 4):30-3.Altmann S HH. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors]. [German]. Strahlentherapie und Onkologie 1999;175(Suppl 4):30-3. Andersen 1987 Andersen E, Pedersen H. Oral ftorafur versus intravenous 5-fluorouracil. A comparative study in patients with colorectal cancer. Acta Oncologica 1987;26(6):433-6.Andersen E PH. Oral ftorafur versus intravenous 5-fluorouracil. A comparative study in patients with colorectal cancer. Acta Oncologica 1987;26(6):433-6. Anderson 1998b Anderson PM, Ramsay NKC, Shu XO, Rydholm N, Rogosheske J, Nicklow R et al. Effect of low dose oral glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplantation 1998;22(4):339-44. Antin 2002 Antin JH, Lee SJ, Neuberg D, Alyea E, Soiffer RJ, Sonis S, et al. A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplantation 2002;29(5):373-7.Antin JH, Lee SJ, Neuberg D, Alyea E, Soiffer RJ, Sonis S, et al. A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplantation 2002; 29(5):373-7. Antonadou 1998 Antonadou D, Athanassiou E, Synodinou M, Koliarakis N, Panoussaki K, Karageorgis P et al. Evaluation of the efficacy of granulocyte macrophage colony stimulating factor (GM-CSF) in the prevention of radiation induced mucositis [abstract]. Radiotherapy Oncology 1998;48(S1):S39. Apaydin 1996 Apaydin A, Karadeniz AN, Aysigi G, Blige N. The effect and therapeutical use of benzydamine HCL on radiation-induced oral cavity and oropharyngeal mucositis. Medical Bulletin Istanbul 1996;29:1:59-63. Aquino 2005 Aquino VM, Harvey AR, Garvin JH, Godder KT, Nieder ML, Adams RH et al. A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplantation 2005;36(7):611-6.Aquino VM, Harvey AR, Garvin JH, Godder KT, Nieder ML, Adams RH, et al. A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplantation. 2005;36(7):611-6. Ardizzoni 2002 Ardizzoni A, Tjan-Heijnen VC, Postmus PE, Buchholz E, Biesma B, Karnicka-Mlodkowska H, et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. Journal of Clinical Oncology 2002;20(19):3947-55.Ardizzoni A, Tjan-Heijnen VC, Postmus PE, Buchholz E, Biesma B, Karnicka-Mlodkowska H, et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.+AFs-comment+AF0-. Arora 2008 Arora H, Pai KM, Maiya A, Vidyasagar MS, Rajeev A. Efficacy of He-Ne Laser in the prevention and treatment of radiotherapy-induced oral mucositis in oral cancer patients. Oral Surgery Oral Medicine Oral Pathology Oral Radiology &amp;amp; Endodontics 2008;186.e1, 105(2):180-6. Awada 2002 Awada A, Biganzoli L, Cufer T, Beex L, Lohrisch C, Batter V, et al. An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes. European Journal of Cancer 2002;38(6):773-8.Awada A, Biganzoli L, Cufer T, Beex L, Lohrisch C, Batter V, et al. An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes.2002+ADs- 38(6):773-8. Awada 2004 Awada A, Gil T, Sales F, Dubuisson M, Vereecken P, Klastersky J et al. Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers. Anti-Cancer Drugs 2004;15(5):499-502.Awada A, Gil T, Sales F, Dubuisson M, Vereecken P, Klastersky J, et al. Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers. Anti-Cancer Drugs. 2004;15(5):499-502. Awidi 2001 Awidi A, Homsi U, Kakail RI, Mubarak A, Hassan A, Kelta M, Martinez P et al. Double-blind, placebo-controlled cross-over study of oral pilocarpine for the prevention of chemotherapy-induced oral mucositis in adult patients with cancer. European Journal of Cancer 2001;37(16):2010-4.Awidi A HU, Kakail RI, Mubarak A, Hassan A, Kelta M, Martinez P, Sulaiti S, Al Qady A, Jamhoury A, Daniel M, Charles C, Ambrose A, El-Aloosy AS. Double-blind, placebo-controlled cross-over study of oral pilocarpine for the prevention of chemotherapy-induced oral mucositis in adult patients with cancer. +AFs-see comments.+AF0-. Awwad 2002 Awwad HK, Lotayef M, Shouman T, Begg AC, Wilson G, Bentzen SM et al. Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cnacer: influence of proliferation. British Journal of Cancer 2002;86(4):517-23. Barasch 1995 Barasch A, Peterson DE, Tanzer JM, D'Ambrososio JA, Nuki K, Schubert MM et al. Helium-Neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer 1995;76(12):2550-6. Baydar 2005 Baydar M, Dikilitas M, Sevinc A, Aydogdu I. Prevention of oral mucositis due to 5-fluorouracil treatment with oral cryotherapy. Journal of the National Medical Association 2005;97(8):1161-4. Bensadoun 1995 Bensadoun R, Cowen D, Nguyen TD, Ciais G, Franquin JC, Dassonville O et al. Low energy laser in the prevention of radiation-induced mucositis: A phase III randomized multicentric study in patients with head and neck cancer. In: Fifth International Congress on Anti-Cancer Chemotherapy. 1995.Bensadoun R, Cowen, D, Nguyen, TD, Ciais, G, Franquin, JC, Dassonville, O, Laudoyer, Y, Chauvel, P, Demard, F, and Zattara, H. Low energy laser in the prevention of radiation-induced mucositis: A phase III randomized multicentric study in patients with head and neck cancer. Fifth International Congress on Anti-Cancer Chemotherapy. 1995 1995. Bensadoun 1999 Bensadoun R, Franquin J, Benezery K, Ciais G, Tardieu C, Dejou J et al. Low energy He/Ne laser in the prevention of radiation induced mucositis: A multicenter phase III double blind study for patients with head and neck cancer. In: Proceedings of ASCO. 1999. Bensadoun RJ, Ciais G, Darcourt V, Franquin JC, Cheynet C, Cowen D et al. Low energy laser in the prevention of radiation induced mucositis: a phase II randomized multicentre study for patients with head and neck cancer. Supportive Care in Cancer 1999;7:SO-13. Bensadoun RJ, Franquin JC, Ciais G, Darcourt V, Schubert MM, Viot M et al. Low-energy He/Ne laser in the prevention of radiation-induced mucositis. A multicentre phase III randomized study in patients with head and neck cancer. Supportive Care in Cancer 1999;7(4):244-52. Bensadoun 2006 Bensadoun RJ, Benezery K, Dassonville O, Magne N, Poissonnet G, Ramaioli A et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). International Journal of Radiation Oncology, Biology, Physics 2006;64(4):983-94.Bensadoun RJ, Benezery K, Dassonville O, Magne N, Poissonnet G, Ramaioli A, et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). International Journal of Radiation Oncology, Biology, Physics. 2006;64(4):983-94. Bentzen 2001 Bentzen SM, Saunders MI, Dische S, Bond SJ. Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial. Radiotherapy Oncology 2001;60(2):123-35. Bergmann 1995 Bergmann OJ, Ellermann-Eriksen S, Mogensen SC, Ellegaard J. Acyclovir given as prophylaxis against oral ulcers in acute myeloid leukaemia: randomised, double blind, placebo controlled trial. BMJ 1995;6(310):116-72. Bleehen 1996 Bleehen NM, Girling DJ, Hopwood P, Lallemand G, Machin D, Stephens RJ et al. Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. British Journal of Cancer 1996;73:406-13.Bleehen NM, Girling DJ, Hopwood P, Lallemand G, Machin D, Stephens RJ, Bailey AJ. Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. British Journal of Cancer 1996 73 406-413. Bolwell 2004 Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplantation 2004;34(7):621-5.Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplantation. 2004;34(7):621-5. Bourhis 2006 Bourhis J, Lapeyre M, Tortochaux J, Rives M, Aghili M, Bourdin S et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. Journal of Clinical Oncology 2006;24(18):2873-8.Bourhis J, Lapeyre M, Tortochaux J, Rives M, Aghili M, Bourdin S, et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. Journal of Clinical Oncology. 2006;24(18):2873-8. Braaksma 2002 Braaksma M, Levendag P. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation. Seminars in Oncology 2002;29(6 Supp 19):63-70.Braaksma M, Levendag P. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation. Seminars in Oncology 2002+ADs- 29(6 Suppl 19):63-70. Buentzel 1999 Buentzel J, Glatzel M, Weinaug R, Schuth J, Kuettner K, Froehlich D. Amifostine in combined radio- and chemomodalities for head and neck cancer. European Journal of Cancer 1999;35(Suppl 4):363 (Abs No 1472).Buentzel J, Glatzel M, Weinaug R, Schuth J, Kuettner K, Froehlich D. Amifostine in combined radio- and chemomodalities for head and neck cancer. European Journal of Cancer. 1999;35(Suppl 4):363 Abstract #1472. Calais 1998 Calais GM, Alfonsi E, Bardet C, Sire H, Bourgeois C, Bergerot B et al. Randomized study comparing radiation alone (RT) versus RT with concomitant chemotherapy (CT) in stages III andf IV oropharynx carcinoma (ARCORO). Preliminary results of the 94.01 study from the French Group of radiation oncology for head and neck cancer (GORTEC). In: Proceedings of Annual Meeting of the American Society of Clinical Oncology. 1998:(Abs No 1484).Calais GM, Alfonsi E, Bardet C, Sire H, Bourgeois C, Bergerot B, et al. Randomized study comparing radiation alone (RT) versus RT with concomitant chemotherapy (CT) in stages III andf IV oropharynx carcinoma (ARCORO). Preliminary results of the 94.01 study from the French Group of radiation oncology for head and neck cancer (GORTEC). Proc-Annu-Meet-Am-Soc-Clin-Oncol. 1998:Abstract # 1484. Calais 2000 Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P et al. [Stage III and IV cancers of the oropharynx: results of a randomized study of Gortec comparing radiotherapy alone with concomitant chemotherapy]. Bulletin du Cancer 2000;87 Spec No:48-53.Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, et al. [Stage III and IV cancers of the oropharynx: results of a randomized study of Gortec comparing radiotherapy alone with concomitant chemotherapy]. [French]. Bulletin du Cancer. 2000;87 Spec No:48-53. Calais 2004 Calais G, Bardet E, Sire C, Alfonsi M, Bourhis J, Rhein B et al. Radiotherapy with concomitant weekly docetaxel for stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC phase II trial. International Journal of Radiation, Oncology, Biology and Physics 2004;58(1 Jan):161-6. Cassidy 2002 Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Annals of Oncology 2002;13(4):566-75.Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. 2002+ADs- 13(4):566-75. Cella 2003 Cella D, Pulliam J, Fuchs H, Miller C, Hurd D, Wingard JR et al. Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cancer 2003;98(2):406-12. Cheng 2001 Cheng KK Molassiotis A, Chang AM, Wai WC, Cheung SS. Evaluation of an oral care protocol intervention in the prevention of chemotherapy-induced oral mucositis in paediatric cancer patients. European Journal of Cancer 2001;37(16):2056-63.Cheng KK MA, Chang AM, Wai WC, Cheung SS. Evaluation of an oral care protocol intervention in the prevention of chemotherapy-induced oral mucositis in paediatric cancer patients. 2001+ADs-37(16):2056-63. Cheng 2002 Cheng KKF, Malassiotis A, Chang AM. An oral care protocol intervention to prevent chemotherapy-induced oral mucositis in paediatric cancer patients: a pilot study. European Journal of Oncology Nursing 2002;6(2):66-74.Cheng KKF MA, Chang AM. An oral care protocol intervention to prevent chemotherapy-induced oral mucositis in paediatric cancer patients: a pilot study... including commentary by Parr M. European Journal of Oncology Nursing: EUR J ONCOL NURS 2002+ADs- 6. 6(2. 2):66-74. Cheng 2003 Cheng KK, Chang AM. Palliation of oral mucositis symptoms in pediatric patients treated with cancer chemotherapy. Cancer Nursing 2003;26(6):476-84.Cheng KK, Chang AM. Palliation of oral mucositis symptoms in pediatric patients treated with cancer chemotherapy. Cancer Nursing 2003; 26(6):476-84. Cheng 2004a Cheng KK. Children's acceptance and tolerance of chlorhexidine and benzydamine oral rinses in the treatment of chemotherapy-induced oropharyngeal mucositis. European Journal of Oncology Nursing 2004;8(4):341-9.Cheng KK. Children's acceptance and tolerance of chlorhexidine and benzydamine oral rinses in the treatment of chemotherapy-induced oropharyngeal mucositis. European Journal of Oncology Nursing. 2004;8(4):341-9. Cheng 2004b Cheng KK, Chang AM, Yuen MP. Prevention of oral mucositis in paediatric patients treated with chemotherapy; a randomised crossover trial comparing two protocols of oral care. European Journal of Cancer 2004;40(8):1208-16.Cheng KK, Chang AM, Yuen MP. Prevention of oral mucositis in paediatric patients treated with chemotherapy; a randomised crossover trial comparing two protocols of oral care. Eur J Cancer 2004;40(8):1208-16. Chi 1994 Chi KH, Chen SY, Chan WK, Yen SH, Liang MJ, Chou KC, et al. Effect of granulocyte macrophage colony stimulating factor (GM-CSF) on oral mucositis in head and neck cancer patients after cisplatin, 5- FU and leucovorin chemotherapy [abstract]. Proceedings of the American Society of Clinical Oncology 1994;13:428, Abstract 1469. Chi 1995 Chi KH, Chen CH, Chan WK, Yen SH, Liang MJ, Chou KC et al. Effect of granulocyte-macrophage colony-stimulating factor (GH-CFS) on oral mucositis in head and neck cancer patients after cisplatin, 5-FU and leucovorin chemotherapy. In: Proceedings of Annual Meeting American Society of Clinical Oncology. Vol. 13. 1994:A1469. Chi KH, Chen SY, Chan WK, Yen SH, Liang MJ, Chou KC et al. Effect of granulocyte-macrophage colony-stimulating factor (GH-CFS) on oral mucositis in head and neck cancer patients after cisplatin, 5-FU and leucovorin chemotherapy. Journal of Clinical Oncology 1995;13(10):2620-8. Chiara 2000 Chiara S, Nobile MT, Vincenti M, Gozza A, Heouaine A, Marceca F, et al. Sucralfate in the treatment of chemotherapy-induced stomatitis: a double-blind, placebo-controlled pilot study [abstract]. Proceedings of the American Society of Clinical Oncology 2000;19:630a, Abstract 2485. Clarke 2001 Clarke SJ, Abdi E, Davis ID, Schnell FM, Zalcberg JR, Gutheil J, et al. Recombinant human keratinocyte growth factor (rHuKGF) prevents chemotherapy-induced mucositis in patients with advanced colorectal cancer: a randomized phase II trial [abstract]. Proceedings of the American Society of Clinical Oncology 2001;20 (Pt 1):383a, Abstract 1529. Collova 2004 Collova E, Castagna L, Nozza A, Perfetti V, Patrone F, Danova M et al. New approaches for reduction of oral mucositis in patients undergoing high-dose chemotherapy with hematopoietic stem cell support. Bone Marrow Transplantation 2004;33(Suppl 1):S323-S4.Collova E, Castagna L, Nozza A, Perfetti V, Patrone F, Danova M, et al. New approaches for reduction of oral mucositis in patients undergoing high-dose chemotherapy with hematopoietic stem cell support [abstract]. Bone Marrow Transplantation. 2004;33(Suppl 1):S323-S4. Colombat 1995 Colombat P, Colin B. Comparison of fluconazole and amphotericin B in the prevention of mucositis in patients with long term aplasia. Bone Marrow Transplantation 1995;15:178.Colombat P, Colin B, et al. Comparison of fluconazole and amphotericin B in the prevention of mucositis in patients with long term aplasia [abstract]. Bone-Marrow-Transplant. 1995;15:178. Costa 1999 Costa EMMB, Pinto LP, Fernandes MZ, Costa ALL. Preventing oral complications in leukemic children submitted to chemotherapy. Journal of Dental Research 1999;78:1021 (Abs No B-220). Costa 2003 Costa EM, Fernandes MZ, Quinder LB, de Souza LB, Pinto LP. Evaluation of an oral preventive protocol in children with acute lymphoblastic leukemia. Pesquisa Odontologica Brasileira 2003;17(2):147-50.Costa EM, Fernandes MZ, Quinder LB, de Souza LB, Pinto LP. Evaluation of an oral preventive protocol in children with acute lymphoblastic leukemia. Pesqui Odontol Bras. 2003 Apr-Jun;17(2):147-50. Cowen 1997 Cowen D, Tardieu C, Resbeut M, Hannoun-Levi JM, Alzieu C, Schubert M et al. Low energy helium-neon laser presents oral mucositis after high-dose chemo-radiotherapy: results of a double-blind randomized trial. International Journal of Radiation Oncology, Biology and Physics 1996;36(1S):264 (A1041). Cowen D, Tardieu C, Schubert M, Peterson D, Resbeut M, Faucher C et al. Low energy Helium-neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: Results of a double blind randomized trial. International Journal of Radiation Oncology, Biology and Physics 1997;38(4):697-703. Crawford 1994 Crawford J, Glaspy J, Vincent M, Tomita D, Mazanet R. Effect of filgrastim (r-metHug-CSF) on oral mucositis in patients with small cell lung cancer (SCLC) receiving chemotherapy (cyclophosphamide, doxorubicin and etoposide, CAE). In: Proceedings of Annual Meeting of American Society Clinical Oncology. Vol. 13. 1994:(Abs No A1523).Crawford J, Glaspy J, Vincent M, Tomita D, Mazanet R. Effect of filgrastim (r-metHug-CSF) on oral mucositis in patients with small cell lung cancer (SCLC) receiving chemotherapy (cyclophosphamide, doxorubicin and etoposide, CAE). Proc-Annu-Meet-Am-Soc-Clin-Oncol. 1994;13:Abs. A1523. Crispino 1997 Crispino SP, Olmi C, Fallai F, Rossi S, Marsoni A, Tinazzi M, et al. Conventional radiotherapy (RT) versus accelerated hyperfractionated RT versus conventional RT and concomitant chemotherapy in locally advanced oropharyngeal carcinoma (ORO-93/01). In: Proceedings of the American Society of Clinical Oncology. 1997.Crispino SP, Olmi C, Fallai F, Rossi S, Marsoni A, Tinazzi M, et al. Conventional radiotherapy (RT) versus accelerated hyperfractionated RT versus conventional RT and concomitant chemotherapy in locally advanced oropharyngeal carcinoma (ORO-93/01). Proc Am Soc Clin Oncol. 1997. Cruz 1997 Cruz J, Fonseca E, Rodriguez CA, Gomez-Bernal A, Martin G, Sanchez P et al. Randomized trial of cisplatin (P) plus 5-fluorouracil (F) with or without folinic acid in locally advanced head and neck cancer (LAHNC). In: Proceedings of the European Cancer Conference. 1997:(Abs No 854).Cruz J, Fonseca E, Rodriguez CA, Gomez-Bernal A, Martin G, Sanchez P, et al. Randomized trial of cisplatin (P) plus 5-fluorouracil (F) with or without folinic acid in locally advanced head and neck cancer (LAHNC). Proc-Eur-Cancer-Conf (ECCO). 1997:Abstract #854. Cunningham 1995 Cunningham D, Zalcberg JR, Rath U, Olver I, van Cutsem EV, Sevensson C et al. 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. European Journal of Cancer 1995;31A(12):1945-54. De Boer 2002 De Boer RH, Eisen TG, Ellis PA, Johnston SR, Walsh G, Ashley S et al. A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer. Annals of Oncology 2002;13(6):889-94. Decker-Baummann 1999 Decker-Baumann C, Buhl K, Frohmuller S, von Herbay A, Dueck M, Schlag PM. Reduction of chemotherapy-induced side-effects by parenteral glutamine supplementation in patients with metastatic colorectal cancer. European Journal of Cancer 1999;35(2):202-7. Denham 1999 Denham JW, Peters LJ, Johansen J, Poulsen M, Lamb DS, Hindley A et al. Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer? Radiotherapy Oncology 1999;52(2):157-64. Djuric 2006 Djuric M, Hillier-Kolarov V, Belic A, Jankovic L. Mucositis prevention by improved dental care in acute leukemia patients. Supportive Care in Cancer 2006;14(2):137-46.Djuric M, Hillier-Kolarov V, Belic A, Jankovic L. Mucositis prevention by improved dental care in acute leukemia patients. Supportive Care in Cancer. 2006;14(2):137-46. Dobrowsky 1998 Dobrowsky W, Naude J, Widder J, Dobrowsky E, Millesi W, Pavelka R et al. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer. International Journal of Radiation Oncology, Biology and Physics 1998;42(4):803-6.Dobrowsky W NJ, Widder J, Dobrowsky E, Millesi W, Pavelka R, Grasl C, Reichel M. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer. International Journal of Radiation Oncology, Biology, Physics 1998;42(4):803-6. Doroshow 1987 Doroshow JH, Berthtand M, Newman E, Multhauf P, Leong L, Blayney D et al. Preliminary analysis of a randomized comparison of 5-fluorouracil versus 5-fluorouracil and high-dose continuous-infusion folinic acid in disseminated colorectal cancer. NCI Monographs 1987;5:171-4.Doroshow JH BM, Newman E, Multhauf P, Leong L, Blayney D, Goldberg D, Margolin K, Carr B, Akman S, et al. Preliminary analysis of a randomized comparison of 5-fluorouracil versus 5-fluorouracil and high-dose continuous-infusion folinic acid in disseminated colorectal cancer. NCI Monographs 1987(5):171-4. Dose 1989 Dose AM, Loprinzi CL, Cianflone S, Etzell P, Burnham N, Therneau T, et al. A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis. A North Central Cancer Treatment Group and Mayo clinic study [abstract]. Proceedings of the American Society of Clinical Oncology 1989;8:341, Abstract 1328. Dose 1990 Dose AM, Mahood D, Loprinzi CL, Gainey D, Sorensen JM, Therneau T, et al. A controlled trial of oral cryotherapy for preventing stomatitis in patients receiving 5- fluorouracil (5FU) plus leucovorin (LV). A North Central Cancer Treatment Group and Mayo Clinic study [abstract]. Proceedings of the American Society of Clinical Oncology 1990;9:321, Abstract 1242. Dreicer 1997 Dreicer R, Propert KJ, Kuzel T, Kirkwood JM, O'Dwyer PJ, Loehrer PJ. A phase II trial of edatrexate in patients with advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study. American Journal of Clinical Oncology 1997;20(3):251-3. Dudjak 1987 Dudjak LA. Mouth care for mucositis due to radiation therapy. Cancer Nursing 1987;10(3):131-40. Edelman 1998 Edelman MJ, Gandara Dr, Perez EA, Lau D, Lauder I, Turrell C et al. Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy. Investigational New Drugs 1998;16(1):69-75. Eisen 2003 Eisen D, Essel J, Broun ER, Sigmund D, DeVoe M,. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. Bone Marrow Transplantation 2003;31(1):51-5. El-Sayed 2000 El-Sayed S, Nabid A, MacKenzie R, Gelinas M, Hay J, Shelley et al. Prophylaxis of radiation associated mucositis (RAM) in head and neck cancer, results of a double blind phase III trail evaluating the clinical efficacy of an antimicrobial lozenge utilizing a new validated mucositis scoring system. In: Proceedings of the 42nd Annual Meeting of the American Society of Therapeutic Oncology. Vol. 321. 2000:(Abs No 2115).El-Sayed S, Nabid, A, MacKenzie, R, Gelinas, M, Hay, J, Shelley, W, Berthelet, E, Lau, H, Duncan, G, and Epstein, J. Prophylaxis of radiation associated mucositis (RAM) in head and neck cancer, results of a double blind phase III trail evaluating the clinical efficacy of an antimicrobial lozenge utilizing a new validated mucositis scoring system. El-Sayed 2002b El-Sayed S, Epstein J, Minish E, Burns P, Hay J, Laukkanen E. A pilot study evaluating the safety and microbiologic efficacy of an economically viable antimicrobial lozenge in patients with head and neck cancer receiving radiation therapy. Head &amp;amp; Neck 2002;24(1):6-15.El-Sayed S, Epstein J, Minish E, Burns P, Hay J, Laukkanen E.A pilot study evaluating the safety and microbiologic efficacy of an economically viable antimicrobial lozenge in patients with head and neck cancer receiving radiation therapy. Head Neck. 2002 Jan;24(1):6-15. Epstein 1986 Epstein JB, Stephenson-Moore P. Benzydamine hydrochloride in prevention and management of pain in oral mucositis associated with radiation therapy. Oral Surgery, Oral Medicine, Oral Pathology 1986;62(2):145-8. Epstein 1989 Epstein JB, Stevenson-Moore P, Jackson S, Mohamed JH, Spinelli JJ. Prevention of oral mucositis in radiation therapy: A controlled study with benzydamine hydrochloride rinse. International Journal of Radiation Oncology, Biology and Physics 1989;16(6):1571-5. Epstein 1992 Epstein JB, Vickars L, Spinalli J, Reece D. Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. Oral Surgery, Oral Medicine, Oral Pathology 1992;73(6):682-9. Epstein 1994 Epstein JB, Wong FLW. The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy. International Journal of Radiation Oncology, Biology and Physics 1994;28(3):693-8. Epstein 1999 Epstein J, Silverman S Jr, Pagerino D, Lockhart P, Schubert M, Crockett R. Benzydamine HCL for prophylaxis of irradiation induced oral mucositis: a randomized double-blind, multicenter study. Supportive Care in Cancer 1999;7 Suppl:169 (Abs No O-18).Epstein J, Silverman S, Jr Pagerino D, Lockhart P, Schubert M, Crockett R. Benzydamine HCL fro prophilaxis of irradiation oral mucositis: a randomized double-blind, multicenter study. Supportive Care in Cancer. 1999;7 Suppl.(Abstr O-18):169. Epstein 2001 Epstein JB, Silverman S, Paggiarino DA, Crockett S, Schubert MM, Senzer NN et al. Benzydamine HCI for prophylaxis of radiation-induced oral mucositis. Cancer 2001;92(4):875-85. Erkisi 1996 Erkisi M, Erkurt E, Ozbarlas S, Burgut R, Doran F, Seyrek E. The use of recombinant human granulocyte colony-stimulating factor in combination with single or fractionated doses of ifosfamide and doxorubicin in patients with advanced soft tissue sarcoma. Journal of Chemotherapy 1996;8(3):224-8. Etiz 1998 Etiz M, Erkal HS, Serin M, Kucuk B, Hepari A, Tulunay O et al. Clinicohistopathological evaluation of effectiveness of sucralfate in prevention of severe radiation-induced mucositis in patients with head and neck malignancies. Radiotherapy Oncology 1998;48(S1):S68. Etiz 2000 Etiz D, Erkal HS, Serin M, Kucuk B, Hepari A, Elhan AH et al. Clinical and histopathological evaluation of sucralfate in prevention of oral mucositis induced by radiation therapy in patients with head and neck malignancies. Oral Oncology 2000;36(1):116-20. Evans 1990 Evans G, Mahendra P, Brightwell M, Jestivfe K, Marcus R. A double blind randomised trial of oral GMCFS mouthwash versus placebo in the treatment of mucositis following PBSC/bone marrow transplantation. Bone Marrow Transplantation 1998;21(S1):S88. Evans WK, Wierzbicki R, Shepherd FA, Rusthoven J, Stewart DJ, Aitken SE et al. 5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung. Cancer Investigation 1990;8(3-4):345-9. Ezzat 2005 Ezzat M, Shouman T, Zaza K, Safwat A, El-Khoudary A, El-Senosi M et al. A randomized study of accelerated fractionation radiotherapy with and without mitomycin C in the treatment of locally advanced head and neck cancer. Journal of the Egyptian National Cancer Institute 2005;17(2):85-92.Ezzat M, Shouman T, Zaza K, Safwat A, El-Khoudary A, El-Senosi M, et al. A randomized study of accelerated fractionation radiotherapy with and without mitomycin C in the treatment of locally advanced head and neck cancer. Journal of Egyptian National Cancer Institute. 2005;17(2):85-92. Fahlke 1999 Fahlke J, Ridwelski K, Lippert H. High-dose therapy with combined 5-fluorouracil and folinic acid with and without amifostine in the treatment of patients with metastatic colorectal carcinoma. International Journal of Colorectal Disease 1999;14(2):128-30. Falcone 2001 Falcone A, Allergrini G, Masi G, Lencioni M, Panner E, Brunetti I. 5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer. Oncology 2001;61(1):28-35. Fay 1994 Fay JW, Lazarus H, Herzig R, Saez R, Stevens DA, Collins RH Jr et al. Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study. Blood 1994;84(7):2151-7.Fay JW LH, Herzig R, Saez R, Stevens DA, Collins RH Jr, Pineiro LA, Cooper BW, DiCesare J, Campion M, et al. Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study. Blood 1994;84(7):2151-7. Feber 1995 Feber T. Mouth care for patients receiving oral irradiation. Professional Nurse 1995;10(10):666-70. Feber 1996 Feber T. Management of mucositis in oral irradiation. Clinical Oncology 1996;8(2):106-11. Ferreira 2002 Ferreira PR, Fleck J, Filho AB, Barletta D, Barletta A, Diehl A et al. Protective effect of vitamin E (VE) in head and neck cancer radiation induced mucositis: a double-blind randomized trial. In: Proceedings of American Society of Clinical Oncology Meeting. 2002:(Abs No 909).Ferreira P FJ, Filho A, Barletta D, Barletta A, Diehl A, de Azambuja E. Protective effect of vitamin E (VE ) in head and neck cancer radiation induced mucositis: a double-blind randomized trial. Proceedings of ASCO 2002. Ferreira 2002a Ferreira RR, Fleck JF, Filho AB, Barletta D, Barletta A, Diehl A, et al. Positive effect of vitamin E (VE) in head and neck cancer radiation induced mucositis: a double-blind randomized trial [abstract]. Proceedings of the American Society of Clinical Oncology 2002;21 (Pt 1):228a, Abstract 909. Ferreira 2004 Ferreira PR, Fleck JF, Diehl A, Barletta D, Braga-Filho A, Barletta A et al. Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial. Head &amp;amp; Neck 2004;26(4):313-21.Ferreira PR, Fleck JF, Diehl A, Barletta D, Braga-Filho A, Barletta A, et al. Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial. Head Neck 2004;26(4):313-21. Ferretti 1985 Ferretti G, Largent B, Brown A, Lillich T, Ash R. The effect of chlorhexidine mouthrinse on mucositis, plaque, gingivitis and stain in bone marrow transplant patients. Journal of Dental Research 1985;64(Special Issue):235 (Abs No 546). Fidler 1995 Fidler P, Loprinzi CL, O'Fallon JR, Michalak J, Novotny P, Hayes D, et al. A controlled evaluation of chamomile for preventing stomatitis in patients receiving 5-fluorouracil based chemotherapy: A North Central Cancer Treatment Group trial [abstract]. Proceedings of the American Society of Clinical Oncology 1995;14:534, Abstract 1765. Foncuberta 2001 Foncuberta MC, Cagnoni PJ, Brandts CH, Mandanas R, Fields K, Derigs HG et al. Topical transforming growth factor-beta3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors. Journal of Immunotherapy 2001;24(4):384-8.Foncuberta M, PJ C, CH B, R M, K F, HG D, et al. Topical transforming growth factor-beta3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors. Journal of Immunotherapy 2001;24(4):384-388. Gabison 1995 Gabison R. Can zinc picolinate in patients receiving chemotherapy for metastatic colorectal carcinoma prevent stomatitis? European Journal of Cancer 1995;31A(Suppl 5):S258 (Abs No 1234). Gandara 1997 Gandara DR, Edelman MJ, Crowley JJ, Lau DH, Livingston RB. Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study.. Cancer Chemotherapy and Pharmacology 1997;41:75-78. Genot-Klastersky 2008 Genot-Klastersky MT, Klastersky J, Awada F, Awada A, Crombez P, Martinez MD, et al. The use of low-energy laser (LEL) for the prevention of chemotherapy- and/or radiotherapy-induced oral mucositis in cancer patients: results from two prospective studies. Support Care Cancer 2008. Giles 2003b Giles FJ, Faderl S, Thomas DA, Cortes JE, Garcia-Manero G, Douer D et al. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. Journal of Clinical Oncology 2003;21(6):1050-6.Giles FJ FS, Thomas DA, Cortes JE, Garcia-Manero G, Douer D, Levine AM, Koller CA, Jeha SS, O'Brien SM, Estey EH, Kantarjian HM. Randomized Phase I/II Study of Troxacitabine Combined With Cytarabine, Idarubicin, or Topotecan in Patients With Refractory Myeloid Leukemias. Journal of Clinical Oncology 2003+ADs-21(6):1050-1056. Gladkov 2007 Gladkov OA, Vazhenin AV, Sharabura TM, Kandakova E, Galiatova Iu V, Sychev VI, et al. [Effectiveness of different regimes of combined treatment (cisplatin+ radiotherapy) for intraoral and oropharyngeal cancer]. [Russian]. Voprosy Onkologii 2007;53(5):575-7. Goldberg 2003 Goldberg S. Safety and tolerability of en3247 in the prevention of oral mucositis associated with chemotherapy with or without total body irradiation: results of a randomized, double-blind, placebo-controlled trial. In: Proceedings of the American Society of Clinical Oncology. 2003:770.Goldberg S. Safety and tolerability of en3247 in the prevention of oral mucositis associated with chemotherapy with or without total body irradiation: results of a randomized, double-blind, placebo-controlled trial [abstract]. Proceedings of the American Society of Clinical Oncology. 2003:770. Gordon 1993 Gordon B, Spadinger A, Hodges E, Coccia P. Effect of granulocyte macrophage colony stimulating factor (GMCSF) on oral mucositis after autologous bone marrow transplantation [abstract]. Proceedings of the American Society of Clinical Oncology 1993;12:432, Abstract 1489. Grotz 2001 Grotz KA, Henneicke-Von Zepelin H-H, Kohnen R, Kutzner J. Belz GG. Prophylaxis of mucositis and dry mouth after head and neck radiotherapy. A new treatment. Krankenhauspharmazie 2002;23(5):193-8. Grotz KA, Wustenberg P, Kohnen R, Al-Nawas B, Henneicke-von Zepelin H, Bockisch A et al. Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutine in patients with head and neck cancer- a prospective, randomized, placebo-controlled, double-blind study. British Journal of Oral and Maxillofacial Surgery 2001;39(1):34-9. Gujral 1999 Gujral MS, Patnaik PM, Kaul R, Daftary GV, Parikh HK, Tamhankar CP et al. Oral enzymes preventing side effects of radiation therapy in patients with head and neck cancers. European Journal of Cancer 1999;35(Suppl 4):168 (Abs No 634).Gujral MS PPKRDGPHTCSW. Oral enzymes preventing side effects of radiation therapy in patients with head and neck cancers. European Journal of Cancer 1999+ADs-35(Suppl. 4):Page 168 Abstract +ACM-634. Gutierrez 1996 Gutierrez AR, Boizas EC, Carreras PS, Rodriguez CS, Rodriguez OA, Chicote MJV et al. Fluconazol as prophylaxis of radioinduced oral mucositis. Preliminary study [Fluconazol en la profilaxis de la mucositis oral radioinducida. Estudio preliminar]. Oncologia 1996;19(6):56-9.Gutierrez AR BE, Carreras PS, Rodriguez CS, Rodriguez OA, Chicote MJV, Palacios AN, Solbes RS, Ripoll JJS. Fluconazol as prophylaxis of radioinduced oral mucositis. Preliminary study. Oncologia 1996;19(6):56-59. Hanson 1995 Hanson WR, Marks JE, Reddy SP, Simon S, Mihalo WE, Tova Y. Protection from radiation-induced oral mucositis by a mouth rinse containing the prostaglandin E1 analog, misoprostol: A placebo controlled double blind clinical trial. Advances in Experimental Medicine and Biology 1997;400B:811-8. Hanson WR, Marks JE, Reddy SP, Simon S, Mihalo WE, Tova Y. Protection from radiation-induced oral mucositis by misoprostol, a prostaglandin E(1) analog: a placebo-controlled, double-blind clinical trial. American Journal of Therapeutics 1995;2(11):850-7. Harris 1995 Harris JR, Russell NH, Hunter AE. Folinic acid mouthwashes do not reduce the degree of mucositis in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplantation 1995;15(S2):S164. Hartmann 1999 Hartmann J, von Vangerow A, Knop S, Brugger W, Fels L, Stolte H et al. A randomized trial comparing the toxicity and the treatment costs of HD-VIC plus PBSC transplantation with or without amifostine (AMI) in patients with solid tumors. European Journal of Cancer 1999;35(Suppl 4):361 (Abs No 1464).Hartmann J, von Vangerow A, Knop S, Brugger W, Fels L, Stolte H, et al. A randomized trial comparing the toxicity and the treatment costs of HD-VIC plus PBSC transplantation with or without amifostine (AMI) in patients with solid tumors. European Journal of Cancer. 1999;35(Suppl 4):361, Abstr #1464. He 2004 He XY, Hu CS, Wu YR. Radioprotective effect of amifostine in nasopharyngeal carcinoma. Acta Academiae Medicinae Shanghai 2004;31(1).He XY, Hu CS, Wu YR. Radioprotective effect of amifostine in nasopharyngeal carcinoma. Acta Academiae Medicinae Shanghai. 2004;31(1). Hickey 1982 Hickey AJ, Toth BB, Lindquist SB. Effect of intravenous hyperalimentation and oral care on the development of oral stomatitis during cancer chemotherapy. The Journal of Prosthetic Dentistry 1982;47(2):188-93. Horsley 2007 Horsley P, Bauer JD, Mazkowiack R, Gardner R, Bashford J. Palifermin improves severe mucositis, swallowing problems, nutrition impact symptoms, and length of stay in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer 2007;15(1):105-9. Howell 1983 Howell SB, Pfeifle CE, Wung WE. Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection. Cancer 1983;51(2):220-5.Howell SB PC, Wung WE. Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection. Cancer 1983;51(2):220-5. Hu 2003 Hu K, Ship JA, Harrison LB. Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/IV head and neck cancer. Seminars in Oncology 2003;30(6 Suppl 18):40-8.Hu K, Ship JA, Harrison LB. Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/IV head and neck cancer. [Review] [36 refs]. Seminars in Oncology 2003; 30(6 Suppl 18):40-8. Inagaki 2006 Inagaki N. [Report on the treatment of infections complicating hematological diseases. Case 2. Two cases of deep-seated mycosis developing during chemotherapy of leukemia]. [Japanese]. Japanese Journal of Antibiotics 2007;60(5):317-8. Ito 2002 Ito A, Hanawa T, Fujii E. The preventive effect of allopurinol spray on stomatitis induced by anti-cancer drugs. Gan To Kagaku Ryoho 2002;29(4):563-7. Jebb 1995 Jebb SA, Marcus R, Elia M. A pilot study of oral glutamine supplementation in patients receiving bone marrow transplants. Clinical Nutrition 1995;14:162-5. Johnson 2002 Johnson DJ, Scott CB, Marks JE, Seay TE, Atkins JN, Berk LB et al. Assessment of quality of life and oral function of patients participating in a phase II study of radioprotection of oral and pharyngeal mucosa by the prostaglandin E(1) analog misoprostol (RTOG 96-07). International Journal or Radiation Oncology Biology and Physics 2002;54(5):1455-9.Johnson DJ, Scott CB, Marks JE, Seay TE, Atkins JN, Berk LB, Meoz RT, Wheeler JA.Assessment of quality of life and oral function of patients participating in a phase II study of radioprotection of oral and pharyngeal mucosa by the prostaglandin E(1) analog misoprostol (RTOG 96-07). Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1455-9. Kante 1995 Kante V. Comparative study of two prophylactic regimes for the prevention of mucositis in autologous bone marrow transplants. Bone Marrow Transplantation 1995;15:253.Kante V, et al. Comparative study of two prophylactic regimes for the prevention of mucositis in autologous bone marrow transplants [abstract]. Bone-Marrow-Transplant. 1995;15:253. Karthaus 1998 Karthaus M, Rosenthal C, Huebner G, Paul H, Elser C, Hertenstein B et al. Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial. Bone Marrow Transplantation 1998;22(8):781-5.Karthaus M, Rosenthal C, Huebner G, Paul H, Elser C, Hertenstein B et al. Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial. Bone Marrow Transplant 1998;22:781-5. Kasten-Sportes 2003 Kasten-Sportes C. Randomized study of acupuncture for mucositis-related pain secondary to high-dose chemotherapy in patients undergoing hematopoietic stem cell transplantation. PDQ (NCI-03-C-0125) 2003.Kasten-Sportes C. Randomized Study of Acupuncture for Mucositis-Related Pain Secondary to High-Dose Chemotherapy in Patients Undergoing Hematopoietic Stem Cell Transplantation. PDQ, NCI-03-C-0125. 2003 2003. Kenny 1990 Kenny SA. Effect of two oral care protocols on the incidence of stomatitis in hematology patients. Cancer Nursing 1990;13(6):345-53. Klocke 2006 Klocke J, Cannon M, Gissinger D, Bayer R, Devoe C, John V. Prevention of mucositis in auto BMT/stem cell transplant patients. Oncology Nursing Forum 2006;33(2):454.Klocke J, Cannon M, Gissinger D, Bayer R, Devoe C, John V. Prevention of mucositis in auto BMT/stem cell transplant patients. Oncology Nursing Forum. 2006;33(2):454. Kokkonen 2002 Kokkonen J, Mottonen M, Karttunen TJ, Lanning M. Mucosal pathology of the upper gastrointestinal tract associated with intensive chemotherapy in children: Vitamin a supplements do not prevent lesions. Pediatric Hematology and Oncology 2002;19(3):181-92.Kokkonen JMMKTLM. Mucosal pathology of the upper gastrointestinal tract associated with intensive chemotherapy in children: Vitamin a supplements do not prevent lesions. Pediatric Hematology +ACY- Oncology 2002+ADs- Vol 19(3): 181-192. Kuhn 2009 Kuhn A, Porto FA, Miraglia P, Brunetto AL. Low-level infrared laser therapy in chemotherapy-induced oral mucositis: a randomized placebo-controlled trial in children. Journal of Pediatric Hematology/Oncology 2009;31(1):33-7. Kuriakose 2002 Kuriakose P, Gandara DR, Perez EA. Phase I trial of edatrexate in advanced breast and other cancers.[comment]. Cancer Investigation 2002;20(4):473-9. Labar 1990 Labar B, Pavletic Z, Bogdanic V, Nemet D, Aurer I, Jakie J. Prostaglandin E2 for prevention of oral mucositis in patients with leukaemia undergoing bone marrow transplantation: a radomized double-blind clinical trial. Experimental Hematology 1990;18:700. Labbate 2003 Labbate R, Lehn CN, Denardin OVP. Effects of chlorhexidine mouthwash on radiation induced mucosistis in head and neck cancer. Revista Brasileira de Otorrinolaringologia 2003;69(3):349-54.Labbate R, Lehn CN, Denardin OVP. Effects of chlorhexidine mouthwash on radiation induced mucosistis in head and neck cancer. Revista Brasileira de Otorrinolaringologia. 2003;69(3):349-54. Leong 1995 Leong L, Sakurai C, Sebastian W, Shaw N, Grant E, Grant M et al. Phase III trial assessing the use of oral thymidine (THY) for prevention of fluorouracil (5-FU)-induced mucositis. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology. Vol. 14. 1995:A334. Levendag 1998 Lavendag PC, Wijers OB, Harms RE, Schmitz PIM, Wilms BE, Visch LL. Mucositis prevention by selective elimination of oral flora in irradiated cancers of the head and neck: a prospective randomized study. Radiotherapy Oncology 1998;48:S10. Levi 1997 Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997;350(9079):681-6.Levi F ZR, Misset J-L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997+ADs-350(9079):681-686. Lievens 1998 Lievens Y, Haustermans K, van den Weyngaert D, van den Bogaert W, Scalliet P, Hutsebaut L et al. Does sucralfate reduce the acute side-effects in head and neck cancer treated with radiotherapy? A double-blind randomized trial. Radiotherapy Oncology 1998;47(2):149-53. Lin 2006 Lin J, Wang X, Fan Z. A study on quantizing evaluation on stomatitis of malignant tumor patients undergoing large dose of chemotherapy [Chinese]. Chinese Nursing Research 2008;22(2A):328-9. Lin LC, Que J, Lin LK, Lin FC. Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study. International Journal of Radiation Oncology, Biology, Physics 2006;65(3):745-50.Lin LC, Que J, Lin LK, Lin FC. Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study. International Journal of Radiation Oncology, Biology, Physics. 2006;65(3):745-50. Lopez 1994 Lopez I, Goudou C, Ribrag V, Sauvage C, Hazebroucq G, Dreyfus F. Traitement des mucites par la vitamine E lors de l'administration d'anti-neoplasiques neutropeniants. Annuals Medicine Interne 1994;145(6):405-8. Loprinzi 1997 Loprinzi CL, Ghosh C, Camoriano J, Sloan J, Steen PD, Michalak JC et al. Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy. Journal of Clinical Oncology 1997;15(3):1235-8. Lorusso 2003 Lorusso D, Ferrandina G, Greggi S, Gadducci A, Pignata S, Tateo S. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Annals of Oncology 2003;14(7):1086-93.Lorusso D FG, Greggi S, Gadducci A, Pignata S, Tateo S, Biamonte R, Manzione L, Di Vagno G, Ferrau' F, Scambia G, Multicenter Italian Trials in Ovarian Cancer invesitgators. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Annals of Oncology 2003;14(7):1086-93. Lozada 1998 Lozada-Nur F, Schoelch M, Fu K, Muscoplat C, Trivedi M, Smith C et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. In: Proceedings of the Annual Meeting of the Society of Clinical Oncology. 1998:1541. Maddocks-Jennings 2009 Maddocks-Jennings W, Wilkinson JM, Cavanagh HM, Shillington D. Evaluating the effects of the essential oils Leptospermum scoparium (manuka) and Kunzea ericoides (kanuka) on radiotherapy induced mucositis: a randomized, placebo controlled feasibility study. European Journal of Oncology Nursing 2009;13(2):87-93. Madero 1999 Madero L, Diaz MA, Ortega JJ, Olive T, Martinez A, Badell I et al. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates engraftment kinetics after allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia. Haematologica 1999;84(2):133-7.Madero L DM, Ortega JJ, Olive T, Martinez A, Badell I, Munoz A, Gomez P. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates engraftment kinetics after allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia. Haematologica 1999;84(2):133-7. Mahmoud 1996 Mahmoud HK SE, Kamel M, El HMA, Nassar A. Influence of folinic acid rescue on methotrexate-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation. Tumor Diagnostik Und Therapie 1996;17(1):18-21.Mahmoud HK SE, Kamel M, El HMA, Nassar A. Influence of folinic acid rescue on methotrexate-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation. Tumor Diagnostik Und Therapie. 1996+ADs-17(1):18-21. Malaker 1991 Malaker K, Anderson BJ, Beecroft WA, Hodson DI. Management of oral mucosal dysplasia with beta-carotene retinoic acid: a pilot cross-over study. Cancer Detection and Prevention 1991;15(5):335-40.Malaker K, Anderson BJ, Beecroft WA, Hodson DI. Management of oral mucosal dysplasia with beta-carotene retinoic acid: a pilot cross-over study. Cancer Detection +ACY- Prevention 1991+ADs-15(5):335-40. Mantovani 2003 Mantovani G, Massa E, Astara G, Murgia V, Gramignano G, Lusso MR et al. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs. Oncology Reports 2003;10(1):197-206.Mantovani G, Massa E, Astara G, Murgia V, Gramignano G, Lusso MR, et al. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs. Oncology Reports 2003+ADs- 10(1):197-206. Marcial 1994 Marcial F, Schubert M, Niccoli-Filho WD, Lloid ME, Kelly J, Franquin JC et al. A phase I/II nonblinded randomized trial to determine the efficacy of low-energy laser to prevent oral mucositis resulting from conditioning regimens for bone marrow transplantation. Oral Surgery, Oral Medicine, Oral Pathology 1994;78(6):738. Martin 2006 Martin M, Lluch A, Segui MA, Ruiz A, Ramos M, Adrover E, et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.[see comment]. Annals of Oncology 2006;17(8):1205-12. Masucci 2005 Masucci G, Broman P, Kelly C, Lindahl S, Malmberg L, Reizenstein J et al. Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy: a multicenter open randomized phase III study. Medical Oncology 2005;22(3):247-56.Masucci G, Broman P, Kelly C, Lindahl S, Malmberg L, Reizenstein J, et al. Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy: a multicenter open randomized phase III study. Medical Oncology. 2005;22(3):247-56. Matejka 1990 Matejka M, Nell A, Kment G, Schein A, Leukauf M, Porteder H et al. Local benefit of prostaglandin E2 in radiochemotherapy-induced oral mucositis. British Journal of Oral Maxillofacial Surgery 1990;28(2):89-91.Matejka M, Nell A, Kment G, Schein A, Leukauf M, Porteder H, Mailath G, Sinzinger H.Local benefit of prostaglandin E2 in radiochemotherapy-induced oral mucositis. Br J Oral Maxillofac Surg. 1990 Apr;28(2):89-91. McGaw 1985 McGaw WT, Belch A. Oral complications of acute leukemia: prophylactic impact of a chlorhexidine mouthrinse regimen. Oral Surgery, Oral Medicine, Oral Pathology 1985;60(3):275-80.McGaw WT, Belch A. Oral complications of acute leukemia: prophylactic impact of a chlorhexidine mouthrinse regimen. Oral Surg Oral Med Oral Pathol 1985;60:275-80. McIlroy 1996 McIlroy P. Radiation mucositis: a new approach to prevention and treatment. European Journal of Cancer Care 1996;5(3):153-8. Merte 1999 Merte H, Wied R, Engenhart-Cabillic R. Der effekt von immunglobulinen in der behandlung der radiogenen dermatitis und mukositis bei patienten mit hals-nasen und rachentumoren. Strahlentherapy und Onkologie 1999;175(1):135. Mills 1995 Mills W, Strang J, Goldstone AH, Linch DC. Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma. Leukemia &amp;amp; Lymphoma 1995;17(3-4):263-70. Minn 1999 Minn HR, Makkonen TA, Jekunen A, Vilja P, Tuominen J, Joensuu H. Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study. International Journal of Radiation Oncology Biology Physics 1999;45(3 Suppl):239.Minn HR, Makkonen TA, Jekunen A, Vilja P, Tuominen J, Joensuu H. Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study [abstract]. International Journal of Radiation Oncology Biology Physics. 1999;45(3 Suppl):239. Mohanta 1992 Mohanta PK, Singhal RM, Jindel R, Sharma RL, Julka PK. Hydroxyurea as a radiation sensitizer in malignancies of the head anc neck. Indian Journal of Radiology and Imaging 1992;2(2):143-6. Mok 2007 Mok TSK, Yeo W, Johnson PJ, Hui P, Ho WM, Lam KC, et al. A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. Annals of Oncology 2007;18(4):768-74. Mori 2006 Mori T, Yamazaki R, Aisa Y, Nakazato T, Kudo M, Yashima T, et al. Brief oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. Supportive Care in Cancer 2006;14(4):392-5. Nicholl 1995 Nicholl TA, Nimmo CR, Shepherd JD, Phillips P, Jewweson PJ. Amphotericin B infusion-related toxicity: comparison of two- and four-hour infusions. Annals of Pharmacotherapy 1995;29(11):1081-7. Niibe 1985b Niibe H, Takahashi I, Mitsuhashi N, Miyaishi K, Itoh J, Maehara Y et al. An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study.2 Abdominal and pelvic tumours. Nippon Gan Chiryo Gakkai Shi 1985;20(5):994-1001. Nikoletti 2005 Nikoletti S, Hyde S, Shaw T, Myers H, Kristjanson LJ. Comparison of plain ice and flavoured ice for preventing oral mucositis associated with the use of 5 fluorouracil. Journal of Clinical Nursing 2005;14(6):750-3. Ohnmacht 2001 Ohnmacht GA, Phan GQ, Mavroukakis SA, Steinberg SM, Shea YR, Witebsky FG et al. A prospective, randomized, double-blind, placebo-controlled trial evaluating the effect of nystatin on the development of oral irritation in patients receiving high-dose intravenous interleukin-2. Journal of Immunotherapy 2001;24(2):188-92.Ohnmacht GA PG, Mavroukakis SA, Steinberg SM, Shea YR, Witebsky FG, McIntyre LS, Goodwin RS, Muehlbauer PM, Morton KE, Rogers-Freezer LJ, Seipp CA, Rosenberg SA, Marincola FM. A prospective, randomized, double-blind, placebo-controlled trial evaluating the effect of nystatin on the development of oral irritation in patients receiving high-dose intravenous interleukin-2. Journal of Immunotherapy 2001;24(2):188-92. Okuno 1997 Okuno SH, Foote RL, Loprinzi CL, Gulavita S, Sloan JA, Earle J et al. A randomized trial of a nonabsorbable antibiotic lozenge given to alleviate radiation-induced mucositis. Cancer 1997;79(1):2193-9. Okuno 1998 Okuno SH, Swan L, Ebbert C. Phase III placebo-controlled clinical trial evaluation of glutamine for decreasing mucositis in patients receiving 5 FU (Fluorouracil)-based chemotherapy. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1998:256. Okutomi 2000 Okutomi T, Kato Y, Ichihara H, Hyodo I, Fujitsuka H, Yasuda S et al. [Clinical effects of adjuvant therapy using Z-100 (Ancer 20 injection) for oral cancer--prevention of stomatitis and hematopoietic impairment]. Gan To Kagaku Ryoho 2000;27(1):65-71.Okutomi T, Kato Y, Ichihara H, Hyodo I, Fujitsuka H, Yasuda S, Tatematsu N. [Clinical effects of adjuvant therapy using Z-100 (Ancer 20 injection) for oral cancer--prevention of stomatitis and hematopoietic impairment] Gan To Kagaku Ryoho. 2000 Jan;27(1):65-71. Papadeas 2007 Papadeas E, Naxakis S, Riga M, Kalofonos Ch. Prevention of 5-fluorouracil-related stomatitis by oral cryotherapy: a randomized controlled study. European Journal Oncology Nursing 2007;1:60-5. Papas 1984 Papas A, Johansen E. Prevention of mucositis in oncology patients undegoing radiation therapy. Journal of Dental Research 1984;63(Special Issue March):311 (Abs No 1267).Papas A, E J. Prevention of Mucositis in Oncology Patients Undegoing Radiation Therapy (JDR Abstract). J-Dent-Res 1984;63(Special Issue March):311 (Abs 1267). Peters 1993 Peters E, Antczak-Bouckoms A, Burdick E. Meta-analysis of chlorhexidine in the prevention of mucositis from chemotherapy. Journal of Dental Research 1993;Special Issue(259):1249.Peters E A-BA, Burdick E. Meta-Analysis of Chlorhexidine in the Prevention of Mucositis from Chemotherapy (IADR Abstract). Journal of Dental Research 1993+ADs-72:259 (Abs No 1249). Peterson 2003 Peterson DE, Petit RG. Phase III study: AES-14 in chemotherapy patients at risk for mucositis. In: Proceedings of the American Society of Clinical Oncology. 2003:725.Peterson DE, Petit RG. Phase III study: AES-14 in chemotherapy patients at risk for mucositis [abstract]. Proceedings of the American Society of Clinical Oncology. 2003:725. Petit 2001 Petit RG, II, French C. Phase III clinical trial design considerations for oral treatments of chemotherapy - induced mucositis: AES-14 (uptake-facilitated L-glutamine) pivotal studies [abstract]. Proceedings of the American Society of Clinical Oncology 2001;20 (Pt 2):301b, Abstract 2954. Pfeiffer 1989 Pfeiffer P, May O. Sucralfate prophylaxis of chemotherapy-induced stomatitis. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1989. Pfeiffer 1989a Pfeiffer P, Hansen SO, Madsen EL, May O. Sucralfate prophylaxis of chemotherapy-induced stomatitis [abstract]. Proceedings of the American Society of Clinical Oncology 1989;8:171, Abstract 665. Phillips 2002 Phillips II, GL. The potential of amifostine in high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Seminars in Oncology 2002;29(6 Supp 19):53-6. Piccirillo 2003 Piccirillo N, De Matteis S, Laurenti L, Chiusolo P, Sora F, Pittiruti M et al. Glutamine-enriched parenteral nutrition after autologous peripheral blood stem cell transplantation: effects on immune reconstitution and mucositis. Haematologica 2003;88(2):192-200. Porta 1994 Porta C, Moroni M, Nastasi G, Montecucco CM, Caporali R, Notario A. Allopurinol mouthwashes can reduce oral mucositis in chemotherapy-treated patients. Annals of Oncology 1994;5(Suppl 8):208.Porta C, Moroni M, Nastasi G, Montecucco CM, Caporali R, Notario A. Allopurinol mouthwashes can reduce oral mucositis in chemotherapy-treated patients. Annals of Oncology. 1994;5(Suppl 8):208. Pouli 1999 Pouli A, Nikiforakis E. A prospective randomized trial of GM-CFS mouthwash versus sodium bicarbonate mouthwash in the treatment of stomatitis following allogeneic bone marrow transplantation. Bone Marrow Transplantation 1999;23:S166. Prada 1985 Prada A, Lozza L, Moglia D, Sala L, Chiesa F. Effects of benzydamine on radio-polychemotherapeutic mucositis of the oral cavity. International Journal of Tissue Reaction 1985;7(3):237-9. Pyrhonen 1995 Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. British Journal of Cancer 1995;71(3):587-91.Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. British Journal of Cancer. 1996;71(3):587-91. Pytlik 2002 Pytlik R, Benes P, Patorkova M, Chocenska E, Gregora E, Prochazka B et al. Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo controlled study. Bone Marrow Transplantation 2002;30(12):953-61.Pytlik R, Benes P, Patorkova M, Chocenska E, Gregora E, Prochazka B, et al. Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo controlled study. Bone Marrow Transplantation 2002+ADs- 30(12):953-61. Rabinovitch 2006 Rabinovitch R, Grant B, Berkey BA, Raben D, Ang KK, Fu KK et al. Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: a secondary analysis of RTOG trial 90-03. Head &amp;amp; Neck 2006;28(4):287-96.Rabinovitch R, Grant B, Berkey BA, Raben D, Ang KK, Fu KK, et al. Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: a secondary analysis of RTOG trial 90-03. Head &amp;amp; Neck. 2006;28(4):287-96. Rades 2004 Rades D, Fehlauer F, Bajrovic A, Mahlmann B, Richter E, Alberti W. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiotherapy and Oncology 2004;70(3):261-4.Rades D, Fehlauer F, Bajrovic A, Mahlmann B, Richter E, Alberti W. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.[see comment]. Radiotherapy &amp;amp; Oncology. 2004;70(3):261-4. Radmard 2002 Radmard A, Niewohner-Desbordes U, Wagner W. [rhGM-CSF in the treatment of radiogenic mucositis: prospective randomised phase-II study on the effectivity and tolerance of rhGM-CSF in the treatment of oral mucositis under radiotherapy of head and neck tumors]. Strahlentherapie und Onkologie 2002;178(Suppl 1):24.Radmard A, Niewohner-Desbordes U, Wagner W. [ rhGM-CSF in the treatment of radiogenic mucositis: prospective randomised phase-II study on the effectivity and tolerance of rhGM-CSF in the treatment of oral mucositis under radiotherapy of head and neck tumors. ]. Strahlentherapie und Onkologie. 2002;178(Sondernr 1):24. Raether 1989 Raether D, Walker PO, Bostrum B, Weisdorf D. Effectiveness of oral chlorhexidine for reducing stomatitis in a pediatric bone marrow transplant population. Pediatric Dentistry 1989;11(1):37-42.Raether D, Walker PO, Bostrum B, Weisdorf D. Effectiveness of oral chlorhexidine for reducing stomatitis in a pediatric bone marrow transplant population. Pediatric Dentistry 1989;11:37-42. Robustelli 1999 Robustelli della Cuna FS, Ucci G, Cuomo AM, Goglio AM. Galenic preparation for the prophylaxsis of oral mucositis induced by 5-fluororacil continous infusion. Supportive Care in Cancer 1999;7 Suppl:132 (Abs No P-67).Robustelli della Cuna FS, Ucci G, Cuomo AM, Goglio AM. Galenic preparation for the prophylaxsis of oral mucositis induced by 5-fluororacil continous infusion. Supportive Care in Cancer. 1999;7 Suppl.(Abstr P-67):132. Rocci 2005 Rocci L, Vincenzi B, Santini D, Tonini G. [Timing of 5-fluorouracile infusion: a randomized clinical trial]. International Nursing Perspectives 2005;5(2):53-60.Rocci L, Vincenzi B, Santini D, Tonini G. Timing of 5-fluorouracile infusion: a randomized clinical trial [Italian]. International Nursing Perspectives. 2005;5(2):53-60. (32 ref). Rojas 2001 Rojas de Morales T, Zambrano O, Rivera L, Navas R, Chaparro N, Bernardonni C et al. Oral-disease prevention in children with cancer: testing preventive protocol effectiveness. Medicina Oral 2001;6(5):326-34.Rojas de Morales T ZO, Rivera L, Navas R, Chaparro N, Bernardonni C, Rivera F, Fonseca N, Tirado DM. Oral-disease prevention in children with cancer: testing preventive protocol effectiveness. Medicina Oral 2001+ADs-6(5):326-34. Rutkauskas 1993 Rutkauskas JS, Davis JW. Effects of chlorhexidine during immunosuppressive chemotherapy: A preliminary report. Oral Surgery, Oral Medicine, Oral Pathology 1993;76(4):441-8.Rutkausas JS, Davis JW. Effects of chlorhexidine during immunosuppressive chemotherapy: A preliminary report. Oral Surg Oral Med Oral Path 1993;76:441-8. Ryu 2007 Ryu JK, Swann S, LeVeque F, Scarantino CW, Johnson D, Chen A, et al. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901. International Journal of Radiation Oncology, Biology, Physics 2007;67(3):643-50. Samaranayake 1988 Samaranayake LP, Robertson AG, MacFarlane TW, Hunter IP, MacFarlane G, Soutar DS et al. The effect of chlorhexidine and benzydamine mouthwashes on mucositis induced by therapeutic irradiation. Clinical Radiology 1988;39(3):291-4. Sato 1997 Sato A, Kumagai S, Sakaki K, Morikawa H, Song ST, Mori S. [Inhibition of 5-fluorouracil-cisplatin-induced stomatitis by oral cryotherapy: use of an ice-bar containing fibrinolysin and deoxyribonuclease comiben (Elase)]. Gan to Kagaku Ryoho [Japanese Journal of Cancer &amp;amp; Chemotherapy] 1997;24(9):1135-9. Sato 2006 Sato A, Saisho-Hattori T, Koizumi Y, Minegishi M, Iinuma K, Imaizumi M. Prophylaxis of mucosal toxicity by oral propantheline and cryotherapy in children with malignancies undergoing myeloablative chemo-radiotherapy. Tohoku Journal of Experimental Medicine 2006;210(4):315-20. Scarantino 2001a Scarantino CW, LeVeque FG, Scott CB, White RL, Rotman M, Hodson DI et al. A phase III study of concomitant oral pilocarpine to reduce hypo-salivation and mucositis assocated with curative radiation therapy (RT) in head and neck (H&amp;amp;N) cancer patients. RTOG 9709. In: Proceedings of the American Society of Clinical Oncology. 2001:(Abs No 897).Scarantino C LF, Scott C, White R, Rotman M, Hodson D, Meredith R, Foote R, Brachman D. A Phase III Study of Concomitant Oral Pilocarpine to Reduce Hypo-Salivation and Mucositis Assocated with Curative Radiation Therapy (RT) in Head and Neck (H&amp;amp;N) Cancer Patients. RTOG 9709. Proceedings of ASCO 2001. Scarantino 2001b Sadar CM, Heard R, Prathikanti R, Lau D, Danilenko D, Hunt T et al. Safety, pharmacokinetics and biological activity of rHuKGF in normal volunteers.. Growth Factors and Cytokines;Abstract 761:172. Scarantino CW, Leveque F, Scott C, White RL, Rotman M, Hodson DI et al. A Phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97-09. International Journal of Radiation Oncology, Biology, Physics 2001;51(3 Suppl 1):85-6.Scarantino CW, Leveque F, Scott C, White RL, Rotman M, Hodson DI, et al. A Phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97-09 [abstract]. International Journal of Radiation Oncology Biology Physics. 2001;51(3 Suppl 1):85-6. Schuster 2008 Schuster MW, Anaissie E, Hurd D, Bensinger W, Mason J, McCarty J, et al. Final analysis of the phase II, randomized, double-blind, placebo-controlled trial of single-dose velafermin (CG53135-05) for the prevention of oral mucositis. Journal of Supportive Oncology 2007;5(4 SUPPL. 2):58-9. Schuster MW, Shore TB, Harpel JG, Greenberg J, Jalilizeinali B, Possley S, et al. Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant. Supportive Care in Cancer 2008;16(5):477-83. Schwerkkoske 1999 Schwerkkoske J, Schwartzberg L, Weaver CH, Schwertschlag US, Goodfellow J, Berdosian CL. A phase I double-masked, placebo-controlled study to evaluate tolerability of Neumega (rhIL-11; Oprelvekin) to reduce mucositis in patients with solid tumors or lymphoma receiving high-dose chemotherapy (CT) with autologous peripheral blood stem cell reinfusion (PBSCT). In: Proceedings of the American Society of Clinical Oncology. Vol. 18. 1999:584a.Schwerkkoske J, Schwartzberg L, Weaver CH, Schwertschlag US, Goodfellow J, Berdosian CL. A phase I double-masked, placebo-controlled study to evaluate tolerability of Neumega (rhIL-11; Oprelvekin) to reduce mucositis in patients with solid tumors or lymphoma receiving high-dose chemotherapy (CT) with autologous peripheral blood stem cell reinfusion (PBSCT) [abstract]. Proceedings of the American Society of Clinical Oncology. 1999;18:584a. Schwerkoske 1999 Schwerkoske J, Schwartzberg L, Weaver CH, Schwertschlag US, Goodfellow J, Bedrosian CL. A phase 1 double-masked, placebo-controlled study to evaluate tolerability of Neumega&amp;#174; (rhIL-11; oprelvekin) to reduce mucositis in patients with solid tumors or lymphoma receiving high-dose chemotherapy (CT) with autologous peripheral blood stem cell reinfusion (PBSCT) [abstract]. Proceedings of the American Society of Clinical Oncology 1999;18:584a, Abstract 2256. Shea 2007 Shea TC, Kewalramani T, Mun Y, Jayne G, Dreiling LK. Evaluation of Single-Dose Palifermin To Reduce Oral Mucositis (OM) in Fractionated Total Body Irradiation (fTBI) and High Dose (HD) Chemotherapy with Autologous Peripheral Blood Progenitor Cell (PBPC) Transplantation [abstract]. Blood 2006;108(11 Part 1):875-6. Shea TC, Kewalramani T, Mun Y, Jayne G, Dreiling LK. Evaluation of single-dose palifermin to reduce oral mucositis in fractionated total-body irradiation and high-dose chemotherapy with autologous peripheral blood progenitor cell transplantation. Journal of Supportive Oncology 2007;5(4 SUPPL. 2):60-2. Simoes 2009 Simoes A, Eduardo FP, Luiz AC, Campos L, Sa PH, Cristofaro M, et al. Laser phototherapy as topical prophylaxis against head and neck cancer radiotherapy-induced oral mucositis: comparison between low and high/low power lasers. Lasers in Surgery &amp;amp; Medicine 2009;41(4):264-70. Spadaro 1991 Spadaro P, Buemi B, Ferraro G, Marabello G, Russi E, Pergolizzi S. Prophylaxis of chemotherapy-radiotherapy induced mucositis or oral fungal infection with vitamin E + vitamin A and Fluconazolo. European Journal of Cancer 1991;27(Suppl 2):S288. Spielberger 2001 Spielberger RT, Stiff P, Emmanouilides C, Yanovich S, Bensinger W, Hedrick E, et al. Efficacy of recombinant human keratinocyte growth factor (rHuKGF) in reducing mucositis in patients with hematologic malignancies undergoing autologous peripheral blood progenitor cell transplantation (auto-PBPCT) after radiation-based conditioning - results of a phase 2 trial [abstract]. Proceedings of the American Society of Clinical Oncology 2001;20 (Pt 1):7a, Abstract 25. Staar 2001 Staar S. Benefits and toxicities of accelerated radiochemo- versus accelerated radiotherapy in advanced head and neck cancer - Results of a German randomized study. European Journal of Cancer 2001;37(Suppl 6):38 (Abs No 126).Staar S EHRVDAFMSMVPSPSHMR. Benefits and toxicities of accelerated radiochemo- versus accelerated radiotherapy in advanced head and neck cancer - Results of a German randomized study. European Journal of Cancer. 2001 2001;37(Suppl 6):38 Abs. 126. Stokman 2004 Stokman MA, Wachters FM, Koopmans P, Burgerhof JG, Groen HJ, Spijkervet FK et al. Outcome of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis. A phase II study. Anticancer Research 2004;24(5B):3263-7.Stokman MA, Wachters FM, Koopmans P, Burgerhof JG, Groen HJ, Spijkervet FK, et al. Outcome of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis. A phase II study. Anticancer Research. 2004;24(5B):3263-7. Su 2004a Su C, Mehta V, Ravikumar L, Shah R, Pinto H, Halpern J et al. Phase II double-blind randomized study comparing oral aloe vera (AV) versus placebo to prevent radiation (RT)-related mucositis in patients with head and neck (HN) neoplasms. In: Proceedings of the Amercian Society of Clinical Oncology. 2004.Su C, Mehta, V, Ravikumar, L, Shah, R, Pinto, H, Halpern, J, Koong, A, Goffinet, D, and Le, Q-T. Phase II double-blind randomized study comparing oral aloe vera (AV) versus placebo to prevent radiation (RT)-related mucositis in patients with head and neck (HN) neoplasms. Proceedings of ASCO. 2003 2003. Su 2004b Su YB. Double-blind, randomized trial of granulocyte-colony stimulating factor (GCSF) versus (v.) placebo during postoperative radiation (RT) for advanced resectable squamous cell head and neck cancer (SCCHN): impact on mucositis. Journal of Clinical Oncology 2004;22(Suppl):14S. Suc 1999 Suc A, Gandemer V, Le Deley MC, Schmitt C, Pichard-Leandri E, French Group. Gum98: Preventing mucositis with chewing gum in children receiving chemotherapy, a multicentric trial. Supportive Care in Cancer 1999;7S:180 (Abs No P-60). Svanberg 2004 Svanberg A, &amp;#214;hrn K. Cryotherapy during chemotherapy - could it delay or alleviate the development of mucositis? Bone Marrow Transplantation 2004;33(Suppl 1):S292.Svanberg A, &amp;#214;hrn K. Cryotherapy during chemotherapy - could it delay or alleviate the development of mucositis? [abstract]. Bone Marrow Transplantation. 2004;33(Suppl 1):S292. Svanberg 2007 Svanberg A, Birgegard G, Ohrn K. Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy--a randomized controlled trial. Supportive Care in Cancer 2007;15(10):1155-61. Sykes 2004 Sykes AJ, Slevin NJ, MacDougall RH, Ironside JAD, Mais KL. Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck. Radiotherapy and Oncology 2004;71(1):81-4. Symonds 1995 Symonds RP, Thomas M, Alcock SR, Khorrami J, McEllroy P, McMuuuray A. The reduction of radiation mucositis by antibiotic pastilles: a placebo-controlled double-blind trial. European Journal Surgery Oncology 1995;21:447.Symonds RP TM, Alcock SR, and et al. The reduction of radiation mucositis by antibiotic pastilles: a placebo-controlled double-blind trial [abstract]. Eur-J-Surg-Oncol 1995;21:447. Teshima 1986 Teshima T. [Clinical evaluation of kenalog ointment for radiation mucositis of patients with head and neck cancer]. Yakuri to Chiryo (Japanese Pharmacology and Therapeutics) 1986;14(11):7163-6.Teshima T, et al. [Clinical Evaluation of Kenalog Ointment for Radiation Mucositis of Patients with Head and Neck Cancer]. Yakuri to Chiryo (Japanese Pharmacology and Therapeutics). 1986;14(11):7163-6. Thieblemont 2002 Thieblemont C, Dumontet C, Saad H, Roch N, Bouafia F, Arnaud P et al. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplantation 2002;30(11):769-75.Thieblemont C, C D, H S, N R, F B, P A, et al. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplantation 2002;30(11):769-75. Throuvalas 1995 Throuvalas N, Antonadou D, Pulizzi M, Sarris G. Evaluation of the efficacy and safety of GM-CSF in the prophylaxis of mucositis in patients with head and neck cancer treated with RT. European Journal of Cancer 1995;31(Suppl 5):S93 (Abs No 431).Throuvalas Nao. Evaluation of the efficacy and safety of GM-CSF in the prophylaxis of mucositis in patients with head and neck cancer treated with RT. European Journal of Cancer 1995;31?(Suppl 5):S93 Abs. 431. Tiemann 2006 Tiemann P, Toelg M, Ramos FM. Administration of Ratanhia-based herbal oral care products for the prophylaxis of oral mucositis in cancer chemotherapy patients: a clinical trial. Evid Based Complement Alternat Med 2007;4(3):361-6. Toubai 2003 Toubai T, Tanaka J, Fujisawa F, Kondo Y, Imamura M, Ota S et al. Effect of prophylaxis against myocosis in patients with hematological malignancy disease: efficacy of dosage of itraconazole. Japanese Journal of Antibiotics 2003;56(1):61-5.Toubai T, Tanaka J, Fujisawa F, Kondo Y, Imamura M, Ota S, et al. Effect of prophylaxis against myocosis in patients with hematological malignancy disease: efficacy of dosage of itraconazole. +AFs-Japanese+AF0-. Japanese Journal of Antibiotics 2003+ADs- 56(1):61-5. Uchiyama 2005 Uchiyama Y, Murakami S, Kakimoto N, Nakatani A, Furukawa S. Effectiveness of Cepharanthin in decreasing interruptions during radiation therapy for oral cancer. Oral Radiology 2005;21(1):41-4.Uchiyama Y, Murakami S, Kakimoto N, Nakatani A, Furukawa S. Effectiveness of Cepharanthin in decreasing interruptions during radiation therapy for oral cancer. Oral Radiology. 2005;21(1):41-4. Vacha 1999 Vacha P, Marx M, Engel A, Richter E, Feyerabend T. Side effects of postoperative radiochemotherapy with amisfostine versus radiotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial [Nebenwirkungen einer posoperativen radiochemotherapie mit amifostin versus alleiniger radiochemotherapie bei kopf-hals-tumoren. Vorlaufige ergebnisse einer prospektiv randomisierten untersuchung]. Strahlentherapie und onkologie 1999;175(S4):18-22. Vacha 2003 Vacha P, Fehlauer F, Mahlmann B, Marx M, Hinke A, Sommer K et al. Randomized phase III trial of postoperative radiochemotherapy amifostine in head and neck cancer: Is there evidence for radioprotection? Strahlentherapie und Onkologie 2003;179(6):385-9.Vacha PFFMBMMHASKREFT. Randomized phase III trial of postoperative radiochemotherapy amifostine in head and neck cancer: Is there evidence for radioprotection? Strahlentherapie und Onkologie 2003+ADs- Vol 179(6): 385-389. Valcarcel 2002a Valcarcel D, Sanz M, Sureda A, Sala M, Munoz L, Subira M et al. Topically applied recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) for oropharyngeal mucositis (OM) in stem cell transplantation recipients: a randomized double-blind placebo-controlled study. Bone Marrow Transplantation 2002;Suppl 2:S20.Valcarcel D, Sanz M, Sureda A, Sala M, Munoz L, Subira M, et al. Topically applied recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) for oropharyngeal mucositis (OM) in stem cell transplantation recipients: a randomized double-blind placebo-controlled study [abstract]. Bone Marrow Transplantation. 2002(Suppl 2):S20. Valcarcel 2002b Valcarcel D, Sanz MA Jr, Sureda A, Sala M, Munoz L, Subira M et al. Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study. Bone Marrow Transplantation 2002;29(9):783-7.Valcarcel D, Sanz MAJ, Sureda A, Sala M, Munoz L, Subira M, et al. Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study. Bone Marrow Transplantation. 2002 2002; 29(9):783-7. Valc&amp;#225;rcel 1997 Valc&amp;#225;rcel F, De la Torre A, Arag&amp;#243;n G, Lanz&amp;#243;s E, Rodr&amp;#237;guez R, Veiras C. Double-blind randomized and pilot study on the potential of thymostimulin to reduce the incidence of mucositis in head and neck cancer patients with radical radiotherapy. In: Oncolog&amp;#237;a IX Congreso Nacional de la Asociaci&amp;#243;n Espa&amp;#241;ola de Radioterapia y Oncolog&amp;#237;a. Vol. 20. 1997:161.Valc&amp;#225;rcel F, De la Torre A, Arag&amp;#243;n G, Lanz&amp;#243;s E, Rodr&amp;#237;guez R, Veiras C. Double-blind randomized and pilot study on the potential of thymostimulin to reduce the incidence of mucositis in head and neck cancr patients with radical radiotherapy. Oncolog&amp;#237;a IX Congreso Nacional de la Asociaci&amp;#243;n Espa&amp;#241;ola de Radioterapia y Oncolog&amp;#237;a. 1997;20(10 - Congreso):161. van Zaanen 1994 van Zaanen HC, van der Lelie H, Timmer JG, Furst P, Sauerwein HP. Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapy-induced toxicity. Cancer 1994;74(10):2879-84.van Zaanen HC vdLH, Timmer JG, Furst P, Sauerwein HP. Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapy-induced toxicity. Cancer 1994;74(10):2879-84. Verdi 1995 Verdi CJ, Garewal HS, Koenig LM, Vaughn B, Burkhead T. A double-blind, randomized, placebo-controlled, crossover trial of pentoxiflline for the prevention of chemotherapy-induced oral mucositis. Osomopore 1995;80(1):36-42. Vesole 1999 Vesole D, Fuchs HJ. IB-367 reduces the number of days of severe oral mucositis complicating myeloablative chemotherapy. Blood 1999;94(10 Suppl 1):154 (Abs No 675).Vesole DHaF, H. J. IB-367 reduces the number of days of severe oral mucositis complicating myeloablative chemotherapy [abstract]. Blood 1999;94(10 Suppl 1):154a. Vitello 2000 Vitello M, Cianio SG. A comparison of two mouthrinse agents used during head/neck radiation. Journal of Dental Research 2000;79(Special Issue):215 (Abs No 576). Wagner 2002 Wagner W, Radmard A, Niewohner-Desbordes U, Haus U, Matt J. rhGM-CSF in the treatment of radiotherapy induced mucositis-prospective randomized, double-blind study to investigate the feasibility and effectiveness of rhGM-CSF in patients with head and neck cancer. In: Proceedings of the American Society for Therapeutic Radiology and Oncology Meeting. 2002:311 (Abs No 2175). Wang 2002b Wang HM, Wang CS, Chen JS, Chen IH, Liao CT, Chang TC. Cisplatin, tegafur, and leucovorin: a moderately effective and minimally toxic outpatient neoadjuvant chemotherapy for locally advanced squamous cell carcinoma of the head and neck. Cancer 2002;94(11):2989-95. Ward 2007 Ward E, Smith M, Henderson M, Reid U, Lewis I, Kinsey S, et al. The effect of high-dose enteral glutamine on the incidence and severity of mucositis in paediatric oncology patients. Eur J Clin Nutr 2007. Warde 2002 Warde P, O'Sullivan B, Aslanidis J, Kroll B, Lockwood G, Waldron J et al. A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. International Journal of Radiation Oncology Biology and Physics 2002;54(1):9-13.Warde P, O'Sullivan, B, Aslanidis, J, Kroll, B, Lockwood, G, Waldron, J, Payne, D, Bayley, A, Ringash, J, Kim, J, Liu, F, Maxymiw, W, Sprague, S, and Cummings, B. A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002+ADs-54(1):9-13. Weisdorf 1989 Weisdorf DJ, Bostrom B, Raether D, Mattingly M, Walker P, Pihlstrom B et al. Oropharyngeal mucositis complicating bone marrow transplantation: prognostic factors and the effect of chlorhexidine mouthrinse. Bone Marrow Transplantation 1989;4(1):89-95.Weisdorf DJ, Bostrom B, Raether D, Mattingly M, Walker P, Pihlstrom B et al. Oropharyngeal mucostitis complicating bone marrow transplantation: prognostic factors and the effect of chlorhexidine mouthrinse. Bone Marrow Transplant 1989;4:89-95. Weiss 1990 Weiss GR, Green S, Hannigan EV, Boutselis JG, Surwit EA, Wallace DL et al. A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial. Gynecologic Oncology 1990;37(3):354-8.Weiss GR GS, Hannigan EV, Boutselis JG, Surwit EA, Wallace DL, Alberts DS. A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial. Gynecologic Oncology 1990;37(3):354-8. Whelan 2002 Whelan HT, Connelly JF, Hodgson BD, Barbeau L, Post AC, Bullard G et al. NASA light-emitting diodes for the prevention of oral mucositis in pediatric bone marrow transplant patients. Journal of Clinical Laser Medicine &amp;amp; Surgery 2002;20(6):319-24. Whelan 2004 Whelan H. Phase II randomized study of NASA-developed light-emitting diode therapy for the prevention of oral mucositis in children receiving a myeloablative conditioning regimen comprising chemotherapy with or without radiotherapy followed by first allogeneic bone marrow transplantation. http://www.clinicaltrials.gov (accessed 2003).Whelan H. Phase II Randomized Study of NASA-Developed Light-Emitting Diode Therapy For the Prevention of Oral Mucositis in Children Receiving a Myeloablative Conditioning Regimen Comprising Chemotherapy With or Without Radiotherapy Followed By First Allogeneic Bone Marrow Transplantation. National Institutes of Health, ClinicalTrials.Gov [http://www.clinicaltrials.gov] 2003. Wollina 2002 Wollina U, Christen N, Kostler E, Schorcht J. On prophylaxis and treatment of radiation-induced dermatitis and mucositis. Zeitschrift fur Hautkrankheiten 2002;77(9):418-23. Wymenga 1999a Wymenga AN, van der Graaf WT, Hofstra LS, Timens W, Spijkervet FK, Hospers GAP et al. TGF-b3 mouthwashes aimed at prevention of chemotherapy induced mucositis, a phase-I study. Supportive Care in Cancer 1999;7:168. Wymenga 1999b Wymenga AN, van der Graaf WT, Hofstra LS, Spijkervet FK, Timens W, Timmer-Bosscha H et al. Phase I study of transforming growth factor-beta3 mouthwashes for prevention of chemotherapy-induced mucositis. Clinical Cancer Research 1999;5(6):1363-8.Wymenga AN, van der Graaf WT, Hofstra LS, Spijkervet FK, Timens W, Timmer-Bosscha H, Sluiter WJ, van Buuren AH, Mulder NH, de Vries EG.Phase I study of transforming growth factor-beta3 mouthwashes for prevention of chemotherapy-induced mucositis. Clin Cancer Res. 1999 Jun;5(6):1363-8. Yokomizo 2004 Yokomizo H, Yoshimatsu K, Hashimoto M, Ishibashi K, Umehara A, Yoshida K et al. Prophylactic efficacy of allopurinol ice ball for leucovorin/5-fluorouracil therapy-induced stomatitis. Anticancer Research 2004;24(2C):1131-4.Yokomizo H, Yoshimatsu K, Hashimoto M, Ishibashi K, Umehara A, Yoshida K, et al. Prophylactic efficacy of allopurinol ice ball for leucovorin/5-fluorouracil therapy-induced stomatitis. Anticancer Research. 2004;24(2C):1131-4. Zalcberg 1995 Zalcberg J, Cunningham D, Rath U, Olver I, Kerr D, van Cutsem E et al. 'Tomudex' (ZD1694) has a higher response rate, significantly less leucopenia and mucositis and a simpler dosing regimen than 5-Fluorouracil (5-FU) and leucovorin (LV) for advanced colorectal cancer (CRC): first results of a phase III study. European Journal of Cancer 1995;31f:S146 (Abs No 701). Studies awaiting classification Ongoing studies Haddad 2003 Haddad R, Wirth L, Costello R, Weeks L, Posner M. Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. Seminars in Oncology 2003;30(6 Suppl 18):84-8.Haddad R, Wirth L, Costello R, Weeks L, Posner M. Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. Seminars in Oncology 2003; 30(6 Suppl 18):84-8. National 2008 National Cancer I. Phase III comparison of oral capsaicin lozenge versus placebo lozenge for radiation-induced mucositis [completed]. ClinicalTrials.gov [accessed 31 Jul 2008] 2008:ClinicalTrials.gov ID: NCT00003610. National 2008a National Cancer I. A phase III study to test the efficacy and safety of GM-CSF to reduce the severity and duration of mucosal Injury and pain (mucositis) associated with curative radiation therapy in head and neck cancer patients [completed]. ClinicalTrials.gov [accessed 31 Jul 2008] 2008:ClinicalTrials.gov ID: NCT00008398. Other references Additional references Andreassen 2003 Barasch 2003 Begg 1996 Bellm 2002 Chang 2003 Clarkson 2004 Clarkson 2007a Clarkson 2007b De Pauw 1997 Denning 1992 Duncan 2003 Elbourne 2002 Gotzsche 2002 J Briggs Inst 1998 Kowanko 1998 Lortholary 1997 McGuire 2004 Meunier 1994 Moher 2001 Rubenstein 2004 Savarese 2003 Sonis 2004 Stevens 1995 Stokman 2006 Sunderland 2001 Symonds 1998 Verdi 1993 White 1993 Worthington 2004a Worthington 2004b Worthington 2007 Wright 2003 Other published versions of this review Clarkson 2000 Clarkson 2003a Worthington 2006 Classification pending references Data and analyses 1 Acyclovir versus placebo 1.1 Mucositis (absent versus present) 2 Allopurinol versus placebo/no treatment 2.1 Mucositis (absent versus present) 2.2 Mucositis (0-1 versus 2+) 2.3 Mucositis (0-2 versus 3+) 2.4 Mucositis (absent versus present) 2.5 Mucositis (0-1 versus 2+) 2.6 Mucositis (0-2 versus 3+) 3 Aloe vera versus placebo 3.1 Mucositis (0-1 versus 2+) 4 Amifostine versus placebo/no treatment 4.1 Mucositis (absent versus present) 4.2 Mucositis (0-1 versus 2+) 4.3 Mucositis (0-2 versus 3+) 4.4 Survival at 24 months 4.5 Recurrence at 18 months after cancer treatment 4.6 Incomplete response to radiotherapy 4.7 Delay to radiotherapy 4.8 Hypotension 4.9 Nausea 4.10 Vomiting 5 Antibiotic pastille or paste versus placebo/no treatment 5.1 Mucositis (absent versus present) 5.2 Mucositis (0-1 versus 2+) 5.3 Mucositis (0-2 versus 3+) 6 Benzydamine versus placebo 6.1 Mucositis (absent versus present) 6.3 Mucositis (0-2 versus 3+) 7 Beta carotene versus control 7.1 Mucositis (0-2 versus 3+) 8 Calcium phosphate versus placebo 8.1 Mucositis (absent versus present) 8.2 Mucositis (0-1 versus 2+) 8.3 Mucositis (0-2 versus 3+) 9 Chewing gum versus no chewing gum 9.1 Mucositis (absent versus present) 9.2 Mucositis (0-2 versus 3+) 10 Camomile versus placebo 10.1 Mucositis (absent versus present) 10.2 Mucositis (0-1 versus 2+) 10.3 Mucositis (0-2 versus 3+) 11 Chinese medicine versus control 11.1 Mucositis (absent versus present) 11.2 Mucositis (0-1 versus 2+) 11.3 Mucositis (0-2 versus 3+) 12 Chlorhexidine versus placebo/no treatment 12.1 Mucositis (absent versus present) 12.2 Mucositis (0-1 versus 2+) 12.3 Mucositis (0-2 versus 3+) 12.4 Mucositis (absent versus present) 12.5 Mucositis (0-1 versus 2+) 12.6 Mucositis (0-2 versus 3+) 13 Chlorhexidine versus cryotherapy 13.1 Mucositis (absent versus present) 13.2 Mucositis (0-1 versus 2+) 13.3 Mucositis (0-2 versus 3+) 14 Cryotherapy versus no treatment 14.1 Mucositis (absent versus present) 14.2 Mucositis (0-1 versus 2+) 14.3 Mucositis (0-2 versus 3+) 14.4 Mucositis (absent versus present) 14.5 Mucositis (0-1 versus 2+) 14.6 Mucositis (0-2 versus 3+) 15 Cryotherapy 30 min versus 60 min 15.1 Mucositis (absent versus present) 15.2 Mucositis (0-1 versus 2+) 15.3 Mucositis (0-2 versus 3+) 16 Etoposide: bolus versus continuous 16.1 Mucositis (absent versus present) 16.2 Mucositis (0-1 versus 2+) 16.3 Mucositis (0-2 versus 3+) 17 Folinic acid versus no treatment 17.1 Mucositis (absent versus present) 17.2 Mucositis (0-1 versus 2+) 17.3 Mucositis (0-2 versus 3+) 18 Glutamine versus placebo 18.1 Mucositis (absent versus present) 18.2 Mucositis (0-1 versus 2+) 18.3 Mucositis (0-2 versus 3+) 18.4 Mucositis (absent versus present) 18.5 Mucositis (0-1 versus 2+) 18.6 Mucositis (0-2 versus 3+) 19 G-CSF versus no treatment 19.1 Mucositis (absent versus present) 19.2 Mucositis (0-1 versus 2+) 19.3 Mucositis (0-2 versus 3+) 20 GM-CSF versus no treatment 20.1 Mucositis (absent versus present) 20.2 Mucositis (0-1 versus 2+) 20.3 Mucositis (0-2 versus 3+) 21 GM-CFS versus sucralfate 21.1 Mucositis (0-1 versus 2+) 21.2 Mucositis (0-2 versus 3+) 22 Histamine gel versus placebo 22.1 Mucositis (absent versus present) 22.2 Mucositis (0-2 versus 3+) 23 Honey versus control 23.1 Mucositis (absent versus present) 23.2 Mucositis (0-1 versus 2+) 23.3 Mucositis (0-2 versus 3+) 24 Hydrolytic enzymes versus no treatment 24.1 Mucositis (absent versus present) 24.2 Mucositis (0-1 versus 2+) 24.3 Mucositis (0-2 versus 3+) 25 Indomethacin versus placebo 25.1 Mucositis (0-1 versus 2+) 26 Iseganan versus placebo 26.1 Mucositis (absent versus present) 26.2 Mucositis (0-1 versus 2+) 26.3 Mucositis (0-2 versus 3+) 27 Keratinocyte GF versus placebo 27.1 Mucositis (absent versus present) 27.2 Mucositis (0-1 versus 2+) 27.3 Mucositis (0-2 versus 3+) 28 Keratinocyte: 50 mg versus 25 mg 28.1 Mucositis (0-1 versus 2+) 28.2 Mucositis (0-2 versus 3+) 29 Laser versus no treatment 29.2 Mucositis (absent versus present) 29.3 Mucositis (0-1 versus 2+) 29.4 Mucositis (0-2 versus 3+) 30 Laser versus povidine 30.1 Mucositis (0-1 versus 2+) 30.2 Mucositis (0-2 versus 3+) 31 Misonidazole versus control 31.1 Mucositis (absent versus present) 31.2 Mucositis (0-1 versus 2+) 31.3 Mucositis (0-2 versus 3+) 31.4 New Outcome 32 Oral care protocol versus none 32.1 Mucositis (absent versus present) 32.2 Mucositis (0-1 versus 2+) 32.3 Mucositis (0-2 versus 3+) 33 Pentoxifylline versus no treatment 33.1 Mucositis (0-1 versus 2+) 34 Pilocarpine versus placebo 34.1 Mucositis (absent versus present) 34.2 Mucositis (0-1 versus 2+) 34.3 Mucositis (0-2 versus 3+) 35 Povidone versus water 35.1 Mucositis (absent versus present) 35.2 Mucositis (0-1 versus 2+) 35.3 Mucositis (0-2 versus 3+) 36 Prednisone versus placebo 36.1 Mucositis (absent versus present) 36.2 Mucositis (0-1 versus 2+) 36.3 Mucositis (0-2 versus 3+) 37 Propantheline anticholinergic versus placebo 37.1 Mucositis (absent versus present) 38 Prostaglandin versus placebo 38.1 Mucositis (absent versus present) 38.2 Mucositis (0-1 versus 2+) 38.3 Mucositis (0-2 versus 3+) 39 Radiotherapy: am versus pm 39.3 Mucositis (0-2 versus 3+) 40 Sucralfate versus placebo 40.1 Mucositis (absent versus present) 40.2 Mucositis (0-1 versus 2+) 40.3 Mucositis (0-2 versus 3+) 40.4 Mucositis (absent versus present) 40.5 Mucositis (0-1 versus 2+) 40.6 Mucositis (0-2 versus 3+) 41 Systemic antibiotic clarithromycin versus no treatment 41.1 Mucositis (0-1 versus 2+) 42 Traumeel versus placebo 42.1 Mucositis (absent versus present) 43 Zinc sulphate versus placebo 43.1 Mucositis (absent versus present) 43.2 Mucositis (0-1 versus 2+) 43.3 Mucositis (0-2 versus 3+) 44 Active treatment versus placebo/no treatment 44.1 Mucositis (absent versus present) 44.1.1 Aclyclovir versus placebo 44.1.2 Allopurinol versus placebo/no treatment 44.1.3 Amifostine versus no treatment 44.1.4 Antibiotic (pastille or paste) versus placebo 44.1.5 Benzydamine versus placebo 44.1.6 Chinese medicine versus control (Dobell's solution) 44.1.7 Calcium phosphate versus placebo 44.1.8 Camomile versus placebo 44.1.9 Chlorhexidine versus placebo or no treatment 44.1.10 Folinic acid versus no treatment 44.1.11 Glutamine versus placebo 44.1.12 GM-CSF versus no treatment 44.1.13 Histamine gel versus placebo 44.1.14 Honey versus control 44.1.15 Hydrolytic enzymes versus no treatment 44.1.16 Ice chips versus no treatment 44.1.17 Iseganan versus placebo 44.1.18 Misonidazole versus control 44.1.19 Oral care protocol versus none 44.1.20 Pilocarpine versus placebo 44.1.21 Povidone versus water 44.1.22 Prednisone versus placebo 44.1.23 Propantheline versus placebo 44.1.24 Prostaglandin versus placebo 44.1.25 Sucralfate versus placebo 44.1.26 Traumeel versus placebo 44.1.27 Zinc sulphate versus placebo 44.1.28 Palifermin versus placebo 44.2 Mucositis (0-1 versus 2+) 44.2.1 Aloe vera versus placebo 44.2.2 Amifostine versus placebo or no treatment 44.2.3 Antibiotic pastille or paste versus placebo or no treatment 44.2.4 Calcium phosphate versus placebo 44.2.5 Camomile versus placebo 44.2.6 Chinese medicine versus control (Dobell's solution) 44.2.7 Chlorhexidine versus placebo or no treatment 44.2.8 Folinic acid versus no treatment 44.2.9 Glutamine versus placebo 44.2.10 GM-CSF versus no treatment 44.2.11 Hydrolic enzymes versus no treatment 44.2.12 Ice chips versus no treatment 44.2.13 Indomethacin versus placebo 44.2.14 Iseganan versus placebo 44.2.15 Keratinocyte GF versus placebo 44.2.16 Misonidazole versus control 44.2.17 Oral care protocol versus none 44.2.18 Pentoxifylline versus no treatment 44.2.19 Pilocarpine versus placebo 44.2.20 Povidone versus water 44.2.21 Prednisone versus placebo 44.2.22 Sucralfate versus placebo 44.2.23 Systemic antibiotic clarithromycin versus no treatment 44.2.24 Zinc sulphate versus placebo 44.3 Mucositis (0-2 versus 3+) 44.3.1 Amifostine versus no treatment 44.3.2 Antibiotic pastille or paste versus placebo 44.3.3 Beta carotene versus control 44.3.4 Calcium phosphate versus placebo 44.3.5 Camomile versus placebo 44.3.6 Chinese medicine versus control (Dobell's solution) 44.3.7 Chlorhexidine versus placebo or no treatment 44.3.8 Folinic acid versus no treatment 44.3.9 Glutamine versus placebo 44.3.10 GM-CSF versus placebo 44.3.11 Histamine gel versus placebo 44.3.12 Honey versus control 44.3.13 Hydrolytic enzymes versus no treatment 44.3.14 Ice chips versus no treatment 44.3.15 Iseganan versus placebo 44.3.16 Keratinocyte GF versus placebo 44.3.17 Misonidazole versus control 44.3.18 Oral care protocol versus none 44.3.19 Pilocarpine versus placebo 44.3.20 Povidone versus water 44.3.21 Prednisone versus placebo 44.3.22 Prostaglandin versus placebo 44.3.23 Sucralfate versus placebo 44.3.24 Zinc sulphate 45 Comparisons between active interventions 45.1 Mucositis (absent versus present) 45.1.1 Cryotherapy: 30 min versus 60 min 45.1.2 Etoposide: bolus versus continuous 45.2 Mucositis (0-1 versus 2+) 45.2.1 Cryotherapy: 30 min versus 60 min 45.2.2 Etoposide: bolus versus continuous 45.2.3 GM-CFS versus sucralfate 45.2.4 Keratinocyte: 50 mg versus 25 mg 45.3 Mucositis (0-2 versus 3+) 45.3.1 Cryotherapy: 30 min versus 60 min 45.3.2 Etoposide: bolus versus continuous 45.3.3 GM-CSF versus sucralfate 45.3.4 Keratinocyte: 50 mg versus 25 mg 46 Side effects 46.1 Amifostine 46.1.1 Survival at 24 months 46.1.2 Recurrence at 18 months after cancer treatment 46.1.3 Incomplete response to radiotherapy 46.1.4 Delay to radiotherapy 46.1.5 Hypotension 46.1.6 Nausea 46.1.7 Vomiting 47 Epidermal GF 47.2 Mucositis (0-1 versus 2+) Figures Figure 1 (Analysis 26.1) Figure 2 (Analysis 27.1) Figure 3 (Analysis 27.2) Figure 4 (Analysis 27.3) Figure 5 (Analysis 1.1) Sources of support Internal sources The University of Manchester, UK Chief Scientists Office, Scottish Executive, UK NHS Education for Scotland, UK University of Dundee, UK External sources NIDCR grant ref 1 DE016950-01, USA Feedback Appendices 1 Cochrane Oral Health Group Trials Register search strategy Appendix title Appendix text 2 CENTRAL search strategy Appendix title Appendix text 3 MEDLINE via OVID search strategy Appendix title Appendix text 4 EMBASE SS via OVID search strategy Appendix title Appendix text 5 CANCERLIT search strategy Appendix title Appendix text 6 SIGLE search strategy Appendix title Appendix text 7 LILACS search strategy Appendix title Appendix text 8 CINAHL via EBSCO search strategy Appendix title Appendix text&lt;/p&gt;" NOTES_MODIFIED="2010-07-25 21:37:51 +0100" NOTES_MODIFIED_BY="[Empty name]">
<NAME>NIDCR grant ref 1 DE016950-01</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-04-26 14:24:16 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2011-02-17 09:09:39 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-06-16 16:28:01 +0100" MODIFIED_BY="[Empty name]">Interventions for preventing oral mucositis for patients with cancer receiving treatment</TITLE>
<SUMMARY_BODY MODIFIED="2011-02-17 09:09:39 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment for cancer (including bone marrow transplant) can cause oral mucositis (severe ulcers in the mouth). This painful condition can cause difficulties in eating, drinking and swallowing, and may also be associated with infections which may require the patient to stay longer in hospital. Different strategies are used to try and prevent this condition, and the review of trials found that some of these are effective. Two interventions, cryotherapy (ice chips) and keratinocyte growth factor (palifermin) showed some benefit in preventing mucositis. Sucralfate is effective in reducing the severity of mucositis, and a further seven interventions, aloe vera, amifostine, intravenous glutamine, granulocyte-colony stimulating factor (G-CSF), honey, laser and antibiotic lozenges containing polymixin/tobramycin/amphotericin (PTA) showed weaker evidence of benefit. These were evaluated in patients with different types of cancer, undergoing different types of cancer treatment. Benefits may be restricted to the disease and treatment combinations evaluated.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-02-17 10:48:24 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2010-09-06 09:22:26 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment of cancer is increasingly more effective but is associated with short and long term side effects. Oral side effects remain a major source of illness despite the use of a variety of agents to prevent them. One of these side effects is oral mucositis (mouth ulcers).</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-09-06 09:22:21 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the effectiveness of prophylactic agents for oral mucositis in patients with cancer receiving treatment, compared with other potentially active interventions, placebo or no treatment.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-02-17 10:48:24 +0000" MODIFIED_BY="[Empty name]">
<P>Electronic searches of Cochrane Oral Health Group and PaPaS Trials Registers (to 16 February 2011), CENTRAL (<I>The Cochrane Library</I> 2011, Issue 1), MEDLINE via OVID (1950 to 16 February 2011), EMBASE via OVID (1980 to 16 February 2011), CINAHL via EBSCO (1980 to 16 February 2011), CANCERLIT via PubMed (1950 to 16 February 2011), OpenSIGLE (1980 to 2005) and LILACS via the Virtual Health Library (1980 to 16 February 2011) were undertaken. Reference lists from relevant articles were searched and the authors of eligible trials were contacted to identify trials and obtain additional information.<BR/>
</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-11-05 15:24:22 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials of interventions to prevent oral mucositis in patients receiving treatment for cancer.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-11-09 09:06:26 +0000" MODIFIED_BY="[Empty name]">
<P>Information regarding methods, participants, interventions, outcome measures, results and risk of bias were independently extracted, in duplicate, by two review authors. Authors were contacted for further details where these were unclear. The Cochrane Collaboration statistical guidelines were followed and risk ratios calculated using random-effects models.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-02-16 11:53:45 +0000" MODIFIED_BY="[Empty name]">
<P>A total of 131 studies with 10,514 randomised participants are now included. Overall only 8% of these studies were assessed as being at low risk of bias. Ten interventions, where there was more than one trial in the meta-analysis, showed some statistically significant evidence of a benefit (albeit sometimes weak) for either preventing or reducing the severity of mucositis, compared to either a placebo or no treatment. These ten interventions were: aloe vera, amifostine, cryotherapy, granulocyte-colony stimulating factor (G-CSF), intravenous glutamine, honey, keratinocyte growth factor, laser, polymixin/tobramycin/amphotericin (PTA) antibiotic pastille/paste and sucralfate.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-02-16 11:53:53 +0000" MODIFIED_BY="[Empty name]">
<P>Ten interventions were found to have some benefit with regard to preventing or reducing the severity of mucositis associated with cancer treatment. The strength of the evidence was variable and implications for practice include consideration that benefits may be specific for certain cancer types and treatment. There is a need for further well designed, and conducted trials with sufficient numbers of participants to perform subgroup analyses by type of disease and chemotherapeutic agent.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-04-26 14:24:16 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2011-02-17 08:55:49 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment for malignancies with cytotoxic chemotherapy or radiotherapy or both are becoming increasingly effective but are associated with short and long term side effects. Among the clinically important acute side effects is the disruption in the function and integrity of the mouth. The consequences of this include severe ulceration (mucositis) and fungal infection of the mouth (oral candidiasis, thrush). These disease and treatment induced complications may also produce oral discomfort or pain, poor nutrition, delays in cancer treatment, increased hospital stays and costs and, in some patients, life threatening infection (septicaemia).</P>
<P>Oral complications remain a major source of illness despite the use of a plethora of prophylactic agents, many of which are not evidence based. Individual cancer centres use different mouth care regimens to prevent mucositis (<LINK REF="REF-Glenny-2004" TYPE="REFERENCE">Glenny 2004</LINK>), frequently with scant evidence of efficacy. Mucositis presents a particular challenge due to its complex biological nature and the range of interventions tested have included mucosal surface protectants, anti-inflammatory formulations, antimicrobials, growth factors and a plethora of other miscellaneous agents. Given the costs to patients and their clinicians of mucositis-related morbidity it is surprising that a uniform approach to mucositis prevention, backed by a strong evidence base, is lacking. There are variations in usage between cancer centres in terms of the mouth care regimen used. Compliance with recommended use of product is variable and there are conflicting reports of the effectiveness of prophylactic agents. The qualitative and quantitative benefits, side effects and costs of oral therapies are of importance to the cancer teams responsible for the treatment of patients.</P>
<P>There have been several traditional reviews published and most of these present a general discussion for both chemotherapy and radiotherapy induced oral side effects (<LINK REF="REF-Andreassen-2003" TYPE="REFERENCE">Andreassen 2003</LINK>; <LINK REF="REF-Chang-2003" TYPE="REFERENCE">Chang 2003</LINK>; <LINK REF="REF-De-Pauw-1997" TYPE="REFERENCE">De Pauw 1997</LINK>; <LINK REF="REF-Denning-1992" TYPE="REFERENCE">Denning 1992</LINK>; <LINK REF="REF-Duncan-2003" TYPE="REFERENCE">Duncan 2003</LINK>; <LINK REF="REF-Lortholary-1997" TYPE="REFERENCE">Lortholary 1997</LINK>; <LINK REF="REF-Savarese-2003" TYPE="REFERENCE">Savarese 2003</LINK>; <LINK REF="REF-Stevens-1995" TYPE="REFERENCE">Stevens 1995</LINK>; <LINK REF="REF-Symonds-1998" TYPE="REFERENCE">Symonds 1998</LINK>; <LINK REF="REF-Verdi--1993" TYPE="REFERENCE">Verdi 1993</LINK>; <LINK REF="REF-White-1993" TYPE="REFERENCE">White 1993</LINK>). The conclusions drawn and recommendations made vary from advocating a particular therapy to recommending oral care procedures that have not been systematically investigated. Three systematic reviews have focused on the prevention of oral mucositis in patients with cancer (<LINK REF="REF-Kowanko-1998" TYPE="REFERENCE">Kowanko 1998</LINK>; <LINK REF="REF-Stokman-2006" TYPE="REFERENCE">Stokman 2006</LINK>; <LINK REF="REF-Sunderland-2001" TYPE="REFERENCE">Sunderland 2001</LINK>). Kowanko and colleagues concluded that for most strategies reviewed there was insufficient evidence to draw any conclusions regarding their effectiveness (<LINK REF="REF-Kowanko-1998" TYPE="REFERENCE">Kowanko 1998</LINK>). Sunderland and colleagues focused exclusively on patients with head and neck cancer. Their main analysis combined all the interventions in one meta-analysis and found a beneficial effect of prophylactic interventions (<LINK REF="REF-Sunderland-2001" TYPE="REFERENCE">Sunderland 2001</LINK>). The most recent published review (<LINK REF="REF-Stokman-2006" TYPE="REFERENCE">Stokman 2006</LINK>) considered eight different interventions and found four which showed a statistically significant effect in preventing the development or severity of mucositis. Since the previous update of this review the most significant development in this field have been the publication of a review of evidence and the development of clinical practice guidelines by the Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology (<LINK REF="REF-Keefe--2007" TYPE="REFERENCE">Keefe 2007</LINK>; <LINK REF="REF-Rubenstein-2004" TYPE="REFERENCE">Rubenstein 2004</LINK>; <LINK REF="REF-Sonis-2004" TYPE="REFERENCE">Sonis 2004</LINK>). The development of clinical practice guidelines highlights the fact that preventing and managing mucositis in cancer patients worldwide is imperative. However, given the large number of clinical trials identified in this systematic review, it is important that researchers work co-operatively to maintain up to date systematic reviews, which can then be used to provide the evidence base for clinical guidelines, which can be adapted at the local level to take account of policy and resources.</P>
<P>A previous version of this Cochrane review looked at the use of prophylactic agents for the prevention of oral mucositis and oral candidiasis in patients with cancer treated by chemotherapy (<LINK REF="REF-Clarkson-2000" TYPE="REFERENCE">Clarkson 2000</LINK>). The review concluded that there was some evidence that using ice chips during the chemotherapy treatment was effective in preventing mucositis. The review was updated in 2003 (<LINK REF="REF-Clarkson-2003a" TYPE="REFERENCE">Clarkson 2003a</LINK>) and this update broadened the oral mucositis part of the initial review and looked at the prevention of oral mucositis in patients receiving any treatment for cancer, including patients with all types of cancer, as well as head and neck cancer, and including comparisons between any interventions for prevention. A second review update was carried out in 2006 (<LINK REF="REF-Worthington-2006" TYPE="REFERENCE">Worthington 2006</LINK>) and reviews on the prevention of oral candidiasis have also been published in <I>The Cochrane Library </I>(<LINK REF="REF-Clarkson-2007a" TYPE="REFERENCE">Clarkson 2007a</LINK>; <LINK REF="REF-Worthington-2004a" TYPE="REFERENCE">Worthington 2004a</LINK>). The third prevention review update was carried out in 2007 (<LINK REF="REF-Worthington-2007" TYPE="REFERENCE">Worthington 2007</LINK>).These reviews form part of a series of Cochrane reviews on the prevention and treatment of oral mucositis, oral candidiasis (<LINK REF="REF-Clarkson-2007b" TYPE="REFERENCE">Clarkson 2007b</LINK>; <LINK REF="REF-Worthington-2007a" TYPE="REFERENCE">Worthington 2007a</LINK>); xerostomia (<LINK REF="REF-Tavender-2004" TYPE="REFERENCE">Tavender 2004</LINK>) and herpes simplex in patients receiving cancer therapy (<LINK REF="REF-Glenny-2009" TYPE="REFERENCE">Glenny 2009</LINK>).</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-11-09 09:10:02 +0000" MODIFIED_BY="[Empty name]">
<P>To evaluate the effectiveness of interventions (which may include placebo or no treatment) for the prevention of oral mucositis in patients with cancer receiving radiotherapy, chemotherapy or targeted therapies.</P>
<P>We also investigated the following secondary outcomes for benefits or harms provided there were three or more trials or one trial with more than 100 participants, otherwise we recorded outcomes reported:<BR/>
</P>
<UL>
<LI>Oral hygiene measures</LI>
<LI>Relief of pain/use of analgesia</LI>
<LI>Duration or severity of dysphagia</LI>
<LI>Use of parenteral nutrition or feeding tube</LI>
<LI>Incidence of systemic infection or use of antibiotics</LI>
<LI>Febrile episodes</LI>
<LI>Blood changes</LI>
<LI>Treatment interruption</LI>
<LI>Days of stay in hospital</LI>
<LI>Toxicity (nausea/vomiting/constipation/diarrhoea)</LI>
<LI>Toxicity - skin changes</LI>
<LI>Toxicity - unspecific</LI>
<LI>Xerostomia</LI>
<LI>Cost of care</LI>
<LI>Patient quality of life</LI>
<LI>Death</LI>
<LI>Weight loss/gain</LI>
<LI>Caloric intake by oral nutrition</LI>
<LI>Eating/drinking difficulty</LI>
<LI>Overall health</LI>
<LI>Recurrence of cancer.</LI>
</UL>
<P>The following subgroup analyses were proposed:<BR/>
</P>
<UL>
<LI>Cancer type (leukaemia, head and neck, other solid tumours and mixed)</LI>
<LI>Cancer treatment (specific, for example 5-fluorouracil (5-FU))</LI>
<LI>Age group (adults, children or both).</LI>
</UL>
</OBJECTIVES>
<METHODS MODIFIED="2011-03-09 15:58:54 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2010-11-09 09:10:28 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>Only randomised controlled trials (RCTs) were eligible for inclusion in this review, including both cross-over and parallel group studies. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-10-21 11:57:23 +0100" MODIFIED_BY="[Empty name]">
<P>Anyone with cancer who received radiotherapy, chemotherapy or targeted therapies.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-11-05 12:16:41 +0000" MODIFIED_BY="[Empty name]">
<P>(This review did not include studies of different cancer treatments when the primary outcome was survival or cure with mucositis as a toxicity.)<BR/>Active agents: any agent prescribed as prophylaxis for oral mucositis.<BR/>Control: may be placebo or no treatment, or another active intervention.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-11-09 09:10:28 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<UL>
<LI>Mucositis (at all levels of severity) (ulcers). Mucositis measured on a 0 to 4 point scale (none to severe) was used and this was dichotomised as any mucositis (0 versus 1+), moderate plus severe mucositis (0 to 1 versus 2+), severe mucositis (0 to 2 versus 3+).</LI>
</UL>
<UL>
<LI>Trials where mucositis is measured using a scale which individually grades multiple components of oral health such as teeth or plaque (<LINK REF="REF-Eilers-1988" TYPE="REFERENCE">Eilers 1988</LINK>), are excluded. It is acknowledged that these oral effects are important, but it is not possible to separate the 'mucositis only' score, from the total score, so this review will not include studies which evaluate mucositis using such component scores.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<UL>
<LI>Oral hygiene measures</LI>
<LI>Relief of pain/use of analgesia</LI>
<LI>Duration or severity of dysphagia</LI>
<LI>Use of parenteral nutrition or feeding tube</LI>
<LI>Incidence of systemic infection or use of antibiotics</LI>
<LI>Febrile episodes</LI>
<LI>Blood changes</LI>
<LI>Treatment interruption</LI>
<LI>Days of stay in hospital</LI>
<LI>Toxicity (nausea/vomiting/constipation/diarrhoea)</LI>
<LI>Toxicity - skin changes</LI>
<LI>Toxicity - unspecific</LI>
<LI>Xerostomia</LI>
<LI>Cost of care</LI>
<LI>Patient quality of life</LI>
<LI>Death</LI>
<LI>Weight loss/gain</LI>
<LI>Caloric intake by oral nutrition</LI>
<LI>Eating/drinking difficulty</LI>
<LI>Overall health</LI>
<LI>Recurrence of cancer.</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-02-17 10:47:40 +0000" MODIFIED_BY="[Empty name]">
<P>This review is part of a series of four reviews on the prevention and treatment of oral candidiasis and oral mucositis in patients with cancer, and the same search strategies were used for all four reviews.<BR/>The searches attempted to identify all relevant trials irrespective of language. Papers not in English were translated by members of The Cochrane Collaboration. Sensitive search strategies were developed for each database using a combination of free text and MeSH terms. The MEDLINE and CANCERLIT searches combined the subject search with the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised trials in MEDLINE: sensitivity maximising version (2009 revision)<I> </I>as referenced in Chapter 6.4.11.1 and detailed in boxes 6.4.a and 6.4.c of the<I> Cochrane Handbook for Systematic Reviews of Interventions v</I>ersion 5.0.2 (updated September 2009) (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>). The EMBASE and CINAHL searches were combined with sensitive search strategies developed by the Cochrane Oral Health Group for identifying randomised controlled trials (RCTs). The LILACs subject search was combined with the Brazilian Cochrane Centre search strategy for identifying RCTs in LILACS.</P>
<P>Electronic searching - the databases searched were:</P>
<UL>
<LI>Cochrane Oral Health Group Trials Register (to 16 February 2011) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>)</LI>
<LI>Cochrane Pain, Palliative and Supportive Care (PaPaS) Group Trials Register (to 16 February 2011) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>)</LI>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2011, Issue 1) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>)</LI>
<LI>MEDLINE via OVID (1950 to 16 February 2011) (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>)</LI>
<LI>EMBASE via OVID (1980 to 16 February 2011) (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>)</LI>
<LI>CANCERLIT via PubMed (1950 to 16 February 2011) (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>)</LI>
<LI>OpenSIGLE (1980 to 2005) (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>)</LI>
<LI>LILACS via The Virtual Health Library (to 16 February 2011) (<LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>)</LI>
<LI>CINAHL via EBSCO (1980 to 16 February 2011) (<LINK REF="APP-08" TYPE="APPENDIX">Appendix 8</LINK>).</LI>
</UL>
<P>Only handsearching carried out by The Cochrane Collaboration was included in the search (<I>see</I> master list <A HREF="http://www.cochrane.org">www.cochrane.org</A>).</P>
<P>The controlled trials database (<A HREF="http://www.controlled-trials.com">www.controlled-trials.com</A>) was also searched to identify ongoing and completed trials and to contact trialists for further information about these trials.</P>
<P>The reference list of related review articles and all articles obtained were checked for further trials. Authors of trial reports and specialists in the field known to the review authors were written to concerning further published and unpublished trials.</P>
<P>The review will be updated every 2 years using the Cochrane Oral Health Group Trials Register, CENTRAL, MEDLINE, EMBASE, CINAHL, CANCERLIT and LILACS. The search of OpenSIGLE was discontinued as this database ceased being updated in 2005.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-03-09 15:58:54 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2010-11-09 09:26:22 +0000" MODIFIED_BY="[Empty name]">
<P>The titles and abstracts (when available) of all reports identified through the electronic searches were scanned independently by two review authors. For studies appearing to meet the inclusion criteria, or for which there were insufficient data in the title and abstract to make a clear decision, the full report was obtained. The full reports, containing names of the authors, institutions, journal of publication and results, obtained from all the electronic and other methods of searching were assessed independently by two authors with expertise in this content area, to establish whether the studies met the inclusion criteria or not. Disagreements were resolved by discussion. Where resolution was not possible, a third review author was consulted. All studies meeting the inclusion criteria then underwent validity assessment and data extraction. Studies rejected at this or subsequent stages were recorded in the 'Characteristics of excluded studies' table, and reasons for exclusion recorded.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-07-26 13:51:02 +0100" MODIFIED_BY="Helen Worthington">
<P>Data were extracted by two review authors independently using specially designed data extraction forms. The characteristics of the trial participants, interventions and outcomes in the included trials are presented in the study tables. Mucositis may be dichotomised at different levels of severity. In order to maximise the availability of similar outcome data we recorded the number of patients in each category of mucositis. We planned to form three dichotomies of mucositis: absent versus present (0 versus 1+), mild versus moderate/severe (0 to 1 versus 2+) and moderate versus severe (0 to 2 versus 3+). Pain was assessed on visual analogue scales (0 to 100), the means and standard deviations for each group were recorded. The duration of trials and timing of assessments were recorded in order to make a decision about which to include for commonality. We also recorded the country where the trial was conducted and whether a dentist was involved in the investigation. Some of the authors were contacted for clarification or for further information.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-11-09 09:28:10 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Need to revisit overall assessment of RoB.  Should it cover all domains assessed rather than just allocation concealment/blind outcome assessment?&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Currently 11 trials are assessed as being at low risk of bias but actually only one trial is low risk across all domains (Su 2006).  Foote 1994, Pitten and Schneider all have individual domains judged to be at high risk of bias.  The other 7 all have items at unclear RoB.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 09:28:10 +0000" NOTES_MODIFIED_BY="[Empty name]">
<P>For any relevant studies identified, two review authors independently graded the relevant trials following the domain-based evaluation described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> 5.0.2 (updated September 2009) (<A HREF="http://archie.cochrane.org/sections/documents/view?document=8D67D37282E26AA201AA9B4D54ED9EBC&amp;format=REVMAN#REF-Higgins-2009#REF-Higgins-2009">Higgins 2009</A>). The review authors then compared evaluations, discussed and resolved any disagreements and reported their assessments in a risk of bias in included studies table in Review Manager (RevMan) software.<BR/>
</P>
<P>An assessment of the overall risk of bias involved the consideration of the relative importance of different domains and studies were to be categorised as low, high or unclear risk of bias.</P>
<P>The review authors were to assess the following domains as 'Yes' (i.e. low risk of bias), 'Unclear' (i.e. uncertain risk of bias) or 'No' (i.e. high risk of bias):</P>
<OL>
<LI>adequate sequence generation;</LI>
<LI>allocation concealment;</LI>
<LI>blinding (of participants, carers and outcome assessors);</LI>
<LI>incomplete outcome data addressed;</LI>
<LI>free of selective outcome reporting;</LI>
<LI>free of other bias.</LI>
</OL>
<P>These risk of bias assessments were then for each study across all domains. Adequate allocation concealment and blinding of outcome assessors were designated as key domains for this assessment.</P>
<P>Overall risk of bias was categorised according to the following:</P>
<UL>
<LI>Low risk of bias (plausible bias unlikely to seriously alter the results) for all key domains;</LI>
<LI>Unclear risk of bias (plausible bias that raises some doubt about the results) if one or more key domains were assessed as unclear; or</LI>
<LI>High risk of bias (plausible bias that seriously weakens confidence in the results) if one or more key domains were assessed to be at high risk of bias.</LI>
</UL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-11-09 09:28:26 +0000" MODIFIED_BY="[Empty name]">
<P>For dichotomous outcomes, the estimate of effect of an intervention was expressed as risk ratios (RR) together with 95% confidence intervals (CIs). For continuous outcomes, mean differences and standard deviations were used to summarise the data for each group using mean differences and 95% CIs. Appropriate data were extracted from the cross-over studies and the generic inverse variance method was used to enter this into RevMan.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2010-07-26 13:44:46 +0100" MODIFIED_BY="Helen Worthington">
<P>The patient was the unit of analysis in all trials.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2010-11-09 09:28:58 +0000" MODIFIED_BY="[Empty name]">
<P>All authors were contacted to retrieve missing data from authors of trials.</P>
<P>The analysis will generally include only the available data (ignoring missing data) however methods for estimating missing standard deviations in Section 7.7.3 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> 5.0.2 (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>) were to be used. Otherwise we do not intend to undertake any imputations nor to use statistical methods to allow for missing data.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-03-09 15:58:54 +0000" MODIFIED_BY="[Empty name]">
<P>The significance of any discrepancies in the estimates of the treatment effects from the different trials was to be assessed by means of Cochran's test for heterogeneity and heterogeneity would have been considered significant if P &lt; 0.1 (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>).</P>
<P>The I<SUP>2</SUP> statistic, which describes the percentage total variation across studies that is due to heterogeneity rather than chance, was used to quantify heterogeneity with I<SUP>2 </SUP>over 50% being considered substantial heterogeneity (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009;</LINK> Section 9.5.2). In order to assist in the readers in the interpretation of heterogeneity we would still have included the pooled meta-analysis in the forest plot because the I<SUP>2</SUP> and Chi<SUP>2</SUP> statistics are helpful. With substantial heterogeneity pooling the data may not be appropriate and this will be considered in the results for each intervention.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2010-11-09 09:29:55 +0000" MODIFIED_BY="[Empty name]">
<P>If there had been sufficient numbers of trials (more than 10) in any meta-analysis, publication bias would have been assessed according to the recommendations on testing for funnel plot asymmetry (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>) as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> 5.0.2 (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>). If asymmetry were identified we would have examined possible causes.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-11-09 09:30:36 +0000" MODIFIED_BY="[Empty name]">
<P>A meta-analysis would have only be conducted if there were studies of similar comparisons reporting the same mucositis outcome measures. Single studies would not be entered into forest plots. Risk ratios were to be combined for dichotomous data, and mean differences for continuous data, using random-effect models provided there were more than three studies in the meta-analysis.</P>
<P>It is possible to conduct cross-over trials in this area as patients may be receiving several chemotherapy sessions, any mucositis completely healing in the periods between the sessions. The treatment effects from cross-over trials were combined with those from parallel group trials where appropriate, using the data from both periods of the cross-over studies (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). The generic inverse variance method incorporated in RevMan was used for all analyses. Where data for the cross-tabulation of pairs were not available, all possible paired comparisons for each study were calculated, giving rise to the same risk ratios values with different confidence intervals. The widest confidence interval was used in the analysis.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2010-11-09 09:30:48 +0000" MODIFIED_BY="[Empty name]">
<P>Clinical heterogeneity was to be assessed by examining the types of participants and interventions for all outcomes in each study. We proposed a priori to conduct subgroup analyses for different cancer types (leukaemia, head and neck, other solid tumours and mixed), cancer treatment (for example 5-fluorouracil (5-FU)) and age groups (children, adults and both). However, there were insufficient trials by intervention type to do this.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2010-07-26 13:48:08 +0100" MODIFIED_BY="Helen Worthington">
<P>It was planned to undertake sensitivity analyses to examine the effect of the study quality assessment on the overall estimates of effect. In addition, the effect of including unpublished literature on the review's findings was also to be examined. There were too few trials to undertake these analyses.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-04-26 14:24:16 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2011-03-09 15:59:03 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Characteristics of the trial settings and investigators</HEADING>
<P>Three hundred and eighty-three reports of trials were initially identified as eligible according to the defined inclusion criteria for this review with regard to study design, participants, interventions and outcomes. From this list, the total number of included trials was 131, there were 10 duplicate reports and 176 studies were excluded.</P>
<P>
<I>See </I>
<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table for further information on each excluded study. In summary, studies were excluded for the following reasons.</P>
<UL>
<LI>Abstracts only available, insufficient information to include study in the review (36 studies: <LINK REF="STD-Antonadou-1998" TYPE="STUDY">Antonadou 1998</LINK>; <LINK REF="STD-Buentzel-1999" TYPE="STUDY">Buentzel 1999</LINK>; <LINK REF="STD-Castro-2009" TYPE="STUDY">Castro 2009</LINK>; <LINK REF="STD-Clarke-2001" TYPE="STUDY">Clarke 2001</LINK>; <LINK REF="STD-Collova-2004" TYPE="STUDY">Collova 2004</LINK>; <LINK REF="STD-Colombat-1995" TYPE="STUDY">Colombat 1995</LINK>; <LINK REF="STD-Costa-1999" TYPE="STUDY">Costa 1999</LINK>; <LINK REF="STD-Gabison-1995" TYPE="STUDY">Gabison 1995</LINK>; <LINK REF="STD-Goldberg-2003" TYPE="STUDY">Goldberg 2003</LINK>; <LINK REF="STD-Gordon-1993" TYPE="STUDY">Gordon 1993</LINK>; <LINK REF="STD-Harris-1995" TYPE="STUDY">Harris 1995</LINK>; <LINK REF="STD-He-2004" TYPE="STUDY">He 2004</LINK>; <LINK REF="STD-Kante-1995" TYPE="STUDY">Kante 1995</LINK>; <LINK REF="STD-Klocke-2006" TYPE="STUDY">Klocke 2006</LINK>; <LINK REF="STD-Lavendag-1998" TYPE="STUDY">Lavendag 1998</LINK>; <LINK REF="STD-Le-2008" TYPE="STUDY">Le 2008</LINK>; <LINK REF="STD-Leong-1995" TYPE="STUDY">Leong 1995</LINK>; <LINK REF="STD-Lozada-1998" TYPE="STUDY">Lozada 1998</LINK>; <LINK REF="STD-Marcial-1994" TYPE="STUDY">Marcial 1994</LINK>; <LINK REF="STD-Merte-1999" TYPE="STUDY">Merte 1999</LINK>; <LINK REF="STD-Papas-1984" TYPE="STUDY">Papas 1984</LINK>; <LINK REF="STD-Pouli-1999" TYPE="STUDY">Pouli 1999</LINK>; <LINK REF="STD-Radmard-2002" TYPE="STUDY">Radmard 2002</LINK>; <LINK REF="STD-Robustelli-1999" TYPE="STUDY">Robustelli 1999</LINK>; <LINK REF="STD-Schwerkoske-1999" TYPE="STUDY">Schwerkoske 1999</LINK>; <LINK REF="STD-Sharma-2009" TYPE="STUDY">Sharma 2009</LINK>; <LINK REF="STD-Shea-2007" TYPE="STUDY">Shea 2007</LINK>; <LINK REF="STD-Shidfar-2008" TYPE="STUDY">Shidfar 2008</LINK>; <LINK REF="STD-Spadaro-1991" TYPE="STUDY">Spadaro 1991</LINK>; <LINK REF="STD-Spielberger-2001" TYPE="STUDY">Spielberger 2001</LINK>; <LINK REF="STD-Throuvalas-1995" TYPE="STUDY">Throuvalas 1995</LINK>; <LINK REF="STD-Valc_x00e1_rcel-1997" TYPE="STUDY">Valcrcel 1997</LINK>; <LINK REF="STD-Vesole-1999" TYPE="STUDY">Vesole 1999</LINK>; <LINK REF="STD-Villar-2009" TYPE="STUDY">Villar 2009</LINK>; <LINK REF="STD-Vitello-2000" TYPE="STUDY">Vitello 2000</LINK>; <LINK REF="STD-Wagner-2002" TYPE="STUDY">Wagner 2002</LINK>).</LI>
<LI>Comparing different cancer treatments including radiotherapy regimens (29 trial reports: <LINK REF="STD-Andersen-1987" TYPE="STUDY">Andersen 1987</LINK>; <LINK REF="STD-Ardizzoni-2002" TYPE="STUDY">Ardizzoni 2002</LINK>; <LINK REF="STD-Awada-2002" TYPE="STUDY">Awada 2002</LINK>; <LINK REF="STD-Awwad-2002" TYPE="STUDY">Awwad 2002</LINK>; <LINK REF="STD-Bensadoun-2006" TYPE="STUDY">Bensadoun 2006</LINK>; <LINK REF="STD-Bentzen-2001" TYPE="STUDY">Bentzen 2001</LINK>; <LINK REF="STD-Bleehen-1996" TYPE="STUDY">Bleehen 1996</LINK>; <LINK REF="STD-Bourhis-2006" TYPE="STUDY">Bourhis 2006</LINK>; <LINK REF="STD-Calais-2000" TYPE="STUDY">Calais 2000</LINK>; <LINK REF="STD-Cassidy-2002" TYPE="STUDY">Cassidy 2002</LINK>; <LINK REF="STD-Cunningham-1995" TYPE="STUDY">Cunningham 1995</LINK>; <LINK REF="STD-Damon-2004" TYPE="STUDY">Damon 2004</LINK>; <LINK REF="STD-De-Boer-2002" TYPE="STUDY">De Boer 2002</LINK>; <LINK REF="STD-Denham-1999" TYPE="STUDY">Denham 1999</LINK>; <LINK REF="STD-Dobrowsky-1998" TYPE="STUDY">Dobrowsky 1998</LINK>; <LINK REF="STD-Doroshow-1987" TYPE="STUDY">Doroshow 1987</LINK>; <LINK REF="STD-Erkisi-1996" TYPE="STUDY">Erkisi 1996</LINK>; <LINK REF="STD-Erlichman-1988" TYPE="STUDY">Erlichman 1988</LINK>; <LINK REF="STD-Ezzat-2005" TYPE="STUDY">Ezzat 2005</LINK>; <LINK REF="STD-Falcone-2001" TYPE="STUDY">Falcone 2001</LINK>; <LINK REF="STD-Giles-2003a" TYPE="STUDY">Giles 2003a</LINK>; <LINK REF="STD-Giles-2003b" TYPE="STUDY">Giles 2003b</LINK>; <LINK REF="STD-Gladkov-2007" TYPE="STUDY">Gladkov 2007</LINK>; <LINK REF="STD-Lee-1989" TYPE="STUDY">Lee 1989</LINK>; <LINK REF="STD-Levi-1997" TYPE="STUDY">Levi 1997</LINK>; <LINK REF="STD-Mahmoud-1996" TYPE="STUDY">Mahmoud 1996</LINK>; <LINK REF="STD-Pyrhonen-1995" TYPE="STUDY">Pyrhonen 1995</LINK>; <LINK REF="STD-Rabinovitch-2006" TYPE="STUDY">Rabinovitch 2006</LINK>; <LINK REF="STD-Rocci-2005" TYPE="STUDY">Rocci 2005</LINK>).</LI>
<LI>Not a randomised controlled trial (64 study reports: <LINK REF="STD-Aisa-2005" TYPE="STUDY">Aisa 2005</LINK>; <LINK REF="STD-Altmann-1999" TYPE="STUDY">Altmann 1999</LINK>; <LINK REF="STD-Arora-2008" TYPE="STUDY">Arora 2008</LINK>; <LINK REF="STD-Awada-2004" TYPE="STUDY">Awada 2004</LINK>; <LINK REF="STD-Baydar-2005" TYPE="STUDY">Baydar 2005</LINK>; <LINK REF="STD-Calais-2004" TYPE="STUDY">Calais 2004</LINK>; <LINK REF="STD-Cheng-2001" TYPE="STUDY">Cheng 2001</LINK>; <LINK REF="STD-Cheng-2002" TYPE="STUDY">Cheng 2002</LINK>; <LINK REF="STD-Colella-2010" TYPE="STUDY">Colella 2010</LINK>; <LINK REF="STD-Costa-2003" TYPE="STUDY">Costa 2003</LINK>; <LINK REF="STD-Dreicer-1997" TYPE="STUDY">Dreicer 1997</LINK>; <LINK REF="STD-Edelman-1998" TYPE="STUDY">Edelman 1998</LINK>; <LINK REF="STD-Eisen-2003" TYPE="STUDY">Eisen 2003</LINK>; <LINK REF="STD-El_x002d_Sayed-2002a" TYPE="STUDY">El-Sayed 2002a</LINK>; <LINK REF="STD-Fahlke-1999" TYPE="STUDY">Fahlke 1999</LINK>; <LINK REF="STD-Fay-1994" TYPE="STUDY">Fay 1994</LINK>; <LINK REF="STD-Foncuberta-2001" TYPE="STUDY">Foncuberta 2001</LINK>; <LINK REF="STD-Gandara-1997" TYPE="STUDY">Gandara 1997</LINK>; <LINK REF="STD-Gutierrez-1996" TYPE="STUDY">Gutierrez 1996</LINK>; <LINK REF="STD-Horsley-2007" TYPE="STUDY">Horsley 2007</LINK>; <LINK REF="STD-Hu-2003" TYPE="STUDY">Hu 2003</LINK>; <LINK REF="STD-Hunter-2007" TYPE="STUDY">Hunter 2007</LINK>; <LINK REF="STD-Inagaki-2006" TYPE="STUDY">Inagaki 2006</LINK>; <LINK REF="STD-Ito-2002" TYPE="STUDY">Ito 2002</LINK>; <LINK REF="STD-Johnson-2002" TYPE="STUDY">Johnson 2002</LINK>; <LINK REF="STD-Ju-2009" TYPE="STUDY">Ju 2009</LINK>; <LINK REF="STD-Karacetin-2004" TYPE="STUDY">Karacetin 2004</LINK>; <LINK REF="STD-Khouri-2009" TYPE="STUDY">Khouri 2009</LINK>; <LINK REF="STD-Kuriakose-2002" TYPE="STUDY">Kuriakose 2002</LINK>; <LINK REF="STD-Labbate-2003" TYPE="STUDY">Labbate 2003</LINK>; <LINK REF="STD-Lugli_x00e9_-2002" TYPE="STUDY">Lugli 2002</LINK>; <LINK REF="STD-Maddocks_x002d_Jennings-2009" TYPE="STUDY">Maddocks-Jennings 2009</LINK>; <LINK REF="STD-Madero-1999" TYPE="STUDY">Madero 1999</LINK>; <LINK REF="STD-Malaker-1991" TYPE="STUDY">Malaker 1991</LINK>; <LINK REF="STD-Mantovani-2003" TYPE="STUDY">Mantovani 2003</LINK>; <LINK REF="STD-Martin-2006" TYPE="STUDY">Martin 2006</LINK>; <LINK REF="STD-Matejka-1990" TYPE="STUDY">Matejka 1990</LINK>; <LINK REF="STD-Mills-1995" TYPE="STUDY">Mills 1995</LINK>; <LINK REF="STD-Mori-2006" TYPE="STUDY">Mori 2006</LINK>; <LINK REF="STD-Nicolatou_x002d_Galitis-2006" TYPE="STUDY">Nicolatou-Galitis 2006</LINK>; <LINK REF="STD-Okutomi-2000" TYPE="STUDY">Okutomi 2000</LINK>; <LINK REF="STD-Papadeas-2007" TYPE="STUDY">Papadeas 2007</LINK>; <LINK REF="STD-Penpattanagul-2007" TYPE="STUDY">Penpattanagul 2007</LINK>; <LINK REF="STD-Peters-1993" TYPE="STUDY">Peters 1993</LINK>; <LINK REF="STD-Phillips-2002" TYPE="STUDY">Phillips 2002</LINK>; <LINK REF="STD-Putwatana-2009" TYPE="STUDY">Putwatana 2009</LINK>; <LINK REF="STD-Sato-1997" TYPE="STUDY">Sato 1997</LINK>; <LINK REF="STD-Sato-2006" TYPE="STUDY">Sato 2006</LINK>; <LINK REF="STD-Schuster-2008" TYPE="STUDY">Schuster 2008</LINK>; <LINK REF="STD-Shabanloei-2009" TYPE="STUDY">Shabanloei 2009</LINK>; <LINK REF="STD-Simoes-2009" TYPE="STUDY">Simoes 2009</LINK>; <LINK REF="STD-Stokman-2004" TYPE="STUDY">Stokman 2004</LINK>; <LINK REF="STD-Thieblemont-2002" TYPE="STUDY">Thieblemont 2002</LINK>; <LINK REF="STD-Tiemann-2006" TYPE="STUDY">Tiemann 2006</LINK>; <LINK REF="STD-Toubai-2003" TYPE="STUDY">Toubai 2003</LINK>; <LINK REF="STD-Uchiyama-2005" TYPE="STUDY">Uchiyama 2005</LINK>; <LINK REF="STD-Wang-2002a" TYPE="STUDY">Wang 2002a</LINK>; <LINK REF="STD-Ward-2007" TYPE="STUDY">Ward 2007</LINK>; <LINK REF="STD-Weiss-1990" TYPE="STUDY">Weiss 1990</LINK>; <LINK REF="STD-Whelan-2002" TYPE="STUDY">Whelan 2002</LINK>; <LINK REF="STD-Whelan-2004" TYPE="STUDY">Whelan 2004</LINK>; <LINK REF="STD-Wollina-2002" TYPE="STUDY">Wollina 2002</LINK>; <LINK REF="STD-Wymenga-1999" TYPE="STUDY">Wymenga 1999</LINK>; <LINK REF="STD-Yokomizo-2004" TYPE="STUDY">Yokomizo 2004</LINK>).</LI>
<LI>Multicomponent oral assessment instruments (which included voice, teeth etc) - specifically excluded in methods section of review (16 trial reports: <LINK REF="STD-Aquino-2005" TYPE="STUDY">Aquino 2005</LINK>; <LINK REF="STD-Cowen-1997" TYPE="STUDY">Cowen 1997</LINK>; <LINK REF="STD-Dudjak-1987" TYPE="STUDY">Dudjak 1987</LINK>; <LINK REF="STD-Epstein-1992" TYPE="STUDY">Epstein 1992</LINK>; <LINK REF="STD-Etiz-2000" TYPE="STUDY">Etiz 2000</LINK>; <LINK REF="STD-Feber-1995" TYPE="STUDY">Feber 1995</LINK>; <LINK REF="STD-Feber-1996" TYPE="STUDY">Feber 1996</LINK>; <LINK REF="STD-Grotz-2001" TYPE="STUDY">Grotz 2001</LINK>; <LINK REF="STD-Jebb-1995" TYPE="STUDY">Jebb 1995</LINK>; <LINK REF="STD-Kenny-1990" TYPE="STUDY">Kenny 1990</LINK>; <LINK REF="STD-McIlroy-1996" TYPE="STUDY">McIlroy 1996</LINK>; <LINK REF="STD-Nikoletti-2005" TYPE="STUDY">Nikoletti 2005</LINK>; <LINK REF="STD-Piccirillo-2003" TYPE="STUDY">Piccirillo 2003</LINK>; <LINK REF="STD-Pytlik-2002" TYPE="STUDY">Pytlik 2002</LINK>; <LINK REF="STD-Rothwell-1990" TYPE="STUDY">Rothwell 1990</LINK>; <LINK REF="STD-Verdi-1995" TYPE="STUDY">Verdi 1995</LINK>).</LI>
<LI>Some mucositis present at baseline (12 trial reports: <LINK REF="STD-Anderson-1998b" TYPE="STUDY">Anderson 1998b</LINK>; <LINK REF="STD-Barasch-1995" TYPE="STUDY">Barasch 1995</LINK>; <LINK REF="STD-Djuric-2006" TYPE="STUDY">Djuric 2006</LINK>; <LINK REF="STD-Ferretti-1990" TYPE="STUDY">Ferretti 1990</LINK>; <LINK REF="STD-Genot_x002d_Klastersky-2008" TYPE="STUDY">Genot-Klastersky 2008</LINK>; <LINK REF="STD-Kuhn-2009" TYPE="STUDY">Kuhn 2009</LINK>; <LINK REF="STD-Lanzos-2010" TYPE="STUDY">Lanzos 2010</LINK>; <LINK REF="STD-Loo-2010" TYPE="STUDY">Loo 2010</LINK>; <LINK REF="STD-Masucci-2005" TYPE="STUDY">Masucci 2005</LINK>; <LINK REF="STD-Prada-1985" TYPE="STUDY">Prada 1985</LINK>; <LINK REF="STD-Ryu-2007" TYPE="STUDY">Ryu 2007</LINK>; <LINK REF="STD-Valcarcel-2002" TYPE="STUDY">Valcarcel 2002</LINK>).</LI>
<LI>Mucositis prevention not purpose of study (one trial report: <LINK REF="STD-Jham-2007" TYPE="STUDY">Jham 2007</LINK>).</LI>
<LI>Data presented as episodes rather than patients, where patients were re-entered into the study, so data not independent (seven trial reports: <LINK REF="STD-Abramoff-2008" TYPE="STUDY">Abramoff 2008</LINK>; <LINK REF="STD-Awidi-2001" TYPE="STUDY">Awidi 2001</LINK>; <LINK REF="STD-Hickey-1982" TYPE="STUDY">Hickey 1982</LINK>; <LINK REF="STD-Karthaus-1998" TYPE="STUDY">Karthaus 1998</LINK>; <LINK REF="STD-Lorusso-2003" TYPE="STUDY">Lorusso 2003</LINK>; <LINK REF="STD-Rojas-2001" TYPE="STUDY">Rojas 2001</LINK>; <LINK REF="STD-van-Zaanen-1994" TYPE="STUDY">van Zaanen 1994</LINK>).</LI>
<LI>Major change to protocol half way through study, blinded and unblinded patient data combined (one trial report: <LINK REF="STD-Okuno-1997" TYPE="STUDY">Okuno 1997</LINK>).</LI>
<LI>Unclear if mucositis present at baseline (one trial report: <LINK REF="STD-Cheng-2006" TYPE="STUDY">Cheng 2006</LINK>).</LI>
<LI>Unclear if randomised (four trial reports: <LINK REF="STD-Apaydin-1996" TYPE="STUDY">Apaydin 1996</LINK>; <LINK REF="STD-Howell-1983" TYPE="STUDY">Howell 1983</LINK>; <LINK REF="STD-Teshima-1986" TYPE="STUDY">Teshima 1986</LINK>; <LINK REF="STD-Zanin-2010" TYPE="STUDY">Zanin 2010</LINK>).</LI>
<LI>No mucositis data - study stopped early because preset stooping rule triggered (two trial reports: <LINK REF="STD-Antin-2002" TYPE="STUDY">Antin 2002</LINK>; <LINK REF="STD-Rades-2004" TYPE="STUDY">Rades 2004</LINK>).</LI>
<LI>No clear mucositis data presented and unable to contact authors (two trial reports: <LINK REF="STD-Niibe-1985" TYPE="STUDY">Niibe 1985</LINK>; <LINK REF="STD-Rutkauskas-1993" TYPE="STUDY">Rutkauskas 1993</LINK>).</LI>
<LI>Design flaw - confounded interventions (one trial report: <LINK REF="STD-Papas-2003" TYPE="STUDY">Papas 2003</LINK>).</LI>
</UL>
<P>Of the 131 included trials 124 were designed as parallel group studies and seven as cross-over studies (<LINK REF="STD-Anderson-1998" TYPE="STUDY">Anderson 1998</LINK>; <LINK REF="STD-Chi-1995" TYPE="STUDY">Chi 1995</LINK>; <LINK REF="STD-Dozono-1989" TYPE="STUDY">Dozono 1989</LINK>; <LINK REF="STD-Jebb-1994" TYPE="STUDY">Jebb 1994</LINK>; <LINK REF="STD-Loprinzi-1990" TYPE="STUDY">Loprinzi 1990</LINK>; <LINK REF="STD-Mahood-1991" TYPE="STUDY">Mahood 1991</LINK>; <LINK REF="STD-Pfeiffer-1990" TYPE="STUDY">Pfeiffer 1990</LINK>). None of the published reports of cross-over studies reported the 'paired' data in an appropriate form to be used in a meta-analysis. All the authors were contacted and replies were received supplying data for three studies (<LINK REF="STD-Anderson-1998" TYPE="STUDY">Anderson 1998</LINK>; <LINK REF="STD-Loprinzi-1990" TYPE="STUDY">Loprinzi 1990</LINK>; <LINK REF="STD-Mahood-1991" TYPE="STUDY">Mahood 1991</LINK>). Data from the other cross-over studies were extracted as outlined in the methods section.</P>
<P>Of the 131 included trials all included data on assessment of mucositis. Ninety-two (70%) of the 131 included trials were conducted at a single site. Thirty-two of these trials were conducted in Europe, 20 in the USA, seven in China, five in India, four in Canada, three in Brazil and Japan, two in Iran, Israel, Thailand, Taiwan and Turkey, and one in each of the following countries: Argentina, Egypt, Hong Kong, Malaysia, Mexico, South Africa, South Korea, and Uruguay. Thirty-six trials were multicentre studies. Ten of these were conducted in the USA (<LINK REF="STD-Blazar-2006" TYPE="STUDY">Blazar 2006</LINK>; <LINK REF="STD-Crawford-1999" TYPE="STUDY">Crawford 1999</LINK>; <LINK REF="STD-Dodd-1996" TYPE="STUDY">Dodd 1996</LINK>; <LINK REF="STD-Freytes-2004" TYPE="STUDY">Freytes 2004</LINK>; <LINK REF="STD-Giles-2004" TYPE="STUDY">Giles 2004</LINK>; <LINK REF="STD-Hanson-1995" TYPE="STUDY">Hanson 1995</LINK>; <LINK REF="STD-Mahood-1991" TYPE="STUDY">Mahood 1991</LINK>; <LINK REF="STD-Meropol-2003" TYPE="STUDY">Meropol 2003</LINK>; <LINK REF="STD-Scarantino-2006" TYPE="STUDY">Scarantino 2006</LINK>; <LINK REF="STD-Spielberger-2004" TYPE="STUDY">Spielberger 2004</LINK>), three in the USA and Canada (<LINK REF="STD-Epstein-2001" TYPE="STUDY">Epstein 2001</LINK>; <LINK REF="STD-Foote-1994" TYPE="STUDY">Foote 1994</LINK>; <LINK REF="STD-Nemunaitis-1995" TYPE="STUDY">Nemunaitis 1995</LINK>), two in the USA and European countries (<LINK REF="STD-Brizel-2000" TYPE="STUDY">Brizel 2000</LINK>; <LINK REF="STD-Buentzel-2006" TYPE="STUDY">Buentzel 2006</LINK>), two in European countries alone (<LINK REF="STD-Castagna-2001" TYPE="STUDY">Castagna 2001</LINK>; <LINK REF="STD-Vokurka-2005" TYPE="STUDY">Vokurka 2005</LINK>), one in the USA, Canada and Europe (<LINK REF="STD-Trotti-2004" TYPE="STUDY">Trotti 2004</LINK>), one in the USA and Australia (<LINK REF="STD-Rosen-2006" TYPE="STUDY">Rosen 2006</LINK>) and one in the USA, Australia and Canada (<LINK REF="STD-Brizel-2008" TYPE="STUDY">Brizel 2008</LINK>). Two studies were conducted in Australia (<LINK REF="STD-Spencer-2005" TYPE="STUDY">Spencer 2005</LINK>; <LINK REF="STD-Veness-2006" TYPE="STUDY">Veness 2006</LINK>), Canada (<LINK REF="STD-Bjarnason-2009" TYPE="STUDY">Bjarnason 2009</LINK>; <LINK REF="STD-El-Sayed-2002" TYPE="STUDY">El Sayed 2002</LINK>), France (<LINK REF="STD-Bensadoun-1999" TYPE="STUDY">Bensadoun 1999;</LINK> <LINK REF="STD-Gandemer-2007" TYPE="STUDY">Gandemer 2007</LINK>), Iran (<LINK REF="STD-Abbasi_x002d_Nazari-2007" TYPE="STUDY">Abbasi-Nazari 2007</LINK>; <LINK REF="STD-Motallebnejad-2008" TYPE="STUDY">Motallebnejad 2008</LINK>) and Taiwan (<LINK REF="STD-Chi-1995" TYPE="STUDY">Chi 1995</LINK>; <LINK REF="STD-Lin-2006" TYPE="STUDY">Lin 2006</LINK>), and one in each of the following countries: China (<LINK REF="STD-Tu-1998" TYPE="STUDY">Tu 1998</LINK>), Germany (<LINK REF="STD-Dorr-2007" TYPE="STUDY">Dorr 2007</LINK>), Italy (<LINK REF="STD-Gori-2007" TYPE="STUDY">Gori 2007</LINK>), South Korea (<LINK REF="STD-Wu-2009" TYPE="STUDY">Wu 2009</LINK>), Russia (<LINK REF="STD-Peterson-2009" TYPE="STUDY">Peterson 2009</LINK>) and Thailand (<LINK REF="STD-Veerasarn-2006" TYPE="STUDY">Veerasarn 2006</LINK>). It was unclear whether the remaining three studies were conducted at a single site or were multisite studies (<LINK REF="STD-Bubley-1989" TYPE="STUDY">Bubley 1989</LINK>; <LINK REF="STD-Lievens-1998" TYPE="STUDY">Lievens 1998</LINK>; <LINK REF="STD-Qin-2007" TYPE="STUDY">Qin 2007</LINK>).</P>
<P>Eighty-one studies (62%) provided funding information. Thirty-seven (28%) trials were funded by the pharmaceutical industry. Twenty-three studies received government funding. Whilst an additional nine trials were funded by a combination of funding sources (<LINK REF="STD-Anderson-1998" TYPE="STUDY">Anderson 1998</LINK>; <LINK REF="STD-Blazar-2006" TYPE="STUDY">Blazar 2006</LINK>; <LINK REF="STD-Cerchietti-2006" TYPE="STUDY">Cerchietti 2006</LINK>; <LINK REF="STD-Dodd-1996" TYPE="STUDY">Dodd 1996</LINK>; <LINK REF="STD-Ferretti-1988" TYPE="STUDY">Ferretti 1988</LINK>; <LINK REF="STD-Foote-1994" TYPE="STUDY">Foote 1994</LINK>; <LINK REF="STD-Makkonen-1994" TYPE="STUDY">Makkonen 1994</LINK>; <LINK REF="STD-Sornsuvit-2008" TYPE="STUDY">Sornsuvit 2008</LINK>; <LINK REF="STD-van-der-Lelie-2001" TYPE="STUDY">van der Lelie 2001</LINK>). Five studies were funded by charities (<LINK REF="STD-Bjarnason-2009" TYPE="STUDY">Bjarnason 2009</LINK>; <LINK REF="STD-Dickson-2000" TYPE="STUDY">Dickson 2000</LINK>; <LINK REF="STD-Franzen-1995" TYPE="STUDY">Franzen 1995</LINK>; <LINK REF="STD-Lilleby-2006" TYPE="STUDY">Lilleby 2006</LINK>; <LINK REF="STD-Lockhart-2005" TYPE="STUDY">Lockhart 2005</LINK>). Four trials reported that they received university funding (<LINK REF="STD-Biswal-2003" TYPE="STUDY">Biswal 2003</LINK>; <LINK REF="STD-Madan-2008" TYPE="STUDY">Madan 2008</LINK>; <LINK REF="STD-Motallebnejad-2008" TYPE="STUDY">Motallebnejad 2008</LINK>; <LINK REF="STD-Yuen-2001" TYPE="STUDY">Yuen 2001</LINK>). Three studies were funded by other sources (<LINK REF="STD-Gori-2007" TYPE="STUDY">Gori 2007</LINK>; <LINK REF="STD-Lin-2006" TYPE="STUDY">Lin 2006</LINK>; <LINK REF="STD-Oberbaum-2001" TYPE="STUDY">Oberbaum 2001</LINK>). The remaining 50 (38%) studies reported either none, or insufficient information about funding sources. A dentist was involved in 26 (20%) of the trials.</P>
<SUBSECTION>
<HEADING LEVEL="4">Studies awaiting assessment</HEADING>
<P>Due to changes in the inclusion criteria for studies in this review, some previously excluded studies are being reconsidered for inclusion in the next update. Information about these studies is in <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Characteristics of the participants</HEADING>
<P>One hundred and fourteen (87%) of the included trials recruited only adult patients, 13 included both adults and children (with a difference in age as large as 1 to 70 years) and three trials were conducted solely on paediatric patients (<LINK REF="STD-Cruz-2007" TYPE="STUDY">Cruz 2007</LINK>; <LINK REF="STD-Gandemer-2007" TYPE="STUDY">Gandemer 2007</LINK>; <LINK REF="STD-Shenep-1988" TYPE="STUDY">Shenep 1988</LINK>), the age group being unclear in one trial (<LINK REF="STD-Mahood-1991" TYPE="STUDY">Mahood 1991</LINK>). The type of cancer for which patients were being treated was exclusively head and neck cancer in 69 trials (53%), leukaemia in 13 trials, solid tumours in 22 trials and a combination of haematological and solid tumours in 21 trials, the cancer type being unclear in six trials. The radiotherapy and/or chemotherapy regimen was described in most of the trials though the chemotherapeutic agents were not always described in full detail. Twenty-nine trials included patients who were undergoing a bone marrow transplant. The chemotherapy regimen included 5-fluorouracil (5-FU) in 25 trials. In 13 of these trials the patients had solid tumours, in six trials patients had head and neck cancer, in two trials patients had mixed cancers and in four trials the cancer type was unclear. It was not always clear if the dose was in a bolus or continuous form. Trials in which patients received radiotherapy generally gave information about the total and daily or weekly dose. Total radiotherapy for head and neck cancer was generally 60 to 74 Gy and the Karnofsky performance &gt; 60.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Characteristics of the interventions</HEADING>
<P>All of the 131 trials provided a clear description of the interventions including the dose and method of administration for the test and control groups. The dosage of the test agents varied for similar products. Thirty-six trials compared an active intervention with no treatment and 87 trials used a placebo control. In some trials the placebo was matched in taste and appearance to the active intervention and in others the following interventions were described as placebo: water, albumin, glycine, sugar solution, polycal, saline. Two trials included in the no treatment control group tested different oral care protocols and in each case one group received limited oral hygiene (usual care) (<LINK REF="STD-Borowski-1994" TYPE="STUDY">Borowski 1994</LINK>; <LINK REF="STD-Shieh-1997" TYPE="STUDY">Shieh 1997</LINK>). A further three trials included in the placebo control group included both a placebo control and a direct comparison (<LINK REF="STD-Freytes-2004" TYPE="STUDY">Freytes 2004</LINK> - two different doses of keratinocyte growth factor, <LINK REF="STD-Madan-2008" TYPE="STUDY">Madan 2008</LINK> - chlorhexidine versus povidone iodine versus salt &amp; soda, and <LINK REF="STD-Sorensen-2008" TYPE="STUDY">Sorensen 2008</LINK> chlorhexidine mouthwash versus ice chips).</P>
<P>A further two trials (<LINK REF="STD-Huang-2003" TYPE="STUDY">Huang 2003</LINK>; <LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK>) compared Chinese medicine to a control described as Dobell's solution, which is "a solution of sodium borate, sodium bicarbonate, phenol, and glycerol, used as a wash for mucous membranes" (<LINK REF="REF-Merck-Index-2010" TYPE="REFERENCE">Merck Index 2010</LINK>). Two trials compared patients receiving radiotherapy in the morning with patients receiving radiotherapy in the afternoon (<LINK REF="STD-Bjarnason-2009" TYPE="STUDY">Bjarnason 2009</LINK>; <LINK REF="STD-Goyal-2009" TYPE="STUDY">Goyal 2009</LINK>). Another four trials compared two active interventions: ice chips sucked for different time periods (30 minutes versus 60 minutes) (<LINK REF="STD-Rocke-1993" TYPE="STUDY">Rocke 1993</LINK>), granulocyte/macrophage colony-stimulating factor (GM-CSF) versus sucralfate (<LINK REF="STD-Saarilahti-2002" TYPE="STUDY">Saarilahti 2002</LINK>), chlorhexidine versus laser (<LINK REF="STD-Arun-Maiya-2006" TYPE="STUDY">Arun Maiya 2006</LINK>) and polaprezinc versus azulene (<LINK REF="STD-Watanabe-2010" TYPE="STUDY">Watanabe 2010</LINK>).</P>
<P>The interventions for the 131 studies assessing oral mucositis were:<BR/>
</P>
<UL>
<LI>aciclovir (<LINK REF="STD-Bubley-1989" TYPE="STUDY">Bubley 1989</LINK>)</LI>
<LI>allopurinol mouthrinse (<LINK REF="STD-Abbasi_x002d_Nazari-2007" TYPE="STUDY">Abbasi-Nazari 2007</LINK>; <LINK REF="STD-Dozono-1989" TYPE="STUDY">Dozono 1989</LINK>; <LINK REF="STD-Loprinzi-1990" TYPE="STUDY">Loprinzi 1990</LINK>; <LINK REF="STD-Panahi-2009" TYPE="STUDY">Panahi 2009</LINK>)</LI>
<LI>aloe vera (<LINK REF="STD-Puataweepong-2009" TYPE="STUDY">Puataweepong 2009</LINK>; <LINK REF="STD-Su-2004" TYPE="STUDY">Su 2004</LINK>;)</LI>
<LI>amifostine (<LINK REF="STD-Antonadou-2002" TYPE="STUDY">Antonadou 2002</LINK>; <LINK REF="STD-Bourhis-2000" TYPE="STUDY">Bourhis 2000</LINK>; <LINK REF="STD-Brizel-2000" TYPE="STUDY">Brizel 2000</LINK>; <LINK REF="STD-Buentzel-2006" TYPE="STUDY">Buentzel 2006</LINK>; <LINK REF="STD-Buntzel-1998" TYPE="STUDY">Buntzel 1998</LINK>; <LINK REF="STD-Haddad-2009" TYPE="STUDY">Haddad 2009</LINK>; <LINK REF="STD-Hartmann-2001" TYPE="STUDY">Hartmann 2001</LINK>; <LINK REF="STD-Koukourakis-2000" TYPE="STUDY">Koukourakis 2000</LINK>; <LINK REF="STD-Spencer-2005" TYPE="STUDY">Spencer 2005</LINK>; <LINK REF="STD-Vacha-2003" TYPE="STUDY">Vacha 2003</LINK>; <LINK REF="STD-Veerasarn-2006" TYPE="STUDY">Veerasarn 2006</LINK>)</LI>
<LI>antibiotic pastille or paste (<LINK REF="STD-El-Sayed-2002" TYPE="STUDY">El Sayed 2002</LINK>)</LI>
<LI>antibiotic systemic (clarithromycin) (<LINK REF="STD-Yuen-2001" TYPE="STUDY">Yuen 2001</LINK>)</LI>
<LI>azulene (<LINK REF="STD-Watanabe-2010" TYPE="STUDY">Watanabe 2010</LINK>*)</LI>
<LI>benzydamine (<LINK REF="STD-Epstein-1989" TYPE="STUDY">Epstein 1989</LINK>; <LINK REF="STD-Epstein-2001" TYPE="STUDY">Epstein 2001</LINK>; <LINK REF="STD-Kazemian-2009" TYPE="STUDY">Kazemian 2009</LINK>; <LINK REF="STD-Prada-1987" TYPE="STUDY">Prada 1987</LINK>)</LI>
<LI>beta carotene (<LINK REF="STD-Mills-1988" TYPE="STUDY">Mills 1988</LINK>)</LI>
<LI>chamomile (<LINK REF="STD-Fidler-1996" TYPE="STUDY">Fidler 1996</LINK>)</LI>
<LI>chewing gum (<LINK REF="STD-Gandemer-2007" TYPE="STUDY">Gandemer 2007</LINK>)</LI>
<LI>Chinese herbs (details of herbs used are given in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table) (<LINK REF="STD-Huang-2003" TYPE="STUDY">Huang 2003</LINK>*; <LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK>*)</LI>
<LI>chlorhexidine (<LINK REF="STD-Arun-Maiya-2006" TYPE="STUDY">Arun Maiya 2006</LINK>*; <LINK REF="STD-Dodd-1996" TYPE="STUDY">Dodd 1996</LINK>; <LINK REF="STD-Ferretti-1988" TYPE="STUDY">Ferretti 1988</LINK>; <LINK REF="STD-Foote-1994" TYPE="STUDY">Foote 1994</LINK>; <LINK REF="STD-Madan-2008" TYPE="STUDY">Madan 2008</LINK>*; <LINK REF="STD-McGaw-1985" TYPE="STUDY">McGaw 1985</LINK>; <LINK REF="STD-Pitten-2003" TYPE="STUDY">Pitten 2003</LINK>; <LINK REF="STD-Sorensen-2008" TYPE="STUDY">Sorensen 2008</LINK>; <LINK REF="STD-Spijkervet-1989" TYPE="STUDY">Spijkervet 1989</LINK>; <LINK REF="STD-Wahlin-1989" TYPE="STUDY">Wahlin 1989</LINK>)</LI>
<LI>cryotherapy (<LINK REF="STD-Cascinu-1994" TYPE="STUDY">Cascinu 1994</LINK>; <LINK REF="STD-Gori-2007" TYPE="STUDY">Gori 2007</LINK>; <LINK REF="STD-Lilleby-2006" TYPE="STUDY">Lilleby 2006</LINK>; <LINK REF="STD-Mahood-1991" TYPE="STUDY">Mahood 1991</LINK>; <LINK REF="STD-Rocke-1993" TYPE="STUDY">Rocke 1993</LINK>*; <LINK REF="STD-Svanberg-2007" TYPE="STUDY">Svanberg 2007</LINK>; <LINK REF="STD-Sorensen-2008" TYPE="STUDY">Sorensen 2008</LINK>*)</LI>
<LI>dental stent (<LINK REF="STD-Qin-2007" TYPE="STUDY">Qin 2007</LINK>)</LI>
<LI>epidermal growth factor (<LINK REF="STD-Wu-2009" TYPE="STUDY">Wu 2009</LINK>)</LI>
<LI>glutamine (<LINK REF="STD-Anderson-1998" TYPE="STUDY">Anderson 1998</LINK>; <LINK REF="STD-Cerchietti-2006" TYPE="STUDY">Cerchietti 2006</LINK>; <LINK REF="STD-Choi-2007" TYPE="STUDY">Choi 2007</LINK>; <LINK REF="STD-Dickson-2000" TYPE="STUDY">Dickson 2000</LINK>; <LINK REF="STD-He-2008" TYPE="STUDY">He 2008</LINK>; <LINK REF="STD-Huang-2000" TYPE="STUDY">Huang 2000</LINK>; <LINK REF="STD-Jebb-1994" TYPE="STUDY">Jebb 1994</LINK>; <LINK REF="STD-Li-2006" TYPE="STUDY">Li 2006</LINK>; <LINK REF="STD-Okuno-1999" TYPE="STUDY">Okuno 1999</LINK>; <LINK REF="STD-Sornsuvit-2008" TYPE="STUDY">Sornsuvit 2008</LINK>)</LI>
<LI>granulocyte colony-stimulating factor (G-CSF) (<LINK REF="STD-Crawford-1999" TYPE="STUDY">Crawford 1999</LINK>; <LINK REF="STD-Katano-1995" TYPE="STUDY">Katano 1995</LINK>; <LINK REF="STD-Schneider-1999" TYPE="STUDY">Schneider 1999</LINK>; <LINK REF="STD-Su-2006" TYPE="STUDY">Su 2006</LINK>)</LI>
<LI>granulocyte/macrophage colony-stimulating factor (GM-CSF) (<LINK REF="STD-Cartee-1995" TYPE="STUDY">Cartee 1995</LINK>; <LINK REF="STD-Chi-1995" TYPE="STUDY">Chi 1995</LINK>; <LINK REF="STD-Dazzi-2003" TYPE="STUDY">Dazzi 2003</LINK>; <LINK REF="STD-Ifrah-1999" TYPE="STUDY">Ifrah 1999</LINK>; <LINK REF="STD-Makkonen-2000" TYPE="STUDY">Makkonen 2000</LINK>; <LINK REF="STD-McAleese-2006" TYPE="STUDY">McAleese 2006</LINK>; <LINK REF="STD-Nemunaitis-1995" TYPE="STUDY">Nemunaitis 1995</LINK>; <LINK REF="STD-Saarilahti-2002" TYPE="STUDY">Saarilahti 2002</LINK>*; <LINK REF="STD-van-der-Lelie-2001" TYPE="STUDY">van der Lelie 2001</LINK>)</LI>
<LI>histamine gel (<LINK REF="STD-Elad-2006" TYPE="STUDY">Elad 2006</LINK>)</LI>
<LI>honey (<LINK REF="STD-Biswal-2003" TYPE="STUDY">Biswal 2003</LINK>; <LINK REF="STD-Motallebnejad-2008" TYPE="STUDY">Motallebnejad 2008</LINK>; <LINK REF="STD-Rashad-2008" TYPE="STUDY">Rashad 2008</LINK>)</LI>
<LI>hydrolytic enzymes (details of enzymes used are given in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table) (<LINK REF="STD-Dorr-2007" TYPE="STUDY">Dorr 2007</LINK>; <LINK REF="STD-Gujral-2001" TYPE="STUDY">Gujral 2001</LINK>; <LINK REF="STD-Kaul-1999" TYPE="STUDY">Kaul 1999</LINK>)</LI>
<LI>indigo wood root (<LINK REF="STD-You-2009" TYPE="STUDY">You 2009</LINK>)</LI>
<LI>intestinal trefoil factor (<LINK REF="STD-Peterson-2009" TYPE="STUDY">Peterson 2009</LINK>)</LI>
<LI>iseganan (<LINK REF="STD-Giles-2004" TYPE="STUDY">Giles 2004</LINK>; <LINK REF="STD-Trotti-2004" TYPE="STUDY">Trotti 2004</LINK>)</LI>
<LI>keratinocyte growth factor (GF) (<LINK REF="STD-Blazar-2006" TYPE="STUDY">Blazar 2006</LINK>; <LINK REF="STD-Brizel-2008" TYPE="STUDY">Brizel 2008</LINK>; <LINK REF="STD-Freytes-2004" TYPE="STUDY">Freytes 2004</LINK>*; <LINK REF="STD-Meropol-2003" TYPE="STUDY">Meropol 2003</LINK>; <LINK REF="STD-Rosen-2006" TYPE="STUDY">Rosen 2006</LINK>; <LINK REF="STD-Spielberger-2004" TYPE="STUDY">Spielberger 2004</LINK>; <LINK REF="STD-Vadhan_x002d_Raj-2010" TYPE="STUDY">Vadhan-Raj 2010</LINK>)</LI>
<LI>laser (<LINK REF="STD-Antunes-2007" TYPE="STUDY">Antunes 2007</LINK>; <LINK REF="STD-Arun-Maiya-2006" TYPE="STUDY">Arun Maiya 2006</LINK>*; <LINK REF="STD-Bensadoun-1999" TYPE="STUDY">Bensadoun 1999</LINK>; <LINK REF="STD-Chor-2010" TYPE="STUDY">Chor 2010</LINK>; <LINK REF="STD-Cruz-2007" TYPE="STUDY">Cruz 2007</LINK>; <LINK REF="STD-Schubert-2007" TYPE="STUDY">Schubert 2007</LINK>)</LI>
<LI>non-steroidal anti-inflammatory drug (<LINK REF="STD-Pillsbury-1986" TYPE="STUDY">Pillsbury 1986</LINK>)</LI>
<LI>oral care (<LINK REF="STD-Borowski-1994" TYPE="STUDY">Borowski 1994</LINK>; <LINK REF="STD-Shieh-1997" TYPE="STUDY">Shieh 1997</LINK>)</LI>
<LI>pentoxifylline (<LINK REF="STD-Attal-1993" TYPE="STUDY">Attal 1993</LINK>)</LI>
<LI>pilocarpine (<LINK REF="STD-Lockhart-2005" TYPE="STUDY">Lockhart 2005</LINK>; <LINK REF="STD-Scarantino-2006" TYPE="STUDY">Scarantino 2006</LINK>)</LI>
<LI>PTA (polymixin/tobramycin/amphotericin) lozenges/paste (<LINK REF="STD-Stokman-2003" TYPE="STUDY">Stokman 2003</LINK>; <LINK REF="STD-Symonds-1996" TYPE="STUDY">Symonds 1996</LINK>; <LINK REF="STD-Wijers-2001" TYPE="STUDY">Wijers 2001</LINK>)</LI>
<LI>polaprezinc (<LINK REF="STD-Watanabe-2010" TYPE="STUDY">Watanabe 2010</LINK>*)</LI>
<LI>povidone iodine (<LINK REF="STD-Arun-Maiya-2006" TYPE="STUDY">Arun Maiya 2006</LINK>; <LINK REF="STD-Madan-2008" TYPE="STUDY">Madan 2008</LINK>*; <LINK REF="STD-Rahn-1997" TYPE="STUDY">Rahn 1997</LINK>; <LINK REF="STD-Vokurka-2005" TYPE="STUDY">Vokurka 2005</LINK>)</LI>
<LI>prednisone (<LINK REF="STD-Leborgne-1997" TYPE="STUDY">Leborgne 1997</LINK>)</LI>
<LI>propantheline anticholinergic (<LINK REF="STD-Ahmed-1993" TYPE="STUDY">Ahmed 1993</LINK>)</LI>
<LI>prostaglandin (<LINK REF="STD-Duenas-1996" TYPE="STUDY">Duenas 1996</LINK>; <LINK REF="STD-Hanson-1995" TYPE="STUDY">Hanson 1995</LINK>; <LINK REF="STD-Labar-1993" TYPE="STUDY">Labar 1993</LINK>; <LINK REF="STD-Pillsbury-1986" TYPE="STUDY">Pillsbury 1986</LINK>; <LINK REF="STD-Veness-2006" TYPE="STUDY">Veness 2006</LINK>)</LI>
<LI>radiation: morning versus evening (<LINK REF="STD-Bjarnason-2009" TYPE="STUDY">Bjarnason 2009</LINK>*, <LINK REF="STD-Goyal-2009" TYPE="STUDY">Goyal 2009</LINK>*)</LI>
<LI>shenqi-fanghou (<LINK REF="STD-Hu-2005" TYPE="STUDY">Hu 2005</LINK>)</LI>
<LI>superoxide dismutase (SOD) (<LINK REF="STD-Tu-1998" TYPE="STUDY">Tu 1998</LINK>)</LI>
<LI>sucralfate (<LINK REF="STD-Carter-1999" TYPE="STUDY">Carter 1999</LINK>; <LINK REF="STD-Castagna-2001" TYPE="STUDY">Castagna 2001</LINK>; <LINK REF="STD-Cengiz-1999" TYPE="STUDY">Cengiz 1999</LINK>; <LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>; <LINK REF="STD-Evensen-2001" TYPE="STUDY">Evensen 2001</LINK>; <LINK REF="STD-Franzen-1995" TYPE="STUDY">Franzen 1995</LINK>; <LINK REF="STD-Lievens-1998" TYPE="STUDY">Lievens 1998</LINK>; <LINK REF="STD-Makkonen-1994" TYPE="STUDY">Makkonen 1994</LINK>; <LINK REF="STD-Nottage-2003" TYPE="STUDY">Nottage 2003</LINK>; <LINK REF="STD-Pfeiffer-1990" TYPE="STUDY">Pfeiffer 1990</LINK>; <LINK REF="STD-Saarilahti-2002" TYPE="STUDY">Saarilahti 2002</LINK>*; <LINK REF="STD-Scherlacher-1990" TYPE="STUDY">Scherlacher 1990</LINK>; <LINK REF="STD-Shenep-1988" TYPE="STUDY">Shenep 1988</LINK>)</LI>
<LI>traumeel (<LINK REF="STD-Oberbaum-2001" TYPE="STUDY">Oberbaum 2001</LINK>)</LI>
<LI>yangygin-humo decoctalion (<LINK REF="STD-Dai-2009" TYPE="STUDY">Dai 2009</LINK>)</LI>
<LI>zinc sulphate (<LINK REF="STD-Ertekin-2004" TYPE="STUDY">Ertekin 2004</LINK>; <LINK REF="STD-Lin-2006" TYPE="STUDY">Lin 2006</LINK>).</LI>
</UL>
<P>* studies with two or more different active treatments.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Characteristics of outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Mucositis</HEADING>
<P>All trials used a graded scale to record the severity of mucositis. Most described the index used or referred to published criteria, mainly World Health Organization (WHO) or European Organization for Research and Treatment of Cancer (EORTC). Scales were similar to the 5-point WHO scale ranging from 0 (normal) to 4 (severe). The categories initially relate to visible changes in the mucosa and gradually record pain and inability to eat solid foods. The duration of the trials varied from a few days up to a year after treatment. The interval during which mucositis was recorded varied from 5 to 90 days or until the end of the radiotherapy, or the leukocyte count was above 8000 mm. Several studies presented data at different time points, with the median time point being 28 days. The nearest assessment to 28 days was used for all studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>There was little consistency on the other outcome measures reported.<BR/>
</P>
<UL>
<LI>Oral hygiene measures (<LINK REF="STD-Biswal-2003" TYPE="STUDY">Biswal 2003</LINK>; <LINK REF="STD-Cruz-2007" TYPE="STUDY">Cruz 2007</LINK>; <LINK REF="STD-Dodd-1996" TYPE="STUDY">Dodd 1996</LINK>; <LINK REF="STD-El-Sayed-2002" TYPE="STUDY">El Sayed 2002</LINK>; <LINK REF="STD-Elad-2006" TYPE="STUDY">Elad 2006</LINK>; <LINK REF="STD-Ertekin-2004" TYPE="STUDY">Ertekin 2004</LINK>; <LINK REF="STD-Evensen-2001" TYPE="STUDY">Evensen 2001</LINK>; <LINK REF="STD-Ferretti-1988" TYPE="STUDY">Ferretti 1988</LINK>; <LINK REF="STD-Foote-1994" TYPE="STUDY">Foote 1994</LINK>; <LINK REF="STD-Gandemer-2007" TYPE="STUDY">Gandemer 2007</LINK>; <LINK REF="STD-Kazemian-2009" TYPE="STUDY">Kazemian 2009</LINK>; <LINK REF="STD-Leborgne-1997" TYPE="STUDY">Leborgne 1997</LINK>; <LINK REF="STD-Lockhart-2005" TYPE="STUDY">Lockhart 2005</LINK>; <LINK REF="STD-Makkonen-1994" TYPE="STUDY">Makkonen 1994</LINK>; <LINK REF="STD-Makkonen-2000" TYPE="STUDY">Makkonen 2000</LINK>; <LINK REF="STD-McGaw-1985" TYPE="STUDY">McGaw 1985</LINK>; <LINK REF="STD-Rahn-1997" TYPE="STUDY">Rahn 1997</LINK>; <LINK REF="STD-Rashad-2008" TYPE="STUDY">Rashad 2008</LINK>; <LINK REF="STD-Scherlacher-1990" TYPE="STUDY">Scherlacher 1990</LINK>; <LINK REF="STD-Spijkervet-1989" TYPE="STUDY">Spijkervet 1989</LINK>; <LINK REF="STD-Stokman-2003" TYPE="STUDY">Stokman 2003</LINK>; <LINK REF="STD-Symonds-1996" TYPE="STUDY">Symonds 1996</LINK>; <LINK REF="STD-Vadhan_x002d_Raj-2010" TYPE="STUDY">Vadhan-Raj 2010</LINK>; <LINK REF="STD-Vokurka-2005" TYPE="STUDY">Vokurka 2005</LINK>; <LINK REF="STD-Wahlin-1989" TYPE="STUDY">Wahlin 1989</LINK>; <LINK REF="STD-Wijers-2001" TYPE="STUDY">Wijers 2001</LINK>; <LINK REF="STD-Wu-2009" TYPE="STUDY">Wu 2009</LINK>).</LI>
<LI>Relief of pain/use of analgesia (morphine) (<LINK REF="STD-Antunes-2007" TYPE="STUDY">Antunes 2007</LINK>; <LINK REF="STD-Arun-Maiya-2006" TYPE="STUDY">Arun Maiya 2006</LINK>; <LINK REF="STD-Attal-1993" TYPE="STUDY">Attal 1993</LINK>; <LINK REF="STD-Bensadoun-1999" TYPE="STUDY">Bensadoun 1999</LINK>; <LINK REF="STD-Blazar-2006" TYPE="STUDY">Blazar 2006</LINK>; <LINK REF="STD-Brizel-2008" TYPE="STUDY">Brizel 2008</LINK>; <LINK REF="STD-Carter-1999" TYPE="STUDY">Carter 1999</LINK>; <LINK REF="STD-Castagna-2001" TYPE="STUDY">Castagna 2001</LINK>; <LINK REF="STD-Cengiz-1999" TYPE="STUDY">Cengiz 1999</LINK>; <LINK REF="STD-Cerchietti-2006" TYPE="STUDY">Cerchietti 2006</LINK>; <LINK REF="STD-Cruz-2007" TYPE="STUDY">Cruz 2007</LINK>; <LINK REF="STD-Dazzi-2003" TYPE="STUDY">Dazzi 2003</LINK>; <LINK REF="STD-Dorr-2007" TYPE="STUDY">Dorr 2007</LINK>; <LINK REF="STD-El-Sayed-2002" TYPE="STUDY">El Sayed 2002</LINK>; <LINK REF="STD-Epstein-1989" TYPE="STUDY">Epstein 1989</LINK>; <LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>; <LINK REF="STD-Epstein-2001" TYPE="STUDY">Epstein 2001</LINK>; <LINK REF="STD-Ertekin-2004" TYPE="STUDY">Ertekin 2004</LINK>; <LINK REF="STD-Ferretti-1988" TYPE="STUDY">Ferretti 1988</LINK>; <LINK REF="STD-Franzen-1995" TYPE="STUDY">Franzen 1995</LINK>; <LINK REF="STD-Freytes-2004" TYPE="STUDY">Freytes 2004</LINK>; <LINK REF="STD-Gandemer-2007" TYPE="STUDY">Gandemer 2007</LINK>; <LINK REF="STD-Giles-2004" TYPE="STUDY">Giles 2004</LINK>; <LINK REF="STD-Hanson-1995" TYPE="STUDY">Hanson 1995</LINK>; <LINK REF="STD-Lilleby-2006" TYPE="STUDY">Lilleby 2006</LINK>; <LINK REF="STD-Lockhart-2005" TYPE="STUDY">Lockhart 2005</LINK>; <LINK REF="STD-Makkonen-2000" TYPE="STUDY">Makkonen 2000</LINK>; <LINK REF="STD-Meropol-2003" TYPE="STUDY">Meropol 2003</LINK>; <LINK REF="STD-Nottage-2003" TYPE="STUDY">Nottage 2003</LINK>; <LINK REF="STD-Oberbaum-2001" TYPE="STUDY">Oberbaum 2001</LINK>; <LINK REF="STD-Peterson-2009" TYPE="STUDY">Peterson 2009</LINK>; <LINK REF="STD-Pfeiffer-1990" TYPE="STUDY">Pfeiffer 1990</LINK>; <LINK REF="STD-Prada-1987" TYPE="STUDY">Prada 1987</LINK>; <LINK REF="STD-Puataweepong-2009" TYPE="STUDY">Puataweepong 2009</LINK>; <LINK REF="STD-Rosen-2006" TYPE="STUDY">Rosen 2006</LINK>; <LINK REF="STD-Saarilahti-2002" TYPE="STUDY">Saarilahti 2002</LINK>; <LINK REF="STD-Schubert-2007" TYPE="STUDY">Schubert 2007</LINK>; <LINK REF="STD-Shenep-1988" TYPE="STUDY">Shenep 1988</LINK>; <LINK REF="STD-Shieh-1997" TYPE="STUDY">Shieh 1997</LINK>; <LINK REF="STD-Spencer-2005" TYPE="STUDY">Spencer 2005</LINK>; <LINK REF="STD-Spielberger-2004" TYPE="STUDY">Spielberger 2004</LINK>; <LINK REF="STD-Su-2004" TYPE="STUDY">Su 2004</LINK>; <LINK REF="STD-Svanberg-2007" TYPE="STUDY">Svanberg 2007</LINK>; <LINK REF="STD-Trotti-2004" TYPE="STUDY">Trotti 2004</LINK>; <LINK REF="STD-Tu-1998" TYPE="STUDY">Tu 1998</LINK>; <LINK REF="STD-Vadhan_x002d_Raj-2010" TYPE="STUDY">Vadhan-Raj 2010</LINK>; <LINK REF="STD-van-der-Lelie-2001" TYPE="STUDY">van der Lelie 2001</LINK>; <LINK REF="STD-Veness-2006" TYPE="STUDY">Veness 2006</LINK>; <LINK REF="STD-Vokurka-2005" TYPE="STUDY">Vokurka 2005</LINK>; <LINK REF="STD-Watanabe-2010" TYPE="STUDY">Watanabe 2010</LINK>; <LINK REF="STD-Wijers-2001" TYPE="STUDY">Wijers 2001</LINK>; <LINK REF="STD-Wu-2009" TYPE="STUDY">Wu 2009</LINK>).</LI>
<LI>Duration or severity of dysphagia (<LINK REF="STD-Antonadou-2002" TYPE="STUDY">Antonadou 2002</LINK>; <LINK REF="STD-Bensadoun-1999" TYPE="STUDY">Bensadoun 1999</LINK>; <LINK REF="STD-Bjarnason-2009" TYPE="STUDY">Bjarnason 2009</LINK>; <LINK REF="STD-Bourhis-2000" TYPE="STUDY">Bourhis 2000</LINK>; <LINK REF="STD-Brizel-2008" TYPE="STUDY">Brizel 2008</LINK>; <LINK REF="STD-Buntzel-1998" TYPE="STUDY">Buntzel 1998</LINK>; <LINK REF="STD-Castagna-2001" TYPE="STUDY">Castagna 2001</LINK>; <LINK REF="STD-Cengiz-1999" TYPE="STUDY">Cengiz 1999</LINK>; <LINK REF="STD-Choi-2007" TYPE="STUDY">Choi 2007</LINK>; <LINK REF="STD-Dorr-2007" TYPE="STUDY">Dorr 2007</LINK>; <LINK REF="STD-El-Sayed-2002" TYPE="STUDY">El Sayed 2002</LINK>; <LINK REF="STD-Elad-2006" TYPE="STUDY">Elad 2006</LINK>; <LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>; <LINK REF="STD-Fidler-1996" TYPE="STUDY">Fidler 1996</LINK>; <LINK REF="STD-Franzen-1995" TYPE="STUDY">Franzen 1995</LINK>; <LINK REF="STD-Giles-2004" TYPE="STUDY">Giles 2004</LINK>; <LINK REF="STD-Goyal-2009" TYPE="STUDY">Goyal 2009</LINK>; <LINK REF="STD-Gujral-2001" TYPE="STUDY">Gujral 2001</LINK>; <LINK REF="STD-Haddad-2009" TYPE="STUDY">Haddad 2009</LINK>; <LINK REF="STD-Hartmann-2001" TYPE="STUDY">Hartmann 2001</LINK>; <LINK REF="STD-Kaul-1999" TYPE="STUDY">Kaul 1999</LINK>; <LINK REF="STD-Lievens-1998" TYPE="STUDY">Lievens 1998</LINK>; <LINK REF="STD-Lilleby-2006" TYPE="STUDY">Lilleby 2006</LINK>; <LINK REF="STD-Lockhart-2005" TYPE="STUDY">Lockhart 2005</LINK>; <LINK REF="STD-McAleese-2006" TYPE="STUDY">McAleese 2006</LINK>; <LINK REF="STD-Oberbaum-2001" TYPE="STUDY">Oberbaum 2001</LINK>; <LINK REF="STD-Prada-1987" TYPE="STUDY">Prada 1987</LINK>; <LINK REF="STD-Rosen-2006" TYPE="STUDY">Rosen 2006</LINK>; <LINK REF="STD-Scarantino-2006" TYPE="STUDY">Scarantino 2006</LINK>; <LINK REF="STD-Scherlacher-1990" TYPE="STUDY">Scherlacher 1990</LINK>; <LINK REF="STD-Spielberger-2004" TYPE="STUDY">Spielberger 2004</LINK>; <LINK REF="STD-Su-2006" TYPE="STUDY">Su 2006</LINK>; <LINK REF="STD-Symonds-1996" TYPE="STUDY">Symonds 1996</LINK>; <LINK REF="STD-Trotti-2004" TYPE="STUDY">Trotti 2004</LINK>; <LINK REF="STD-Vadhan_x002d_Raj-2010" TYPE="STUDY">Vadhan-Raj 2010</LINK>; <LINK REF="STD-Veerasarn-2006" TYPE="STUDY">Veerasarn 2006</LINK>; <LINK REF="STD-You-2009" TYPE="STUDY">You 2009</LINK>).</LI>
<LI>Use of parenteral nutrition or feeding tube (<LINK REF="STD-Bjarnason-2009" TYPE="STUDY">Bjarnason 2009</LINK>; <LINK REF="STD-Bourhis-2000" TYPE="STUDY">Bourhis 2000</LINK>; <LINK REF="STD-Brizel-2008" TYPE="STUDY">Brizel 2008</LINK>; <LINK REF="STD-Carter-1999" TYPE="STUDY">Carter 1999</LINK>; <LINK REF="STD-Cerchietti-2006" TYPE="STUDY">Cerchietti 2006</LINK>; <LINK REF="STD-Cruz-2007" TYPE="STUDY">Cruz 2007</LINK>; <LINK REF="STD-Dickson-2000" TYPE="STUDY">Dickson 2000</LINK>; <LINK REF="STD-El-Sayed-2002" TYPE="STUDY">El Sayed 2002</LINK>; <LINK REF="STD-Evensen-2001" TYPE="STUDY">Evensen 2001</LINK>; <LINK REF="STD-Foote-1994" TYPE="STUDY">Foote 1994</LINK>; <LINK REF="STD-Franzen-1995" TYPE="STUDY">Franzen 1995</LINK>; <LINK REF="STD-Gandemer-2007" TYPE="STUDY">Gandemer 2007</LINK>; <LINK REF="STD-Haddad-2009" TYPE="STUDY">Haddad 2009</LINK>; <LINK REF="STD-Hanson-1995" TYPE="STUDY">Hanson 1995</LINK>; <LINK REF="STD-Hartmann-2001" TYPE="STUDY">Hartmann 2001</LINK>; <LINK REF="STD-Leborgne-1997" TYPE="STUDY">Leborgne 1997</LINK>; <LINK REF="STD-Lilleby-2006" TYPE="STUDY">Lilleby 2006</LINK>; <LINK REF="STD-Lockhart-2005" TYPE="STUDY">Lockhart 2005</LINK>; <LINK REF="STD-Rashad-2008" TYPE="STUDY">Rashad 2008</LINK>; <LINK REF="STD-Saarilahti-2002" TYPE="STUDY">Saarilahti 2002</LINK>; <LINK REF="STD-Shenep-1988" TYPE="STUDY">Shenep 1988</LINK>; <LINK REF="STD-Spencer-2005" TYPE="STUDY">Spencer 2005</LINK>; <LINK REF="STD-Spielberger-2004" TYPE="STUDY">Spielberger 2004</LINK>; <LINK REF="STD-Stokman-2003" TYPE="STUDY">Stokman 2003</LINK>; <LINK REF="STD-Su-2006" TYPE="STUDY">Su 2006</LINK>; <LINK REF="STD-Symonds-1996" TYPE="STUDY">Symonds 1996</LINK>; <LINK REF="STD-Trotti-2004" TYPE="STUDY">Trotti 2004</LINK>; <LINK REF="STD-Vadhan_x002d_Raj-2010" TYPE="STUDY">Vadhan-Raj 2010</LINK>; <LINK REF="STD-van-der-Lelie-2001" TYPE="STUDY">van der Lelie 2001</LINK>; <LINK REF="STD-Yuen-2001" TYPE="STUDY">Yuen 2001</LINK>).</LI>
<LI>Incidence of systemic infection or use of antibiotics (<LINK REF="STD-Antunes-2007" TYPE="STUDY">Antunes 2007</LINK>; <LINK REF="STD-Attal-1993" TYPE="STUDY">Attal 1993</LINK>; <LINK REF="STD-Blazar-2006" TYPE="STUDY">Blazar 2006</LINK>; <LINK REF="STD-Borowski-1994" TYPE="STUDY">Borowski 1994</LINK>; <LINK REF="STD-Brizel-2008" TYPE="STUDY">Brizel 2008</LINK>; <LINK REF="STD-Bubley-1989" TYPE="STUDY">Bubley 1989</LINK>; <LINK REF="STD-Buntzel-1998" TYPE="STUDY">Buntzel 1998</LINK>; <LINK REF="STD-Castagna-2001" TYPE="STUDY">Castagna 2001</LINK>; <LINK REF="STD-Cerchietti-2006" TYPE="STUDY">Cerchietti 2006</LINK>; <LINK REF="STD-Crawford-1999" TYPE="STUDY">Crawford 1999</LINK>; <LINK REF="STD-Cruz-2007" TYPE="STUDY">Cruz 2007</LINK>; <LINK REF="STD-Duenas-1996" TYPE="STUDY">Duenas 1996</LINK>; <LINK REF="STD-El-Sayed-2002" TYPE="STUDY">El Sayed 2002</LINK>; <LINK REF="STD-Ertekin-2004" TYPE="STUDY">Ertekin 2004</LINK>; <LINK REF="STD-Ferretti-1988" TYPE="STUDY">Ferretti 1988</LINK>; <LINK REF="STD-Freytes-2004" TYPE="STUDY">Freytes 2004</LINK>; <LINK REF="STD-Gandemer-2007" TYPE="STUDY">Gandemer 2007</LINK>; <LINK REF="STD-Hanson-1995" TYPE="STUDY">Hanson 1995</LINK>; <LINK REF="STD-Hartmann-2001" TYPE="STUDY">Hartmann 2001</LINK>; <LINK REF="STD-Ifrah-1999" TYPE="STUDY">Ifrah 1999</LINK>; <LINK REF="STD-Jebb-1994" TYPE="STUDY">Jebb 1994</LINK>; <LINK REF="STD-Labar-1993" TYPE="STUDY">Labar 1993</LINK>; <LINK REF="STD-McGaw-1985" TYPE="STUDY">McGaw 1985</LINK>; <LINK REF="STD-Pitten-2003" TYPE="STUDY">Pitten 2003</LINK>; <LINK REF="STD-Puataweepong-2009" TYPE="STUDY">Puataweepong 2009</LINK>; <LINK REF="STD-Shenep-1988" TYPE="STUDY">Shenep 1988</LINK>; <LINK REF="STD-Sornsuvit-2008" TYPE="STUDY">Sornsuvit 2008</LINK>; <LINK REF="STD-Spencer-2005" TYPE="STUDY">Spencer 2005</LINK>; <LINK REF="STD-Spielberger-2004" TYPE="STUDY">Spielberger 2004</LINK>; <LINK REF="STD-Su-2004" TYPE="STUDY">Su 2004</LINK>; <LINK REF="STD-Symonds-1996" TYPE="STUDY">Symonds 1996</LINK>; <LINK REF="STD-Trotti-2004" TYPE="STUDY">Trotti 2004</LINK>; <LINK REF="STD-Tu-1998" TYPE="STUDY">Tu 1998</LINK>; <LINK REF="STD-Vadhan_x002d_Raj-2010" TYPE="STUDY">Vadhan-Raj 2010</LINK>; <LINK REF="STD-van-der-Lelie-2001" TYPE="STUDY">van der Lelie 2001</LINK>; <LINK REF="STD-Vokurka-2005" TYPE="STUDY">Vokurka 2005</LINK>; <LINK REF="STD-Wahlin-1989" TYPE="STUDY">Wahlin 1989</LINK>; <LINK REF="STD-Yuen-2001" TYPE="STUDY">Yuen 2001</LINK>).</LI>
<LI>Febrile episodes (<LINK REF="STD-Ahmed-1993" TYPE="STUDY">Ahmed 1993</LINK>; <LINK REF="STD-Anderson-1998" TYPE="STUDY">Anderson 1998</LINK>; <LINK REF="STD-Attal-1993" TYPE="STUDY">Attal 1993</LINK>; <LINK REF="STD-Borowski-1994" TYPE="STUDY">Borowski 1994</LINK>; <LINK REF="STD-Brizel-2000" TYPE="STUDY">Brizel 2000</LINK>; <LINK REF="STD-Chi-1995" TYPE="STUDY">Chi 1995</LINK>; <LINK REF="STD-Chor-2010" TYPE="STUDY">Chor 2010</LINK>; <LINK REF="STD-Crawford-1999" TYPE="STUDY">Crawford 1999</LINK>; <LINK REF="STD-Duenas-1996" TYPE="STUDY">Duenas 1996</LINK>; <LINK REF="STD-Ferretti-1988" TYPE="STUDY">Ferretti 1988</LINK>; <LINK REF="STD-Freytes-2004" TYPE="STUDY">Freytes 2004</LINK>; <LINK REF="STD-Ifrah-1999" TYPE="STUDY">Ifrah 1999</LINK>; <LINK REF="STD-Katano-1995" TYPE="STUDY">Katano 1995</LINK>; <LINK REF="STD-Labar-1993" TYPE="STUDY">Labar 1993</LINK>; <LINK REF="STD-McGaw-1985" TYPE="STUDY">McGaw 1985</LINK>; <LINK REF="STD-Nemunaitis-1995" TYPE="STUDY">Nemunaitis 1995</LINK>; <LINK REF="STD-Pitten-2003" TYPE="STUDY">Pitten 2003</LINK>; <LINK REF="STD-Shenep-1988" TYPE="STUDY">Shenep 1988</LINK>; <LINK REF="STD-Spencer-2005" TYPE="STUDY">Spencer 2005</LINK>; <LINK REF="STD-Spielberger-2004" TYPE="STUDY">Spielberger 2004</LINK>; <LINK REF="STD-van-der-Lelie-2001" TYPE="STUDY">van der Lelie 2001</LINK>; <LINK REF="STD-Vokurka-2005" TYPE="STUDY">Vokurka 2005</LINK>; <LINK REF="STD-Wahlin-1989" TYPE="STUDY">Wahlin 1989</LINK>; <LINK REF="STD-Yuen-2001" TYPE="STUDY">Yuen 2001</LINK>).</LI>
<LI>Blood changes (<LINK REF="STD-Ahmed-1993" TYPE="STUDY">Ahmed 1993</LINK>; <LINK REF="STD-Antonadou-2002" TYPE="STUDY">Antonadou 2002</LINK>; <LINK REF="STD-Attal-1993" TYPE="STUDY">Attal 1993</LINK>; <LINK REF="STD-Blazar-2006" TYPE="STUDY">Blazar 2006</LINK>; <LINK REF="STD-Brizel-2000" TYPE="STUDY">Brizel 2000</LINK>; <LINK REF="STD-Buentzel-2006" TYPE="STUDY">Buentzel 2006</LINK>; <LINK REF="STD-Buntzel-1998" TYPE="STUDY">Buntzel 1998</LINK>; <LINK REF="STD-Cartee-1995" TYPE="STUDY">Cartee 1995</LINK>; <LINK REF="STD-Cascinu-1994" TYPE="STUDY">Cascinu 1994</LINK>; <LINK REF="STD-Cerchietti-2006" TYPE="STUDY">Cerchietti 2006</LINK>; <LINK REF="STD-Chi-1995" TYPE="STUDY">Chi 1995</LINK>; <LINK REF="STD-Crawford-1999" TYPE="STUDY">Crawford 1999</LINK>; <LINK REF="STD-Dazzi-2003" TYPE="STUDY">Dazzi 2003</LINK>; <LINK REF="STD-Dickson-2000" TYPE="STUDY">Dickson 2000</LINK>; <LINK REF="STD-Dorr-2007" TYPE="STUDY">Dorr 2007</LINK>; <LINK REF="STD-Duenas-1996" TYPE="STUDY">Duenas 1996</LINK>; <LINK REF="STD-Elad-2006" TYPE="STUDY">Elad 2006</LINK>; <LINK REF="STD-Epstein-2001" TYPE="STUDY">Epstein 2001</LINK>; <LINK REF="STD-Ertekin-2004" TYPE="STUDY">Ertekin 2004</LINK>; <LINK REF="STD-Ferretti-1988" TYPE="STUDY">Ferretti 1988</LINK>; <LINK REF="STD-Franzen-1995" TYPE="STUDY">Franzen 1995</LINK>; <LINK REF="STD-Freytes-2004" TYPE="STUDY">Freytes 2004</LINK>; <LINK REF="STD-Hartmann-2001" TYPE="STUDY">Hartmann 2001</LINK>; <LINK REF="STD-Huang-2003" TYPE="STUDY">Huang 2003</LINK>; <LINK REF="STD-Ifrah-1999" TYPE="STUDY">Ifrah 1999</LINK>; <LINK REF="STD-Katano-1995" TYPE="STUDY">Katano 1995</LINK>; <LINK REF="STD-Labar-1993" TYPE="STUDY">Labar 1993</LINK>; <LINK REF="STD-Li-2006" TYPE="STUDY">Li 2006</LINK>; <LINK REF="STD-Lilleby-2006" TYPE="STUDY">Lilleby 2006</LINK>; <LINK REF="STD-Lin-2006" TYPE="STUDY">Lin 2006</LINK>; <LINK REF="STD-Mahood-1991" TYPE="STUDY">Mahood 1991</LINK>; <LINK REF="STD-Makkonen-2000" TYPE="STUDY">Makkonen 2000</LINK>; <LINK REF="STD-Meropol-2003" TYPE="STUDY">Meropol 2003</LINK>; <LINK REF="STD-Nemunaitis-1995" TYPE="STUDY">Nemunaitis 1995</LINK>; <LINK REF="STD-Pitten-2003" TYPE="STUDY">Pitten 2003</LINK>; <LINK REF="STD-Rocke-1993" TYPE="STUDY">Rocke 1993</LINK>; <LINK REF="STD-Rosen-2006" TYPE="STUDY">Rosen 2006</LINK>; <LINK REF="STD-Saarilahti-2002" TYPE="STUDY">Saarilahti 2002</LINK>; <LINK REF="STD-Schneider-1999" TYPE="STUDY">Schneider 1999</LINK>; <LINK REF="STD-Shenep-1988" TYPE="STUDY">Shenep 1988</LINK>; <LINK REF="STD-Sorensen-2008" TYPE="STUDY">Sorensen 2008</LINK>; <LINK REF="STD-Sornsuvit-2008" TYPE="STUDY">Sornsuvit 2008</LINK>; <LINK REF="STD-Spencer-2005" TYPE="STUDY">Spencer 2005</LINK>; <LINK REF="STD-Spielberger-2004" TYPE="STUDY">Spielberger 2004</LINK>; <LINK REF="STD-Svanberg-2007" TYPE="STUDY">Svanberg 2007</LINK>; <LINK REF="STD-van-der-Lelie-2001" TYPE="STUDY">van der Lelie 2001</LINK>; <LINK REF="STD-Veerasarn-2006" TYPE="STUDY">Veerasarn 2006</LINK>; <LINK REF="STD-Vokurka-2005" TYPE="STUDY">Vokurka 2005</LINK>; <LINK REF="STD-Wahlin-1989" TYPE="STUDY">Wahlin 1989</LINK>; <LINK REF="STD-Wu-2009" TYPE="STUDY">Wu 2009</LINK>; <LINK REF="STD-You-2009" TYPE="STUDY">You 2009</LINK>).</LI>
<LI>Treatment interruption (<LINK REF="STD-Antonadou-2002" TYPE="STUDY">Antonadou 2002</LINK>; <LINK REF="STD-Biswal-2003" TYPE="STUDY">Biswal 2003</LINK>; <LINK REF="STD-Bjarnason-2009" TYPE="STUDY">Bjarnason 2009</LINK>; <LINK REF="STD-Bourhis-2000" TYPE="STUDY">Bourhis 2000</LINK>; <LINK REF="STD-Brizel-2000" TYPE="STUDY">Brizel 2000</LINK>; <LINK REF="STD-Brizel-2008" TYPE="STUDY">Brizel 2008</LINK>; <LINK REF="STD-Carter-1999" TYPE="STUDY">Carter 1999</LINK>; <LINK REF="STD-Dazzi-2003" TYPE="STUDY">Dazzi 2003</LINK>; <LINK REF="STD-El-Sayed-2002" TYPE="STUDY">El Sayed 2002</LINK>; <LINK REF="STD-Foote-1994" TYPE="STUDY">Foote 1994</LINK>; <LINK REF="STD-Franzen-1995" TYPE="STUDY">Franzen 1995</LINK>; <LINK REF="STD-Haddad-2009" TYPE="STUDY">Haddad 2009</LINK>; <LINK REF="STD-Huang-2003" TYPE="STUDY">Huang 2003</LINK>; <LINK REF="STD-Ifrah-1999" TYPE="STUDY">Ifrah 1999</LINK>; <LINK REF="STD-Koukourakis-2000" TYPE="STUDY">Koukourakis 2000</LINK>; <LINK REF="STD-Leborgne-1997" TYPE="STUDY">Leborgne 1997</LINK>; <LINK REF="STD-Makkonen-1994" TYPE="STUDY">Makkonen 1994</LINK>; <LINK REF="STD-Makkonen-2000" TYPE="STUDY">Makkonen 2000</LINK>; <LINK REF="STD-Pfeiffer-1990" TYPE="STUDY">Pfeiffer 1990</LINK>; <LINK REF="STD-Puataweepong-2009" TYPE="STUDY">Puataweepong 2009</LINK>; <LINK REF="STD-Saarilahti-2002" TYPE="STUDY">Saarilahti 2002</LINK>; <LINK REF="STD-Trotti-2004" TYPE="STUDY">Trotti 2004</LINK>; <LINK REF="STD-van-der-Lelie-2001" TYPE="STUDY">van der Lelie 2001</LINK>; <LINK REF="STD-Vadhan_x002d_Raj-2010" TYPE="STUDY">Vadhan-Raj 2010</LINK>; <LINK REF="STD-Veness-2006" TYPE="STUDY">Veness 2006</LINK>; <LINK REF="STD-Wu-2009" TYPE="STUDY">Wu 2009</LINK>; <LINK REF="STD-You-2009" TYPE="STUDY">You 2009</LINK>).</LI>
<LI>Days of stay in hospital (<LINK REF="STD-Antonadou-2002" TYPE="STUDY">Antonadou 2002</LINK>; <LINK REF="STD-Attal-1993" TYPE="STUDY">Attal 1993</LINK>; <LINK REF="STD-Cerchietti-2006" TYPE="STUDY">Cerchietti 2006</LINK>; <LINK REF="STD-Chor-2010" TYPE="STUDY">Chor 2010</LINK>; <LINK REF="STD-Dickson-2000" TYPE="STUDY">Dickson 2000</LINK>; <LINK REF="STD-Duenas-1996" TYPE="STUDY">Duenas 1996</LINK>; <LINK REF="STD-Ifrah-1999" TYPE="STUDY">Ifrah 1999</LINK>; <LINK REF="STD-Lilleby-2006" TYPE="STUDY">Lilleby 2006</LINK>; <LINK REF="STD-McGaw-1985" TYPE="STUDY">McGaw 1985</LINK>; <LINK REF="STD-Saarilahti-2002" TYPE="STUDY">Saarilahti 2002</LINK>; <LINK REF="STD-Sornsuvit-2008" TYPE="STUDY">Sornsuvit 2008</LINK>; <LINK REF="STD-van-der-Lelie-2001" TYPE="STUDY">van der Lelie 2001</LINK>).</LI>
<LI>Toxicity - nausea/vomiting/constipation/diarrhoea (<LINK REF="STD-Antonadou-2002" TYPE="STUDY">Antonadou 2002</LINK>; <LINK REF="STD-Blazar-2006" TYPE="STUDY">Blazar 2006</LINK>; <LINK REF="STD-Bourhis-2000" TYPE="STUDY">Bourhis 2000</LINK>; <LINK REF="STD-Brizel-2000" TYPE="STUDY">Brizel 2000</LINK>; <LINK REF="STD-Brizel-2008" TYPE="STUDY">Brizel 2008</LINK>; <LINK REF="STD-Bubley-1989" TYPE="STUDY">Bubley 1989</LINK>; <LINK REF="STD-Buentzel-2006" TYPE="STUDY">Buentzel 2006</LINK>; <LINK REF="STD-Cascinu-1994" TYPE="STUDY">Cascinu 1994</LINK>; <LINK REF="STD-Castagna-2001" TYPE="STUDY">Castagna 2001</LINK>; <LINK REF="STD-Cengiz-1999" TYPE="STUDY">Cengiz 1999</LINK>; <LINK REF="STD-Dickson-2000" TYPE="STUDY">Dickson 2000</LINK>; <LINK REF="STD-Duenas-1996" TYPE="STUDY">Duenas 1996</LINK>; <LINK REF="STD-El-Sayed-2002" TYPE="STUDY">El Sayed 2002</LINK>; <LINK REF="STD-Elad-2006" TYPE="STUDY">Elad 2006</LINK>; <LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>; <LINK REF="STD-Epstein-2001" TYPE="STUDY">Epstein 2001</LINK>; <LINK REF="STD-Ertekin-2004" TYPE="STUDY">Ertekin 2004</LINK>; <LINK REF="STD-Fidler-1996" TYPE="STUDY">Fidler 1996</LINK>; <LINK REF="STD-Freytes-2004" TYPE="STUDY">Freytes 2004</LINK>; <LINK REF="STD-Gandemer-2007" TYPE="STUDY">Gandemer 2007</LINK>; <LINK REF="STD-Giles-2004" TYPE="STUDY">Giles 2004</LINK>; <LINK REF="STD-Gujral-2001" TYPE="STUDY">Gujral 2001</LINK>; <LINK REF="STD-Haddad-2009" TYPE="STUDY">Haddad 2009</LINK>; <LINK REF="STD-Hartmann-2001" TYPE="STUDY">Hartmann 2001</LINK>; <LINK REF="STD-He-2008" TYPE="STUDY">He 2008</LINK>; <LINK REF="STD-Kazemian-2009" TYPE="STUDY">Kazemian 2009</LINK>; <LINK REF="STD-Labar-1993" TYPE="STUDY">Labar 1993</LINK>; <LINK REF="STD-Li-2006" TYPE="STUDY">Li 2006</LINK>; <LINK REF="STD-Lievens-1998" TYPE="STUDY">Lievens 1998</LINK>; <LINK REF="STD-Lockhart-2005" TYPE="STUDY">Lockhart 2005</LINK>; <LINK REF="STD-Mahood-1991" TYPE="STUDY">Mahood 1991</LINK>; <LINK REF="STD-Meropol-2003" TYPE="STUDY">Meropol 2003</LINK>; <LINK REF="STD-Nottage-2003" TYPE="STUDY">Nottage 2003</LINK>; <LINK REF="STD-Oberbaum-2001" TYPE="STUDY">Oberbaum 2001</LINK>; <LINK REF="STD-Okuno-1999" TYPE="STUDY">Okuno 1999</LINK>; <LINK REF="STD-Peterson-2009" TYPE="STUDY">Peterson 2009</LINK>; <LINK REF="STD-Pfeiffer-1990" TYPE="STUDY">Pfeiffer 1990</LINK>; <LINK REF="STD-Rocke-1993" TYPE="STUDY">Rocke 1993</LINK>; <LINK REF="STD-Rosen-2006" TYPE="STUDY">Rosen 2006</LINK>; <LINK REF="STD-Scarantino-2006" TYPE="STUDY">Scarantino 2006</LINK>; <LINK REF="STD-Shenep-1988" TYPE="STUDY">Shenep 1988</LINK>; <LINK REF="STD-Sornsuvit-2008" TYPE="STUDY">Sornsuvit 2008</LINK>; <LINK REF="STD-Spencer-2005" TYPE="STUDY">Spencer 2005</LINK>; <LINK REF="STD-Trotti-2004" TYPE="STUDY">Trotti 2004</LINK>; <LINK REF="STD-Tu-1998" TYPE="STUDY">Tu 1998</LINK>; <LINK REF="STD-Vadhan_x002d_Raj-2010" TYPE="STUDY">Vadhan-Raj 2010</LINK>; <LINK REF="STD-Yuen-2001" TYPE="STUDY">Yuen 2001</LINK>).</LI>
<LI>Toxicity - skin changes (<LINK REF="STD-Antonadou-2002" TYPE="STUDY">Antonadou 2002</LINK>; <LINK REF="STD-Blazar-2006" TYPE="STUDY">Blazar 2006</LINK>; <LINK REF="STD-Bourhis-2000" TYPE="STUDY">Bourhis 2000</LINK>; <LINK REF="STD-Buntzel-1998" TYPE="STUDY">Buntzel 1998</LINK>; <LINK REF="STD-Choi-2007" TYPE="STUDY">Choi 2007</LINK>; <LINK REF="STD-Dickson-2000" TYPE="STUDY">Dickson 2000</LINK>; <LINK REF="STD-Dorr-2007" TYPE="STUDY">Dorr 2007</LINK>; <LINK REF="STD-El-Sayed-2002" TYPE="STUDY">El Sayed 2002</LINK>; <LINK REF="STD-Evensen-2001" TYPE="STUDY">Evensen 2001</LINK>; <LINK REF="STD-Giles-2004" TYPE="STUDY">Giles 2004</LINK>; <LINK REF="STD-Goyal-2009" TYPE="STUDY">Goyal 2009</LINK>; <LINK REF="STD-Gujral-2001" TYPE="STUDY">Gujral 2001</LINK>; <LINK REF="STD-Haddad-2009" TYPE="STUDY">Haddad 2009</LINK>; <LINK REF="STD-Kaul-1999" TYPE="STUDY">Kaul 1999</LINK>; <LINK REF="STD-Lievens-1998" TYPE="STUDY">Lievens 1998</LINK>; <LINK REF="STD-Lin-2006" TYPE="STUDY">Lin 2006</LINK>; <LINK REF="STD-Meropol-2003" TYPE="STUDY">Meropol 2003</LINK>; <LINK REF="STD-Rosen-2006" TYPE="STUDY">Rosen 2006</LINK>; <LINK REF="STD-Scarantino-2006" TYPE="STUDY">Scarantino 2006</LINK>; <LINK REF="STD-Shenep-1988" TYPE="STUDY">Shenep 1988</LINK>; <LINK REF="STD-Spielberger-2004" TYPE="STUDY">Spielberger 2004</LINK>; <LINK REF="STD-Tu-1998" TYPE="STUDY">Tu 1998</LINK>; <LINK REF="STD-Vacha-2003" TYPE="STUDY">Vacha 2003</LINK>; <LINK REF="STD-Yuen-2001" TYPE="STUDY">Yuen 2001</LINK>).</LI>
<LI>Toxicity - unspecific (<LINK REF="STD-Buentzel-2006" TYPE="STUDY">Buentzel 2006</LINK>; <LINK REF="STD-Cerchietti-2006" TYPE="STUDY">Cerchietti 2006</LINK>; <LINK REF="STD-Chi-1995" TYPE="STUDY">Chi 1995</LINK>; <LINK REF="STD-Duenas-1996" TYPE="STUDY">Duenas 1996</LINK>; <LINK REF="STD-El-Sayed-2002" TYPE="STUDY">El Sayed 2002</LINK>; <LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>; <LINK REF="STD-Fidler-1996" TYPE="STUDY">Fidler 1996</LINK>; <LINK REF="STD-Freytes-2004" TYPE="STUDY">Freytes 2004</LINK>; <LINK REF="STD-Giles-2004" TYPE="STUDY">Giles 2004</LINK>; <LINK REF="STD-Gujral-2001" TYPE="STUDY">Gujral 2001</LINK>; <LINK REF="STD-Mahood-1991" TYPE="STUDY">Mahood 1991</LINK>; <LINK REF="STD-Makkonen-1994" TYPE="STUDY">Makkonen 1994</LINK>; <LINK REF="STD-Makkonen-2000" TYPE="STUDY">Makkonen 2000</LINK>; <LINK REF="STD-Okuno-1999" TYPE="STUDY">Okuno 1999</LINK>; <LINK REF="STD-Puataweepong-2009" TYPE="STUDY">Puataweepong 2009</LINK>; <LINK REF="STD-Spielberger-2004" TYPE="STUDY">Spielberger 2004</LINK>; <LINK REF="STD-Su-2006" TYPE="STUDY">Su 2006</LINK>; <LINK REF="STD-Tu-1998" TYPE="STUDY">Tu 1998</LINK>).</LI>
<LI>Xerostomia (<LINK REF="STD-Antonadou-2002" TYPE="STUDY">Antonadou 2002</LINK>; <LINK REF="STD-Bourhis-2000" TYPE="STUDY">Bourhis 2000</LINK>; <LINK REF="STD-Brizel-2000" TYPE="STUDY">Brizel 2000</LINK>; <LINK REF="STD-Brizel-2008" TYPE="STUDY">Brizel 2008</LINK>; <LINK REF="STD-Buentzel-2006" TYPE="STUDY">Buentzel 2006</LINK>; <LINK REF="STD-Buntzel-1998" TYPE="STUDY">Buntzel 1998</LINK>; <LINK REF="STD-Castagna-2001" TYPE="STUDY">Castagna 2001</LINK>; <LINK REF="STD-Cengiz-1999" TYPE="STUDY">Cengiz 1999</LINK>; <LINK REF="STD-Dazzi-2003" TYPE="STUDY">Dazzi 2003</LINK>; <LINK REF="STD-Elad-2006" TYPE="STUDY">Elad 2006</LINK>; <LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>; <LINK REF="STD-Epstein-2001" TYPE="STUDY">Epstein 2001</LINK>; <LINK REF="STD-Goyal-2009" TYPE="STUDY">Goyal 2009</LINK>; <LINK REF="STD-Hartmann-2001" TYPE="STUDY">Hartmann 2001</LINK>; <LINK REF="STD-Koukourakis-2000" TYPE="STUDY">Koukourakis 2000</LINK>; <LINK REF="STD-Lockhart-2005" TYPE="STUDY">Lockhart 2005</LINK>; <LINK REF="STD-Makkonen-2000" TYPE="STUDY">Makkonen 2000</LINK>; <LINK REF="STD-McAleese-2006" TYPE="STUDY">McAleese 2006</LINK>; <LINK REF="STD-Meropol-2003" TYPE="STUDY">Meropol 2003</LINK>; <LINK REF="STD-Nottage-2003" TYPE="STUDY">Nottage 2003</LINK>; <LINK REF="STD-Oberbaum-2001" TYPE="STUDY">Oberbaum 2001</LINK>; <LINK REF="STD-Saarilahti-2002" TYPE="STUDY">Saarilahti 2002</LINK>; <LINK REF="STD-Scarantino-2006" TYPE="STUDY">Scarantino 2006</LINK>; <LINK REF="STD-Spencer-2005" TYPE="STUDY">Spencer 2005</LINK>; <LINK REF="STD-Vacha-2003" TYPE="STUDY">Vacha 2003</LINK>; <LINK REF="STD-Veerasarn-2006" TYPE="STUDY">Veerasarn 2006</LINK>; <LINK REF="STD-Watanabe-2010" TYPE="STUDY">Watanabe 2010</LINK>).</LI>
<LI>Cost (<LINK REF="STD-Bourhis-2000" TYPE="STUDY">Bourhis 2000</LINK>; <LINK REF="STD-Brizel-2000" TYPE="STUDY">Brizel 2000</LINK>; <LINK REF="STD-Buentzel-2006" TYPE="STUDY">Buentzel 2006</LINK>; <LINK REF="STD-Buntzel-1998" TYPE="STUDY">Buntzel 1998</LINK>; <LINK REF="STD-Choi-2007" TYPE="STUDY">Choi 2007</LINK>; <LINK REF="STD-Dodd-1996" TYPE="STUDY">Dodd 1996</LINK>; <LINK REF="STD-Haddad-2009" TYPE="STUDY">Haddad 2009</LINK>; <LINK REF="STD-Hartmann-2001" TYPE="STUDY">Hartmann 2001</LINK>; <LINK REF="STD-Hu-2005" TYPE="STUDY">Hu 2005</LINK>; <LINK REF="STD-Huang-2000" TYPE="STUDY">Huang 2000</LINK>; <LINK REF="STD-Koukourakis-2000" TYPE="STUDY">Koukourakis 2000</LINK>; <LINK REF="STD-Makkonen-2000" TYPE="STUDY">Makkonen 2000</LINK>; <LINK REF="STD-McAleese-2006" TYPE="STUDY">McAleese 2006</LINK>; <LINK REF="STD-Nemunaitis-1995" TYPE="STUDY">Nemunaitis 1995</LINK>; <LINK REF="STD-Nottage-2003" TYPE="STUDY">Nottage 2003</LINK>; <LINK REF="STD-Sornsuvit-2008" TYPE="STUDY">Sornsuvit 2008</LINK>; <LINK REF="STD-Su-2006" TYPE="STUDY">Su 2006</LINK>; <LINK REF="STD-Yuen-2001" TYPE="STUDY">Yuen 2001</LINK>).</LI>
<LI>Patient quality of life (<LINK REF="STD-Bjarnason-2009" TYPE="STUDY">Bjarnason 2009</LINK>; <LINK REF="STD-Brizel-2000" TYPE="STUDY">Brizel 2000</LINK>; <LINK REF="STD-McAleese-2006" TYPE="STUDY">McAleese 2006</LINK>; <LINK REF="STD-Nottage-2003" TYPE="STUDY">Nottage 2003</LINK>; <LINK REF="STD-Scarantino-2006" TYPE="STUDY">Scarantino 2006</LINK>; <LINK REF="STD-Spielberger-2004" TYPE="STUDY">Spielberger 2004</LINK>; <LINK REF="STD-Veness-2006" TYPE="STUDY">Veness 2006</LINK>).</LI>
<LI>Death (<LINK REF="STD-Ahmed-1993" TYPE="STUDY">Ahmed 1993</LINK>; <LINK REF="STD-Attal-1993" TYPE="STUDY">Attal 1993</LINK>; <LINK REF="STD-Bjarnason-2009" TYPE="STUDY">Bjarnason 2009</LINK>; <LINK REF="STD-Blazar-2006" TYPE="STUDY">Blazar 2006</LINK>; <LINK REF="STD-Brizel-2008" TYPE="STUDY">Brizel 2008</LINK>; <LINK REF="STD-Dickson-2000" TYPE="STUDY">Dickson 2000</LINK>; <LINK REF="STD-Dodd-1996" TYPE="STUDY">Dodd 1996</LINK>; <LINK REF="STD-Epstein-2001" TYPE="STUDY">Epstein 2001</LINK>; <LINK REF="STD-Ertekin-2004" TYPE="STUDY">Ertekin 2004</LINK>; <LINK REF="STD-Ferretti-1988" TYPE="STUDY">Ferretti 1988</LINK>; <LINK REF="STD-Giles-2004" TYPE="STUDY">Giles 2004</LINK>; <LINK REF="STD-Gujral-2001" TYPE="STUDY">Gujral 2001</LINK>; <LINK REF="STD-Kazemian-2009" TYPE="STUDY">Kazemian 2009</LINK>; <LINK REF="STD-Leborgne-1997" TYPE="STUDY">Leborgne 1997</LINK>; <LINK REF="STD-Madan-2008" TYPE="STUDY">Madan 2008</LINK>; <LINK REF="STD-Mills-1988" TYPE="STUDY">Mills 1988</LINK>; <LINK REF="STD-Oberbaum-2001" TYPE="STUDY">Oberbaum 2001</LINK>; <LINK REF="STD-Rahn-1997" TYPE="STUDY">Rahn 1997</LINK>; <LINK REF="STD-Rosen-2006" TYPE="STUDY">Rosen 2006</LINK>; <LINK REF="STD-Schubert-2007" TYPE="STUDY">Schubert 2007</LINK>; <LINK REF="STD-Spielberger-2004" TYPE="STUDY">Spielberger 2004</LINK>).</LI>
<LI>Weight loss/gain (<LINK REF="STD-Antonadou-2002" TYPE="STUDY">Antonadou 2002</LINK>; <LINK REF="STD-Biswal-2003" TYPE="STUDY">Biswal 2003</LINK>; <LINK REF="STD-Bjarnason-2009" TYPE="STUDY">Bjarnason 2009</LINK>; <LINK REF="STD-Brizel-2000" TYPE="STUDY">Brizel 2000</LINK>; <LINK REF="STD-Buentzel-2006" TYPE="STUDY">Buentzel 2006</LINK>; <LINK REF="STD-Buntzel-1998" TYPE="STUDY">Buntzel 1998</LINK>; <LINK REF="STD-Carter-1999" TYPE="STUDY">Carter 1999</LINK>; <LINK REF="STD-Cengiz-1999" TYPE="STUDY">Cengiz 1999</LINK>; <LINK REF="STD-Cerchietti-2006" TYPE="STUDY">Cerchietti 2006</LINK>; <LINK REF="STD-El-Sayed-2002" TYPE="STUDY">El Sayed 2002</LINK>; <LINK REF="STD-Elad-2006" TYPE="STUDY">Elad 2006</LINK>; <LINK REF="STD-Ertekin-2004" TYPE="STUDY">Ertekin 2004</LINK>; <LINK REF="STD-Foote-1994" TYPE="STUDY">Foote 1994</LINK>; <LINK REF="STD-Freytes-2004" TYPE="STUDY">Freytes 2004</LINK>; <LINK REF="STD-Haddad-2009" TYPE="STUDY">Haddad 2009</LINK>; <LINK REF="STD-Hanson-1995" TYPE="STUDY">Hanson 1995</LINK>; <LINK REF="STD-He-2008" TYPE="STUDY">He 2008</LINK>; <LINK REF="STD-Hu-2005" TYPE="STUDY">Hu 2005</LINK>; <LINK REF="STD-Huang-2000" TYPE="STUDY">Huang 2000</LINK>; <LINK REF="STD-Koukourakis-2000" TYPE="STUDY">Koukourakis 2000</LINK>; <LINK REF="STD-Leborgne-1997" TYPE="STUDY">Leborgne 1997</LINK>; <LINK REF="STD-Lievens-1998" TYPE="STUDY">Lievens 1998</LINK>; <LINK REF="STD-Lilleby-2006" TYPE="STUDY">Lilleby 2006</LINK>; <LINK REF="STD-Lin-2006" TYPE="STUDY">Lin 2006</LINK>; <LINK REF="STD-Makkonen-2000" TYPE="STUDY">Makkonen 2000</LINK>; <LINK REF="STD-Motallebnejad-2008" TYPE="STUDY">Motallebnejad 2008</LINK>; <LINK REF="STD-Nottage-2003" TYPE="STUDY">Nottage 2003</LINK>; <LINK REF="STD-Pillsbury-1986" TYPE="STUDY">Pillsbury 1986</LINK>; <LINK REF="STD-Puataweepong-2009" TYPE="STUDY">Puataweepong 2009</LINK>; <LINK REF="STD-Qin-2007" TYPE="STUDY">Qin 2007</LINK>; <LINK REF="STD-Shenep-1988" TYPE="STUDY">Shenep 1988</LINK>; <LINK REF="STD-Sornsuvit-2008" TYPE="STUDY">Sornsuvit 2008</LINK>; <LINK REF="STD-Stokman-2003" TYPE="STUDY">Stokman 2003</LINK>; <LINK REF="STD-Su-2004" TYPE="STUDY">Su 2004</LINK>; <LINK REF="STD-Su-2006" TYPE="STUDY">Su 2006</LINK>; <LINK REF="STD-Symonds-1996" TYPE="STUDY">Symonds 1996</LINK>; <LINK REF="STD-Trotti-2004" TYPE="STUDY">Trotti 2004</LINK>; <LINK REF="STD-Vacha-2003" TYPE="STUDY">Vacha 2003</LINK>; <LINK REF="STD-Veerasarn-2006" TYPE="STUDY">Veerasarn 2006</LINK>; <LINK REF="STD-Veness-2006" TYPE="STUDY">Veness 2006</LINK>; <LINK REF="STD-Wu-2009" TYPE="STUDY">Wu 2009</LINK>; <LINK REF="STD-You-2009" TYPE="STUDY">You 2009</LINK>).</LI>
<LI>Caloric intake by oral nutrition (<LINK REF="STD-Castagna-2001" TYPE="STUDY">Castagna 2001</LINK>; <LINK REF="STD-Cruz-2007" TYPE="STUDY">Cruz 2007</LINK>; <LINK REF="STD-Dickson-2000" TYPE="STUDY">Dickson 2000</LINK>; <LINK REF="STD-Freytes-2004" TYPE="STUDY">Freytes 2004</LINK>; <LINK REF="STD-Hartmann-2001" TYPE="STUDY">Hartmann 2001</LINK>; <LINK REF="STD-He-2008" TYPE="STUDY">He 2008</LINK>; <LINK REF="STD-Lilleby-2006" TYPE="STUDY">Lilleby 2006</LINK>; <LINK REF="STD-Pfeiffer-1990" TYPE="STUDY">Pfeiffer 1990</LINK>; <LINK REF="STD-Shenep-1988" TYPE="STUDY">Shenep 1988</LINK>; <LINK REF="STD-Spencer-2005" TYPE="STUDY">Spencer 2005</LINK>; <LINK REF="STD-Watanabe-2010" TYPE="STUDY">Watanabe 2010</LINK>).</LI>
<LI>Eating/drinking difficulty (<LINK REF="STD-Anderson-1998" TYPE="STUDY">Anderson 1998</LINK>; <LINK REF="STD-Carter-1999" TYPE="STUDY">Carter 1999</LINK>; <LINK REF="STD-Cengiz-1999" TYPE="STUDY">Cengiz 1999</LINK>; <LINK REF="STD-Cerchietti-2006" TYPE="STUDY">Cerchietti 2006</LINK>; <LINK REF="STD-Dickson-2000" TYPE="STUDY">Dickson 2000</LINK>; <LINK REF="STD-El-Sayed-2002" TYPE="STUDY">El Sayed 2002</LINK>; <LINK REF="STD-Evensen-2001" TYPE="STUDY">Evensen 2001</LINK>; <LINK REF="STD-Franzen-1995" TYPE="STUDY">Franzen 1995</LINK>; <LINK REF="STD-Freytes-2004" TYPE="STUDY">Freytes 2004</LINK>; <LINK REF="STD-Jebb-1994" TYPE="STUDY">Jebb 1994</LINK>; <LINK REF="STD-Lilleby-2006" TYPE="STUDY">Lilleby 2006</LINK>; <LINK REF="STD-Lockhart-2005" TYPE="STUDY">Lockhart 2005</LINK>; <LINK REF="STD-Nottage-2003" TYPE="STUDY">Nottage 2003</LINK>; <LINK REF="STD-Oberbaum-2001" TYPE="STUDY">Oberbaum 2001</LINK>; <LINK REF="STD-Pfeiffer-1990" TYPE="STUDY">Pfeiffer 1990</LINK>; <LINK REF="STD-Prada-1987" TYPE="STUDY">Prada 1987</LINK>; <LINK REF="STD-Rashad-2008" TYPE="STUDY">Rashad 2008</LINK>; <LINK REF="STD-Rosen-2006" TYPE="STUDY">Rosen 2006</LINK>; <LINK REF="STD-Scarantino-2006" TYPE="STUDY">Scarantino 2006</LINK>; <LINK REF="STD-Shenep-1988" TYPE="STUDY">Shenep 1988</LINK>; <LINK REF="STD-Sornsuvit-2008" TYPE="STUDY">Sornsuvit 2008</LINK>; <LINK REF="STD-Spielberger-2004" TYPE="STUDY">Spielberger 2004</LINK>; <LINK REF="STD-Stokman-2003" TYPE="STUDY">Stokman 2003</LINK>; <LINK REF="STD-Symonds-1996" TYPE="STUDY">Symonds 1996</LINK>; <LINK REF="STD-Vadhan_x002d_Raj-2010" TYPE="STUDY">Vadhan-Raj 2010</LINK>).</LI>
<LI>Overall health (<LINK REF="STD-Antonadou-2002" TYPE="STUDY">Antonadou 2002</LINK>; <LINK REF="STD-Bourhis-2000" TYPE="STUDY">Bourhis 2000</LINK>; <LINK REF="STD-Brizel-2000" TYPE="STUDY">Brizel 2000</LINK>; <LINK REF="STD-Buentzel-2006" TYPE="STUDY">Buentzel 2006</LINK>; <LINK REF="STD-Elad-2006" TYPE="STUDY">Elad 2006</LINK>; <LINK REF="STD-Ertekin-2004" TYPE="STUDY">Ertekin 2004</LINK>; <LINK REF="STD-Haddad-2009" TYPE="STUDY">Haddad 2009</LINK>; <LINK REF="STD-Ifrah-1999" TYPE="STUDY">Ifrah 1999</LINK>; <LINK REF="STD-Jebb-1994" TYPE="STUDY">Jebb 1994</LINK>; <LINK REF="STD-Lilleby-2006" TYPE="STUDY">Lilleby 2006</LINK>; <LINK REF="STD-Makkonen-2000" TYPE="STUDY">Makkonen 2000</LINK>; <LINK REF="STD-McAleese-2006" TYPE="STUDY">McAleese 2006</LINK>; <LINK REF="STD-Nemunaitis-1995" TYPE="STUDY">Nemunaitis 1995</LINK>; <LINK REF="STD-Rosen-2006" TYPE="STUDY">Rosen 2006</LINK>; <LINK REF="STD-Shenep-1988" TYPE="STUDY">Shenep 1988</LINK>; <LINK REF="STD-Su-2004" TYPE="STUDY">Su 2004</LINK>; <LINK REF="STD-Su-2006" TYPE="STUDY">Su 2006</LINK>; <LINK REF="STD-Wu-2009" TYPE="STUDY">Wu 2009</LINK>).</LI>
<LI>Recurrence of cancer (<LINK REF="STD-Ahmed-1993" TYPE="STUDY">Ahmed 1993</LINK>; <LINK REF="STD-Attal-1993" TYPE="STUDY">Attal 1993</LINK>; <LINK REF="STD-Bjarnason-2009" TYPE="STUDY">Bjarnason 2009</LINK>; <LINK REF="STD-Blazar-2006" TYPE="STUDY">Blazar 2006</LINK>; <LINK REF="STD-Brizel-2000" TYPE="STUDY">Brizel 2000</LINK>; <LINK REF="STD-Brizel-2008" TYPE="STUDY">Brizel 2008</LINK>; <LINK REF="STD-Cerchietti-2006" TYPE="STUDY">Cerchietti 2006</LINK>; <LINK REF="STD-Chi-1995" TYPE="STUDY">Chi 1995</LINK>; <LINK REF="STD-Dickson-2000" TYPE="STUDY">Dickson 2000</LINK>; <LINK REF="STD-Duenas-1996" TYPE="STUDY">Duenas 1996</LINK>; <LINK REF="STD-Goyal-2009" TYPE="STUDY">Goyal 2009</LINK>; <LINK REF="STD-Gujral-2001" TYPE="STUDY">Gujral 2001</LINK>; <LINK REF="STD-Leborgne-1997" TYPE="STUDY">Leborgne 1997</LINK>; <LINK REF="STD-Li-2006" TYPE="STUDY">Li 2006</LINK>; <LINK REF="STD-Makkonen-2000" TYPE="STUDY">Makkonen 2000</LINK>; <LINK REF="STD-Mills-1988" TYPE="STUDY">Mills 1988</LINK>; <LINK REF="STD-Okuno-1999" TYPE="STUDY">Okuno 1999</LINK>; <LINK REF="STD-Pillsbury-1986" TYPE="STUDY">Pillsbury 1986</LINK>; <LINK REF="STD-Rosen-2006" TYPE="STUDY">Rosen 2006</LINK>; <LINK REF="STD-Saarilahti-2002" TYPE="STUDY">Saarilahti 2002</LINK>; <LINK REF="STD-Schneider-1999" TYPE="STUDY">Schneider 1999</LINK>; <LINK REF="STD-Spielberger-2004" TYPE="STUDY">Spielberger 2004</LINK>; <LINK REF="STD-Vadhan_x002d_Raj-2010" TYPE="STUDY">Vadhan-Raj 2010</LINK>; <LINK REF="STD-Watanabe-2010" TYPE="STUDY">Watanabe 2010</LINK>).</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-11-10 15:17:54 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Adequate sequence generation</HEADING>
<P>Twenty-seven studies (21%) were deemed to have adequate sequence generation, and therefore were classified as being at low risk of bias for this domain. Thirteen of these studies employed computer-based sequence generation; while, four studies employed minimization. Four studies did not provide enough information about the randomisation process; however it was the opinion of the assessors that the setting of these trials made adequate randomisation likely. These studies were conducted at the Dana Faber cancer institute (<LINK REF="STD-Haddad-2009" TYPE="STUDY">Haddad 2009</LINK>), the Memorial Sloan Kettering Cancer Centre (<LINK REF="STD-Su-2004" TYPE="STUDY">Su 2004</LINK>), the Duke Centre (<LINK REF="STD-Cartee-1995" TYPE="STUDY">Cartee 1995</LINK>) and the Finish cancer registry (<LINK REF="STD-Makkonen-2000" TYPE="STUDY">Makkonen 2000</LINK>).One study used biased coin randomisation (<LINK REF="STD-Su-2004" TYPE="STUDY">Su 2004</LINK>). Of the remaining five studies, three used a table of random numbers (<LINK REF="STD-Huang-2003" TYPE="STUDY">Huang 2003;</LINK> <LINK REF="STD-Koukourakis-2000" TYPE="STUDY">Koukourakis 2000</LINK>; <LINK REF="STD-Pitten-2003" TYPE="STUDY">Pitten 2003</LINK>), and two studies provided limited information but made reference to appropriate literature concerning randomisation (<LINK REF="STD-Brizel-2000" TYPE="STUDY">Brizel 2000;</LINK> <LINK REF="STD-Shieh-1997" TYPE="STUDY">Shieh 1997</LINK>). Those studies considered to use an inappropriate method of randomisation were excluded; therefore no studies were given a decision of no for this category. The remaining 104 studies (79%) were judged as 'unclear'. The majority of these unclear studies gave no more information than that they were 'randomised'. Four studies stated that they employed the "closed envelope" method of randomisation. However, no information was provided about whether these envelopes were shuffled prior to the patient being randomised. They were therefore classified as "unclear".</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adequate allocation concealment</HEADING>
<P>Nineteen studies (14%) employed adequate methods of allocation concealment and were therefore classified as being at low risk of bias. Central randomisation was mentioned in 15 studies, with eight studies employing pharmacy controlled randomisation, six studies communicating by telephone, and one study by fax (<LINK REF="STD-Gandemer-2007" TYPE="STUDY">Gandemer 2007</LINK>). Two studies employed sequentially numbered drug containers which were identical in appearance (<LINK REF="STD-Foote-1994" TYPE="STUDY">Foote 1994;</LINK> <LINK REF="STD-Madan-2008" TYPE="STUDY">Madan 2008</LINK>). Two studies (1.5%) used open number tables without concealment and were therefore deemed to be at high risk of bias (<LINK REF="STD-Huang-2003" TYPE="STUDY">Huang 2003;</LINK> <LINK REF="STD-Koukourakis-2000" TYPE="STUDY">Koukourakis 2000</LINK>). The remaining 111 studies were classified as unclear.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding</HEADING>
<P>Blinding was assessed for three different groups: patients, carers and outcome assessors.</P>
<P>Carer blinding: Nineteen studies (15%) described some method of blinding and were therefore deemed to be at low risk of bias for carer blinding. Forty-five studies (34%) were classified as being at high risk of bias, as no blinding was employed. Sixty-seven (51%) studies were classified as 'unclear'.</P>
<P>Patient blinding: Forty-five studies were classified as being at high risk of bias for patient blinding. The majority of these were studies which employed no blinding, however one study was described by its authors as double blind, but then went on to state that a patient withdrew from the study because they were not allocated the intervention of interest (<LINK REF="STD-Wu-2009" TYPE="STUDY">Wu 2009</LINK>). The assessors were concerned that this suggested a failure in the blinding of patients in this study, and therefore decided to characterise the study at high risk of bias for all three blinding categories. Seventy-five studies (58%) were deemed to be at low risk of bias for patient blinding. Eleven studies (8%) were classified as unclear. Of these studies, four were deemed unclear as they employed the use of a placebo control, and therefore blinding could not be discounted, while three studies were assessed for risk of bias from a data collection sheet provided by a translator without any additional information. Of the remaining four 'unclear' studies, one study which compared povidone-iodine to saline was described as 'blind' to patients, however, this was considered by the assessors to be an inappropriate control as presumably the iodine solution would differ in colour from the saline (<LINK REF="STD-Vokurka-2005" TYPE="STUDY">Vokurka 2005</LINK>). Another which investigated zinc in head and neck patients receiving a mix of radiotherapy and chemoradiotherapy (<LINK REF="STD-Ertekin-2004" TYPE="STUDY">Ertekin 2004</LINK>), was classified as unclear for two reasons: firstly, because the study authors described the need for a double blind study in the introduction, and then failed to provide any information about blinding in the remainder of the text, and secondly, because the authors used empty capsules as the control, and the assessors were concerned that this would be noticeable to the patients. The third study (<LINK REF="STD-Vadhan_x002d_Raj-2010" TYPE="STUDY">Vadhan-Raj 2010</LINK>) was deemed unclear because the authors stated that adverse events associated with the intervention (keratinocyte growth factor) may have affected the integrity of the blinding. The remaining trial (<LINK REF="STD-Ahmed-1993" TYPE="STUDY">Ahmed 1993</LINK>) only stated that "trial drugs were administered blind", without any additional information.</P>
<P>Outcome assessor blinding: Seventy-seven studies (59%) were deemed to describe any method of outcome assessor blinding adequately and were considered to be at low risk of bias. Sixteen studies (12%) were classified as unclear and 38 studies (29%) were given a decision of 'no' and were therefore considered to be at high risk of bias in this category. In a subanalysis of those studies providing blinding information, only 19 studies gave specific information regarding the blinding of an outcome assessor. The remaining 58 studies were only described as "double blind" by the authors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Incomplete outcome data addressed</HEADING>
<P>One hundred and six studies (82%) were considered to be at low risk of bias for this category. Seventeen studies (13%) were given a decision of unclear and eight were considered to be at high risk of bias. These seven studies experienced a high rate of drop out.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Free of selective reporting</HEADING>
<P>Forty-nine (37%) studies were deemed to be free of selective reporting for mucositis grade, which was determined prior to assessment as the outcome of interest for this category. These studies were therefore deemed to be at a low risk of bias. The remaining 82 studies were classified as unclear. These studies tended to only provide subsets of data for severe mucositis (grade &gt; 2) rather than all the information of interest. No studies were given a decision of 'no', and consequently classified at high risk of bias, as studies which did not provide mucositis information for at least one of the dichotomies of interest could not be included in the review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Free of other bias</HEADING>
<P>Thirty-five studies (27%) were deemed to be at high risk of bias in the final 'other' category. A baseline imbalance was reported by 11 studies. Three studies reported gender imbalances (<LINK REF="STD-Abbasi_x002d_Nazari-2007" TYPE="STUDY">Abbasi-Nazari 2007;</LINK> <LINK REF="STD-Makkonen-1994" TYPE="STUDY">Makkonen 1994</LINK>; <LINK REF="STD-Puataweepong-2009" TYPE="STUDY">Puataweepong 2009</LINK>), while three studies reported age imbalances (<LINK REF="STD-Bensadoun-1999" TYPE="STUDY">Bensadoun 1999</LINK>; <LINK REF="STD-Ifrah-1999" TYPE="STUDY">Ifrah 1999</LINK>; <LINK REF="STD-Makkonen-1994" TYPE="STUDY">Makkonen 1994</LINK>). Two or more baseline imbalances were reported by four studies (<LINK REF="STD-Bensadoun-1999" TYPE="STUDY">Bensadoun 1999</LINK>; <LINK REF="STD-Ifrah-1999" TYPE="STUDY">Ifrah 1999;</LINK> <LINK REF="STD-Makkonen-1994" TYPE="STUDY">Makkonen 1994</LINK>; <LINK REF="STD-Puataweepong-2009" TYPE="STUDY">Puataweepong 2009</LINK>). <LINK REF="STD-Puataweepong-2009" TYPE="STUDY">Puataweepong 2009</LINK> reported baseline imbalances in both patient gender (P = 0.03) and previous surgery (P = 0.04). Meanwhile, in the <LINK REF="STD-Ifrah-1999" TYPE="STUDY">Ifrah 1999</LINK> study, patients randomised to receive GM-CSF in the intervention arm of the study, were older (P = 0.04) and more likely to have the Philadelphia chromosomal re-arrangement (P = 0.026). Baseline imbalances in age and gender were reported by Makkonen and colleagues (<LINK REF="STD-Makkonen-1994" TYPE="STUDY">Makkonen 1994</LINK>). Bensadoun and colleagues reported imbalances in the number of patients receiving supplementary application of laser to the neck, which was hypothesised to exert a distant beneficial effect. In this study patients in the intervention group also tended to be older. However, no P values were presented by the authors for this imbalance (<LINK REF="STD-Bensadoun-1999" TYPE="STUDY">Bensadoun 1999</LINK>). Risk of bias was assessed for eight studies from a data collection form completed by a translator. Loprinzi and colleagues initially aimed to recruit 120 patients into their allopurinol study, however, the power calculation was re-run after 77 patients and as the results were found to favour the intervention, the study was terminated and the data published (<LINK REF="STD-Loprinzi-1990" TYPE="STUDY">Loprinzi 1990</LINK>). In the Duenas and colleagues study (<LINK REF="STD-Duenas-1996" TYPE="STUDY">Duenas 1996</LINK>), an interim analysis conducted in the 16 patients recruited into the study showed a significant different in favour of the placebo, and the authors therefore decided to cease recruitment. Epstein and colleagues also report the results of an interim analysis, in this case a trial of 33 patients which compared sucralfate to placebo. This trial was terminated after an interim analysis suggested that the impact of sucralfate on mucositis prevention was minimal (<LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Overall risk of bias</HEADING>
<P>
<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.<BR/>Eleven studies were assessed at low overall risk of bias (8%) (<LINK REF="STD-Cartee-1995" TYPE="STUDY">Cartee 1995;</LINK> <LINK REF="STD-Dazzi-2003" TYPE="STUDY">Dazzi 2003;</LINK> <LINK REF="STD-Foote-1994" TYPE="STUDY">Foote 1994</LINK>; <LINK REF="STD-Madan-2008" TYPE="STUDY">Madan 2008</LINK>; <LINK REF="STD-Oberbaum-2001" TYPE="STUDY">Oberbaum 2001</LINK>; <LINK REF="STD-Pitten-2003" TYPE="STUDY">Pitten 2003</LINK>; <LINK REF="STD-Saarilahti-2002" TYPE="STUDY">Saarilahti 2002</LINK>; <LINK REF="STD-Schneider-1999" TYPE="STUDY">Schneider 1999</LINK>; <LINK REF="STD-Shenep-1988" TYPE="STUDY">Shenep 1988</LINK>; <LINK REF="STD-Stokman-2003" TYPE="STUDY">Stokman 2003</LINK>; <LINK REF="STD-Su-2006" TYPE="STUDY">Su 2006</LINK>), 82 (63%) were described as unclear and the remaining 38 studies (29%) were defined as being at high overall risk of bias (<LINK REF="STD-Antonadou-2002" TYPE="STUDY">Antonadou 2002</LINK>; <LINK REF="STD-Antunes-2007" TYPE="STUDY">Antunes 2007</LINK>; <LINK REF="STD-Biswal-2003" TYPE="STUDY">Biswal 2003</LINK>; <LINK REF="STD-Bjarnason-2009" TYPE="STUDY">Bjarnason 2009</LINK>; <LINK REF="STD-Borowski-1994" TYPE="STUDY">Borowski 1994</LINK>; <LINK REF="STD-Bourhis-2000" TYPE="STUDY">Bourhis 2000</LINK>; <LINK REF="STD-Brizel-2000" TYPE="STUDY">Brizel 2000</LINK>; <LINK REF="STD-Buntzel-1998" TYPE="STUDY">Buntzel 1998</LINK>; <LINK REF="STD-Cascinu-1994" TYPE="STUDY">Cascinu 1994</LINK>; <LINK REF="STD-Chi-1995" TYPE="STUDY">Chi 1995</LINK>; <LINK REF="STD-Choi-2007" TYPE="STUDY">Choi 2007</LINK>; <LINK REF="STD-Dai-2009" TYPE="STUDY">Dai 2009</LINK>; <LINK REF="STD-Dozono-1989" TYPE="STUDY">Dozono 1989</LINK>; <LINK REF="STD-Gandemer-2007" TYPE="STUDY">Gandemer 2007</LINK>; <LINK REF="STD-Gori-2007" TYPE="STUDY">Gori 2007</LINK>; <LINK REF="STD-Gujral-2001" TYPE="STUDY">Gujral 2001</LINK>; <LINK REF="STD-Haddad-2009" TYPE="STUDY">Haddad 2009</LINK>; <LINK REF="STD-Hartmann-2001" TYPE="STUDY">Hartmann 2001</LINK>; <LINK REF="STD-Huang-2000" TYPE="STUDY">Huang 2000</LINK>; <LINK REF="STD-Katano-1995" TYPE="STUDY">Katano 1995</LINK>; <LINK REF="STD-Kaul-1999" TYPE="STUDY">Kaul 1999</LINK>; <LINK REF="STD-Koukourakis-2000" TYPE="STUDY">Koukourakis 2000</LINK>; <LINK REF="STD-Lilleby-2006" TYPE="STUDY">Lilleby 2006</LINK>; <LINK REF="STD-Makkonen-2000" TYPE="STUDY">Makkonen 2000</LINK>; <LINK REF="STD-Mills-1988" TYPE="STUDY">Mills 1988</LINK>; <LINK REF="STD-Rahn-1997" TYPE="STUDY">Rahn 1997</LINK>; <LINK REF="STD-Rashad-2008" TYPE="STUDY">Rashad 2008</LINK>; <LINK REF="STD-Rocke-1993" TYPE="STUDY">Rocke 1993</LINK>; <LINK REF="STD-Shieh-1997" TYPE="STUDY">Shieh 1997</LINK>; <LINK REF="STD-Spencer-2005" TYPE="STUDY">Spencer 2005</LINK>; <LINK REF="STD-Svanberg-2007" TYPE="STUDY">Svanberg 2007</LINK>; <LINK REF="STD-Vacha-2003" TYPE="STUDY">Vacha 2003</LINK>; <LINK REF="STD-Vadhan_x002d_Raj-2010" TYPE="STUDY">Vadhan-Raj 2010</LINK>; <LINK REF="STD-Veerasarn-2006" TYPE="STUDY">Veerasarn 2006</LINK>; <LINK REF="STD-Wahlin-1989" TYPE="STUDY">Wahlin 1989</LINK>; <LINK REF="STD-Watanabe-2010" TYPE="STUDY">Watanabe 2010</LINK>; <LINK REF="STD-Wu-2009" TYPE="STUDY">Wu 2009</LINK>; <LINK REF="STD-Yuen-2001" TYPE="STUDY">Yuen 2001</LINK>).</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-04-26 14:24:16 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Interventions with more than one trial</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Allopurinol versus placebo/no treatment (Analysis 1.1; Analysis 1.2; Analysis 1.3)</HEADING>
<P>There were four trials (<LINK REF="STD-Abbasi_x002d_Nazari-2007" TYPE="STUDY">Abbasi-Nazari 2007</LINK>; <LINK REF="STD-Dozono-1989" TYPE="STUDY">Dozono 1989</LINK>; <LINK REF="STD-Loprinzi-1990" TYPE="STUDY">Loprinzi 1990</LINK>; <LINK REF="STD-Panahi-2009" TYPE="STUDY">Panahi 2009</LINK>), two designed as cross-over studies (<LINK REF="STD-Dozono-1989" TYPE="STUDY">Dozono 1989</LINK>; <LINK REF="STD-Loprinzi-1990" TYPE="STUDY">Loprinzi 1990</LINK>), which compared allopurinol mouthrinse with placebo or no treatment. Three of these studies were conducted in patients undergoing treatment with chemotherapy for solid tumours. One study was conducted in patients receiving radiotherapy +/- chemotherapy for head and neck cancer (<LINK REF="STD-Abbasi_x002d_Nazari-2007" TYPE="STUDY">Abbasi-Nazari 2007</LINK>). Data were provided for all three outcome categories.</P>
<P>All trials provided data for the outcome category of any mucositis, and there was no statistically significant difference between allopurinol and control, risk ratio (RR) 0.77 (95% confidence interval (CI) 0.50 to 1.19, P = 0.24, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). Two trials, both assessed as being at unclear risk of bias, provided data for the moderate plus severe and severe outcome categories (<LINK REF="STD-Abbasi_x002d_Nazari-2007" TYPE="STUDY">Abbasi-Nazari 2007</LINK>; <LINK REF="STD-Panahi-2009" TYPE="STUDY">Panahi 2009</LINK>). There was substantial heterogeneity in both the moderate plus severe meta-analysis (Chi<SUP>2</SUP> = 8.24, degrees of freedom (df) = 1, P = 0.004, I<SUP>2 </SUP>= 88%, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) and the severe meta-analysis (Chi<SUP>2</SUP> = 13.14, df = 1, P = 0.0003, I<SUP>2 </SUP>= 92%, <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>), probably due to differences with regard to the type of tumour and cancer treatment in the trials. The effect estimates from these trials are inconsistent; the risk of bias is unclear and there is substantial heterogeneity.</P>
<P>Overall, there is weak inconsistent evidence which is insufficient to indicate a benefit of allopurinol in the prevention of mucositis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Aloe vera solution versus placebo (Analysis 2.1)</HEADING>
<P>Two trials (<LINK REF="STD-Puataweepong-2009" TYPE="STUDY">Puataweepong 2009</LINK>; <LINK REF="STD-Su-2004" TYPE="STUDY">Su 2004</LINK>), comprising a total of 119 patients with head and neck cancer undergoing radiotherapy or chemoradiotherapy compared aloe vera with placebo. Both trials were found to be at unclear risk of bias. Both provided data for the outcome category of prevention of moderate plus severe mucositis and showed a statistically significant benefit in favour of aloe vera, RR 0.74 (95% CI 0.58 to 0.96, P = 0.02, <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) with moderate heterogeneity (Chi<SUP>2</SUP> = 2.42, df = 1 (P = 0.12); I<SUP>2</SUP> = 59%).</P>
<P>
<LINK REF="STD-Su-2004" TYPE="STUDY">Su 2004</LINK> found a statistically significant reduction in severe mucositis in the aloe vera group but <LINK REF="STD-Puataweepong-2009" TYPE="STUDY">Puataweepong 2009</LINK> found no difference between the groups with regard to the prevention of any mucositis (Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>Overall, there is weak unreliable evidence that aloe vera may be beneficial in the prevention of moderate to severe mucositis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Amifostine versus placebo/no treatment (Analysis 3.1; Analysis 3.2; Analysis 3.3)</HEADING>
<P>Eleven trials compared amifostine with no treatment (<LINK REF="STD-Antonadou-2002" TYPE="STUDY">Antonadou 2002</LINK>; <LINK REF="STD-Bourhis-2000" TYPE="STUDY">Bourhis 2000</LINK>; <LINK REF="STD-Brizel-2000" TYPE="STUDY">Brizel 2000</LINK>; <LINK REF="STD-Buntzel-1998" TYPE="STUDY">Buntzel 1998</LINK>; <LINK REF="STD-Haddad-2009" TYPE="STUDY">Haddad 2009</LINK>; <LINK REF="STD-Hartmann-2001" TYPE="STUDY">Hartmann 2001</LINK>; <LINK REF="STD-Koukourakis-2000" TYPE="STUDY">Koukourakis 2000</LINK>; <LINK REF="STD-Spencer-2005" TYPE="STUDY">Spencer 2005</LINK>; <LINK REF="STD-Vacha-2003" TYPE="STUDY">Vacha 2003</LINK>; <LINK REF="STD-Veerasarn-2006" TYPE="STUDY">Veerasarn 2006</LINK>) or a placebo (<LINK REF="STD-Buentzel-2006" TYPE="STUDY">Buentzel 2006</LINK>). Most of the trials recruited adults with head and neck cancer being treated with radiotherapy (<LINK REF="STD-Bourhis-2000" TYPE="STUDY">Bourhis 2000</LINK>; <LINK REF="STD-Brizel-2000" TYPE="STUDY">Brizel 2000</LINK>; <LINK REF="STD-Veerasarn-2006" TYPE="STUDY">Veerasarn 2006</LINK>) or chemo-radiotherapy (<LINK REF="STD-Antonadou-2002" TYPE="STUDY">Antonadou 2002</LINK>; <LINK REF="STD-Buentzel-2006" TYPE="STUDY">Buentzel 2006</LINK>; <LINK REF="STD-Buntzel-1998" TYPE="STUDY">Buntzel 1998</LINK>; <LINK REF="STD-Haddad-2009" TYPE="STUDY">Haddad 2009</LINK>; <LINK REF="STD-Vacha-2003" TYPE="STUDY">Vacha 2003</LINK>). Two trials (<LINK REF="STD-Hartmann-2001" TYPE="STUDY">Hartmann 2001</LINK>; <LINK REF="STD-Spencer-2005" TYPE="STUDY">Spencer 2005</LINK>) included patients having bone marrow transplants, and one trial (<LINK REF="STD-Koukourakis-2000" TYPE="STUDY">Koukourakis 2000</LINK>) included adults with solid tumours receiving radiotherapy. Eight trials were found to be at high risk of bias (<LINK REF="STD-Antonadou-2002" TYPE="STUDY">Antonadou 2002</LINK>; <LINK REF="STD-Bourhis-2000" TYPE="STUDY">Bourhis 2000</LINK>; <LINK REF="STD-Brizel-2000" TYPE="STUDY">Brizel 2000</LINK>; <LINK REF="STD-Haddad-2009" TYPE="STUDY">Haddad 2009</LINK>; <LINK REF="STD-Koukourakis-2000" TYPE="STUDY">Koukourakis 2000</LINK>; <LINK REF="STD-Spencer-2005" TYPE="STUDY">Spencer 2005</LINK>; <LINK REF="STD-Vacha-2003" TYPE="STUDY">Vacha 2003</LINK>; <LINK REF="STD-Veerasarn-2006" TYPE="STUDY">Veerasarn 2006</LINK>) and three trials were found to be at unclear risk of bias (<LINK REF="STD-Buentzel-2006" TYPE="STUDY">Buentzel 2006</LINK>; <LINK REF="STD-Buntzel-1998" TYPE="STUDY">Buntzel 1998</LINK>; <LINK REF="STD-Hartmann-2001" TYPE="STUDY">Hartmann 2001</LINK>).</P>
<P>Three trials provided data for the outcome of any mucositis. There was a significant but small benefit for amifostine preventing mucositis in this outcome category with RR = 0.95 (95% CI 0.91 to 0.99, P = 0.007, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
<P>Six heterogeneous trials provided data for moderate plus severe mucositis demonstrating a benefit for amifostine compared with placebo or no treatment, RR = 0.75 (95% CI 0.58 to 0.96, P = 0.02, <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>). However, this meta-analysis showed substantial heterogeneity: Chi<SUP>2</SUP> = 25.86, df = 5, P &lt; 0.0001, I<SUP>2 </SUP>= 81%, which is not explained by cancer treatment (radiotherapy or chemotherapy) or dose of amifostine.</P>
<P>Nine trials provided data for severe mucositis and the pooled meta-analysis showed weak evidence of a possible benefit for amifostine in the prevention of severe mucositis, RR = 0.68 (95% CI 0.45 to 1.03, P = 0.07, <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>).</P>
<P>A further trial (<LINK REF="STD-Vacha-2003" TYPE="STUDY">Vacha 2003</LINK>) at high risk of bias provided a graph of weekly mean mucositis scores and the text indicated that there was a statistically significant difference in favour of amifostine compared to no treatment at 2 weeks, however no overall result was given in this paper (Additional <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
<P>The results from these 11 studies indicate that there is weak unreliable evidence that amifostine may prevent oral mucositis in adults.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Benzydamine versus placebo</HEADING>
<P>Four studies compared benzydamine mouthwash (marketed as Difflam) with placebo, in a combined total of 332 patients. <LINK REF="STD-Kazemian-2009" TYPE="STUDY">Kazemian 2009</LINK> found a statistically significant reduction in severe mucositis and <LINK REF="STD-Prada-1987" TYPE="STUDY">Prada 1987</LINK> found a statistically significant reduction in the development of any mucositis associated with benzydamine (Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Both studies were assessed as being at unclear risk of bias.</P>
<P>Two further studies (<LINK REF="STD-Epstein-1989" TYPE="STUDY">Epstein 1989</LINK>; <LINK REF="STD-Epstein-2001" TYPE="STUDY">Epstein 2001</LINK>), both assessed as being at unclear risk of bias, compared benzydamine with placebo and used other mucositis indices to evaluate the outcome. Both trials reported statistically significant differences in favour of benzydamine (Additional <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
<P>There is weak unreliable evidence that the use of benzydamine may reduce the development of mucositis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Chlorhexidine versus placebo/no treatment (Analysis 4.1; Analysis 4.2; Analysis 4.3)</HEADING>
<P>Nine trials, with a total of 692 participants, compared chlorhexidine mouthwash with either a placebo or no treatment control group. Four trials (<LINK REF="STD-Dodd-1996" TYPE="STUDY">Dodd 1996</LINK>; <LINK REF="STD-Ferretti-1988" TYPE="STUDY">Ferretti 1988</LINK>; <LINK REF="STD-Foote-1994" TYPE="STUDY">Foote 1994</LINK>; <LINK REF="STD-Sorensen-2008" TYPE="STUDY">Sorensen 2008</LINK>) provided data for the first outcome category (any mucositis), three trials (<LINK REF="STD-Foote-1994" TYPE="STUDY">Foote 1994</LINK>; <LINK REF="STD-Pitten-2003" TYPE="STUDY">Pitten 2003</LINK>; <LINK REF="STD-Sorensen-2008" TYPE="STUDY">Sorensen 2008</LINK> ) provided data for the second outcome level, moderate plus severe mucositis, and four trials (<LINK REF="STD-Foote-1994" TYPE="STUDY">Foote 1994</LINK>; <LINK REF="STD-Sorensen-2008" TYPE="STUDY">Sorensen 2008</LINK>; <LINK REF="STD-Spijkervet-1989" TYPE="STUDY">Spijkervet 1989</LINK>; <LINK REF="STD-Wahlin-1989" TYPE="STUDY">Wahlin 1989</LINK>) provided data for severe mucositis (grade 3 or greater).</P>
<P>
<LINK REF="STD-Madan-2008" TYPE="STUDY">Madan 2008</LINK> compared three active treatments: chlorhexidine, povidone iodine, and salt/soda mouthwashes with placebo, and <LINK REF="STD-McGaw-1985" TYPE="STUDY">McGaw 1985</LINK> compared chlorhexidine mouthwash with placebo, and both these studies presented data as mean mucositis scores for each group (Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>Three studies were found to be at low risk of bias (<LINK REF="STD-Foote-1994" TYPE="STUDY">Foote 1994</LINK>; <LINK REF="STD-Pitten-2003" TYPE="STUDY">Pitten 2003</LINK>; <LINK REF="STD-Madan-2008" TYPE="STUDY">Madan 2008</LINK>), one study was found to be at high risk of bias (<LINK REF="STD-Wahlin-1989" TYPE="STUDY">Wahlin 1989</LINK>). The remaining five studies were found to be at unclear risk of bias (<LINK REF="STD-Dodd-1996" TYPE="STUDY">Dodd 1996</LINK>; <LINK REF="STD-Ferretti-1988" TYPE="STUDY">Ferretti 1988</LINK>; <LINK REF="STD-McGaw-1985" TYPE="STUDY">McGaw 1985</LINK>; <LINK REF="STD-Sorensen-2008" TYPE="STUDY">Sorensen 2008</LINK>; <LINK REF="STD-Spijkervet-1989" TYPE="STUDY">Spijkervet 1989</LINK>).</P>
<P>There was substantial heterogeneity in the meta-analysis of any mucositis (Chi<SUP>2</SUP> = 30.49, df = 3, P &lt; 0.00001, I<SUP>2 </SUP>= 90%, <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>) and moderate plus severe (Chi<SUP>2</SUP> = 10.84, df = 2, P = 0.004, I<SUP>2 </SUP>= 82%, <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>) mucositis levels which may be partly due to clinical differences between the studies in terms of the cancer type and treatment. In one trial (<LINK REF="STD-Foote-1994" TYPE="STUDY">Foote 1994</LINK>) patients received radiotherapy for head and neck cancer, in three trials (<LINK REF="STD-Dodd-1996" TYPE="STUDY">Dodd 1996</LINK>; <LINK REF="STD-Pitten-2003" TYPE="STUDY">Pitten 2003</LINK>; <LINK REF="STD-Sorensen-2008" TYPE="STUDY">Sorensen 2008</LINK>) patients received chemotherapy for either solid tumours or mixed cancers and in the fifth study (<LINK REF="STD-Ferretti-1988" TYPE="STUDY">Ferretti 1988</LINK>) patients were undergoing chemotherapy conditioning prior to bone marrow transplant.</P>
<P>There was no evidence that chlorhexidine was more effective than placebo or no treatment for any of the outcomes evaluated (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>; <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>).</P>
<P>Two further trials (<LINK REF="STD-Madan-2008" TYPE="STUDY">Madan 2008</LINK>; <LINK REF="STD-McGaw-1985" TYPE="STUDY">McGaw 1985</LINK>) at low and unclear risk of bias respectively, reported statistically significant differences in mean mucositis scores in each group which favoured chlorhexidine over placebo (Additional <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
<P>Overall, there is no evidence of a benefit for chlorhexidine compared with placebo or no treatment, for the prevention of mucositis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cryotherapy (ice chips) versus no treatment (Analysis 5.1; Analysis 5.2; Analysis 5.3)</HEADING>
<P>Six trials (<LINK REF="STD-Cascinu-1994" TYPE="STUDY">Cascinu 1994</LINK>; <LINK REF="STD-Gori-2007" TYPE="STUDY">Gori 2007</LINK>; <LINK REF="STD-Lilleby-2006" TYPE="STUDY">Lilleby 2006</LINK>; <LINK REF="STD-Mahood-1991" TYPE="STUDY">Mahood 1991</LINK>; <LINK REF="STD-Sorensen-2008" TYPE="STUDY">Sorensen 2008</LINK>; <LINK REF="STD-Svanberg-2007" TYPE="STUDY">Svanberg 2007</LINK>) compared cryotherapy (ice chips) with either no treatment or placebo (saline) control. Five trials used a parallel group design and one (<LINK REF="STD-Mahood-1991" TYPE="STUDY">Mahood 1991</LINK>) was a cross-over trial. Three of these studies investigated the use of cryotherapy in patients receiving chemotherapy with 5-FU (<LINK REF="STD-Cascinu-1994" TYPE="STUDY">Cascinu 1994</LINK>; <LINK REF="STD-Mahood-1991" TYPE="STUDY">Mahood 1991</LINK>; <LINK REF="STD-Sorensen-2008" TYPE="STUDY">Sorensen 2008</LINK>); participants in the trial by <LINK REF="STD-Gori-2007" TYPE="STUDY">Gori 2007</LINK> received methotrexate, in <LINK REF="STD-Lilleby-2006" TYPE="STUDY">Lilleby 2006</LINK> they were receiving melphalan conditioning in preparation for stem cell transplantation, and in <LINK REF="STD-Svanberg-2007" TYPE="STUDY">Svanberg 2007</LINK> patients received either chemotherapy or total body irradiation prior to bone marrow or stem cell transplantation. Four of these studies were found to be at high risk of bias, and two studies was found to be at unclear risk of bias (<LINK REF="STD-Mahood-1991" TYPE="STUDY">Mahood 1991</LINK>; <LINK REF="STD-Sorensen-2008" TYPE="STUDY">Sorensen 2008</LINK>). Five trials presented data in a format suitable for inclusion in meta-analysis.</P>
<P>There was evidence of a benefit associated with the use of ice chips for each of the three outcome categories of mucositis, with RRs of 0.74 (95% CI 0.57 to 0.95, P = 0.02, <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>), 0.53 (95% CI 0.31 to 0.91, P = 0.02, <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>) and 0.36 (95% CI 0.17 to 0.77, P = 0.008, <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>) respectively. However, substantial heterogeneity, likely to be related to the diversity of clinical conditions and treatments, was also identified in each meta-analysis: Chi<SUP>2</SUP> = 14.77, df = 4, P = 0.005, I<SUP>2 </SUP>= 73% for any mucositis (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>), Chi<SUP>2</SUP> = 19.02, df = 4, P = 0.0008, I<SUP>2 </SUP>= 79% for moderate plus severe (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>), and Chi<SUP>2</SUP> = 14.31, df = 4, P = 0.006, I<SUP>2 </SUP>= 72% for the severe outcome category (<LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>).</P>
<P>The trial by <LINK REF="STD-Svanberg-2007" TYPE="STUDY">Svanberg 2007</LINK> also found that cryotherapy reduced the development of mucositis and oral pain requiring treatment with opioids (Additional <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
<P>Overall, these six heterogeneous trials provide some evidence, with substantial risk of bias, that ice chips are effective in preventing or reducing the severity of mucositis in patients receiving chemotherapy and/or radiotherapy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Glutamine versus placebo/usual care (Analysis 6.1; Analysis 6.2; Analysis 6.3)</HEADING>
<P>Ten trials (<LINK REF="STD-Anderson-1998" TYPE="STUDY">Anderson 1998</LINK>; <LINK REF="STD-Cerchietti-2006" TYPE="STUDY">Cerchietti 2006</LINK>; <LINK REF="STD-Choi-2007" TYPE="STUDY">Choi 2007</LINK>; <LINK REF="STD-Dickson-2000" TYPE="STUDY">Dickson 2000</LINK>; <LINK REF="STD-He-2008" TYPE="STUDY">He 2008</LINK>; <LINK REF="STD-Huang-2000" TYPE="STUDY">Huang 2000</LINK>; <LINK REF="STD-Jebb-1994" TYPE="STUDY">Jebb 1994</LINK>; <LINK REF="STD-Li-2006" TYPE="STUDY">Li 2006</LINK>; <LINK REF="STD-Okuno-1999" TYPE="STUDY">Okuno 1999</LINK>; <LINK REF="STD-Sornsuvit-2008" TYPE="STUDY">Sornsuvit 2008</LINK>)evaluating 433 patients compared the use of glutamine with either a placebo (nine trials) or best supportive care (<LINK REF="STD-Choi-2007" TYPE="STUDY">Choi 2007</LINK>).Two of these trials were designed as cross-over studies (<LINK REF="STD-Anderson-1998" TYPE="STUDY">Anderson 1998</LINK>; <LINK REF="STD-Jebb-1994" TYPE="STUDY">Jebb 1994</LINK>) and both had data from more than 40% of randomised participants missing from the outcome evaluation.The remaining eight trials used a parallel group design.The smallest trial evaluated only 13 patients (<LINK REF="STD-Anderson-1998" TYPE="STUDY">Anderson 1998</LINK>) and the largest evaluated 124 patients (<LINK REF="STD-Okuno-1999" TYPE="STUDY">Okuno 1999</LINK>). Three trials were conducted in the USA (<LINK REF="STD-Anderson-1998" TYPE="STUDY">Anderson 1998</LINK>; <LINK REF="STD-Dickson-2000" TYPE="STUDY">Dickson 2000</LINK>; <LINK REF="STD-Okuno-1999" TYPE="STUDY">Okuno 1999</LINK>), two in China (<LINK REF="STD-He-2008" TYPE="STUDY">He 2008</LINK>; <LINK REF="STD-Li-2006" TYPE="STUDY">Li 2006</LINK>), and one each in Argentina (<LINK REF="STD-Cerchietti-2006" TYPE="STUDY">Cerchietti 2006</LINK>), Korea (<LINK REF="STD-Choi-2007" TYPE="STUDY">Choi 2007</LINK>), Taiwan (<LINK REF="STD-Huang-2000" TYPE="STUDY">Huang 2000</LINK>), Thailand (<LINK REF="STD-Sornsuvit-2008" TYPE="STUDY">Sornsuvit 2008</LINK>), and the UK (<LINK REF="STD-Jebb-1994" TYPE="STUDY">Jebb 1994</LINK>). Two trials were conducted in head and neck cancers undergoing radiation (<LINK REF="STD-Huang-2000" TYPE="STUDY">Huang 2000</LINK>) or chemoradiation (<LINK REF="STD-Cerchietti-2006" TYPE="STUDY">Cerchietti 2006</LINK>). Five studies were conducted in patients with solid cancers receiving radiotherapy (<LINK REF="STD-Anderson-1998" TYPE="STUDY">Anderson 1998</LINK>; <LINK REF="STD-Choi-2007" TYPE="STUDY">Choi 2007</LINK>; <LINK REF="STD-He-2008" TYPE="STUDY">He 2008</LINK>; <LINK REF="STD-Jebb-1994" TYPE="STUDY">Jebb 1994</LINK>; <LINK REF="STD-Li-2006" TYPE="STUDY">Li 2006</LINK>). The remaining three studies were conducted in patients with cancers of the blood receiving chemotherapy (<LINK REF="STD-Sornsuvit-2008" TYPE="STUDY">Sornsuvit 2008</LINK>), a group of patients with mixed cancers receiving a mix of radiotherapy and chemotherapy (<LINK REF="STD-Dickson-2000" TYPE="STUDY">Dickson 2000</LINK>) and a group of patients, with unclear cancer type, receiving chemotherapy.</P>
<P>Three trials used a glutamine suspension and instructed patients to either swish it around the mouth and swallow, twice daily (<LINK REF="STD-Anderson-1998" TYPE="STUDY">Anderson 1998</LINK>; <LINK REF="STD-Okuno-1999" TYPE="STUDY">Okuno 1999</LINK>) or swish and then expectorate (<LINK REF="STD-Huang-2000" TYPE="STUDY">Huang 2000</LINK>).A further four trials compared oral supplementation with 30 grams of glutamine daily (<LINK REF="STD-Choi-2007" TYPE="STUDY">Choi 2007</LINK>; <LINK REF="STD-Dickson-2000" TYPE="STUDY">Dickson 2000</LINK>; <LINK REF="STD-Li-2006" TYPE="STUDY">Li 2006</LINK>) or 15 grams per day (<LINK REF="STD-Jebb-1994" TYPE="STUDY">Jebb 1994</LINK>).</P>
<P>For all three levels of mucositis prevention (any mucositis, moderate to severe or severe), there was no evidence that oral glutamine was different from placebo in the groups of five studies which reported each level of mucositis (RR = 0.78, 95% CI 0.57 to 1.08, P = 0.13, <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>; RR = 0.88, 95% CI 0.69 to 1.12, P = 0.31, <LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>; and RR = 0.69, 95% CI 0.37 to 1.29, P = 0.24, <LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK> respectively.There was substantial heterogeneity between these studies, in part due to the lower dose in two studies (<LINK REF="STD-Jebb-1994" TYPE="STUDY">Jebb 1994</LINK> 15 g/day, <LINK REF="STD-Huang-2000" TYPE="STUDY">Huang 2000</LINK> swish and expectorate) and the lack of a placebo control in another study which was assessed as being at high risk of bias (<LINK REF="STD-Choi-2007" TYPE="STUDY">Choi 2007</LINK>).The risk of bias was assessed as high in <LINK REF="STD-Huang-2000" TYPE="STUDY">Huang 2000</LINK> and unclear in the other five studies, but it should be noted that both the cross-over studies (<LINK REF="STD-Anderson-1998" TYPE="STUDY">Anderson 1998</LINK>; <LINK REF="STD-Jebb-1994" TYPE="STUDY">Jebb 1994</LINK>) had in excess of 40% loss to follow-up.</P>
<P>The remaining three studies compared intravenous (IV) glutamine supplementation with placebo using approximately 30 grams/day (<LINK REF="STD-Cerchietti-2006" TYPE="STUDY">Cerchietti 2006</LINK>; <LINK REF="STD-Sornsuvit-2008" TYPE="STUDY">Sornsuvit 2008</LINK>) or 20 grams/day added to parenteral nutrition (<LINK REF="STD-He-2008" TYPE="STUDY">He 2008</LINK>). These trials were small (16 to 48 participants) and all are assessed as being at unclear risk of bias.Only one trial reported the prevention of any grade of mucositis or moderate to severe mucositis and found no difference between glutamine and placebo (<LINK REF="STD-Sornsuvit-2008" TYPE="STUDY">Sornsuvit 2008</LINK>).All three trials (including a total of 93 participants) reported the outcome of prevention of severe mucositis, and found a statistically significant 75% decrease in severe mucositis associated with IV glutamine supplementation (RR = 0.25, 95% CI 0.10 to 0.62, P = 0.002, <LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>). This result should be interpreted with caution as it is based on small numbers of participants in studies at unclear risk of bias.</P>
<P>Overall, there is no evidence of a benefit for oral glutamine supplementation in the prevention of mucositis but there is weak evidence, from small trials at unclear risk of bias, that intravenous glutamine supplementation may be beneficial for the prevention of severe mucositis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">G-CSF (Analysis 7.1; Analysis 7.2)</HEADING>
<P>Three trials, ranging in size from 14 to 195 patients, compared granulocyte colony-stimulating factor (G-CSF) with placebo (<LINK REF="STD-Crawford-1999" TYPE="STUDY">Crawford 1999</LINK>; <LINK REF="STD-Schneider-1999" TYPE="STUDY">Schneider 1999</LINK>; <LINK REF="STD-Su-2006" TYPE="STUDY">Su 2006</LINK>) (total n = 249) and one compared G-CSF with no treatment (<LINK REF="STD-Katano-1995" TYPE="STUDY">Katano 1995</LINK>) (n = 14), for the prevention of mucositis associated with chemotherapy (<LINK REF="STD-Crawford-1999" TYPE="STUDY">Crawford 1999</LINK>; <LINK REF="STD-Katano-1995" TYPE="STUDY">Katano 1995</LINK>) for solid tumours, or chemoradiotherapy (<LINK REF="STD-Schneider-1999" TYPE="STUDY">Schneider 1999</LINK>) or radiotherapy (<LINK REF="STD-Su-2006" TYPE="STUDY">Su 2006</LINK>) for head and neck cancers. Of the four studies in this group, <LINK REF="STD-Crawford-1999" TYPE="STUDY">Crawford 1999</LINK> has unclear risk of bias, <LINK REF="STD-Katano-1995" TYPE="STUDY">Katano 1995</LINK> has high risk of bias, and both <LINK REF="STD-Su-2006" TYPE="STUDY">Su 2006</LINK> and <LINK REF="STD-Schneider-1999" TYPE="STUDY">Schneider 1999</LINK> were found to be at low risk of bias. However, the data presented in the <LINK REF="STD-Schneider-1999" TYPE="STUDY">Schneider 1999</LINK> paper are from an interim analysis after the trial was stopped early for reasons that are unclear. In <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK> two trials show a benefit associated with G-CSF in the prevention of any mucositis and two do not. As well as substantial clinical heterogeneity with regard to the primary tumours and cancer treatments, there is a very high level of statistical heterogeneity (Chi<SUP>2</SUP> = 20.48, df = 3, P = 0.0001, I<SUP>2 </SUP>= 85%) among these four trials such that combining the results by meta-analysis is not appropriate. There was a statistically significant reduction in the incidence of severe mucositis in the G-CSF groups compared to placebo (RR 0.36, 95% CI 0.15 to 0.86, P = 0.02, <LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>) in two homogenous trials (<LINK REF="STD-Schneider-1999" TYPE="STUDY">Schneider 1999</LINK>; <LINK REF="STD-Su-2006" TYPE="STUDY">Su 2006</LINK>). However, <LINK REF="STD-Su-2006" TYPE="STUDY">Su 2006</LINK> found no statistically significant difference between G-CSF and placebo in the prevention of moderate plus severe mucositis.</P>
<P>Overall there is weak evidence that G-CSF may be beneficial in the prevention of severe mucositis in patients with head and neck cancer undergoing radiotherapy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">GM-CSF versus placebo/no treatment (Analysis 8.1; Analysis 8.2; Analysis 8.3)</HEADING>
<P>Eight trials compared granulocyte/macrophage colony-stimulating factor (GM-CSF) with a placebo or no treatment control group. Five trials were placebo controlled (<LINK REF="STD-Cartee-1995" TYPE="STUDY">Cartee 1995</LINK>; <LINK REF="STD-Dazzi-2003" TYPE="STUDY">Dazzi 2003</LINK>; <LINK REF="STD-Ifrah-1999" TYPE="STUDY">Ifrah 1999</LINK>; <LINK REF="STD-Nemunaitis-1995" TYPE="STUDY">Nemunaitis 1995</LINK>; <LINK REF="STD-van-der-Lelie-2001" TYPE="STUDY">van der Lelie 2001</LINK>) and three trials had a no treatment control group (<LINK REF="STD-Chi-1995" TYPE="STUDY">Chi 1995</LINK>; <LINK REF="STD-Makkonen-2000" TYPE="STUDY">Makkonen 2000</LINK>; <LINK REF="STD-McAleese-2006" TYPE="STUDY">McAleese 2006</LINK>). Three studies were conducted in patients receiving chemotherapy (<LINK REF="STD-Chi-1995" TYPE="STUDY">Chi 1995</LINK>) or radiotherapy for head and neck cancer (<LINK REF="STD-Makkonen-2000" TYPE="STUDY">Makkonen 2000</LINK>; <LINK REF="STD-McAleese-2006" TYPE="STUDY">McAleese 2006</LINK>). Two studies were conducted in patients with solid cancers receiving chemotherapy (<LINK REF="STD-Cartee-1995" TYPE="STUDY">Cartee 1995</LINK>; <LINK REF="STD-Dazzi-2003" TYPE="STUDY">Dazzi 2003</LINK>). The remaining studies were conducted in patients with a mix of cancers receiving either radiotherapy (<LINK REF="STD-van-der-Lelie-2001" TYPE="STUDY">van der Lelie 2001</LINK>) or chemotherapy (<LINK REF="STD-Ifrah-1999" TYPE="STUDY">Ifrah 1999</LINK>), or a mix of different therapies (<LINK REF="STD-Nemunaitis-1995" TYPE="STUDY">Nemunaitis 1995</LINK>).</P>
<P>Two trials were found to be at low risk of bias (<LINK REF="STD-Cartee-1995" TYPE="STUDY">Cartee 1995</LINK>; <LINK REF="STD-Dazzi-2003" TYPE="STUDY">Dazzi 2003</LINK>), two trials were found to be at high risk of bias (<LINK REF="STD-Chi-1995" TYPE="STUDY">Chi 1995</LINK>; <LINK REF="STD-Makkonen-2000" TYPE="STUDY">Makkonen 2000</LINK>) and the remaining four studies were assessed as being at unclear risk of bias.</P>
<P>Two trials provided data for any mucositis, and moderate to severe mucositis outcome categories, with six trials providing data for the severe mucositis outcome category. There was no statistically significant difference between GM-CSF and control for any of the outcome categories (<LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>; <LINK REF="CMP-008.02" TYPE="ANALYSIS">Analysis 8.2</LINK>; <LINK REF="CMP-008.03" TYPE="ANALYSIS">Analysis 8.3</LINK>).</P>
<P>In the trial by <LINK REF="STD-Makkonen-2000" TYPE="STUDY">Makkonen 2000</LINK> all patients in both groups developed mucositis and "there was no significant difference in the frequency or degree of radiation-induced mucositis between GM-CSF and the control groups". <LINK REF="STD-Chi-1995" TYPE="STUDY">Chi 1995</LINK> reported a cross-over study of 20 patients, assessed as being at high risk of bias, which showed some period effect from the first treatment period to the second. The study reports a statistically significant benefit favouring GM-CSF.</P>
<P>Based on these eight trials of 433 patients there is no evidence that GM-CSF is different from either placebo or no treatment in the prevention of mucositis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Honey versus no treatment control (Analysis 9.1; Analysis 9.2; Analysis 9.3)</HEADING>
<P>Three trials (<LINK REF="STD-Biswal-2003" TYPE="STUDY">Biswal 2003</LINK>; <LINK REF="STD-Motallebnejad-2008" TYPE="STUDY">Motallebnejad 2008</LINK>; <LINK REF="STD-Rashad-2008" TYPE="STUDY">Rashad 2008</LINK>), each with 40 randomised patients, compared honey with a no treatment control for the prevention of mucositis. In <LINK REF="STD-Biswal-2003" TYPE="STUDY">Biswal 2003</LINK>, 20 patients in Malaysia with head and neck cancer, who were undergoing radiotherapy, smeared honey on their mouth, and then swallowed slowly to coat the mucosa, both prior to and after radiotherapy. Patients in the control group received radiotherapy only. This intervention was replicated some 4 years later in Iran (<LINK REF="STD-Motallebnejad-2008" TYPE="STUDY">Motallebnejad 2008</LINK>) in another group of 40 patients undergoing radiotherapy for head and neck cancer and also in Egypt (<LINK REF="STD-Rashad-2008" TYPE="STUDY">Rashad 2008</LINK>) in a group of patients undergoing chemoradiotherapy for head and neck cancer. In <LINK REF="STD-Motallebnejad-2008" TYPE="STUDY">Motallebnejad 2008</LINK> outcome assessors were blinded to treatment allocation and risk of bias in this study was assessed as unclear, and in the other two studies there was no blinding or allocation concealment and risk of bias is assessed as high. None of these trials provided any information on compliance with treatment and none recorded any drop outs or losses to follow-up.</P>
<P>There is weak unreliable evidence from these three small trials that honey is associated with a moderate benefit with regard to the prevention of any mucositis (RR 0.70, 85% CI 0.56 to 0.88, P = 0.002), moderate to severe mucositis (RR 0.48, 95% CI 0.31 to 0.74, P = 0.0009) and severe mucositis (RR 0.26, 95% CI 0.13 to 0.52, P = 0.0002). However, in view of the considerable statistical heterogeneity and high risk of bias these results should be interpreted with caution.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Hydrolytic enzymes versus no treatment (Analysis 10.1; Analysis 10.2)</HEADING>
<P>Three trials (<LINK REF="STD-Dorr-2007" TYPE="STUDY">Dorr 2007</LINK>; <LINK REF="STD-Gujral-2001" TYPE="STUDY">Gujral 2001</LINK>; <LINK REF="STD-Kaul-1999" TYPE="STUDY">Kaul 1999</LINK>) compared hydrolytic enzymes with either a placebo (<LINK REF="STD-Dorr-2007" TYPE="STUDY">Dorr 2007</LINK>) or radiotherapy only control, in a total of 210 patients receiving radiotherapy for head and neck cancers. <LINK REF="STD-Dorr-2007" TYPE="STUDY">Dorr 2007</LINK> was double blind, but overall risk of bias was unclear, and <LINK REF="STD-Gujral-2001" TYPE="STUDY">Gujral 2001</LINK> and <LINK REF="STD-Kaul-1999" TYPE="STUDY">Kaul 1999</LINK> were assessed as being at high risk of bias overall.</P>
<P>Two trials reported the outcome category of any mucositis (<LINK REF="STD-Gujral-2001" TYPE="STUDY">Gujral 2001</LINK>; <LINK REF="STD-Kaul-1999" TYPE="STUDY">Kaul 1999</LINK>) with conflicting results (<LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK>) and considerable statistical heterogeneity, so these data were not pooled.</P>
<P>All three trials provided data for the prevention of moderate plus severe mucositis. There was considerable heterogeneity identified so these data were not pooled. The placebo controlled study found no difference between the groups (<LINK REF="STD-Dorr-2007" TYPE="STUDY">Dorr 2007</LINK>) but the other two studies, both at high risk of bias, found a benefit favouring hydrolytic enzymes with radiotherapy compared to radiotherapy alone which was not statistically significant.</P>
<P>The three trials also had some differences with regard to the ingredients in the hydrolytic enzyme intervention. <LINK REF="STD-Dorr-2007" TYPE="STUDY">Dorr 2007</LINK> and <LINK REF="STD-Gujral-2001" TYPE="STUDY">Gujral 2001</LINK> used a preparation containing papain 100 mg, trypsin 40 mg and chymotrypsin 40 mg, and <LINK REF="STD-Kaul-1999" TYPE="STUDY">Kaul 1999</LINK> used a preparation containing papain, trypsin, chymotrypsin, pancreatin, rutin and bromelain.</P>
<P>In summary, the evidence from these three trials is conflicting, and all trials are at some risk of bias. There is insufficient evidence that the use of hydrolytic enzymes to prevent mucositis associated with radiotherapy for head and neck cancers is significantly different from placebo or no treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Iseganan versus placebo (Analysis 11.1; Analysis 11.2)</HEADING>
<P>Two studies (<LINK REF="STD-Giles-2004" TYPE="STUDY">Giles 2004</LINK>; <LINK REF="STD-Trotti-2004" TYPE="STUDY">Trotti 2004</LINK>), comprising a total of 1013 patients, both at unclear risk of bias, compared iseganan with placebo for different outcome categories of mucositis. One study was conducted in patients with a mix of cancers receiving a range of different cancer treatments (<LINK REF="STD-Giles-2004" TYPE="STUDY">Giles 2004</LINK>). The other study was conducted in patients with head and neck cancers receiving a mix of cancer therapies (<LINK REF="STD-Trotti-2004" TYPE="STUDY">Trotti 2004</LINK>). These studies provided data for the moderate plus severe and severe outcome categories of mucositis, and both meta-analyses showed no evidence of a difference between iseganan and placebo (<LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>; <LINK REF="CMP-011.02" TYPE="ANALYSIS">Analysis 11.2</LINK>).</P>
<P>Overall there is no evidence from these trials that iseganan is more or less effective than placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Keratinocyte GF versus placebo (Analysis 12.1; Analysis 12.2; Analysis 12.3)</HEADING>
<P>Seven trials compared keratinocyte growth factor (GF) (marketed as either Palifermin or Velafermin) with placebo (<LINK REF="STD-Blazar-2006" TYPE="STUDY">Blazar 2006</LINK>; <LINK REF="STD-Brizel-2008" TYPE="STUDY">Brizel 2008</LINK>; <LINK REF="STD-Freytes-2004" TYPE="STUDY">Freytes 2004</LINK>; <LINK REF="STD-Meropol-2003" TYPE="STUDY">Meropol 2003</LINK>; <LINK REF="STD-Rosen-2006" TYPE="STUDY">Rosen 2006</LINK>; <LINK REF="STD-Spielberger-2004" TYPE="STUDY">Spielberger 2004</LINK>; <LINK REF="STD-Vadhan_x002d_Raj-2010" TYPE="STUDY">Vadhan-Raj 2010</LINK>). Six studies were judged to be at unclear risk of bias. One study was judged to be at high risk of bias (<LINK REF="STD-Vadhan_x002d_Raj-2010" TYPE="STUDY">Vadhan-Raj 2010</LINK>). Two provided data for any mucositis, seven for moderate plus severe and six for severe. All three mucositis outcome categories showed evidence of a benefit associated with keratinocyte GF with RR 0.82 (95% CI 0.71 to 0.94, P = 0.005, <LINK REF="CMP-012.01" TYPE="ANALYSIS">Analysis 12.1</LINK>) for any mucositis, RR 0.74 (95% CI 0.62 to 0.89, P = 0.002, <LINK REF="CMP-012.02" TYPE="ANALYSIS">Analysis 12.2</LINK>) for moderate plus severe mucositis and RR 0.72 (95% CI 0.58 to 0.90, P = 0.004, <LINK REF="CMP-012.03" TYPE="ANALYSIS">Analysis 12.3</LINK>) for severe mucositis.</P>
<P>However, there is substantial heterogeneity in the any mucositis (Chi<SUP>2</SUP> = 10.11, df = 1, P = 0.001, I<SUP>2 </SUP>= 90%, <LINK REF="CMP-012.01" TYPE="ANALYSIS">Analysis 12.1</LINK>) and moderate to severe mucositis outcome categories (Chi<SUP>2</SUP> = 50.75, df = 6, P &lt; 0.00001, I<SUP>2 </SUP>= 88%, <LINK REF="CMP-012.02" TYPE="ANALYSIS">Analysis 12.2</LINK>). From the table below there is no evidence that this heterogeneity can be explained by differences between the studies in terms of cancer type, cancer treatment, dose or type of keratinocyte GF.</P>
<P>From these seven trials there is some evidence that keratinocyte growth factor is effective in the prevention of mucositis.</P>
<TABLE COLS="7" ROWS="8">
<TR>
<TH VALIGN="TOP">
<P>Author</P>
</TH>
<TH VALIGN="TOP">
<P>Type of keratinocyte</P>
</TH>
<TH VALIGN="TOP">
<P>Dose of keratinocyte</P>
</TH>
<TH VALIGN="TOP">
<P>Schedule</P>
</TH>
<TH VALIGN="TOP">
<P>Number and gender of patients</P>
</TH>
<TH VALIGN="TOP">
<P>Cancer type</P>
</TH>
<TH VALIGN="TOP">
<P>Treatment</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Blazar-2006" TYPE="STUDY">Blazar 2006</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Palifermin</P>
</TD>
<TD VALIGN="TOP">
<P>40 g/kg or 60 g/kg</P>
</TD>
<TD VALIGN="TOP">
<P>Cohort 1: patients randomised to placebo or palifermin at either 40 g (8 patients, total dose 240 g) or 60 g (10 patients, total dose 360 g) per day for 3 days before conditioning (days -11 to -9) and for 3 days after transplant (days 0, 1 and 2).</P>
<P>Cohort 2: 14 patients received palifermin at 60 g/day, for 3 days before conditioning (day -11 to -9) and then for 6 days after transplant (days 0-2 and then days 7-9) (9 doses total). Total dose of palifermin received was 540 g.</P>
<P>Cohort 3: 37 patients received palifermin at 60 g/day for 3 days before conditioning (day -11 to -9) and then for 9 days after transplant (days 0-2, 7-9 and 14-16) (12 doses total). Total dose of palifermin received was 720 g</P>
</TD>
<TD VALIGN="TOP">
<P>100 (58M/ 42F)</P>
</TD>
<TD VALIGN="TOP">
<P>Leukaemia, lymphoma, myelodysplastic syndrome</P>
</TD>
<TD VALIGN="TOP">
<P>Allogeneic stem cell transplant.</P>
<P>Cyclophosphamide 60 mg/kg per day, TBI total dose = 13.2 Gy (fractionated as 165 Gy twice daily for 4 days)</P>
<P>or</P>
<P>busulfan 1 mg/kg per dose given 4 times daily for 4 days then cyclophosphamide 60 mg/kg per day for 2 days</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Brizel-2008" TYPE="STUDY">Brizel 2008</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Palifermin</P>
</TD>
<TD VALIGN="TOP">
<P>60 g (67 patients)</P>
</TD>
<TD VALIGN="TOP">
<P>1 dose administered weekly on the Friday before the first week of chemotherapy (then continued each Friday for 7 consecutive weeks). 2 additional doses given weeks 8 and 9</P>
</TD>
<TD VALIGN="TOP">
<P>99 (82M/17F)</P>
</TD>
<TD VALIGN="TOP">
<P>Head and neck</P>
</TD>
<TD VALIGN="TOP">
<P>Chemotherapy (cisplatin 20 mg/m<SUP>2</SUP>/d IV bolus and fluorouracil 1000 mg/m<SUP>2</SUP>/d continuous infusion) administered for first 4 days of the first and fifth weeks of radiotherapy.</P>
<P>Radiotherapy (daily fractions of 2 Gy until 70 Gy)</P>
<P>or</P>
<P>hyperfractionated radiotherapy (1.25 Gy twice daily until 72 Gy)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Freytes-2004" TYPE="STUDY">Freytes 2004</LINK></P>
</TD>
<TD VALIGN="TOP">
<P>Repifermin</P>
</TD>
<TD VALIGN="TOP">
<P>25 g/kg or 50 g/kg</P>
</TD>
<TD VALIGN="TOP">
<P>Cohort 1: 25 g/kg repifermin.</P>
<P>Cohort 2: 50 g/kg repifermin</P>
</TD>
<TD VALIGN="TOP">
<P>42 (31M/11F)</P>
</TD>
<TD VALIGN="TOP">
<P>Haematologic malignancies or lymphoma</P>
</TD>
<TD VALIGN="TOP">
<P>Autologous stem cell transplant.</P>
<P>Cyclophosphamide, etoposide and carmustine, or</P>
<P>melphalan monotherapy, or melphalan combination, or cyclophosphamide + TBI or</P>
<P>thiotepa + TBI or cyclophosphamide + busulfan</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Meropol-2003" TYPE="STUDY">Meropol 2003</LINK></P>
</TD>
<TD VALIGN="TOP">
<P>Palifermin</P>
</TD>
<TD VALIGN="TOP">
<P>1 g/kg/d or 10 g/kg/d or 20 g/kg/d or 40 g/kg/d or 60 g/kg/d or 80 g/kg/d</P>
<P/>
<P/>
</TD>
<TD VALIGN="TOP">
<P>All cohorts received palifermin on days 1 to 3 of each cycle.</P>
<P>Cohort 1: 1 g/kg/d palifermin</P>
<P>Cohort 2: 10 g/kg/d palifermin</P>
<P>Cohort 3: 20 g/kg/d palifermin</P>
<P>Cohort 4: 40 g/kg/d palifermin</P>
<P>Cohort 4: 60 g/kg/d palifermin</P>
<P>Cohort 5: 80 g/kg/d palifermin.</P>
<P>27 placebo patients (randomised 1:1 in cohort 1 and 2:1 in all other cohorts)</P>
</TD>
<TD VALIGN="TOP">
<P>81(47M/34F)</P>
</TD>
<TD VALIGN="TOP">
<P>Metastatic colorectal cancer</P>
</TD>
<TD VALIGN="TOP">
<P>Leucovorin 20 mg/m<SUP>2</SUP> by IV followed immediately by 425 mg/m<SUP>2</SUP> for 5 consecutive days on days 4 to 8 of each 28 day cycle</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Rosen-2006" TYPE="STUDY">Rosen 2006</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Palifermin</P>
</TD>
<TD VALIGN="TOP">
<P>40 g/kg per day (28 patients)</P>
</TD>
<TD VALIGN="TOP">
<P>3 consecutive days before chemotherapy </P>
</TD>
<TD VALIGN="TOP">
<P>64 (42M/22F)</P>
</TD>
<TD VALIGN="TOP">
<P>Solid tumours (colon and rectum)</P>
</TD>
<TD VALIGN="TOP">
<P>Chemotherapy</P>
<P>(5-FU 425 mg/m<SUP>2</SUP>/day IV for 5 days, leucovorin 20 mg/m<SUP>2</SUP>/day for 5 days)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Spielberger-2004" TYPE="STUDY">Spielberger 2004</LINK></P>
</TD>
<TD VALIGN="TOP">
<P>Palifermin</P>
</TD>
<TD VALIGN="TOP">
<P>60 g/kg per day</P>
</TD>
<TD VALIGN="TOP">
<P>3 consecutive days (starting 3 days before TBI)and 3 consecutive doses after transplantation (day 0, day 1, day 2)</P>
</TD>
<TD VALIGN="TOP">
<P>212 (131M/81F)</P>
</TD>
<TD VALIGN="TOP">
<P>Lymphoma, leukaemia and multiple myeloma</P>
</TD>
<TD VALIGN="TOP">
<P>Autologous stem cell transplant. </P>
<P>TBI (total 1200 Gy)</P>
<P>chemotherapy included etoposide (60 mg/kg) and cyclophosphamide (100 mg/kg)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Vadhan_x002d_Raj-2010" TYPE="STUDY">Vadhan-Raj 2010</LINK>
</P>
</TD>
<TD>
<P>Palifermin</P>
</TD>
<TD>
<P>180 g/kg</P>
</TD>
<TD>
<P>1 dose 3 days before chemotherapy</P>
</TD>
<TD>
<P>48 (25M/23F)</P>
</TD>
<TD>
<P>Sarcoma</P>
</TD>
<TD>
<P>Chemotherapy</P>
<P>(doxorubicin 90 mg/m<SUP>2 </SUP>over 72 hours, ifosfamide 10 m/m<SUP>2 </SUP>3 hour infusion for 4 days)</P>
</TD>
</TR>
</TABLE>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Laser versus placebo or sham control (Analysis 13.1; Analysis 13.2; Analysis 13.3)</HEADING>
<P>Five studies (<LINK REF="STD-Antunes-2007" TYPE="STUDY">Antunes 2007</LINK>; <LINK REF="STD-Bensadoun-1999" TYPE="STUDY">Bensadoun 1999</LINK>; <LINK REF="STD-Chor-2010" TYPE="STUDY">Chor 2010</LINK>; <LINK REF="STD-Cruz-2007" TYPE="STUDY">Cruz 2007</LINK>; <LINK REF="STD-Schubert-2007" TYPE="STUDY">Schubert 2007</LINK>), comprising a total of 234 patients, compared laser with a sham laser placebo or no treatment control. Data were provided for all three outcome categories of mucositis. Four of these trials were found to be at unclear risk of bias (<LINK REF="STD-Bensadoun-1999" TYPE="STUDY">Bensadoun 1999</LINK>; <LINK REF="STD-Chor-2010" TYPE="STUDY">Chor 2010</LINK>; <LINK REF="STD-Cruz-2007" TYPE="STUDY">Cruz 2007</LINK>; <LINK REF="STD-Schubert-2007" TYPE="STUDY">Schubert 2007</LINK>) and one was assessed to be at high risk of bias (<LINK REF="STD-Antunes-2007" TYPE="STUDY">Antunes 2007</LINK>). Two trials were conducted in patients with a mix of cancers (<LINK REF="STD-Antunes-2007" TYPE="STUDY">Antunes 2007</LINK>; <LINK REF="STD-Cruz-2007" TYPE="STUDY">Cruz 2007</LINK>), one in patients with head and neck cancer undergoing radiotherapy (<LINK REF="STD-Bensadoun-1999" TYPE="STUDY">Bensadoun 1999</LINK>), one in patients with haematological malignancies undergoing a range of treatments (<LINK REF="STD-Schubert-2007" TYPE="STUDY">Schubert 2007</LINK>) and in the remaining study, the type of cancer and cancer treatment was unclear (<LINK REF="STD-Chor-2010" TYPE="STUDY">Chor 2010</LINK>).</P>
<P>There was no evidence of a difference in the incidence of any mucositis (RR 0.91, 95% CI 0.71 to 1.17, P = 0.47, <LINK REF="CMP-013.01" TYPE="ANALYSIS">Analysis 13.1</LINK>) or moderate plus severe mucositis (RR 0.64, 95% CI 0.38 to 1.08, P = 0.10, <LINK REF="CMP-013.02" TYPE="ANALYSIS">Analysis 13.2</LINK>) between the laser and control, but there was a statistically significant 80% reduction in the incidence of severe mucositis in the laser group compared to sham or no treatment control (RR 0.20, 95% CI 0.06 to 0.62, P = 0.006, <LINK REF="CMP-013.03" TYPE="ANALYSIS">Analysis 13.3</LINK>).</P>
<P>There was substantial heterogeneity in both the moderate plus severe (Chi<SUP>2</SUP> = 4.62, df = 1, P &lt; 0.03, I<SUP>2 </SUP>= 78%, <LINK REF="CMP-013.02" TYPE="ANALYSIS">Analysis 13.2</LINK>) and severe outcome categories (Chi<SUP>2</SUP> = 3.20, df = 1, P = 0.07, I<SUP>2 </SUP>= 69%, <LINK REF="CMP-013.03" TYPE="ANALYSIS">Analysis 13.3</LINK>), which may be partly explained by a variation in the laser wavelengths used in the trials: one trial used a wavelength of 660 nm (<LINK REF="STD-Antunes-2007" TYPE="STUDY">Antunes 2007</LINK>) while the other study used a wavelength of 780 nm (<LINK REF="STD-Cruz-2007" TYPE="STUDY">Cruz 2007</LINK>). In addition,<LINK REF="STD-Cruz-2007" TYPE="STUDY">Cruz 2007</LINK> recruited children, while <LINK REF="STD-Antunes-2007" TYPE="STUDY">Antunes 2007</LINK> recruited adults. Both studies were conducted in patients undergoing stem cell transplantation.</P>
<P>The study by <LINK REF="STD-Bensadoun-1999" TYPE="STUDY">Bensadoun 1999</LINK> reported the outcome in terms of a mean grade of mucositis in each group over the duration of radiotherapy, and found a statistically significant difference favouring laser (Additional <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). <LINK REF="STD-Schubert-2007" TYPE="STUDY">Schubert 2007</LINK> compared two different lasers (650 nm and 780 nm) with a placebo arm in patients undergoing myeloablative therapy prior to bone marrow transplantation. Mean mucositis scores using the oral mucositis index were reported every 3 days over the 21 day treatment period. "The peak severity of mucositis that generally occurs during the second week of transplant was reduced in the 650 nm laser group" (Additional <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
<P>Overall there is weak evidence from two small studies at some risk of bias that low energy laser application may be beneficial in preventing severe mucositis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Oral care protocol versus none (Additional Table 1)</HEADING>
<P>Two studies (<LINK REF="STD-Borowski-1994" TYPE="STUDY">Borowski 1994</LINK>; <LINK REF="STD-Shieh-1997" TYPE="STUDY">Shieh 1997</LINK>) compared an intense oral care protocol with none (usual care). <LINK REF="STD-Borowski-1994" TYPE="STUDY">Borowski 1994</LINK> included 166 patients both adults and children undergoing bone marrow transplantation (study has unclear risk of bias) and <LINK REF="STD-Shieh-1997" TYPE="STUDY">Shieh 1997</LINK> included 30 adults undergoing radiotherapy for head and neck cancers (study at high risk of bias).</P>
<P>
<LINK REF="STD-Borowski-1994" TYPE="STUDY">Borowski 1994</LINK> found no evidence of a difference between the groups with regard to the prevention of moderate plus severe or severe mucositis, but <LINK REF="STD-Shieh-1997" TYPE="STUDY">Shieh 1997</LINK> found a statistically significant difference favouring the oral care protocol in the prevention of any mucositis (Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>Based on these two studies there is no evidence that specific oral care protocols are any different from usual care with regard to the prevention of mucositis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Pilocarpine versus placebo (Analysis 14.1; Analysis 14.2; Additional Table 1)</HEADING>
<P>Two trials, both found to be at unclear risk of bias, compared pilocarpine versus placebo in patients with mixed cancers receiving a range of therapies (<LINK REF="STD-Lockhart-2005" TYPE="STUDY">Lockhart 2005</LINK>) and patients with head and neck cancer receiving radiotherapy (<LINK REF="STD-Scarantino-2006" TYPE="STUDY">Scarantino 2006</LINK>). The two trials showed inconsistent results and no evidence of benefit was found with regard to the prevention of mucositis for any of the outcome categories (<LINK REF="CMP-014.01" TYPE="ANALYSIS">Analysis 14.1</LINK>; <LINK REF="CMP-014.02" TYPE="ANALYSIS">Analysis 14.2</LINK>; Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>Therefore there is no evidence from these two studies that pilocarpine is more or less effective than placebo in preventing mucositis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Povidone versus water (Analysis 15.1; Analysis 15.2; Analysis 15.3)</HEADING>
<P>Two trials compared povidone with water or saline (<LINK REF="STD-Rahn-1997" TYPE="STUDY">Rahn 1997</LINK>; <LINK REF="STD-Vokurka-2005" TYPE="STUDY">Vokurka 2005</LINK>). One of these studies was found to be at unclear (<LINK REF="STD-Vokurka-2005" TYPE="STUDY">Vokurka 2005</LINK>) risk of bias, and the other study was found to be at high risk of bias (<LINK REF="STD-Rahn-1997" TYPE="STUDY">Rahn 1997</LINK>). No statistically significant differences were found for any of the outcome categories (<LINK REF="CMP-015.01" TYPE="ANALYSIS">Analysis 15.1</LINK>; <LINK REF="CMP-015.02" TYPE="ANALYSIS">Analysis 15.2</LINK>; <LINK REF="CMP-015.03" TYPE="ANALYSIS">Analysis 15.3</LINK>).</P>
<P>There is no evidence from these two studies that povidone is more or less effective than placebo in preventing mucositis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Prostaglandin versus placebo (Analysis 16.1; Analysis 16.2)</HEADING>
<P>Four trials, all found to be at unclear risk of bias, compared prostaglandin with a placebo (<LINK REF="STD-Duenas-1996" TYPE="STUDY">Duenas 1996</LINK>; <LINK REF="STD-Hanson-1995" TYPE="STUDY">Hanson 1995</LINK>; <LINK REF="STD-Labar-1993" TYPE="STUDY">Labar 1993</LINK>; <LINK REF="STD-Veness-2006" TYPE="STUDY">Veness 2006</LINK>). Participants (total of 228) had a range of cancers including head and neck (<LINK REF="STD-Hanson-1995" TYPE="STUDY">Hanson 1995</LINK>; <LINK REF="STD-Veness-2006" TYPE="STUDY">Veness 2006</LINK>), haematological (<LINK REF="STD-Labar-1993" TYPE="STUDY">Labar 1993</LINK>) and mixed locations (<LINK REF="STD-Duenas-1996" TYPE="STUDY">Duenas 1996</LINK>), treated by radiotherapy, radiotherapy and/or chemotherapy, and chemotherapy respectively. There was no statistically significant difference between prostaglandin and placebo for the prevention of any mucositis (<LINK REF="CMP-016.01" TYPE="ANALYSIS">Analysis 16.1</LINK>), or the prevention of severe mucositis (<LINK REF="CMP-016.02" TYPE="ANALYSIS">Analysis 16.2</LINK>). The trial by <LINK REF="STD-Hanson-1995" TYPE="STUDY">Hanson 1995</LINK> reported conflicting results for results for the two study centres (Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>There is no evidence from these four trials that prostaglandin is different from placebo in the prevention of mucositis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">PTA antibiotic pastille or paste versus placebo (Analysis 17.1; Analysis 17.2)</HEADING>
<P>Two trials compared antibiotic + antifungal pastilles (containing polymixin, tobramycin and amphotericin (PTA)) with a placebo (<LINK REF="STD-Stokman-2003" TYPE="STUDY">Stokman 2003</LINK>; <LINK REF="STD-Symonds-1996" TYPE="STUDY">Symonds 1996</LINK>) and one trial compared PTA antibiotic paste with a placebo (<LINK REF="STD-Wijers-2001" TYPE="STUDY">Wijers 2001</LINK>). In total 356 patients, all undergoing radiotherapy for head and neck cancers, were included in the trials. <LINK REF="STD-Stokman-2003" TYPE="STUDY">Stokman 2003</LINK> was assessed as being at low risk of bias and the other two trials at unclear risk of bias.</P>
<P>Two trials provided data for any mucositis (<LINK REF="STD-Symonds-1996" TYPE="STUDY">Symonds 1996</LINK>; <LINK REF="STD-Wijers-2001" TYPE="STUDY">Wijers 2001</LINK>) and the pooled estimate showed evidence of a benefit favouring PTA for the prevention of any mucositis (RR 0.87, 95% CI 0.78 to 0.96, P = 0.008, <LINK REF="CMP-017.01" TYPE="ANALYSIS">Analysis 17.1</LINK>). With regard to the prevention of severe mucositis there was evidence of a difference between PTA and placebo in the two studies that provided data for this outcome (<LINK REF="STD-Stokman-2003" TYPE="STUDY">Stokman 2003</LINK>; <LINK REF="STD-Wijers-2001" TYPE="STUDY">Wijers 2001</LINK>; <LINK REF="CMP-017.02" TYPE="ANALYSIS">Analysis 17.2</LINK>). Likewise there was no statistically significant difference with regard to moderate plus severe mucositis in the only study that provided data for this outcome category (<LINK REF="STD-Wijers-2001" TYPE="STUDY">Wijers 2001</LINK>; Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>In summary there is some weak evidence that the use of PTA applied locally may prevent mucositis in adults with head and neck cancer undergoing radiotherapy, but further high quality trials are required to confirm this.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Radiation: morning versus afternoon (Analysis 18.1)</HEADING>
<P>Two trials (<LINK REF="STD-Bjarnason-2009" TYPE="STUDY">Bjarnason 2009</LINK>; <LINK REF="STD-Goyal-2009" TYPE="STUDY">Goyal 2009</LINK>), with a total of 428 patients, compared radiotherapy delivered in the morning to administration of radiotherapy in the evening, in patients with head and neck cancers. One of these studies was found to be at high risk of bias (<LINK REF="STD-Bjarnason-2009" TYPE="STUDY">Bjarnason 2009</LINK>) and the other study was assessed as being at unclear risk of bias (<LINK REF="STD-Goyal-2009" TYPE="STUDY">Goyal 2009</LINK>). No evidence of a difference was found for the prevention of severe mucositis (<LINK REF="CMP-018.01" TYPE="ANALYSIS">Analysis 18.1</LINK>) from the two studies, nor for the prevention of moderate plus severe mucositis in <LINK REF="STD-Goyal-2009" TYPE="STUDY">Goyal 2009</LINK> (Additional <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
<P>From these two studies there is no evidence that the time of day that radiotherapy treatment is delivered makes a difference with regard to the prevention of mucositis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sucralfate versus placebo/usual care (Analysis 19.1; Analysis 19.2; Analysis 19.3)</HEADING>
<P>Twelve parallel group trials evaluated the use of sucralfate; 10 compared sucralfate mouthwash with placebo (<LINK REF="STD-Carter-1999" TYPE="STUDY">Carter 1999</LINK>; <LINK REF="STD-Castagna-2001" TYPE="STUDY">Castagna 2001</LINK>; <LINK REF="STD-Cengiz-1999" TYPE="STUDY">Cengiz 1999</LINK>; <LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>; <LINK REF="STD-Franzen-1995" TYPE="STUDY">Franzen 1995</LINK>; <LINK REF="STD-Lievens-1998" TYPE="STUDY">Lievens 1998</LINK>; <LINK REF="STD-Makkonen-1994" TYPE="STUDY">Makkonen 1994</LINK>; <LINK REF="STD-Nottage-2003" TYPE="STUDY">Nottage 2003</LINK>; <LINK REF="STD-Pfeiffer-1990" TYPE="STUDY">Pfeiffer 1990</LINK>; <LINK REF="STD-Shenep-1988" TYPE="STUDY">Shenep 1988</LINK>),and one compared sucralfate mouthwash with usual care (<LINK REF="STD-Scherlacher-1990" TYPE="STUDY">Scherlacher 1990</LINK>).The remaining trial in this group compared sucralfate mouthwash with placebo, but also instructed all participants to apply sucralfate gel to the skin on one side of the radiation area (resulting in possible contamination of the placebo group) (<LINK REF="STD-Evensen-2001" TYPE="STUDY">Evensen 2001</LINK>). Four trials were conducted in Scandinavia (<LINK REF="STD-Evensen-2001" TYPE="STUDY">Evensen 2001;</LINK> <LINK REF="STD-Franzen-1995" TYPE="STUDY">Franzen 1995</LINK>;<LINK REF="STD-Makkonen-1994" TYPE="STUDY">Makkonen 1994</LINK>; <LINK REF="STD-Pfeiffer-1990" TYPE="STUDY">Pfeiffer 1990</LINK>), four in Europe (<LINK REF="STD-Castagna-2001" TYPE="STUDY">Castagna 2001</LINK>; <LINK REF="STD-Cengiz-1999" TYPE="STUDY">Cengiz 1999</LINK>; <LINK REF="STD-Lievens-1998" TYPE="STUDY">Lievens 1998</LINK>; <LINK REF="STD-Scherlacher-1990" TYPE="STUDY">Scherlacher 1990</LINK>), two in the USA (<LINK REF="STD-Carter-1999" TYPE="STUDY">Carter 1999</LINK>; <LINK REF="STD-Shenep-1988" TYPE="STUDY">Shenep 1988</LINK>), and two in Canada (<LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>; <LINK REF="STD-Nottage-2003" TYPE="STUDY">Nottage 2003</LINK>). Only one of these studies was found to be at low risk of bias (<LINK REF="STD-Shenep-1988" TYPE="STUDY">Shenep 1988</LINK>). All other studies were assessed as being at unclear risk of bias.</P>
<P>Most of the trials recruited participants with head and neck cancer undergoing radiotherapy (<LINK REF="STD-Cengiz-1999" TYPE="STUDY">Cengiz 1999</LINK>; <LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>; <LINK REF="STD-Evensen-2001" TYPE="STUDY">Evensen 2001</LINK>; <LINK REF="STD-Franzen-1995" TYPE="STUDY">Franzen 1995</LINK>; <LINK REF="STD-Lievens-1998" TYPE="STUDY">Lievens 1998</LINK>; <LINK REF="STD-Makkonen-1994" TYPE="STUDY">Makkonen 1994</LINK>; <LINK REF="STD-Scherlacher-1990" TYPE="STUDY">Scherlacher 1990</LINK>;) and of the remainder two recruited participants with head and neck cancer undergoing either chemotherapy or combined treatments (<LINK REF="STD-Carter-1999" TYPE="STUDY">Carter 1999</LINK>; <LINK REF="STD-Pfeiffer-1990" TYPE="STUDY">Pfeiffer 1990</LINK>) and three recruited patients with both a range of cancers and treatment regimens. Patients were instructed to swish the solution in their mouths for 5 minutes, three or four times a day and either swallow the solution or expectorate.</P>
<P>Because the intervention and comparison in <LINK REF="STD-Evensen-2001" TYPE="STUDY">Evensen 2001</LINK> are unique in this sucralfate group, the results are reported in Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. There was no evidence from this study, at unclear risk of bias, that sucralfate mouthwash plus sucralfate gel applied to the skin is different from sucralfate gel alone in the prevention of mucositis.</P>
<P>There was no evidence of a difference between the sucralfate group and the placebo group in the proportion of patients who developed any mucositis in the three trials, all at unclear risk of bias, that reported this outcome (RR 1.00, 95% CI 0.91 to 1.10, P = 0.93, <LINK REF="CMP-019.01" TYPE="ANALYSIS">Analysis 19.1</LINK>).</P>
<P>However there was some evidence that sucralfate may be beneficial in the prevention of moderate plus severe mucositis in the four trials that reported this outcome (RR 0.75, 95% CI 0.54 to 1.04, P = 0.08, <LINK REF="CMP-019.02" TYPE="ANALYSIS">Analysis 19.2</LINK>). One of these trials was at low risk of bias and the remaining three were assessed as unclear.</P>
<P>Seven trials, one at low and six at unclear risk of bias, provide evidence that sucralfate was effective in the prevention of severe mucositis, with a 33% reduction in severe mucositis in the sucralfate group compared to placebo (RR 0.67, 95% CI 0.48 to 0.92, P = 0.01, <LINK REF="CMP-019.03" TYPE="ANALYSIS">Analysis 19.3</LINK>).</P>
<P>A further two trials (<LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>; <LINK REF="STD-Lievens-1998" TYPE="STUDY">Lievens 1998</LINK>) reported outcome data in a different format, but neither found a statistically significant difference between sucralfate and placebo in the prevention of mucositis (Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>From 9 trials including a total of 516 participants, which compared sucralfate mouthwash with placebo, and provided data for meta-analysis, there is some evidence that sucralfate may prevent moderate plus severe mucositis and stronger evidence of a 33% reduction in severe mucositis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Zinc sulphate versus placebo</HEADING>
<P>Two trials (<LINK REF="STD-Ertekin-2004" TYPE="STUDY">Ertekin 2004</LINK>; <LINK REF="STD-Lin-2006" TYPE="STUDY">Lin 2006</LINK>) including a total of 127 patients with head and neck cancer undergoing chemotherapy and/or radiotherapy compared oral zinc supplementation with placebo. Both trials were assessed as being at unclear risk of bias.</P>
<P>
<LINK REF="STD-Ertekin-2004" TYPE="STUDY">Ertekin 2004</LINK> found no statistically significant difference between zinc supplementation and placebo with regard to the prevention of any mucositis, but a statistically significant difference favouring zinc supplementation in the prevention of moderate plus severe and severe mucositis (Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). The other study evaluating this comparison (<LINK REF="STD-Lin-2006" TYPE="STUDY">Lin 2006</LINK>) presented results in graphs and stated that there was no statistically significant difference between the groups (Additional <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
<P>There is conflicting evidence from these two studies and more research is necessary to determine whether zinc supplementation is better than placebo with regard to the prevention of mucositis.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparisons evaluated by a single study</HEADING>
<P>Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> presents the data from the comparisons for which there was only one trial evaluating a comparison or only one trial reporting data for one or more of the mucositis outcome categories.</P>
<P>We have summarised the data from the single trials below, indicating where a statistically significant difference is shown (detailed data given in Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<UL>
<LI>Aciclovir versus placebo - <LINK REF="STD-Bubley-1989" TYPE="STUDY">Bubley 1989</LINK>: no statistically significant difference for the prevention of any mucositis. Study assessed as being at unclear risk of bias.</LI>
<LI>BCoG (bacitracin, cotrimoxazole, gentamicin) antibiotic pastilles - <LINK REF="STD-El-Sayed-2002" TYPE="STUDY">El Sayed 2002</LINK>: no statistically significant difference between antibiotic and placebo for any of the outcome categories. Study assessed as being at unclear risk of bias.</LI>
<LI>Beta carotene versus no treatment control - <LINK REF="STD-Mills-1988" TYPE="STUDY">Mills 1988</LINK>: no statistically significant difference for severe mucositis. Study assessed as being at high risk of bias.</LI>
<LI>Camomile versus placebo - <LINK REF="STD-Fidler-1996" TYPE="STUDY">Fidler 1996</LINK>: no statistically significant difference for all levels of mucositis. Study assessed as being at unclear risk of bias.</LI>
<LI>Chewing gum versus no chewing gum - <LINK REF="STD-Gandemer-2007" TYPE="STUDY">Gandemer 2007</LINK>: no statistically significant difference for any or severe mucositis. Study assessed as being at high risk of bias.</LI>
<LI>Clarithromycin (systemic antibiotic) versus no treatment - <LINK REF="STD-Yuen-2001" TYPE="STUDY">Yuen 2001</LINK>: no statistically significant difference for moderate plus severe mucositis. Study assessed as being at high risk of bias.</LI>
<LI>Dental stent versus no treatment control - <LINK REF="STD-Qin-2007" TYPE="STUDY">Qin 2007</LINK>: no statistically significant difference for moderate plus severe or severe mucositis. Study assessed as being at unclear risk of bias.</LI>
<LI>Epidermal growth factor versus placebo - <LINK REF="STD-Wu-2009" TYPE="STUDY">Wu 2009</LINK>: statistically significant benefit for prevention of moderate plus severe mucositis. Study judged at high risk of bias.</LI>
<LI>Histamine gel versus placebo - <LINK REF="STD-Elad-2006" TYPE="STUDY">Elad 2006</LINK>: no statistically significant difference for any or severe mucositis. Study assessed as being at unclear risk of bias.</LI>
<LI>Indomethacin versus placebo - <LINK REF="STD-Pillsbury-1986" TYPE="STUDY">Pillsbury 1986</LINK>: no statistically significant difference for the prevention of moderate plus severe mucositis. Study assessed as being at unclear risk of bias.</LI>
<LI>Indigo wood root versus saline - <LINK REF="STD-You-2009" TYPE="STUDY">You 2009</LINK>: no statistically significant difference for moderate to severe mucositis. Significant benefit for the prevention of severe mucositis. Study assessed as being at unclear risk of bias.</LI>
<LI>Intestinal trefoil factor versus placebo - <LINK REF="STD-Peterson-2009" TYPE="STUDY">Peterson 2009</LINK>: statistically significant benefit for prevention of any mucositis and moderate plus severe mucositis, no statistically significant difference for severe only mucositis. Study assessed as being at unclear risk of bias.</LI>
<LI>Pentoxifylline versus no treatment - <LINK REF="STD-Attal-1993" TYPE="STUDY">Attal 1993</LINK>: no statistically significant difference for moderate to severe mucositis. Study assessed as being at unclear risk of bias.</LI>
<LI>Prednisone versus placebo - <LINK REF="STD-Leborgne-1997" TYPE="STUDY">Leborgne 1997</LINK>: no statistically significant difference for all levels of mucositis. Study assessed as being at unclear risk of bias.</LI>
<LI>Propantheline versus placebo - <LINK REF="STD-Ahmed-1993" TYPE="STUDY">Ahmed 1993</LINK>: no statistically significant difference for any mucositis. Study assessed as being at unclear risk of bias.</LI>
<LI>Shenqi-fanghou versus no treatment - <LINK REF="STD-Hu-2005" TYPE="STUDY">Hu 2005</LINK>: statistically significant benefit for the prevention of any, moderate plus severe and severe mucositis. Study assessed as being at unclear risk of bias.</LI>
<LI>Superoxide dismutase (SOD) versus placebo - <LINK REF="STD-Tu-1998" TYPE="STUDY">Tu 1998</LINK>: no statistically significant difference for the prevention of any mucositis. Study assessed as being at unclear risk of bias.</LI>
<LI>Traumeel versus placebo - <LINK REF="STD-Oberbaum-2001" TYPE="STUDY">Oberbaum 2001</LINK>: no statistically significant difference was found for any mucositis. Study assessed as being at low risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparisons of two active interventions for preventing mucositis</HEADING>
<P>Most of the studies compared an active intervention to either placebo or no treatment. However, two trials (<LINK REF="STD-Freytes-2004" TYPE="STUDY">Freytes 2004</LINK>; <LINK REF="STD-Sorensen-2008" TYPE="STUDY">Sorensen 2008</LINK>) had three comparative treatment arms (two active plus placebo) and the results of the direct comparisons are included in Additional <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> and summarised below. A further two of these trials (<LINK REF="STD-Bjarnason-2009" TYPE="STUDY">Bjarnason 2009</LINK>; <LINK REF="STD-Goyal-2009" TYPE="STUDY">Goyal 2009</LINK>) evaluated morning versus afternoon delivery of radiotherapy and the results are described in the section 'Interventions with more than one trial' because both studies used the same interventions. Further details are in <LINK REF="CMP-018.01" TYPE="ANALYSIS">Analysis 18.1</LINK> and Additional <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>.</P>
<P>A further seven trials directly compared two active interventions only (<LINK REF="STD-Arun-Maiya-2006" TYPE="STUDY">Arun Maiya 2006</LINK>; <LINK REF="STD-Dai-2009" TYPE="STUDY">Dai 2009</LINK>; <LINK REF="STD-Huang-2003" TYPE="STUDY">Huang 2003</LINK>; <LINK REF="STD-Rocke-1993" TYPE="STUDY">Rocke 1993</LINK>; <LINK REF="STD-Saarilahti-2002" TYPE="STUDY">Saarilahti 2002</LINK>; <LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK>; <LINK REF="STD-Watanabe-2010" TYPE="STUDY">Watanabe 2010</LINK>). The data reported in these trials are recorded in Additional <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>, and the outcomes are summarised in the list below.</P>
<UL>
<LI>Chinese herbs (mix of six types) versus Dobell's solution (<LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK>: significant benefit for prevention of any and moderate plus severe mucositis. Study judged at unclear risk of bias).</LI>
<LI>Chinese herbs (mix of 11 types) versus Dobell's solution (<LINK REF="STD-Huang-2003" TYPE="STUDY">Huang 2003</LINK>: significant benefit for the prevention of moderate plus severe and severe mucositis. Study judged at unclear risk of bias).</LI>
<LI>Chlorhexidine verus cryotherapy (<LINK REF="STD-Sorensen-2008" TYPE="STUDY">Sorensen 2008</LINK>: no statistically significant difference for all levels of mucositis).</LI>
<LI>Cryotherapy 30 versus 60 minutes (<LINK REF="STD-Rocke-1993" TYPE="STUDY">Rocke 1993</LINK>: no statistically significant difference for all levels of mucositis).</LI>
<LI>GM-CSF versus sucralfate (<LINK REF="STD-Saarilahti-2002" TYPE="STUDY">Saarilahti 2002</LINK>: no statistically significant difference for moderate plus severe and severe mucositis).</LI>
<LI>Keratinocyte growth factor 50 versus 25 mg (<LINK REF="STD-Freytes-2004" TYPE="STUDY">Freytes 2004</LINK>: no statistically significant difference for moderate plus severe and severe only mucositis).</LI>
<LI>Laser versus povidone (<LINK REF="STD-Arun-Maiya-2006" TYPE="STUDY">Arun Maiya 2006</LINK>: statistically significant for moderate plus severe, and severe only mucositis. Study judged at unclear risk of bias).</LI>
<LI>Polaprezinc versus azulene (<LINK REF="STD-Watanabe-2010" TYPE="STUDY">Watanabe 2010</LINK>: statistically significant benefit for polaprezinc for moderate plus severe, and severe only mucositis).</LI>
<LI>Yangyin humo decoctalion versus 'traditional Western medicine' (<LINK REF="STD-Dai-2009" TYPE="STUDY">Dai 2009</LINK>: significant benefit for the prevention of moderate plus severe mucositis. Study judged at high risk of bias).</LI>
</UL>
<P>Where there was no statistically significant difference between the interventions compared, it is acknowledged that this could be because the interventions were either equally effective or equally ineffective.</P>
<P>This review proposed to conduct subgroup analyses for different cancer types, cancer treatments and age groups. We were unable to undertake this as there were insufficient numbers of studies in the subgroups. However we did look at whether the heterogeneity was explained by different cancer types or treatments for amifostine and keratinocyte growth factor, by undertaking a sensitivity analysis and this is reported under these interventions in the section above.</P>
<P>We prepared summary of findings tables for those interventions where there was a substantial body of evidence comprising a combined total of at least 550 participants in at least three trials. Selection of interventions to be included in summary of findings tables was not influenced by the results of the trials. Five interventions with a substantial body of evidence were identified. For four interventions there was a substantial body of evidence showing some effectiveness: cryotherapy (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>), amifostine (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>), keratinocyte growth factor (<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>) and sucralfate (<LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>). The body of evidence concerning chlorhexidine (<LINK REF="SOF-05" TYPE="SOF">Summary of findings table 5</LINK>) showed no evidence that chlorhexidine was different from placebo or no treatment in the prevention of mucositis.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-03-09 16:45:57 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2011-03-09 16:45:57 +0000" MODIFIED_BY="[Empty name]">
<P>This update has identified a further 42 included trials which have been published in less than 3 years, bringing the total number of included studies up to 131. The trials included in this review have evaluated 43 different interventions and recruited a total of 10,514 patients.</P>
<P>There is some evidence of a benefit for cryotherapy (ice chips) and keratinocyte growth factor based on a body of evidence comprising at least 6 trials and at least 550 participants for each of these interventions. However all these trials were assessed as being at either high or unclear risk of bias.</P>
<UL>
<LI>
<B>Cryotherapy</B> was found to be beneficial in the prevention of all the outcome categories of mucositis. Specifically the prevention of any mucositis RR = 0.74 (95% CI 0.57 to 0.95, P = 0.02), moderate plus severe mucositis RR = 0.53 (95% CI 0.31 to 0.91, P = 0.02), and severe mucositis RR = 0.36 (95% CI 0.17 to 0.77, P = 0.008).</LI>
<LI>
<B>Keratinocyte Growth Factor</B> was found to be beneficial for the prevention of all the outcome categories of mucositis, with RR = 0.82 (95% CI 0.71 to 0.94, P = 0.005) for any mucositis, RR = 0.74 (95% CI 0.62 to 0.89, P = 0.002) for moderate plus severe mucositis and RR = 0.72 (95% CI 0.58 to 0.90, P = 0.004) for severe mucositis.</LI>
</UL>
<P>There is weak unreliable evidence of a benefit for the following eight interventions based on a smaller body of evidence (2 to 5 trials) involving 90 to 350 participants. Most of the trials in this group are assessed as being at either high or unclear risk of bias.</P>
<UL>
<LI>
<B>Aloe vera:</B> weak unreliable evidence that solution was beneficial for the prevention of moderate to severe mucositis: RR = 0.74 (95% CI 0.58 to 0.96; P = 0.02).</LI>
<LI>
<B>Amifostine **:</B> weak unreliable evidence from 11 low quality trials (8 trials high risk of bias and 3 unclear risk of bias)<B> </B>that amifostine is beneficial for the prevention of any mucositis: RR = 0.95 (95% CI 0.91 to 0.99, P = 0.007) and moderate to severe mucositis: RR = 0.75 (95% CI 0.58 to 0.96, P = 0.02).</LI>
<LI>
<B>Glutamine (intravenous): </B>weak unreliable evidence that glutamine administered intravenously is beneficial for the prevention of severe mucositis (RR = 0.25, 95% CI 0.10 to 0.62).</LI>
<LI>
<B>Granulocyte - Colony Stimulating Factor *:</B> (G-CSF) weak evidence that G-CSF is effective for the prevention of severe mucositis (RR = 0.36, 95% CI 0.15 to 0.86, P = 0.02) based on two small trials at low risk of bias</LI>
<LI>
<B>Honey:</B> weak unreliable evidence, with substantial heterogeneity, that honey may be beneficial in the prevention of any mucositis (RR = 0.70, 85% CI 0.56 to 0.88, P = 0.002), moderate to severe mucositis (RR = 0.48, 95% CI 0.31 to 0.74, P = 0.0009) and severe mucositis (RR = 0.26, 95% CI 0.13 to 0.52, P = 0.0002).</LI>
<LI>
<B>Laser:</B> weak unreliable evidence that laser is beneficial for the prevention of severe mucositis: RR = 0.20 (95% CI 0.06 to 0.62, P = 0.006).</LI>
<LI>
<B>Polymixin/Tobramycin/Amphotericin (PTA) lozenges/paste *: </B>weak unreliable evidence that PTA lozenges may be beneficial for the prevention of any mucositis: RR = 0.87 (95% CI 0.78 to 0.96, P = 0.008).</LI>
<LI>
<B>Sucralfate:</B> evidence that sucralfate is effective in the prevention of severe mucositis, with a 33% reduction in severe mucositis in the sucralfate group compared to placebo (RR = 0.67, 95% CI 0.48 to 0.92, P = 0.01)</LI>
</UL>
<P>
<B>* </B>Conclusions based on at least one trial with a low risk of bias.</P>
<P>
<B>**</B> Conclusions based on larger body of weak unreliable evidence.</P>
<P>The mechanisms by which these ten interventions act to either prevent mucositis or reduce the severity of mucositis in cancer patients receiving treatment, is not clearly established. There are various explanations put forward in the literature, as to how the 'effective' interventions listed above might mitigate the effects of cancer treatment on the oral mucosa, but it is beyond the scope of this systematic review to comment further.</P>
<P>Overall, three interventions (aloe vera, PTA antibiotics and honey) were investigated almost exclusively in patients with head and neck cancer undergoing radiotherapy.Cryotherapy was investigated solely in patients with haematological malignancies undergoing chemotherapy or stem cell transplantation.Sucralfate was investigated mostly in patients with head and neck cancer undergoing radiotherapy, with a minority of trials including participants with other cancer types.The remainder (amifostine, granulocyte-colony stimulating factor, intravenous glutamine, keratinocyte growth factor, and laser treatment) were tested in combinations of patients with head and neck cancer, other solid tumours and haematological malignancies undergoing radiotherapy, stem cell transplantation, non-myeloablative chemotherapy or a combination.</P>
<P>Of the chemotherapeutic agents used to treat cancer, 5-fluouracil was the most frequently reported.However, a wide variety of different agents and schedules were examined, precluding analysis specific to a particular chemotherapy regimen.</P>
<P>It is important to note that a substantial body of evidence concerning chlorhexidine, has clearly shown no evidence of a benefit compared to either placebo or no treatment.</P>
<UL>
<LI>
<B>Chlorhexidine</B> - no evidence of a benefit for chlorhexidine based on 9 trials including a total of more than 650 participants. Risk of bias was assessed as low in 3 trials, high in one trial, and unclear in the remaining five trials.</LI>
</UL>
<P>In conclusion, there is some evidence of the effectiveness of cryotherapy and keratinocyte growth factor, and weaker evidence of a benefit associated with aloe vera, amifostine, glutamine (intravenous), granulocyte-colony stimulating factor, honey, laser, PTA antibiotic pastille/paste and sucralfate. There is no evidence of a benefit associated with the use of chlorhexidine.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2010-11-30 10:26:16 +0000" MODIFIED_BY="[Empty name]">
<P>The number and range of interventions studied and reported in this review indicate the importance of this condition to clinicians and patients and the lack of a well-defined and effective means of prevention of oral mucositis in cancer patients. The presumed modes of action of the different interventions are very varied and include free radical scavenging (amifostine), local vasoconstriction (cryotherapy), reductions in concurrent mucosal infection (antibiotic pastilles) and enhancement of wound healing (honey, keratinocyte growth factor). Nine of the 43 interventions examined were found to have some evidence of a benefit, albeit sometimes weak, in preventing or reducing the severity of mucositis. </P>
<P>Despite the large number of trials included in the review few interventions were studied by several independent groups.This has led to limitations in the strength and generalisability of the evidence and several groups have highlighted the need for a co-ordinated research agenda (<LINK REF="REF-Wright-2003" TYPE="REFERENCE">Wright 2003</LINK>).The eligible trials varied in their setting, design, country of conduct, financial support and quality.The majority (79%) were conducted primarily by medical teams who did not report the involvement of dental practitioners.It was unfortunate that many studies presented data in a format unsuitable for meta-analysis in this review. The use of structured abstracts and adherence to the Consolidated Standards of Reporting Trials (CONSORT) guidelines would greatly improve the conduct and reporting of randomised controlled trials (RCTs), allowing a greater number to be included in future meta-analyses (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>; <LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>).</P>
<P>With respect to publication bias, several negative studies for mucositis have been reported and we congratulate the authors and editors for doing so. It was not possible to detect any existing publication bias, as there were insufficient studies in each meta-analysis investigating the same interventions. This review has focused heavily on the prevention of mucositis in adults due to a lack of true RCTs conducted in paediatric populations, highlighting the difficulties of conducting research in this patient population.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2011-02-17 08:53:25 +0000" MODIFIED_BY="[Empty name]">
<P>All studies included in this update of the review were assessed for risk of bias in six categories: adequate sequence generation, adequate allocation concealment, blinding (of patients, carers and outcome assessors), incomplete outcome data addressed, free of selective reporting and free of other bias. Overall risk of bias was described for each included study. Studies were deemed to be at low risk of overall bias if they were assessed as being at low risk for both allocation concealment and outcome assessor blinding. Only 10 studies (7.6%) met both criteria. Eighty-three studies (63.4%) were described as being at unclear overall risk of bias. The remaining 38 studies (29%) were found to be at high overall risk of bias. In general, methods of allocation concealment were not reported in publications, or poorly described by authors, which prevented the study being described as at low risk of bias for this category. The use of adequate allocation concealment, together with the publication of full descriptions of any methods used, needs to be incorporated into future trials. Of the 77 studies described as double blind, only 19 studies specifically stated that the outcome assessor was blinded. Adequate outcome assessor blinding is crucial to obtain unbiased assessments, even with the most objective of assessment instruments. It is both possible and highly desirable that future trials employ adequate outcome assessor blinding, even where blinding of patients or support staff to the intervention is impossible.</P>
<P>Although there was general consistency among the included studies in the number of categories of mucositis severity, scoring systems were not always clearly defined. The most frequently used assessment instrument in this review was the World Health Organization (WHO) score, followed by the Radiation Therapy Oncology Group (RTOG) instrument. Since our last review update, a systematic review has been published (<LINK REF="REF-Gibson-2010" TYPE="REFERENCE">Gibson 2010</LINK>) which identified 54 oral assessment instruments in the literature. In order for the results of future studies to be synthesised with others, it is recommended that authors should employ a 'simple' assessment, in addition to any multicomponent instrument, to allow for data to be dichotomised.</P>
<P>The appearances of mucositis and oral candidiasis can be similar, and moreover, the two frequently co-exist. Consequently, if the assessors were lacking experience in the differential diagnosis of these oral lesions, the validity of mucositis scores may have been compromised. Candidiasis was not routinely screened for or reported in the trials included in this review, and the addition of candidiasis screening may assist in the differential diagnosis and treatment of the two conditions.</P>
<P>The reporting of secondary outcomes other than mucositis severity was variable and these outcomes were mentioned more frequently in trials published within the last 5 years. The types of outcome reported have changed to reflect characteristics of greater clinical relevance to clinicians and patients (<LINK REF="REF-Bellm-2002" TYPE="REFERENCE">Bellm 2002</LINK>; <A HREF="https://outlook.manchester.ac.uk/owa/redir.aspx?C=1e489e3537b3477ea02d5c363f9494a8&amp;URL=https%3a%2f%2fmail.google.com%2fmail%2fhtml%2fcompose%2fstatic_files%2fChang%25202003">Chang 2003</A>; <A HREF="https://outlook.manchester.ac.uk/owa/redir.aspx?C=1e489e3537b3477ea02d5c363f9494a8&amp;URL=https%3a%2f%2fmail.google.com%2fmail%2fhtml%2fcompose%2fstatic_files%2fSonis%25202004">Sonis 2004</A>; <A HREF="https://outlook.manchester.ac.uk/owa/redir.aspx?C=1e489e3537b3477ea02d5c363f9494a8&amp;URL=https%3a%2f%2fmail.google.com%2fmail%2fhtml%2fcompose%2fstatic_files%2fWright%25202003">Wright 2003</A>). In addition to reporting mucositis-related outcomes some groups reported known side effects of the interventions.For some trials these side effects were reported only in the intervention group and it was not clear if there were any events in the control group.In future trials these side effects should be measured and reported on all patients in both groups in a consistent manner. This adverse event data should be presented per patient and not per episode.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2010-11-09 11:16:24 +0000" MODIFIED_BY="[Empty name]">
<P>The meta-analyses in this review include only studies where mucositis outcomes were graded on a 0-4 scale. The most recent update of the review has also included a further 13 studies where the outcomes are recorded in Additional <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>, and the results are incorporated into the text of the review. However, 16 trial reports were excluded from this systematic review because the authors collected outcome data using an instrument which individually graded components of oral health, to produce a composite score (<LINK REF="REF-Eilers-1988" TYPE="REFERENCE">Eilers 1988</LINK>). As such instruments include in the total score categories such as teeth and voice, the scores are not comparable with scales that measure only mucositis.</P>
<P>A further 16 trials are awaiting classification pending further information being made available by the authors of the papers and it is hoped that these trials may be included in future updates of this review.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2010-11-30 10:55:35 +0000" MODIFIED_BY="[Empty name]">
<P>This updated systematic review has identified nine interventions for the prevention of mucositis for which there is evidence of effectiveness. Four of these interventions: amifostine, locally applied antibiotic (PTA), cryotherapy and keratinocyte growth factor, have also been identified as having some evidence of effectiveness by practice guidelines and other systematic reviews (<LINK REF="REF-Keefe--2007" TYPE="REFERENCE">Keefe 2007</LINK>; <LINK REF="REF-McDonnell-2007" TYPE="REFERENCE">McDonnell 2007</LINK>; <LINK REF="REF-Sasse-2006" TYPE="REFERENCE">Sasse 2006</LINK>; <LINK REF="REF-Stokman-2006" TYPE="REFERENCE">Stokman 2006</LINK>). We have also found weak evidence to support the effectiveness of the use of aloe vera, granulocyte-colony stimulating factor and honey for the prevention of oral mucositis, but we are not aware of other systematic reviews which support the use of these interventions.</P>
<P>Regarding the use of laser for the prevention of mucositis there is evidence based on two studies that laser reduces the incidence of severe mucositis, a finding which is supported by a Cochrane review on the treatment of oral mucositis which found that laser treatment was effective in reducing the severity of established mucositis (<LINK REF="REF-Clarkson-2010" TYPE="REFERENCE">Clarkson 2010</LINK>).</P>
<P>Our systematic review includes a small study by <LINK REF="STD-Oberbaum-2001" TYPE="STUDY">Oberbaum 2001</LINK> (n = 32) which is also included in another systematic review by <LINK REF="REF-Kassab-2009" TYPE="REFERENCE">Kassab 2009</LINK> which evaluated homeopathic interventions for the adverse effects of cancer treatments. In their review, Kassab et al reported the mucositis outcome as mean area under the curve for each group, and found a statistically significant difference favouring traumeel, the homeopathic intervention. In our systematic review we used a different outcome category: prevention of any mucositis, and found no statistically significant difference between traumeel and placebo. Both reviews assessed this study as being at low risk of bias. We agree with Kassab et al that further research is required to confirm any benefit of this intervention.</P>
<P>Our updated systematic review has found some weak evidence for the effectiveness of intravenous glutamine in the prevention of severe oral mucositis, based on three trials that have been published since 2006, but this intervention is not recommended by the current Multinational Association of Supportive Care in Cancer (MASCC) guidelines, based on a single study from 2002 (Keefe 2007). There are plans to update these guidelines in the near future.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-03-09 16:58:11 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2011-03-09 16:53:50 +0000" MODIFIED_BY="[Empty name]">
<P>Cryotherapy (ice chips) and Keratinocyte Growth Factor (Palifermin) have shown some evidence of benefit in the prevention of mucositis. There is weaker less reliable evidence of a benefit associated with aloe vera, amifostine, intravenous glutamine supplementation, granulocyte-colony stimulating factor, honey, laser, polymixin/tobramycin/amphotericin (PTA) lozenges and sucralfate.</P>
<P>There is no evidence that chlorhexidine is more effective that placebo and this intervention should not be used in the prevention of mucositis.</P>
<P>The patient groups studied were diverse, the associated treatment modalities were varied and the strength of the evidence of effectiveness was variable. As some interventions were studied exclusively in certain patient groups receiving specific treatment modalities generalisation of the results to other tumour types and treatment modalities must be done with caution as some benefits may be specific to certain cancer types and treatments.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-03-09 16:58:11 +0000" MODIFIED_BY="[Empty name]">
<P>There is a need for well designed and conducted trials of interventions to prevent mucositis induced by chemotherapy, radiotherapy or targeted therapies. Such trials should be reported according to the Consolidated Standards of Reporting Trials (CONSORT) guidelines with sufficient numbers of participants to perform subgroup analyses by type of disease and chemotherapeutic agent. This review has highlighted several interventions (aloe vera, amifostine, G-CSF, PTA antibiotic pastille/paste, cryotherapy, intravenous glutamine, honey, keratinocyte growth factor and laser therapy) with evidence of effectiveness from more than one trial included in a meta-analysis.Further research into the benefits and harms of these interventions and whether these results can be generalized to other forms of cancer and its treatment should be conducted. In addition, as several agents were reported to show efficacy in a single trial, further well designed, adequately powered randomised controlled trials of these and other novel agents for mucositis prevention should be undertaken. The concurrent use of two or more interventions, with different modes of action, may be worth evaluating in well conducted, adequately powered randomised controlled trials.</P>
<P>We recognise the importance of multicomponent indices for oral health. However, to facilitate comparison between interventions for preventing mucositis it would be helpful if researchers used a simple mucositis index with a 0-4 scale (e.g. World Health Organization (WHO), Radiation Therapy Oncology Group (RTOG), National Cancer Institute - Common Toxicity Criteria (NCI-CTC)) as part of their outcome evaluation.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-11-09 11:23:54 +0000" MODIFIED_BY="[Empty name]">
<P>Thanks go to Luisa Fernandez Mauleffinch (Managing Editor, Cochrane Oral Health Group) and Phil Riley (Assistant Managing Editor) their help with the administration of the review, for locating all the articles, sending out letters to authors and helping collate the information for the review.</P>
<P>The help and expertise of the following is gratefully acknowledged: Marco Esposito (Italian translations, The University of Manchester); Tatiana Macfarlane (Russian translations, University of Aberdeen); Malgorzata Bala (Polish translations, Jagiellonian University Medical College, Poland), Joannna Zakrzewska (Polish translations, Eastman Dental Hospital), Valeria Marinho (Spanish/Portuguese translations, Queen Mary's School of Medicine and Dentistry); Shi Zongdao, Xie Huixu, Wang Ping, Yifan Zhang, Chunjie Li and Wu Jiapei (Chinese translations, Sichuan University); Mikako Hayashi and Kumiko Kasashi (Japanese translations, University of Osaka) and Toru Naito (Japanese translations, Fukuoka Dental College) for providing translations of the trial reports and completing the data extraction forms.</P>
<P>We would also like to thank the following investigators who replied to our request for additional information about their trials: HS Antunes, G Bjarnason, S Cascinu, D Cella, L Cruz, MJ Dodd, GA Ferretti, T Feyerabend, P Gotzshe, CL Loprinzi, S Wang and Drs PM Anderson, B Bensinger, BM Biswal, C Bokemeyer, J Bourhis, H Brincker, J Buentzel, L Cerchietti, LWC Chow, L Damon, C Dazzi, TC Dickson, P Dietrich, A Duenas-Gonzalez, S El Sayed, S Elad, MV Ertkin, GA Ferretti, R Foote, L Frazen, C Freytes, J Hartmann, M Heydt, R Haddad, E Huang, N Ifrah, SA Jebb, M Katano, J Leborgne, P Lockhart, G Masucci, M Motallebneja, SH Okuno, DE Peterson, N Piccirillo, HC Pillsbury, R Rahn, K Saarilahti, C Scarantino, JL Shenep, JA Sloan, A Spencer, R Spielberger, C Sportes, M Stokman, C Su, RP Symonds, A Trotti, S Vadhan-Raj, YB Wahlin, and H Whelan.</P>
<P>We would also like to thank those who have provided comments and editorial input into this review.</P>
<P>The administration of this review has been aided by a USA NIDCR grant, reference 1 R03 DE0 16950-01.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]">
<P>None known.<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-11-09 11:24:24 +0000" MODIFIED_BY="[Empty name]">
<P>Helen Worthington (HW) and Jan Clarkson (JC) wrote the protocol and 2000, 2003, 2006 and 2007 updates of the review.</P>
<P>The 2010 update was co-ordinated by Gemma Bryan (GB) and HW. GB, HW, JC independently and in duplicate assessed the eligibility of the trials. GB, HW, JC, Susan Furness (SF), Anne-Marie Glenny (A-MG), andAnne Littlewood (AL) independently and in duplicate extracted the information to complete the characteristics of included studies, and assessed the risk of bias of the trials. Data extraction was done by HW, GB, JC and AL and HW conducted the statistical analysis. GB, HW, JC, SF, A-MG, AL, Martin McCabe (MMcC) wrote the review. MMcC, Stefan Meyer (SM) and Tasneem Khalid (TK) provided a clinical perspective on the cancer, cancer treatments and interventions for preventing mucositis.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2010-11-09 11:24:33 +0000" MODIFIED_BY="[Empty name]">
<P>Clarification of the reason for exclusion of trials which report only multicomponent oral health indices.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]">
<P>The title of the protocol was originally 'Oral care for patients with cancer treated with chemotherapy (excluding head and neck cancer).'</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-04-26 13:45:52 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-04-26 13:45:52 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2012-04-26 13:45:52 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abbasi_x002d_Nazari-2007" MODIFIED="2010-11-09 12:26:43 +0000" MODIFIED_BY="[Empty name]" NAME="Abbasi-Nazari 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-09 12:26:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Abbasi Nazari M, Sadrolhefazi B, Nikoofar A, Erfan M, Azizian H, Alamy M</AU>
<TI>Allopurinol mouthwash for prevention or alleviation radiotherapy induced oral mucositis: a randomized, placebo-controlled trial</TI>
<SO>Daru</SO>
<YR>2007</YR>
<VL>15</VL>
<NO>4</NO>
<PG>227-30</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ahmed-1993" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Ahmed 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ahmed T, Engelking C, Szalyga J, Helson L, Coombe N, Cook P et al</AU>
<TI>Propantheline prevention of mucositis from etoposide</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1993</YR>
<VL>12</VL>
<NO>2</NO>
<PG>131-2</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Anderson-1998" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Anderson 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Anderson PM, Schroeder G, Skubitz KM. Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer 1998;83:1433-9.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:19 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson PM, Schroeder G, Skubitz KM</AU>
<TI>Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy</TI>
<SO>Cancer</SO>
<YR>1998</YR>
<VL>83</VL>
<NO>7</NO>
<PG>1433-9</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Antonadou-2002" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Antonadou 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N</AU>
<TI>Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer</TI>
<SO>International Journal of Radiation Oncology, Biology and Physics</SO>
<YR>2002</YR>
<VL>52</VL>
<NO>3</NO>
<PG>739-47</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Antunes-2007" MODIFIED="2010-11-09 12:27:00 +0000" MODIFIED_BY="[Empty name]" NAME="Antunes 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-09 12:27:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Antunes HS, de Azevedo AM, da Silva Bouzas LF, Adao CA, Pinheiro CT, Mayhe R et al</AU>
<TI>Low-power laser in the prevention of induced oral mucositis in bone marrow transplantation patients: a randomized trial</TI>
<SO>Blood</SO>
<YR>2007</YR>
<VL>109</VL>
<NO>5</NO>
<PG>2250-5</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arun-Maiya-2006" MODIFIED="2010-11-09 12:27:17 +0000" MODIFIED_BY="[Empty name]" NAME="Arun Maiya 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-09 12:27:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Arun Maiya G, Sagar MS, Fernandes D</AU>
<TI>Effect of low level helium-neon (He-Ne) laser therapy in the prevention &amp; treatment of radiation induced mucositis in head &amp; neck cancer patients.[see comment]</TI>
<SO>The Indian Journal of Medical Research</SO>
<YR>2006</YR>
<VL>124</VL>
<NO>4</NO>
<PG>399-402</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Attal-1993" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Attal 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Attal M, Huguet F, Rubie H, Charlet J-P, Schlaifer D, Huynh A et al</AU>
<TI>Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: A prospective, randomized trial</TI>
<SO>Blood</SO>
<YR>1993</YR>
<VL>82</VL>
<NO>3</NO>
<PG>732-6</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bensadoun-1999" MODIFIED="2011-02-24 13:54:47 +0000" MODIFIED_BY="[Empty name]" NAME="Bensadoun 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-11-09 12:32:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bensadoun R, Cowen D, Nguyen TD, Ciais G, Franquin JC, Dassonville O et al</AU>
<TI>Low energy laser in the prevention of radiation-induced mucositis: A phase III randomized multicentric study in patients with head and neck cancer</TI>
<SO>Fifth International Congress on Anti-Cancer Chemotherapy</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-06-20 20:27:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bensadoun R, Franquin J, Benezery K, Ciais G, Tardieu C, Dejou J et al</AU>
<TI>Low energy He/Ne laser in the prevention of radiation induced mucositis: A multicenter phase III double blind study for patients with head and neck cancer</TI>
<SO>Proceedings of ASCO</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-06-20 20:27:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bensadoun RJ, Ciais G, Darcourt V, Franquin JC, Cheynet C, Cowen D et al</AU>
<TI>Low energy laser in the prevention of radiation induced mucositis: a phase II randomized multicentre study for patients with head and neck cancer</TI>
<SO>Supportive Care in Cancer</SO>
<YR>1999</YR>
<VL>7</VL>
<PG>SO-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 12:33:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bensadoun RJ, Franquin JC, Ciais G, Darcourt V, Schubert MM, Viot M et al</AU>
<TI>Low-energy He/Ne laser in the prevention of radiation-induced mucositis. A multicentre phase III randomized study in patients with head and neck cancer</TI>
<SO>Supportive Care in Cancer</SO>
<YR>1999</YR>
<VL>7</VL>
<NO>4</NO>
<PG>244-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Biswal-2003" MODIFIED="2010-11-09 13:24:48 +0000" MODIFIED_BY="[Empty name]" NAME="Biswal 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-11-09 12:34:22 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Biswal BZAAN. Topical application of honey in the management of radiation mucositis. A preliminary study. Supportive Care in Cancer 2003+ADs- Vol 11(4): 242-248.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 12:34:22 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Biswal BM, Zakaria A, Ahmad NM</AU>
<TI>Topical application of honey in the management of radiation mucositis: a preliminary study</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2003</YR>
<VL>11</VL>
<NO>4</NO>
<PG>242-8</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 13:24:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Biswal BM, Zakaria A, Nik Min A</AU>
<TI>Topical application of honey in the management of radiation mucositis: A randomized study</TI>
<SO>International Journal of Cancer</SO>
<YR>2002</YR>
<VL>100 Supp 13</VL>
<PG>480 (Abstract 1109)</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bjarnason-2009" MODIFIED="2010-11-09 12:37:18 +0000" MODIFIED_BY="[Empty name]" NAME="Bjarnason 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-09 12:37:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bjarnason GA, MacKenzie RG, Nabid A, Hodson ID, El-Sayed S, Grimard L et al</AU>
<TI>Comparison of toxicity associated with early morning versus late afternoon radiotherapy in pateints with head and neck cancer: a prospective randomized trial of the National Cancer Institute of the Canada Clinical Trials Group (HN3)</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2009</YR>
<VL>73</VL>
<NO>1</NO>
<PG>166-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blazar-2006" MODIFIED="2010-11-09 12:37:47 +0000" MODIFIED_BY="[Empty name]" NAME="Blazar 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-09 12:37:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Blazar BR, Weisdorf DJ, Defor T, Goldman A, Braun T, Silver S et al</AU>
<TI>Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT)</TI>
<SO>Blood</SO>
<YR>2006</YR>
<VL>108</VL>
<NO>9</NO>
<PG>3216-22</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borowski-1994" MODIFIED="2010-11-09 12:38:01 +0000" MODIFIED_BY="[Empty name]" NAME="Borowski 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-11-09 12:38:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borowski B, Benhamou E, Pico JL, Laplanche A, Margainaud JP, Hayat M</AU>
<TI>Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: a randomised controlled trial comparing two protocols of dental care</TI>
<SO>European Journal of Cancer. Part B, Oral Oncology</SO>
<YR>1994</YR>
<VL>30B</VL>
<NO>2</NO>
<PG>93-7</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bourhis-2000" MODIFIED="2010-11-09 12:38:53 +0000" MODIFIED_BY="[Empty name]" NAME="Bourhis 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-11-09 12:38:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bourhis J, De Crevoisier R, Abdulkarim B, Deutsch E, Lusinchi A, Luboinski B et al</AU>
<TI>A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2000</YR>
<VL>46</VL>
<NO>5</NO>
<PG>1105-8</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 12:38:53 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Bourhis J, Rosine D. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma. +AFs-Review+AF0- +AFs-9 refs+AF0-. 2002+ADs- 29(6 Suppl 19):61-2.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 12:38:53 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bourhis J, Rosine D</AU>
<TI>Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma</TI>
<SO>Seminars in Oncology</SO>
<YR>2002</YR>
<VL>29</VL>
<NO>6 Supp 19</NO>
<PG>61-2</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brizel-2000" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Brizel 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brizel DM, Wasserman TH, Henke H, Strnad V, Rudat V, Monnier A et al</AU>
<TI>Phase III randomized trial of amifostine as a radioprotector in head and neck cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>19</NO>
<PG>3339-45</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brizel-2008" MODIFIED="2010-11-09 12:39:30 +0000" MODIFIED_BY="[Empty name]" NAME="Brizel 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-11-09 12:39:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Brizel DM, Murphy BA, Rosenthal DI, Pandya KJ, Gluck S, Brizel HE et al</AU>
<TI>Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>15</NO>
<PG>2489-96</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bubley-1989" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Bubley 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bubley GJ, Chapman B, Chapman SK, Crumpacker CS, Schnipper LE</AU>
<TI>Effect of acyclovir on radiation- and chemotherapy-induced mouth lesions</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1989</YR>
<VL>33</VL>
<NO>6</NO>
<PG>862-5</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buentzel-2006" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Buentzel 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Buentzel J, Micke O, Adamietz IA, Monnier A, Glatzel M, de Vries A. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. International Journal of Radiation Oncology, Biology, Physics. 2006;64(3):684-91.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:19 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buentzel J, Micke O, Adamietz IA, Monnier A, Glatzel M, de Vries A</AU>
<TI>Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2006</YR>
<VL>64</VL>
<NO>3</NO>
<PG>684-91</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buntzel-1998" MODIFIED="2010-11-09 12:40:54 +0000" MODIFIED_BY="[Empty name]" NAME="Buntzel 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bennett CL, Lane D, Stinson T, Glatzel M, Buntzel J</AU>
<TI>Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: Preliminary results from a randomized phase II clinical trial from Germany</TI>
<SO>Cancer Investigation</SO>
<YR>2001</YR>
<VL>19</VL>
<NO>2</NO>
<PG>107-13</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 12:40:54 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Buntzel J, Glatzel M, Kuttner K, Weinaug R, Frohlich D. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. 2002+ADs- 12(1 Suppl 1):4-13.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 12:40:54 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buntzel J, Glatzel M, Kuttner K, Weinaug R, Frohlich D</AU>
<TI>Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer</TI>
<SO>Seminars in Radiation Oncology</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>1 Supp 1</NO>
<PG>4-13</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buntzel J, Kuttner K, Frohlich D, Glatzel M</AU>
<TI>Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer</TI>
<SO>Annals of Oncology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>5</NO>
<PG>505-9</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Buntzel J, Schuth J, Kuttner K, Glatzel M</AU>
<TI>Radiochemotherapy with amifostine cytoprotection for head and neck cancer</TI>
<SO>Supportive Care in Cancer</SO>
<YR>1998</YR>
<VL>6</VL>
<NO>2</NO>
<PG>155-60</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cartee-1995" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Cartee 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Cartee L, Petros WP, Rosner GL, Gilbert C, Moore S, Affronti ML et al. Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomised, double blind, dose-ranging study. Cytokine 1995;7: 471-7.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:19 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cartee L, Petros WP, Rosner GL, Gilbert C, Moore S, Affronti ML et al</AU>
<TI>Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study</TI>
<SO>Cytokine</SO>
<YR>1995</YR>
<VL>7</VL>
<NO>5</NO>
<PG>471-7</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carter-1999" MODIFIED="2010-07-25 21:37:51 +0100" MODIFIED_BY="[Empty name]" NAME="Carter 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-07-25 21:37:51 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt; Makkonen TA, Minn H, Jekunen A, Vilja P, Tuominen J, Joeensuu H. Granulocyte Macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: A prospective randomized study. International Journal of Radiation Oncology, Biology and Physics 2000;46(3):525-34. McAleese 2006 McAleese JJ, Bishop KM, A'Hern R, Henk JM. Randomized phase II study of GM-CSF to reduce mucositis caused by accelerated radiotherapy of laryngeal cancer. British Journal of Radiology 2006;79(943):608-13. Meropol 2003 Meropol NJ, Somer RA, Gutheil J, Pelley RJ, Modiano MR, Rowinsky EK et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. Journal of Clinical Oncology 2003;21(8):1452-8.Meropol NJ, Somer RA, Gutheil J, Pelley RJ, Modiano MR, Rowinsky EK, et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant.+AFs-comment+AF0-. Journal of Clinical Oncology 2003+ADs- 21(8):1452-8. Mills 1988 Mills EE. The modifying effect of beta-carotene on radiation and chemotherapy induced oral mucositis. British Journal of Cancer 1988;57(4):416-7. Motallebnejad 2008 Motallebnejad M, Akram S, Moghadamnia A, Moulana Z, Omidi S. The effect of topical application of pure honey on radiation-induced mucositis: a randomized clinical trial. Journal of Contemporary Dental Practice [Electronic Resource] 2008;9(3):40-7. Naidu 2005 Naidu MU, Ramana GV, Ratnam SV, Sudhavani T, Naidu KJ, Roy P et al. A randomised, double-blind, parallel, placebo-controlled study to evaluate the efficacy of MF 5232 (Mucotrol), a concentrated oral gel wafer, in the treatment of oral mucositis. Drugs in R&amp;amp;D 2005;6(5):291-8. Nemunaitis 1995 Nemunaitis J, Rosenfeld CS, Ash R, Freedman MH, Deeg HJ, Appelbaum F et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplantation 1995;15(6):949-54. Niibe 1985 Niibe H, Takahashi I, Mitsuhashi N, Miyaishi K, Itoh J, Maehara Y et al. An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study.1. Head and neck tumors. Nippon-gan-chiryo-gakkai-shi 1985;20(5):984-93. Nottage 2003 Nottage M, McLachlan SA, Brittain MA, Oza A, Hedley D, Feld R, et al. Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial. Supportive Care in Cancer 2003;11(1):41-7.Nottage M, McLachlan SA, Brittain MA, Oza A, Hedley D, Feld R, et al. Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial. Supportive Care in Cancer 2003+ADs- 11(1):41-7. Oberbaum 2001 Oberbaum M, Yaniv I, Ben-Gal Y, Stein J, Ben-Zvi N, Freedman LS et al. A randomized, controlled clinical trial of the homeopathic medication TRAUMEEL S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation. American Cancer Society 2001;92(3):684-90. Oberbaum M, Yaniv I, Ben-Gal Y, Stein J, Ben-Zvi N, Freedman LS et al. A randomized, controlled clinical trial of the homoeopathic medication Traumeel S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation. Biologische Medizin 2002;31(1):25-31.Oberbaum MYIB-GYSJZNFLBD. A randomized, controlled clinical trial of the homoeopathic medication Traumeel S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation. Biologische Medizin 2002+ADs- Vol 31(1): 25-31. Oberbaum MY. Randomized, controlled study to prove the effectiveness of traumeel (R)s in the management of chemotherapy-induced stomatitis in children and young adults undergoing bone-marrow transplantation. Biol Medizin 2002;31(1):26-31. Okuno 1999 Okuno SH, Woodhouse CO, Loprinzi CL, Sloan JA, LaVasseur BI, Clemens-Schutjer D et al. Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy. American Journal of Clinical Oncology 1999;22(3):258-61. Papas 2003Reconsider inclusion as patients received active mouthwash + active Fl plate versus placebo (Fl) mouthwash and placebo plate. Papas AS, Clark RE, Martuscelli G, O'Loughlin KT, Johansen E, Miller KB. A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplantation 2003;31(8):705-12.Papas AS, Clark RE, Martuscelli G, O'Loughlin KT, Johansen E, Miller KB. A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplantation 2003+ADs- 31(8):705-12. Peterson 2007 Peterson DE, Jones JB, Petit RG. Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer 2007;109(2):322-31. Pfeiffer 1990 Pfeiffer P, Madsen EL, Hansen O, May O. Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy. Acta Oncologica 1990;29(2):171-3. Pillsbury 1986 Pillsbury HC 3rd, Webster WP, Rosenman J. Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers. Archives of Otolaryngology - Head &amp;amp; Neck Surgery 1986;112(5):552-3.Pillsbury HC 3rd WW, Rosenman J. Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers. Archives of Otolaryngology -- Head &amp;amp; Neck Surgery 1986;112(5):552-3. Pitten 2003 Pitten FA, Kiefer T, Buth C, Doelken G, Kramer A. Do cancer patients with chemotherapy-induced leukopenia benefit from an antiseptic chlorhexidine-based oral rinse? A double-blind, block-randomized, controlled study. Journal of Hospital Infection 2003;53(4):283-91.Pitten FA, Kiefer T, Buth C, Doelken G, Kramer A. Do cancer patients with chemotherapy-induced leukopenia benefit from an antiseptic chlorhexidine-based oral rinse? A double-blind, block-randomized, controlled study. Journal of Hospital Infection 2003+ADs- 53(4):283-91. Prada 1987 Prada A, Chiesa F. Effects of benzydamine on the oral mucositis during antineoplastic radiotherapy and/or intra-arterial chemotherapy. International Journal of Tissue Reaction 1987;9(2):115-9. Rahn 1997 Adamietz IA, Rahn R, Bottcher HD, Schafer V, Reimer K, Fleischer W. Prophylaxis of radiochemotherapy-induced mucositis. Efficacy of prophylactic oral rinsing with povidone iodine solution [Pophylaxe der radiochemotherapeutisch bedingten mukositis]. Stranhlentherapie und Onkologie 1998;174(3):149-55. Adamietz IA, Rhan R, Bottcher HD, Schafer V, Reimer K, Fleischer W. Prophylaxis with povidone-iodine against induction of oral mucositis by radiochemotherapy. Supportive Care in Cancer 1998;6(4):373-7. Rahn R AI, Bottcher HD, Reimer K, and Fleischer W. PVP-iodine solution as a mucositis prophylaxis by radiotherapy. Deutsche Zeitschrift fur Mund-, Kiefer- und Gesichtschirurgie 1996;20(3):137-9. Rahn R, Adamietz IA, Boettcher HD, Schaefer V, Reimer K, Fleischer W. Povidone-iodine to prevent mucositis in patients during antineoplastic radiochemotherapy. Dermatology 1997;195(Suppl 2):57-61. Rashad 2008 Rashad UM, Al-Gezawy SM, El-Gezawy E, Azzaz AN. Honey as topical prophylaxis against radiochemotherapy-induced mucositis in head and neck cancer. Journal of Laryngology &amp;amp; Otology 2009;123(2):223-8. Rocke 1993 Rocke LK, Loprinzi CL, Lee JK, Kunselman SJ, Iverson RK, Finck G et al. A randomized clinical trial of two different durations or oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. Cancer 1993;72(7):2234-8. Rosen 2006 Rosen LS, Abdi E, Davis ID, Gutheil J, Schnell FM, Zalcberg J, et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.[see comment]. Journal of Clinical Oncology 2006;24(33):5194-200. Rothwell 1990 Rothwell BR. Palliation of radiation-related mucositis. Special Care in Dentistry 1990:21-25. Saarilahti 2002 Saarilahti K, Kajanti M, Joensuu T, Kouri M, Joensuu H. Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized phase III study. International Journal of Radiation Oncology Biology and Physics 2002;54(2):479-85.Saarilahti K KM, Joensuu T, Kouri M, Joensuu H. Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized phase III study. International Journal of Radiation Oncology, Biology, Physics 2002+ADs-54(2):479-85. Scarantino 2006 Scarantino C, LeVeque F, Swann RS, White R, Schulsinger A, Hodson DI et al. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients. The Journal of Supportive Oncology 2006;4(5):252-8.Scarantino C, LeVeque F, Swann RS, White R, Schulsinger A, Hodson DI, et al. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients. The Journal of Supportive Oncology. 2006;4(5):252-8. Scherlacher 1990 Scherlacher A, Beaufort-Spontin F. [Radiotherapy of head-neck neoplasms: prevention of inflammation of the mucosa by sucralfate treatment]. [German]. HNO 1990;38(1):24-8.Scherlacher A B-SF. [Radiotherapy of head-neck neoplasms: prevention of inflammation of the mucosa by sucralfate treatment]. [German]. HNO 1990;38(1):24-8. Schneider 1999 Schneider SB, Nishimura RD, Zimmerman RP, Tran L, Shiplacoff J, Tormey M et al. Filgrastim (r-metHuG-CSF) and its potential use in the reduction of radiation-induced oropharyngeal mucositis: An interim look at a randomized, double blind, placebo-controlled trial. Cytokines, Cellular and Molecular Therapy 1999;5(3):175-80. Schubert 2007 Schubert MM, Eduardo FP, Guthrie KA, Franquin JC, Bensadoun RJ, Migliorati CA, et al. A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Supportive Care in Cancer 2007;15(10):1145-54. Shenep 1988 Shenep JL, Kalwinsky DK, Hutson PR, George SL, Dodge RK, Blankenship KR et al. Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositis. Journal of Pediatrics 1988;113(4):758-63.Shenep JL, Kalwinsky DK, Hutson PR, George SL, Dodge RK, Blankenship KR et al. Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositis. J Pediatr 1988;113:758-63.[published erratum appears in J Paediatr 1989 May; 114(5):900] Shieh 1997 Shieh SH, Wang ST, Tsai ST, Tseng CC. Mouth care for nasopharyngeal cancer patients undergoing radiotherapy. Oral Oncology 1997;33(1):36-41. Sorensen 2008 Sorensen J, Skovsgaard T, Bork E, Damstrup L, Ingeberg S. Double blind, placebo-controlled randomized study of chlorhexidine prophylaxis for chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) [abstract] 2001. Journal of Clinical Oncology : ASCO annual meeting proceedings 2006;24(18S Part I):470. Sorensen JB, Skovsgaard T, Bork E, Damstrup L, Ingeberg S. Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies. Cancer 2008;112(7):1600-6. Sornsuvit 2008 Sornsuvit C, Komindr S, Chuncharunee S, Wanikiat P, Archararit N, Santanirand P. Pilot Study: effects of parenteral glutamine dipeptide supplementation on neutrophil functions and prevention of chemotherapy-induced side-effects in acute myeloid leukaemia patients. Journal of International Medical Research 2008;36(6):1383-91. Spencer 2005 Spencer A, Horvath N, Gibson J, Prince HM, Herrmann R, Bashford J et al. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplantation 2005;35(10):971-7.Spencer A, Horvath N, Gibson J, Prince HM, Herrmann R, Bashford J, et al. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplantation. 2005;35(10):971-7. Spielberger 2004 Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. The New England Journal of Medicine 2004;351(25):2590-8. Spijkervet 1989 Spijkervet FKL, van Saene HK, Panders AK, Vermey A, van Saene JJ, Mehta DM et al. Effects of chlorhexidine rinsing on the oropharyngeal ecology in patients with head and neck cancer who have irradiation mucositis. Oral Surgery, Oral Medicine, Oral Pathology 1989;67(2):154-61. Stokman 2003 Stokman MA, Spijkervet FK, Burlage FR, Dijkstra PU, Manson WL, de Vries EG et al. Oral mucositis and selective elimination of oral flora in head and neck cancer patients receiving radiotherapy: a double-blind randomised clinical trial. British Journal of Cancer 2003;88(7):1012-6. Su 2003 Su C, Mehta V, Ravikumar L, Shah R, Pinto H, Halpern J et al. Phase II double-blind randomized study comparing oral aloe vera (AV) versus placebo to prevent radiation (RT)-related mucositis in patients with head and neck (HN) neoplasms. International Journal of Radiation, Oncology, Biology and Physics 2004;60(1 Sept):171-7.Su C, Mehta, V, Ravikumar, L, Shah, R, Pinto, H, Halpern, J, Koong, A, Goffinet, D, and Le, Q-T. Phase II double-blind randomized study comparing oral aloe vera (AV) versus placebo to prevent radiation (RT)-related mucositis in patients with head and neck (HN) neoplasms. Proceedings of ASCO 2003. Su 2006 Su YB, Vickers AJ, Zelefsky MJ, Kraus DH, Shaha AR, Shah JP, et al. Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor during postoperative radiotherapy for squamous head and neck cancer.[see comment]. Cancer Journal 2006;12(3):182-8. Symonds 1996 Symonds RP, McIlroy P, Khorrami J, Pyper E, Alcock SR, McCallum I et al. The reduction of radiation mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial. British Journal of Cancer 1996;74(2):312-7. Trotti 2004 Trotti A, Garden A, Warde P, Symonds P, Langer C, Redman R et al. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. International Journal of Radiation Oncology, Biology and Physics 2004;58(3):674-81.Trotti A, Garden A, Warde P, Symonds P, Langer C, Redman R, et al. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. International Journal of Radiation Oncology, Biology, Physics 2004; 58(3):674-81. Trotti A, Garden AS, Warde P, Symonds P, Langer C, Fleming T et al. Phase III trial of iseganan HCL oral solution (iseganan) for reducing oral mucositis severity in patients receiving radiotherapy for head and neck malignancies (PROMPT-RT). In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 2002:(Abs No 908). van der Lelie 2001 van der Lelie H, Thomas BL, van Oers RH, Ek-Post M, Sjamsoedin SA, van Dijk-Overtoom ML et al. Effect of locally applied GM-CSF on oral mucositis after stem cell transplantation: a prospective placebo-controlled double-blind study. Annals of Hematology 2001;80(3):150-4. Veerasarn 2006 Veerasarn V, Phromratanapongse P, Suntornpong N, Lorvidhaya V, Sukthomya V, Chitapanarux I, et al. Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand 2006;89(12):2056-67. Veness 2006 Veness MJ, Foroudi F, Gebski V, Timms I, Sathiyaseelan Y, Cakir B, et al. Use of topical misoprostol to reduce radiation-induced mucositis: results of a randomized, double-blind, placebo-controlled trial. Australasian Radiology 2006;50(5):468-74. Vokurka 2005 Vokurka S, Bystricka E, Koza V, Scudlova J, Pavlicova V, Valentova D, et al. The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT--results of a randomized multicentre study. Supportive Care in Cancer 2005;13(7):554-8.Vokurka S, Bystricka E, Koza V, Scudlova J, Pavlicova V, Valentova D, et al. The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT--results of a randomized multicentre study. Supportive Care in Cancer. 2005;13(7):554-8. Wahlin 1989 Wahlin YB. Effects of chlorhexidine mouthrinse on the oral health in patients with acute leukemia. Oral Surgery, Oral Medicine, Oral Pathology 1989;68(3):279-87.Wahlin YD. Effects of chlorhexidine mouth rinse on the oral health in patients with acute leukemia. Oral Surg Oral Med Oral Path 1989;68:279-87. Wang 2002a Wang J. Effect on Chinese herbs decoction gargling to treat and to prevent chemotherapy caused stomatitis. Chinese Nursing Research 2002;16(10):578-9. Wijers 2001 Wijers OB, Levendag PC, Harms ER, Gan-Teng AM, Schmitz PI, Hendriks WD et al. Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: A placebo-controlled double-blind randomized study. International Journal of Radiation Oncology, Biology and Physics 2001;50(2):343-52. Wu 2009 Wu PA, Kim YH, Lavori PW, Hoppe RT, Stockerl-Goldstein KE. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome. Biology of Blood &amp;amp; Marrow Transplantation 2009;15(8):982-90. You 2009 You WC, Hsieh CC, Huang JT. Effect of extracts from indigowood root (Isatis indigotica Fort.) on immune responses in radiation-induced mucositis. Journal of Alternative &amp;amp; Complementary Medicine 2009;15(7):771-8. Yuen 2001 Yuen KY, Woo PCY, Tai JW, Lie AK, Luk J, Liang R. Effects of clarithromycin on oral mucositis in bone marrow transplant recipients. Haematologica 2001;86(5):554-5. Excluded studies Abramoff 2008 Abramoff MM, Lopes NN, Lopes LA, Dib LL, Guilherme A, Caran EM, et al. Low-level laser therapy in the prevention and treatment of chemotherapy-induced oral mucositis in young patients. Photomed Laser Surg 2008;26(4):393-400. Adamietz 1997 Adamietz IA, Rahn R, Bottcher HD, Reimer K, Fleischer W. Prophylaxis of radiation induced oral mucositis with povidone iodine. Supportive Care in Cancer 1997;5 Suppl:165 (Abs No 48).Adamietz IA, Rahn R, Bottcher HD, Reimer K, Fleischer W. Prophylaxis of radiation induced oral mucositis with povidone iodine. Supportive Care in Cancer. 1997;5 Suppl(Abstr 48):165. Ahn 2008 Ahn YWH, Song S, Kim Y, Oh Y, Lee C, and, et al. The therapeutic effect of recombinant human epidermal growth factor (rhEGF) on mucositis in patients with head and neck cancer undergoing radiotherapy with or without chemotherapy: a double-blind placebo-controlled prospective phase II multi-institutional study. J Clin Oncol 2008;26(suppl):Abstract no: 6021. Aisa 2005 Aisa Y, Mori T, Kudo M, Yashima T, Kondo S, Yokoyama A et al. Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients.. Supportive Care in Cancer 2005;13(4):266-9. Altmann 1999 Altmann S Hoffmanns H. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors]. [German]. Strahlentherapie und Onkologie 1999;175(Suppl 4):30-3.Altmann S HH. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors]. [German]. Strahlentherapie und Onkologie 1999;175(Suppl 4):30-3. Andersen 1987 Andersen E, Pedersen H. Oral ftorafur versus intravenous 5-fluorouracil. A comparative study in patients with colorectal cancer. Acta Oncologica 1987;26(6):433-6.Andersen E PH. Oral ftorafur versus intravenous 5-fluorouracil. A comparative study in patients with colorectal cancer. Acta Oncologica 1987;26(6):433-6. Anderson 1998b Anderson PM, Ramsay NKC, Shu XO, Rydholm N, Rogosheske J, Nicklow R et al. Effect of low dose oral glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplantation 1998;22(4):339-44. Antin 2002 Antin JH, Lee SJ, Neuberg D, Alyea E, Soiffer RJ, Sonis S, et al. A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplantation 2002;29(5):373-7.Antin JH, Lee SJ, Neuberg D, Alyea E, Soiffer RJ, Sonis S, et al. A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplantation 2002; 29(5):373-7. Antonadou 1998 Antonadou D, Athanassiou E, Synodinou M, Koliarakis N, Panoussaki K, Karageorgis P et al. Evaluation of the efficacy of granulocyte macrophage colony stimulating factor (GM-CSF) in the prevention of radiation induced mucositis [abstract]. Radiotherapy Oncology 1998;48(S1):S39. Apaydin 1996 Apaydin A, Karadeniz AN, Aysigi G, Blige N. The effect and therapeutical use of benzydamine HCL on radiation-induced oral cavity and oropharyngeal mucositis. Medical Bulletin Istanbul 1996;29:1:59-63. Aquino 2005 Aquino VM, Harvey AR, Garvin JH, Godder KT, Nieder ML, Adams RH et al. A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplantation 2005;36(7):611-6.Aquino VM, Harvey AR, Garvin JH, Godder KT, Nieder ML, Adams RH, et al. A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplantation. 2005;36(7):611-6. Ardizzoni 2002 Ardizzoni A, Tjan-Heijnen VC, Postmus PE, Buchholz E, Biesma B, Karnicka-Mlodkowska H, et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. Journal of Clinical Oncology 2002;20(19):3947-55.Ardizzoni A, Tjan-Heijnen VC, Postmus PE, Buchholz E, Biesma B, Karnicka-Mlodkowska H, et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.+AFs-comment+AF0-. Arora 2008 Arora H, Pai KM, Maiya A, Vidyasagar MS, Rajeev A. Efficacy of He-Ne Laser in the prevention and treatment of radiotherapy-induced oral mucositis in oral cancer patients. Oral Surgery Oral Medicine Oral Pathology Oral Radiology &amp;amp; Endodontics 2008;186.e1, 105(2):180-6. Awada 2002 Awada A, Biganzoli L, Cufer T, Beex L, Lohrisch C, Batter V, et al. An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes. European Journal of Cancer 2002;38(6):773-8.Awada A, Biganzoli L, Cufer T, Beex L, Lohrisch C, Batter V, et al. An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes.2002+ADs- 38(6):773-8. Awada 2004 Awada A, Gil T, Sales F, Dubuisson M, Vereecken P, Klastersky J et al. Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers. Anti-Cancer Drugs 2004;15(5):499-502.Awada A, Gil T, Sales F, Dubuisson M, Vereecken P, Klastersky J, et al. Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers. Anti-Cancer Drugs. 2004;15(5):499-502. Awidi 2001 Awidi A, Homsi U, Kakail RI, Mubarak A, Hassan A, Kelta M, Martinez P et al. Double-blind, placebo-controlled cross-over study of oral pilocarpine for the prevention of chemotherapy-induced oral mucositis in adult patients with cancer. European Journal of Cancer 2001;37(16):2010-4.Awidi A HU, Kakail RI, Mubarak A, Hassan A, Kelta M, Martinez P, Sulaiti S, Al Qady A, Jamhoury A, Daniel M, Charles C, Ambrose A, El-Aloosy AS. Double-blind, placebo-controlled cross-over study of oral pilocarpine for the prevention of chemotherapy-induced oral mucositis in adult patients with cancer. +AFs-see comments.+AF0-. Awwad 2002 Awwad HK, Lotayef M, Shouman T, Begg AC, Wilson G, Bentzen SM et al. Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cnacer: influence of proliferation. British Journal of Cancer 2002;86(4):517-23. Barasch 1995 Barasch A, Peterson DE, Tanzer JM, D'Ambrososio JA, Nuki K, Schubert MM et al. Helium-Neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer 1995;76(12):2550-6. Baydar 2005 Baydar M, Dikilitas M, Sevinc A, Aydogdu I. Prevention of oral mucositis due to 5-fluorouracil treatment with oral cryotherapy. Journal of the National Medical Association 2005;97(8):1161-4. Bensadoun 1995 Bensadoun R, Cowen D, Nguyen TD, Ciais G, Franquin JC, Dassonville O et al. Low energy laser in the prevention of radiation-induced mucositis: A phase III randomized multicentric study in patients with head and neck cancer. In: Fifth International Congress on Anti-Cancer Chemotherapy. 1995.Bensadoun R, Cowen, D, Nguyen, TD, Ciais, G, Franquin, JC, Dassonville, O, Laudoyer, Y, Chauvel, P, Demard, F, and Zattara, H. Low energy laser in the prevention of radiation-induced mucositis: A phase III randomized multicentric study in patients with head and neck cancer. Fifth International Congress on Anti-Cancer Chemotherapy. 1995 1995. Bensadoun 1999 Bensadoun R, Franquin J, Benezery K, Ciais G, Tardieu C, Dejou J et al. Low energy He/Ne laser in the prevention of radiation induced mucositis: A multicenter phase III double blind study for patients with head and neck cancer. In: Proceedings of ASCO. 1999. Bensadoun RJ, Ciais G, Darcourt V, Franquin JC, Cheynet C, Cowen D et al. Low energy laser in the prevention of radiation induced mucositis: a phase II randomized multicentre study for patients with head and neck cancer. Supportive Care in Cancer 1999;7:SO-13. Bensadoun RJ, Franquin JC, Ciais G, Darcourt V, Schubert MM, Viot M et al. Low-energy He/Ne laser in the prevention of radiation-induced mucositis. A multicentre phase III randomized study in patients with head and neck cancer. Supportive Care in Cancer 1999;7(4):244-52. Bensadoun 2006 Bensadoun RJ, Benezery K, Dassonville O, Magne N, Poissonnet G, Ramaioli A et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). International Journal of Radiation Oncology, Biology, Physics 2006;64(4):983-94.Bensadoun RJ, Benezery K, Dassonville O, Magne N, Poissonnet G, Ramaioli A, et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). International Journal of Radiation Oncology, Biology, Physics. 2006;64(4):983-94. Bentzen 2001 Bentzen SM, Saunders MI, Dische S, Bond SJ. Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial. Radiotherapy Oncology 2001;60(2):123-35. Bergmann 1995 Bergmann OJ, Ellermann-Eriksen S, Mogensen SC, Ellegaard J. Acyclovir given as prophylaxis against oral ulcers in acute myeloid leukaemia: randomised, double blind, placebo controlled trial. BMJ 1995;6(310):116-72. Bleehen 1996 Bleehen NM, Girling DJ, Hopwood P, Lallemand G, Machin D, Stephens RJ et al. Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. British Journal of Cancer 1996;73:406-13.Bleehen NM, Girling DJ, Hopwood P, Lallemand G, Machin D, Stephens RJ, Bailey AJ. Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. British Journal of Cancer 1996 73 406-413. Bolwell 2004 Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplantation 2004;34(7):621-5.Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplantation. 2004;34(7):621-5. Bourhis 2006 Bourhis J, Lapeyre M, Tortochaux J, Rives M, Aghili M, Bourdin S et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. Journal of Clinical Oncology 2006;24(18):2873-8.Bourhis J, Lapeyre M, Tortochaux J, Rives M, Aghili M, Bourdin S, et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. Journal of Clinical Oncology. 2006;24(18):2873-8. Braaksma 2002 Braaksma M, Levendag P. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation. Seminars in Oncology 2002;29(6 Supp 19):63-70.Braaksma M, Levendag P. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation. Seminars in Oncology 2002+ADs- 29(6 Suppl 19):63-70. Buentzel 1999 Buentzel J, Glatzel M, Weinaug R, Schuth J, Kuettner K, Froehlich D. Amifostine in combined radio- and chemomodalities for head and neck cancer. European Journal of Cancer 1999;35(Suppl 4):363 (Abs No 1472).Buentzel J, Glatzel M, Weinaug R, Schuth J, Kuettner K, Froehlich D. Amifostine in combined radio- and chemomodalities for head and neck cancer. European Journal of Cancer. 1999;35(Suppl 4):363 Abstract #1472. Calais 1998 Calais GM, Alfonsi E, Bardet C, Sire H, Bourgeois C, Bergerot B et al. Randomized study comparing radiation alone (RT) versus RT with concomitant chemotherapy (CT) in stages III andf IV oropharynx carcinoma (ARCORO). Preliminary results of the 94.01 study from the French Group of radiation oncology for head and neck cancer (GORTEC). In: Proceedings of Annual Meeting of the American Society of Clinical Oncology. 1998:(Abs No 1484).Calais GM, Alfonsi E, Bardet C, Sire H, Bourgeois C, Bergerot B, et al. Randomized study comparing radiation alone (RT) versus RT with concomitant chemotherapy (CT) in stages III andf IV oropharynx carcinoma (ARCORO). Preliminary results of the 94.01 study from the French Group of radiation oncology for head and neck cancer (GORTEC). Proc-Annu-Meet-Am-Soc-Clin-Oncol. 1998:Abstract # 1484. Calais 2000 Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P et al. [Stage III and IV cancers of the oropharynx: results of a randomized study of Gortec comparing radiotherapy alone with concomitant chemotherapy]. Bulletin du Cancer 2000;87 Spec No:48-53.Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, et al. [Stage III and IV cancers of the oropharynx: results of a randomized study of Gortec comparing radiotherapy alone with concomitant chemotherapy]. [French]. Bulletin du Cancer. 2000;87 Spec No:48-53. Calais 2004 Calais G, Bardet E, Sire C, Alfonsi M, Bourhis J, Rhein B et al. Radiotherapy with concomitant weekly docetaxel for stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC phase II trial. International Journal of Radiation, Oncology, Biology and Physics 2004;58(1 Jan):161-6. Cassidy 2002 Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Annals of Oncology 2002;13(4):566-75.Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. 2002+ADs- 13(4):566-75. Cella 2003 Cella D, Pulliam J, Fuchs H, Miller C, Hurd D, Wingard JR et al. Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cancer 2003;98(2):406-12. Cheng 2001 Cheng KK Molassiotis A, Chang AM, Wai WC, Cheung SS. Evaluation of an oral care protocol intervention in the prevention of chemotherapy-induced oral mucositis in paediatric cancer patients. European Journal of Cancer 2001;37(16):2056-63.Cheng KK MA, Chang AM, Wai WC, Cheung SS. Evaluation of an oral care protocol intervention in the prevention of chemotherapy-induced oral mucositis in paediatric cancer patients. 2001+ADs-37(16):2056-63. Cheng 2002 Cheng KKF, Malassiotis A, Chang AM. An oral care protocol intervention to prevent chemotherapy-induced oral mucositis in paediatric cancer patients: a pilot study. European Journal of Oncology Nursing 2002;6(2):66-74.Cheng KKF MA, Chang AM. An oral care protocol intervention to prevent chemotherapy-induced oral mucositis in paediatric cancer patients: a pilot study... including commentary by Parr M. European Journal of Oncology Nursing: EUR J ONCOL NURS 2002+ADs- 6. 6(2. 2):66-74. Cheng 2003 Cheng KK, Chang AM. Palliation of oral mucositis symptoms in pediatric patients treated with cancer chemotherapy. Cancer Nursing 2003;26(6):476-84.Cheng KK, Chang AM. Palliation of oral mucositis symptoms in pediatric patients treated with cancer chemotherapy. Cancer Nursing 2003; 26(6):476-84. Cheng 2004a Cheng KK. Children's acceptance and tolerance of chlorhexidine and benzydamine oral rinses in the treatment of chemotherapy-induced oropharyngeal mucositis. European Journal of Oncology Nursing 2004;8(4):341-9.Cheng KK. Children's acceptance and tolerance of chlorhexidine and benzydamine oral rinses in the treatment of chemotherapy-induced oropharyngeal mucositis. European Journal of Oncology Nursing. 2004;8(4):341-9. Cheng 2004b Cheng KK, Chang AM, Yuen MP. Prevention of oral mucositis in paediatric patients treated with chemotherapy; a randomised crossover trial comparing two protocols of oral care. European Journal of Cancer 2004;40(8):1208-16.Cheng KK, Chang AM, Yuen MP. Prevention of oral mucositis in paediatric patients treated with chemotherapy; a randomised crossover trial comparing two protocols of oral care. Eur J Cancer 2004;40(8):1208-16. Chi 1994 Chi KH, Chen SY, Chan WK, Yen SH, Liang MJ, Chou KC, et al. Effect of granulocyte macrophage colony stimulating factor (GM-CSF) on oral mucositis in head and neck cancer patients after cisplatin, 5- FU and leucovorin chemotherapy [abstract]. Proceedings of the American Society of Clinical Oncology 1994;13:428, Abstract 1469. Chi 1995 Chi KH, Chen CH, Chan WK, Yen SH, Liang MJ, Chou KC et al. Effect of granulocyte-macrophage colony-stimulating factor (GH-CFS) on oral mucositis in head and neck cancer patients after cisplatin, 5-FU and leucovorin chemotherapy. In: Proceedings of Annual Meeting American Society of Clinical Oncology. Vol. 13. 1994:A1469. Chi KH, Chen SY, Chan WK, Yen SH, Liang MJ, Chou KC et al. Effect of granulocyte-macrophage colony-stimulating factor (GH-CFS) on oral mucositis in head and neck cancer patients after cisplatin, 5-FU and leucovorin chemotherapy. Journal of Clinical Oncology 1995;13(10):2620-8. Chiara 2000 Chiara S, Nobile MT, Vincenti M, Gozza A, Heouaine A, Marceca F, et al. Sucralfate in the treatment of chemotherapy-induced stomatitis: a double-blind, placebo-controlled pilot study [abstract]. Proceedings of the American Society of Clinical Oncology 2000;19:630a, Abstract 2485. Clarke 2001 Clarke SJ, Abdi E, Davis ID, Schnell FM, Zalcberg JR, Gutheil J, et al. Recombinant human keratinocyte growth factor (rHuKGF) prevents chemotherapy-induced mucositis in patients with advanced colorectal cancer: a randomized phase II trial [abstract]. Proceedings of the American Society of Clinical Oncology 2001;20 (Pt 1):383a, Abstract 1529. Collova 2004 Collova E, Castagna L, Nozza A, Perfetti V, Patrone F, Danova M et al. New approaches for reduction of oral mucositis in patients undergoing high-dose chemotherapy with hematopoietic stem cell support. Bone Marrow Transplantation 2004;33(Suppl 1):S323-S4.Collova E, Castagna L, Nozza A, Perfetti V, Patrone F, Danova M, et al. New approaches for reduction of oral mucositis in patients undergoing high-dose chemotherapy with hematopoietic stem cell support [abstract]. Bone Marrow Transplantation. 2004;33(Suppl 1):S323-S4. Colombat 1995 Colombat P, Colin B. Comparison of fluconazole and amphotericin B in the prevention of mucositis in patients with long term aplasia. Bone Marrow Transplantation 1995;15:178.Colombat P, Colin B, et al. Comparison of fluconazole and amphotericin B in the prevention of mucositis in patients with long term aplasia [abstract]. Bone-Marrow-Transplant. 1995;15:178. Costa 1999 Costa EMMB, Pinto LP, Fernandes MZ, Costa ALL. Preventing oral complications in leukemic children submitted to chemotherapy. Journal of Dental Research 1999;78:1021 (Abs No B-220). Costa 2003 Costa EM, Fernandes MZ, Quinder LB, de Souza LB, Pinto LP. Evaluation of an oral preventive protocol in children with acute lymphoblastic leukemia. Pesquisa Odontologica Brasileira 2003;17(2):147-50.Costa EM, Fernandes MZ, Quinder LB, de Souza LB, Pinto LP. Evaluation of an oral preventive protocol in children with acute lymphoblastic leukemia. Pesqui Odontol Bras. 2003 Apr-Jun;17(2):147-50. Cowen 1997 Cowen D, Tardieu C, Resbeut M, Hannoun-Levi JM, Alzieu C, Schubert M et al. Low energy helium-neon laser presents oral mucositis after high-dose chemo-radiotherapy: results of a double-blind randomized trial. International Journal of Radiation Oncology, Biology and Physics 1996;36(1S):264 (A1041). Cowen D, Tardieu C, Schubert M, Peterson D, Resbeut M, Faucher C et al. Low energy Helium-neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: Results of a double blind randomized trial. International Journal of Radiation Oncology, Biology and Physics 1997;38(4):697-703. Crawford 1994 Crawford J, Glaspy J, Vincent M, Tomita D, Mazanet R. Effect of filgrastim (r-metHug-CSF) on oral mucositis in patients with small cell lung cancer (SCLC) receiving chemotherapy (cyclophosphamide, doxorubicin and etoposide, CAE). In: Proceedings of Annual Meeting of American Society Clinical Oncology. Vol. 13. 1994:(Abs No A1523).Crawford J, Glaspy J, Vincent M, Tomita D, Mazanet R. Effect of filgrastim (r-metHug-CSF) on oral mucositis in patients with small cell lung cancer (SCLC) receiving chemotherapy (cyclophosphamide, doxorubicin and etoposide, CAE). Proc-Annu-Meet-Am-Soc-Clin-Oncol. 1994;13:Abs. A1523. Crispino 1997 Crispino SP, Olmi C, Fallai F, Rossi S, Marsoni A, Tinazzi M, et al. Conventional radiotherapy (RT) versus accelerated hyperfractionated RT versus conventional RT and concomitant chemotherapy in locally advanced oropharyngeal carcinoma (ORO-93/01). In: Proceedings of the American Society of Clinical Oncology. 1997.Crispino SP, Olmi C, Fallai F, Rossi S, Marsoni A, Tinazzi M, et al. Conventional radiotherapy (RT) versus accelerated hyperfractionated RT versus conventional RT and concomitant chemotherapy in locally advanced oropharyngeal carcinoma (ORO-93/01). Proc Am Soc Clin Oncol. 1997. Cruz 1997 Cruz J, Fonseca E, Rodriguez CA, Gomez-Bernal A, Martin G, Sanchez P et al. Randomized trial of cisplatin (P) plus 5-fluorouracil (F) with or without folinic acid in locally advanced head and neck cancer (LAHNC). In: Proceedings of the European Cancer Conference. 1997:(Abs No 854).Cruz J, Fonseca E, Rodriguez CA, Gomez-Bernal A, Martin G, Sanchez P, et al. Randomized trial of cisplatin (P) plus 5-fluorouracil (F) with or without folinic acid in locally advanced head and neck cancer (LAHNC). Proc-Eur-Cancer-Conf (ECCO). 1997:Abstract #854. Cunningham 1995 Cunningham D, Zalcberg JR, Rath U, Olver I, van Cutsem EV, Sevensson C et al. 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. European Journal of Cancer 1995;31A(12):1945-54. De Boer 2002 De Boer RH, Eisen TG, Ellis PA, Johnston SR, Walsh G, Ashley S et al. A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer. Annals of Oncology 2002;13(6):889-94. Decker-Baummann 1999 Decker-Baumann C, Buhl K, Frohmuller S, von Herbay A, Dueck M, Schlag PM. Reduction of chemotherapy-induced side-effects by parenteral glutamine supplementation in patients with metastatic colorectal cancer. European Journal of Cancer 1999;35(2):202-7. Denham 1999 Denham JW, Peters LJ, Johansen J, Poulsen M, Lamb DS, Hindley A et al. Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer? Radiotherapy Oncology 1999;52(2):157-64. Djuric 2006 Djuric M, Hillier-Kolarov V, Belic A, Jankovic L. Mucositis prevention by improved dental care in acute leukemia patients. Supportive Care in Cancer 2006;14(2):137-46.Djuric M, Hillier-Kolarov V, Belic A, Jankovic L. Mucositis prevention by improved dental care in acute leukemia patients. Supportive Care in Cancer. 2006;14(2):137-46. Dobrowsky 1998 Dobrowsky W, Naude J, Widder J, Dobrowsky E, Millesi W, Pavelka R et al. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer. International Journal of Radiation Oncology, Biology and Physics 1998;42(4):803-6.Dobrowsky W NJ, Widder J, Dobrowsky E, Millesi W, Pavelka R, Grasl C, Reichel M. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer. International Journal of Radiation Oncology, Biology, Physics 1998;42(4):803-6. Doroshow 1987 Doroshow JH, Berthtand M, Newman E, Multhauf P, Leong L, Blayney D et al. Preliminary analysis of a randomized comparison of 5-fluorouracil versus 5-fluorouracil and high-dose continuous-infusion folinic acid in disseminated colorectal cancer. NCI Monographs 1987;5:171-4.Doroshow JH BM, Newman E, Multhauf P, Leong L, Blayney D, Goldberg D, Margolin K, Carr B, Akman S, et al. Preliminary analysis of a randomized comparison of 5-fluorouracil versus 5-fluorouracil and high-dose continuous-infusion folinic acid in disseminated colorectal cancer. NCI Monographs 1987(5):171-4. Dose 1989 Dose AM, Loprinzi CL, Cianflone S, Etzell P, Burnham N, Therneau T, et al. A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis. A North Central Cancer Treatment Group and Mayo clinic study [abstract]. Proceedings of the American Society of Clinical Oncology 1989;8:341, Abstract 1328. Dose 1990 Dose AM, Mahood D, Loprinzi CL, Gainey D, Sorensen JM, Therneau T, et al. A controlled trial of oral cryotherapy for preventing stomatitis in patients receiving 5- fluorouracil (5FU) plus leucovorin (LV). A North Central Cancer Treatment Group and Mayo Clinic study [abstract]. Proceedings of the American Society of Clinical Oncology 1990;9:321, Abstract 1242. Dreicer 1997 Dreicer R, Propert KJ, Kuzel T, Kirkwood JM, O'Dwyer PJ, Loehrer PJ. A phase II trial of edatrexate in patients with advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study. American Journal of Clinical Oncology 1997;20(3):251-3. Dudjak 1987 Dudjak LA. Mouth care for mucositis due to radiation therapy. Cancer Nursing 1987;10(3):131-40. Edelman 1998 Edelman MJ, Gandara Dr, Perez EA, Lau D, Lauder I, Turrell C et al. Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy. Investigational New Drugs 1998;16(1):69-75. Eisen 2003 Eisen D, Essel J, Broun ER, Sigmund D, DeVoe M,. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. Bone Marrow Transplantation 2003;31(1):51-5. El-Sayed 2000 El-Sayed S, Nabid A, MacKenzie R, Gelinas M, Hay J, Shelley et al. Prophylaxis of radiation associated mucositis (RAM) in head and neck cancer, results of a double blind phase III trail evaluating the clinical efficacy of an antimicrobial lozenge utilizing a new validated mucositis scoring system. In: Proceedings of the 42nd Annual Meeting of the American Society of Therapeutic Oncology. Vol. 321. 2000:(Abs No 2115).El-Sayed S, Nabid, A, MacKenzie, R, Gelinas, M, Hay, J, Shelley, W, Berthelet, E, Lau, H, Duncan, G, and Epstein, J. Prophylaxis of radiation associated mucositis (RAM) in head and neck cancer, results of a double blind phase III trail evaluating the clinical efficacy of an antimicrobial lozenge utilizing a new validated mucositis scoring system. El-Sayed 2002b El-Sayed S, Epstein J, Minish E, Burns P, Hay J, Laukkanen E. A pilot study evaluating the safety and microbiologic efficacy of an economically viable antimicrobial lozenge in patients with head and neck cancer receiving radiation therapy. Head &amp;amp; Neck 2002;24(1):6-15.El-Sayed S, Epstein J, Minish E, Burns P, Hay J, Laukkanen E.A pilot study evaluating the safety and microbiologic efficacy of an economically viable antimicrobial lozenge in patients with head and neck cancer receiving radiation therapy. Head Neck. 2002 Jan;24(1):6-15. Epstein 1986 Epstein JB, Stephenson-Moore P. Benzydamine hydrochloride in prevention and management of pain in oral mucositis associated with radiation therapy. Oral Surgery, Oral Medicine, Oral Pathology 1986;62(2):145-8. Epstein 1989 Epstein JB, Stevenson-Moore P, Jackson S, Mohamed JH, Spinelli JJ. Prevention of oral mucositis in radiation therapy: A controlled study with benzydamine hydrochloride rinse. International Journal of Radiation Oncology, Biology and Physics 1989;16(6):1571-5. Epstein 1992 Epstein JB, Vickars L, Spinalli J, Reece D. Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. Oral Surgery, Oral Medicine, Oral Pathology 1992;73(6):682-9. Epstein 1994 Epstein JB, Wong FLW. The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy. International Journal of Radiation Oncology, Biology and Physics 1994;28(3):693-8. Epstein 1999 Epstein J, Silverman S Jr, Pagerino D, Lockhart P, Schubert M, Crockett R. Benzydamine HCL for prophylaxis of irradiation induced oral mucositis: a randomized double-blind, multicenter study. Supportive Care in Cancer 1999;7 Suppl:169 (Abs No O-18).Epstein J, Silverman S, Jr Pagerino D, Lockhart P, Schubert M, Crockett R. Benzydamine HCL fro prophilaxis of irradiation oral mucositis: a randomized double-blind, multicenter study. Supportive Care in Cancer. 1999;7 Suppl.(Abstr O-18):169. Epstein 2001 Epstein JB, Silverman S, Paggiarino DA, Crockett S, Schubert MM, Senzer NN et al. Benzydamine HCI for prophylaxis of radiation-induced oral mucositis. Cancer 2001;92(4):875-85. Erkisi 1996 Erkisi M, Erkurt E, Ozbarlas S, Burgut R, Doran F, Seyrek E. The use of recombinant human granulocyte colony-stimulating factor in combination with single or fractionated doses of ifosfamide and doxorubicin in patients with advanced soft tissue sarcoma. Journal of Chemotherapy 1996;8(3):224-8. Etiz 1998 Etiz M, Erkal HS, Serin M, Kucuk B, Hepari A, Tulunay O et al. Clinicohistopathological evaluation of effectiveness of sucralfate in prevention of severe radiation-induced mucositis in patients with head and neck malignancies. Radiotherapy Oncology 1998;48(S1):S68. Etiz 2000 Etiz D, Erkal HS, Serin M, Kucuk B, Hepari A, Elhan AH et al. Clinical and histopathological evaluation of sucralfate in prevention of oral mucositis induced by radiation therapy in patients with head and neck malignancies. Oral Oncology 2000;36(1):116-20. Evans 1990 Evans G, Mahendra P, Brightwell M, Jestivfe K, Marcus R. A double blind randomised trial of oral GMCFS mouthwash versus placebo in the treatment of mucositis following PBSC/bone marrow transplantation. Bone Marrow Transplantation 1998;21(S1):S88. Evans WK, Wierzbicki R, Shepherd FA, Rusthoven J, Stewart DJ, Aitken SE et al. 5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung. Cancer Investigation 1990;8(3-4):345-9. Ezzat 2005 Ezzat M, Shouman T, Zaza K, Safwat A, El-Khoudary A, El-Senosi M et al. A randomized study of accelerated fractionation radiotherapy with and without mitomycin C in the treatment of locally advanced head and neck cancer. Journal of the Egyptian National Cancer Institute 2005;17(2):85-92.Ezzat M, Shouman T, Zaza K, Safwat A, El-Khoudary A, El-Senosi M, et al. A randomized study of accelerated fractionation radiotherapy with and without mitomycin C in the treatment of locally advanced head and neck cancer. Journal of Egyptian National Cancer Institute. 2005;17(2):85-92. Fahlke 1999 Fahlke J, Ridwelski K, Lippert H. High-dose therapy with combined 5-fluorouracil and folinic acid with and without amifostine in the treatment of patients with metastatic colorectal carcinoma. International Journal of Colorectal Disease 1999;14(2):128-30. Falcone 2001 Falcone A, Allergrini G, Masi G, Lencioni M, Panner E, Brunetti I. 5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer. Oncology 2001;61(1):28-35. Fay 1994 Fay JW, Lazarus H, Herzig R, Saez R, Stevens DA, Collins RH Jr et al. Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study. Blood 1994;84(7):2151-7.Fay JW LH, Herzig R, Saez R, Stevens DA, Collins RH Jr, Pineiro LA, Cooper BW, DiCesare J, Campion M, et al. Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study. Blood 1994;84(7):2151-7. Feber 1995 Feber T. Mouth care for patients receiving oral irradiation. Professional Nurse 1995;10(10):666-70. Feber 1996 Feber T. Management of mucositis in oral irradiation. Clinical Oncology 1996;8(2):106-11. Ferreira 2002 Ferreira PR, Fleck J, Filho AB, Barletta D, Barletta A, Diehl A et al. Protective effect of vitamin E (VE) in head and neck cancer radiation induced mucositis: a double-blind randomized trial. In: Proceedings of American Society of Clinical Oncology Meeting. 2002:(Abs No 909).Ferreira P FJ, Filho A, Barletta D, Barletta A, Diehl A, de Azambuja E. Protective effect of vitamin E (VE ) in head and neck cancer radiation induced mucositis: a double-blind randomized trial. Proceedings of ASCO 2002. Ferreira 2002a Ferreira RR, Fleck JF, Filho AB, Barletta D, Barletta A, Diehl A, et al. Positive effect of vitamin E (VE) in head and neck cancer radiation induced mucositis: a double-blind randomized trial [abstract]. Proceedings of the American Society of Clinical Oncology 2002;21 (Pt 1):228a, Abstract 909. Ferreira 2004 Ferreira PR, Fleck JF, Diehl A, Barletta D, Braga-Filho A, Barletta A et al. Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial. Head &amp;amp; Neck 2004;26(4):313-21.Ferreira PR, Fleck JF, Diehl A, Barletta D, Braga-Filho A, Barletta A, et al. Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial. Head Neck 2004;26(4):313-21. Ferretti 1985 Ferretti G, Largent B, Brown A, Lillich T, Ash R. The effect of chlorhexidine mouthrinse on mucositis, plaque, gingivitis and stain in bone marrow transplant patients. Journal of Dental Research 1985;64(Special Issue):235 (Abs No 546). Fidler 1995 Fidler P, Loprinzi CL, O'Fallon JR, Michalak J, Novotny P, Hayes D, et al. A controlled evaluation of chamomile for preventing stomatitis in patients receiving 5-fluorouracil based chemotherapy: A North Central Cancer Treatment Group trial [abstract]. Proceedings of the American Society of Clinical Oncology 1995;14:534, Abstract 1765. Foncuberta 2001 Foncuberta MC, Cagnoni PJ, Brandts CH, Mandanas R, Fields K, Derigs HG et al. Topical transforming growth factor-beta3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors. Journal of Immunotherapy 2001;24(4):384-8.Foncuberta M, PJ C, CH B, R M, K F, HG D, et al. Topical transforming growth factor-beta3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors. Journal of Immunotherapy 2001;24(4):384-388. Gabison 1995 Gabison R. Can zinc picolinate in patients receiving chemotherapy for metastatic colorectal carcinoma prevent stomatitis? European Journal of Cancer 1995;31A(Suppl 5):S258 (Abs No 1234). Gandara 1997 Gandara DR, Edelman MJ, Crowley JJ, Lau DH, Livingston RB. Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study.. Cancer Chemotherapy and Pharmacology 1997;41:75-78. Genot-Klastersky 2008 Genot-Klastersky MT, Klastersky J, Awada F, Awada A, Crombez P, Martinez MD, et al. The use of low-energy laser (LEL) for the prevention of chemotherapy- and/or radiotherapy-induced oral mucositis in cancer patients: results from two prospective studies. Support Care Cancer 2008. Giles 2003b Giles FJ, Faderl S, Thomas DA, Cortes JE, Garcia-Manero G, Douer D et al. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. Journal of Clinical Oncology 2003;21(6):1050-6.Giles FJ FS, Thomas DA, Cortes JE, Garcia-Manero G, Douer D, Levine AM, Koller CA, Jeha SS, O'Brien SM, Estey EH, Kantarjian HM. Randomized Phase I/II Study of Troxacitabine Combined With Cytarabine, Idarubicin, or Topotecan in Patients With Refractory Myeloid Leukemias. Journal of Clinical Oncology 2003+ADs-21(6):1050-1056. Gladkov 2007 Gladkov OA, Vazhenin AV, Sharabura TM, Kandakova E, Galiatova Iu V, Sychev VI, et al. [Effectiveness of different regimes of combined treatment (cisplatin+ radiotherapy) for intraoral and oropharyngeal cancer]. [Russian]. Voprosy Onkologii 2007;53(5):575-7. Goldberg 2003 Goldberg S. Safety and tolerability of en3247 in the prevention of oral mucositis associated with chemotherapy with or without total body irradiation: results of a randomized, double-blind, placebo-controlled trial. In: Proceedings of the American Society of Clinical Oncology. 2003:770.Goldberg S. Safety and tolerability of en3247 in the prevention of oral mucositis associated with chemotherapy with or without total body irradiation: results of a randomized, double-blind, placebo-controlled trial [abstract]. Proceedings of the American Society of Clinical Oncology. 2003:770. Gordon 1993 Gordon B, Spadinger A, Hodges E, Coccia P. Effect of granulocyte macrophage colony stimulating factor (GMCSF) on oral mucositis after autologous bone marrow transplantation [abstract]. Proceedings of the American Society of Clinical Oncology 1993;12:432, Abstract 1489. Grotz 2001 Grotz KA, Henneicke-Von Zepelin H-H, Kohnen R, Kutzner J. Belz GG. Prophylaxis of mucositis and dry mouth after head and neck radiotherapy. A new treatment. Krankenhauspharmazie 2002;23(5):193-8. Grotz KA, Wustenberg P, Kohnen R, Al-Nawas B, Henneicke-von Zepelin H, Bockisch A et al. Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutine in patients with head and neck cancer- a prospective, randomized, placebo-controlled, double-blind study. British Journal of Oral and Maxillofacial Surgery 2001;39(1):34-9. Gujral 1999 Gujral MS, Patnaik PM, Kaul R, Daftary GV, Parikh HK, Tamhankar CP et al. Oral enzymes preventing side effects of radiation therapy in patients with head and neck cancers. European Journal of Cancer 1999;35(Suppl 4):168 (Abs No 634).Gujral MS PPKRDGPHTCSW. Oral enzymes preventing side effects of radiation therapy in patients with head and neck cancers. European Journal of Cancer 1999+ADs-35(Suppl. 4):Page 168 Abstract +ACM-634. Gutierrez 1996 Gutierrez AR, Boizas EC, Carreras PS, Rodriguez CS, Rodriguez OA, Chicote MJV et al. Fluconazol as prophylaxis of radioinduced oral mucositis. Preliminary study [Fluconazol en la profilaxis de la mucositis oral radioinducida. Estudio preliminar]. Oncologia 1996;19(6):56-9.Gutierrez AR BE, Carreras PS, Rodriguez CS, Rodriguez OA, Chicote MJV, Palacios AN, Solbes RS, Ripoll JJS. Fluconazol as prophylaxis of radioinduced oral mucositis. Preliminary study. Oncologia 1996;19(6):56-59. Hanson 1995 Hanson WR, Marks JE, Reddy SP, Simon S, Mihalo WE, Tova Y. Protection from radiation-induced oral mucositis by a mouth rinse containing the prostaglandin E1 analog, misoprostol: A placebo controlled double blind clinical trial. Advances in Experimental Medicine and Biology 1997;400B:811-8. Hanson WR, Marks JE, Reddy SP, Simon S, Mihalo WE, Tova Y. Protection from radiation-induced oral mucositis by misoprostol, a prostaglandin E(1) analog: a placebo-controlled, double-blind clinical trial. American Journal of Therapeutics 1995;2(11):850-7. Harris 1995 Harris JR, Russell NH, Hunter AE. Folinic acid mouthwashes do not reduce the degree of mucositis in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplantation 1995;15(S2):S164. Hartmann 1999 Hartmann J, von Vangerow A, Knop S, Brugger W, Fels L, Stolte H et al. A randomized trial comparing the toxicity and the treatment costs of HD-VIC plus PBSC transplantation with or without amifostine (AMI) in patients with solid tumors. European Journal of Cancer 1999;35(Suppl 4):361 (Abs No 1464).Hartmann J, von Vangerow A, Knop S, Brugger W, Fels L, Stolte H, et al. A randomized trial comparing the toxicity and the treatment costs of HD-VIC plus PBSC transplantation with or without amifostine (AMI) in patients with solid tumors. European Journal of Cancer. 1999;35(Suppl 4):361, Abstr #1464. He 2004 He XY, Hu CS, Wu YR. Radioprotective effect of amifostine in nasopharyngeal carcinoma. Acta Academiae Medicinae Shanghai 2004;31(1).He XY, Hu CS, Wu YR. Radioprotective effect of amifostine in nasopharyngeal carcinoma. Acta Academiae Medicinae Shanghai. 2004;31(1). Hickey 1982 Hickey AJ, Toth BB, Lindquist SB. Effect of intravenous hyperalimentation and oral care on the development of oral stomatitis during cancer chemotherapy. The Journal of Prosthetic Dentistry 1982;47(2):188-93. Horsley 2007 Horsley P, Bauer JD, Mazkowiack R, Gardner R, Bashford J. Palifermin improves severe mucositis, swallowing problems, nutrition impact symptoms, and length of stay in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer 2007;15(1):105-9. Howell 1983 Howell SB, Pfeifle CE, Wung WE. Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection. Cancer 1983;51(2):220-5.Howell SB PC, Wung WE. Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection. Cancer 1983;51(2):220-5. Hu 2003 Hu K, Ship JA, Harrison LB. Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/IV head and neck cancer. Seminars in Oncology 2003;30(6 Suppl 18):40-8.Hu K, Ship JA, Harrison LB. Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/IV head and neck cancer. [Review] [36 refs]. Seminars in Oncology 2003; 30(6 Suppl 18):40-8. Inagaki 2006 Inagaki N. [Report on the treatment of infections complicating hematological diseases. Case 2. Two cases of deep-seated mycosis developing during chemotherapy of leukemia]. [Japanese]. Japanese Journal of Antibiotics 2007;60(5):317-8. Ito 2002 Ito A, Hanawa T, Fujii E. The preventive effect of allopurinol spray on stomatitis induced by anti-cancer drugs. Gan To Kagaku Ryoho 2002;29(4):563-7. Jebb 1995 Jebb SA, Marcus R, Elia M. A pilot study of oral glutamine supplementation in patients receiving bone marrow transplants. Clinical Nutrition 1995;14:162-5. Johnson 2002 Johnson DJ, Scott CB, Marks JE, Seay TE, Atkins JN, Berk LB et al. Assessment of quality of life and oral function of patients participating in a phase II study of radioprotection of oral and pharyngeal mucosa by the prostaglandin E(1) analog misoprostol (RTOG 96-07). International Journal or Radiation Oncology Biology and Physics 2002;54(5):1455-9.Johnson DJ, Scott CB, Marks JE, Seay TE, Atkins JN, Berk LB, Meoz RT, Wheeler JA.Assessment of quality of life and oral function of patients participating in a phase II study of radioprotection of oral and pharyngeal mucosa by the prostaglandin E(1) analog misoprostol (RTOG 96-07). Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1455-9. Kante 1995 Kante V. Comparative study of two prophylactic regimes for the prevention of mucositis in autologous bone marrow transplants. Bone Marrow Transplantation 1995;15:253.Kante V, et al. Comparative study of two prophylactic regimes for the prevention of mucositis in autologous bone marrow transplants [abstract]. Bone-Marrow-Transplant. 1995;15:253. Karthaus 1998 Karthaus M, Rosenthal C, Huebner G, Paul H, Elser C, Hertenstein B et al. Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial. Bone Marrow Transplantation 1998;22(8):781-5.Karthaus M, Rosenthal C, Huebner G, Paul H, Elser C, Hertenstein B et al. Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial. Bone Marrow Transplant 1998;22:781-5. Kasten-Sportes 2003 Kasten-Sportes C. Randomized study of acupuncture for mucositis-related pain secondary to high-dose chemotherapy in patients undergoing hematopoietic stem cell transplantation. PDQ (NCI-03-C-0125) 2003.Kasten-Sportes C. Randomized Study of Acupuncture for Mucositis-Related Pain Secondary to High-Dose Chemotherapy in Patients Undergoing Hematopoietic Stem Cell Transplantation. PDQ, NCI-03-C-0125. 2003 2003. Kenny 1990 Kenny SA. Effect of two oral care protocols on the incidence of stomatitis in hematology patients. Cancer Nursing 1990;13(6):345-53. Klocke 2006 Klocke J, Cannon M, Gissinger D, Bayer R, Devoe C, John V. Prevention of mucositis in auto BMT/stem cell transplant patients. Oncology Nursing Forum 2006;33(2):454.Klocke J, Cannon M, Gissinger D, Bayer R, Devoe C, John V. Prevention of mucositis in auto BMT/stem cell transplant patients. Oncology Nursing Forum. 2006;33(2):454. Kokkonen 2002 Kokkonen J, Mottonen M, Karttunen TJ, Lanning M. Mucosal pathology of the upper gastrointestinal tract associated with intensive chemotherapy in children: Vitamin a supplements do not prevent lesions. Pediatric Hematology and Oncology 2002;19(3):181-92.Kokkonen JMMKTLM. Mucosal pathology of the upper gastrointestinal tract associated with intensive chemotherapy in children: Vitamin a supplements do not prevent lesions. Pediatric Hematology +ACY- Oncology 2002+ADs- Vol 19(3): 181-192. Kuhn 2009 Kuhn A, Porto FA, Miraglia P, Brunetto AL. Low-level infrared laser therapy in chemotherapy-induced oral mucositis: a randomized placebo-controlled trial in children. Journal of Pediatric Hematology/Oncology 2009;31(1):33-7. Kuriakose 2002 Kuriakose P, Gandara DR, Perez EA. Phase I trial of edatrexate in advanced breast and other cancers.[comment]. Cancer Investigation 2002;20(4):473-9. Labar 1990 Labar B, Pavletic Z, Bogdanic V, Nemet D, Aurer I, Jakie J. Prostaglandin E2 for prevention of oral mucositis in patients with leukaemia undergoing bone marrow transplantation: a radomized double-blind clinical trial. Experimental Hematology 1990;18:700. Labbate 2003 Labbate R, Lehn CN, Denardin OVP. Effects of chlorhexidine mouthwash on radiation induced mucosistis in head and neck cancer. Revista Brasileira de Otorrinolaringologia 2003;69(3):349-54.Labbate R, Lehn CN, Denardin OVP. Effects of chlorhexidine mouthwash on radiation induced mucosistis in head and neck cancer. Revista Brasileira de Otorrinolaringologia. 2003;69(3):349-54. Leong 1995 Leong L, Sakurai C, Sebastian W, Shaw N, Grant E, Grant M et al. Phase III trial assessing the use of oral thymidine (THY) for prevention of fluorouracil (5-FU)-induced mucositis. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology. Vol. 14. 1995:A334. Levendag 1998 Lavendag PC, Wijers OB, Harms RE, Schmitz PIM, Wilms BE, Visch LL. Mucositis prevention by selective elimination of oral flora in irradiated cancers of the head and neck: a prospective randomized study. Radiotherapy Oncology 1998;48:S10. Levi 1997 Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997;350(9079):681-6.Levi F ZR, Misset J-L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997+ADs-350(9079):681-686. Lievens 1998 Lievens Y, Haustermans K, van den Weyngaert D, van den Bogaert W, Scalliet P, Hutsebaut L et al. Does sucralfate reduce the acute side-effects in head and neck cancer treated with radiotherapy? A double-blind randomized trial. Radiotherapy Oncology 1998;47(2):149-53. Lin 2006 Lin J, Wang X, Fan Z. A study on quantizing evaluation on stomatitis of malignant tumor patients undergoing large dose of chemotherapy [Chinese]. Chinese Nursing Research 2008;22(2A):328-9. Lin LC, Que J, Lin LK, Lin FC. Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study. International Journal of Radiation Oncology, Biology, Physics 2006;65(3):745-50.Lin LC, Que J, Lin LK, Lin FC. Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study. International Journal of Radiation Oncology, Biology, Physics. 2006;65(3):745-50. Lopez 1994 Lopez I, Goudou C, Ribrag V, Sauvage C, Hazebroucq G, Dreyfus F. Traitement des mucites par la vitamine E lors de l'administration d'anti-neoplasiques neutropeniants. Annuals Medicine Interne 1994;145(6):405-8. Loprinzi 1997 Loprinzi CL, Ghosh C, Camoriano J, Sloan J, Steen PD, Michalak JC et al. Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy. Journal of Clinical Oncology 1997;15(3):1235-8. Lorusso 2003 Lorusso D, Ferrandina G, Greggi S, Gadducci A, Pignata S, Tateo S. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Annals of Oncology 2003;14(7):1086-93.Lorusso D FG, Greggi S, Gadducci A, Pignata S, Tateo S, Biamonte R, Manzione L, Di Vagno G, Ferrau' F, Scambia G, Multicenter Italian Trials in Ovarian Cancer invesitgators. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Annals of Oncology 2003;14(7):1086-93. Lozada 1998 Lozada-Nur F, Schoelch M, Fu K, Muscoplat C, Trivedi M, Smith C et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. In: Proceedings of the Annual Meeting of the Society of Clinical Oncology. 1998:1541. Maddocks-Jennings 2009 Maddocks-Jennings W, Wilkinson JM, Cavanagh HM, Shillington D. Evaluating the effects of the essential oils Leptospermum scoparium (manuka) and Kunzea ericoides (kanuka) on radiotherapy induced mucositis: a randomized, placebo controlled feasibility study. European Journal of Oncology Nursing 2009;13(2):87-93. Madero 1999 Madero L, Diaz MA, Ortega JJ, Olive T, Martinez A, Badell I et al. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates engraftment kinetics after allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia. Haematologica 1999;84(2):133-7.Madero L DM, Ortega JJ, Olive T, Martinez A, Badell I, Munoz A, Gomez P. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates engraftment kinetics after allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia. Haematologica 1999;84(2):133-7. Mahmoud 1996 Mahmoud HK SE, Kamel M, El HMA, Nassar A. Influence of folinic acid rescue on methotrexate-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation. Tumor Diagnostik Und Therapie 1996;17(1):18-21.Mahmoud HK SE, Kamel M, El HMA, Nassar A. Influence of folinic acid rescue on methotrexate-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation. Tumor Diagnostik Und Therapie. 1996+ADs-17(1):18-21. Malaker 1991 Malaker K, Anderson BJ, Beecroft WA, Hodson DI. Management of oral mucosal dysplasia with beta-carotene retinoic acid: a pilot cross-over study. Cancer Detection and Prevention 1991;15(5):335-40.Malaker K, Anderson BJ, Beecroft WA, Hodson DI. Management of oral mucosal dysplasia with beta-carotene retinoic acid: a pilot cross-over study. Cancer Detection +ACY- Prevention 1991+ADs-15(5):335-40. Mantovani 2003 Mantovani G, Massa E, Astara G, Murgia V, Gramignano G, Lusso MR et al. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs. Oncology Reports 2003;10(1):197-206.Mantovani G, Massa E, Astara G, Murgia V, Gramignano G, Lusso MR, et al. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs. Oncology Reports 2003+ADs- 10(1):197-206. Marcial 1994 Marcial F, Schubert M, Niccoli-Filho WD, Lloid ME, Kelly J, Franquin JC et al. A phase I/II nonblinded randomized trial to determine the efficacy of low-energy laser to prevent oral mucositis resulting from conditioning regimens for bone marrow transplantation. Oral Surgery, Oral Medicine, Oral Pathology 1994;78(6):738. Martin 2006 Martin M, Lluch A, Segui MA, Ruiz A, Ramos M, Adrover E, et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.[see comment]. Annals of Oncology 2006;17(8):1205-12. Masucci 2005 Masucci G, Broman P, Kelly C, Lindahl S, Malmberg L, Reizenstein J et al. Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy: a multicenter open randomized phase III study. Medical Oncology 2005;22(3):247-56.Masucci G, Broman P, Kelly C, Lindahl S, Malmberg L, Reizenstein J, et al. Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy: a multicenter open randomized phase III study. Medical Oncology. 2005;22(3):247-56. Matejka 1990 Matejka M, Nell A, Kment G, Schein A, Leukauf M, Porteder H et al. Local benefit of prostaglandin E2 in radiochemotherapy-induced oral mucositis. British Journal of Oral Maxillofacial Surgery 1990;28(2):89-91.Matejka M, Nell A, Kment G, Schein A, Leukauf M, Porteder H, Mailath G, Sinzinger H.Local benefit of prostaglandin E2 in radiochemotherapy-induced oral mucositis. Br J Oral Maxillofac Surg. 1990 Apr;28(2):89-91. McGaw 1985 McGaw WT, Belch A. Oral complications of acute leukemia: prophylactic impact of a chlorhexidine mouthrinse regimen. Oral Surgery, Oral Medicine, Oral Pathology 1985;60(3):275-80.McGaw WT, Belch A. Oral complications of acute leukemia: prophylactic impact of a chlorhexidine mouthrinse regimen. Oral Surg Oral Med Oral Pathol 1985;60:275-80. McIlroy 1996 McIlroy P. Radiation mucositis: a new approach to prevention and treatment. European Journal of Cancer Care 1996;5(3):153-8. Merte 1999 Merte H, Wied R, Engenhart-Cabillic R. Der effekt von immunglobulinen in der behandlung der radiogenen dermatitis und mukositis bei patienten mit hals-nasen und rachentumoren. Strahlentherapy und Onkologie 1999;175(1):135. Mills 1995 Mills W, Strang J, Goldstone AH, Linch DC. Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma. Leukemia &amp;amp; Lymphoma 1995;17(3-4):263-70. Minn 1999 Minn HR, Makkonen TA, Jekunen A, Vilja P, Tuominen J, Joensuu H. Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study. International Journal of Radiation Oncology Biology Physics 1999;45(3 Suppl):239.Minn HR, Makkonen TA, Jekunen A, Vilja P, Tuominen J, Joensuu H. Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study [abstract]. International Journal of Radiation Oncology Biology Physics. 1999;45(3 Suppl):239. Mohanta 1992 Mohanta PK, Singhal RM, Jindel R, Sharma RL, Julka PK. Hydroxyurea as a radiation sensitizer in malignancies of the head anc neck. Indian Journal of Radiology and Imaging 1992;2(2):143-6. Mok 2007 Mok TSK, Yeo W, Johnson PJ, Hui P, Ho WM, Lam KC, et al. A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. Annals of Oncology 2007;18(4):768-74. Mori 2006 Mori T, Yamazaki R, Aisa Y, Nakazato T, Kudo M, Yashima T, et al. Brief oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. Supportive Care in Cancer 2006;14(4):392-5. Nicholl 1995 Nicholl TA, Nimmo CR, Shepherd JD, Phillips P, Jewweson PJ. Amphotericin B infusion-related toxicity: comparison of two- and four-hour infusions. Annals of Pharmacotherapy 1995;29(11):1081-7. Niibe 1985b Niibe H, Takahashi I, Mitsuhashi N, Miyaishi K, Itoh J, Maehara Y et al. An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study.2 Abdominal and pelvic tumours. Nippon Gan Chiryo Gakkai Shi 1985;20(5):994-1001. Nikoletti 2005 Nikoletti S, Hyde S, Shaw T, Myers H, Kristjanson LJ. Comparison of plain ice and flavoured ice for preventing oral mucositis associated with the use of 5 fluorouracil. Journal of Clinical Nursing 2005;14(6):750-3. Ohnmacht 2001 Ohnmacht GA, Phan GQ, Mavroukakis SA, Steinberg SM, Shea YR, Witebsky FG et al. A prospective, randomized, double-blind, placebo-controlled trial evaluating the effect of nystatin on the development of oral irritation in patients receiving high-dose intravenous interleukin-2. Journal of Immunotherapy 2001;24(2):188-92.Ohnmacht GA PG, Mavroukakis SA, Steinberg SM, Shea YR, Witebsky FG, McIntyre LS, Goodwin RS, Muehlbauer PM, Morton KE, Rogers-Freezer LJ, Seipp CA, Rosenberg SA, Marincola FM. A prospective, randomized, double-blind, placebo-controlled trial evaluating the effect of nystatin on the development of oral irritation in patients receiving high-dose intravenous interleukin-2. Journal of Immunotherapy 2001;24(2):188-92. Okuno 1997 Okuno SH, Foote RL, Loprinzi CL, Gulavita S, Sloan JA, Earle J et al. A randomized trial of a nonabsorbable antibiotic lozenge given to alleviate radiation-induced mucositis. Cancer 1997;79(1):2193-9. Okuno 1998 Okuno SH, Swan L, Ebbert C. Phase III placebo-controlled clinical trial evaluation of glutamine for decreasing mucositis in patients receiving 5 FU (Fluorouracil)-based chemotherapy. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1998:256. Okutomi 2000 Okutomi T, Kato Y, Ichihara H, Hyodo I, Fujitsuka H, Yasuda S et al. [Clinical effects of adjuvant therapy using Z-100 (Ancer 20 injection) for oral cancer--prevention of stomatitis and hematopoietic impairment]. Gan To Kagaku Ryoho 2000;27(1):65-71.Okutomi T, Kato Y, Ichihara H, Hyodo I, Fujitsuka H, Yasuda S, Tatematsu N. [Clinical effects of adjuvant therapy using Z-100 (Ancer 20 injection) for oral cancer--prevention of stomatitis and hematopoietic impairment] Gan To Kagaku Ryoho. 2000 Jan;27(1):65-71. Papadeas 2007 Papadeas E, Naxakis S, Riga M, Kalofonos Ch. Prevention of 5-fluorouracil-related stomatitis by oral cryotherapy: a randomized controlled study. European Journal Oncology Nursing 2007;1:60-5. Papas 1984 Papas A, Johansen E. Prevention of mucositis in oncology patients undegoing radiation therapy. Journal of Dental Research 1984;63(Special Issue March):311 (Abs No 1267).Papas A, E J. Prevention of Mucositis in Oncology Patients Undegoing Radiation Therapy (JDR Abstract). J-Dent-Res 1984;63(Special Issue March):311 (Abs 1267). Peters 1993 Peters E, Antczak-Bouckoms A, Burdick E. Meta-analysis of chlorhexidine in the prevention of mucositis from chemotherapy. Journal of Dental Research 1993;Special Issue(259):1249.Peters E A-BA, Burdick E. Meta-Analysis of Chlorhexidine in the Prevention of Mucositis from Chemotherapy (IADR Abstract). Journal of Dental Research 1993+ADs-72:259 (Abs No 1249). Peterson 2003 Peterson DE, Petit RG. Phase III study: AES-14 in chemotherapy patients at risk for mucositis. In: Proceedings of the American Society of Clinical Oncology. 2003:725.Peterson DE, Petit RG. Phase III study: AES-14 in chemotherapy patients at risk for mucositis [abstract]. Proceedings of the American Society of Clinical Oncology. 2003:725. Petit 2001 Petit RG, II, French C. Phase III clinical trial design considerations for oral treatments of chemotherapy - induced mucositis: AES-14 (uptake-facilitated L-glutamine) pivotal studies [abstract]. Proceedings of the American Society of Clinical Oncology 2001;20 (Pt 2):301b, Abstract 2954. Pfeiffer 1989 Pfeiffer P, May O. Sucralfate prophylaxis of chemotherapy-induced stomatitis. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1989. Pfeiffer 1989a Pfeiffer P, Hansen SO, Madsen EL, May O. Sucralfate prophylaxis of chemotherapy-induced stomatitis [abstract]. Proceedings of the American Society of Clinical Oncology 1989;8:171, Abstract 665. Phillips 2002 Phillips II, GL. The potential of amifostine in high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Seminars in Oncology 2002;29(6 Supp 19):53-6. Piccirillo 2003 Piccirillo N, De Matteis S, Laurenti L, Chiusolo P, Sora F, Pittiruti M et al. Glutamine-enriched parenteral nutrition after autologous peripheral blood stem cell transplantation: effects on immune reconstitution and mucositis. Haematologica 2003;88(2):192-200. Porta 1994 Porta C, Moroni M, Nastasi G, Montecucco CM, Caporali R, Notario A. Allopurinol mouthwashes can reduce oral mucositis in chemotherapy-treated patients. Annals of Oncology 1994;5(Suppl 8):208.Porta C, Moroni M, Nastasi G, Montecucco CM, Caporali R, Notario A. Allopurinol mouthwashes can reduce oral mucositis in chemotherapy-treated patients. Annals of Oncology. 1994;5(Suppl 8):208. Pouli 1999 Pouli A, Nikiforakis E. A prospective randomized trial of GM-CFS mouthwash versus sodium bicarbonate mouthwash in the treatment of stomatitis following allogeneic bone marrow transplantation. Bone Marrow Transplantation 1999;23:S166. Prada 1985 Prada A, Lozza L, Moglia D, Sala L, Chiesa F. Effects of benzydamine on radio-polychemotherapeutic mucositis of the oral cavity. International Journal of Tissue Reaction 1985;7(3):237-9. Pyrhonen 1995 Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. British Journal of Cancer 1995;71(3):587-91.Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. British Journal of Cancer. 1996;71(3):587-91. Pytlik 2002 Pytlik R, Benes P, Patorkova M, Chocenska E, Gregora E, Prochazka B et al. Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo controlled study. Bone Marrow Transplantation 2002;30(12):953-61.Pytlik R, Benes P, Patorkova M, Chocenska E, Gregora E, Prochazka B, et al. Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo controlled study. Bone Marrow Transplantation 2002+ADs- 30(12):953-61. Rabinovitch 2006 Rabinovitch R, Grant B, Berkey BA, Raben D, Ang KK, Fu KK et al. Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: a secondary analysis of RTOG trial 90-03. Head &amp;amp; Neck 2006;28(4):287-96.Rabinovitch R, Grant B, Berkey BA, Raben D, Ang KK, Fu KK, et al. Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: a secondary analysis of RTOG trial 90-03. Head &amp;amp; Neck. 2006;28(4):287-96. Rades 2004 Rades D, Fehlauer F, Bajrovic A, Mahlmann B, Richter E, Alberti W. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiotherapy and Oncology 2004;70(3):261-4.Rades D, Fehlauer F, Bajrovic A, Mahlmann B, Richter E, Alberti W. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.[see comment]. Radiotherapy &amp;amp; Oncology. 2004;70(3):261-4. Radmard 2002 Radmard A, Niewohner-Desbordes U, Wagner W. [rhGM-CSF in the treatment of radiogenic mucositis: prospective randomised phase-II study on the effectivity and tolerance of rhGM-CSF in the treatment of oral mucositis under radiotherapy of head and neck tumors]. Strahlentherapie und Onkologie 2002;178(Suppl 1):24.Radmard A, Niewohner-Desbordes U, Wagner W. [ rhGM-CSF in the treatment of radiogenic mucositis: prospective randomised phase-II study on the effectivity and tolerance of rhGM-CSF in the treatment of oral mucositis under radiotherapy of head and neck tumors. ]. Strahlentherapie und Onkologie. 2002;178(Sondernr 1):24. Raether 1989 Raether D, Walker PO, Bostrum B, Weisdorf D. Effectiveness of oral chlorhexidine for reducing stomatitis in a pediatric bone marrow transplant population. Pediatric Dentistry 1989;11(1):37-42.Raether D, Walker PO, Bostrum B, Weisdorf D. Effectiveness of oral chlorhexidine for reducing stomatitis in a pediatric bone marrow transplant population. Pediatric Dentistry 1989;11:37-42. Robustelli 1999 Robustelli della Cuna FS, Ucci G, Cuomo AM, Goglio AM. Galenic preparation for the prophylaxsis of oral mucositis induced by 5-fluororacil continous infusion. Supportive Care in Cancer 1999;7 Suppl:132 (Abs No P-67).Robustelli della Cuna FS, Ucci G, Cuomo AM, Goglio AM. Galenic preparation for the prophylaxsis of oral mucositis induced by 5-fluororacil continous infusion. Supportive Care in Cancer. 1999;7 Suppl.(Abstr P-67):132. Rocci 2005 Rocci L, Vincenzi B, Santini D, Tonini G. [Timing of 5-fluorouracile infusion: a randomized clinical trial]. International Nursing Perspectives 2005;5(2):53-60.Rocci L, Vincenzi B, Santini D, Tonini G. Timing of 5-fluorouracile infusion: a randomized clinical trial [Italian]. International Nursing Perspectives. 2005;5(2):53-60. (32 ref). Rojas 2001 Rojas de Morales T, Zambrano O, Rivera L, Navas R, Chaparro N, Bernardonni C et al. Oral-disease prevention in children with cancer: testing preventive protocol effectiveness. Medicina Oral 2001;6(5):326-34.Rojas de Morales T ZO, Rivera L, Navas R, Chaparro N, Bernardonni C, Rivera F, Fonseca N, Tirado DM. Oral-disease prevention in children with cancer: testing preventive protocol effectiveness. Medicina Oral 2001+ADs-6(5):326-34. Rutkauskas 1993 Rutkauskas JS, Davis JW. Effects of chlorhexidine during immunosuppressive chemotherapy: A preliminary report. Oral Surgery, Oral Medicine, Oral Pathology 1993;76(4):441-8.Rutkausas JS, Davis JW. Effects of chlorhexidine during immunosuppressive chemotherapy: A preliminary report. Oral Surg Oral Med Oral Path 1993;76:441-8. Ryu 2007 Ryu JK, Swann S, LeVeque F, Scarantino CW, Johnson D, Chen A, et al. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901. International Journal of Radiation Oncology, Biology, Physics 2007;67(3):643-50. Samaranayake 1988 Samaranayake LP, Robertson AG, MacFarlane TW, Hunter IP, MacFarlane G, Soutar DS et al. The effect of chlorhexidine and benzydamine mouthwashes on mucositis induced by therapeutic irradiation. Clinical Radiology 1988;39(3):291-4. Sato 1997 Sato A, Kumagai S, Sakaki K, Morikawa H, Song ST, Mori S. [Inhibition of 5-fluorouracil-cisplatin-induced stomatitis by oral cryotherapy: use of an ice-bar containing fibrinolysin and deoxyribonuclease comiben (Elase)]. Gan to Kagaku Ryoho [Japanese Journal of Cancer &amp;amp; Chemotherapy] 1997;24(9):1135-9. Sato 2006 Sato A, Saisho-Hattori T, Koizumi Y, Minegishi M, Iinuma K, Imaizumi M. Prophylaxis of mucosal toxicity by oral propantheline and cryotherapy in children with malignancies undergoing myeloablative chemo-radiotherapy. Tohoku Journal of Experimental Medicine 2006;210(4):315-20. Scarantino 2001a Scarantino CW, LeVeque FG, Scott CB, White RL, Rotman M, Hodson DI et al. A phase III study of concomitant oral pilocarpine to reduce hypo-salivation and mucositis assocated with curative radiation therapy (RT) in head and neck (H&amp;amp;N) cancer patients. RTOG 9709. In: Proceedings of the American Society of Clinical Oncology. 2001:(Abs No 897).Scarantino C LF, Scott C, White R, Rotman M, Hodson D, Meredith R, Foote R, Brachman D. A Phase III Study of Concomitant Oral Pilocarpine to Reduce Hypo-Salivation and Mucositis Assocated with Curative Radiation Therapy (RT) in Head and Neck (H&amp;amp;N) Cancer Patients. RTOG 9709. Proceedings of ASCO 2001. Scarantino 2001b Sadar CM, Heard R, Prathikanti R, Lau D, Danilenko D, Hunt T et al. Safety, pharmacokinetics and biological activity of rHuKGF in normal volunteers.. Growth Factors and Cytokines;Abstract 761:172. Scarantino CW, Leveque F, Scott C, White RL, Rotman M, Hodson DI et al. A Phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97-09. International Journal of Radiation Oncology, Biology, Physics 2001;51(3 Suppl 1):85-6.Scarantino CW, Leveque F, Scott C, White RL, Rotman M, Hodson DI, et al. A Phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97-09 [abstract]. International Journal of Radiation Oncology Biology Physics. 2001;51(3 Suppl 1):85-6. Schuster 2008 Schuster MW, Anaissie E, Hurd D, Bensinger W, Mason J, McCarty J, et al. Final analysis of the phase II, randomized, double-blind, placebo-controlled trial of single-dose velafermin (CG53135-05) for the prevention of oral mucositis. Journal of Supportive Oncology 2007;5(4 SUPPL. 2):58-9. Schuster MW, Shore TB, Harpel JG, Greenberg J, Jalilizeinali B, Possley S, et al. Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant. Supportive Care in Cancer 2008;16(5):477-83. Schwerkkoske 1999 Schwerkkoske J, Schwartzberg L, Weaver CH, Schwertschlag US, Goodfellow J, Berdosian CL. A phase I double-masked, placebo-controlled study to evaluate tolerability of Neumega (rhIL-11; Oprelvekin) to reduce mucositis in patients with solid tumors or lymphoma receiving high-dose chemotherapy (CT) with autologous peripheral blood stem cell reinfusion (PBSCT). In: Proceedings of the American Society of Clinical Oncology. Vol. 18. 1999:584a.Schwerkkoske J, Schwartzberg L, Weaver CH, Schwertschlag US, Goodfellow J, Berdosian CL. A phase I double-masked, placebo-controlled study to evaluate tolerability of Neumega (rhIL-11; Oprelvekin) to reduce mucositis in patients with solid tumors or lymphoma receiving high-dose chemotherapy (CT) with autologous peripheral blood stem cell reinfusion (PBSCT) [abstract]. Proceedings of the American Society of Clinical Oncology. 1999;18:584a. Schwerkoske 1999 Schwerkoske J, Schwartzberg L, Weaver CH, Schwertschlag US, Goodfellow J, Bedrosian CL. A phase 1 double-masked, placebo-controlled study to evaluate tolerability of Neumega&amp;#174; (rhIL-11; oprelvekin) to reduce mucositis in patients with solid tumors or lymphoma receiving high-dose chemotherapy (CT) with autologous peripheral blood stem cell reinfusion (PBSCT) [abstract]. Proceedings of the American Society of Clinical Oncology 1999;18:584a, Abstract 2256. Shea 2007 Shea TC, Kewalramani T, Mun Y, Jayne G, Dreiling LK. Evaluation of Single-Dose Palifermin To Reduce Oral Mucositis (OM) in Fractionated Total Body Irradiation (fTBI) and High Dose (HD) Chemotherapy with Autologous Peripheral Blood Progenitor Cell (PBPC) Transplantation [abstract]. Blood 2006;108(11 Part 1):875-6. Shea TC, Kewalramani T, Mun Y, Jayne G, Dreiling LK. Evaluation of single-dose palifermin to reduce oral mucositis in fractionated total-body irradiation and high-dose chemotherapy with autologous peripheral blood progenitor cell transplantation. Journal of Supportive Oncology 2007;5(4 SUPPL. 2):60-2. Simoes 2009 Simoes A, Eduardo FP, Luiz AC, Campos L, Sa PH, Cristofaro M, et al. Laser phototherapy as topical prophylaxis against head and neck cancer radiotherapy-induced oral mucositis: comparison between low and high/low power lasers. Lasers in Surgery &amp;amp; Medicine 2009;41(4):264-70. Spadaro 1991 Spadaro P, Buemi B, Ferraro G, Marabello G, Russi E, Pergolizzi S. Prophylaxis of chemotherapy-radiotherapy induced mucositis or oral fungal infection with vitamin E + vitamin A and Fluconazolo. European Journal of Cancer 1991;27(Suppl 2):S288. Spielberger 2001 Spielberger RT, Stiff P, Emmanouilides C, Yanovich S, Bensinger W, Hedrick E, et al. Efficacy of recombinant human keratinocyte growth factor (rHuKGF) in reducing mucositis in patients with hematologic malignancies undergoing autologous peripheral blood progenitor cell transplantation (auto-PBPCT) after radiation-based conditioning - results of a phase 2 trial [abstract]. Proceedings of the American Society of Clinical Oncology 2001;20 (Pt 1):7a, Abstract 25. Staar 2001 Staar S. Benefits and toxicities of accelerated radiochemo- versus accelerated radiotherapy in advanced head and neck cancer - Results of a German randomized study. European Journal of Cancer 2001;37(Suppl 6):38 (Abs No 126).Staar S EHRVDAFMSMVPSPSHMR. Benefits and toxicities of accelerated radiochemo- versus accelerated radiotherapy in advanced head and neck cancer - Results of a German randomized study. European Journal of Cancer. 2001 2001;37(Suppl 6):38 Abs. 126. Stokman 2004 Stokman MA, Wachters FM, Koopmans P, Burgerhof JG, Groen HJ, Spijkervet FK et al. Outcome of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis. A phase II study. Anticancer Research 2004;24(5B):3263-7.Stokman MA, Wachters FM, Koopmans P, Burgerhof JG, Groen HJ, Spijkervet FK, et al. Outcome of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis. A phase II study. Anticancer Research. 2004;24(5B):3263-7. Su 2004a Su C, Mehta V, Ravikumar L, Shah R, Pinto H, Halpern J et al. Phase II double-blind randomized study comparing oral aloe vera (AV) versus placebo to prevent radiation (RT)-related mucositis in patients with head and neck (HN) neoplasms. In: Proceedings of the Amercian Society of Clinical Oncology. 2004.Su C, Mehta, V, Ravikumar, L, Shah, R, Pinto, H, Halpern, J, Koong, A, Goffinet, D, and Le, Q-T. Phase II double-blind randomized study comparing oral aloe vera (AV) versus placebo to prevent radiation (RT)-related mucositis in patients with head and neck (HN) neoplasms. Proceedings of ASCO. 2003 2003. Su 2004b Su YB. Double-blind, randomized trial of granulocyte-colony stimulating factor (GCSF) versus (v.) placebo during postoperative radiation (RT) for advanced resectable squamous cell head and neck cancer (SCCHN): impact on mucositis. Journal of Clinical Oncology 2004;22(Suppl):14S. Suc 1999 Suc A, Gandemer V, Le Deley MC, Schmitt C, Pichard-Leandri E, French Group. Gum98: Preventing mucositis with chewing gum in children receiving chemotherapy, a multicentric trial. Supportive Care in Cancer 1999;7S:180 (Abs No P-60). Svanberg 2004 Svanberg A, &amp;#214;hrn K. Cryotherapy during chemotherapy - could it delay or alleviate the development of mucositis? Bone Marrow Transplantation 2004;33(Suppl 1):S292.Svanberg A, &amp;#214;hrn K. Cryotherapy during chemotherapy - could it delay or alleviate the development of mucositis? [abstract]. Bone Marrow Transplantation. 2004;33(Suppl 1):S292. Svanberg 2007 Svanberg A, Birgegard G, Ohrn K. Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy--a randomized controlled trial. Supportive Care in Cancer 2007;15(10):1155-61. Sykes 2004 Sykes AJ, Slevin NJ, MacDougall RH, Ironside JAD, Mais KL. Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck. Radiotherapy and Oncology 2004;71(1):81-4. Symonds 1995 Symonds RP, Thomas M, Alcock SR, Khorrami J, McEllroy P, McMuuuray A. The reduction of radiation mucositis by antibiotic pastilles: a placebo-controlled double-blind trial. European Journal Surgery Oncology 1995;21:447.Symonds RP TM, Alcock SR, and et al. The reduction of radiation mucositis by antibiotic pastilles: a placebo-controlled double-blind trial [abstract]. Eur-J-Surg-Oncol 1995;21:447. Teshima 1986 Teshima T. [Clinical evaluation of kenalog ointment for radiation mucositis of patients with head and neck cancer]. Yakuri to Chiryo (Japanese Pharmacology and Therapeutics) 1986;14(11):7163-6.Teshima T, et al. [Clinical Evaluation of Kenalog Ointment for Radiation Mucositis of Patients with Head and Neck Cancer]. Yakuri to Chiryo (Japanese Pharmacology and Therapeutics). 1986;14(11):7163-6. Thieblemont 2002 Thieblemont C, Dumontet C, Saad H, Roch N, Bouafia F, Arnaud P et al. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplantation 2002;30(11):769-75.Thieblemont C, C D, H S, N R, F B, P A, et al. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplantation 2002;30(11):769-75. Throuvalas 1995 Throuvalas N, Antonadou D, Pulizzi M, Sarris G. Evaluation of the efficacy and safety of GM-CSF in the prophylaxis of mucositis in patients with head and neck cancer treated with RT. European Journal of Cancer 1995;31(Suppl 5):S93 (Abs No 431).Throuvalas Nao. Evaluation of the efficacy and safety of GM-CSF in the prophylaxis of mucositis in patients with head and neck cancer treated with RT. European Journal of Cancer 1995;31?(Suppl 5):S93 Abs. 431. Tiemann 2006 Tiemann P, Toelg M, Ramos FM. Administration of Ratanhia-based herbal oral care products for the prophylaxis of oral mucositis in cancer chemotherapy patients: a clinical trial. Evid Based Complement Alternat Med 2007;4(3):361-6. Toubai 2003 Toubai T, Tanaka J, Fujisawa F, Kondo Y, Imamura M, Ota S et al. Effect of prophylaxis against myocosis in patients with hematological malignancy disease: efficacy of dosage of itraconazole. Japanese Journal of Antibiotics 2003;56(1):61-5.Toubai T, Tanaka J, Fujisawa F, Kondo Y, Imamura M, Ota S, et al. Effect of prophylaxis against myocosis in patients with hematological malignancy disease: efficacy of dosage of itraconazole. +AFs-Japanese+AF0-. Japanese Journal of Antibiotics 2003+ADs- 56(1):61-5. Uchiyama 2005 Uchiyama Y, Murakami S, Kakimoto N, Nakatani A, Furukawa S. Effectiveness of Cepharanthin in decreasing interruptions during radiation therapy for oral cancer. Oral Radiology 2005;21(1):41-4.Uchiyama Y, Murakami S, Kakimoto N, Nakatani A, Furukawa S. Effectiveness of Cepharanthin in decreasing interruptions during radiation therapy for oral cancer. Oral Radiology. 2005;21(1):41-4. Vacha 1999 Vacha P, Marx M, Engel A, Richter E, Feyerabend T. Side effects of postoperative radiochemotherapy with amisfostine versus radiotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial [Nebenwirkungen einer posoperativen radiochemotherapie mit amifostin versus alleiniger radiochemotherapie bei kopf-hals-tumoren. Vorlaufige ergebnisse einer prospektiv randomisierten untersuchung]. Strahlentherapie und onkologie 1999;175(S4):18-22. Vacha 2003 Vacha P, Fehlauer F, Mahlmann B, Marx M, Hinke A, Sommer K et al. Randomized phase III trial of postoperative radiochemotherapy amifostine in head and neck cancer: Is there evidence for radioprotection? Strahlentherapie und Onkologie 2003;179(6):385-9.Vacha PFFMBMMHASKREFT. Randomized phase III trial of postoperative radiochemotherapy amifostine in head and neck cancer: Is there evidence for radioprotection? Strahlentherapie und Onkologie 2003+ADs- Vol 179(6): 385-389. Valcarcel 2002a Valcarcel D, Sanz M, Sureda A, Sala M, Munoz L, Subira M et al. Topically applied recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) for oropharyngeal mucositis (OM) in stem cell transplantation recipients: a randomized double-blind placebo-controlled study. Bone Marrow Transplantation 2002;Suppl 2:S20.Valcarcel D, Sanz M, Sureda A, Sala M, Munoz L, Subira M, et al. Topically applied recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) for oropharyngeal mucositis (OM) in stem cell transplantation recipients: a randomized double-blind placebo-controlled study [abstract]. Bone Marrow Transplantation. 2002(Suppl 2):S20. Valcarcel 2002b Valcarcel D, Sanz MA Jr, Sureda A, Sala M, Munoz L, Subira M et al. Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study. Bone Marrow Transplantation 2002;29(9):783-7.Valcarcel D, Sanz MAJ, Sureda A, Sala M, Munoz L, Subira M, et al. Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study. Bone Marrow Transplantation. 2002 2002; 29(9):783-7. Valc&amp;#225;rcel 1997 Valc&amp;#225;rcel F, De la Torre A, Arag&amp;#243;n G, Lanz&amp;#243;s E, Rodr&amp;#237;guez R, Veiras C. Double-blind randomized and pilot study on the potential of thymostimulin to reduce the incidence of mucositis in head and neck cancer patients with radical radiotherapy. In: Oncolog&amp;#237;a IX Congreso Nacional de la Asociaci&amp;#243;n Espa&amp;#241;ola de Radioterapia y Oncolog&amp;#237;a. Vol. 20. 1997:161.Valc&amp;#225;rcel F, De la Torre A, Arag&amp;#243;n G, Lanz&amp;#243;s E, Rodr&amp;#237;guez R, Veiras C. Double-blind randomized and pilot study on the potential of thymostimulin to reduce the incidence of mucositis in head and neck cancr patients with radical radiotherapy. Oncolog&amp;#237;a IX Congreso Nacional de la Asociaci&amp;#243;n Espa&amp;#241;ola de Radioterapia y Oncolog&amp;#237;a. 1997;20(10 - Congreso):161. van Zaanen 1994 van Zaanen HC, van der Lelie H, Timmer JG, Furst P, Sauerwein HP. Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapy-induced toxicity. Cancer 1994;74(10):2879-84.van Zaanen HC vdLH, Timmer JG, Furst P, Sauerwein HP. Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapy-induced toxicity. Cancer 1994;74(10):2879-84. Verdi 1995 Verdi CJ, Garewal HS, Koenig LM, Vaughn B, Burkhead T. A double-blind, randomized, placebo-controlled, crossover trial of pentoxiflline for the prevention of chemotherapy-induced oral mucositis. Osomopore 1995;80(1):36-42. Vesole 1999 Vesole D, Fuchs HJ. IB-367 reduces the number of days of severe oral mucositis complicating myeloablative chemotherapy. Blood 1999;94(10 Suppl 1):154 (Abs No 675).Vesole DHaF, H. J. IB-367 reduces the number of days of severe oral mucositis complicating myeloablative chemotherapy [abstract]. Blood 1999;94(10 Suppl 1):154a. Vitello 2000 Vitello M, Cianio SG. A comparison of two mouthrinse agents used during head/neck radiation. Journal of Dental Research 2000;79(Special Issue):215 (Abs No 576). Wagner 2002 Wagner W, Radmard A, Niewohner-Desbordes U, Haus U, Matt J. rhGM-CSF in the treatment of radiotherapy induced mucositis-prospective randomized, double-blind study to investigate the feasibility and effectiveness of rhGM-CSF in patients with head and neck cancer. In: Proceedings of the American Society for Therapeutic Radiology and Oncology Meeting. 2002:311 (Abs No 2175). Wang 2002b Wang HM, Wang CS, Chen JS, Chen IH, Liao CT, Chang TC. Cisplatin, tegafur, and leucovorin: a moderately effective and minimally toxic outpatient neoadjuvant chemotherapy for locally advanced squamous cell carcinoma of the head and neck. Cancer 2002;94(11):2989-95. Ward 2007 Ward E, Smith M, Henderson M, Reid U, Lewis I, Kinsey S, et al. The effect of high-dose enteral glutamine on the incidence and severity of mucositis in paediatric oncology patients. Eur J Clin Nutr 2007. Warde 2002 Warde P, O'Sullivan B, Aslanidis J, Kroll B, Lockwood G, Waldron J et al. A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. International Journal of Radiation Oncology Biology and Physics 2002;54(1):9-13.Warde P, O'Sullivan, B, Aslanidis, J, Kroll, B, Lockwood, G, Waldron, J, Payne, D, Bayley, A, Ringash, J, Kim, J, Liu, F, Maxymiw, W, Sprague, S, and Cummings, B. A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002+ADs-54(1):9-13. Weisdorf 1989 Weisdorf DJ, Bostrom B, Raether D, Mattingly M, Walker P, Pihlstrom B et al. Oropharyngeal mucositis complicating bone marrow transplantation: prognostic factors and the effect of chlorhexidine mouthrinse. Bone Marrow Transplantation 1989;4(1):89-95.Weisdorf DJ, Bostrom B, Raether D, Mattingly M, Walker P, Pihlstrom B et al. Oropharyngeal mucostitis complicating bone marrow transplantation: prognostic factors and the effect of chlorhexidine mouthrinse. Bone Marrow Transplant 1989;4:89-95. Weiss 1990 Weiss GR, Green S, Hannigan EV, Boutselis JG, Surwit EA, Wallace DL et al. A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial. Gynecologic Oncology 1990;37(3):354-8.Weiss GR GS, Hannigan EV, Boutselis JG, Surwit EA, Wallace DL, Alberts DS. A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial. Gynecologic Oncology 1990;37(3):354-8. Whelan 2002 Whelan HT, Connelly JF, Hodgson BD, Barbeau L, Post AC, Bullard G et al. NASA light-emitting diodes for the prevention of oral mucositis in pediatric bone marrow transplant patients. Journal of Clinical Laser Medicine &amp;amp; Surgery 2002;20(6):319-24. Whelan 2004 Whelan H. Phase II randomized study of NASA-developed light-emitting diode therapy for the prevention of oral mucositis in children receiving a myeloablative conditioning regimen comprising chemotherapy with or without radiotherapy followed by first allogeneic bone marrow transplantation. http://www.clinicaltrials.gov (accessed 2003).Whelan H. Phase II Randomized Study of NASA-Developed Light-Emitting Diode Therapy For the Prevention of Oral Mucositis in Children Receiving a Myeloablative Conditioning Regimen Comprising Chemotherapy With or Without Radiotherapy Followed By First Allogeneic Bone Marrow Transplantation. National Institutes of Health, ClinicalTrials.Gov [http://www.clinicaltrials.gov] 2003. Wollina 2002 Wollina U, Christen N, Kostler E, Schorcht J. On prophylaxis and treatment of radiation-induced dermatitis and mucositis. Zeitschrift fur Hautkrankheiten 2002;77(9):418-23. Wymenga 1999a Wymenga AN, van der Graaf WT, Hofstra LS, Timens W, Spijkervet FK, Hospers GAP et al. TGF-b3 mouthwashes aimed at prevention of chemotherapy induced mucositis, a phase-I study. Supportive Care in Cancer 1999;7:168. Wymenga 1999b Wymenga AN, van der Graaf WT, Hofstra LS, Spijkervet FK, Timens W, Timmer-Bosscha H et al. Phase I study of transforming growth factor-beta3 mouthwashes for prevention of chemotherapy-induced mucositis. Clinical Cancer Research 1999;5(6):1363-8.Wymenga AN, van der Graaf WT, Hofstra LS, Spijkervet FK, Timens W, Timmer-Bosscha H, Sluiter WJ, van Buuren AH, Mulder NH, de Vries EG.Phase I study of transforming growth factor-beta3 mouthwashes for prevention of chemotherapy-induced mucositis. Clin Cancer Res. 1999 Jun;5(6):1363-8. Yokomizo 2004 Yokomizo H, Yoshimatsu K, Hashimoto M, Ishibashi K, Umehara A, Yoshida K et al. Prophylactic efficacy of allopurinol ice ball for leucovorin/5-fluorouracil therapy-induced stomatitis. Anticancer Research 2004;24(2C):1131-4.Yokomizo H, Yoshimatsu K, Hashimoto M, Ishibashi K, Umehara A, Yoshida K, et al. Prophylactic efficacy of allopurinol ice ball for leucovorin/5-fluorouracil therapy-induced stomatitis. Anticancer Research. 2004;24(2C):1131-4. Zalcberg 1995 Zalcberg J, Cunningham D, Rath U, Olver I, Kerr D, van Cutsem E et al. 'Tomudex' (ZD1694) has a higher response rate, significantly less leucopenia and mucositis and a simpler dosing regimen than 5-Fluorouracil (5-FU) and leucovorin (LV) for advanced colorectal cancer (CRC): first results of a phase III study. European Journal of Cancer 1995;31f:S146 (Abs No 701). Studies awaiting classification Ongoing studies Haddad 2003 Haddad R, Wirth L, Costello R, Weeks L, Posner M. Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. Seminars in Oncology 2003;30(6 Suppl 18):84-8.Haddad R, Wirth L, Costello R, Weeks L, Posner M. Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. Seminars in Oncology 2003; 30(6 Suppl 18):84-8. National 2008 National Cancer I. Phase III comparison of oral capsaicin lozenge versus placebo lozenge for radiation-induced mucositis [completed]. ClinicalTrials.gov [accessed 31 Jul 2008] 2008:ClinicalTrials.gov ID: NCT00003610. National 2008a National Cancer I. A phase III study to test the efficacy and safety of GM-CSF to reduce the severity and duration of mucosal Injury and pain (mucositis) associated with curative radiation therapy in head and neck cancer patients [completed]. ClinicalTrials.gov [accessed 31 Jul 2008] 2008:ClinicalTrials.gov ID: NCT00008398. Other references Additional references Andreassen 2003 Barasch 2003 Begg 1996 Bellm 2002 Chang 2003 Clarkson 2004 Clarkson 2007a Clarkson 2007b De Pauw 1997 Denning 1992 Duncan 2003 Elbourne 2002 Gotzsche 2002 J Briggs Inst 1998 Kowanko 1998 Lortholary 1997 McGuire 2004 Meunier 1994 Moher 2001 Rubenstein 2004 Savarese 2003 Sonis 2004 Stevens 1995 Stokman 2006 Sunderland 2001 Symonds 1998 Verdi 1993 White 1993 Worthington 2004a Worthington 2004b Worthington 2007 Wright 2003 Other published versions of this review Clarkson 2000 Clarkson 2003a Worthington 2006 Classification pending references Data and analyses 1 Acyclovir versus placebo 1.1 Mucositis (absent versus present) 2 Allopurinol versus placebo/no treatment 2.1 Mucositis (absent versus present) 2.2 Mucositis (0-1 versus 2+) 2.3 Mucositis (0-2 versus 3+) 2.4 Mucositis (absent versus present) 2.5 Mucositis (0-1 versus 2+) 2.6 Mucositis (0-2 versus 3+) 3 Aloe vera versus placebo 3.1 Mucositis (0-1 versus 2+) 4 Amifostine versus placebo/no treatment 4.1 Mucositis (absent versus present) 4.2 Mucositis (0-1 versus 2+) 4.3 Mucositis (0-2 versus 3+) 4.4 Survival at 24 months 4.5 Recurrence at 18 months after cancer treatment 4.6 Incomplete response to radiotherapy 4.7 Delay to radiotherapy 4.8 Hypotension 4.9 Nausea 4.10 Vomiting 5 Antibiotic pastille or paste versus placebo/no treatment 5.1 Mucositis (absent versus present) 5.2 Mucositis (0-1 versus 2+) 5.3 Mucositis (0-2 versus 3+) 6 Benzydamine versus placebo 6.1 Mucositis (absent versus present) 6.3 Mucositis (0-2 versus 3+) 7 Beta carotene versus control 7.1 Mucositis (0-2 versus 3+) 8 Calcium phosphate versus placebo 8.1 Mucositis (absent versus present) 8.2 Mucositis (0-1 versus 2+) 8.3 Mucositis (0-2 versus 3+) 9 Chewing gum versus no chewing gum 9.1 Mucositis (absent versus present) 9.2 Mucositis (0-2 versus 3+) 10 Camomile versus placebo 10.1 Mucositis (absent versus present) 10.2 Mucositis (0-1 versus 2+) 10.3 Mucositis (0-2 versus 3+) 11 Chinese medicine versus control 11.1 Mucositis (absent versus present) 11.2 Mucositis (0-1 versus 2+) 11.3 Mucositis (0-2 versus 3+) 12 Chlorhexidine versus placebo/no treatment 12.1 Mucositis (absent versus present) 12.2 Mucositis (0-1 versus 2+) 12.3 Mucositis (0-2 versus 3+) 12.4 Mucositis (absent versus present) 12.5 Mucositis (0-1 versus 2+) 12.6 Mucositis (0-2 versus 3+) 13 Chlorhexidine versus cryotherapy 13.1 Mucositis (absent versus present) 13.2 Mucositis (0-1 versus 2+) 13.3 Mucositis (0-2 versus 3+) 14 Cryotherapy versus no treatment 14.1 Mucositis (absent versus present) 14.2 Mucositis (0-1 versus 2+) 14.3 Mucositis (0-2 versus 3+) 14.4 Mucositis (absent versus present) 14.5 Mucositis (0-1 versus 2+) 14.6 Mucositis (0-2 versus 3+) 15 Cryotherapy 30 min versus 60 min 15.1 Mucositis (absent versus present) 15.2 Mucositis (0-1 versus 2+) 15.3 Mucositis (0-2 versus 3+) 16 Etoposide: bolus versus continuous 16.1 Mucositis (absent versus present) 16.2 Mucositis (0-1 versus 2+) 16.3 Mucositis (0-2 versus 3+) 17 Folinic acid versus no treatment 17.1 Mucositis (absent versus present) 17.2 Mucositis (0-1 versus 2+) 17.3 Mucositis (0-2 versus 3+) 18 Glutamine versus placebo 18.1 Mucositis (absent versus present) 18.2 Mucositis (0-1 versus 2+) 18.3 Mucositis (0-2 versus 3+) 18.4 Mucositis (absent versus present) 18.5 Mucositis (0-1 versus 2+) 18.6 Mucositis (0-2 versus 3+) 19 G-CSF versus no treatment 19.1 Mucositis (absent versus present) 19.2 Mucositis (0-1 versus 2+) 19.3 Mucositis (0-2 versus 3+) 20 GM-CSF versus no treatment 20.1 Mucositis (absent versus present) 20.2 Mucositis (0-1 versus 2+) 20.3 Mucositis (0-2 versus 3+) 21 GM-CFS versus sucralfate 21.1 Mucositis (0-1 versus 2+) 21.2 Mucositis (0-2 versus 3+) 22 Histamine gel versus placebo 22.1 Mucositis (absent versus present) 22.2 Mucositis (0-2 versus 3+) 23 Honey versus control 23.1 Mucositis (absent versus present) 23.2 Mucositis (0-1 versus 2+) 23.3 Mucositis (0-2 versus 3+) 24 Hydrolytic enzymes versus no treatment 24.1 Mucositis (absent versus present) 24.2 Mucositis (0-1 versus 2+) 24.3 Mucositis (0-2 versus 3+) 25 Indomethacin versus placebo 25.1 Mucositis (0-1 versus 2+) 26 Iseganan versus placebo 26.1 Mucositis (absent versus present) 26.2 Mucositis (0-1 versus 2+) 26.3 Mucositis (0-2 versus 3+) 27 Keratinocyte GF versus placebo 27.1 Mucositis (absent versus present) 27.2 Mucositis (0-1 versus 2+) 27.3 Mucositis (0-2 versus 3+) 28 Keratinocyte: 50 mg versus 25 mg 28.1 Mucositis (0-1 versus 2+) 28.2 Mucositis (0-2 versus 3+) 29 Laser versus no treatment 29.2 Mucositis (absent versus present) 29.3 Mucositis (0-1 versus 2+) 29.4 Mucositis (0-2 versus 3+) 30 Laser versus povidine 30.1 Mucositis (0-1 versus 2+) 30.2 Mucositis (0-2 versus 3+) 31 Misonidazole versus control 31.1 Mucositis (absent versus present) 31.2 Mucositis (0-1 versus 2+) 31.3 Mucositis (0-2 versus 3+) 31.4 New Outcome 32 Oral care protocol versus none 32.1 Mucositis (absent versus present) 32.2 Mucositis (0-1 versus 2+) 32.3 Mucositis (0-2 versus 3+) 33 Pentoxifylline versus no treatment 33.1 Mucositis (0-1 versus 2+) 34 Pilocarpine versus placebo 34.1 Mucositis (absent versus present) 34.2 Mucositis (0-1 versus 2+) 34.3 Mucositis (0-2 versus 3+) 35 Povidone versus water 35.1 Mucositis (absent versus present) 35.2 Mucositis (0-1 versus 2+) 35.3 Mucositis (0-2 versus 3+) 36 Prednisone versus placebo 36.1 Mucositis (absent versus present) 36.2 Mucositis (0-1 versus 2+) 36.3 Mucositis (0-2 versus 3+) 37 Propantheline anticholinergic versus placebo 37.1 Mucositis (absent versus present) 38 Prostaglandin versus placebo 38.1 Mucositis (absent versus present) 38.2 Mucositis (0-1 versus 2+) 38.3 Mucositis (0-2 versus 3+) 39 Radiotherapy: am versus pm 39.3 Mucositis (0-2 versus 3+) 40 Sucralfate versus placebo 40.1 Mucositis (absent versus present) 40.2 Mucositis (0-1 versus 2+) 40.3 Mucositis (0-2 versus 3+) 40.4 Mucositis (absent versus present) 40.5 Mucositis (0-1 versus 2+) 40.6 Mucositis (0-2 versus 3+) 41 Systemic antibiotic clarithromycin versus no treatment 41.1 Mucositis (0-1 versus 2+) 42 Traumeel versus placebo 42.1 Mucositis (absent versus present) 43 Zinc sulphate versus placebo 43.1 Mucositis (absent versus present) 43.2 Mucositis (0-1 versus 2+) 43.3 Mucositis (0-2 versus 3+) 44 Active treatment versus placebo/no treatment 44.1 Mucositis (absent versus present) 44.1.1 Aclyclovir versus placebo 44.1.2 Allopurinol versus placebo/no treatment 44.1.3 Amifostine versus no treatment 44.1.4 Antibiotic (pastille or paste) versus placebo 44.1.5 Benzydamine versus placebo 44.1.6 Chinese medicine versus control (Dobell's solution) 44.1.7 Calcium phosphate versus placebo 44.1.8 Camomile versus placebo 44.1.9 Chlorhexidine versus placebo or no treatment 44.1.10 Folinic acid versus no treatment 44.1.11 Glutamine versus placebo 44.1.12 GM-CSF versus no treatment 44.1.13 Histamine gel versus placebo 44.1.14 Honey versus control 44.1.15 Hydrolytic enzymes versus no treatment 44.1.16 Ice chips versus no treatment 44.1.17 Iseganan versus placebo 44.1.18 Misonidazole versus control 44.1.19 Oral care protocol versus none 44.1.20 Pilocarpine versus placebo 44.1.21 Povidone versus water 44.1.22 Prednisone versus placebo 44.1.23 Propantheline versus placebo 44.1.24 Prostaglandin versus placebo 44.1.25 Sucralfate versus placebo 44.1.26 Traumeel versus placebo 44.1.27 Zinc sulphate versus placebo 44.1.28 Palifermin versus placebo 44.2 Mucositis (0-1 versus 2+) 44.2.1 Aloe vera versus placebo 44.2.2 Amifostine versus placebo or no treatment 44.2.3 Antibiotic pastille or paste versus placebo or no treatment 44.2.4 Calcium phosphate versus placebo 44.2.5 Camomile versus placebo 44.2.6 Chinese medicine versus control (Dobell's solution) 44.2.7 Chlorhexidine versus placebo or no treatment 44.2.8 Folinic acid versus no treatment 44.2.9 Glutamine versus placebo 44.2.10 GM-CSF versus no treatment 44.2.11 Hydrolic enzymes versus no treatment 44.2.12 Ice chips versus no treatment 44.2.13 Indomethacin versus placebo 44.2.14 Iseganan versus placebo 44.2.15 Keratinocyte GF versus placebo 44.2.16 Misonidazole versus control 44.2.17 Oral care protocol versus none 44.2.18 Pentoxifylline versus no treatment 44.2.19 Pilocarpine versus placebo 44.2.20 Povidone versus water 44.2.21 Prednisone versus placebo 44.2.22 Sucralfate versus placebo 44.2.23 Systemic antibiotic clarithromycin versus no treatment 44.2.24 Zinc sulphate versus placebo 44.3 Mucositis (0-2 versus 3+) 44.3.1 Amifostine versus no treatment 44.3.2 Antibiotic pastille or paste versus placebo 44.3.3 Beta carotene versus control 44.3.4 Calcium phosphate versus placebo 44.3.5 Camomile versus placebo 44.3.6 Chinese medicine versus control (Dobell's solution) 44.3.7 Chlorhexidine versus placebo or no treatment 44.3.8 Folinic acid versus no treatment 44.3.9 Glutamine versus placebo 44.3.10 GM-CSF versus placebo 44.3.11 Histamine gel versus placebo 44.3.12 Honey versus control 44.3.13 Hydrolytic enzymes versus no treatment 44.3.14 Ice chips versus no treatment 44.3.15 Iseganan versus placebo 44.3.16 Keratinocyte GF versus placebo 44.3.17 Misonidazole versus control 44.3.18 Oral care protocol versus none 44.3.19 Pilocarpine versus placebo 44.3.20 Povidone versus water 44.3.21 Prednisone versus placebo 44.3.22 Prostaglandin versus placebo 44.3.23 Sucralfate versus placebo 44.3.24 Zinc sulphate 45 Comparisons between active interventions 45.1 Mucositis (absent versus present) 45.1.1 Cryotherapy: 30 min versus 60 min 45.1.2 Etoposide: bolus versus continuous 45.2 Mucositis (0-1 versus 2+) 45.2.1 Cryotherapy: 30 min versus 60 min 45.2.2 Etoposide: bolus versus continuous 45.2.3 GM-CFS versus sucralfate 45.2.4 Keratinocyte: 50 mg versus 25 mg 45.3 Mucositis (0-2 versus 3+) 45.3.1 Cryotherapy: 30 min versus 60 min 45.3.2 Etoposide: bolus versus continuous 45.3.3 GM-CSF versus sucralfate 45.3.4 Keratinocyte: 50 mg versus 25 mg 46 Side effects 46.1 Amifostine 46.1.1 Survival at 24 months 46.1.2 Recurrence at 18 months after cancer treatment 46.1.3 Incomplete response to radiotherapy 46.1.4 Delay to radiotherapy 46.1.5 Hypotension 46.1.6 Nausea 46.1.7 Vomiting 47 Epidermal GF 47.2 Mucositis (0-1 versus 2+) Figures Figure 1 (Analysis 26.1) Figure 2 (Analysis 27.1) Figure 3 (Analysis 27.2) Figure 4 (Analysis 27.3) Figure 5 (Analysis 1.1) Sources of support Internal sources The University of Manchester, UK Chief Scientists Office, Scottish Executive, UK NHS Education for Scotland, UK University of Dundee, UK External sources NIDCR grant ref 1 DE016950-01, USA Feedback Appendices 1 Cochrane Oral Health Group Trials Register search strategy Appendix title Appendix text 2 CENTRAL search strategy Appendix title Appendix text 3 MEDLINE via OVID search strategy Appendix title Appendix text 4 EMBASE SS via OVID search strategy Appendix title Appendix text 5 CANCERLIT search strategy Appendix title Appendix text 6 SIGLE search strategy Appendix title Appendix text 7 LILACS search strategy Appendix title Appendix text 8 CINAHL via EBSCO search strategy Appendix title Appendix text&lt;/p&gt;" NOTES_MODIFIED="2010-07-25 21:37:51 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carter DL, Hebert ME, Smink K, Leopold KA, Clough RL, Brizel DM</AU>
<TI>Double blind randomized trial of sucralfate vs placebo radial radiotherapy for head and neck cancers</TI>
<SO>Head and Neck</SO>
<YR>1999</YR>
<VL>21</VL>
<NO>8</NO>
<PG>760-6</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Cascinu-1994" MODIFIED="2010-11-09 12:41:26 +0000" MODIFIED_BY="[Empty name]" NAME="Cascinu 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-11-09 12:41:26 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Cascinu S, Fedeli A, Fedeli SL, Catalano G. Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. Eur J Cancer B Oral Oncol 1994;30B:234-6.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 12:41:26 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cascinu S, Fedeli A, Fedeli SL, Catalano G</AU>
<TI>Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis</TI>
<SO>European Journal of Cancer. Part B, Oral Oncology</SO>
<YR>1994</YR>
<VL>30B</VL>
<NO>4</NO>
<PG>234-6</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Castagna-2001" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Castagna 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Castagna L BE, Pedraza E, Luboinski M, Forni M, Brandes I, Pico JL, Dietrich PY. Prevention of mucositis in bone marrow transplantation: a double blind randomised controlled trial of sucralfate. Annals of Oncology 2001+ADs-12(7):953-5.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:19 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Castagna L, Benhamou E, Pedraza E, Luboinski M, Forni M, Brandes I et al</AU>
<TI>Prevention of mucositis in bone marrow transplantation: a double blind randomised controlled trial of sucralfate</TI>
<SO>Annals of Oncology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>7</NO>
<PG>953-5</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cengiz-1999" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Cengiz 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cengiz M, Ozyar E, Ozturk D, Akyol F, Atahan IL, Hayran M</AU>
<TI>Sucralfate in the prevention of radiation-induced oral mucositis</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>1999</YR>
<VL>28</VL>
<NO>1</NO>
<PG>40-3</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cerchietti-2006" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Cerchietti 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cerchietti LC, Navigante AH, Lutteral MA, Castro MA, Kirchuk R, Bonomi M et al</AU>
<TI>Double-blinded, placebo-controlled trial on intravenous L-alanyl-L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2006</YR>
<VL>65</VL>
<NO>5</NO>
<PG>1330-7</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chi-1995" MODIFIED="2010-11-09 13:25:41 +0000" MODIFIED_BY="[Empty name]" NAME="Chi 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-11-09 12:44:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chi KH, Chen CH, Chan WK, Chow KC, Chen SY, Yen SH et al</AU>
<TI>Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil and leucovorin chemotherapy</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1995</YR>
<VL>13</VL>
<NO>10</NO>
<PG>2620-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 13:25:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Chi KH, Chen CH, Chan WK, Yen SH, Liang MJ, Chou KC et al</AU>
<TI>Effect of granulocyte-macrophage colony-stimulating factor (GH-CFS) on oral mucositis in head and neck cancer patients after cisplatin, 5-FU and leucovorin chemotherapy</TI>
<SO>Proceedings of Annual Meeting American Society of Clinical Oncology</SO>
<YR>1994</YR>
<VL>13</VL>
<PG>Abstract 1469</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Choi-2007" MODIFIED="2010-11-09 12:45:15 +0000" MODIFIED_BY="[Empty name]" NAME="Choi 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-09 12:45:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Choi K, Lee SS, Oh SJ, Lim SY, Lim SY, Jeon WK et al</AU>
<TI>The effect of oral glutamine on 5-flurouracil/ leucovorin-induced mucositis/ stomatitis assessed by intestinal permeability test</TI>
<SO>Clinical Nutrition</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>1</NO>
<PG>57-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chor-2010" MODIFIED="2011-02-24 13:55:34 +0000" MODIFIED_BY="[Empty name]" NAME="Chor 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-10-25 10:41:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chor A, Torres SR, Maiolino A, Nucci M</AU>
<TI>Low-power laser to prevent oral mucositis in autologous hematopoietic stem cell transplantation</TI>
<SO>European Journal of Haematology</SO>
<YR>2010</YR>
<VL>84</VL>
<NO>2</NO>
<PG>178-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crawford-1999" MODIFIED="2010-11-09 13:26:25 +0000" MODIFIED_BY="[Empty name]" NAME="Crawford 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-11-09 13:26:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Crawford J, Glaspy J, Vincent M, Tomita D, Mazanet R</AU>
<TI>Effect of filgrastim (r-metHug-CSF) on oral mucositis in patients with small cell lung cancer (SCLC) receiving chemotherapy (cyclophosphamide, doxorubicin and etoposide, CAE)</TI>
<SO>Proceedings of Annual Meeting of American Society Clinical Oncology</SO>
<YR>1994</YR>
<VL>13</VL>
<PG>Abstract A1523</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-04 16:21:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Crawford J, Tomita DK, Mazanet R, Glaspy J, Ozer H</AU>
<TI>Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy</TI>
<SO>Cytokines, Cellular and Molecular Therapy</SO>
<YR>1999</YR>
<VL>5</VL>
<NO>4</NO>
<PG>187-93</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cruz-2007" MODIFIED="2010-11-09 12:46:29 +0000" MODIFIED_BY="[Empty name]" NAME="Cruz 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-09 12:46:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Cruz LB, Ribeiro AS, Rech A, Rosa LG, Castro CG Jr, Brunetto AL et al</AU>
<TI>Influence of low-energy laser in the prevention of oral mucositis in children with cancer receiving chemotherapy</TI>
<SO>Pediatric Blood &amp; Cancer</SO>
<YR>2007</YR>
<VL>48</VL>
<NO>4</NO>
<PG>435-40</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dai-2009" MODIFIED="2010-11-09 12:47:34 +0000" MODIFIED_BY="[Empty name]" NAME="Dai 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-09 12:47:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dai AW, Li ZY, Wang LH, Li SY, Yang H</AU>
<TI>Effect of Yangyin Humo Decoction on oral mucomembranous reaction to radiotherapy</TI>
<SO>Chinese Journal of Integrative Medicine</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>4</NO>
<PG>303-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dazzi-2003" MODIFIED="2010-11-09 13:26:46 +0000" MODIFIED_BY="[Empty name]" NAME="Dazzi 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-11-09 12:47:48 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Dazzi C, Cariello A, Giovanis P, Monti M, Vertogen B, Leoni M, et al. Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double blind, randomized, placebo-controlled study. Annals of Oncology 2003+ADs- 14(4):559-63.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 12:47:48 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dazzi C, Cariello A, Giovanis P, Monti M, Vertogen B, Leoni M et al</AU>
<TI>Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double blind, randomized, placebo-controlled study</TI>
<SO>Annals of Oncology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>4</NO>
<PG>559-63</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 13:26:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dazzi C, Cariello A, Monti M, Giovanis P, Vertogen B, Nanni O et al</AU>
<TI>Prophylaxis with GM-CSF mouthwash does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high dose chemotherapy with autogous PBPC rescue: A double blind randomized placebo-controlled study</TI>
<SO>Annals of Oncology</SO>
<YR>2002</YR>
<VL>13 Suppl 5</VL>
<PG>167 (Abstract 617)</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dickson-2000" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Dickson 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coghlin Dickson TM, Wong RM, Offrin RS, Shizuru JA, Johnston LJ, Hu WW et al</AU>
<TI>Effect of oral glutamine supplementation during bone marrow transplantation</TI>
<SO>Journal of Parenteral and Enteral Nutrition</SO>
<YR>2000</YR>
<VL>24</VL>
<NO>2</NO>
<PG>61-6</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Dodd-1996" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Dodd 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Dodd MJ, Larson PJ, Dibble SL, Miaskowski C, Greenspan D, MacPhail L, Hauck WW, Paul SM, Ignoffo R, Shiba G. Randomised clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncol Nurs Forum 1996;23: 921-7.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:19 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dodd MJ, Larson PJ, Dibble SL, Miaskowski C, Greenspan D, MacPhail L et al</AU>
<TI>Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy</TI>
<SO>Oncological Nursing Forum</SO>
<YR>1996</YR>
<VL>23</VL>
<NO>6</NO>
<PG>921-7</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dorr-2007" MODIFIED="2010-11-09 12:50:08 +0000" MODIFIED_BY="[Empty name]" NAME="Dorr 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-09 12:50:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Dorr W, Herrmann T, Study Group</AU>
<TI>Efficacy of Wobe-Mugos E for reduction of oral mucositis after radiotherapy : results of a prospective, randomized, placebo-controlled, triple-blind phase III multicenter study</TI>
<SO>Strahlentherapie und Onkologie</SO>
<YR>2007</YR>
<VL>183</VL>
<NO>3</NO>
<PG>121-7</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dozono-1989" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Dozono 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dozono H, Nakamura K, Motoya T, Nakamura S, Shinmura R, Miwa K et al</AU>
<TI>Prevention of stomatitis induced by anti-cancer drugs</TI>
<SO>Gan-to-kagaku-ryoho</SO>
<YR>1989</YR>
<VL>16</VL>
<NO>10</NO>
<PG>3449-51</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Duenas-1996" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Duenas 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Duenas Gonzalez A, Sobrevilla Calvo P, Frias Mendivil M, Gallardo Rincon D, Lara Medina F, Aguilar Ponce L, et al. Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomised double-blind study. Bone Marrow Transplant 1996;17: 809-12.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:19 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duenas-Gonzalez A, Sobrevilla-Calvo P, Frias-Mendivil M, Gallardo-Rincon D, Lara-Medina F, Aguilar-Ponce L et al</AU>
<TI>Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>5</NO>
<PG>809-12</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elad-2006" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Elad 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Elad S, Ackerstein A, Bitan M, Shapira MY, Resnick I, Gesundheit B, et al. A prospective, double-blind phase II study evaluating the safety and efficacy of a topical histamine gel for the prophylaxis of oral mucositis in patients post hematopoietic stem cell transplantation. Bone Marrow Transplantation. 2006;37(8):757-62.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:19 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elad S, Ackerstein A, Bitan M, Shapira MY, Resnick I, Gesundheit B et al</AU>
<TI>A prospective, double-blind phase II study evaluating the safety and efficacy of a topical histamine gel for the prophylaxis of oral mucositis in patients post hematopoietic stem cell transplantation</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2006</YR>
<VL>37</VL>
<NO>8</NO>
<PG>757-62</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-El-Sayed-2002" MODIFIED="2011-02-24 13:56:50 +0000" MODIFIED_BY="[Empty name]" NAME="El Sayed 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-11-09 12:50:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duncan GG, Epstein JB, Tu D, El Sayed S, Bezjak A, Ottaway J et al</AU>
<TI>Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis</TI>
<SO>Head &amp; Neck</SO>
<YR>2005</YR>
<VL>27</VL>
<NO>5</NO>
<PG>421-8</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>El-Sayed S, Nabid A, Shelley W, Hay J, Balogh J, Gelinas M et al</AU>
<TI>Prophylaxis of radiation-associated mucositis in conventionally treated patients with head and neck cancer: a double-blind, phase III, randomized, controlled trial evaluating the clinical efficacy of an antimicrobial lozenge using a validated mucositis scoring system</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>19</NO>
<PG>3956-63</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Epstein-1989" MODIFIED="2010-11-09 12:51:07 +0000" MODIFIED_BY="[Empty name]" NAME="Epstein 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-11-09 12:51:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Epstein JB, Stevenson-Moore P, Jackson S, Mohamed JH, Spinelli JJ</AU>
<TI>Prevention of oral mucositis in radiation therapy: a controlled study with benzydamine hydrochloride rinse</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1989</YR>
<VL>16</VL>
<NO>6</NO>
<PG>1571-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Epstein-1994" MODIFIED="2010-11-09 12:51:53 +0000" MODIFIED_BY="[Empty name]" NAME="Epstein 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-11-09 12:51:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Epstein JB, Wong FLW</AU>
<TI>The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1994</YR>
<VL>28</VL>
<NO>3</NO>
<PG>693-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Epstein-2001" MODIFIED="2010-11-09 13:27:16 +0000" MODIFIED_BY="[Empty name]" NAME="Epstein 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-11-09 13:27:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Epstein J, Silverman S Jr, Pagerino D, Lockhart P, Schubert M, Crockett R</AU>
<TI>Benzydamine HCL for prophylaxis of irradiation induced oral mucositis: a randomized double-blind, multicenter study</TI>
<SO>Supportive Care in Cancer</SO>
<YR>1999</YR>
<VL>7</VL>
<PG>Abstract O-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 12:54:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Epstein JB, Silverman S Jr, Paggiarino DA, Crockett S, Schubert MM, Senzer NN et al</AU>
<TI>Benzydamine HCI for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial</TI>
<SO>Cancer</SO>
<YR>2001</YR>
<VL>92</VL>
<NO>4</NO>
<PG>875-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ertekin-2004" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Ertekin 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Ertekin MV, Koc M, Karslioglu I, Sezen O. Zinc sulfate in the prevention of radiation-induced oropharyngeal mucositis: a prospective, placebo-controlled, randomized study. International Journal of Radiation Oncology, Biology, Physics 2004; 58(1):167-74.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:19 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ertekin MV, Koc M, Karslioglu I, Sezen O</AU>
<TI>Zinc sulfate in the prevention of radiation-induced oropharyngeal mucositis: a prospective, placebo-controlled, randomized study</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2004</YR>
<VL>58</VL>
<NO>1</NO>
<PG>167-74</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evensen-2001" MODIFIED="2009-09-15 14:43:49 +0100" MODIFIED_BY="Helen Worthington" NAME="Evensen 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-09-15 14:43:49 +0100" MODIFIED_BY="Helen Worthington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evensen JF, Bjordal K, Jacobsen AB, Lokkevik E, Tausjo JE</AU>
<TI>Effects of Na-sucrose octasulfate on skin and mucosa reactions during radiotherapy of head and neck cancers--a randomized prospective study</TI>
<SO>Acta Oncologica</SO>
<YR>2001</YR>
<VL>40</VL>
<NO>6</NO>
<PG>751-5</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Ferretti-1988" MODIFIED="2010-11-09 13:27:33 +0000" MODIFIED_BY="[Empty name]" NAME="Ferretti 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-11-09 13:27:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferretti G, Largent B, Brown A, Lillich T, Ash R</AU>
<TI>The effect of chlorhexidine mouthrinse on mucositis, plaque, gingivitis and stain in bone marrow transplant patients</TI>
<SO>Journal of Dental Research</SO>
<YR>1985</YR>
<VL>64</VL>
<PG>235 (Abstract 546)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 12:55:54 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Ferretti GA, Largent BM, Ash RC, Kaplan A, Brown AT, Lillich TL. Chlorhexidine for prophylaxis against oral infections and associated complications in patients receiving bone marrow transplants. JADA 1987;114;461-7.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 12:55:54 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferretti GA, Ash RC, Brown AT, Largent BM, Kaplan A, Lillich TT</AU>
<TI>Chlorhexidine for prophylaxis against oral infections and associated complications in patients receiving bone marrow transplants</TI>
<SO>Journal of the American Dental Association</SO>
<YR>1987</YR>
<VL>114</VL>
<NO>4</NO>
<PG>461-7</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Ferretti GA, Ash RC, Brown AT, Parr MD, Romond EH, Lillich TT. Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse. Bone Marrow transplant 1988;3:483-93.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:19 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ferretti GA, Ash RC, Brown AT, Parr MD, Romond EH, Lillich TT</AU>
<TI>Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1988</YR>
<VL>3</VL>
<NO>5</NO>
<PG>483-93</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fidler-1996" MODIFIED="2010-11-09 12:57:06 +0000" MODIFIED_BY="[Empty name]" NAME="Fidler 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-11-09 12:56:38 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Fidler P, Loprinzi CL, O'Fallon JR, Leitch JM, Lee JK, Hayes DL et al. Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis. Cancer 1996;77:522-5.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 12:56:38 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fidler P, Loprinzi CL, O'Fallon JR, Leitch JM, Lee JK, Hayes DL et al</AU>
<TI>Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis</TI>
<SO>Cancer</SO>
<YR>1996</YR>
<VL>77</VL>
<NO>3</NO>
<PG>522-5</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 12:57:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Fidler P, Loprinzi CL, O'Fallon JR, Michalak J, Novotny P, Hayes D</AU>
<TI>A controlled evaluation of chamomile for preventing stomatitis in patients receiving 5-fluorouracil based chemotherapy: A North Central Cancer Treatment Group trial</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>1995</YR>
<VL>14</VL>
<PG>534 (Abstract 1765)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Foote-1994" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Foote 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Foote RL, Loprinzi CL, Frank AR, O'Fallon JR, Gulavita S, Tewfik HH et al</AU>
<TI>Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1994</YR>
<VL>12</VL>
<NO>12</NO>
<PG>2630-3</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Franzen-1995" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Franzen 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Franzen L, Henriksson R, Littbrand B, Zackrisson B</AU>
<TI>Effects of sucralfate on mucositis during and following radiotherapy of malignancies in the head and neck region</TI>
<SO>Acta Oncologica</SO>
<YR>1995</YR>
<VL>34</VL>
<NO>2</NO>
<PG>219-23</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Freytes-2004" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Freytes 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Freytes CO, Ratanatharathorn V, Taylor C, Abboud C, Chesser N, Restrepo A, et al. Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation. Clinical Cancer Research. 2004;10(24):8318-24.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:19 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Freytes CO, Ratanatharathorn V, Taylor C, Abboud C, Chesser N, Restrepo A et al</AU>
<TI>Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation</TI>
<SO>Clinical Cancer Research</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>24</NO>
<PG>8318-24</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gandemer-2007" MODIFIED="2010-11-09 13:27:55 +0000" MODIFIED_BY="[Empty name]" NAME="Gandemer 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-09 12:58:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Gandemer V, Le Deley MC, Dollfus C, Auvrignon A, Bonnaure-Mallet M, Duval M et al</AU>
<TI>Multicenter randomized trial of chewing gum for preventing oral mucositis in children receiving chemotherapy</TI>
<SO>Journal of Pediatric Hematology/Oncology</SO>
<YR>2007</YR>
<VL>29</VL>
<NO>2</NO>
<PG>86-94</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 13:27:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suc A, Gandemer V, Le Deley MC, Schmitt C, Pichard-Leandri E, French Group</AU>
<TI>Gum98: Preventing mucositis with chewing gum in children receiving chemotherapy, a multicentric trial</TI>
<SO>Supportive Care in Cancer</SO>
<YR>1999</YR>
<VL>7S</VL>
<PG>180 (Abstract P-60)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giles-2004" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Giles 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Giles FJ, Rodriguez R, Weisdorf D, Wingard JR, Martin PJ, Fleming TR, et al. A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leukemia Research. 2004;28(6):559-65.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:19 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giles FJ, Rodriguez R, Weisdorf D, Wingard JR, Martin PJ, Fleming TR et al</AU>
<TI>A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy</TI>
<SO>Leukemia Research</SO>
<YR>2004</YR>
<VL>28</VL>
<NO>6</NO>
<PG>559-65</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gori-2007" MODIFIED="2010-11-09 12:58:45 +0000" MODIFIED_BY="[Empty name]" NAME="Gori 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-09 12:58:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Gori E, Arpinati M, Bonifazi F, Errico A, Mega A, Alberani F et al</AU>
<TI>Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2007</YR>
<VL>39</VL>
<NO>6</NO>
<PG>347-52</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goyal-2009" MODIFIED="2010-11-09 12:59:06 +0000" MODIFIED_BY="[Empty name]" NAME="Goyal 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-09 12:59:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Goyal M, Shukla P, Gupta D, Bisht SS, Dhawan A, Gupta S et al</AU>
<TI>Oral mucositis in morning vs. evening irradiated patients: a randomised prospective study</TI>
<SO>International Journal of Radiation Biology</SO>
<YR>2009</YR>
<VL>85</VL>
<NO>6</NO>
<PG>504-9</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gujral-2001" MODIFIED="2010-11-09 13:28:14 +0000" MODIFIED_BY="[Empty name]" NAME="Gujral 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-11-09 13:28:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gujral MS, Patnaik PM, Kaul R, Daftary GV, Parikh HK, Tamhankar CP et al</AU>
<TI>Oral enzymes preventing side effects of radiation therapy in patients with head and neck cancers</TI>
<SO>European Journal of Cancer</SO>
<YR>1999</YR>
<VL>35 Suppl 4</VL>
<PG>168 (Abstract 634)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 13:00:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gujral MS, Patnaik PM, Kaul R, Parikh HK, Conradt C, Tamhankar CP et al</AU>
<TI>Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers</TI>
<SO>Cancer Chemotherapy and Pharmacology</SO>
<YR>2001</YR>
<VL>47 Suppl</VL>
<PG>S23-8</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haddad-2009" MODIFIED="2010-11-09 13:01:35 +0000" MODIFIED_BY="[Empty name]" NAME="Haddad 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-09 13:01:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haddad R, Sonis S, Posner M, Wirth L, Costello R, Braschayko P et al</AU>
<TI>Randomised phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer</TI>
<SO>Cancer</SO>
<YR>2009</YR>
<VL>115</VL>
<NO>19</NO>
<PG>4514-23</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hanson-1995" MODIFIED="2010-11-09 13:02:37 +0000" MODIFIED_BY="[Empty name]" NAME="Hanson 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-11-09 13:02:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hanson WR, Marks JE, Reddy SP, Simon S, Mihalo WE, Tova Y</AU>
<TI>Protection from radiation-induced oral mucositis by a mouth rinse containing the prostaglandin E1 analog, misoprostol: a placebo controlled double blind clinical trial</TI>
<SO>Advances in Experimental Medicine and Biology</SO>
<YR>1997</YR>
<VL>400B</VL>
<PG>811-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 13:02:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hanson WR, Marks JE, Reddy SP, Simon S, Mihalo WE, Tova Y</AU>
<TI>Protection from radiation-induced oral mucositis by misoprostol, a prostaglandin E(1) analog: a placebo-controlled, double-blind clinical trial</TI>
<SO>American Journal of Therapeutics</SO>
<YR>1995</YR>
<VL>2</VL>
<NO>11</NO>
<PG>850-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hartmann-2001" MODIFIED="2010-11-09 13:29:44 +0000" MODIFIED_BY="[Empty name]" NAME="Hartmann 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-11-09 13:29:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hartmann J, von Vangerow A, Knop S, Brugger W, Fels L, Stolte H et al</AU>
<TI>A randomized trial comparing the toxicity and the treatment costs of HD-VIC plus PBSC transplantation with or without amifostine (AMI) in patients with solid tumors</TI>
<SO>European Journal of Cancer</SO>
<YR>1999</YR>
<VL>35 Suppl 4</VL>
<PG>361 (Abstract 1464)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 13:29:05 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Hartmann JT vVA, Fels LM, Knop S, Stolte H, Kanz L, Bokemeyer C. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation. British Journal of Cancer 2001+ADs-84(3):313-20.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 13:29:05 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hartmann JT, von Vangerow A, Fels LM, Knop S, Stolte H, Kanz L et al</AU>
<TI>A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation</TI>
<SO>British Journal of Cancer</SO>
<YR>2001</YR>
<VL>84</VL>
<NO>3</NO>
<PG>313-20</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-He-2008" MODIFIED="2010-11-09 13:03:51 +0000" MODIFIED_BY="[Empty name]" NAME="He 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-11-09 13:03:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>He Y-F, Chen J, Wang G, Sun Y-B, Wang Y, Du J-P et al</AU>
<TI>Randomised controlled trial on application of parenteral alanyl-glutamine dipeptide in chemotherapy of advanced patients with esophageal and cardiac carcinoma</TI>
<SO>Chinese Journal of Cancer Prevention and Treatment</SO>
<YR>2008</YR>
<VL>15</VL>
<NO>12</NO>
<PG>936-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hu-2005" MODIFIED="2010-11-09 13:04:40 +0000" MODIFIED_BY="[Empty name]" NAME="Hu 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-11-09 13:04:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Hu YR, Wu CQ, Liu YJ, Wang Y, Li X, Zhong H et al</AU>
<TI>Clinical observation on effect of shenqi fanghou recipe in preventing and treating radiation injury in patients with head and neck tumor</TI>
<SO>Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>7</NO>
<PG>623-5</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2000" MODIFIED="2010-11-09 13:05:19 +0000" MODIFIED_BY="[Empty name]" NAME="Huang 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-11-09 13:05:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang EY, Leung SW, Wang CJ, Chen HC, Sun LM, Fang FM et al</AU>
<TI>Oral glutamine to alleviate radiation-induced oral mucositis: a pilot randomized trial</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2000</YR>
<VL>46</VL>
<NO>3</NO>
<PG>535-9</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2003" MODIFIED="2010-11-09 13:06:03 +0000" MODIFIED_BY="[Empty name]" NAME="Huang 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-11-09 13:06:03 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Huang GX, Zhao C, Han F, Zhang B, Qiu HJ, Xu BP, et al. [Clinical study in prophylactic use of chinese medicine to prevent chemoradiotherapy induced mucositis in nasopharyngeal carcinoma]. Ai Zheng 2003;22(10):1084-7.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 13:06:03 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang GX, Zhao C, Han F, Zhang B, Qiu HJ, Xu BP et al</AU>
<TI>Clinical study in prophylactic use of chinese medicine to prevent chemoradiotherapy induced mucositis in nasopharyngeal carcinoma</TI>
<SO>Ai Zheng</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>10</NO>
<PG>1084-7</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ifrah-1999" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Ifrah 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Ifrah N WF, Jouet J-P, Francois S, Lamy T, Linassier C, Pignon B, Berthou C, Guyotat D, Cahn J-Y, Harousseau J-L, Briere J, Tellier Z, Desablens B, Lioure B, Caillot D, Cassassus P, Audhuy B. Intensive short term therapy with granulocyte-macrophage-colony stimulating factor support, similar to therapy for acute myeloblastic leukemia, does not improve overall results for adults with acute lymphoblastic leukemia. Cancer 1999+ADs-86(8):1496-1505.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:19 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ifrah N, Witz F, Jouet JP, Francois S, Lamy T, Linassier C et al</AU>
<TI>Intensive short term therapy with granulocyte-macrophage-colony stimulating factor support, similar to therapy for acute myeloblastic leukemia, does not improve overall results for adults with acute lymphoblastic leukemia</TI>
<SO>American Cancer Society</SO>
<YR>1999</YR>
<VL>86</VL>
<NO>8</NO>
<PG>1496-505</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Jebb-1994" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Jebb 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Jebb SA, Osborne RJ, Maughan TS, Mohideen N, Mack P, Mort D et al. 5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation. Br J Cancer 1994;70:732-5.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:19 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jebb SA, Osborne RJ, Maughan TS, Mohideen N, Mack P, Mort D et al</AU>
<TI>5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation</TI>
<SO>British Journal of Cancer</SO>
<YR>1994</YR>
<VL>70</VL>
<NO>4</NO>
<PG>732-5</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katano-1995" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Katano 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Katano M, Nakamura M, Matsuo T, Iyama A, Hisatsugu T</AU>
<TI>Effect of granulocyte colony-stimulating factor (G-CSF) on chemotherapy-induced oral mucositis</TI>
<SO>Surgery Today</SO>
<YR>1995</YR>
<VL>25</VL>
<NO>3</NO>
<PG>202-6</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaul-1999" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Kaul 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kaul R, Mishra BK, Sutradar P, Choudhary V, Gujral MS</AU>
<TI>The role of Wobe-Mugos in reducing acute sequele of radiation in head and neck cancers - a clinical phase-III randomized trial</TI>
<SO>Indian Journal of Cancer</SO>
<YR>1999</YR>
<VL>36</VL>
<NO>2-4</NO>
<PG>141-8</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaul RVC</AU>
<TI>To evaluate the effect of Wobe mugos hydrolytic enzyme therapy on inflammation induced by external radiotherapy in patients of head and neck cancers</TI>
<SO>Bahrain Medical Bulletin</SO>
<YR>2001</YR>
<VL>23</VL>
<NO>3</NO>
<PG>116-8</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kazemian-2009" MODIFIED="2009-08-06 14:11:27 +0100" MODIFIED_BY="[Empty name]" NAME="Kazemian 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-08-06 14:11:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Kazemian A, Kamian S, Aghili M, Hashemi FA, Haddad P</AU>
<TI>Benzydamine for prophylaxis of radiation-induced oral mucositis in head and neck cancers: a double-blind placebo-controlled randomized clinical trial</TI>
<SO>European Journal of Cancer Care</SO>
<YR>2009</YR>
<VL>18</VL>
<NO>2</NO>
<PG>174-8</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koukourakis-2000" MODIFIED="2010-11-09 13:07:01 +0000" MODIFIED_BY="[Empty name]" NAME="Koukourakis 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-11-09 13:07:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koukourakis MI, Kyrias G, Kakolyris S, Kouroussis C, Frangiadaki C, Giatromanolaki A et al</AU>
<TI>Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>11</NO>
<PG>2226-33</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Labar-1993" MODIFIED="2010-11-09 13:07:47 +0000" MODIFIED_BY="[Empty name]" NAME="Labar 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-11-09 13:07:32 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Labar B, Mrsic M, Pavletic Z, Bogdanic V, Nemet D, Aurer I et al. Prostaglandin E2 for prophylaxis of oral mucositis following BMT. Bone Marrow Transplant 1993;11:379-82.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 13:07:32 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Labar B, Mrsic M, Pavletic Z, Bogdanic V, Nemet D, Aurer I et al</AU>
<TI>Prostaglandin E2 for prophylaxis of oral mucositis following BMT</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1993</YR>
<VL>11</VL>
<NO>5</NO>
<PG>379-82</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 13:07:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Labar B, Pavletic Z, Bogdanic V, Nemet D, Aurer I, Jakie J</AU>
<TI>Prostaglandin E2 for prevention of oral mucositis in patients with leukaemia undergoing bone marrow transplantation: a randomized double-blind clinical trial</TI>
<SO>Experimental Hematology</SO>
<YR>1990</YR>
<VL>18</VL>
<PG>700</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Leborgne-1997" MODIFIED="2010-05-13 14:30:38 +0100" MODIFIED_BY="[Empty name]" NAME="Leborgne 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leborgne JH, Leborgne F, Zubizarreta E, Ortega B, Mezzera J</AU>
<TI>Corticosteroids and radiation mucositis in head and neck cancer. A double-blind placebo-controlled randomized trial</TI>
<SO>Radiotherapy and Oncology</SO>
<YR>1997</YR>
<VL>47</VL>
<NO>2</NO>
<PG>145-8</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2006" MODIFIED="2009-07-31 16:08:34 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-31 16:08:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Li Y, Yu Z, Liu F, Tan L, Wu B, Li J</AU>
<TI>Oral glutamine ameliorates chemotherapy-induced changes of intestinal permeability and does not interfere with the antitumor effect of chemotherapy in patients with breast cancer: a prospective randomized trial</TI>
<SO>Tumori</SO>
<YR>2006</YR>
<VL>92</VL>
<NO>5</NO>
<PG>396-401</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lievens-1998" MODIFIED="2010-11-09 13:08:14 +0000" MODIFIED_BY="[Empty name]" NAME="Lievens 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-11-09 13:08:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lievens Y, Haustermans K, van den Weyngaert D, van den Bogaert W, Scalliet P, Hutsebaut L et al</AU>
<TI>Does sucralfate reduce the acute side-effects in head and neck cancer treated with radiotherapy? A double-blind randomized trial</TI>
<SO>Radiotherapy and Oncology</SO>
<YR>1998</YR>
<VL>47</VL>
<NO>2</NO>
<PG>149-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lilleby-2006" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Lilleby 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Lilleby K, Garcia P, Gooley T, McDonnnell P, Taber R, Holmberg L, et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation. 2006;37(11):1031-5.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:19 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lilleby K, Garcia P, Gooley T, McDonnnell P, Taber R, Holmberg L et al</AU>
<TI>A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2006</YR>
<VL>37</VL>
<NO>11</NO>
<PG>1031-5</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2006" MODIFIED="2010-11-09 13:10:10 +0000" MODIFIED_BY="[Empty name]" NAME="Lin 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-09 13:09:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin J, Wang X, Fan Z</AU>
<TI>A study on quantizing evaluation on stomatitis of malignant tumor patients undergoing large dose of chemotherapy</TI>
<SO>Chinese Nursing Research</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>2A</NO>
<PG>328-9</PG>
<IDENTIFIERS MODIFIED="2010-11-09 13:09:34 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 13:10:10 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Lin LC, Que J, Lin LK, Lin FC. Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study. International Journal of Radiation Oncology, Biology, Physics. 2006;65(3):745-50.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 13:10:10 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lin LC, Que J, Lin LK, Lin FC</AU>
<TI>Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2006</YR>
<VL>65</VL>
<NO>3</NO>
<PG>745-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lockhart-2005" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Lockhart 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Lockhart PB, Brennan MT, Kent ML, Packman CH, Norton HJ, Fox PC, et al. Randomized controlled trial of pilocarpine hydrochloride for the moderation of oral mucositis during autologous blood stem cell transplantation. Bone Marrow Transplantation. 2005;35(7):713-20.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:19 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lockhart PB, Brennan MT, Kent ML, Packman CH, Norton HJ, Fox PC et al</AU>
<TI>Randomized controlled trial of pilocarpine hydrochloride for the moderation of oral mucositis during autologous blood stem cell transplantation</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2005</YR>
<VL>35</VL>
<NO>7</NO>
<PG>713-20</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Loprinzi-1990" MODIFIED="2010-11-09 13:11:09 +0000" MODIFIED_BY="[Empty name]" NAME="Loprinzi 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-11-09 13:10:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dose AM, Loprinzi CL, Cianflone S, Etzell P, Burnham N, Therneau T</AU>
<TI>A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis. A North Central Cancer Treatment Group and Mayo clinic study</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>1989</YR>
<VL>8</VL>
<PG>341 (Abstract 1328)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 13:11:09 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Loprinzi CL, Cainflone SG, Dose AM, Etzell PS, Burnham NL, Therneau TM et al. A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouacil-induced stomatitis. Cancer 1990;65:1879-82.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 13:11:09 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Loprinzi CL, Cainflone SG, Dose AM, Etzell PS, Burnham NL, Therneau TM et al</AU>
<TI>A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis</TI>
<SO>Cancer</SO>
<YR>1990</YR>
<VL>65</VL>
<NO>8</NO>
<PG>1879-82</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Madan-2008" MODIFIED="2010-11-09 13:11:22 +0000" MODIFIED_BY="[Empty name]" NAME="Madan 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-11-09 13:11:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Madan PD, Sequeira PS, Shenoy K, Shetty J</AU>
<TI>The effect of three mouthwashes on radiation-induced oral mucositis in patients with head and neck malignancies: a randomized control trial</TI>
<SO>Journal of Cancer Research and Therapeutics</SO>
<YR>2008</YR>
<VL>4</VL>
<NO>1</NO>
<PG>3-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahood-1991" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Mahood 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Mahood DJ, Dose AM, Loprinzi CL, Veeder MH, Athmann LM, Thereau TM et al. Inhibitation of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol 1991;9:449-52.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:19 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mahood DJ, Dose AM, Loprinzi CL, Veeder MH, Athmann LM, Thereau TM et al</AU>
<TI>Inhibition of fluorouracil-induced stomatitis by oral cryotherapy</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1991</YR>
<VL>9</VL>
<NO>3</NO>
<PG>449-52</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Makkonen-1994" MODIFIED="2010-11-09 13:11:49 +0000" MODIFIED_BY="[Empty name]" NAME="Makkonen 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-11-09 13:11:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Makkonen TA, Bostrom P, Vilja P, Joensuu H</AU>
<TI>Sucralfate mouth washing in the prevention of radiation-induced mucositis: A placebo-controlled double-blind randomized study</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1994</YR>
<VL>30</VL>
<NO>1</NO>
<PG>177-82</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Makkonen-2000" MODIFIED="2010-11-09 13:12:59 +0000" MODIFIED_BY="[Empty name]" NAME="Makkonen 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-11-09 13:12:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Makkonen TA, Minn H, Jekunen A, Vilja P, Tuominen J, Joeensuu H</AU>
<TI>Granulocyte Macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2000</YR>
<VL>46</VL>
<NO>3</NO>
<PG>525-34</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 13:12:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Minn HR, Makkonen TA, Jekunen A, Vilja P, Tuominen J, Joensuu H</AU>
<TI>Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1999</YR>
<VL>45 Suppl 3</VL>
<PG>239</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McAleese-2006" MODIFIED="2010-11-09 13:13:31 +0000" MODIFIED_BY="[Empty name]" NAME="McAleese 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-09 13:13:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McAleese JJ, Bishop KM, A'Hern R, Henk JM</AU>
<TI>Randomized phase II study of GM-CSF to reduce mucositis caused by accelerated radiotherapy of laryngeal cancer</TI>
<SO>The British Journal of Radiology</SO>
<YR>2006</YR>
<VL>79</VL>
<NO>943</NO>
<PG>608-13</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McGaw-1985" MODIFIED="2010-11-09 13:14:14 +0000" MODIFIED_BY="[Empty name]" NAME="McGaw 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-11-09 13:14:14 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;McGaw WT, Belch A. Oral complications of acute leukemia: prophylactic impact of a chlorhexidine mouthrinse regimen. Oral Surg Oral Med Oral Pathol 1985;60:275-80.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 13:14:14 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McGaw WT, Belch A</AU>
<TI>Oral complications of acute leukemia: prophylactic impact of a chlorhexidine mouth rinse regimen</TI>
<SO>Oral Surgery, Oral Medicine, and Oral Pathology</SO>
<YR>1985</YR>
<VL>60</VL>
<NO>3</NO>
<PG>275-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meropol-2003" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Meropol 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Meropol NJ, Somer RA, Gutheil J, Pelley RJ, Modiano MR, Rowinsky EK, et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant.+AFs-comment+AF0-. Journal of Clinical Oncology 2003+ADs- 21(8):1452-8.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:19 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meropol NJ, Somer RA, Gutheil J, Pelley RJ, Modiano MR, Rowinsky EK et al</AU>
<TI>Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>8</NO>
<PG>1452-8</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mills-1988" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Mills 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mills EE</AU>
<TI>The modifying effect of beta-carotene on radiation and chemotherapy induced oral mucositis</TI>
<SO>British Journal of Cancer</SO>
<YR>1988</YR>
<VL>57</VL>
<NO>4</NO>
<PG>416-7</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Motallebnejad-2008" MODIFIED="2010-11-09 13:14:39 +0000" MODIFIED_BY="[Empty name]" NAME="Motallebnejad 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-11-09 13:14:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Motallebnejad M, Akram S, Moghadamnia A, Moulana Z, Omidi S</AU>
<TI>The effect of topical application of pure honey on radiation-induced mucositis: a randomized clinical trial</TI>
<SO>The Journal of Contemporary Dental Practice</SO>
<YR>2008</YR>
<VL>9</VL>
<NO>3</NO>
<PG>40-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nemunaitis-1995" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Nemunaitis 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nemunaitis J, Rosenfeld CS, Ash R, Freedman MH, Deeg HJ, Appelbaum F et al</AU>
<TI>Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>6</NO>
<PG>949-54</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nottage-2003" MODIFIED="2010-11-09 13:14:50 +0000" MODIFIED_BY="[Empty name]" NAME="Nottage 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-11-09 13:14:50 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Nottage M, McLachlan SA, Brittain MA, Oza A, Hedley D, Feld R, et al. Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial. Supportive Care in Cancer 2003+ADs- 11(1):41-7.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 13:14:50 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nottage M, McLachlan SA, Brittain MA, Oza A, Hedley D, Feld R et al</AU>
<TI>Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2003</YR>
<VL>11</VL>
<NO>1</NO>
<PG>41-7</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oberbaum-2001" MODIFIED="2010-11-08 12:26:08 +0000" MODIFIED_BY="[Empty name]" NAME="Oberbaum 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Oberbaum M, Yaniv I, Ben-Gal Y, Stein J, Ben-Zvi N, Freedman LS et al</AU>
<TI>A randomized, controlled clinical trial of the homeopathic medication TRAUMEEL S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation</TI>
<SO>American Cancer Society</SO>
<YR>2001</YR>
<VL>92</VL>
<NO>3</NO>
<PG>684-90</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Oberbaum MYIB-GYSJZNFLBD. A randomized, controlled clinical trial of the homoeopathic medication Traumeel S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation. Biologische Medizin 2002+ADs- Vol 31(1): 25-31.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:19 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oberbaum M, Yaniv I, Ben-Gal Y, Stein J, Ben-Zvi N, Freedman LS et al</AU>
<TI>A randomized, controlled clinical trial of the homoeopathic medication Traumeel S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation</TI>
<SO>Biologische Medizin</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>25-31</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Okuno-1999" MODIFIED="2010-11-09 13:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Okuno 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-11-05 08:32:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Okuno SH, Swan L, Ebbert C</AU>
<TI>Phase III placebo-controlled clinical trial evaluation of glutamine for decreasing mucositis in patients receiving 5 FU (Fluorouracil)-based chemotherapy</TI>
<SO>Proceedings of the Annual Meeting of the American Society of Clinical Oncology</SO>
<YR>1998</YR>
<PG>256</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 13:16:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Okuno SH, Woodhouse CO, Loprinzi CL, Sloan JA, LaVasseur BI, Clemens-Schutjer D et al</AU>
<TI>Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy</TI>
<SO>American Journal of Clinical Oncology</SO>
<YR>1999</YR>
<VL>22</VL>
<NO>3</NO>
<PG>258-61</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Panahi-2009" MODIFIED="2010-11-09 13:17:30 +0000" MODIFIED_BY="[Empty name]" NAME="Panahi 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-09 13:17:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Panahi Y, Ala S, Saeedi M, Okhovatian A, Bazzaz N, Naghizadeh MM</AU>
<TI>Allopurinol mouth rinse for prophylaxis of fluorouracil-induced mucositis</TI>
<SO>European Journal of Cancer Care</SO>
<YR>2010</YR>
<VL>19</VL>
<NO>3</NO>
<PG>308-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peterson-2009" MODIFIED="2010-11-09 13:31:28 +0000" MODIFIED_BY="[Empty name]" NAME="Peterson 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-09 13:31:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barker NP, Peterson DE, Akhmadullina LI, Rodionova I, Sherman NZ, Gertner JM et al</AU>
<TI>Prophylaxis of recurrent chemotherapy-induced oral mucositis: a phase II multicenter, randomized, placebo-controlled trial of recombinant human intestinal trefoil factor (rhITF)</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<PG>505 (Abstract 9514)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 13:21:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Peterson DE, Barker NP, Akhmadullina LI, Rodionova I, Sherman NZ, Davidenko IS et al</AU>
<TI>Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>26</NO>
<PG>4333-8</PG>
<IDENTIFIERS MODIFIED="2010-11-04 16:32:59 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pfeiffer-1990" MODIFIED="2010-11-09 13:23:41 +0000" MODIFIED_BY="[Empty name]" NAME="Pfeiffer 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-11-09 13:22:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pfeiffer P, Hansen SO, Madsen EL, May O</AU>
<TI>Sucralfate prophylaxis of chemotherapy-induced stomatitis</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>1989</YR>
<VL>8</VL>
<PG>171 (Abstract 665)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 13:23:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pfeiffer P, Madsen EL, Hansen O, May O</AU>
<TI>Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy</TI>
<SO>Acta Oncologica</SO>
<YR>1990</YR>
<VL>29</VL>
<NO>2</NO>
<PG>171-3</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pillsbury-1986" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Pillsbury 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Pillsbury HC 3rd WW, Rosenman J. Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers. Archives of Otolaryngology -- Head &amp;amp; Neck Surgery 1986;112(5):552-3.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:19 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pillsbury HC 3rd, Webster WP, Rosenman J</AU>
<TI>Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers</TI>
<SO>Archives of Otolaryngology - Head &amp; Neck Surgery</SO>
<YR>1986</YR>
<VL>112</VL>
<NO>5</NO>
<PG>552-3</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pitten-2003" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Pitten 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Pitten FA, Kiefer T, Buth C, Doelken G, Kramer A. Do cancer patients with chemotherapy-induced leukopenia benefit from an antiseptic chlorhexidine-based oral rinse? A double-blind, block-randomized, controlled study. Journal of Hospital Infection 2003+ADs- 53(4):283-91.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:19 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pitten FA, Kiefer T, Buth C, Doelken G, Kramer A</AU>
<TI>Do cancer patients with chemotherapy-induced leukopenia benefit from an antiseptic chlorhexidine-based oral rinse? A double-blind, block-randomized, controlled study</TI>
<SO>Journal of Hospital Infection</SO>
<YR>2003</YR>
<VL>53</VL>
<NO>4</NO>
<PG>283-91</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prada-1987" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Prada 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prada A, Chiesa F</AU>
<TI>Effects of benzydamine on the oral mucositis during antineoplastic radiotherapy and/or intra-arterial chemotherapy</TI>
<SO>International Journal of Tissue Reaction</SO>
<YR>1987</YR>
<VL>9</VL>
<NO>2</NO>
<PG>115-9</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Puataweepong-2009" MODIFIED="2012-04-26 13:45:52 +0100" MODIFIED_BY="[Empty name]" NAME="Puataweepong 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-04-26 13:45:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Puataweepong P, Dhanachai M, Dangprasert S, Sithatani C, Sawangsilp T, Narkwong L et al</AU>
<TI>The efficacy of oral aloe vera for radiation induced mucositis in head and neck cancer patients: a double-blind placebo controlled study</TI>
<SO>Asian Biomedicine</SO>
<YR>2009</YR>
<VL>3</VL>
<NO>4</NO>
<PG>375-82</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qin-2007" MODIFIED="2010-11-09 13:33:44 +0000" MODIFIED_BY="[Empty name]" NAME="Qin 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-09 13:33:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qin WJ, Luo W, Lin SR, Sun Y, Li FM, Liu XQ et al</AU>
<TI>Sparing normal oral tissues with individual dental stent in radiotherapy for primary nasopharyngeal carcinoma patients</TI>
<SO>Ai Zheng</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>3</NO>
<PG>285-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rahn-1997" MODIFIED="2010-11-09 13:35:51 +0000" MODIFIED_BY="[Empty name]" NAME="Rahn 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-11-09 13:34:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adamietz IA, Rahn R, Bottcher HD, Reimer K, Fleischer W</AU>
<TI>Prophylaxis of radiation induced oral mucositis with povidone iodine</TI>
<SO>Supportive Care in Cancer</SO>
<YR>1997</YR>
<VL>5 Suppl</VL>
<PG>165 (Abstract 48)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 13:35:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adamietz IA, Rahn R, Bottcher HD, Schafer V, Reimer K, Fleischer W</AU>
<TI>Prophylaxis of radiochemotherapy-induced mucositis. Efficacy of prophylactic oral rinsing with povidone iodine solution</TI>
<SO>Stranhlentherapie und Onkologie</SO>
<YR>1998</YR>
<VL>174</VL>
<NO>3</NO>
<PG>149-55</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adamietz IA, Rhan R, Bottcher HD, Schafer V, Reimer K, Fleischer W</AU>
<TI>Prophylaxis with povidone-iodine against induction of oral mucositis by radiochemotherapy</TI>
<SO>Supportive Care in Cancer</SO>
<YR>1998</YR>
<VL>6</VL>
<NO>4</NO>
<PG>373-7</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rahn R AI, Bottcher HD, Reimer K, and Fleischer W</AU>
<TI>PVP-iodine solution as a mucositis prophylaxis by radiotherapy</TI>
<SO>Deutsche Zeitschrift fur Mund-, Kiefer- und Gesichtschirurgie</SO>
<YR>1996</YR>
<VL>20</VL>
<NO>3</NO>
<PG>137-9</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 13:35:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rahn R, Adamietz IA, Boettcher HD, Schaefer V, Reimer K, Fleischer W</AU>
<TI>Povidone-iodine to prevent mucositis in patients during antineoplastic radiochemotherapy</TI>
<SO>Dermatology</SO>
<YR>1997</YR>
<VL>195 Suppl 2</VL>
<PG>57-61</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rashad-2008" MODIFIED="2010-11-09 13:36:24 +0000" MODIFIED_BY="[Empty name]" NAME="Rashad 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-11-09 13:36:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Rashad UM, Al-Gezawy SM, El-Gezawy E, Azzaz AN</AU>
<TI>Honey as topical prophylaxis against radiochemotherapy-induced mucositis in head and neck cancer</TI>
<SO>The Journal of Laryngology and Otology</SO>
<YR>2009</YR>
<VL>123</VL>
<NO>2</NO>
<PG>223-8</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rocke-1993" MODIFIED="2010-11-09 13:36:47 +0000" MODIFIED_BY="[Empty name]" NAME="Rocke 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-11-09 13:36:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dose AM, Mahood D, Loprinzi CL, Gainey D, Sorensen JM, Therneau T</AU>
<TI>A controlled trial of oral cryotherapy for preventing stomatitis in patients receiving 5- fluorouracil (5FU) plus leucovorin (LV). A North Central Cancer Treatment Group and Mayo Clinic study</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>1990</YR>
<VL>9</VL>
<PG>321 (Abstract 1242)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-04 16:28:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rocke LK, Loprinzi CL, Lee JK, Kunselman SJ, Iverson RK, Finck G et al</AU>
<TI>A randomized clinical trial of two different durations or oral cryotherapy for prevention of 5-fluorouracil-related stomatitis</TI>
<SO>Cancer</SO>
<YR>1993</YR>
<VL>72</VL>
<NO>7</NO>
<PG>2234-8</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosen-2006" MODIFIED="2010-11-09 13:37:20 +0000" MODIFIED_BY="[Empty name]" NAME="Rosen 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-09 13:37:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Rosen LS, Abdi E, Davis ID, Gutheil J, Schnell FM, Zalcberg J et al</AU>
<TI>Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>33</NO>
<PG>5194-200</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saarilahti-2002" MODIFIED="2010-11-09 13:38:00 +0000" MODIFIED_BY="[Empty name]" NAME="Saarilahti 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-11-09 13:38:00 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Saarilahti K KM, Joensuu T, Kouri M, Joensuu H. Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized phase III study. International Journal of Radiation Oncology, Biology, Physics 2002+ADs-54(2):479-85.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 13:38:00 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saarilahti K, Kajanti M, Joensuu T, Kouri M, Joensuu H</AU>
<TI>Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized phase III study</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2002</YR>
<VL>54</VL>
<NO>2</NO>
<PG>479-85</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scarantino-2006" MODIFIED="2010-11-09 13:39:03 +0000" MODIFIED_BY="[Empty name]" NAME="Scarantino 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-04 17:51:59 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Scarantino C, LeVeque F, Swann RS, White R, Schulsinger A, Hodson DI, et al. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients. The Journal of Supportive Oncology. 2006;4(5):252-8.&lt;/p&gt;" NOTES_MODIFIED="2010-11-04 17:51:59 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Scarantino C, LeVeque F, Swann RS, White R, Schulsinger A, Hodson DI et al</AU>
<TI>Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients</TI>
<SO>The Journal of Supportive Oncology</SO>
<YR>2006</YR>
<VL>4</VL>
<NO>5</NO>
<PG>252-8</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 13:38:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Scarantino CW, LeVeque FG, Scott CB, White RL, Rotman M, Hodson DI</AU>
<TI>A phase III study of concomitant oral pilocarpine to reduce hypo-salivation and mucositis associated with curative radiation therapy (RT) in head and neck (H&amp;N) cancer patients. RTOG 9709</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>2001</YR>
<PG>Abstract 897</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 13:39:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scarantino CW, Leveque F, Scott C, White RL, Rotman M, Hodson DI</AU>
<TI>A Phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97-09</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2001</YR>
<VL>51</VL>
<NO>3 Suppl 1</NO>
<PG>85-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scherlacher-1990" MODIFIED="2010-11-09 13:39:24 +0000" MODIFIED_BY="[Empty name]" NAME="Scherlacher 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-11-09 13:39:24 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Scherlacher A B-SF. [Radiotherapy of head-neck neoplasms: prevention of inflammation of the mucosa by sucralfate treatment]. [German]. HNO 1990;38(1):24-8.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 13:39:24 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scherlacher A, Beaufort-Spontin F</AU>
<TI>Radiotherapy of head-neck neoplasms: prevention of inflammation of the mucosa by sucralfate treatment</TI>
<SO>HNO</SO>
<YR>1990</YR>
<VL>38</VL>
<NO>1</NO>
<PG>24-8</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schneider-1999" MODIFIED="2010-11-09 13:39:42 +0000" MODIFIED_BY="[Empty name]" NAME="Schneider 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-11-09 13:39:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneider SB, Nishimura RD, Zimmerman RP, Tran L, Shiplacoff J, Tormey M et al</AU>
<TI>Filgrastim (r-metHuG-CSF) and its potential use in the reduction of radiation-induced oropharyngeal mucositis: an interim look at a randomized, double blind, placebo-controlled trial</TI>
<SO>Cytokines, Cellular and Molecular Therapy</SO>
<YR>1999</YR>
<VL>5</VL>
<NO>3</NO>
<PG>175-80</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schubert-2007" MODIFIED="2010-11-09 13:40:01 +0000" MODIFIED_BY="[Empty name]" NAME="Schubert 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-09 13:40:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Schubert MM, Eduardo FP, Guthrie KA, Franquin JC, Bensadoun RJ, Migliorati CA et al</AU>
<TI>A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2007</YR>
<VL>15</VL>
<NO>10</NO>
<PG>1145-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Shenep-1988" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Shenep 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Shenep JL, Kalwinsky DK, Hutson PR, George SL, Dodge RK, Blankenship KR et al. Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositis. J Pediatr 1988;113:758-63.&lt;/p&gt;&lt;p&gt;[published erratum appears in J Paediatr 1989 May; 114(5):900]&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:19 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shenep JL, Kalwinsky DK, Hutson PR, George SL, Dodge RK, Blankenship KR et al</AU>
<TI>Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositis</TI>
<SO>Journal of Pediatrics</SO>
<YR>1988</YR>
<VL>113</VL>
<NO>4</NO>
<PG>758-63</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shieh-1997" MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" NAME="Shieh 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shieh SH, Wang ST, Tsai ST, Tseng CC</AU>
<TI>Mouth care for nasopharyngeal cancer patients undergoing radiotherapy</TI>
<SO>Oral Oncology</SO>
<YR>1997</YR>
<VL>33</VL>
<NO>1</NO>
<PG>36-41</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sorensen-2008" MODIFIED="2010-11-09 13:41:33 +0000" MODIFIED_BY="[Empty name]" NAME="Sorensen 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-11-09 13:41:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sorensen J, Skovsgaard T, Bork E, Damstrup L, Ingeberg S</AU>
<TI>Double blind, placebo-controlled randomized study of chlorhexidine prophylaxis for chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy)</TI>
<SO>Journal of Clinical Oncology : ASCO annual meeting proceedings</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>18S Part I</NO>
<PG>470</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 13:41:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Sorensen JB, Skovsgaard T, Bork E, Damstrup L, Ingeberg S</AU>
<TI>Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies</TI>
<SO>Cancer</SO>
<YR>2008</YR>
<VL>112</VL>
<NO>7</NO>
<PG>1600-6</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sornsuvit-2008" MODIFIED="2010-11-09 13:41:52 +0000" MODIFIED_BY="[Empty name]" NAME="Sornsuvit 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-11-09 13:41:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Sornsuvit C, Komindr S, Chuncharunee S, Wanikiat P, Archararit N, Santanirand P</AU>
<TI>Pilot Study: effects of parenteral glutamine dipeptide supplementation on neutrophil functions and prevention of chemotherapy-induced side-effects in acute myeloid leukaemia patients</TI>
<SO>The Journal of International Medical Research</SO>
<YR>2008</YR>
<VL>36</VL>
<NO>6</NO>
<PG>1383-91</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spencer-2005" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Spencer 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Spencer A, Horvath N, Gibson J, Prince HM, Herrmann R, Bashford J, et al. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplantation. 2005;35(10):971-7.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spencer A, Horvath N, Gibson J, Prince HM, Herrmann R, Bashford J et al</AU>
<TI>Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2005</YR>
<VL>35</VL>
<NO>10</NO>
<PG>971-7</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spielberger-2004" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Spielberger 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al</AU>
<TI>Palifermin for oral mucositis after intensive therapy for hematologic cancers</TI>
<SO>The New England Journal of Medicine</SO>
<YR>2004</YR>
<VL>351</VL>
<NO>25</NO>
<PG>2590-8</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spijkervet-1989" MODIFIED="2010-11-09 13:42:38 +0000" MODIFIED_BY="[Empty name]" NAME="Spijkervet 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-11-09 13:42:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spijkervet FK, van Saene HK, Panders AK, Vermey A, van Saene JJ, Mehta DM et al</AU>
<TI>Effect of chlorhexidine rinsing on the oropharyngeal ecology in patients with head and neck cancer who have irradiation mucositis</TI>
<SO>Oral Surgery, Oral Medicine, and Oral Pathology</SO>
<YR>1989</YR>
<VL>67</VL>
<NO>2</NO>
<PG>154-61</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stokman-2003" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Stokman 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stokman MA, Spijkervet FK, Burlage FR, Dijkstra PU, Manson WL, de Vries EG et al</AU>
<TI>Oral mucositis and selective elimination of oral flora in head and neck cancer patients receiving radiotherapy: a double-blind randomised clinical trial</TI>
<SO>British Journal of Cancer</SO>
<YR>2003</YR>
<VL>88</VL>
<NO>7</NO>
<PG>1012-6</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Su-2004" MODIFIED="2011-02-24 14:01:18 +0000" MODIFIED_BY="[Empty name]" NAME="Su 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-11-05 08:48:23 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Su C, Mehta, V, Ravikumar, L, Shah, R, Pinto, H, Halpern, J, Koong, A, Goffinet, D, and Le, Q-T. Phase II double-blind randomized study comparing oral aloe vera (AV) versus placebo to prevent radiation (RT)-related mucositis in patients with head and neck (HN) neoplasms. Proceedings of ASCO. 2003 2003.&lt;/p&gt;" NOTES_MODIFIED="2010-11-05 08:48:23 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Su C, Mehta V, Ravikumar L, Shah R, Pinto H, Halpern J et al</AU>
<TI>Phase II double-blind randomized study comparing oral aloe vera (AV) versus placebo to prevent radiation (RT)-related mucositis in patients with head and neck (HN) neoplasms</TI>
<SO>Proceedings of the Amercian Society of Clinical Oncology</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 13:44:50 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Su C, Mehta, V, Ravikumar, L, Shah, R, Pinto, H, Halpern, J, Koong, A, Goffinet, D, and Le, Q-T. Phase II double-blind randomized study comparing oral aloe vera (AV) versus placebo to prevent radiation (RT)-related mucositis in patients with head and neck (HN) neoplasms. Proceedings of ASCO 2003.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 13:44:50 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Su C, Mehta V, Ravikumar L, Shah R, Pinto H, Halpern J et al</AU>
<TI>Phase II double-blind randomized study comparing oral aloe vera versus placebo to prevent radiation-related mucositis in patients with head-and-neck neoplasms</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2004</YR>
<VL>60</VL>
<NO>1</NO>
<PG>171-7</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Su-2006" MODIFIED="2010-11-09 13:45:51 +0000" MODIFIED_BY="[Empty name]" NAME="Su 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-09 13:45:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Su YB, Vickers AJ, Zelefsky MJ, Kraus DH, Shaha AR, Shah JP et al</AU>
<TI>Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor during postoperative radiotherapy for squamous head and neck cancer</TI>
<SO>Cancer Journal</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>3</NO>
<PG>182-8</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 13:45:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Su YB</AU>
<TI>Double-blind, randomized trial of granulocyte-colony stimulating factor (GCSF) versus (v.) placebo during postoperative radiation (RT) for advanced resectable squamous cell head and neck cancer (SCCHN): impact on mucositis</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22 Suppl</VL>
<PG>14S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svanberg-2007" MODIFIED="2010-11-09 13:47:09 +0000" MODIFIED_BY="[Empty name]" NAME="Svanberg 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-09 13:46:33 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Svanberg A, &amp;#214;hrn K. Cryotherapy during chemotherapy - could it delay or alleviate the development of mucositis? [abstract]. Bone Marrow Transplantation. 2004;33(Suppl 1):S292.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 13:46:33 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svanberg A, hrn K</AU>
<TI>Cryotherapy during chemotherapy - could it delay or alleviate the development of mucositis?</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2004</YR>
<VL>33 Suppl 1</VL>
<PG>S292</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 13:47:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Svanberg A, Birgegard G, Ohrn K</AU>
<TI>Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy--a randomized controlled trial</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2007</YR>
<VL>15</VL>
<NO>10</NO>
<PG>1155-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Symonds-1996" MODIFIED="2010-11-04 14:45:10 +0000" MODIFIED_BY="[Empty name]" NAME="Symonds 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-11-04 14:45:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Symonds RP, McIlroy P, Khorrami J, Pyper E, Alcock SR, McCallum I et al</AU>
<TI>The reduction of radiation mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial</TI>
<SO>British Journal of Cancer</SO>
<YR>1996</YR>
<VL>74</VL>
<NO>2</NO>
<PG>312-7</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-04 14:44:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Symonds RP, Thomas M, Alcock SR, Khorrami J, McEllroy P, McMuray A</AU>
<TI>The reduction of radiation mucositis by antibiotic pastilles: a placebo-controlled double-blind trial</TI>
<SO>European Journal Surgery Oncology</SO>
<YR>1995</YR>
<VL>21</VL>
<PG>447</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trotti-2004" MODIFIED="2010-11-09 13:48:29 +0000" MODIFIED_BY="[Empty name]" NAME="Trotti 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-11-09 13:47:59 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Trotti A, Garden A, Warde P, Symonds P, Langer C, Redman R, et al. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. International Journal of Radiation Oncology, Biology, Physics 2004; 58(3):674-81.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 13:47:59 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Trotti A, Garden A, Warde P, Symonds P, Langer C, Redman R et al</AU>
<TI>A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2004</YR>
<VL>58</VL>
<NO>3</NO>
<PG>674-81</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 13:48:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Trotti A, Garden AS, Warde P, Symonds P, Langer C, Fleming T et al</AU>
<TI>Phase III trial of iseganan HCL oral solution (iseganan) for reducing oral mucositis severity in patients receiving radiotherapy for head and neck malignancies (PROMPT-RT)</TI>
<SO>Proceedings of the Annual Meeting of the American Society of Clinical Oncology</SO>
<YR>2002</YR>
<PG>Abstract 908</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tu-1998" MODIFIED="2010-11-09 13:49:24 +0000" MODIFIED_BY="[Empty name]" NAME="Tu 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-11-09 13:49:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tu Q, Tang J, Shen L, Lei Y, Yu S, Zhou J et al</AU>
<TI>The second phase clinical observation of anti-radiation effect by superoxide dismutase</TI>
<SO>Bulletin of Hunan Medical University</SO>
<YR>1998</YR>
<VL>23</VL>
<NO>3</NO>
<PG>308-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vacha-2003" MODIFIED="2010-11-09 13:50:57 +0000" MODIFIED_BY="[Empty name]" NAME="Vacha 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-11-09 13:50:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vacha P, Fehlauer F, Mahlmann B, Marx M, Hinke A, Sommer K et al</AU>
<TI>Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer: Is there evidence for radioprotection?</TI>
<SO>Strahlentherapie und Onkologie</SO>
<YR>2003</YR>
<VL>179</VL>
<NO>6</NO>
<PG>385-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 13:50:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vacha P, Marx M, Engel A, Richter E, Feyerabend T</AU>
<TI>Side effects of postoperative radiochemotherapy with amisfostine versus radiotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial</TI>
<SO>Strahlentherapie und onkologie</SO>
<YR>1999</YR>
<VL>175 Suppl 4</VL>
<PG>18-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vadhan_x002d_Raj-2010" MODIFIED="2010-11-10 15:27:42 +0000" MODIFIED_BY="[Empty name]" NAME="Vadhan-Raj 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-11-09 14:04:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vadhan-Raj S, Trent J, Patel S, Zhou X, Johnson MM, Araujo D et al</AU>
<TI>Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomised trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2010</YR>
<VL>153</VL>
<NO>6</NO>
<PG>358-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-10 15:27:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Vadhan-Raj S, Trent JC, Patel SR, Araujo DM, Ludwig LA, Bailey D et al</AU>
<TI>Randomised, double blind, placebo controlled study of palifermin for the prevention of mucositis in patients receiving doxorubicin chemotherapy</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2008</YR>
<PG>Abs No 9547</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-der-Lelie-2001" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="van der Lelie 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Lelie H, Thomas BL, van Oers RH, Ek-Post M, Sjamsoedin SA, van Dijk-Overtoom ML et al</AU>
<TI>Effect of locally applied GM-CSF on oral mucositis after stem cell transplantation: a prospective placebo-controlled double-blind study</TI>
<SO>Annals of Hematology</SO>
<YR>2001</YR>
<VL>80</VL>
<NO>3</NO>
<PG>150-4</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Veerasarn-2006" MODIFIED="2010-11-09 14:04:46 +0000" MODIFIED_BY="[Empty name]" NAME="Veerasarn 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-09 14:04:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Veerasarn V, Phromratanapongse P, Suntornpong N, Lorvidhaya V, Sukthomya V, Chitapanarux I et al</AU>
<TI>Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function</TI>
<SO>Journal of the Medical Association of Thailand</SO>
<YR>2006</YR>
<VL>89</VL>
<NO>12</NO>
<PG>2056-67</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Veness-2006" MODIFIED="2010-11-09 14:05:01 +0000" MODIFIED_BY="[Empty name]" NAME="Veness 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-09 14:05:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Veness MJ, Foroudi F, Gebski V, Timms I, Sathiyaseelan Y, Cakir B et al</AU>
<TI>Use of topical misoprostol to reduce radiation-induced mucositis: results of a randomized, double-blind, placebo-controlled trial</TI>
<SO>Australasian Radiology</SO>
<YR>2006</YR>
<VL>50</VL>
<NO>5</NO>
<PG>468-74</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vokurka-2005" MODIFIED="2010-11-09 14:05:15 +0000" MODIFIED_BY="[Empty name]" NAME="Vokurka 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-11-09 14:05:15 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Vokurka S, Bystricka E, Koza V, Scudlova J, Pavlicova V, Valentova D, et al. The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT--results of a randomized multicentre study. Supportive Care in Cancer. 2005;13(7):554-8.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 14:05:15 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vokurka S, Bystricka E, Koza V, Scudlova J, Pavlicova V, Valentova D et al</AU>
<TI>The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT--results of a randomized multicentre study</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>7</NO>
<PG>554-8</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Wahlin-1989" MODIFIED="2010-11-09 14:05:26 +0000" MODIFIED_BY="[Empty name]" NAME="Wahlin 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-11-09 14:05:26 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Wahlin YD. Effects of chlorhexidine mouth rinse on the oral health in patients with acute leukemia. Oral Surg Oral Med Oral Path 1989;68:279-87.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 14:05:26 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wahlin YB</AU>
<TI>Effects of chlorhexidine mouthrinse on the oral health in patients with acute leukemia</TI>
<SO>Oral Surgery, Oral Medicine, and Oral Pathology</SO>
<YR>1989</YR>
<VL>68</VL>
<NO>3</NO>
<PG>279-87</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2002" MODIFIED="2011-02-24 14:02:44 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang J</AU>
<TI>Effect on Chinese herbs decoction gargling to treat and to prevent chemotherapy caused stomatitis</TI>
<SO>Chinese Nursing Research</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>10</NO>
<PG>578-9</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Watanabe-2010" MODIFIED="2010-11-09 14:05:45 +0000" MODIFIED_BY="[Empty name]" NAME="Watanabe 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-11-09 14:05:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watanabe T, Ishihara M, Matsuura K, Mizuta K, Itoh Y</AU>
<TI>Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer</TI>
<SO>International Journal of Cancer</SO>
<YR>2010</YR>
<VL>127</VL>
<NO>8</NO>
<PG>1984-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wijers-2001" MODIFIED="2010-11-09 14:06:12 +0000" MODIFIED_BY="[Empty name]" NAME="Wijers 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-11-09 14:06:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wijers OB, Levendag PC, Harms ER, Gan-Teng AM, Schmitz PI, Hendriks WD et al</AU>
<TI>Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: a placebo-controlled double-blind randomized study</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2001</YR>
<VL>50</VL>
<NO>2</NO>
<PG>343-52</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2009" MODIFIED="2010-11-09 14:08:05 +0000" MODIFIED_BY="[Empty name]" NAME="Wu 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-09 14:06:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ahn YWH, Song S, Kim Y, Oh Y, Lee C et al</AU>
<TI>The therapeutic effect of recombinant human epidermal growth factor (rhEGF) on mucositis in patients with head and neck cancer undergoing radiotherapy with or without chemotherapy: a double-blind placebo-controlled prospective phase II multi-institutional study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<PG>Abstract 6021</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 14:07:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee S, Song S, Kim Y, Oh Y, Lee C, Keum K, et al</AU>
<TI>The therapeutic effect of recombinant human epidermal growth factor (rhEGF) on mucositis in patients with head and neck cancer undergoing radiotherapy with or without chemotherapy: a double blind placebo controlled prospective phase II multi-institutional clinical trial</TI>
<SO>International Journal of Radiation Oncology</SO>
<YR>2008</YR>
<VL>72</VL>
<NO>1</NO>
<PG>S32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 14:08:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wu HG, Song SY, Kim YS, Oh YT, Lee CG, Keum KC et al</AU>
<TI>Therapeutic effect of recombinant human epidermal growth factor (RhEGF) on mucositis in patients undergoing radiotherapy, with or without chemotherapy, for head and neck cancer: a double-blind placebo-controlled prospective phase 2 multi-institutional clinical trial</TI>
<SO>Cancer</SO>
<YR>2009</YR>
<VL>115</VL>
<NO>16</NO>
<PG>3699-708</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-You-2009" MODIFIED="2010-11-09 14:09:45 +0000" MODIFIED_BY="[Empty name]" NAME="You 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-09 14:09:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>You WC, Hsieh CC, Huang JT</AU>
<TI>Effect of extracts from indigowood root (Isatis indigotica Fort.) on immune responses in radiation-induced mucositis</TI>
<SO>Journal of Alternative and Complementary Medicine</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>7</NO>
<PG>771-8</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yuen-2001" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Yuen 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yuen KY, Woo PCY, Tai JW, Lie AK, Luk J, Liang R</AU>
<TI>Effects of clarithromycin on oral mucositis in bone marrow transplant recipients</TI>
<SO>Haematologica</SO>
<YR>2001</YR>
<VL>86</VL>
<NO>5</NO>
<PG>554-5</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-03-08 14:05:14 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abramoff-2008" MODIFIED="2010-11-09 14:11:05 +0000" MODIFIED_BY="[Empty name]" NAME="Abramoff 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-11-09 14:11:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abramoff MM, Lopes NN, Lopes LA, Dib LL, Guilherme A, Caran EM et al</AU>
<TI>Low-level laser therapy in the prevention and treatment of chemotherapy-induced oral mucositis in young patients</TI>
<SO>Photomedicine and Laser Surgery</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>4</NO>
<PG>393-400</PG>
<IDENTIFIERS MODIFIED="2010-11-09 14:11:05 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aisa-2005" MODIFIED="2010-11-09 14:11:20 +0000" MODIFIED_BY="[Empty name]" NAME="Aisa 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-11-09 14:11:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aisa Y, Mori T, Kudo M, Yashima T, Kondo S, Yokoyama A et al</AU>
<TI>Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>4</NO>
<PG>266-9</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Altmann-1999" MODIFIED="2010-11-09 14:12:00 +0000" MODIFIED_BY="[Empty name]" NAME="Altmann 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-11-09 14:12:00 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Altmann S HH. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors]. [German]. Strahlentherapie und Onkologie 1999;175(Suppl 4):30-3.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 14:12:00 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Altmann S, Hoffmanns H</AU>
<TI>Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors</TI>
<SO>Strahlentherapie und Onkologie</SO>
<YR>1999</YR>
<VL>175 Suppl 4</VL>
<PG>30-3</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andersen-1987" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Andersen 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Andersen E PH. Oral ftorafur versus intravenous 5-fluorouracil. A comparative study in patients with colorectal cancer. Acta Oncologica 1987;26(6):433-6.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andersen E, Pedersen H</AU>
<TI>Oral ftorafur versus intravenous 5-fluorouracil. A comparative study in patients with colorectal cancer</TI>
<SO>Acta Oncologica</SO>
<YR>1987</YR>
<VL>26</VL>
<NO>6</NO>
<PG>433-6</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1998b" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Anderson 1998b" YEAR="1998">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson PM, Ramsay NKC, Shu XO, Rydholm N, Rogosheske J, Nicklow R et al</AU>
<TI>Effect of low dose oral glutamine on painful stomatitis during bone marrow transplantation</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1998</YR>
<VL>22</VL>
<NO>4</NO>
<PG>339-44</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Antin-2002" MODIFIED="2010-11-09 14:12:43 +0000" MODIFIED_BY="[Empty name]" NAME="Antin 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-11-09 14:12:43 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Antin JH, Lee SJ, Neuberg D, Alyea E, Soiffer RJ, Sonis S, et al. A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplantation 2002; 29(5):373-7.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 14:12:43 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Antin JH, Lee SJ, Neuberg D, Alyea E, Soiffer RJ, Sonis S et al</AU>
<TI>A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2002</YR>
<VL>29</VL>
<NO>5</NO>
<PG>373-7</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Antonadou-1998" MODIFIED="2010-11-09 14:13:17 +0000" MODIFIED_BY="[Empty name]" NAME="Antonadou 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-11-09 14:13:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Antonadou D, Athanassiou E, Synodinou M, Koliarakis N, Panoussaki K, Karageorgis P et al</AU>
<TI>Evaluation of the efficacy of granulocyte macrophage colony stimulating factor (GM-CSF) in the prevention of radiation induced mucositis</TI>
<SO>Radiotherapy Oncology</SO>
<YR>1998</YR>
<VL>48 Suppl 1</VL>
<PG>S39</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Apaydin-1996" MODIFIED="2010-11-09 14:13:43 +0000" MODIFIED_BY="[Empty name]" NAME="Apaydin 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-11-09 14:13:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Apaydin A, Karadeniz AN, Aysigi G, Blige N</AU>
<TI>The effect and therapeutical use of benzydamine HCL on radiation-induced oral cavity and oropharyngeal mucositis</TI>
<SO>Medical Bulletin Istanbul</SO>
<YR>1996</YR>
<VL>29</VL>
<NO>1</NO>
<PG>59-63</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aquino-2005" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Aquino 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Aquino VM, Harvey AR, Garvin JH, Godder KT, Nieder ML, Adams RH, et al. A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplantation. 2005;36(7):611-6.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aquino VM, Harvey AR, Garvin JH, Godder KT, Nieder ML, Adams RH et al</AU>
<TI>A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2005</YR>
<VL>36</VL>
<NO>7</NO>
<PG>611-6</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ardizzoni-2002" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Ardizzoni 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Ardizzoni A, Tjan-Heijnen VC, Postmus PE, Buchholz E, Biesma B, Karnicka-Mlodkowska H, et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.+AFs-comment+AF0-.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ardizzoni A, Tjan-Heijnen VC, Postmus PE, Buchholz E, Biesma B, Karnicka-Mlodkowska H, et al</AU>
<TI>Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>19</NO>
<PG>3947-55</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arora-2008" MODIFIED="2010-11-09 14:14:42 +0000" MODIFIED_BY="[Empty name]" NAME="Arora 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-11-09 14:14:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Arora H, Pai KM, Maiya A, Vidyasagar MS, Rajeev A</AU>
<TI>Efficacy of He-Ne Laser in the prevention and treatment of radiotherapy-induced oral mucositis in oral cancer patients</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, &amp; Endodontics</SO>
<YR>2008</YR>
<VL>105</VL>
<NO>2</NO>
<PG>180-6</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Awada-2002" MODIFIED="2010-11-09 14:15:01 +0000" MODIFIED_BY="[Empty name]" NAME="Awada 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-11-09 14:15:01 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Awada A, Biganzoli L, Cufer T, Beex L, Lohrisch C, Batter V, et al. An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes.2002+ADs- 38(6):773-8.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 14:15:01 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Awada A, Biganzoli L, Cufer T, Beex L, Lohrisch C, Batter V et al</AU>
<TI>An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes</TI>
<SO>European Journal of Cancer</SO>
<YR>2002</YR>
<VL>38</VL>
<NO>6</NO>
<PG>773-8</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Awada-2004" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Awada 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Awada A, Gil T, Sales F, Dubuisson M, Vereecken P, Klastersky J, et al. Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers. Anti-Cancer Drugs. 2004;15(5):499-502.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Awada A, Gil T, Sales F, Dubuisson M, Vereecken P, Klastersky J et al</AU>
<TI>Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers</TI>
<SO>Anti-Cancer Drugs</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>5</NO>
<PG>499-502</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Awidi-2001" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Awidi 2001" YEAR="">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Awidi A HU, Kakail RI, Mubarak A, Hassan A, Kelta M, Martinez P, Sulaiti S, Al Qady A, Jamhoury A, Daniel M, Charles C, Ambrose A, El-Aloosy AS. Double-blind, placebo-controlled cross-over study of oral pilocarpine for the prevention of chemotherapy-induced oral mucositis in adult patients with cancer. +AFs-see comments.+AF0-.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Awidi A, Homsi U, Kakail RI, Mubarak A, Hassan A, Kelta M, Martinez P et al</AU>
<TI>Double-blind, placebo-controlled cross-over study of oral pilocarpine for the prevention of chemotherapy-induced oral mucositis in adult patients with cancer</TI>
<SO>European Journal of Cancer</SO>
<YR>2001</YR>
<VL>37</VL>
<NO>16</NO>
<PG>2010-4</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Awwad-2002" MODIFIED="2010-11-09 14:16:00 +0000" MODIFIED_BY="[Empty name]" NAME="Awwad 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-11-09 14:16:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Awwad HK, Lotayef M, Shouman T, Begg AC, Wilson G, Bentzen SM et al</AU>
<TI>Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation</TI>
<SO>British Journal of Cancer</SO>
<YR>2002</YR>
<VL>86</VL>
<NO>4</NO>
<PG>517-23</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barasch-1995" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Barasch 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barasch A, Peterson DE, Tanzer JM, D'Ambrososio JA, Nuki K, Schubert MM et al</AU>
<TI>Helium-Neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients</TI>
<SO>Cancer</SO>
<YR>1995</YR>
<VL>76</VL>
<NO>12</NO>
<PG>2550-6</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baydar-2005" MODIFIED="2009-08-04 17:49:46 +0100" MODIFIED_BY="[Empty name]" NAME="Baydar 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-08-04 17:49:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baydar M, Dikilitas M, Sevinc A, Aydogdu I</AU>
<TI>Prevention of oral mucositis due to 5-fluorouracil treatment with oral cryotherapy</TI>
<SO>Journal of the National Medical Association</SO>
<YR>2005</YR>
<VL>97</VL>
<NO>8</NO>
<PG>1161-4</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bensadoun-2006" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Bensadoun 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Bensadoun RJ, Benezery K, Dassonville O, Magne N, Poissonnet G, Ramaioli A, et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). International Journal of Radiation Oncology, Biology, Physics. 2006;64(4):983-94.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bensadoun RJ, Benezery K, Dassonville O, Magne N, Poissonnet G, Ramaioli A et al</AU>
<TI>French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC)</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2006</YR>
<VL>64</VL>
<NO>4</NO>
<PG>983-94</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bentzen-2001" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Bentzen 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bentzen SM, Saunders MI, Dische S, Bond SJ</AU>
<TI>Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial</TI>
<SO>Radiotherapy Oncology</SO>
<YR>2001</YR>
<VL>60</VL>
<NO>2</NO>
<PG>123-35</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bleehen-1996" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Bleehen 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Bleehen NM, Girling DJ, Hopwood P, Lallemand G, Machin D, Stephens RJ, Bailey AJ. Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. British Journal of Cancer 1996 73 406-413.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bleehen NM, Girling DJ, Hopwood P, Lallemand G, Machin D, Stephens RJ et al</AU>
<TI>Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis</TI>
<SO>British Journal of Cancer</SO>
<YR>1996</YR>
<VL>73</VL>
<PG>406-13</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bourhis-2006" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Bourhis 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Bourhis J, Lapeyre M, Tortochaux J, Rives M, Aghili M, Bourdin S, et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. Journal of Clinical Oncology. 2006;24(18):2873-8.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bourhis J, Lapeyre M, Tortochaux J, Rives M, Aghili M, Bourdin S et al</AU>
<TI>Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>18</NO>
<PG>2873-8</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Braaksma-2002" MODIFIED="2011-03-08 13:49:49 +0000" MODIFIED_BY="[Empty name]" NAME="Braaksma 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-03-08 13:49:49 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Braaksma M, Levendag P. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation. Seminars in Oncology 2002+ADs- 29(6 Suppl 19):63-70.&lt;/p&gt;" NOTES_MODIFIED="2011-03-08 13:49:49 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Braaksma M, Levendag P</AU>
<TI>Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation</TI>
<SO>Seminars in Oncology</SO>
<YR>2002</YR>
<VL>29</VL>
<NO>6 Supp 19</NO>
<PG>63-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buentzel-1999" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Buentzel 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Buentzel J, Glatzel M, Weinaug R, Schuth J, Kuettner K, Froehlich D. Amifostine in combined radio- and chemomodalities for head and neck cancer. European Journal of Cancer. 1999;35(Suppl 4):363 Abstract #1472.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buentzel J, Glatzel M, Weinaug R, Schuth J, Kuettner K, Froehlich D</AU>
<TI>Amifostine in combined radio- and chemomodalities for head and neck cancer</TI>
<SO>European Journal of Cancer</SO>
<YR>1999</YR>
<VL>35</VL>
<NO>Suppl 4</NO>
<PG>363 (Abs No 1472)</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Calais-2000" MODIFIED="2010-11-09 14:17:49 +0000" MODIFIED_BY="[Empty name]" NAME="Calais 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-11-09 14:17:13 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, et al. [Stage III and IV cancers of the oropharynx: results of a randomized study of Gortec comparing radiotherapy alone with concomitant chemotherapy]. [French]. Bulletin du Cancer. 2000;87 Spec No:48-53.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 14:17:13 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P et al</AU>
<TI>Stage III and IV cancers of the oropharynx: results of a randomized study of Gortec comparing radiotherapy alone with concomitant chemotherapy</TI>
<SO>Bulletin du Cancer</SO>
<YR>2000</YR>
<VL>87 Spec No</VL>
<PG>48-53</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 14:17:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Calais GM, Alfonsi E, Bardet C, Sire H, Bourgeois C, Bergerot B et al</AU>
<TI>Randomized study comparing radiation alone (RT) versus RT with concomitant chemotherapy (CT) in stages III and IV oropharynx carcinoma (ARCORO). Preliminary results of the 94.01 study from the French Group of radiation oncology for head and neck cancer (GORTEC)</TI>
<SO>Proceedings of Annual Meeting of the American Society of Clinical Oncology</SO>
<YR>1998</YR>
<PG>Abstract 1484</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Calais-2004" MODIFIED="2010-11-09 14:18:13 +0000" MODIFIED_BY="[Empty name]" NAME="Calais 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-11-09 14:18:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Calais G, Bardet E, Sire C, Alfonsi M, Bourhis J, Rhein B et al</AU>
<TI>Radiotherapy with concomitant weekly docetaxel for stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC phase II trial</TI>
<SO>International Journal of Radiation, Oncology, Biology, Physics</SO>
<YR>2004</YR>
<VL>58</VL>
<NO>1</NO>
<PG>161-6</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cassidy-2002" MODIFIED="2010-11-09 14:18:36 +0000" MODIFIED_BY="[Empty name]" NAME="Cassidy 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-11-09 14:18:36 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. 2002+ADs- 13(4):566-75.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 14:18:36 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M et al</AU>
<TI>First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin</TI>
<SO>Annals of Oncology</SO>
<YR>2002</YR>
<VL>13</VL>
<NO>4</NO>
<PG>566-75</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Castro-2009" MODIFIED="2010-11-09 14:21:11 +0000" MODIFIED_BY="[Empty name]" NAME="Castro 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-09 14:21:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Castro G Jr, de Lima AG, Lopes DR, Ortegosa MV, Rosalmeida MC, Gil E et al</AU>
<TI>Oral mucositis prevention by low-level laser therapy in head and neck cancer patients submitted to concurrent chemoradiation: a prospective randomized trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2009</YR>
<VL>27 Suppl</VL>
<PG>15S (Abstract 6019)</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cella-2003" MODIFIED="2011-03-08 13:46:12 +0000" MODIFIED_BY="[Empty name]" NAME="Cella 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-03-08 13:46:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cella D, Pulliam J, Fuchs H, Miller C, Hurd D, Wingard JR et al</AU>
<TI>Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy</TI>
<SO>Cancer</SO>
<YR>2003</YR>
<VL>98</VL>
<NO>2</NO>
<PG>406-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-2001" MODIFIED="2010-11-09 14:21:30 +0000" MODIFIED_BY="[Empty name]" NAME="Cheng 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-11-09 14:21:30 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Cheng KK MA, Chang AM, Wai WC, Cheung SS. Evaluation of an oral care protocol intervention in the prevention of chemotherapy-induced oral mucositis in paediatric cancer patients. 2001+ADs-37(16):2056-63.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 14:21:30 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng KK, Molassiotis A, Chang AM, Wai WC, Cheung SS</AU>
<TI>Evaluation of an oral care protocol intervention in the prevention of chemotherapy-induced oral mucositis in paediatric cancer patients</TI>
<SO>European Journal of Cancer</SO>
<YR>2001</YR>
<VL>37</VL>
<NO>16</NO>
<PG>2056-63</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-2002" MODIFIED="2010-10-22 10:12:11 +0100" MODIFIED_BY="[Empty name]" NAME="Cheng 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-10-22 10:12:11 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Cheng KKF MA, Chang AM. An oral care protocol intervention to prevent chemotherapy-induced oral mucositis in paediatric cancer patients: a pilot study... including commentary by Parr M. European Journal of Oncology Nursing: EUR J ONCOL NURS 2002+ADs- 6. 6(2. 2):66-74.&lt;/p&gt;" NOTES_MODIFIED="2010-10-22 10:12:11 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng KKF, Molassiotis A, Chang AM</AU>
<TI>An oral care protocol intervention to prevent chemotherapy-induced oral mucositis in paediatric cancer patients: a pilot study</TI>
<SO>European Journal of Oncology Nursing</SO>
<YR>2002</YR>
<VL>6</VL>
<NO>2</NO>
<PG>66-74</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-2006" MODIFIED="2010-11-09 14:22:14 +0000" MODIFIED_BY="[Empty name]" NAME="Cheng 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-09 14:22:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng KK-F, Yuen JKT</AU>
<TI>A pilot study of chlorhexidine and benzydamine oral rinses for the prevention and treatment of irradiation mucositis in patients with head and neck cancers</TI>
<SO>Cancer Nursing</SO>
<YR>2006</YR>
<VL>29</VL>
<NO>5</NO>
<PG>423-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clarke-2001" MODIFIED="2010-11-09 14:23:11 +0000" MODIFIED_BY="[Empty name]" NAME="Clarke 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-11-09 14:23:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Clarke SJ, Abdi E, Davis ID, Schnell FM, Zalcberg JR, Gutheil J et al</AU>
<TI>Recombinant human keratinocyte growth factor (rHuKGF) prevents chemotherapy-induced mucositis in patients with advanced colorectal cancer: a randomized phase II trial</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>2001</YR>
<VL>20 (Pt 1)</VL>
<PG>383a (Abstract 1529)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colella-2010" MODIFIED="2010-11-09 14:23:45 +0000" MODIFIED_BY="[Empty name]" NAME="Colella 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-11-09 14:23:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colella G, Cannavale R, Vicidomini A, Rinaldi G, Compilato D, Campisi G</AU>
<TI>Efficacy of a spray compound containing a pool of collagen precursor synthetic aminoacids (l-proline, l-leucine, l-lysine and glycine) combined with sodium hyaluronate to manage chemo/radiotherapy-induced oral mucositis: preliminary data of an open trial</TI>
<SO>International Journal of Immunopathology and Pharmacology</SO>
<YR>2010</YR>
<VL>23</VL>
<NO>1</NO>
<PG>143-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Collova-2004" MODIFIED="2010-11-09 14:24:08 +0000" MODIFIED_BY="[Empty name]" NAME="Collova 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-11-09 14:24:08 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Collova E, Castagna L, Nozza A, Perfetti V, Patrone F, Danova M, et al. New approaches for reduction of oral mucositis in patients undergoing high-dose chemotherapy with hematopoietic stem cell support [abstract]. Bone Marrow Transplantation. 2004;33(Suppl 1):S323-S4.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 14:24:08 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Collova E, Castagna L, Nozza A, Perfetti V, Patrone F, Danova M et al</AU>
<TI>New approaches for reduction of oral mucositis in patients undergoing high-dose chemotherapy with hematopoietic stem cell support</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2004</YR>
<VL>33 Suppl 1</VL>
<PG>S323-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colombat-1995" NAME="Colombat 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Colombat P, Colin B, et al. Comparison of fluconazole and amphotericin B in the prevention of mucositis in patients with long term aplasia [abstract]. Bone-Marrow-Transplant. 1995;15:178.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colombat P, Colin B</AU>
<TI>Comparison of fluconazole and amphotericin B in the prevention of mucositis in patients with long term aplasia</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1995</YR>
<VL>15</VL>
<PG>178</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Costa-1999" MODIFIED="2010-11-09 14:24:50 +0000" MODIFIED_BY="[Empty name]" NAME="Costa 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-11-09 14:24:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Costa EMMB, Pinto LP, Fernandes MZ, Costa ALL</AU>
<TI>Preventing oral complications in leukemic children submitted to chemotherapy</TI>
<SO>Journal of Dental Research</SO>
<YR>1999</YR>
<VL>78</VL>
<PG>1021 (Abstract B-220)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Costa-2003" NAME="Costa 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Costa EM, Fernandes MZ, Quinder LB, de Souza LB, Pinto LP. Evaluation of an oral preventive protocol in children with acute lymphoblastic leukemia. Pesqui Odontol Bras. 2003 Apr-Jun;17(2):147-50.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Costa EM, Fernandes MZ, Quinder LB, de Souza LB, Pinto LP</AU>
<TI>Evaluation of an oral preventive protocol in children with acute lymphoblastic leukemia</TI>
<SO>Pesquisa Odontologica Brasileira</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>2</NO>
<PG>147-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cowen-1997" MODIFIED="2010-11-09 14:26:06 +0000" MODIFIED_BY="[Empty name]" NAME="Cowen 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-11-09 14:25:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cowen D, Tardieu C, Resbeut M, Hannoun-Levi JM, Alzieu C, Schubert M et al</AU>
<TI>Low energy helium-neon laser presents oral mucositis after high-dose chemo-radiotherapy: results of a double-blind randomized trial</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1996</YR>
<VL>36 Suppl 1</VL>
<PG>264 (Abstract 1041)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 14:26:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cowen D, Tardieu C, Schubert M, Peterson D, Resbeut M, Faucher C et al</AU>
<TI>Low energy Helium-neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: results of a double blind randomized trial</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1997</YR>
<VL>38</VL>
<NO>4</NO>
<PG>697-703</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cunningham-1995" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Cunningham 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cunningham D, Zalcberg JR, Rath U, Olver I, van Cutsem EV, Sevensson C et al</AU>
<TI>'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia</TI>
<SO>European Journal of Cancer</SO>
<YR>1995</YR>
<VL>31A</VL>
<NO>12</NO>
<PG>1945-54</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Damon-2004" MODIFIED="2010-03-12 16:02:00 +0000" MODIFIED_BY="[Empty name]" NAME="Damon 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-03-12 16:02:00 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Damon LE, Johnston LJ, Ries CA, Rugo HS, Case D, Ault K, et al. Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule. Cancer Chemotherapy &amp;amp; Pharmacology. 2004;53(6):468-74.&lt;/p&gt;" NOTES_MODIFIED="2010-03-12 16:02:00 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Damon LE, Johnston LJ, Ries CA, Rugo HS, Case D, Ault K et al</AU>
<TI>Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule</TI>
<SO>Cancer Chemotherapy and Pharmacology</SO>
<YR>2004</YR>
<VL>53</VL>
<NO>6</NO>
<PG>468-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Boer-2002" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="De Boer 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Boer RH, Eisen TG, Ellis PA, Johnston SR, Walsh G, Ashley S et al</AU>
<TI>A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer</TI>
<SO>Annals of Oncology</SO>
<YR>2002</YR>
<VL>13</VL>
<NO>6</NO>
<PG>889-94</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Denham-1999" MODIFIED="2010-11-09 14:26:31 +0000" MODIFIED_BY="[Empty name]" NAME="Denham 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-11-09 14:26:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Denham JW, Peters LJ, Johansen J, Poulsen M, Lamb DS, Hindley A et al</AU>
<TI>Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer?</TI>
<SO>Radiotherapy and Oncology</SO>
<YR>1999</YR>
<VL>52</VL>
<NO>2</NO>
<PG>157-64</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Djuric-2006" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Djuric 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Djuric M, Hillier-Kolarov V, Belic A, Jankovic L. Mucositis prevention by improved dental care in acute leukemia patients. Supportive Care in Cancer. 2006;14(2):137-46.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Djuric M, Hillier-Kolarov V, Belic A, Jankovic L</AU>
<TI>Mucositis prevention by improved dental care in acute leukemia patients</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2006</YR>
<VL>14</VL>
<NO>2</NO>
<PG>137-46</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dobrowsky-1998" MODIFIED="2010-11-09 14:26:41 +0000" MODIFIED_BY="[Empty name]" NAME="Dobrowsky 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-11-09 14:26:41 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Dobrowsky W NJ, Widder J, Dobrowsky E, Millesi W, Pavelka R, Grasl C, Reichel M. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer. International Journal of Radiation Oncology, Biology, Physics 1998;42(4):803-6.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 14:26:41 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dobrowsky W, Naude J, Widder J, Dobrowsky E, Millesi W, Pavelka R et al</AU>
<TI>Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1998</YR>
<VL>42</VL>
<NO>4</NO>
<PG>803-6</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Doroshow-1987" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Doroshow 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Doroshow JH BM, Newman E, Multhauf P, Leong L, Blayney D, Goldberg D, Margolin K, Carr B, Akman S, et al. Preliminary analysis of a randomized comparison of 5-fluorouracil versus 5-fluorouracil and high-dose continuous-infusion folinic acid in disseminated colorectal cancer. NCI Monographs 1987(5):171-4.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doroshow JH, Berthtand M, Newman E, Multhauf P, Leong L, Blayney D et al</AU>
<TI>Preliminary analysis of a randomized comparison of 5-fluorouracil versus 5-fluorouracil and high-dose continuous-infusion folinic acid in disseminated colorectal cancer</TI>
<SO>NCI Monographs</SO>
<YR>1987</YR>
<VL>5</VL>
<PG>171-4</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dreicer-1997" MODIFIED="2009-08-04 17:52:20 +0100" MODIFIED_BY="[Empty name]" NAME="Dreicer 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-08-04 17:52:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dreicer R, Propert KJ, Kuzel T, Kirkwood JM, O'Dwyer PJ, Loehrer PJ</AU>
<TI>A phase II trial of edatrexate in patients with advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study</TI>
<SO>American Journal of Clinical Oncology</SO>
<YR>1997</YR>
<VL>20</VL>
<NO>3</NO>
<PG>251-3</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dudjak-1987" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Dudjak 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dudjak LA</AU>
<TI>Mouth care for mucositis due to radiation therapy</TI>
<SO>Cancer Nursing</SO>
<YR>1987</YR>
<VL>10</VL>
<NO>3</NO>
<PG>131-40</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Edelman-1998" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Edelman 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edelman MJ, Gandara Dr, Perez EA, Lau D, Lauder I, Turrell C et al</AU>
<TI>Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy</TI>
<SO>Investigational New Drugs</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>1</NO>
<PG>69-75</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eisen-2003" MODIFIED="2010-11-09 14:26:53 +0000" MODIFIED_BY="[Empty name]" NAME="Eisen 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-11-09 14:26:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eisen D, Essel J, Broun ER, Sigmund D, DeVoe M</AU>
<TI>Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2003</YR>
<VL>31</VL>
<NO>1</NO>
<PG>51-5</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-El_x002d_Sayed-2002a" MODIFIED="2011-02-24 13:57:01 +0000" MODIFIED_BY="[Empty name]" NAME="El-Sayed 2002a" YEAR="2002">
<REFERENCE MODIFIED="2010-10-26 09:59:24 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;El-Sayed S, Epstein J, Minish E, Burns P, Hay J, Laukkanen E.A pilot study evaluating the safety and microbiologic efficacy of an economically viable antimicrobial lozenge in patients with head and neck cancer receiving radiation therapy. Head Neck. 2002 Jan;24(1):6-15.&lt;/p&gt;" NOTES_MODIFIED="2010-10-26 09:59:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>El-Sayed S, Epstein J, Minish E, Burns P, Hay J, Laukkanen E</AU>
<TI>A pilot study evaluating the safety and microbiologic efficacy of an economically viable antimicrobial lozenge in patients with head and neck cancer receiving radiation therapy</TI>
<SO>Head &amp; Neck</SO>
<YR>2002</YR>
<VL>24</VL>
<NO>1</NO>
<PG>6-15</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 14:28:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>El-Sayed S, Nabid A, MacKenzie R, Gelinas M, Hay J, Shelley et al</AU>
<TI>Prophylaxis of radiation associated mucositis (RAM) in head and neck cancer, results of a double blind phase III trail evaluating the clinical efficacy of an antimicrobial lozenge utilizing a new validated mucositis scoring system</TI>
<SO>Proceedings of the 42nd Annual Meeting of the American Society for Therapeutic Radiology and Oncology</SO>
<YR>2000</YR>
<VL>321</VL>
<PG>Abstract 2115</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Epstein-1992" MODIFIED="2010-11-09 14:28:56 +0000" MODIFIED_BY="[Empty name]" NAME="Epstein 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-11-09 14:28:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Epstein JB, Vickars L, Spinalli J, Reece D</AU>
<TI>Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation</TI>
<SO>Oral Surgery, Oral Medicine, and Oral Pathology</SO>
<YR>1992</YR>
<VL>73</VL>
<NO>6</NO>
<PG>682-9</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Erkisi-1996" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Erkisi 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Erkisi M, Erkurt E, Ozbarlas S, Burgut R, Doran F, Seyrek E</AU>
<TI>The use of recombinant human granulocyte colony-stimulating factor in combination with single or fractionated doses of ifosfamide and doxorubicin in patients with advanced soft tissue sarcoma</TI>
<SO>Journal of Chemotherapy</SO>
<YR>1996</YR>
<VL>8</VL>
<NO>3</NO>
<PG>224-8</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Erlichman-1988" MODIFIED="2010-11-09 14:29:32 +0000" MODIFIED_BY="[Empty name]" NAME="Erlichman 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-11-09 14:29:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Erlichman C, Fine S, Wong A, Elhakim T</AU>
<TI>A randomized trial of fluorouracil and folonic acid in patients with metastatic colorectal carcinoma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1988</YR>
<VL>6</VL>
<NO>3</NO>
<PG>469-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 14:29:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Erlichman C</AU>
<TI>Fluorouracil and leucovorin for metastatic colorectal cancer</TI>
<SO>Journal of Chemotherapy</SO>
<YR>1990</YR>
<VL>2 Suppl 1</VL>
<PG>38-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Etiz-2000" MODIFIED="2010-11-09 14:30:15 +0000" MODIFIED_BY="[Empty name]" NAME="Etiz 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-10-26 10:01:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Etiz D, Erkal HS, Serin M, Kucuk B, Hepari A, Elhan AH et al</AU>
<TI>Clinical and histopathological evaluation of sucralfate in prevention of oral mucositis induced by radiation therapy in patients with head and neck malignancies</TI>
<SO>Oral Oncology</SO>
<YR>2000</YR>
<VL>36</VL>
<NO>1</NO>
<PG>116-20</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 14:30:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Etiz M, Erkal HS, Serin M, Kucuk B, Hepari A, Tulunay O et al</AU>
<TI>Clinicohistopathological evaluation of effectiveness of sucralfate in prevention of severe radiation-induced mucositis in patients with head and neck malignancies</TI>
<SO>Radiotherapy Oncology</SO>
<YR>1998</YR>
<VL>48 Suppl 1</VL>
<PG>S68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ezzat-2005" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Ezzat 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Ezzat M, Shouman T, Zaza K, Safwat A, El-Khoudary A, El-Senosi M, et al. A randomized study of accelerated fractionation radiotherapy with and without mitomycin C in the treatment of locally advanced head and neck cancer. Journal of Egyptian National Cancer Institute. 2005;17(2):85-92.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ezzat M, Shouman T, Zaza K, Safwat A, El-Khoudary A, El-Senosi M et al</AU>
<TI>A randomized study of accelerated fractionation radiotherapy with and without mitomycin C in the treatment of locally advanced head and neck cancer</TI>
<SO>Journal of the Egyptian National Cancer Institute</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>2</NO>
<PG>85-92</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fahlke-1999" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Fahlke 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fahlke J, Ridwelski K, Lippert H</AU>
<TI>High-dose therapy with combined 5-fluorouracil and folinic acid with and without amifostine in the treatment of patients with metastatic colorectal carcinoma</TI>
<SO>International Journal of Colorectal Disease</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>2</NO>
<PG>128-30</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Falcone-2001" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Falcone 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Falcone A, Allergrini G, Masi G, Lencioni M, Panner E, Brunetti I</AU>
<TI>5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer</TI>
<SO>Oncology</SO>
<YR>2001</YR>
<VL>61</VL>
<NO>1</NO>
<PG>28-35</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fay-1994" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Fay 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Fay JW LH, Herzig R, Saez R, Stevens DA, Collins RH Jr, Pineiro LA, Cooper BW, DiCesare J, Campion M, et al. Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study. Blood 1994;84(7):2151-7.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fay JW, Lazarus H, Herzig R, Saez R, Stevens DA, Collins RH Jr et al</AU>
<TI>Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study</TI>
<SO>Blood</SO>
<YR>1994</YR>
<VL>84</VL>
<NO>7</NO>
<PG>2151-7</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feber-1995" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Feber 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feber T</AU>
<TI>Mouth care for patients receiving oral irradiation</TI>
<SO>Professional Nurse</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>10</NO>
<PG>666-70</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feber-1996" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Feber 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feber T</AU>
<TI>Management of mucositis in oral irradiation</TI>
<SO>Clinical Oncology</SO>
<YR>1996</YR>
<VL>8</VL>
<NO>2</NO>
<PG>106-11</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferreira-2004" MODIFIED="2011-03-08 13:53:55 +0000" MODIFIED_BY="[Empty name]" NAME="Ferreira 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-03-08 13:53:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Ferreira PR, Fleck JF, Diehl A, Barletta D, Braga-Filho A, Barletta A, et al. Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial. Head Neck 2004;26(4):313-21.&lt;/p&gt;" NOTES_MODIFIED="2011-03-08 13:53:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferreira PR, Fleck JF, Diehl A, Barletta D, Braga-Filho A, Barletta A et al</AU>
<TI>Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial</TI>
<SO>Head &amp; Neck</SO>
<YR>2004</YR>
<VL>26</VL>
<NO>4</NO>
<PG>313-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-03-08 13:53:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ferreira RR, Fleck JF, Filho AB, Barletta D, Barletta A, Diehl A et al</AU>
<TI>Protective effect of vitamin E (VE) in head and neck cancer radiation induced mucositis: a double-blind randomized trial</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>2002</YR>
<VL>21 (Pt 1)</VL>
<PG>228a</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Ferretti-1990" MODIFIED="2010-11-09 14:30:54 +0000" MODIFIED_BY="[Empty name]" NAME="Ferretti 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-11-09 14:30:54 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Ferretti GA, Raybould TP, Brown AT, Macdonal JS, Greenwood M, Maruyama Y et al. Oral Surg Oral Med Oral Pathol 1990;69:331-8.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 14:30:54 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferretti GA, Raybould TP, Brown AT, Macdonal JS, Greenwood M, Maruyama Y et al</AU>
<TI>Chlorhexidine prophylaxis for chemotherapy- and radiotherapy- induced stomatitis: a randomised double-blind trial</TI>
<SO>Oral Surgery, Oral Medicine, and Oral Pathology</SO>
<YR>1990</YR>
<VL>69</VL>
<NO>3</NO>
<PG>331-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Foncuberta-2001" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Foncuberta 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Foncuberta M, PJ C, CH B, R M, K F, HG D, et al. Topical transforming growth factor-beta3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors. Journal of Immunotherapy 2001;24(4):384-388.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Foncuberta MC, Cagnoni PJ, Brandts CH, Mandanas R, Fields K, Derigs HG et al</AU>
<TI>Topical transforming growth factor-beta3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors</TI>
<SO>Journal of Immunotherapy</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>4</NO>
<PG>384-8</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gabison-1995" MODIFIED="2010-11-09 14:31:45 +0000" MODIFIED_BY="[Empty name]" NAME="Gabison 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-11-09 14:31:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gabison R</AU>
<TI>Can zinc picolinate in patients receiving chemotherapy for metastatic colorectal carcinoma prevent stomatitis?</TI>
<SO>European Journal of Cancer</SO>
<YR>1995</YR>
<VL>31 Suppl 6</VL>
<PG>S258 (Abstract 1234)</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gandara-1997" MODIFIED="2010-11-09 14:32:19 +0000" MODIFIED_BY="[Empty name]" NAME="Gandara 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-11-09 14:32:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gandara DR, Edelman MJ, Crowley JJ, Lau DH, Livingston RB</AU>
<TI>Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study</TI>
<SO>Cancer Chemotherapy and Pharmacology</SO>
<YR>1997</YR>
<VL>41</VL>
<NO>1</NO>
<PG>75-8</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Genot_x002d_Klastersky-2008" MODIFIED="2010-11-09 14:33:05 +0000" MODIFIED_BY="[Empty name]" NAME="Genot-Klastersky 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-11-09 14:33:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Genot-Klastersky MT, Klastersky J, Awada F, Awada A, Crombez P, Martinez MD et al</AU>
<TI>The use of low-energy laser (LEL) for the prevention of chemotherapy- and/or radiotherapy-induced oral mucositis in cancer patients: results from two prospective studies</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2008</YR>
<VL>16</VL>
<NO>12</NO>
<PG>1381-7</PG>
<IDENTIFIERS MODIFIED="2010-11-05 10:14:57 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghoreishi-2007" MODIFIED="2011-03-08 13:55:37 +0000" MODIFIED_BY="[Empty name]" NAME="Ghoreishi 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-03-08 13:55:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Ghoreishi Z, Shidfar F, Iravani M, Esfahani A, Ghavamzadeh A</AU>
<TI>Effect of vitamin E on chemotherapy-induced mucositis and neutropenia in leukemic patients undergoing bone marrow transplantation</TI>
<SO>Asia-Pacific Journal of Clinical Oncology</SO>
<YR>2007</YR>
<VL>3</VL>
<NO>3</NO>
<PG>113-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giles-2003a" MODIFIED="2010-06-19 22:39:44 +0100" MODIFIED_BY="[Empty name]" NAME="Giles 2003a" YEAR="2003">
<REFERENCE MODIFIED="2010-06-19 22:39:44 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Giles FJ, Miller CB, Hurd DD, Wingard JR, Fleming TR, Sonis ST, et al. A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial). Leukemia &amp;amp; Lymphoma. 2003;44(7):1165-72.&lt;/p&gt;" NOTES_MODIFIED="2010-06-19 22:39:44 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giles FJ, Miller CB, Hurd DD, Wingard JR, Fleming TR, Sonis ST et al</AU>
<TI>A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial)</TI>
<SO>Leukemia &amp; Lymphoma</SO>
<YR>2003</YR>
<VL>44</VL>
<NO>7</NO>
<PG>1165-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giles-2003b" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Giles 2003b" YEAR="2003">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Giles FJ FS, Thomas DA, Cortes JE, Garcia-Manero G, Douer D, Levine AM, Koller CA, Jeha SS, O'Brien SM, Estey EH, Kantarjian HM. Randomized Phase I/II Study of Troxacitabine Combined With Cytarabine, Idarubicin, or Topotecan in Patients With Refractory Myeloid Leukemias. Journal of Clinical Oncology 2003+ADs-21(6):1050-1056.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giles FJ, Faderl S, Thomas DA, Cortes JE, Garcia-Manero G, Douer D et al</AU>
<TI>Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>6</NO>
<PG>1050-6</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gladkov-2007" MODIFIED="2010-11-09 14:33:29 +0000" MODIFIED_BY="[Empty name]" NAME="Gladkov 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-09 14:33:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Gladkov OA, Vazhenin AV, Sharabura TM, Kandakova E, Galiatova Iu V, Sychev VI et al</AU>
<TI>Effectiveness of different regimes of combined treatment (cisplatin+ radiotherapy) for intraoral and oropharyngeal cancer</TI>
<SO>Voprosy Onkologii</SO>
<YR>2007</YR>
<VL>53</VL>
<NO>5</NO>
<PG>575-7</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldberg-2003" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Goldberg 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Goldberg S. Safety and tolerability of en3247 in the prevention of oral mucositis associated with chemotherapy with or without total body irradiation: results of a randomized, double-blind, placebo-controlled trial [abstract]. Proceedings of the American Society of Clinical Oncology. 2003:770.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Goldberg S</AU>
<TI>Safety and tolerability of en3247 in the prevention of oral mucositis associated with chemotherapy with or without total body irradiation: results of a randomized, double-blind, placebo-controlled trial</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>2003</YR>
<PG>770</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gordon-1993" MODIFIED="2010-11-09 14:34:14 +0000" MODIFIED_BY="[Empty name]" NAME="Gordon 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-11-09 14:34:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gordon B, Spadinger A, Hodges E, Coccia P</AU>
<TI>Effect of granulocyte macrophage colony stimulating factor (GMCSF) on oral mucositis after autologous bone marrow transplantation</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>1993</YR>
<VL>12</VL>
<PG>432 (Abstract 1489)</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grotz-2001" MODIFIED="2010-11-09 14:35:34 +0000" MODIFIED_BY="[Empty name]" NAME="Grotz 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-11-09 14:35:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grotz KA, Henneicke-Von Zepelin HH, Kohnen R, Kutzner J, Belz GG</AU>
<TI>Prophylaxis of mucositis and dry mouth after head and neck radiotherapy. A new treatment</TI>
<SO>Krankenhauspharmazie</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>5</NO>
<PG>193-8</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 14:35:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Grotz KA, Wustenberg P, Kohnen R, Al-Nawas B, Henneicke-von Zepelin HH, Bockisch A et al</AU>
<TI>Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutine in patients with head and neck cancer- a prospective, randomized, placebo-controlled, double-blind study</TI>
<SO>The British Journal of Oral and Maxillofacial Surgery</SO>
<YR>2001</YR>
<VL>39</VL>
<NO>1</NO>
<PG>34-9</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gutierrez-1996" MODIFIED="2010-11-09 14:36:07 +0000" MODIFIED_BY="[Empty name]" NAME="Gutierrez 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-11-09 14:36:07 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Gutierrez AR BE, Carreras PS, Rodriguez CS, Rodriguez OA, Chicote MJV, Palacios AN, Solbes RS, Ripoll JJS. Fluconazol as prophylaxis of radioinduced oral mucositis. Preliminary study. Oncologia 1996;19(6):56-59.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 14:36:07 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gutierrez AR, Boizas EC, Carreras PS, Rodriguez CS, Rodriguez OA, Chicote MJV et al</AU>
<TI>Fluconazol as prophylaxis of radioinduced oral mucositis. Preliminary study</TI>
<SO>Oncologia</SO>
<YR>1996</YR>
<VL>19</VL>
<NO>6</NO>
<PG>56-9</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harris-1995" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Harris 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harris JR, Russell NH, Hunter AE</AU>
<TI>Folinic acid mouthwashes do not reduce the degree of mucositis in patients undergoing allogeneic bone marrow transplantation</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>S2</NO>
<PG>S164</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-He-2004" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="He 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;He XY, Hu CS, Wu YR. Radioprotective effect of amifostine in nasopharyngeal carcinoma. Acta Academiae Medicinae Shanghai. 2004;31(1).&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>He XY, Hu CS, Wu YR</AU>
<TI>Radioprotective effect of amifostine in nasopharyngeal carcinoma</TI>
<SO>Acta Academiae Medicinae Shanghai</SO>
<YR>2004</YR>
<VL>31</VL>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hickey-1982" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Hickey 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hickey AJ, Toth BB, Lindquist SB</AU>
<TI>Effect of intravenous hyperalimentation and oral care on the development of oral stomatitis during cancer chemotherapy</TI>
<SO>The Journal of Prosthetic Dentistry</SO>
<YR>1982</YR>
<VL>47</VL>
<NO>2</NO>
<PG>188-93</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horsley-2007" MODIFIED="2009-08-04 16:19:13 +0100" MODIFIED_BY="[Empty name]" NAME="Horsley 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-04 16:19:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Horsley P, Bauer JD, Mazkowiack R, Gardner R, Bashford J</AU>
<TI>Palifermin improves severe mucositis, swallowing problems, nutrition impact symptoms, and length of stay in patients undergoing hematopoietic stem cell transplantation</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2007</YR>
<VL>15</VL>
<NO>1</NO>
<PG>105-9</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Howell-1983" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Howell 1983" YEAR="1983">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Howell SB PC, Wung WE. Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection. Cancer 1983;51(2):220-5.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Howell SB, Pfeifle CE, Wung WE</AU>
<TI>Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection</TI>
<SO>Cancer</SO>
<YR>1983</YR>
<VL>51</VL>
<NO>2</NO>
<PG>220-5</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hu-2003" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Hu 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Hu K, Ship JA, Harrison LB. Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/IV head and neck cancer. [Review] [36 refs]. Seminars in Oncology 2003; 30(6 Suppl 18):40-8.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hu K, Ship JA, Harrison LB</AU>
<TI>Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/IV head and neck cancer</TI>
<SO>Seminars in Oncology</SO>
<YR>2003</YR>
<VL>30</VL>
<NO>6 Suppl 18</NO>
<PG>40-8</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hunter-2007" MODIFIED="2010-11-09 14:36:34 +0000" MODIFIED_BY="[Empty name]" NAME="Hunter 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-09 14:36:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Hunter A, Mahendra P, Wilson K, Fields P, Cook G, Peniker A et al</AU>
<TI>A randomized, double-blind, placebo-controlled, multicenter trial of ATL-104, a swallowable mouthwash, in patients with oral mucositis following peripheral blood stem cell transplantation</TI>
<SO>Journal of Supportive Oncology</SO>
<YR>2007</YR>
<VL>5</VL>
<NO>4 Suppl 2</NO>
<PG>52-3</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hwang-2004" MODIFIED="2011-03-08 13:57:44 +0000" MODIFIED_BY="[Empty name]" NAME="Hwang 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-03-08 13:57:44 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Hwang WY, Koh LP, Ng HJ, Tan PH, Chuah CT, Fook SC, et al. A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation. 2004;34(1):51-6.&lt;/p&gt;" NOTES_MODIFIED="2011-03-08 13:57:44 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hwang WY, Koh LP, Ng HJ, Tan PH, Chuah CT, Fook SC et al</AU>
<TI>A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2004</YR>
<VL>34</VL>
<NO>1</NO>
<PG>51-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Inagaki-2006" MODIFIED="2010-11-09 14:37:05 +0000" MODIFIED_BY="[Empty name]" NAME="Inagaki 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-09 14:37:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Inagaki N</AU>
<TI>Report on the treatment of infections complicating hematological diseases. Case 2. Two cases of deep-seated mycosis developing during chemotherapy of leukaemia</TI>
<SO>Japanese Journal of Antibiotics</SO>
<YR>2007</YR>
<VL>60</VL>
<NO>5</NO>
<PG>317-8</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ito-2002" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Ito 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ito A, Hanawa T, Fujii E</AU>
<TI>The preventive effect of allopurinol spray on stomatitis induced by anti-cancer drugs</TI>
<SO>Gan To Kagaku Ryoho</SO>
<YR>2002</YR>
<VL>29</VL>
<NO>4</NO>
<PG>563-7</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jebb-1995" MODIFIED="2010-11-09 14:37:15 +0000" MODIFIED_BY="[Empty name]" NAME="Jebb 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-11-09 14:37:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jebb SA, Marcus R, Elia M</AU>
<TI>A pilot study of oral glutamine supplementation in patients receiving bone marrow transplants</TI>
<SO>Clinical Nutrition</SO>
<YR>1995</YR>
<VL>14</VL>
<NO>3</NO>
<PG>162-5</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jham-2007" MODIFIED="2010-11-09 14:38:09 +0000" MODIFIED_BY="[Empty name]" NAME="Jham 2007" YEAR="2009">
<REFERENCE MODIFIED="2010-11-09 14:37:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jham BC, Chen H, Carvalho AL, Freire AR</AU>
<TI>A randomized phase III prospective trial of bethanechol to prevent mucositis, candidiasis, and taste loss in patients with head and neck cancer undergoing radiotherapy: a secondary analysis</TI>
<SO>Journal of Oral Science</SO>
<YR>2009</YR>
<VL>51</VL>
<NO>4</NO>
<PG>565-72</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 14:38:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jham BC, Teixeira IV, Aboud CG, Carvalho AL, Coelho Mde M, Freire AR</AU>
<TI>A randomized phase III prospective trial of bethanechol to prevent radiotherapy-induced salivary gland damage in patients with head and neck cancer</TI>
<SO>Oral Oncology</SO>
<YR>2007</YR>
<VL>43</VL>
<NO>2</NO>
<PG>137-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-2002" MODIFIED="2010-11-09 14:38:29 +0000" MODIFIED_BY="[Empty name]" NAME="Johnson 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-11-09 14:38:29 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Johnson DJ, Scott CB, Marks JE, Seay TE, Atkins JN, Berk LB, Meoz RT, Wheeler JA.Assessment of quality of life and oral function of patients participating in a phase II study of radioprotection of oral and pharyngeal mucosa by the prostaglandin E(1) analog misoprostol (RTOG 96-07). Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1455-9.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 14:38:29 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson DJ, Scott CB, Marks JE, Seay TE, Atkins JN, Berk LB et al</AU>
<TI>Assessment of quality of life and oral function of patients participating in a phase II study of radioprotection of oral and pharyngeal mucosa by the prostaglandin E(1) analog misoprostol (RTOG 96-07)</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2002</YR>
<VL>54</VL>
<NO>5</NO>
<PG>1455-9</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ju-2009" MODIFIED="2010-11-09 14:39:14 +0000" MODIFIED_BY="[Empty name]" NAME="Ju 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-09 14:39:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ju G-JF, Lu P-H, Wang W-X, Jiao Y-H</AU>
<TI>Effect of systematic oropharyngeal managament in prevention of acute radiation mucositis</TI>
<SO>Chinese Journal of Cancer Prevention and Treatment</SO>
<YR>2009</YR>
<VL>16</VL>
<NO>13</NO>
<PG>1031-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kante-1995" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Kante 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Kante V, et al. Comparative study of two prophylactic regimes for the prevention of mucositis in autologous bone marrow transplants [abstract]. Bone-Marrow-Transplant. 1995;15:253.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kante V</AU>
<TI>Comparative study of two prophylactic regimes for the prevention of mucositis in autologous bone marrow transplants</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1995</YR>
<VL>15</VL>
<PG>253</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karacetin-2004" MODIFIED="2009-10-02 12:34:37 +0100" MODIFIED_BY="Helen Worthington" NAME="Karacetin 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-10-02 12:34:37 +0100" MODIFIED_BY="Helen Worthington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karacetin D, Yucel B, Leblebicioglu B, Aksakal O, Maral O, Incekara O</AU>
<TI>A randomized trial of amifostine as radioprotector in the radiotherapy of head and neck cancer</TI>
<SO>Journal of B.U.ON.</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>1</NO>
<PG>23-6</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karthaus-1998" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Karthaus 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Karthaus M, Rosenthal C, Huebner G, Paul H, Elser C, Hertenstein B et al. Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial. Bone Marrow Transplant 1998;22:781-5.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karthaus M, Rosenthal C, Huebner G, Paul H, Elser C, Hertenstein B et al</AU>
<TI>Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1998</YR>
<VL>22</VL>
<NO>8</NO>
<PG>781-5</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kenny-1990" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Kenny 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kenny SA</AU>
<TI>Effect of two oral care protocols on the incidence of stomatitis in hematology patients</TI>
<SO>Cancer Nursing</SO>
<YR>1990</YR>
<VL>13</VL>
<NO>6</NO>
<PG>345-53</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khouri-2009" MODIFIED="2010-11-09 14:41:02 +0000" MODIFIED_BY="[Empty name]" NAME="Khouri 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-09 14:41:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khouri VY, Stracieri AB, Rodrigues MC, Moraes DA, Pieroni F, Simoes BP et al</AU>
<TI>Use of therapeutic laser for prevention and treatment of oral mucositis</TI>
<SO>Brazilian Dental Journal</SO>
<YR>2009</YR>
<VL>20</VL>
<NO>3</NO>
<PG>215-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klocke-2006" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Klocke 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Klocke J, Cannon M, Gissinger D, Bayer R, Devoe C, John V. Prevention of mucositis in auto BMT/stem cell transplant patients. Oncology Nursing Forum. 2006;33(2):454.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klocke J, Cannon M, Gissinger D, Bayer R, Devoe C, John V</AU>
<TI>Prevention of mucositis in auto BMT/stem cell transplant patients</TI>
<SO>Oncology Nursing Forum</SO>
<YR>2006</YR>
<VL>33</VL>
<NO>2</NO>
<PG>454</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuhn-2009" MODIFIED="2009-08-06 15:32:15 +0100" MODIFIED_BY="[Empty name]" NAME="Kuhn 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-08-06 15:32:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Kuhn A, Porto FA, Miraglia P, Brunetto AL</AU>
<TI>Low-level infrared laser therapy in chemotherapy-induced oral mucositis: a randomized placebo-controlled trial in children</TI>
<SO>Journal of Pediatric Hematology/Oncology</SO>
<YR>2009</YR>
<VL>31</VL>
<NO>1</NO>
<PG>33-7</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuriakose-2002" MODIFIED="2010-11-09 14:41:29 +0000" MODIFIED_BY="[Empty name]" NAME="Kuriakose 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-11-09 14:41:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Kuriakose P, Gandara DR, Perez EA</AU>
<TI>Phase I trial of edatrexate in advanced breast and other cancers</TI>
<SO>Cancer Investigation</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>4</NO>
<PG>473-9</PG>
<IDENTIFIERS MODIFIED="2010-11-09 14:41:29 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Labbate-2003" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Labbate 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Labbate R, Lehn CN, Denardin OVP. Effects of chlorhexidine mouthwash on radiation induced mucosistis in head and neck cancer. Revista Brasileira de Otorrinolaringologia. 2003;69(3):349-54.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Labbate R, Lehn CN, Denardin OVP</AU>
<TI>Effects of chlorhexidine mouthwash on radiation induced mucosistis in head and neck cancer</TI>
<SO>Revista Brasileira de Otorrinolaringologia</SO>
<YR>2003</YR>
<VL>69</VL>
<NO>3</NO>
<PG>349-54</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lanzos-2010" MODIFIED="2010-11-09 14:42:11 +0000" MODIFIED_BY="[Empty name]" NAME="Lanzos 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-11-09 14:42:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lanzos I, Herrera D, Santos S, O'Connor A, Pena C, Lanzos E et al</AU>
<TI>Mucositis in irradiated cancer patients: effects of an antiseptic mouthrinse</TI>
<SO>Medicina Oral, Patologia Oral y Cirugia Bucal</SO>
<YR>2010</YR>
<VL>15</VL>
<NO>5</NO>
<PG>e732-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lavendag-1998" MODIFIED="2010-11-05 11:24:24 +0000" MODIFIED_BY="[Empty name]" NAME="Lavendag 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lavendag PC, Wijers OB, Harms RE, Schmitz PIM, Wilms BE, Visch LL</AU>
<TI>Mucositis prevention by selective elimination of oral flora in irradiated cancers of the head and neck: a prospective randomized study</TI>
<SO>Radiotherapy Oncology</SO>
<YR>1998</YR>
<VL>48</VL>
<PG>S10</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Le-2008" MODIFIED="2010-11-09 14:44:36 +0000" MODIFIED_BY="[Empty name]" NAME="Le 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-11-09 14:42:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henke M, Alfonsi M, Foa P et al</AU>
<TI>Palifermin significantly reduces severe oral mucositis in subjects with resected locally advanced head and neck cancer undergoing post-operative concurrent radio-chemotherapy</TI>
<SO>Radiotherapy Oncology</SO>
<YR>2008</YR>
<VL>88 Suppl 2</VL>
<PG>S152</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 14:44:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Le Q, Kim H, Schneider C, Murakzy G, Skladowski K, Reinisch S et al</AU>
<TI>Palifermin reduces severe oral mucositis in subjects with locally advanced head and neck cancer undergoing chemoradiotherapy</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2008</YR>
<VL>72 Suppl 1</VL>
<PG>S32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1989" MODIFIED="2010-04-29 10:21:29 +0100" MODIFIED_BY="[Empty name]" NAME="Lee 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-04-29 10:21:29 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Lee DJ PT, Stetz J, Order SE, Weissberg JB, Fischer JJ. A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04). International Journal of Radiation Oncology, Biology, Physics 1989;16(2):465-70.&lt;/p&gt;" NOTES_MODIFIED="2010-04-29 10:21:29 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee DJ, Pajak TF, Stetz J, Order SE, Weissberg JB, Fischer JJ</AU>
<TI>A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04)</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1989</YR>
<VL>16</VL>
<NO>2</NO>
<PG>465-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leong-1995" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Leong 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Leong L, Sakurai C, Sebastian W, Shaw N, Grant E, Grant M et al</AU>
<TI>Phase III trial assessing the use of oral thymidine (THY) for prevention of fluorouracil (5-FU)-induced mucositis</TI>
<SO>Proceedings of the Annual Meeting of the American Society of Clinical Oncology</SO>
<YR>1995</YR>
<VL>14</VL>
<PG>A334</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levi-1997" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Levi 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Levi F ZR, Misset J-L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997+ADs-350(9079):681-686.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levi F, Zidani R, Misset JL</AU>
<TI>Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<NO>9079</NO>
<PG>681-6</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loo-2010" MODIFIED="2010-11-09 14:45:50 +0000" MODIFIED_BY="[Empty name]" NAME="Loo 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-11-09 14:45:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loo WT, Jin L, Chow LW, Cheung M.N, Wang M</AU>
<TI>Rhodiola algida improves chemotherapy-induced oral mucositis in breast cancer patients</TI>
<SO>Expert Opinion on Investigational Drugs</SO>
<YR>2010</YR>
<VL>19 Suppl 1</VL>
<PG>S91-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lopez-1994" MODIFIED="2011-03-08 14:00:28 +0000" MODIFIED_BY="[Empty name]" NAME="Lopez 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-03-08 14:00:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lopez I, Goudou C, Ribrag V, Sauvage C, Hazebroucq G, Dreyfus F</AU>
<TI>Treatment of mucositis with vitamin E during administration of neutropenic antineoplastic agents</TI>
<SO>Annales de Medecine Interne</SO>
<YR>1994</YR>
<VL>145</VL>
<NO>6</NO>
<PG>405-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lopez_x002d_Campo-2004" MODIFIED="2011-03-08 13:14:23 +0000" MODIFIED_BY="[Empty name]" NAME="Lopez-Campo 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-03-08 13:14:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Lopez-Campo JH</AU>
<TI>Chemotherapy induced stomatitis management using collagenase vs a liquid mixture</TI>
<SO>Pediatric Blood and Cancer</SO>
<YR>2004</YR>
<VL>43</VL>
<NO>4</NO>
<MD>RCT ?prev or ? treatment of OM</MD>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lorusso-2003" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Lorusso 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Lorusso D FG, Greggi S, Gadducci A, Pignata S, Tateo S, Biamonte R, Manzione L, Di Vagno G, Ferrau' F, Scambia G, Multicenter Italian Trials in Ovarian Cancer invesitgators. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Annals of Oncology 2003;14(7):1086-93.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lorusso D, Ferrandina G, Greggi S, Gadducci A, Pignata S, Tateo S</AU>
<TI>Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients</TI>
<SO>Annals of Oncology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>7</NO>
<PG>1086-93</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lozada-1998" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Lozada 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lozada-Nur F, Schoelch M, Fu K, Muscoplat C, Trivedi M, Smith C et al</AU>
<TI>A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy</TI>
<SO>Proceedings of the Annual Meeting of the Society of Clinical Oncology</SO>
<YR>1998</YR>
<PG>1541</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lugli_x00e9_-2002" MODIFIED="2010-11-09 14:46:35 +0000" MODIFIED_BY="[Empty name]" NAME="Lugli 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-11-09 14:46:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lugli PF, Mura G, Mura A, Angius A, Soru G, Farris A</AU>
<TI>Prevention of periodontopathy and oral mucositis during antineoplastic chemotherapy. Clinical study</TI>
<SO>Minerva Stomatologica</SO>
<YR>2002</YR>
<VL>51</VL>
<NO>6</NO>
<PG>231-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maddocks_x002d_Jennings-2009" MODIFIED="2009-08-06 13:39:46 +0100" MODIFIED_BY="[Empty name]" NAME="Maddocks-Jennings 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-08-06 13:39:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Maddocks-Jennings W, Wilkinson JM, Cavanagh HM, Shillington D</AU>
<TI>Evaluating the effects of the essential oils Leptospermum scoparium (manuka) and Kunzea ericoides (kanuka) on radiotherapy induced mucositis: a randomized, placebo controlled feasibility study</TI>
<SO>European Journal of Oncology Nursing</SO>
<YR>2009</YR>
<VL>13</VL>
<NO>2</NO>
<PG>87-93</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Madero-1999" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Madero 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Madero L DM, Ortega JJ, Olive T, Martinez A, Badell I, Munoz A, Gomez P. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates engraftment kinetics after allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia. Haematologica 1999;84(2):133-7.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Madero L, Diaz MA, Ortega JJ, Olive T, Martinez A, Badell I et al</AU>
<TI>Recombinant human granulocyte-macrophage colony-stimulating factor accelerates engraftment kinetics after allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia</TI>
<SO>Haematologica</SO>
<YR>1999</YR>
<VL>84</VL>
<NO>2</NO>
<PG>133-7</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahmoud-1996" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Mahmoud 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Mahmoud HK SE, Kamel M, El HMA, Nassar A. Influence of folinic acid rescue on methotrexate-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation. Tumor Diagnostik Und Therapie. 1996+ADs-17(1):18-21.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mahmoud HK SE, Kamel M, El HMA, Nassar A</AU>
<TI>Influence of folinic acid rescue on methotrexate-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation</TI>
<SO>Tumor Diagnostik Und Therapie</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>18-21</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malaker-1991" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Malaker 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Malaker K, Anderson BJ, Beecroft WA, Hodson DI. Management of oral mucosal dysplasia with beta-carotene retinoic acid: a pilot cross-over study. Cancer Detection +ACY- Prevention 1991+ADs-15(5):335-40.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malaker K, Anderson BJ, Beecroft WA, Hodson DI</AU>
<TI>Management of oral mucosal dysplasia with beta-carotene retinoic acid: a pilot cross-over study</TI>
<SO>Cancer Detection and Prevention</SO>
<YR>1991</YR>
<VL>15</VL>
<NO>5</NO>
<PG>335-40</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mantovani-2003" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Mantovani 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Mantovani G, Massa E, Astara G, Murgia V, Gramignano G, Lusso MR, et al. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs. Oncology Reports 2003+ADs- 10(1):197-206.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mantovani G, Massa E, Astara G, Murgia V, Gramignano G, Lusso MR et al</AU>
<TI>Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs</TI>
<SO>Oncology Reports</SO>
<YR>2003</YR>
<VL>10</VL>
<NO>1</NO>
<PG>197-206</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marcial-1994" MODIFIED="2010-11-09 14:46:59 +0000" MODIFIED_BY="[Empty name]" NAME="Marcial 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-11-09 14:46:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marcial F, Schubert M, Niccoli-Filho WD, Lloid ME, Kelly J, Franquin JC et al</AU>
<TI>A phase I/II nonblinded randomized trial to determine the efficacy of low-energy laser to prevent oral mucositis resulting from conditioning regimens for bone marrow transplantation</TI>
<SO>Oral Surgery, Oral Medicine, and Oral Pathology</SO>
<YR>1994</YR>
<VL>78</VL>
<NO>6</NO>
<PG>738</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin-2006" MODIFIED="2010-11-09 14:47:19 +0000" MODIFIED_BY="[Empty name]" NAME="Martin 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-09 14:47:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Martin M, Lluch A, Segui MA, Ruiz A, Ramos M, Adrover E et al</AU>
<TI>Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen</TI>
<SO>Annals of Oncology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>8</NO>
<PG>1205-12</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Masucci-2005" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Masucci 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Masucci G, Broman P, Kelly C, Lindahl S, Malmberg L, Reizenstein J, et al. Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy: a multicenter open randomized phase III study. Medical Oncology. 2005;22(3):247-56.&lt;/p&gt;" NOTES_MODIFIED="2010-03-05 23:18:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Masucci G, Broman P, Kelly C, Lindahl S, Malmberg L, Reizenstein J et al</AU>
<TI>Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy: a multicenter open randomized phase III study</TI>
<SO>Medical Oncology</SO>
<YR>2005</YR>
<VL>22</VL>
<NO>3</NO>
<PG>247-56</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matejka-1990" MODIFIED="2010-11-09 14:47:50 +0000" MODIFIED_BY="[Empty name]" NAME="Matejka 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-11-09 14:47:50 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Matejka M, Nell A, Kment G, Schein A, Leukauf M, Porteder H, Mailath G, Sinzinger H.Local benefit of prostaglandin E2 in radiochemotherapy-induced oral mucositis. Br J Oral Maxillofac Surg. 1990 Apr;28(2):89-91.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 14:47:50 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matejka M, Nell A, Kment G, Schein A, Leukauf M, Porteder H et al</AU>
<TI>Local benefit of prostaglandin E2 in radiochemotherapy-induced oral mucositis</TI>
<SO>The British Journal of Oral &amp; Maxillofacial Surgery</SO>
<YR>1990</YR>
<VL>28</VL>
<NO>2</NO>
<PG>89-91</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McIlroy-1996" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="McIlroy 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McIlroy P</AU>
<TI>Radiation mucositis: a new approach to prevention and treatment</TI>
<SO>European Journal of Cancer Care</SO>
<YR>1996</YR>
<VL>5</VL>
<NO>3</NO>
<PG>153-8</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Merte-1999" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Merte 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Merte H, Wied R, Engenhart-Cabillic R</AU>
<TI>Der effekt von immunglobulinen in der behandlung der radiogenen dermatitis und mukositis bei patienten mit hals-nasen und rachentumoren</TI>
<SO>Strahlentherapy und Onkologie</SO>
<YR>1999</YR>
<VL>175</VL>
<NO>1</NO>
<PG>135</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mills-1995" MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Mills 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mills W, Strang J, Goldstone AH, Linch DC</AU>
<TI>Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma</TI>
<SO>Leukemia &amp; Lymphoma</SO>
<YR>1995</YR>
<VL>17</VL>
<NO>3-4</NO>
<PG>263-70</PG>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-05 23:18:20 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mori-2006" MODIFIED="2010-11-09 14:48:18 +0000" MODIFIED_BY="[Empty name]" NAME="Mori 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-09 14:48:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Mori T, Yamazaki R, Aisa Y, Nakazato T, Kudo M, Yashima T et al</AU>
<TI>Brief oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2006</YR>
<VL>14</VL>
<NO>4</NO>
<PG>392-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nicolatou_x002d_Galitis-2006" MODIFIED="2010-11-09 14:48:48 +0000" MODIFIED_BY="[Empty name]" NAME="Nicolatou-Galitis 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-09 14:48:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nicolatou-Galitis O, Velegraki A, Sotiropoulou-Lontou A, Dardoufas K, Kouloulias V, Kyprianou K et al</AU>
<TI>Effect of fluconazole antifungal prophylaxis on oral mucositis in head and neck cancer patients receiving radiotherapy</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2006</YR>
<VL>14</VL>
<NO>1</NO>
<PG>44-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niibe-1985" MODIFIED="2010-11-09 14:51:49 +0000" MODIFIED_BY="[Empty name]" NAME="Niibe 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-11-09 14:51:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Niibe H, Takahashi I, Mitsuhashi N, Miyaishi K, Itoh J, Maehara Y et al</AU>
<TI>An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study. 1. Head and neck tumors</TI>
<SO>Nippon Gan Chiryo Gakkai Shi</SO>
<YR>1985</YR>
<VL>20</VL>
<NO>5</NO>
<PG>984-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 14:50:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Niibe H, Takahashi I, Miyaishi K, Mitsuhashi N, Maehara Y, Nakajima N et al</AU>
<TI>An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study. 2. Abdominal and pelvic tumours</TI>
<SO>Nippon Gan Chiryo Gakkai Shi</SO>
<YR>1985</YR>
<VL>20</VL>
<NO>5</NO>
<PG>994-1001</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nikoletti-2005" MODIFIED="2010-11-03 16:16:13 +0000" MODIFIED_BY="[Empty name]" NAME="Nikoletti 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-11-03 16:16:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Nikoletti S, Hyde S, Shaw T, Myers H, Kristjanson LJ</AU>
<TI>Comparison of plain ice and flavoured ice for preventing oral mucositis associated with the use of 5 fluorouracil</TI>
<SO>Journal of Clinical Nursing</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>6</NO>
<PG>750-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Okuno-1997" NAME="Okuno 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okuno SH, Foote RL, Loprinzi CL, Gulavita S, Sloan JA, Earle J et al</AU>
<TI>A randomized trial of a nonabsorbable antibiotic lozenge given to alleviate radiation-induced mucositis</TI>
<SO>Cancer</SO>
<YR>1997</YR>
<VL>79</VL>
<NO>1</NO>
<PG>2193-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Okutomi-2000" MODIFIED="2010-11-09 14:52:10 +0000" MODIFIED_BY="[Empty name]" NAME="Okutomi 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-11-09 14:52:10 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Okutomi T, Kato Y, Ichihara H, Hyodo I, Fujitsuka H, Yasuda S, Tatematsu N. [Clinical effects of adjuvant therapy using Z-100 (Ancer 20 injection) for oral cancer--prevention of stomatitis and hematopoietic impairment] Gan To Kagaku Ryoho. 2000 Jan;27(1):65-71.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 14:52:10 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okutomi T, Kato Y, Ichihara H, Hyodo I, Fujitsuka H, Yasuda S et al</AU>
<TI>Clinical effects of adjuvant therapy using Z-100 (Ancer 20 injection) for oral cancer--prevention of stomatitis and hematopoietic impairment</TI>
<SO>Gan To Kagaku Ryoho</SO>
<YR>2000</YR>
<VL>27</VL>
<NO>1</NO>
<PG>65-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Papadeas-2007" MODIFIED="2010-11-09 14:52:25 +0000" MODIFIED_BY="[Empty name]" NAME="Papadeas 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-09 14:52:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Papadeas E, Naxakis S, Riga M, Kalofonos Ch</AU>
<TI>Prevention of 5-fluorouracil-related stomatitis by oral cryotherapy: a randomized controlled study</TI>
<SO>European Journal Oncology Nursing</SO>
<YR>2007</YR>
<VL>11</VL>
<NO>1</NO>
<PG>60-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Papas-1984" MODIFIED="2010-10-25 10:05:09 +0100" MODIFIED_BY="[Empty name]" NAME="Papas 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-10-25 10:05:09 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Papas A, E J. Prevention of Mucositis in Oncology Patients Undegoing Radiation Therapy (JDR Abstract). J-Dent-Res 1984;63(Special Issue March):311 (Abs 1267).&lt;/p&gt;" NOTES_MODIFIED="2010-10-25 10:05:09 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Papas A, Johansen E</AU>
<TI>Prevention of mucositis in oncology patients undergoing radiation therapy</TI>
<SO>Journal of Dental Research</SO>
<YR>1984</YR>
<VL>63</VL>
<NO>Special Issue March</NO>
<PG>311 (Abs No 1267)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Papas-2003" MODIFIED="2010-11-03 18:02:39 +0000" MODIFIED_BY="[Empty name]" NAME="Papas 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-12 16:40:30 +0000" MODIFIED_BY="Helen Worthington" NOTES="&lt;p&gt;Papas AS, Clark RE, Martuscelli G, O'Loughlin KT, Johansen E, Miller KB. A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplantation 2003+ADs- 31(8):705-12.&lt;/p&gt;" NOTES_MODIFIED="2010-01-12 16:40:30 +0000" NOTES_MODIFIED_BY="Helen Worthington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Papas AS, Clark RE, Martuscelli G, O'Loughlin KT, Johansen E, Miller KB</AU>
<TI>A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2003</YR>
<VL>31</VL>
<NO>8</NO>
<PG>705-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Penpattanagul-2007" MODIFIED="2010-11-09 14:56:29 +0000" MODIFIED_BY="[Empty name]" NAME="Penpattanagul 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-09 14:56:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Penpattanagul S</AU>
<TI>Reduced incidence and severity of acute radiation mucositis by WF10 (immunokine) as adjunct to standard of cure in the management of head &amp; neck cancer patients</TI>
<SO>Journal of the Medical Association of Thailand</SO>
<YR>2007</YR>
<VL>90</VL>
<NO>8</NO>
<PG>1590-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peters-1993" NAME="Peters 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Peters E A-BA, Burdick E. Meta-Analysis of Chlorhexidine in the Prevention of Mucositis from Chemotherapy (IADR Abstract). Journal of Dental Research 1993+ADs-72:259 (Abs No 1249).&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peters E, Antczak-Bouckoms A, Burdick E</AU>
<TI>Meta-analysis of chlorhexidine in the prevention of mucositis from chemotherapy</TI>
<SO>Journal of Dental Research</SO>
<YR>1993</YR>
<VL>Special Issue</VL>
<NO>259</NO>
<PG>1249</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Phillips-2002" MODIFIED="2010-11-09 14:56:46 +0000" MODIFIED_BY="[Empty name]" NAME="Phillips 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-11-09 14:56:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Phillips GL 2nd</AU>
<TI>The potential of amifostine in high-dose chemotherapy and autologous hematopoietic stem cell transplantation</TI>
<SO>Seminars in Oncology</SO>
<YR>2002</YR>
<VL>29</VL>
<NO>6 Supp 19</NO>
<PG>53-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piccirillo-2003" NAME="Piccirillo 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piccirillo N, De Matteis S, Laurenti L, Chiusolo P, Sora F, Pittiruti M et al</AU>
<TI>Glutamine-enriched parenteral nutrition after autologous peripheral blood stem cell transplantation: effects on immune reconstitution and mucositis</TI>
<SO>Haematologica</SO>
<YR>2003</YR>
<VL>88</VL>
<NO>2</NO>
<PG>192-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pouli-1999" NAME="Pouli 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pouli A, Nikiforakis E</AU>
<TI>A prospective randomized trial of GM-CFS mouthwash versus sodium bicarbonate mouthwash in the treatment of stomatitis following allogeneic bone marrow transplantation</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1999</YR>
<VL>23</VL>
<PG>S166</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prada-1985" NAME="Prada 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prada A, Lozza L, Moglia D, Sala L, Chiesa F</AU>
<TI>Effects of benzydamine on radio-polychemotherapeutic mucositis of the oral cavity</TI>
<SO>International Journal of Tissue Reaction</SO>
<YR>1985</YR>
<VL>7</VL>
<NO>3</NO>
<PG>237-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Putwatana-2009" MODIFIED="2010-11-09 14:57:11 +0000" MODIFIED_BY="[Empty name]" NAME="Putwatana 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-09 14:57:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Putwatana P, Sanmanowong P, Oonprasertpong L, Junda T, Pitiporn S, Narkwong L</AU>
<TI>Relief of radiation-induced oral mucositis in head and neck cancer</TI>
<SO>Cancer Nursing</SO>
<YR>2009</YR>
<VL>32</VL>
<NO>1</NO>
<PG>82-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pyrhonen-1995" NAME="Pyrhonen 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. British Journal of Cancer. 1996;71(3):587-91.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M</AU>
<TI>Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer</TI>
<SO>British Journal of Cancer</SO>
<YR>1995</YR>
<VL>71</VL>
<NO>3</NO>
<PG>587-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pytlik-2002" NAME="Pytlik 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Pytlik R, Benes P, Patorkova M, Chocenska E, Gregora E, Prochazka B, et al. Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo controlled study. Bone Marrow Transplantation 2002+ADs- 30(12):953-61.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pytlik R, Benes P, Patorkova M, Chocenska E, Gregora E, Prochazka B et al</AU>
<TI>Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo controlled study</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2002</YR>
<VL>30</VL>
<NO>12</NO>
<PG>953-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rabinovitch-2006" NAME="Rabinovitch 2006" YEAR="2006">
<REFERENCE NOTES="&lt;p&gt;Rabinovitch R, Grant B, Berkey BA, Raben D, Ang KK, Fu KK, et al. Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: a secondary analysis of RTOG trial 90-03. Head &amp;amp; Neck. 2006;28(4):287-96.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rabinovitch R, Grant B, Berkey BA, Raben D, Ang KK, Fu KK et al</AU>
<TI>Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: a secondary analysis of RTOG trial 90-03</TI>
<SO>Head &amp; Neck</SO>
<YR>2006</YR>
<VL>28</VL>
<NO>4</NO>
<PG>287-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rades-2004" NAME="Rades 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Rades D, Fehlauer F, Bajrovic A, Mahlmann B, Richter E, Alberti W. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.[see comment]. Radiotherapy &amp;amp; Oncology. 2004;70(3):261-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rades D, Fehlauer F, Bajrovic A, Mahlmann B, Richter E, Alberti W</AU>
<TI>Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients</TI>
<SO>Radiotherapy and Oncology</SO>
<YR>2004</YR>
<VL>70</VL>
<NO>3</NO>
<PG>261-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Radmard-2002" MODIFIED="2010-11-09 14:57:47 +0000" MODIFIED_BY="[Empty name]" NAME="Radmard 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-11-09 14:57:47 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Radmard A, Niewohner-Desbordes U, Wagner W. [ rhGM-CSF in the treatment of radiogenic mucositis: prospective randomised phase-II study on the effectivity and tolerance of rhGM-CSF in the treatment of oral mucositis under radiotherapy of head and neck tumors. ]. Strahlentherapie und Onkologie. 2002;178(Sondernr 1):24.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 14:57:47 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Radmard A, Niewohner-Desbordes U, Wagner W</AU>
<TI>rhGM-CSF in the treatment of radiogenic mucositis: prospective randomised phase-II study on the effectivity and tolerance of rhGM-CSF in the treatment of oral mucositis under radiotherapy of head and neck tumors</TI>
<SO>Strahlentherapie und Onkologie</SO>
<YR>2002</YR>
<VL>178 Suppl 1</VL>
<PG>24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raether-1989" MODIFIED="2011-03-08 14:03:19 +0000" MODIFIED_BY="[Empty name]" NAME="Raether 1989" YEAR="1989">
<REFERENCE MODIFIED="2011-03-08 14:03:19 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Raether D, Walker PO, Bostrum B, Weisdorf D. Effectiveness of oral chlorhexidine for reducing stomatitis in a pediatric bone marrow transplant population. Pediatric Dentistry 1989;11:37-42.&lt;/p&gt;" NOTES_MODIFIED="2011-03-08 14:03:19 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raether D, Walker PO, Bostrum B, Weisdorf D</AU>
<TI>Effectiveness of oral chlorhexidine for reducing stomatitis in a pediatric bone marrow transplant population</TI>
<SO>Pediatric Dentistry</SO>
<YR>1989</YR>
<VL>11</VL>
<NO>1</NO>
<PG>37-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robustelli-1999" NAME="Robustelli 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Robustelli della Cuna FS, Ucci G, Cuomo AM, Goglio AM. Galenic preparation for the prophylaxsis of oral mucositis induced by 5-fluororacil continous infusion. Supportive Care in Cancer. 1999;7 Suppl.(Abstr P-67):132.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robustelli della Cuna FS, Ucci G, Cuomo AM, Goglio AM</AU>
<TI>Galenic preparation for the prophylaxsis of oral mucositis induced by 5-fluororacil continous infusion</TI>
<SO>Supportive Care in Cancer</SO>
<YR>1999</YR>
<VL>7 Suppl</VL>
<PG>132 (Abs No P-67)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rocci-2005" MODIFIED="2010-11-09 14:58:05 +0000" MODIFIED_BY="[Empty name]" NAME="Rocci 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-11-09 14:58:05 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Rocci L, Vincenzi B, Santini D, Tonini G. Timing of 5-fluorouracile infusion: a randomized clinical trial [Italian]. International Nursing Perspectives. 2005;5(2):53-60. (32 ref).&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 14:58:05 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rocci L, Vincenzi B, Santini D, Tonini G</AU>
<TI>Timing of 5-fluorouracile infusion: a randomized clinical trial</TI>
<SO>International Nursing Perspectives</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>2</NO>
<PG>53-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rojas-2001" NAME="Rojas 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Rojas de Morales T ZO, Rivera L, Navas R, Chaparro N, Bernardonni C, Rivera F, Fonseca N, Tirado DM. Oral-disease prevention in children with cancer: testing preventive protocol effectiveness. Medicina Oral 2001+ADs-6(5):326-34.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rojas de Morales T, Zambrano O, Rivera L, Navas R, Chaparro N, Bernardonni C et al</AU>
<TI>Oral-disease prevention in children with cancer: testing preventive protocol effectiveness</TI>
<SO>Medicina Oral</SO>
<YR>2001</YR>
<VL>6</VL>
<NO>5</NO>
<PG>326-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rothwell-1990" MODIFIED="2010-11-04 17:54:28 +0000" MODIFIED_BY="[Empty name]" NAME="Rothwell 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-10-25 11:08:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rothwell BR</AU>
<TI>Palliation of radiation-related mucositis</TI>
<SO>Special Care in Dentistry</SO>
<YR>1990</YR>
<VL>10</VL>
<NO>1</NO>
<PG>21-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-11-04 17:54:28 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rutkauskas-1993" MODIFIED="2010-11-09 14:58:16 +0000" MODIFIED_BY="[Empty name]" NAME="Rutkauskas 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-11-09 14:58:16 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Rutkausas JS, Davis JW. Effects of chlorhexidine during immunosuppressive chemotherapy: A preliminary report. Oral Surg Oral Med Oral Path 1993;76:441-8.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 14:58:16 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rutkauskas JS, Davis JW</AU>
<TI>Effects of chlorhexidine during immunosuppressive chemotherapy: A preliminary report</TI>
<SO>Oral Surgery, Oral Medicine, and Oral Pathology</SO>
<YR>1993</YR>
<VL>76</VL>
<NO>4</NO>
<PG>441-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ryu-2007" MODIFIED="2010-11-09 14:58:25 +0000" MODIFIED_BY="[Empty name]" NAME="Ryu 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-09 14:58:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Ryu JK, Swann S, LeVeque F, Scarantino CW, Johnson D, Chen A et al</AU>
<TI>The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2007</YR>
<VL>67</VL>
<NO>3</NO>
<PG>643-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Samaranayake-1988" MODIFIED="2011-03-08 14:04:16 +0000" MODIFIED_BY="[Empty name]" NAME="Samaranayake 1988" YEAR="1988">
<REFERENCE MODIFIED="2011-03-08 14:04:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Samaranayake LP, Robertson AG, MacFarlane TW, Hunter IP, MacFarlane G, Soutar DS et al</AU>
<TI>The effect of chlorhexidine and benzydamine mouthwashes on mucositis induced by therapeutic irradiation</TI>
<SO>Clinical Radiology</SO>
<YR>1988</YR>
<VL>39</VL>
<NO>3</NO>
<PG>291-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sato-1997" MODIFIED="2010-11-09 14:58:48 +0000" MODIFIED_BY="[Empty name]" NAME="Sato 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-11-09 14:58:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sato A, Kumagai S, Sakaki K, Morikawa H, Song ST, Mori S</AU>
<TI>Inhibition of 5-fluorouracil-cisplatin-induced stomatitis by oral cryotherapy: use of an ice-bar containing fibrinolysin and deoxyribonuclease comiben (Elase)</TI>
<SO>Gan to Kagaku Ryoho</SO>
<YR>1997</YR>
<VL>24</VL>
<NO>9</NO>
<PG>1135-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sato-2006" MODIFIED="2010-11-09 14:59:15 +0000" MODIFIED_BY="[Empty name]" NAME="Sato 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-09 14:59:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Sato A, Saisho-Hattori T, Koizumi Y, Minegishi M, Iinuma K, Imaizumi M</AU>
<TI>Prophylaxis of mucosal toxicity by oral propantheline and cryotherapy in children with malignancies undergoing myeloablative chemo-radiotherapy</TI>
<SO>The Tohoku Journal of Experimental Medicine</SO>
<YR>2006</YR>
<VL>210</VL>
<NO>4</NO>
<PG>315-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schuster-2008" MODIFIED="2010-11-09 14:59:57 +0000" MODIFIED_BY="[Empty name]" NAME="Schuster 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-11-09 14:59:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Schuster MW, Anaissie E, Hurd D, Bensinger W, Mason J, McCarty J et al</AU>
<TI>Final analysis of the phase II, randomized, double-blind, placebo-controlled trial of single-dose velafermin (CG53135-05) for the prevention of oral mucositis</TI>
<SO>Journal of Supportive Oncology</SO>
<YR>2007</YR>
<VL>5</VL>
<NO>4 Suppl 2</NO>
<PG>58-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 14:59:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schuster MW, Shore TB, Harpel JG, Greenberg J, Jalilizeinali B, Possley S et al</AU>
<TI>Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2008</YR>
<VL>16</VL>
<NO>5</NO>
<PG>477-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwerkoske-1999" MODIFIED="2010-11-09 15:00:35 +0000" MODIFIED_BY="[Empty name]" NAME="Schwerkoske 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-11-09 15:00:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Schwerkoske J, Schwartzberg L, Weaver CH, Schwertschlag US, Goodfellow J, Bedrosian CL</AU>
<TI>A phase 1 double-masked, placebo-controlled study to evaluate tolerability of Neumega (rhIL-11; oprelvekin) to reduce mucositis in patients with solid tumors or lymphoma receiving high-dose chemotherapy (CT) with autologous peripheral blood stem cell reinfusion (PBSCT)</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>1999</YR>
<VL>18</VL>
<PG>584a (Abstract 2256)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shabanloei-2009" MODIFIED="2010-11-09 15:01:04 +0000" MODIFIED_BY="[Empty name]" NAME="Shabanloei 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-09 15:01:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shabanloei R, Ahmadi F, Vaez J, Ansarin K, Hajizadeh E, Javadzadeh Y et al</AU>
<TI>Allopurinol, chamomile and normal saline mouth washes for the prevention of chemotherapy- induced stomatitis</TI>
<SO>Journal of Clinical and Diagnostic Research</SO>
<YR>2009</YR>
<VL>3</VL>
<NO>3</NO>
<PG>1537-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-2009" MODIFIED="2010-11-09 15:02:16 +0000" MODIFIED_BY="[Empty name]" NAME="Sharma 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-09 15:02:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma A, Rath GK, Choudhary SP, Thakar A, Mohanti BK, Bahadur S et al</AU>
<TI>A randomized double-blind phase III study of efficacy of lactobacillus CD2 lozenges in preventing radiation- and chemotherapy- induced oral mucositis in head and neck cancer patients: Interim analysis</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>15S</NO>
<PG>6008</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shea-2007" MODIFIED="2010-11-09 15:04:46 +0000" MODIFIED_BY="[Empty name]" NAME="Shea 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-09 15:04:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shea TC, Kewalramani T, Mun Y, Jayne G, Dreiling LK</AU>
<TI>Evaluation of single-dose palifermin to reduce oral mucositis (OM) in fractionated total body irradiation (fTBI) and high dose (HD) chemotherapy with autologous peripheral blood progenitor cell (PBPC) transplantation</TI>
<SO>Blood</SO>
<YR>2006</YR>
<VL>108</VL>
<NO>11 Part 1</NO>
<PG>875-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 15:04:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shea TC, Kewalramani T, Mun Y, Jayne G, Dreiling LK</AU>
<TI>Evaluation of single-dose palifermin to reduce oral mucositis in fractionated total-body irradiation and high-dose chemotherapy with autologous peripheral blood progenitor cell transplantation</TI>
<SO>Journal of Supportive Oncology</SO>
<YR>2007</YR>
<VL>5</VL>
<NO>4 Suppl 2</NO>
<PG>60-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shidfar-2008" MODIFIED="2010-11-09 15:05:12 +0000" MODIFIED_BY="[Empty name]" NAME="Shidfar 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-11-09 15:05:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shidfar F, Ghorayshi Z, Iravani M, Aghahosseini F</AU>
<TI>The effects of vitamin E intakes on mucositis and neutropenia in patients with Leukamia</TI>
<SO>Pediatric Blood Cancer</SO>
<YR>2008</YR>
<VL>50 Suppl 5</VL>
<PG>165</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simoes-2009" MODIFIED="2010-11-09 15:05:38 +0000" MODIFIED_BY="[Empty name]" NAME="Simoes 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-09 15:05:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simoes A, Eduardo FP, Luiz AC, Campos L, Sa PH, Cristofaro M et al</AU>
<TI>Laser phototherapy as topical prophylaxis against head and neck cancer radiotherapy-induced oral mucositis: comparison between low and high/low power lasers</TI>
<SO>Lasers in Surgery and Medicine</SO>
<YR>2009</YR>
<VL>41</VL>
<NO>4</NO>
<PG>264-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spadaro-1991" MODIFIED="2010-11-09 15:05:55 +0000" MODIFIED_BY="[Empty name]" NAME="Spadaro 1991" YEAR="">
<REFERENCE MODIFIED="2010-11-09 15:05:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spadaro P, Buemi B, Ferraro G, Marabello G, Russi E, Pergolizzi S</AU>
<TI>Prophylaxis of chemotherapy-radiotherapy induced mucositis or oral fungal infection with vitamin E + vitamin A and Fluconazolo</TI>
<SO>European Journal of Cancer</SO>
<YR>1991</YR>
<VL>27 Suppl 2</VL>
<PG>S288</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spielberger-2001" MODIFIED="2010-11-09 15:06:36 +0000" MODIFIED_BY="[Empty name]" NAME="Spielberger 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-11-09 15:06:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Spielberger RT, Stiff P, Emmanouilides C, Yanovich S, Bensinger W, Hedrick E et al</AU>
<TI>Efficacy of recombinant human keratinocyte growth factor (rHuKGF) in reducing mucositis in patients with hematologic malignancies undergoing autologous peripheral blood progenitor cell transplantation (auto-PBPCT) after radiation-based conditioning - results of a phase 2 trial</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>2001</YR>
<VL>20 (Pt 1)</VL>
<PG>7a (Abstract 25)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stokman-2004" NAME="Stokman 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Stokman MA, Wachters FM, Koopmans P, Burgerhof JG, Groen HJ, Spijkervet FK, et al. Outcome of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis. A phase II study. Anticancer Research. 2004;24(5B):3263-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stokman MA, Wachters FM, Koopmans P, Burgerhof JG, Groen HJ, Spijkervet FK et al</AU>
<TI>Outcome of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis. A phase II study</TI>
<SO>Anticancer Research</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>5B</NO>
<PG>3263-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Teshima-1986" MODIFIED="2010-11-09 15:07:13 +0000" MODIFIED_BY="[Empty name]" NAME="Teshima 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-11-09 15:07:13 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Teshima T, et al. [Clinical Evaluation of Kenalog Ointment for Radiation Mucositis of Patients with Head and Neck Cancer]. Yakuri to Chiryo (Japanese Pharmacology and Therapeutics). 1986;14(11):7163-6.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 15:07:13 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teshima T</AU>
<TI>Clinical evaluation of kenalog ointment for radiation mucositis of patients with head and neck cancer</TI>
<SO>Yakuri to Chiryo</SO>
<YR>1986</YR>
<VL>14</VL>
<NO>11</NO>
<PG>7163-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thieblemont-2002" NAME="Thieblemont 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Thieblemont C, C D, H S, N R, F B, P A, et al. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplantation 2002;30(11):769-75.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thieblemont C, Dumontet C, Saad H, Roch N, Bouafia F, Arnaud P et al</AU>
<TI>Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2002</YR>
<VL>30</VL>
<NO>11</NO>
<PG>769-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Throuvalas-1995" MODIFIED="2010-11-09 15:07:42 +0000" MODIFIED_BY="[Empty name]" NAME="Throuvalas 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-11-09 15:07:42 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Throuvalas Nao. Evaluation of the efficacy and safety of GM-CSF in the prophylaxis of mucositis in patients with head and neck cancer treated with RT. European Journal of Cancer 1995;31?(Suppl 5):S93 Abs. 431.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 15:07:42 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Throuvalas N, Antonadou D, Pulizzi M, Sarris G</AU>
<TI>Evaluation of the efficacy and safety of GM-CSF in the prophylaxis of mucositis in patients with head and neck cancer treated with RT</TI>
<SO>European Journal of Cancer</SO>
<YR>1995</YR>
<VL>31 Suppl 5</VL>
<PG>S93 (Abstract 431)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tiemann-2006" MODIFIED="2010-11-09 15:08:41 +0000" MODIFIED_BY="[Empty name]" NAME="Tiemann 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-09 15:08:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Tiemann P, Toelg M, Ramos FM</AU>
<TI>Administration of Ratanhia-based herbal oral care products for the prophylaxis of oral mucositis in cancer chemotherapy patients: a clinical trial</TI>
<SO>Evidence Based Complementary and Alternative Medicine</SO>
<YR>2007</YR>
<VL>4</VL>
<NO>3</NO>
<PG>361-6</PG>
<IDENTIFIERS MODIFIED="2010-11-09 15:08:41 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Toubai-2003" NAME="Toubai 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Toubai T, Tanaka J, Fujisawa F, Kondo Y, Imamura M, Ota S, et al. Effect of prophylaxis against myocosis in patients with hematological malignancy disease: efficacy of dosage of itraconazole. +AFs-Japanese+AF0-. Japanese Journal of Antibiotics 2003+ADs- 56(1):61-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Toubai T, Tanaka J, Fujisawa F, Kondo Y, Imamura M, Ota S et al</AU>
<TI>Effect of prophylaxis against myocosis in patients with hematological malignancy disease: efficacy of dosage of itraconazole</TI>
<SO>Japanese Journal of Antibiotics</SO>
<YR>2003</YR>
<VL>56</VL>
<NO>1</NO>
<PG>61-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uchiyama-2005" NAME="Uchiyama 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;Uchiyama Y, Murakami S, Kakimoto N, Nakatani A, Furukawa S. Effectiveness of Cepharanthin in decreasing interruptions during radiation therapy for oral cancer. Oral Radiology. 2005;21(1):41-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uchiyama Y, Murakami S, Kakimoto N, Nakatani A, Furukawa S</AU>
<TI>Effectiveness of Cepharanthin in decreasing interruptions during radiation therapy for oral cancer</TI>
<SO>Oral Radiology</SO>
<YR>2005</YR>
<VL>21</VL>
<NO>1</NO>
<PG>41-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Valc_x00e1_rcel-1997" NAME="Valcrcel 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Valc&amp;#225;rcel F, De la Torre A, Arag&amp;#243;n G, Lanz&amp;#243;s E, Rodr&amp;#237;guez R, Veiras C. Double-blind randomized and pilot study on the potential of thymostimulin to reduce the incidence of mucositis in head and neck cancr patients with radical radiotherapy. Oncolog&amp;#237;a IX Congreso Nacional de la Asociaci&amp;#243;n Espa&amp;#241;ola de Radioterapia y Oncolog&amp;#237;a. 1997;20(10 - Congreso):161.&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Valcrcel F, De la Torre A, Aragn G, Lanzs E, Rodrguez R, Veiras C</AU>
<TI>Double-blind randomized and pilot study on the potential of thymostimulin to reduce the incidence of mucositis in head and neck cancer patients with radical radiotherapy</TI>
<SO>Oncologa IX Congreso Nacional de la Asociacin Espaola de Radioterapia y Oncologa</SO>
<YR>1997</YR>
<VL>20</VL>
<PG>161</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Valcarcel-2002" MODIFIED="2010-11-09 15:17:05 +0000" MODIFIED_BY="[Empty name]" NAME="Valcarcel 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-11-09 15:17:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Valcarcel D, Sanz M, Sureda A, Sala M, Munoz L, Subira M et al</AU>
<TI>Topically applied recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) for oropharyngeal mucositis (OM) in stem cell transplantation recipients: a randomized double-blind placebo-controlled study</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2002</YR>
<VL>Suppl 2</VL>
<PG>S20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-10-26 15:40:41 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Valcarcel D, Sanz MAJ, Sureda A, Sala M, Munoz L, Subira M, et al. Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study. Bone Marrow Transplantation. 2002 2002; 29(9):783-7.&lt;/p&gt;" NOTES_MODIFIED="2010-10-26 15:40:41 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Valcarcel D, Sanz MA Jr, Sureda A, Sala M, Munoz L, Subira M et al</AU>
<TI>Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2002</YR>
<VL>29</VL>
<NO>9</NO>
<PG>783-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Zaanen-1994" NAME="van Zaanen 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;van Zaanen HC vdLH, Timmer JG, Furst P, Sauerwein HP. Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapy-induced toxicity. Cancer 1994;74(10):2879-84.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Zaanen HC, van der Lelie H, Timmer JG, Furst P, Sauerwein HP</AU>
<TI>Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapy-induced toxicity</TI>
<SO>Cancer</SO>
<YR>1994</YR>
<VL>74</VL>
<NO>10</NO>
<PG>2879-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verdi-1995" NAME="Verdi 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verdi CJ, Garewal HS, Koenig LM, Vaughn B, Burkhead T</AU>
<TI>A double-blind, randomized, placebo-controlled, crossover trial of pentoxiflline for the prevention of chemotherapy-induced oral mucositis</TI>
<SO>Osomopore</SO>
<YR>1995</YR>
<VL>80</VL>
<NO>1</NO>
<PG>36-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vesole-1999" NAME="Vesole 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Vesole DHaF, H. J. IB-367 reduces the number of days of severe oral mucositis complicating myeloablative chemotherapy [abstract]. Blood 1999;94(10 Suppl 1):154a.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vesole D, Fuchs HJ</AU>
<TI>IB-367 reduces the number of days of severe oral mucositis complicating myeloablative chemotherapy</TI>
<SO>Blood</SO>
<YR>1999</YR>
<VL>94</VL>
<NO>10 Suppl 1</NO>
<PG>154 (Abs No 675)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Villar-2009" MODIFIED="2010-11-09 15:19:52 +0000" MODIFIED_BY="[Empty name]" NAME="Villar 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-09 15:19:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Villar RC, de Lima AG, Junior GC, Gil E, Rosalmedia MC, Antequera W et al</AU>
<TI>Prophylactic low energy laser application to prevent chemoradiation-induced oral mucositis: a prospective and randomized trial</TI>
<SO>International journal of Oncology, Biology, Physics</SO>
<YR>2009</YR>
<VL>75</VL>
<NO>3</NO>
<PG>S30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vitello-2000" NAME="Vitello 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vitello M, Cianio SG</AU>
<TI>A comparison of two mouthrinse agents used during head/neck radiation</TI>
<SO>Journal of Dental Research</SO>
<YR>2000</YR>
<VL>79</VL>
<NO>Special Issue</NO>
<PG>215 (Abs No 576)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wagner-2002" MODIFIED="2010-11-09 15:20:21 +0000" MODIFIED_BY="[Empty name]" NAME="Wagner 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-11-09 15:20:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Wagner W, Radmard A, Niewohner-Desbordes U, Haus U, Matt J</AU>
<TI>rhGM-CSF in the treatment of radiotherapy induced mucositis-prospective randomized, double-blind study to investigate the feasibility and effectiveness of rhGM-CSF in patients with head and neck cancer</TI>
<SO>Proceedings of the American Society for Therapeutic Radiology and Oncology Meeting</SO>
<YR>2002</YR>
<PG>311 (Abstract 2175)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2002a" MODIFIED="2011-02-24 14:02:50 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2002a" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang HM, Wang CS, Chen JS, Chen IH, Liao CT, Chang TC</AU>
<TI>Cisplatin, tegafur, and leucovorin: a moderately effective and minimally toxic outpatient neoadjuvant chemotherapy for locally advanced squamous cell carcinoma of the head and neck</TI>
<SO>Cancer</SO>
<YR>2002</YR>
<VL>94</VL>
<NO>11</NO>
<PG>2989-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ward-2007" MODIFIED="2010-11-09 15:21:51 +0000" MODIFIED_BY="[Empty name]" NAME="Ward 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-09 15:21:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ward E, Smith M, Henderson M, Reid U, Lewis I, Kinsey S et al</AU>
<TI>The effect of high-dose enteral glutamine on the incidence and severity of mucositis in paediatric oncology patients</TI>
<SO>European Journal of Clinical Nutrition</SO>
<YR>2007</YR>
<VL>63</VL>
<NO>1</NO>
<PG>134-40</PG>
<IDENTIFIERS MODIFIED="2010-11-09 15:21:09 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Warde-2002" MODIFIED="2011-03-08 14:01:37 +0000" MODIFIED_BY="[Empty name]" NAME="Warde 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-03-08 14:01:37 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Warde P, O'Sullivan, B, Aslanidis, J, Kroll, B, Lockwood, G, Waldron, J, Payne, D, Bayley, A, Ringash, J, Kim, J, Liu, F, Maxymiw, W, Sprague, S, and Cummings, B. A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002+ADs-54(1):9-13.&lt;/p&gt;" NOTES_MODIFIED="2011-03-08 14:01:37 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Warde P, O'Sullivan B, Aslanidis J, Kroll B, Lockwood G, Waldron J et al</AU>
<TI>A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2002</YR>
<VL>54</VL>
<NO>1</NO>
<PG>9-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weisdorf-1989" MODIFIED="2011-03-08 14:05:14 +0000" MODIFIED_BY="[Empty name]" NAME="Weisdorf 1989" YEAR="1989">
<REFERENCE MODIFIED="2011-03-08 14:05:14 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Weisdorf DJ, Bostrom B, Raether D, Mattingly M, Walker P, Pihlstrom B et al. Oropharyngeal mucostitis complicating bone marrow transplantation: prognostic factors and the effect of chlorhexidine mouthrinse. Bone Marrow Transplant 1989;4:89-95.&lt;/p&gt;" NOTES_MODIFIED="2011-03-08 14:05:14 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weisdorf DJ, Bostrom B, Raether D, Mattingly M, Walker P, Pihlstrom B et al</AU>
<TI>Oropharyngeal mucositis complicating bone marrow transplantation: prognostic factors and the effect of chlorhexidine mouthrinse</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1989</YR>
<VL>4</VL>
<NO>1</NO>
<PG>89-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weiss-1990" NAME="Weiss 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Weiss GR GS, Hannigan EV, Boutselis JG, Surwit EA, Wallace DL, Alberts DS. A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial. Gynecologic Oncology 1990;37(3):354-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weiss GR, Green S, Hannigan EV, Boutselis JG, Surwit EA, Wallace DL et al</AU>
<TI>A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial</TI>
<SO>Gynecologic Oncology</SO>
<YR>1990</YR>
<VL>37</VL>
<NO>3</NO>
<PG>354-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whelan-2002" NAME="Whelan 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whelan HT, Connelly JF, Hodgson BD, Barbeau L, Post AC, Bullard G et al</AU>
<TI>NASA light-emitting diodes for the prevention of oral mucositis in pediatric bone marrow transplant patients</TI>
<SO>Journal of Clinical Laser Medicine &amp; Surgery</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>6</NO>
<PG>319-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whelan-2004" NAME="Whelan 2004" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Whelan H. Phase II Randomized Study of NASA-Developed Light-Emitting Diode Therapy For the Prevention of Oral Mucositis in Children Receiving a Myeloablative Conditioning Regimen Comprising Chemotherapy With or Without Radiotherapy Followed By First Allogeneic Bone Marrow Transplantation. National Institutes of Health, ClinicalTrials.Gov [http://www.clinicaltrials.gov] 2003.&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Whelan H</AU>
<TI>Phase II randomized study of NASA-developed light-emitting diode therapy for the prevention of oral mucositis in children receiving a myeloablative conditioning regimen comprising chemotherapy with or without radiotherapy followed by first allogeneic bone marrow transplantation</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>(accessed 2003)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wollina-2002" NAME="Wollina 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wollina U, Christen N, Kostler E, Schorcht J</AU>
<TI>On prophylaxis and treatment of radiation-induced dermatitis and mucositis</TI>
<SO>Zeitschrift fur Hautkrankheiten</SO>
<YR>2002</YR>
<VL>77</VL>
<NO>9</NO>
<PG>418-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wymenga-1999" MODIFIED="2010-11-09 15:23:02 +0000" MODIFIED_BY="[Empty name]" NAME="Wymenga 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-11-09 15:22:14 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Wymenga AN, van der Graaf WT, Hofstra LS, Spijkervet FK, Timens W, Timmer-Bosscha H, Sluiter WJ, van Buuren AH, Mulder NH, de Vries EG.Phase I study of transforming growth factor-beta3 mouthwashes for prevention of chemotherapy-induced mucositis. Clin Cancer Res. 1999 Jun;5(6):1363-8.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 15:22:14 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wymenga AN, van der Graaf WT, Hofstra LS, Spijkervet FK, Timens W, Timmer-Bosscha H et al</AU>
<TI>Phase I study of transforming growth factor-beta3 mouthwashes for prevention of chemotherapy-induced mucositis</TI>
<SO>Clinical Cancer Research</SO>
<YR>1999</YR>
<VL>5</VL>
<NO>6</NO>
<PG>1363-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 15:23:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wymenga AN, van der Graaf WT, Hofstra LS, Timens W, Spijkervet FK, Hospers GAP et al</AU>
<TI>TGF-b3 mouthwashes aimed at prevention of chemotherapy induced mucositis, a phase-I study</TI>
<SO>Supportive Care in Cancer</SO>
<YR>1999</YR>
<VL>7 (Suppl)</VL>
<PG>168 (Abstract 0-15)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yokomizo-2004" MODIFIED="2010-06-09 11:27:02 +0100" MODIFIED_BY="[Empty name]" NAME="Yokomizo 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Yokomizo H, Yoshimatsu K, Hashimoto M, Ishibashi K, Umehara A, Yoshida K, et al. Prophylactic efficacy of allopurinol ice ball for leucovorin/5-fluorouracil therapy-induced stomatitis. Anticancer Research. 2004;24(2C):1131-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yokomizo H, Yoshimatsu K, Hashimoto M, Ishibashi K, Umehara A, Yoshida K et al</AU>
<TI>Prophylactic efficacy of allopurinol ice ball for leucovorin/5-fluorouracil therapy-induced stomatitis</TI>
<SO>Anticancer Research</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>2C</NO>
<PG>1131-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zanin-2010" MODIFIED="2010-11-09 15:24:10 +0000" MODIFIED_BY="[Empty name]" NAME="Zanin 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-11-09 15:24:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zanin T, Zanin F, Carvalhosa AA, Castro PH, Pacheco MT, Zanin IC et al</AU>
<TI>Use of 660-nm diode laser in the prevention and treatment of human oral mucositis induced by radiotherapy and chemotherapy</TI>
<SO>Photomedicine and Laser Surgery</SO>
<YR>2010</YR>
<VL>28</VL>
<NO>2</NO>
<PG>233-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-01-17 14:25:27 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-2003" MODIFIED="2010-11-03 15:26:38 +0000" MODIFIED_BY="[Empty name]" NAME="Cheng 2003" YEAR="2004">
<REFERENCE MODIFIED="2010-11-03 15:26:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng KK, Chang AM, Yuen MP</AU>
<TI>Prevention of oral mucositis in paediatric patients treated with chemotherapy; a randomised crossover trial comparing two protocols of oral care</TI>
<SO>European Journal of Cancer</SO>
<YR>2004</YR>
<VL>40</VL>
<NO>8</NO>
<PG>1208-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 15:26:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng KK, Chang AM</AU>
<TI>Palliation of oral mucositis symptoms in pediatric patients treated with cancer chemotherapy</TI>
<SO>Cancer Nursing</SO>
<YR>2003</YR>
<VL>26</VL>
<NO>6</NO>
<PG>476-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 15:26:38 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Cheng KK. Children's acceptance and tolerance of chlorhexidine and benzydamine oral rinses in the treatment of chemotherapy-induced oropharyngeal mucositis. European Journal of Oncology Nursing. 2004;8(4):341-9.&lt;/p&gt;" NOTES_MODIFIED="2010-11-03 15:26:38 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng KK</AU>
<TI>Children's acceptance and tolerance of chlorhexidine and benzydamine oral rinses in the treatment of chemotherapy-induced oropharyngeal mucositis</TI>
<SO>European Journal of Oncology Nursing</SO>
<YR>2004</YR>
<VL>8</VL>
<NO>4</NO>
<PG>341-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Koning-2007" MODIFIED="2010-11-09 15:26:04 +0000" MODIFIED_BY="[Empty name]" NAME="de Koning 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-09 15:26:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Koning BA, Philipsen-Geerling B, Hoijer M, Hahlen K, Buller HA, Pieters R</AU>
<TI>Protection against chemotherapy induced mucositis by TGF-beta(2) in childhood cancer patients: results from a randomized cross-over study</TI>
<SO>Paediatric Blood &amp; Cancer</SO>
<YR>2007</YR>
<VL>48</VL>
<NO>5</NO>
<PG>532-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grzegorczyk-2006" MODIFIED="2010-11-09 15:30:23 +0000" MODIFIED_BY="[Empty name]" NAME="Grzegorczyk 2006" YEAR="">
<REFERENCE MODIFIED="2010-11-09 15:30:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grzegorczyk-Jazwinska A, Dwilewicz-Trojaczek J, Kozak I, Karakulska-Prystupiuk E, Gorska R</AU>
<TI>Effect of locally applied G-CSF on oral mucositis after autogeneic and allogeneic stem cell transplantation</TI>
<SO>Acta Haematologica Polonica</SO>
<YR>2006</YR>
<VL>37</VL>
<NO>2</NO>
<PG>225-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jellema-2006" MODIFIED="2010-11-09 15:31:34 +0000" MODIFIED_BY="[Empty name]" NAME="Jellema 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-09 15:31:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jellema AP, Slotman BJ, Muller MJ, Leemans CR, Smeele LE, Hoekman K et al</AU>
<TI>Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: A prospective randomized study in squamous cell head and neck cancer</TI>
<SO>Cancer</SO>
<YR>2006</YR>
<VL>107</VL>
<NO>3</NO>
<PG>544-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peterson-2007" MODIFIED="2010-11-09 15:35:19 +0000" MODIFIED_BY="[Empty name]" NAME="Peterson 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-09 15:33:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Peterson DE, Jones JB, Petit RG</AU>
<TI>Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy</TI>
<SO>Cancer</SO>
<YR>2007</YR>
<VL>109</VL>
<NO>2</NO>
<PG>322-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-04 17:12:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Peterson DE, Petit RG</AU>
<TI>AES-14 in chemotherapy patients at risk for mucositis. Phase III study</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>2003</YR>
<VL>725</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 15:35:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Petit RG, II, French C</AU>
<TI>Phase III clinical trial design considerations for oral treatments of chemotherapy - induced mucositis: AES-14 (uptake-facilitated L-glutamine) pivotal studies</TI>
<SO>Proceedings of the American Society of Clinical Oncology</SO>
<YR>2001</YR>
<VL>20 (Pt 2)</VL>
<PG>301b (Abstract 2954)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2010" MODIFIED="2010-11-09 15:37:09 +0000" MODIFIED_BY="[Empty name]" NAME="Wu 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-11-09 15:37:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wu S, Cui T, Zhao C, Pan J, Xu B, Tian Y et al</AU>
<TI>A prospective, randomized, multi-center trial to investigate Actovegin in prevention and treatment of acute oral mucositis caused by chemoradiotherapy for nasopharyngeal carcinoma</TI>
<SO>Radiotherapy and Oncology</SO>
<YR>2010</YR>
<VL>97</VL>
<NO>1</NO>
<PG>113-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 15:36:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu S, Cui T, Zhao C, Pan J, Xu B, Tian Y et al</AU>
<TI>A randomised controlled multicentre trial of actovegin against acute oral mucositis induced by chemo-radiotherapy for nasopharyngeal carcinoma</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2008</YR>
<VL>72 Suppl 1</VL>
<PG>S380</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yasuda-2011" MODIFIED="2012-01-17 14:25:27 +0000" MODIFIED_BY="[Empty name]" NAME="Yasuda 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-01-17 14:25:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<TI>Preventive Effect of Rebamipide Gargle on Chemoradiotherpy-Induced Oral Mucositis in Patients with Oral Cancer: a Pilot Study</TI>
<SO>J Oral Maxillofac Res 2011 (Oct-Dec);2(4):e3</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhe-2000" MODIFIED="2011-07-21 15:03:12 +0100" MODIFIED_BY="[Empty name]" NAME="Zhe 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-07-21 15:03:12 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;copy of paper requested SF 18/11/2010&lt;/p&gt;" NOTES_MODIFIED="2011-07-21 15:03:12 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhe H, Ding Z, Guo QM, Cheng BQ</AU>
<TI>Prevention and treatment of oral mucositis caused by radiotherapy in patients with nasopharyngeal carcinoma</TI>
<SO>Journal of Ningxia Medical College</SO>
<YR>2000</YR>
<VL>22</VL>
<NO>2</NO>
<PG>99-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2010-11-03 13:56:46 +0000" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-07-21 15:07:00 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-11-10 14:55:26 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Andreassen-2003" NAME="Andreassen 2003" TYPE="JOURNAL_ARTICLE">
<AU>Andreassen CN, Grau C, Lindegaard JC</AU>
<TI>Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy</TI>
<SO>Seminars in Radiation Oncology</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>1</NO>
<PG>62-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1996" MODIFIED="2008-06-16 17:16:14 +0100" MODIFIED_BY="[Empty name]" NAME="Begg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I et al</AU>
<TI>Improving the quality of reporting of randomized controlled trials: the CONSORT statement</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<NO>8</NO>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bellm-2002" NAME="Bellm 2002" TYPE="JOURNAL_ARTICLE">
<AU>Bellm LA, Cunningham G, Durnell L, Eilers J, Epstein JB, Fleming T et al</AU>
<TI>Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: oral mucositis patient provider advisory board</TI>
<SO>Cancer Investigation</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>5-6</NO>
<PG>793-800</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chang-2003" NAME="Chang 2003" TYPE="JOURNAL_ARTICLE">
<AU>Chang VT, Ingham J</AU>
<TI>Symptom control</TI>
<SO>Cancer Investigation</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>4</NO>
<PG>564-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarkson-2007a" MODIFIED="2010-11-09 15:37:49 +0000" MODIFIED_BY="[Empty name]" NAME="Clarkson 2007a" TYPE="COCHRANE_REVIEW">
<AU>Clarkson JE, Worthington HV, Eden TOB</AU>
<TI>Interventions for preventing oral candidiasis for patients with cancer receiving treatment</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD003807. DOI: 10.1002/14651858.CD003807.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Clarkson-2007b" MODIFIED="2010-11-09 15:38:50 +0000" MODIFIED_BY="[Empty name]" NAME="Clarkson 2007b" TYPE="COCHRANE_REVIEW">
<AU>Clarkson JE, Worthington HV, Eden TOB</AU>
<TI>Interventions for treating oral mucositis for patients with cancer receiving treatment</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2010-11-09 15:38:50 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-11-09 15:38:50 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD001973. DOI: 10.1002/14651858.CD001973.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Clarkson-2010" MODIFIED="2010-11-09 15:39:10 +0000" MODIFIED_BY="[Empty name]" NAME="Clarkson 2010" TYPE="COCHRANE_REVIEW">
<AU>Clarkson JE, Worthington HV, Furness S, McCabe M, Khalid T, Meyer S</AU>
<TI>Interventions for treating oral mucositis for patients with cancer receiving treatment</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2010-11-09 15:39:10 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-11-09 15:39:10 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD001973. DOI: 10.1002/14651858.CD001973.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-De-Pauw-1997" NAME="De Pauw 1997" TYPE="JOURNAL_ARTICLE">
<AU>De Pauw BE</AU>
<TI>Practical modalities for prevention of fungal infections in cancer patients</TI>
<SO>European Journal of Clinical Microbiological Infectious Diseases</SO>
<YR>1997</YR>
<VL>16</VL>
<NO>1</NO>
<PG>32-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Denning-1992" NAME="Denning 1992" TYPE="JOURNAL_ARTICLE">
<AU>Denning DW, Donnelly JP, Hellreigel KP, Ito J, Martino P, van't Wout JW</AU>
<TI>Antifungal prophylaxis during neutropenia or allogeneic bone marrow transplantation: what is the state of the art?</TI>
<SO>Chemotherapy</SO>
<YR>1992</YR>
<VL>38</VL>
<NO>S1</NO>
<PG>43-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duncan-2003" MODIFIED="2010-11-09 15:39:46 +0000" MODIFIED_BY="[Empty name]" NAME="Duncan 2003" TYPE="JOURNAL_ARTICLE">
<AU>Duncan M, Grant G</AU>
<TI>Oral and intestinal mucositis - causes and possible treatments</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>9</NO>
<PG>853-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2010-11-09 15:40:13 +0000" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eilers-1988" MODIFIED="2010-11-03 14:48:58 +0000" MODIFIED_BY="[Empty name]" NAME="Eilers 1988" TYPE="JOURNAL_ARTICLE">
<AU>Eilers J, Berger AM, Petersen MC</AU>
<TI>Development, testing, and application of the oral assessment guide</TI>
<SO>Oncology Nursing Forum</SO>
<YR>1988</YR>
<VL>15</VL>
<NO>3</NO>
<PG>325-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gibson-2010" MODIFIED="2010-11-09 15:40:32 +0000" MODIFIED_BY="[Empty name]" NAME="Gibson 2010" TYPE="JOURNAL_ARTICLE">
<AU>Gibson F, Auld EM, Bryan G, Coulson S, Craig JV, Glenny AM</AU>
<TI>A systematic review of oral assessment instruments: what can we recommend to practitioners in children's and young people's cancer care?</TI>
<SO>Cancer Nursing</SO>
<YR>2010</YR>
<VL>33</VL>
<NO>4</NO>
<PG>E1-E19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glenny-2004" MODIFIED="2010-11-09 15:41:32 +0000" MODIFIED_BY="[Empty name]" NAME="Glenny 2004" TYPE="JOURNAL_ARTICLE">
<AU>Glenny AM, Gibson F, Auld E, Coulson S, Clarkson JE, Craig JV et al</AU>
<TI>A survey of current practice with regard to oral care for children being treated for cancer</TI>
<SO>European Journal of Cancer</SO>
<YR>2004</YR>
<VL>40</VL>
<NO>8</NO>
<PG>1217-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glenny-2009" MODIFIED="2010-11-09 15:45:43 +0000" MODIFIED_BY="[Empty name]" NAME="Glenny 2009" TYPE="COCHRANE_REVIEW">
<AU>Glenny AM, Fernandez Mauleffinch LM, Pavitt S, Walsh T</AU>
<TI>Interventions for the prevention and treatment of herpes simplex virus in patients treated for cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2010-11-09 15:45:43 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-11-09 15:45:43 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD006706. DOI: 10.1002/14651858.CD006706.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2010-11-10 14:55:26 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2009" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions version 5.0.2 (updated September 2009)</TI>
<SO>The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kassab-2009" MODIFIED="2010-11-09 15:50:25 +0000" MODIFIED_BY="[Empty name]" NAME="Kassab 2009" TYPE="COCHRANE_REVIEW">
<AU>Kassab S, Cummings M, Berkovitz S, van Haselen R, Fisher P</AU>
<TI>Homeopathic medicines for adverse effects of cancer treatments</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2010-11-09 15:50:18 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-11-09 15:50:18 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD004845. DOI: 10.1002/14651858.CD004845.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Keefe--2007" MODIFIED="2010-11-09 15:51:32 +0000" MODIFIED_BY="[Empty name]" NAME="Keefe  2007" TYPE="JOURNAL_ARTICLE">
<AU>Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE et al</AU>
<TI>Updated clinical practice guidelines for the prevention and treatment of mucositis</TI>
<SO>Cancer</SO>
<YR>2007</YR>
<VL>109</VL>
<NO>5</NO>
<PG>820-31</PG>
<IDENTIFIERS MODIFIED="2010-10-22 15:43:11 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Kowanko-1998" NAME="Kowanko 1998" TYPE="OTHER">
<AU>Kowanko I, Long L, Hodgkinson B, Evans D</AU>
<TI>The effectiveness of strategies for preventing and treating chemotherapy and radiation induced oral mucositis in patients with cancer</TI>
<SO>Joanna Briggs Institute for Evidence Based Nursing and Midwifery</SO>
<YR>1998</YR>
<PG>1-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lortholary-1997" NAME="Lortholary 1997" TYPE="JOURNAL_ARTICLE">
<AU>Lortholary O, Dupont B</AU>
<TI>Antifungal prophylaxis during neutropenia and immunodeficiency</TI>
<SO>Clinical Microbiological Review</SO>
<YR>1997</YR>
<VL>10</VL>
<NO>3</NO>
<PG>477-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McDonnell-2007" MODIFIED="2010-10-27 09:25:09 +0100" MODIFIED_BY="[Empty name]" NAME="McDonnell 2007" TYPE="OTHER">
<AU>McDonnell AM, Lenz KL</AU>
<TI>Palifermin: role in the prevention of chemotherapy- and radiation-induced mucositis</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>2007</YR>
<VL>41</VL>
<NO>1</NO>
<PG>86-94</PG>
<MD>get</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Merck-Index-2010" MODIFIED="2010-11-09 15:54:54 +0000" MODIFIED_BY="[Empty name]" NAME="Merck Index 2010" TYPE="OTHER">
<AU>O'Neil, Maryadele J (editors)</AU>
<TI>The Merck Index: an encyclopedia of chemicals, drugs and biologicals</TI>
<SO>MedicinesComplete. Available from</SO>
<PG>http://www.medicinescomplete.com/mc/merck/2010/08591.htm?q=%22dobell%22&amp;t=search&amp;ss=text&amp;p=1#_hit (accessed 4 November 2010)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman DG</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>134</VL>
<NO>8</NO>
<PG>657-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rubenstein-2004" NAME="Rubenstein 2004" TYPE="JOURNAL_ARTICLE">
<AU>Rubestein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J et al</AU>
<TI>Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis</TI>
<SO>Cancer Supplement</SO>
<YR>2004</YR>
<VL>100</VL>
<NO>9</NO>
<PG>2026-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sasse-2006" MODIFIED="2010-11-09 15:56:05 +0000" MODIFIED_BY="[Empty name]" NAME="Sasse 2006" TYPE="OTHER">
<AU>Sasse AD, Clark LG, Sasse EC, Clark OA</AU>
<TI>Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2006</YR>
<VL>64</VL>
<NO>3</NO>
<PG>784-91</PG>
<MD>get</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Savarese-2003" NAME="Savarese 2003" TYPE="JOURNAL_ARTICLE">
<AU>Savarese DM, Savy G, Vahdat L, Wischmeyer PE, Corey B</AU>
<TI>Prevention of chemotherapy and radiation toxicity with glutamine</TI>
<SO>Cancer Treatment Reviews</SO>
<YR>2003</YR>
<VL>29</VL>
<NO>6</NO>
<PG>501-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sonis-2004" NAME="Sonis 2004" TYPE="JOURNAL_ARTICLE">
<AU>Sonis ST, Elting LS, Keefe D, Peterson ED, Schubert M, Hauer-Jensen M et al</AU>
<TI>Perspectives on cancer therapy-induced mucosal injury</TI>
<SO>Cancer Supplement</SO>
<YR>2004</YR>
<VL>100</VL>
<NO>9</NO>
<PG>1995-2025</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stevens-1995" NAME="Stevens 1995" TYPE="JOURNAL_ARTICLE">
<AU>Stevens DA</AU>
<TI>Therapy for opportunistic fungal infections: past present and future</TI>
<SO>Indian Journal of Cancer</SO>
<YR>1995</YR>
<VL>32</VL>
<NO>1</NO>
<PG>1-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stokman-2006" NAME="Stokman 2006" TYPE="JOURNAL_ARTICLE">
<AU>Stokman MA, Spijkervet FK, Boezen HM, Schouten JP, Roodenburg JL, de Vries EG</AU>
<TI>Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses</TI>
<SO>Journal of Dental Research</SO>
<YR>2006</YR>
<VL>85</VL>
<NO>8</NO>
<PG>690-700</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sunderland-2001" MODIFIED="2010-11-09 15:56:36 +0000" MODIFIED_BY="[Empty name]" NAME="Sunderland 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sutherland SE, Browman GP</AU>
<TI>Prophylaxis of oral mucositis in irradiated head-and-neck cancer patients: a proposed classification scheme of interventions and meta-analysis of randomized controlled trials</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>4</NO>
<PG>917-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Symonds-1998" MODIFIED="2008-06-16 17:17:03 +0100" MODIFIED_BY="[Empty name]" NAME="Symonds 1998" TYPE="JOURNAL_ARTICLE">
<AU>Symonds RP</AU>
<TI>Treatment-induced mucositis: an old problem with new remedies</TI>
<SO>British Journal of Cancer</SO>
<YR>1998</YR>
<VL>77(10)</VL>
<PG>1689-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tavender-2004" MODIFIED="2010-11-09 15:57:21 +0000" MODIFIED_BY="[Empty name]" NAME="Tavender 2004" TYPE="COCHRANE_PROTOCOL">
<AU>Tavender E, Davies AN, Glenny AM</AU>
<TI>Pharmacological interventions for preventing salivary gland dysfunction following radiotherapy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2010-10-25 11:12:14 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-10-25 11:12:14 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="DOI: 10.1002/14651858.CD004940"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Verdi--1993" NAME="Verdi  1993" TYPE="JOURNAL_ARTICLE">
<AU>Verdi CJ</AU>
<TI>Cancer therapy and oral mucositis</TI>
<SO>Drug Safety</SO>
<YR>1993</YR>
<VL>9</VL>
<NO>3</NO>
<PG>185-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-White-1993" NAME="White 1993" TYPE="JOURNAL_ARTICLE">
<AU>White M</AU>
<TI>Antifungal prophylaxis</TI>
<SO>Current Opinion in Infectious Diseases</SO>
<YR>1993</YR>
<VL>6</VL>
<PG>737-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Worthington-2004a" NAME="Worthington 2004a" TYPE="COCHRANE_REVIEW">
<AU>Worthington HV, Clarkson JE, Eden OB</AU>
<TI>Interventions for treating oral mucositis for patients with cancer receiving treatment</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD001973. DOI: 10.1002/14651858.CD001973.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Worthington-2007a" MODIFIED="2010-11-09 15:58:03 +0000" MODIFIED_BY="[Empty name]" NAME="Worthington 2007a" TYPE="COCHRANE_REVIEW">
<AU>Worthington HV, Clarkson JE, Eden TOB</AU>
<TI>Interventions for treating oral candidiasis for patients with cancer receiving treatment</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD001972. DOI: 10.1002/14651858.CD001972.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wright-2003" NAME="Wright 2003" TYPE="JOURNAL_ARTICLE">
<AU>Wright JR, McKenzie M, DeAngelis C, Foroudi F, Paul N, Rajaraman M et al</AU>
<TI>Radiation induced mucositis: co-ordinating a research agenda</TI>
<SO>Clinical Oncology</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>8</NO>
<PG>473-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2011-02-17 08:57:37 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Clarkson-2000" MODIFIED="2011-02-17 08:57:37 +0000" MODIFIED_BY="[Empty name]" NAME="Clarkson 2000" TYPE="COCHRANE_REVIEW">
<AU>Clarkson JE, Worthington HV, Eden OB</AU>
<TI>Prevention of oral mucositis or oral candidiasis for patients with cancer receiving chemotherapy (excluding head and neck cancer)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-02-17 08:57:37 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Clarkson-2003a" NAME="Clarkson 2003a" TYPE="COCHRANE_REVIEW">
<AU>Clarkson JE, Worthington HV, Eden OB</AU>
<TI>Interventions for preventing oral mucositis for patients with cancer receiving treatment</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD000978. DOI: 10.1002/14651858.CD000978"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Worthington-2006" NAME="Worthington 2006" TYPE="COCHRANE_REVIEW">
<AU>Worthington HV, Clarkson JE, Eden OB</AU>
<TI>Interventions for preventing oral mucositis for patients with cancer receiving treatment</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD000978. DOI: 10.1002/14651858.CD000978.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Worthington-2007" MODIFIED="2010-11-10 15:39:44 +0000" MODIFIED_BY="[Empty name]" NAME="Worthington 2007" TYPE="COCHRANE_REVIEW">
<AU>Worthington HV, Clarkson JE, Eden TOB</AU>
<TI>Interventions for preventing oral mucositis for patients with cancer receiving treatment</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2010-11-10 15:39:44 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-11-10 15:39:39 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000978.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2011-07-21 15:07:00 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Ashktorab-2010" MODIFIED="2011-03-08 14:08:55 +0000" MODIFIED_BY="[Empty name]" NAME="Ashktorab 2010" NOTES="&lt;p&gt;Iranian language - needs translation&lt;/p&gt;" NOTES_MODIFIED="2011-03-08 14:08:55 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="OTHER">
<AU>Ashktorab T, Yazdani Z, Mojab F, Majd HA, Madani H</AU>
<TI>Preventive effects of an oral rinse Peppermint essence on chemotherapy-induced oral mucosistis</TI>
<SO>Koomesh</SO>
<YR>2010</YR>
<VL>12</VL>
<NO>1</NO>
<PG>8-13</PG>
<MD>Incl in Prev of OM</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Buntzel-2010" MODIFIED="2011-03-08 12:46:56 +0000" MODIFIED_BY="[Empty name]" NAME="Buntzel 2010" TYPE="OTHER">
<AU>Buntzel J, Riesenbeck D, Glatzel M, Berndt-Skorka R, Riedel T, Mucke R, et al</AU>
<TI>Limited effects of selenium substitution in the prevention of radiation-associated toxicities. results of a randomized study in head and neck cancer patients</TI>
<SO>Anticancer Research</SO>
<YR>2010</YR>
<VL>30</VL>
<NO>5</NO>
<PG>1829-32</PG>
<MD>?Incl in Prev of OM</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chen-2006" MODIFIED="2010-11-18 14:41:09 +0000" MODIFIED_BY="[Empty name]" NAME="Chen 2006" NOTES="Center of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China. xianglongchen@21cn.comcopy of paper requested SF 18/11/2010" NOTES_MODIFIED="2010-11-18 14:41:09 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Chen XL, Shi YS</AU>
<TI>Effect of vitamin B12 mixed solution inhalation for acute radiation-induced mucosal injury</TI>
<SO>Nan fang yi ke da xue xue bao</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>4</NO>
<PG>512-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goel-2010" MODIFIED="2011-03-08 12:46:56 +0000" MODIFIED_BY="[Empty name]" NAME="Goel 2010" TYPE="OTHER">
<AU>Goel A, Tripathi A, Chand P, Singh SV, Pant MC, Nagar A</AU>
<TI>Use of positioning stents in lingual carcinoma patients subjected to radiotherapy</TI>
<SO>International Journal of Prosthodontics</SO>
<YR>2010</YR>
<VL>23</VL>
<NO>5</NO>
<PG>450-2</PG>
<MD>? incl in prev of OM</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gouvea-2010" MODIFIED="2011-03-08 12:46:56 +0000" MODIFIED_BY="[Empty name]" NAME="Gouvea 2010" TYPE="OTHER">
<AU>Gouvea de Lima A, Villar RC, de Castro G, Jr., Antequera R, Gil E, et al</AU>
<TI>Oral Mucositis Prevention by Low-Level Laser Therapy in Head-and-Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy: A Phase III Randomized Study</TI>
<SO>Int J Radiat Oncol Biol Phys</SO>
<YR>2010</YR>
<MD>Incl in Prev of OM</MD>
<IDENTIFIERS MODIFIED="2011-03-08 12:46:53 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER OTHERTYPE="1879-355X" TYPE="OTHER" VALUE="(Electronic). 0360-3016 (Linking)"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Khanal-2010" MODIFIED="2011-03-08 12:46:56 +0000" MODIFIED_BY="[Empty name]" NAME="Khanal 2010" TYPE="OTHER">
<AU>Khanal B, Baliga M, Uppal N</AU>
<TI>Effect of topical honey on limitation of radiation-induced oral mucositis: an intervention study</TI>
<SO>Int J Oral Maxillofac Surg</SO>
<YR>2010</YR>
<VL>39</VL>
<NO>12</NO>
<PG>1181-5</PG>
<MD>Incl in Prev of OM</MD>
<IDENTIFIERS MODIFIED="2011-03-08 12:46:53 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER OTHERTYPE="1399-0020" TYPE="OTHER" VALUE="(Electronic). 0901-5027 (Linking)"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ladenstein-2010" MODIFIED="2011-03-08 12:46:56 +0000" MODIFIED_BY="[Empty name]" NAME="Ladenstein 2010" TYPE="OTHER">
<AU>Ladenstein R, Valteau-Couanet D, Brock P, Yaniv I, Castel V, Laureys G, et al</AU>
<TI>Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2010</YR>
<VL>28</VL>
<NO>21</NO>
<PG>3516-24</PG>
<MD>RCT on prophylaxis with GCSF ? mucositis outcomes</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lanzos-2010" MODIFIED="2011-03-08 12:46:56 +0000" MODIFIED_BY="[Empty name]" NAME="Lanzos 2010" TYPE="OTHER">
<AU>Lanzos I, Herrera D, Santos S, O'Connor A, Pena C, Lanzos E, et al</AU>
<TI>Mucositis in irradiated cancer patients: effects of an antiseptic mouthrinse</TI>
<SO>Medicina Oral, Patologia Oral y Cirugia Bucal</SO>
<YR>2010</YR>
<VL>15</VL>
<NO>5</NO>
<PG>e732-8</PG>
<MD>Incl in Prev of OM</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lin-2010" MODIFIED="2011-03-08 12:46:56 +0000" MODIFIED_BY="[Empty name]" NAME="Lin 2010" TYPE="OTHER">
<AU>Lin YS, Lin LC, Lin SW, Chang CP</AU>
<TI>Discrepancy of the effects of zinc supplementation on the prevention of radiotherapy-induced mucositis between patients with nasopharyngeal carcinoma and those with oral cancers: subgroup analysis of a double-blind, randomized study</TI>
<SO>Nutrition &amp; Cancer</SO>
<YR>2010</YR>
<VL>62</VL>
<NO>5</NO>
<PG>682-91</PG>
<MD>Incl in Prev of OM</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Okuno-1997" MODIFIED="2011-07-21 15:07:00 +0100" MODIFIED_BY="[Empty name]" NAME="Okuno 1997" NOTES="&lt;p&gt;To be added to excluded studies - reason Major protocol change part way through recruitment.&amp;#160; Data not interpretable. SF has pdf on file&lt;/p&gt;" NOTES_MODIFIED="2011-07-21 15:07:00 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="OTHER">
<AU>Okuno S, Foote R, Loprinzi C, Gulavita S, Sloan J, J. E, et al</AU>
<TI>A randomized trial of a nonabsorbable antibiotic lozenge given to alleviate radiation-induced mucositis</TI>
<SO>Cancer</SO>
<YR>1997</YR>
<VL>79</VL>
<NO>11</NO>
<PG>2193-9</PG>
<MD>Clinical Trial</MD>
<IDENTIFIERS MODIFIED="2011-07-21 15:04:06 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER OTHERTYPE="0008-543X" TYPE="OTHER" VALUE="(Print)"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Panahi-2010" MODIFIED="2011-03-08 12:46:56 +0000" MODIFIED_BY="[Empty name]" NAME="Panahi 2010" TYPE="OTHER">
<AU>Panahi Y, Ala S, Saeedi M, Okhovatian A, Bazzaz N, Naghizadeh MM</AU>
<TI>Allopurinol mouth rinse for prophylaxis of fluorouracil-induced mucositis</TI>
<SO>European Journal of Cancer Care</SO>
<YR>2010</YR>
<VL>19</VL>
<NO>3</NO>
<PG>308-12</PG>
<MD>Incl prev of OM - allopurinol</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Radiation-2010" MODIFIED="2011-03-08 12:46:56 +0000" MODIFIED_BY="[Empty name]" NAME="Radiation 2010" TYPE="OTHER">
<AU>Radiation Therapy Oncology G, National Cancer I</AU>
<TI>Palifermin in lessening oral mucositis in patients undergoing radiation therapy and chemotherapy for locally advanced head and neck cancer</TI>
<SO>ClinicalTrials.gov [accessed 17 Jul 2010]</SO>
<YR>2010</YR>
<PG>ClinicalTrials.gov ID: NCT00360971</PG>
<MD>? incl prev of OM</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Silva-2011" MODIFIED="2011-03-08 12:46:56 +0000" MODIFIED_BY="[Empty name]" NAME="Silva 2011" TYPE="OTHER">
<AU>Silva GB, Mendonca EF, Bariani C, Antunes HS, Silva MA</AU>
<TI>The prevention of induced oral mucositis with low-level laser therapy in bone marrow transplantation patients: a randomized clinical trial</TI>
<SO>Photomed Laser Surg</SO>
<YR>2011</YR>
<VL>29</VL>
<NO>1</NO>
<PG>27-31</PG>
<MD>incl prev of OM</MD>
<IDENTIFIERS MODIFIED="2011-03-08 12:46:53 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER OTHERTYPE="1557-8550" TYPE="OTHER" VALUE="(Electronic). 1549-5418 (Linking)"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Southwest-2010" MODIFIED="2011-03-08 12:46:56 +0000" MODIFIED_BY="[Empty name]" NAME="Southwest 2010" TYPE="OTHER">
<AU>Southwest Oncology G, National Cancer I</AU>
<TI>Glutamine in treating mucositis caused by radiation therapy in patients with newly diagnosed cancer of the mouth or throat [terminated]</TI>
<SO>ClinicalTrials.gov [accessed 17 Jul 2010]</SO>
<YR>2010</YR>
<PG>ClinicalTrials.gov ID: NCT00006994</PG>
<MD>? need to look at this</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Svanberg-2010" MODIFIED="2011-03-08 12:46:56 +0000" MODIFIED_BY="[Empty name]" NAME="Svanberg 2010" TYPE="OTHER">
<AU>Svanberg A, Ohrn K, Birgegard G</AU>
<TI>Oral cryotherapy reduces mucositis and improves nutrition - a randomised controlled trial</TI>
<SO>Journal of Clinical Nursing</SO>
<YR>2010</YR>
<VL>19</VL>
<NO>15-16</NO>
<PG>2146-51</PG>
<MD>incl prev of OM</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Talaipour-1995" MODIFIED="2011-03-08 12:46:56 +0000" MODIFIED_BY="[Empty name]" NAME="Talaipour 1995" TYPE="OTHER">
<AU>Talaipour AR, Hadad P, Sahba S, Bashizadeh H, Sakhdari SH</AU>
<TI>Chamomile mouth rinse effects on mucositis reduction after radiotherapy</TI>
<SO>Journal of Dentistry Tehran University of Medical Sciences</SO>
<YR>1995</YR>
<VL>13</VL>
<NO>1</NO>
<PG>57-62</PG>
<MD>? incl in either prev or treatment reviews</MD>
<IDENTIFIERS/>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-04-26 12:13:04 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-04-26 12:13:04 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-11-09 16:16:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abbasi_x002d_Nazari-2007">
<CHAR_METHODS MODIFIED="2010-11-09 16:15:14 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group multicentre study conducted in Iran. Unclear if dentist involved in the study. Drop outs: unclear. Duration: 42 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-18 18:12:08 +0100" MODIFIED_BY="[Empty name]">
<P>Adults with cancers of the oral cavity, nasopharynx or hypopharynx treated with radiotherapy or chemoradiotherapy (Cisplatine). Data presented for 24 patients. No dates for start and finish of recruitment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-09 16:15:57 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups: placebo versus allopurinol mouthrinse. 10 mL of solution rinsed three times a day for three minutes. Solution then discarded.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-09 16:16:03 +0000" MODIFIED_BY="[Empty name]">
<P>Authors state that mucositis was graded weekly using the WHO instrument. However, the instrument reproduced in the publication is not the WHO instrument. Other reported outcomes: None.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-09 16:16:08 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: pharmaceutical.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 22:22:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ahmed-1993">
<CHAR_METHODS MODIFIED="2010-10-18 22:22:58 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in USA. Unclear whether dentist was involved in study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with haematological malignancies prior to BMT after conditioning with etoposide. 12 enrolled and completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus propantheline (30 mg every 6 hours during infusion and 12 hours after, for total of 6 doses).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis graded with reference to previous publication. Data presented as number of patients developing mucositis in both groups. Assessment used: day 3. Other reported outcomes: blood counts febrile episodes, survival, tumour response.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-01 11:17:19 +0100" MODIFIED_BY="[Empty name]">
<P>All patients received conditioning regimen of etoposide, cyclophosphamide and carmustine, together with acyclovir, and nystatin or clotrimazole.<BR/>Funding source: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-09 16:20:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anderson-1998">
<CHAR_METHODS MODIFIED="2010-11-09 16:20:14 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, cross-over study conducted in USA. Unclear if dentist was involved in study. Duration 14 days. Recruitment May 1993 to April 1996.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-29 16:12:22 +0100" MODIFIED_BY="[Empty name]">
<P>Children and adults with solid cancer (sarcoma/blastoma) who have previously had chemotherapy and experienced mucositis. 24 patients eligible and enrolled, 13 completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-29 16:12:43 +0100" MODIFIED_BY="[Empty name]">
<P>2 groups, glycine control (described as placebo) versus glutamine (4 ml/M twice daily swish and swallow) for 14 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis (patient's description on 0-4 scale). Grade &gt;= 2 painful mucositis which altered food intake. Assessment used: day 14. Other reported outcomes: none.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-29 16:13:04 +0100" MODIFIED_BY="[Empty name]">
<P>Funding source: charity/university.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 22:18:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Antonadou-2002">
<CHAR_METHODS MODIFIED="2010-10-18 22:18:25 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Greece. Clear information on withdrawals: 3/26 control, 2/24 intervention. Dentist not involved in study. Drop outs: 10%. Duration 3 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-18 22:18:04 +0100" MODIFIED_BY="[Empty name]">
<P>Adults with head and neck cancer. Radiotherapy total 60-74 Gy 2 Gy fractions 5 days weekly. Chemotherapy carboplatin (90 mg/m2 once per week (no surgery before radiotherapy)). 50 patients enrolled between January 1997 and January 1998. 45 completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, no treatment control versus amifostine 300 mg/m2 15-30 min before radiotherapy for 6-7 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis assessed weekly EORTC criteria. Assessment used: day 28. Other reported outcomes: dysphagia, xerostomia, treatment interruptions, haematological changes, side effects (nausea, transient hypotention).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-09 16:25:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Antunes-2007">
<CHAR_METHODS MODIFIED="2010-10-18 22:17:19 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Brazil. Study conducted between January 4th 2004 and May 20th 2005. Dentist involved in study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-18 22:17:23 +0100" MODIFIED_BY="[Empty name]">
<P>Adults with leukaemia, lymphoma or myelodysplastic syndrome undergoing HSCT. 38 patients recruited and completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-09 16:25:28 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, lazer (50 mW InGaAlP diode laser, emitting continuous light at 660 nm, with a real power output of 46.7 mW and energy density (ED) of 4 J/cm2, measured at the fiberoptic end with 0.196 cm2 of section area) versus sham laser control.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-09 16:25:51 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis incidence (OMAS, WHO), correlation between OMAS and WHO, mucositis free survival, ulcerative area extension, evaluator agreement, pain, clinical outcomes.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-09 16:25:36 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-09 16:28:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arun-Maiya-2006">
<CHAR_METHODS MODIFIED="2010-10-22 23:41:00 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in India. Clear information about withdrawals: 0. Unclear if dentist involved in study. Duration: until the completion of radiotherapy. Recruitment took place between January 2003 and January 2004. </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-09 16:28:32 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with carcinoma off the oral cavity receiving radiotherapy (66 Gy in 33 fractions).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-09 16:28:48 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, analgesics, anaesthetics, 0.9% saline and chlorhexidine versus laser (632.8 nm, 10 mW) for 3 minutes, 5 days per week.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-09 16:28:53 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis assessed weekly using the WHO score. Other reported outcome measures: pain.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-09 16:28:57 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-09 16:32:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Attal-1993">
<CHAR_METHODS MODIFIED="2010-10-18 22:16:57 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in France. Clear information on withdrawals: 6/70 control, 6/70 test. Unclear if dentist involved in study. Drop outs: 0%. Duration: day -8 to day +100.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-01 11:20:09 +0100" MODIFIED_BY="[Empty name]">
<P>Adults with mixed blood cancers admitted to BMT unit. 140 patients enrolled 6 died in each group, but all were evaluated. Recruited December 1990 to September 1992.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, no treatment control versus pentoxifylline (oral PTX 1600 mg 1 per day in 4 doses).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number requiring MSO4 for grade II or higher mucositis (by published criteria). Assessment used: day 100. Other reported outcomes: duration of stay in hospital, renal insufficiency, days morphine, fever, septicaemia, 100 day survival.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-09 16:32:29 +0000" MODIFIED_BY="[Empty name]">
<P>All patients received one of 4 possible standard regimens either; Cyclophosphamide +TBI, or cyclophosphamide + bisulfan, or melphalan + TBI or cyclophosphamide + etoposide + carmustine, prior to autologous or allogenic BMT.<BR/>Funding source: not stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-09 16:38:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bensadoun-1999">
<CHAR_METHODS MODIFIED="2010-11-09 16:38:30 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel multisite study conducted in France. Clear information about withdrawals: 0. Dentist involved in study. 30 patients recruited between September 1994 and March 1998. Duration: 5 consecutive days each week during the 7 weeks of radiotherapy.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-20 23:12:31 +0100" MODIFIED_BY="[Empty name]">
<P>Adults with head and neck cancers receiving radiotherapy (at least 65 Gy in total). </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-09 16:34:00 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, sham laser versus laser (wavelength: 632.8 nm; power: 60 mW in Nice and Mareilles, 25 mW in Reims).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-20 23:14:35 +0100" MODIFIED_BY="[Empty name]">
<P>Mucositis assessed weekly using the WHO scale. Other outcome measures: pain, ability to swallow, incidence and duration of treatment gaps. </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-09 16:34:20 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-09 16:37:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Biswal-2003">
<CHAR_METHODS MODIFIED="2010-10-18 22:16:27 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Malaysia. Clear information on withdrawals. Unclear if dentist was involved in study. Drop outs: 0%. Duration: 49 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-09 16:37:17 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with head and neck cancer. 40 patients recruited and evaluated. Recruited November 2000 to October 2001.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, rinse then swallow 20 ml natural honey before radiotherapy, 20 ml after and 20 ml 6 hours after that versus no treatment control.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-30 13:43:26 +0100" MODIFIED_BY="[Empty name]">
<P>Mucositis RTOG grading. Other reported outcomes: weight gain.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-09 16:37:37 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: university. All patients received radiotherapy 60-70 Gy over 6-7 weeks.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-09 16:46:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bjarnason-2009">
<CHAR_METHODS MODIFIED="2010-11-09 16:38:08 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised parallel group multisite study conducted in Canada. Clear information about withdrawals. Dentist involved in study. Recruitment of patients took place between August 1999 and November 2004.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-09 16:46:28 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with head and neck cancers receiving radiotherapy (50-70 Gy).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-22 00:31:27 +0100" MODIFIED_BY="[Empty name]">
<P>2 groups, radiotherapy in the morning (8am to 10am) versus radiotherapy in the evening (4pm to 6pm).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-09 16:46:36 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis assessed weekly using the OMAS instrument. Other reported outcomes: disease reoccurrence, quality of life, compliance with treatment, death, smoking status, weight loss.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-09 16:46:46 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: National Cancer Institute of Canada.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-09 16:49:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blazar-2006">
<CHAR_METHODS MODIFIED="2010-11-09 16:48:27 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group, multisite study conducted in the USA. Clear information about withdrawals: 20 (17 patients withdrew and were replaced). Unclear if dentist involved in study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-09 16:48:47 +0000" MODIFIED_BY="[Empty name]">
<P>Adults and children with haematological malignancies (acute lymphoblastic leukaemia, acute myelogenous leukaemia, chronic myelogenous leukaemia, myelodysplastic syndrome, non-Hodgkin leukaemia, Hodgkin's disease, other) aged between 3 and 65 years old, receiving allogeneic hematopoietic stem cell transplantation. Conditioning regimes: cyclophosphamide and total body irradiation or busulfan and cyclophosphamide.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-09 16:49:08 +0000" MODIFIED_BY="[Empty name]">
<P>3 cohorts, cohort 1 received either palifermin (60 &#956;g/kg in 6 doses), palifermin (40 &#956;g/kg in 6 doses) or placebo. Cohort 2 received palifermin (60 &#956;g/kg in 9 doses) or placebo. Cohort 3 received palifermin (60 &#956;g/kg in 12 doses).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-09 16:49:13 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis assessed weekly using the world health organisation and common toxicities criteria scales. Other reported outcome measures: adverse events, GVHD, hematopoietic recovery, methotrexate dosing, survival and relapse.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-09 16:49:22 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: National Institute of Health grants and Amgen (pharmaceutical)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 22:15:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Borowski-1994">
<CHAR_METHODS MODIFIED="2010-10-18 22:15:37 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in France. Clear information on withdrawals: 7/82 control, 9/84 test. Dentist involved in study. Duration: 30 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-09 10:41:47 +0100" MODIFIED_BY="Helen Worthington">
<P>Children and adults with mixed cancer and candidates for BMT. 166 eligible and enrolled between February 1986 and November 1989 with 150 completing.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, limited oral hygiene versus intense oral hygiene (brushing 3 times per day after meals as instructed by dentist).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Moderate or severe mucositis with detailed description of each category. Assessment used: day 30. Other outcomes: plaque, fever, septicaemia.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Chlorhexidine mouthrinse used at least 5 times daily by both groups. <BR/>Funding source: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 22:14:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bourhis-2000">
<CHAR_METHODS MODIFIED="2010-10-18 22:12:26 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in France. Unclear information on withdrawals: 1 died and 1 refused, unclear which group. Unclear if dentist involved in study. Drop outs: 8%. Duration: unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-09 10:33:01 +0100" MODIFIED_BY="Helen Worthington">
<P>Adults with head and neck cancer, stage IV not amenable to conventional radiosurgical treatment. Karnofsky performance &gt; 60. Radiotherapy 64 Gy in 22-23 days. 26 patients enrolled and randomised between May 1996 and February 1998. 24 were evaluated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-18 22:14:53 +0100" MODIFIED_BY="[Empty name]">
<P>2 groups, no treatment control versus amifostine (subcutaneous infusion 150 mg/m amifostine administered IV twice daily 15-30 minutes prior to each radiotherapy session).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-18 22:14:48 +0100" MODIFIED_BY="[Empty name]">
<P>Max WHO grade (I to IV). Assessment used: day 23. Other reported outcomes: duration of feeding tube, vomiting, liver function, erythema (tolerance of amifostine). Duration of feeding tube.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>RTOG index also given with mean duration of at least grade 3 mucositis. <BR/>Funding source: pharmaceutical.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-09 16:57:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brizel-2000">
<CHAR_METHODS MODIFIED="2010-11-09 16:57:33 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group multisite study conducted in USA, Germany and France. Clear information about withdrawals: none. Unclear if dentist involved in study. Drop outs: 0%. Duration: 1 year.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-09 16:57:46 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with head and neck cancer. Newly diagnosed squamous cell radiation more than or equal to 70% both parotid glands more than or equal to 40 Gy - daily 2 Gy. 315 enrolled and randomised between October 1995 to October 1997. 12 patients never received any treatment or follow-up. The results are presented for the remaining 303.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, no treatment control versus amifostine 200 mg/m2 daily 15-20 minutes prior to radiation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis assessed weekly by physician. Radiation Therapy Oncology Group Scoring systems. Assessment used: day 90. Other reported outcomes: nausea, vomiting, xerostomia, saliva production, survival, local disease control.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: pharmaceutical.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 09:30:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brizel-2008">
<CHAR_METHODS MODIFIED="2010-11-10 09:29:21 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group multisite study conducted in the USA, Canada and Australia. Withdrawals unclear (see ROB). Unclear if dentist involved in study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 09:30:22 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with stage III/IV or IV squamous carcinoma of the oral cavity, oropharynx, hypopharynx and larynx undergoing concurrent chemoradiotherapy. Radiotherapy given in 2 Gy fractions to 70 Gy, hyperfractionated radiotherapy given in 1.25 Gy fractions twice daily. Chemotherapy: cisplatin 20 mg/m<SUP>2</SUP> for 4 days and fluorouracil 1000 mg/m<SUP>2</SUP>/d for 4 days (weeks 1 and 5 of radiotherapy).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 09:30:28 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups: placebo versus palifermin 60 &#956;g once weekly during radiotherapy for 9 consecutive weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-22 23:35:05 +0100" MODIFIED_BY="[Empty name]">
<P>Mucositis assessed weekly using CTCAE (version 2). Other reported outcomes: dysphagia, xerostomia, radiotherapy breaks, supplemental nutrition, safety.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 09:30:38 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: pharmaceutical.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-23 00:15:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bubley-1989">
<CHAR_METHODS MODIFIED="2010-10-23 00:15:49 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in USA. Clear information about withdrawals: 0. Unclear if dentist involved in study. </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with head and neck cancer. Prior positive titre to Herpes Simplex. Results presented for 57 patients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus acyclovir 200 mg tablets 12 hourly.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis assessed by nurse. Assessment used: unclear. Other reported outcomes: herpes simplex virus.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Data presented separately for patients receiving chemo and radiotherapy.<BR/>Funding source: pharmaceutical.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 09:34:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Buentzel-2006">
<CHAR_METHODS MODIFIED="2010-11-10 09:34:09 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group, multicentre study conducted in USA/Europe. Clear information on withdrawals: none. Unclear if dentist involved in study. Drop outs: 22%. Duration: up to 90 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-09 10:30:48 +0100" MODIFIED_BY="Helen Worthington">
<P>Adults with head and neck cancer. 132 enrolled and randomised between October 1996 to October 1998. 102 completed but ITT analysis presented.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus intravenous amifostine (300 mg/m2 before carboplatin 70 mg/m2 and radiotherapy on days 1 to 5 and 21 to 25, and intravenous amifostine 200 mg/m2 or placebo before radiotherapy on 6 to 20 and 26 to 30/35 days).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis graded with reference to RTOG criteria on a 0-4 scale. Assessment used up to 90 days. Other reported outcomes: xerostomia, 1 yr locoregional failure, progression-free survival, overall survival, treatment related adverse events: vomiting, nausea, asthenia, allergic reaction, anaemia, phlebitis, leukopenia, hypotension, allergic reaction.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: industry.<BR/>Pharmacological company provided drug and organised randomisation.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 22:09:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Buntzel-1998">
<CHAR_METHODS MODIFIED="2010-10-18 22:09:12 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Germany. Clear information on withdrawals: none. Unclear if dentist involved in study. Drop outs: 0%. Duration: 6 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with head and neck cancer, hospitalised with stage III-IV tumour, no evidence of systemic infection, liver or renal impairment, tumour resected or excised before adjuvant radiotherapy. 28 patients enrolled, 28 were evaluated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, radiotherapy with or without amifostine (15 min infusion 500 mg preceded by antiemetic regimen of 12 mg dexamethasone and 8 mg ondansetron).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>WHO mucositis grades 3/4. Assessment used: day 42. Other reported outcomes: xerostomia, dysphagia, loss of taste, dermatitis, haematological side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>More data presented but included extra 11 patients in amifostine group who were not entered into study. <BR/>Funding source: pharmaceutical.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 22:08:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cartee-1995">
<CHAR_METHODS MODIFIED="2010-10-18 22:08:55 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in USA. Unclear information on withdrawals: 5 withdrew, unclear from which groups. Dentist involved in study. Drop outs: 10%. Duration: 21 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with breast cancer stage IV, with combination of chemotherapy including 5-FU, adriamycin &amp; methotrexate. First cycle of chemotherapy. 50 patients were enrolled and 45 were evaluated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>5 groups, 0.1% albumin (described as placebo, dose 0), GM-CSF (molgramostim, range of doses, 0.01, 0.10, 1.00, 10.00 mcg/ml. Mouthwash solutions administered 4 times daily starting 24 hours after chemotherapy initiation). Continuing until end of cycle.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis (CALGB GRADE &gt;= 3). Assessment used: day 15. Other reported outcomes: WBC, plasma GM-CSF.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Doses 0.01, 0.10, 1.00, 10.00 were combined and compared with dose 0 (control). <BR/>Funding source: government.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 22:08:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carter-1999">
<CHAR_METHODS MODIFIED="2010-10-18 22:08:45 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in USA. Clear information on withdrawals: none. Dentist Involvement unclear. Drop outs: 0%. Duration: up to 4 months post radiotherapy.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with head and neck cancer receiving curative intent radiotherapy, Karnofsky performance &gt; 60. 102 patients enrolled and 102 completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-24 12:49:26 +0100" MODIFIED_BY="[Empty name]">
<P>2 groups, placebo versus sucralfate (added as suspension of 1 gm sucralfate/15 ml solution) swish 2 minutes and swallow 4 times per day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-24 12:49:30 +0100" MODIFIED_BY="[Empty name]">
<P>RTOG graded mucositis. Assessment used: maximum during treatment at 60 Gy. Other reported outcomes: pain, need for placement of feeding tube, use of narcotics, need for intravenous fluids, diet, need for treatment break. All assessed weekly.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-24 12:37:14 +0100" MODIFIED_BY="[Empty name]">
<P>Funding source: not stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 22:07:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cascinu-1994">
<CHAR_METHODS MODIFIED="2010-10-18 22:07:57 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Italy. Clear information on withdrawals: none. Unclear if dentist involved in study. Drop outs: 0%. Duration: unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with solid cancer (GI &amp; prostate). Chemotherapy: 5-FU. First course of chemotherapy. 84 patients eligible, enrolled and completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, control (no treatment) versus ice chips (cryotherapy, 5 mins before 5-FU for 30 mins after). Checked every week and judgement on mucositis performed on day of next chemotherapy course.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis (global assessment of physician's and patient's description on 0-4 scale). Assessment used: unclear.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Statistical handling of data incorrect as all cycles included but used data from first cycle. <BR/>Funding source: unclear.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 09:39:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Castagna-2001">
<CHAR_METHODS MODIFIED="2010-11-10 09:38:46 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group multicentre study conducted in France, Italy and Switzerland. Clear information about withdrawals: 2/53 sucralfate, 1/52 placebo. Unclear if dentist involved in study. Drop outs: 2.8%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with mixed cancer (hospitalised for allogenic or autologous BMT). 105 enrolled, 102 completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 09:39:02 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, placebo (n = 51) versus 2 g sucralfate (n = 51) every 3 hours daily, swish and swallow, for a maximum of 7 mouthwashes.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis grade 3-4. Other reported outcomes: duration, diarrhoea, caloric intake by oral nutrition.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 09:39:09 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: pharmaceutical.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 22:06:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cengiz-1999">
<CHAR_METHODS MODIFIED="2010-10-18 22:06:33 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Turkey. Clear information on withdrawals: none. Dentist involved in study. Drop outs: 0%. Duration from beginning to end of radiotherapy.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with head and neck cancer. 28 patients enrolled and completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus sucralfate (6 g sucralfate suspension mouthwash 4 doses orally before meals and bedtime).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-26 10:08:40 +0100" MODIFIED_BY="[Empty name]">
<P>RTOG mucositis (0-IV). Topical and systemic analgesic use, weight loss, dry mouth. Assessment used: day 42. Other reported outcomes: pain, difficulty eating, constipation, analgesics, dry mouth.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 22:06:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cerchietti-2006">
<CHAR_METHODS MODIFIED="2010-10-18 22:06:12 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Argentina. Clear information on withdrawals: none. Dentist involvement unclear. Drop outs: 0%. Duration: 60 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-29 16:06:30 +0100" MODIFIED_BY="[Empty name]">
<P>Adults with head and neck cancer. Chemoradiotherapy - radiotherapy 2 Gy /day up to total 70 Gy, plus cisplatin and 5-FU daily on days 1-5 repeated every 3 weeks. 32 enrolled 29 randomised and completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-29 16:07:05 +0100" MODIFIED_BY="[Empty name]">
<P>2 groups, placebo versus glutamine. (patients intravenous L-alanyl-L-glutamine 0.4 g/kg weight/day on each day of chemo through a separate IV line).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis assessed by mean of 3 highest scores by Objective Mucositis Score (OMS) and the WHO grading system on a 0-4 scale. Mucositis graded once/week during chemo and every other day during CRT. Assessment used up to 60 days. Other reported outcomes: pain, feeding tubes, mucositis related hospitalisation, adverse drug effects, body weight change, incidence of local infections, tumour response.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: industry and foundation. Pharmacological company provided drug and organised randomisation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 09:42:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chi-1995">
<CHAR_METHODS MODIFIED="2010-11-10 09:41:07 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised cross-over multisite study conducted in Taiwan. Clear information on withdrawals: 0. Unclear if dentist involved in study. Duration: 10 days (day 5 to day 14)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 09:41:35 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with head and neck cancer undergoing chemotherapy (two cycles of cisplatin 20 mg/m<SUP>2</SUP>/day, fluorouracil 800 mg/m<SUP>2</SUP>/day and leucovorin 90 mg/m<SUP>2</SUP>/day).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 09:41:42 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, no therapy versus GM-CSF (4 &#956;g/kg/day subcutaneously) crossed over for 2nd cycle.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 09:42:08 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis assessed daily for 17 days (0-4 scale). Other outcome measures: tumour response rate, neutrophil and leukocyte counts, adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 09:42:13 +0000" MODIFIED_BY="[Empty name]">
<P>Funding information: government.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 09:43:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Choi-2007">
<CHAR_METHODS MODIFIED="2010-11-10 09:42:50 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Korea. Clear information about withdrawals: 0. Unclear if dentist involved in study. Drop outs: 0%. Recruitment September 2003 to August 2005.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-29 15:56:04 +0100" MODIFIED_BY="[Empty name]">
<P>Adults with solid tumours receiving 5FU chemotherapy. 51 enrolled and randomised, all completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 09:43:07 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, glutamine 30 g/day as supplement administered enterally for 15 days, versus best supportive care. Patients in both groups received cryotherapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-23 00:18:08 +0100" MODIFIED_BY="[Empty name]">
<P>Mucositis severity evaluated using 0-4 scale, CTCAE criteria, any mucositis, &#8805; grade 2 mucositis, &#8805; grade 3 mucositis, cost and adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-29 16:00:34 +0100" MODIFIED_BY="[Empty name]">
<P>Funding source: not stated. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 09:44:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chor-2010">
<CHAR_METHODS MODIFIED="2010-11-10 09:44:00 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised parallel group study conducted in Brazil. Clear information about withdrawals: 0. Dentist involved in study. Duration: 7 days (day -7 to day 0).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-19 17:48:24 +0100" MODIFIED_BY="[Empty name]">
<P>34 adults undergoing autologous transplantation. No disease or treatment information.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 09:44:08 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, sham laser (led) versus laser (diode laser of 50 mW AsGaA1 applied emitting continuous light at 660 nm).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-19 18:21:16 +0100" MODIFIED_BY="[Empty name]">
<P>Mucositis assessed daily from day-2 until discharge using the Tardieu scale. Other outcome measures: febrile episodes, cumulative probability of developing mucositis, length of hospital stay. </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-19 17:22:07 +0100" MODIFIED_BY="[Empty name]">
<P>Funding Source: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 09:57:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Crawford-1999">
<CHAR_METHODS MODIFIED="2010-11-10 09:57:09 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group multicentre study conducted in USA. Unclear information on withdrawals (previously described): 6/110 placebo, 6/101 test. Dentist involvement unclear. Drop outs: 9%. Duration: from day 4 to day 17 of cycle.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-18 22:05:34 +0100" MODIFIED_BY="[Empty name]">
<P>Adults with small cell lung cancer. 211 patients enrolled, 199 evaluated, 195 evaluated on first cycle. </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups: placebo (not described) versus filgrastim (230 ug/m).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>WHO mucositis grades 0-4. Assessment used: day 21. Other reported outcomes: neutropenia, infections complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-29 15:41:31 +0100" MODIFIED_BY="[Empty name]">
<P>Used first cycle data.<BR/>Funding source: not stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 10:00:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cruz-2007">
<CHAR_METHODS MODIFIED="2010-10-20 11:47:46 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised parallel group study conducted in Brazil. Unclear information about withdrawals. Dentist involved in study. Duration: 5 consecutive days from initiation of chemotherapy. Recruitment ran from May 2003 to February 2005. </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 09:58:50 +0000" MODIFIED_BY="[Empty name]">
<P>Children aged between 3 and 18 years old. 62 patients recruited. 56 patients evaluated on second visit, 59 patients evaluated at the 3rd evaluation. 35 patients had leukaemia or lymphoma, 25 patients had solid tumours. All patients received chemotherapy, 24 patients also received a stem cell transplant.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 09:59:29 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, no treatment control versus laser (continuous 780 nm wavelength, 60 mW power, fluence 4 J/cm<SUP>2</SUP>.<SUP> </SUP>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 10:00:34 +0000" MODIFIED_BY="[Empty name]">
<P>Oral assessments performed 3 times (days 1, 8 and 15) using the Common Toxicity Criteria National Cancer Institute toxicity scale (0-4 scale). Other reported outcomes: use of drugs to treat infection, food intake (kcal), nutritional status (BMI), buccal health (number of decayed, missing and filled teeth), white cell count, number of teeth brushing sessions.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 10:00:44 +0000" MODIFIED_BY="[Empty name]">
<P>Funding information: government.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 10:03:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dai-2009">
<CHAR_METHODS MODIFIED="2010-10-18 22:05:07 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in China. Clear information about withdrawals: 0. Unclear if dentist involved in study. Drop outs: 0%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-12 10:10:35 +0100" MODIFIED_BY="Helen Worthington">
<P>Adults with head and neck cancer receiving radiotherapy. 42 enrolled and randomised between January 2008 to December 2008, all completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 10:03:36 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, YHD Humo Decoction (honeysuckle flower 15 g, forsythia fruit 9 g, scullcap root 15 g, glehnia root 15 g, lilyturf root 15 g, crude rehmannia root 15 g, figwort root 15 g, red peony root 10 g, red sage 10 g, milkvetch root 10 g, asiabell root 10 g, balloon flower root 10 g, arctium fruit 10 g, and liquorice 6 g). It was decocted in water, boiling down to 150 mL of decoction, one dose daily, administered in six times by keeping it in the mouth for 2 min and then swallowed. No treatment control. All patients gargled with 2% lidocaine before meals and at night.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-12 10:17:43 +0100" MODIFIED_BY="Helen Worthington">
<P>Mucositis severity evaluated daily using RTOG 0-4 scale and the highest grade reported. Unclear how often this was measured but results reported by grade of mucositis and as days to reach each RTOG grade. </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 10:03:57 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: government.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 22:03:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dazzi-2003">
<CHAR_METHODS MODIFIED="2010-10-18 22:03:31 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Italy. Clear information about withdrawals: 0. Unclear if dentist involved in study. Drop outs: 0%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-09 10:57:43 +0100" MODIFIED_BY="Helen Worthington">
<P>Adults with solid cancer. 90 enrolled and randomised between July 1997 and February 2002, 90 completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus GM-CSF mouthwash (150 ug/day) in 100 cl 4 times per day. Rinse 1 minute. All patients 0.2% chlorhexidine and amphotericin B.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis severity evaluated daily using NCI CTC. Other reported outcomes: oral pain evaluated daily using visual scale and pain requiring opioids.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: none (c).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 10:06:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dickson-2000">
<CHAR_METHODS MODIFIED="2010-11-10 10:05:38 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in USA. Clear information on withdrawals: none. Dentist not involved in study. Drop outs: 0%. Duration: first day of treatment until discharge or max 28 days after transplant. Recruitment June 1995 to August 1997.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 10:05:35 +0000" MODIFIED_BY="[Empty name]">
<P>Adults receiving bone marrow transplant (BMT) or peripheral blood progenitor cell transplant (PBPCT). 58 enrolled and evaluated with leukaemia or lymphoma.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 10:05:47 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, powdered sugar added to food or drink (placebo) versus glutamine (10 g doses mixed with food or liquid chosen by patient) 3 times daily (30 g/day).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-29 15:47:14 +0100" MODIFIED_BY="[Empty name]">
<P>Stamford University Hospital BMT toxicity scale for mucositis scale 0-4. Reported as grade 2+. Parenteral nutrition with TPN. Assessment used: day 28. Other reported outcomes: length of hospital stay. Days in total, parenteral nutrition, diarrhoea, toxicity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 10:06:13 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: pharmaceutical supply product/small grants programme of Stanford University Hospital's Nursing Management Department.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 10:08:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dodd-1996">
<CHAR_METHODS MODIFIED="2010-11-10 10:07:24 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group, multicentre study conducted in USA. Dentist involved in study. Duration: up to 3 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with solid cancer receiving chemotherapy. Followed for 3 cycles of chemotherapy. 303 eligible, 227 enrolled and evaluated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 10:07:45 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups: water control (described as placebo) versus chlorhexidine mouthrinse (0.12%, 20 ml, twice per day).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 10:08:00 +0000" MODIFIED_BY="[Empty name]">
<P>Oral assessment guide (OAG) 0-24, scores over 10 were considered to be oral mucositis. Maximum of 3 months. Assessment used: day 90. Other reported outcomes: survival, cost, time to onset of mucositis, severity of mucositis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 10:08:31 +0000" MODIFIED_BY="[Empty name]">
<P>Severity of mucositis at onset measured. ITT analysis.<BR/>Funding source: government and pharmaceutical.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 10:10:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dorr-2007">
<CHAR_METHODS MODIFIED="2010-11-10 10:10:10 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group multisite study conducted in Germany. Clear information about withdrawals: 8 (4/36 wobe mugos; 4/33 placebo). Unclear if dentist involved in study. Duration: treatment continued until 5 days after radiotherapy. Recruitment conducted between June 1996 and May 2000.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 10:10:18 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with head and neck cancers undergoing radiotherapy (all patients received dose &gt; 40 Gy).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 10:10:31 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, placebo versus wobe mugos (papain 100 mg, trypsin 40 mg and chymotrypsin 40 mg), 3 x 4 tablets per day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 10:10:36 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis assessed weekly using the RTOG/ EORTC classification. Other reported outcomes: side effects, pain on swallowing, dysphagia, skin erythema, skin desquamation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-23 00:09:18 +0100" MODIFIED_BY="[Empty name]">
<P>Funding source: unclear. Figure 1 data used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 22:02:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dozono-1989">
<CHAR_METHODS MODIFIED="2010-10-18 22:02:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, cross-over study conducted in Japan. Clear information on withdrawals: none. Unclear if dentist was involved. Drop outs: 0%. Duration: unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with solid cancer receiving chemotherapy. 15 patients enrolled and completed both periods.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups: no treatment control versus allopurinol mouthwash (carboxymethylcellulose (CMC-Na) 5 g and allopurinol 500 mg, water to 500 ml solution).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Japan Society for Cancer Therapy criteria for stomatitis 0-4 scale.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 10:12:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Duenas-1996">
<CHAR_METHODS MODIFIED="2010-10-18 22:02:41 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Mexico. Clear information on withdrawals: none. Unclear if dentist was involved in study. Drop outs: 0%. Duration: -4 to day 16.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-25 14:19:21 +0100" MODIFIED_BY="[Empty name]">
<P>Adults with mixed cancer undergoing peripheral stem cell transplant, receiving high dose (ifosfamide, carboplatin, etoposide). 15 patients enrolled (16 course of chemotherapy) and completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-25 14:19:44 +0100" MODIFIED_BY="[Empty name]">
<P>2 groups, placebo versus misoprostol (racemic prostaglandin E1 analogue) 250 &#956;g 3 times per day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 10:12:38 +0000" MODIFIED_BY="[Empty name]">
<P>WHO mucositis grades 0-4, candidiasis, days in hospital with range. Assessment used: day 16.<BR/>Other reported outcomes: diarrohea, fever, days in hospital, duration of antibiotics.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>All patients received fluconazole prophylaxis. Also received ranitidine, ketoconazole &amp; ciprofloxacin. Severity of mucositis also given but no SD. Study stopped prematurely due to a significant finding at an interim analysis, favouring the placebo. <BR/>Funding source: government, pharmaceutical. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 10:14:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-El-Sayed-2002">
<CHAR_METHODS MODIFIED="2010-11-10 10:13:19 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group, multicentre study conducted in Canada. Clear information on withdrawals. Dentist not involved in study. Drop outs: 0%. Duration: over radiotherapy.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with head and neck cancer treated with radiotherapy to the oral cavity, pharynx or larynx. 137 enrolled randomised and completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus antimicrobial lozenge (bacitracin, clotrimazole and gentamicin (BCoG) 1 lozenge qid, day 1 to end of radiotherapy).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 10:14:35 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis graded according to the OMAS scale extent of severe mucositis score, worst-ever grade of ulceration/pseudomembrane. Assessment used: time to development of severe mucositis. Other reported outcomes: number of treatment days lost, changes in body weight, worst-ever grade of oral toxicity measured in patient diary, general non-mucosal toxicity assessed by the investigator.<BR/>Mucositis measured twice weekly using the NCI CTC v2 scoring scale and the OMAS scale. Assessment used up to 28 days. Other reported outcomes: oral pain and ability to swallow using 10 cm VAS, salivary flow rate, adverse events nausea and vomiting.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: National Cancer Institute.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 10:17:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Elad-2006">
<CHAR_METHODS MODIFIED="2010-10-18 18:43:50 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Israel, from August 2002 to March 2003. Unclear information on withdrawals. Dentist involvement unclear. Drop outs: 13%. Duration: 28 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-10 10:01:15 +0100" MODIFIED_BY="Anne Littlewood">
<P>Adults with mixed cancer. BMT, total body irradiation, chemotherapy, chemoradiotherapy. 45 enrolled and randomised 39 completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-25 14:21:13 +0100" MODIFIED_BY="[Empty name]">
<P>2 groups, placebo versus topical histamine gel (a semi viscous solution containing 0.12% w/w HDC (histamine dihydrochloride) in a carbomer-based vehicle). Patients instructed to use 5 ml (1 teaspoon) 4 times a day.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 10:17:15 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis measured twice weekly using the NCI CTC v2 scoring scale and the OMAS scale. Assessment used up to 28 days. Other reported outcomes: oral pain and ability to swallow using 10 cm VAS, salivary flow rate, adverse events nausea and vomiting.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-10 10:01:54 +0100" MODIFIED_BY="Anne Littlewood">
<P>Funding source: early part of study funded by industry, rest of funding unclear. All received standard oral care: chlorhexidine mouthrinse 2/day amphotericin B lozenges 4/day. Pharmacological company provided drug and organised randomisation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 10:19:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Epstein-1989">
<CHAR_METHODS MODIFIED="2010-11-10 10:18:12 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group single site study conducted in Canada. Clear information on withdrawals: 6/24 placebo. Dentist involved in study. Drop outs: 12%. No information given about dates of recruitment. Duration: unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 10:18:17 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with head and neck cancer receiving radiotherapy (25 patients received 4500 cGy in 15 daily fractions over 3 weeks, 18 patients received 6000 cGy in 25 daily fractions over 5 weeks). 49 patients enrolled, 43 patients completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 10:18:47 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, placebo (10% alcohol) base versus benzydamine (1.5 mg/ml benzydamine hydrochloride in a 10% alcohol base). Both groups asked to rinse 15 ml for 30 seconds, 4 times daily, and then expectorate.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 10:19:00 +0000" MODIFIED_BY="[Empty name]">
<P>Multivariable scale (area of involvement, severity of inflammation, severity of ulceration and maximum size of ulceration each graded using a 0-3 scale. Scores then combined). Other outcomes measures: pain (at rest and on eating), burning, anesthetic effect of benzydamine, salivary flow rate.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 10:19:03 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: pharmaceutical.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 10:21:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Epstein-1994">
<CHAR_METHODS MODIFIED="2010-10-20 22:13:40 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised parallel group study conducted in Canada. Clear information about withdrawals: 0. Dentist involved in study. Duration: 5-7 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 10:20:54 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with head and neck cancer receiving radiotherapy (either 5000 cGy in 16 fractions or 6000 cGy in 25 fractions). 33 patients randomised and completed study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 10:21:15 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, placebo versus sucralfate (1 g/5 ml). Drug or placebo rinsed and swallowed for 1 or 2 minutes, 4 times daily.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-20 22:23:08 +0100" MODIFIED_BY="[Empty name]">
<P>Mucositis assessed weekly using a cumulative mucositis score (Epstein). Other reported outcome measures: compliance, pain, adverse events, dysphagia, xerostomia.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 10:21:24 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: pharmaceutical.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 10:23:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Epstein-2001">
<CHAR_METHODS MODIFIED="2010-11-10 10:22:41 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised parallel group multisite study conducted in the USA and Canada. Clear information about withdrawals. Unclear if dentist involved in study. Duration: until 2 weeks after completion of radiotherapy.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 10:22:49 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with head and neck cancers receiving radiotherapy (total planned dose of 5000 Gy) or concomitant radiotherapy and chemotherapy (cisplatin, or 5-fluorouracil).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 10:22:57 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, placebo versus benzydamine (0.15%, 1.5 mg/ml). Patients asked to rinse with 15 ml of mouthwash for 2 minutes, 4-8 times daily 173 patients randomised.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 10:23:13 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis assessed at every clinic visit using a multivariable scale (Epstein). Other reported outcome measures: use of analgesics, mouth and throat pain, compliance, number of patients diluting rinses, adverse events, risk of mucositis, weight loss, number of patients needing nasogastric or percutaneous endoscopic gastrostomy tube feeds.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 10:23:18 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: pharmaceutical.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 10:24:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ertekin-2004">
<CHAR_METHODS MODIFIED="2010-10-18 18:40:05 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Turkey, between May 2001 and May 2002. Clear information about withdrawals, 3 in placebo. Dentist not involved in study. Drop outs: 10%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-10 10:07:35 +0100" MODIFIED_BY="Anne Littlewood">
<P>Adults with head and neck cancer. 30 enrolled, 27 completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-10 10:07:39 +0100" MODIFIED_BY="Anne Littlewood">
<P>2 groups, zinc sulphate 50 mg zinc capsules 3 times per day starting first day of radiotherapy until 6 weeks after versus placebo. All patients access to local anaesthetic solutions and analgesic agents.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis RTOG grading. Other reported outcomes: non-steroidal analgesics.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 10:24:14 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-09 17:00:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Evensen-2001">
<CHAR_METHODS MODIFIED="2010-11-10 10:25:41 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Norway. All randomised patients included in evaluation. Dentist involvement unclear. Recruitment September 1995-June 1998.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-26 11:27:08 +0100" MODIFIED_BY="[Empty name]">
<P>Adults with hand and neck cancer undergoing radiotherapy. 60 enrolled, 60 completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-09 17:00:50 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, patients randomised to sucralfate mouthrinse or placebo, swish and spit, 5 times daily and same patients also received sucralfate gel to skin on one side of radiation field and placebo gel to other side of the radiation field (i.e. all patients received some sucralfate gel).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 10:25:58 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis &amp; skin reaction, RTOG grading. Other reported outcomes: food intake.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 10:26:01 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: not stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 10:28:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ferretti-1988">
<CHAR_METHODS MODIFIED="2010-10-18 18:39:47 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in USA. Unclear information on withdrawals: 1/28 control, 4/28 test. Dentist involved in study. Drop outs: 10%. Recruitment period April 1983 to March 1985. Duration: up to 90 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 10:28:22 +0000" MODIFIED_BY="[Empty name]">
<P>Children and adults (1-51 years) with mixed blood haematological and solid cancers receiving BMT. Pretransplant chemoradiotherapy and TBI. 56 patients enrolled and 51 completed, but variable numbers of patients evaluated at each time point (24-50).<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus chlorhexidine gluconate mouthrinse (15 cc 0.12%, 3 times per day for 30s).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-05 21:30:18 +0100" MODIFIED_BY="[Empty name]">
<P>Mucositis (clinical scale 0-3, but then dichotomised and measured at 7, 14, 25, 33, 60 &amp; 90 days). Assessment used: day 33. Other reported outcomes: gross candida (clinical appearance + swab culture or KOH preparation), oral streptococus, yeast, gram -ve bacilli, death, morphine use, febrile episodes, use of antibiotic, blood changes.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-13 15:26:50 +0100" MODIFIED_BY="[Empty name]">
<P>Candidemia (persistant candidiasis) also recorded, with 3 deaths due to candida in the control group. Mean mucositis scores given graphically with bars for SE. Given oral nystatin suspension 15 ml 4 times daily or clotrimazole troches. Supplemental nystatin soaks or popsicles were used liberally.<BR/>Funding source: pharmaceutical and government.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 10:31:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fidler-1996">
<CHAR_METHODS MODIFIED="2010-10-18 18:39:32 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in USA. Unclear information on withdrawals: 1/165 total. Unlcear if dentist involved in study. Drop outs: 1%. Duration: 14 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults, cancer type not given. Chemotherapy: first course 5-FU based. 165 enrolled, 164 clinical evaluation, 135 patient evaluation.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus camomile (30 drops in 100 ml water, 3 times per day).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis (physician and patient scales 0-4). Score judged historically 4-5 weeks after chemotherapy cycle initiation. Additionally patient form filled out on daily basis for first 3 weeks after first day of chemotherapy. Assessment used: day 21. Other reported outcomes: toxicity.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 10:31:12 +0000" MODIFIED_BY="[Empty name]">
<P>Mean daily mucositis scores shown graphically but no SD. All patients used ice chips 5 mins before chemotherapy and for 30 minutes in total.<BR/>Patient's mucositis scores used.<BR/>Funding source: government.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 10:36:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Foote-1994">
<CHAR_METHODS MODIFIED="2010-11-10 10:36:41 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group, multicentre study conducted in USA and Canada. Clear information on withdrawals: none. Unclear if dentist involved in study. Drop outs: 0%. Duration: 14 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with head and neck cancer. 52 patients were eligible, enrolled and evaluated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 10:36:49 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, placebo versus chlorhexidine (15 ml 4 times per day for 130 s).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis scale 0-4 by patient and clinician at weekly intervals. Assessment used: day unclear.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: pharmaceutical and government.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 10:39:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Franzen-1995">
<CHAR_METHODS MODIFIED="2010-10-18 18:39:00 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Sweden. Unclear information on withdrawals: 2/50 total. Unclear if dentist involved in study. Drop outs: 4%. Duration of treatment: 6 weeks (starting 2 weeks after start of radiotherapy).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-26 12:06:03 +0100" MODIFIED_BY="[Empty name]">
<P>Adults with head and neck cancer. 50 patients were randomised and 48 evaluated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus sucralfate (granules of sucralfate an alkaline aluminimum hydroxide of suphated sucrose, swish with 1 dose package 1 g dissolved in water 6 times/day).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 10:39:16 +0000" MODIFIED_BY="[Empty name]">
<P>Patient based assessment of mucositis on 0-3 scale, number with grades 2 or 3 reported. Assessement used: day 28. Other reported outcomes: mucosal reaction, pain, functional impairment. Mucositis evaluations from -2 to 14 weeks.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: charity.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 10:42:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Freytes-2004">
<CHAR_METHODS MODIFIED="2010-11-10 10:40:34 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group, multicentre study conducted in USA. Clear information on withdrawals: none. Dentist not involved in study. Drop outs: 0%. Duration: 28 days after last dose of intervention.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with mixed cancer. BMT. 42 enrolled, randomised and evaluated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 10:40:46 +0000" MODIFIED_BY="[Empty name]">
<P>3 groups, placebo versus repifermin 25 mug/kg and repifermin 50 mug/kg (patients received intravenous repifermin or placebo for 3 days before their autologous haematopoietic stem cell transplantation (auto-HSCT) conditioning regimen and for up to 10 days after auto-HSCT).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 10:42:59 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis measured 3/week until mucositis resolved using the NCI CTC mucositis toxicity scale for bone marrow transplant studies (on a scale of 0-4). Mucositis was also assessed by the OMAS scale. Assessment used: up to day 28. Other reported outcomes: severity and duration of ambient oral and oropharyngeal pain and pain on swallowing, an ability to eat score, narcotic pain medication use, adverse events incuded the frequency, severity and duration of diarrhoea.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 10:45:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gandemer-2007">
<CHAR_METHODS MODIFIED="2010-11-10 10:44:17 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel multicentre study conducted in France. Clear information about withdrawals: 3/73 intervention, 2/72 control. Duration: from first day of chemotherapy to 3 days after the end of chemotherapy. Recruitment conducted between March 1999 and December 2002.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 10:44:44 +0000" MODIFIED_BY="[Empty name]">
<P>Children aged between 5 and 18 years old undergoing chemotherapy. Mix of diseases (osteosarcoma, Hodgkin lymphoma, acute lymphoblastic leukaemia, acute myeloblastic leukaemia, rhabdomysarcoma, lymphoma, Ewing sarcoma). all chemotherapy regimens were associated with at least a 30% rate of grade 3/4 mucositis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 10:44:54 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, no treatment control versus chewing gum. Patients in the chewing gum arm were asked to chew 5-6 pieces of gum per day. All patients received standard oral care (brushing with a soft toothbrush and rinsing with sodium bicarbonate).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 10:45:03 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis assessed daily using the WHO score and a detailed instrument designed by the authors. Other reported outcome measures: pain, abdominal disorders, use of parenteral nutrition, adverse events, infection, factors associated with severe mucositis (multivariate analysis).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-22 22:42:27 +0100" MODIFIED_BY="[Empty name]">
<P>Funding source: publicly funded research grant and a national clinical research grant.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 10:46:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Giles-2004">
<CHAR_METHODS MODIFIED="2010-11-10 10:46:19 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group, multicentre study conducted in USA between November 2001 and June 2002. Clear information on withdrawals: none. Dentist not involved in study. Drop outs: 0%. Duration: 21 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults and children with mixed cancer. BMT. 502 randomised and completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus iseganan (patients received an oral rinse, consisting of iseganan 9 mg or placebo, to be swished/swallowed 6 times daily, for up to 21 days).<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis assessed 3/weekly by the proportion of patients who did not develop a peak NCI CTC stomatitis grade 2 or above. Assessment used up to 21 days. Other reported outcomes: mouth pain, difficulty swallowing, incidence of ulcerative oral mucositis (UOM), opioid use, adverse events included fatigue, anxiety, sore throat, dermatitis, insomnia and erythema.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 10:46:27 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: unclear. Pharmacological company provided drug and organised randomisation.<BR/>Correspondence with Dr D Peterson: clinical trials with iseganan were discontinued approximately 6 years ago. Approval of the drug for oral mucositis was not obtained in the United States.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 16:41:39 +0000" MODIFIED_BY="Helen Worthington" STUDY_ID="STD-Gori-2007">
<CHAR_METHODS MODIFIED="2010-11-10 11:07:42 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel multisite study conducted in Italy between October 2004 and January 2006. Clear information on withdrawals. Unclear if dentist involved in study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-30 16:41:39 +0000" MODIFIED_BY="Helen Worthington">
<P>Adults and children with haematological malignancies undergoing allogeneic stem cell transplantation. All patients received methotrexate (20 mg/m<SUP>2 </SUP>on day +1,<SUP> </SUP>5 mg/m<SUP>2 </SUP>on days +3, +6 and +11). 130 patients were randomised. 8 patients were excluded. 50 patients received folinic acid rescue.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-22 00:52:20 +0100" MODIFIED_BY="[Empty name]">
<P>2 groups, no treatment control versus cryotherapy (1 hour, ice chips or popsicles).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 11:08:33 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis assessed daily using the WHO score. Other reported outcome measures: multivariate analysis of factors affecting mucositis development (lack of folinic acid rescue and use of TBI).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 11:08:36 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: Italian HSCT Nurses Group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 11:10:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goyal-2009">
<CHAR_METHODS MODIFIED="2010-10-18 18:38:19 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in India. All patients underwent oro-dental prophylaxis prior to randomisation. Recruitment conducted from July 2006 until July 2007.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-06 23:38:38 +0100" MODIFIED_BY="[Empty name]">
<P>Adults with head and neck cancer (non-metastatic carcinoma of the oral cavity, pharynx or larynx) receiving radiotherapy. 212 patients randomised. 35 patients excluded. </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 11:09:45 +0000" MODIFIED_BY="[Empty name]">
<P>Morning radiotherapy (8am-11am) versus evening radiotherapy (3pm-6pm).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 11:10:00 +0000" MODIFIED_BY="[Empty name]">
<P>Oral mucositis assessed weekly using RTOG instrument (0-4) for 7 weeks. Week 4 data used (table 3). Other reported outcomes: highest grade of mucositis, response to radiation, dysgeusia, dysphagia, xerostomia, skin reaction.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-06 23:55:56 +0100" MODIFIED_BY="[Empty name]">
<P>Funding source unclear. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 18:38:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gujral-2001">
<CHAR_METHODS MODIFIED="2010-10-18 18:38:03 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in India. Unclear information about withdrawals. Dentist no involved in study. Drop outs: 1%. Duration: 6 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with head and neck cancer. T3 and T4 squamous cell cancer, 100 enrolled, 99 evaluated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, no treatment versus hydrolytic enzymes, papain 100 mg, trypsin 40 mg and chymotrypsin 40 mg. 3 tablets 3 times a day - 3 until + 5.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>RTOG/EORTC scoring. Assessment used: day 54. Other reported outcomes: dysphagia, dermatitis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No oral care except toothbrushing. Funding source: pharmaceutical.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 11:12:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Haddad-2009">
<CHAR_METHODS MODIFIED="2010-11-10 11:11:58 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group, 1 site study conducted in USA. Clear information on withdrawals: none. Unclear if dentist involved in study. Drop outs: 0%. Duration: up to 43 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-09 10:21:10 +0100" MODIFIED_BY="Helen Worthington">
<P>Adults with head and neck cancer. 58 patients enrolled and randomised between May 2003 and April 2006, all completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 11:12:58 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, no amifostine versus intravenous amifostine (500 mg/m concomitant with 4 weekly doses of carboplatin (area under the curve, 1.5) and paclitaxel (45 mg/m) and boost radiation 72 Gy in 42 fractions).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-25 10:28:52 +0000" MODIFIED_BY="Helen Worthington">
<P>Mucositis secondary outcome as determined by Common Terminology Criteria for Adverse Events, version 3.0), assessment every 4 weeks and the worst grade recorded. Only percent of patients with grades 3 and 4 reported.</P>
<P>Other reported outcomes: xerostomia, locoregional failure, progression-free survival, overall survival (all up to 60 months), treatment related adverse events: cytokine level, feeding tubes, swallowing function, breaks in treatment, allergic reaction.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-25 10:28:08 +0000" MODIFIED_BY="Helen Worthington">
<P>Funding source: industry.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 11:14:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hanson-1995">
<CHAR_METHODS MODIFIED="2010-11-10 11:14:06 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group multisite study conducted in the USA. Clear information about withdrawals: 0. Unclear if dentist involved in study. Duration: 5-7 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 11:14:12 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with head and neck cancer undergoing radiotherapy (daily fractions of 2 Gy/day, total dose: 50-70 Gy over 5-7 weeks).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 11:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, placebo tablets or misoprostol tablets (200 &#956;g) dissolved in 15 ml tap water. Patient asked to swish and gargle without swallowing.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-22 18:06:45 +0100" MODIFIED_BY="[Empty name]">
<P>Mucositis assessed weekly using a 0-4 scale. Other reported outcome measures: plasma values of misoprostol in healthy volunteers, ability of physician to guess randomisation after blinded chart review, number of patients receiving antifungals, nasogastric tubes and parotid sparing.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 11:14:28 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: pharmaceutical.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 11:17:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hartmann-2001">
<CHAR_METHODS MODIFIED="2010-11-10 11:16:27 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Germany. Clear information about withdrawals: 0. Unclear if dentist involved in study. Drop outs: 0%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-09 10:27:18 +0100" MODIFIED_BY="Helen Worthington">
<P>Adults with solid cancer. 40 enrolled between August 1997 and January 1999, 40 completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 11:17:01 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, amifostine 910 mg/m, 15 minute IV infusion before carboplatin and ifosfamide for 3 consecutive days versus no amifostine control.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis WHO percentage patients grade 3-4. Other reported outcomes nausea/vomiting, costs of total care, diarrhoea.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-23 00:26:21 +0100" MODIFIED_BY="[Empty name]">
<P>Funding source: pharmaceutical.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 11:18:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-He-2008">
<CHAR_METHODS MODIFIED="2010-11-10 11:17:52 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in China. Clear information about withdrawals: 0. Unclear if dentist involved in study. Drop outs: 0%. Recruitment period: unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-29 15:34:57 +0100" MODIFIED_BY="[Empty name]">
<P>Adults with oesophageal and cardiac cancer receiving chemotherapy. 48 enrolled and randomised, all completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 11:18:01 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, 20 g glutamine daily versus a placebo (compound amino acid) given by 'injection' possibly into parenteral nutrition solution.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 11:18:07 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis severity evaluated using 0-4 scale NCI CTCAE criteria, grade 0, 1, 2 versus grade 3, 4, nausea/vomiting, diarrhoea, leucopenia, weight loss.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-29 15:36:57 +0100" MODIFIED_BY="[Empty name]">
<P>Funding source: government. All above information obtained from Chinese translation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 11:19:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hu-2005">
<CHAR_METHODS MODIFIED="2010-10-18 18:37:30 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in China. Clear information about withdrawals: 0. Unclear if dentist involved in study. Drop outs: 0%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-12 10:44:43 +0100" MODIFIED_BY="Helen Worthington">
<P>Adults with head and neck cancer receiving radiotherapy. 140 enrolled and randomised, all completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 11:19:57 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, Shenqi Fanghou recipe (author named) Chinese herb decoction containing 22 specifically selected herbs such as codonopsis pilosula 30 g, raidx astragali 30 g, Indian buead 30 g, etc. altogether 406 g as a dosage for a day. All the herbs were put into water for boiling then removing the herbs and 400 ml of solution obtained. The patients were asked to intake the solution orally, 200 ml a time and twice a day. No treatment control. All patients gargled with 2% lidocaine before meals and at night.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-12 10:48:39 +0100" MODIFIED_BY="Helen Worthington">
<P>Mucositis severity evaluated using 0-4 scale and the highest grade throughout radiotherapy course reported. Unclear how often this was measured but results reported by grade of mucositis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-12 10:49:47 +0100" MODIFIED_BY="Helen Worthington">
<P>Funding source: unclear. All above information obtained from Chinese translation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 18:37:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2000">
<CHAR_METHODS MODIFIED="2010-10-18 18:37:17 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Taiwan. Clear information about withdrawals: none. Dentist not involved in study. Drop outs: 0%. Duration: beginning of radiation treatment until 25 factions (5 weeks). Recruitment July 1997 to June 1998.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with head and neck cancer. 17 patients were enrolled and evaluated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-29 15:01:07 +0100" MODIFIED_BY="[Empty name]">
<P>2 groups, placebo (30 ml saline) versus glutamine (2 g in 30 ml saline, swish 30 ml 3 mins then expectorate).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinicians assessed subjective mucositis on 0-4 scale and objective RTOG/EORTC 0-4 scale. WHO step of analgesic drugs. Assessment used: day unclear.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-29 15:01:24 +0100" MODIFIED_BY="[Empty name]">
<P>Subjective mucositis scale used. Funding source: not stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 11:28:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2003">
<CHAR_METHODS MODIFIED="2010-10-18 18:36:57 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in China. Clear information on withdrawals. Unclear whether dentist involved in study. Drop outs: 0%. Duration: average radiotherapy 50 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-12 11:04:57 +0100" MODIFIED_BY="Helen Worthington">
<P>Adults with head and neck cancer treated with chemotherapy cisplatin (DDP 30 mg/m) with concomitant radiotherapy. 101 patients recruited and evaluated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 11:28:59 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, Dobell's solution (unclear what this is) gargled 5-8 times daily versus Chinese medicine (sucked and swallowed) 6 times from first to sixth week of radiotherapy. Patients received either Chinese medicine or Dobell's solution 5-8 times daily.<BR/>The decoction is made as solution by cooking the 11 herbs together with water. Doses of the herbs for 1 day are: coastal glehnia 30 g, dwarf lilyturf tuber root 30 g, rehmannia dried root 30 g, figwort rood 15 g, spreading hedyotis herb 30 g, belamcauda rhizome 15 g, platycodon root 15 g, shinyleaf pricklyoash root 15 g, honeysuckle flower 15 g, licorice root 3 g, lalanggrass rhizome 20 g.<BR/>The authors follow theoretical principles of Chinese medicine: treatment should be modified in adapting the changes of the diagnosis. So, if the patients with symptoms of rhinorrhagia or blood clot in the sputum, adding hairy vein agrimony herb 20 g, hyacinth bletilla tuber 15 g; with nausea and vomiting adding red ochre 15 g, magnolis bark of Sichuan 15 g, bamboo shaving 15 g; with obstruction of the nose, adding sibirian cocklebur fruit 15 g, magnolia flower 15 g; with malaise and poor appetite, adding pseudostellaria root 30 g, bighead atractylodes rhizome 15 g, malt 30 g, millet sprout 30 g; with the tongue in dark pink colour, adding root of red rooted salvia 15 g, powder of notoginsen 3 g.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis assessed according to acute oropharyngeal mucositis grade on a 0-4 scale.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-12 10:59:47 +0100" MODIFIED_BY="Helen Worthington">
<P>Pharmacological company provided drug and organised randomisation. This information was provided by Chinese translation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 11:29:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ifrah-1999">
<CHAR_METHODS MODIFIED="2010-10-18 18:36:49 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in France. Unclear information about drop outs. Unclear if dentist involved in study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 11:29:52 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with blood cancer. 67 enrolled and randomised between November 1990 and April 1992, results given on 64.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-09 11:53:19 +0100" MODIFIED_BY="Helen Worthington">
<P>2 groups, rGM-CSF 5 ug/kg as a 6 hour IV infusion versus placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 11:29:59 +0000" MODIFIED_BY="[Empty name]">
<P>WHO mucositis score (&gt; 3).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-23 00:28:06 +0100" MODIFIED_BY="[Empty name]">
<P>Funding source: none.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 11:33:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jebb-1994">
<CHAR_METHODS MODIFIED="2010-10-18 18:36:42 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, cross-over study conducted in UK. Unclear information about withdrawals: 11/28 in total. Dentist not involved in study. recruitment period: not stated.<BR/>Drop outs: 39%. Duration: (1st part) 8 days.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with gastrointestinal cancer undergoing 5-FU &amp; folic acid daily for 5 days and repeated 4 weeks from start. 28 patients enrolled and 17 completed 2 cycles.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 11:33:00 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, glucose polymer (Polycal) (described as placebo) versus glutamine (16 mg daily divided into 4 equal doses and dissolved in 150 ml water before consumption), swish and swallow.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>WHO mucositis score, mouth comfort, ease of eating. Assessment used: day 8.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-29 14:59:07 +0100" MODIFIED_BY="[Empty name]">
<P>Funding source: not stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 11:35:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Katano-1995">
<CHAR_METHODS MODIFIED="2010-11-10 11:34:52 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Japan. Clear information about withdrawals: none. Unclear if dentist involved in study. Drop outs: 0%. Duration: administration ceased when leukocyte exceeded 8000/mm.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 11:35:04 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with solid (breast cancer). 14 patients enrolled and evaluated. Recruitment January 1992 to December 1996.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 11:35:26 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, no treatment versus G-CSF (by injection 125 ug).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>WHO mucositis score (0-4) by clinician. Other reported outcomes: alopecia, fever. Assessment used: day 8.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: pharmaceutical supply product.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 18:36:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kaul-1999">
<CHAR_METHODS MODIFIED="2010-10-18 18:36:26 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in India. Unclear information about withdrawals. Dentist not involved in study. Drop outs unclear. Duration unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with head and neck cancer radiotherapy 50-60 Gy/5-6 weeks. 50 patients enrolled.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, no treatment control versus wobe-mugos enzyme preparation 3 tablets/day 3 days prior to RT until 1 week after.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis. Assessment used: day 28. Other reported outcomes: xerostomia, skin changes, dysphagia, hospitalisation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: none.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-04-26 12:13:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kazemian-2009">
<CHAR_METHODS MODIFIED="2010-11-10 11:37:00 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Iran between 2004 and 2005. Full information given on withdrawals. Dentist involved in study. Drop outs: 19%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-04-26 12:13:04 +0100" MODIFIED_BY="Anne Littlewood">
<P>Adults with head and neck cancer receiving radiotherapy. 100 enrolled in study, 81 were evaluated, 39 in the benzydamine group and 42 in the placebo group.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 11:37:17 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, placebo versus benzydamine (0.15 benzydamine oral rinse). Participants rinsed with 15 ml for 2 minutes, 4 times per day from the first day of radiotherapy treatment to the end.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 11:37:30 +0000" MODIFIED_BY="[Empty name]">
<P>Assessment on the RTOG grading system for oral mucositis, assessment carried out weekly. Other reported outcomes: effects of smoking, effects of chemoradiotherapy.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 11:37:37 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 18:35:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koukourakis-2000">
<CHAR_METHODS MODIFIED="2010-10-18 18:35:54 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Greece. Unclear information on withdrawals 0/20 control, 1/20 test. Unclear if dentist involved in study. Drop outs: 3%. Duration 6-7 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-09 10:24:54 +0100" MODIFIED_BY="Helen Worthington">
<P>Adults with 3 cancer types: thoracic, pelvic, RT postoperative or inoperable dose 64-70 Gy. 140 patients enrolled between July 1997 and May 1999, 130 completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, no treatment control versus amifostine 500 mg daily before RT.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis 0-4 scale combined categories. Assessment used: unclear. Other reported outcomes RT delay, side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Patients selected from other types of cancer because mucositis data available. Funding source: government &amp; pharmaceutical.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 11:40:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Labar-1993">
<CHAR_METHODS MODIFIED="2010-10-18 18:35:43 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Croatia. Clear information about withdrawals: none. Dentist not involved in study. Drop outs: 0%. Duration: +7 to day +21.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children and adults (5-43 years) with blood cancers, undergoing BMT. 60 patients eligible, enrolled and evaluated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus prostaglandin E2 (0.5 mg 3 times per day).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 11:40:45 +0000" MODIFIED_BY="[Empty name]">
<P>Clinical and culture fungal measurement. Mucositis (WHO scale for 0-II vs III+, and 0 vs 1+). Severity over -7 to +35 days. Severity of mucositis also measured but no SD given. Assessment used: day 35. Other reported outcomes: HSV infection, microbiology, vomiting, diarrhoea, fever, death, GVHD (c).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: none.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 11:41:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leborgne-1997">
<CHAR_METHODS MODIFIED="2010-10-23 00:30:03 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Uruguay. Unclear information about withdrawals. Unclear whether dentist involved in study. Drop outs: 4%. Duration 90 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with head and neck cancer radical RT. 69 enrolled, 66 completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus prednisone 40 mg once daily through day 28 reduced dose to day 43.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 11:41:24 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis WHO. Assessment used: unclear. Other reported outcomes: duration of treatment, treatment interruptions, parenteral nutrition, hospital stay, weight loss, locoregional control, survival.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 11:41:25 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: not stated. Mucositis data for all grades of severity obtained after writing to authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 11:43:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2006">
<CHAR_METHODS MODIFIED="2010-11-10 11:42:46 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in China. Clear information about withdrawals: 1 from glutamine group. Unclear if dentist involved in study. Drop outs: 2%. Recruitment March 2001 to December 2002.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 11:42:58 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with breast cancer receiving 5-FU chemotherapy. 60 enrolled and randomised, 59 completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 11:43:09 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, 30 received 30 g oral glutamine per day for 12 days prior to chemotherapy, 29 received placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 11:43:28 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis severity evaluated using 0-4 scale (NCI CTCAE) (grade 3-4). Other reported outcomes: intestinal permeability, intestinal toxicity, plasma glutamine levels.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 11:43:34 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: government.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 11:45:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lievens-1998">
<CHAR_METHODS MODIFIED="2010-10-20 11:06:24 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Belgium. Clear information about withdrawals: 19 (12 sucralfate and 7 placebo). Unclear if dentist involved in study. Duration: 25-33 days (entire duration of therapy).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 11:45:18 +0000" MODIFIED_BY="[Empty name]">
<P>102 adults with head and neck cancers receiving radiotherapy (5 fractions per week, doses ranged from 55 Gy in 25 daily fractions of 2.2 Gy to 66 Gy in 33 daily fractions of 2 Gy).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 11:45:26 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, placebo versus sucralfate (1 g 6 times daily).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 11:45:32 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis scored once weekly using 0-6 scale. Other reported outcome measures: subjective intolerance to radiotherapy treatment, dysphagia, nausea, dermatitis, weight loss, side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 11:45:37 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 11:49:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lilleby-2006">
<CHAR_METHODS MODIFIED="2010-11-10 11:49:40 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in USA. Clear information on withdrawals: 1 in saline group withdrew consent because wanted ice chips. Dentist not involved in study. Drop outs: 2%. Duration: -2 to 28 days post-transplant.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with blood cancer - multiple myeloma scheduled to receive melphalan 200 mg/m followed by BMT- autologous stem cell transplantation (ASCT). 41 enrolled and randomised, 40 completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-20 23:30:06 +0100" MODIFIED_BY="[Empty name]">
<P>2 groups, room temperature normal saline rinse versus ice chips (oral cryotherapy) 30 minutes before and 6 hours after high-dose therapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis was assessed as part of routine care using the NCI CTC grades 0-4. Assessment used: -2 to 28 days. Other reported outcomes: days of total parenteral nutrition (TNP), narcotic use, hospitalisation, weight loss and resumption of oral caloric intake for 28 days after transplant.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: charity.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 11:51:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lin-2006">
<CHAR_METHODS MODIFIED="2010-11-10 11:51:26 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel, multisite study conducted in Taiwan. Clear information on withdrawals: 3 (2 placebo, 1 intervention). Unclear if dentist involved in study. Recruitment conducted from January 2003 until August 2004. Duration: during radiotherapy treatment (approximately 2 months).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 11:51:34 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with head and neck cancers receiving radiotherapy (180 cGy to 200 cGy in 5 weekly fractions) with or without concurrent chemotherapy (no extra information). 100 randomised, 97 completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 11:51:37 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, soya bean oil placebo versus oral zinc (25 mg Pro-Z) (3 capsules a day).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 11:51:54 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis assessed weekly using the RTOG criteria for acute morbidity. Other reported outcome measures: dermatitis, weight loss, interruption of radiotherapy, adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 11:51:59 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: Chi-Mei Foundation Medical Centre.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 18:34:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lockhart-2005">
<CHAR_METHODS MODIFIED="2010-10-18 18:34:58 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in USA. Clear information on withdrawals: none. Unclear whether dentist involved in study. Drop outs: 0%. Duration: unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with mixed cancer. BMT - autologous blood stem cell transplant (ABSCT). 36 enrolled, randomised and completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus pilocarpine (patients were randomised to receive a 5 mg tablet of pilocarpine, or a placebo, during and following chemotherapy).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis assessed every other day using the WHO mucositis score and the authors' own developed data entry forms to capture subjective and objective data, including toxicity criteria. This new tool is a highly modified version of the Southwest Oncology Group (SWOG) toxicity scale. We used the highest score mucositis score recorded, supplied by author. Assessment used: up to day 10. Other reported outcomes: problems with nutrition, oral infection, use of narcotics for mucosal pain, problems with oral hygiene, gingival bleeding, eating, speaking and sleeping (ordinal variables), pain at rest or with swallowing, mouth dryness (VAS scale).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: charity/foundation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 18:34:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Loprinzi-1990">
<CHAR_METHODS MODIFIED="2010-10-18 18:34:50 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised cross-over trial conducted in USA. Clear information on withdrawals: none. Dentist was not involved. Drop outs: 0%. Duration: 5 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with colorectal cancer receiving first 5 day course of 5-FU. 77 patients enrolled, and completed 1st period, only 20 completed 2nd period.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus allupurinol mouthrinse 1 mg/ml made from 450 mg + 150 ml cologel (450 mg/5 mg methylcellulose with 5% alcohol) +450 ml flavouring agent. 20 ml used for 30s immediately after treatment then at 1, 2, 3 hours).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis (physician and patient scales 0-4). Assessed used: day 30.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Data cross-tabulated in a form suitable for meta-analysis provided by authors.<BR/>Funding source: none.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 11:56:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Madan-2008">
<CHAR_METHODS MODIFIED="2010-10-20 23:43:24 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel study conducted in India. Clear information on withdrawals: 4. Unclear if dentist involved in study. Duration: 6 weeks. </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 11:55:48 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with head and neck cancer receiving radiotherapy (2 Gy daily dose, total dose 60 Gy).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 11:55:54 +0000" MODIFIED_BY="[Empty name]">
<P>4 groups, 0.12% chlorhexidine versus 1% povidone-iodine versus salt/sodium bicarbonate versus plain water. All mouthwashes given in doses of 10 ml twice a day for 6 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-21 00:13:54 +0100" MODIFIED_BY="[Empty name]">
<P>Mucositis assessed weekly using WHO scale. Other reported outcome measures: none.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 11:56:00 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: Manipal University, India.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 11:59:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mahood-1991">
<CHAR_METHODS MODIFIED="2010-10-18 18:34:34 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, cross-over study conducted in USA. Unclear information on withdrawals: 2/45 control, 0/50 treatment in first cycle. Dentists not involved in study. Drop outs 2%. Duration from 5 mins before 5-FU and for 30 mins after.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults mostly over 40 years with cancer of the colon (solid cancer). Chemotherapy first 5 day course of 5-FU. 95 patients eligible and enrolled and 93 completed first cycle, however, only 82 patients assessed mucositis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 11:59:09 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, no treatment control versus ice chips (cryotherapy) placed in the mouth 5 mins before each dose of 5-FU and replenished over 30 mins.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis (physician &amp; patients scales 0-4) and historical 1 month after treatment. Assessment used: day 28.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Data cross-tabulated in a form suitable for meta-analysis provided by authors. <BR/>Funding source: government.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 12:00:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Makkonen-1994">
<CHAR_METHODS MODIFIED="2010-11-10 12:00:37 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Finland. Clear information about withdrawals: none mentioned. Dentist involved in study. Drop outs: 0%. Duration: during therapy (9 weeks). Recruitment November 1989 to December 1991.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with head and neck cancer. 40 patients eligible, enrolled and evaluated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus sucralfate (suspension 1 g 6 times per day orally, patients mix granules with 100 ml water rinse for 1 min then swallow). Rinsed throughout radiotherapy, dose 45-73 Gy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-26 12:29:46 +0100" MODIFIED_BY="[Empty name]">
<P>Mucositis on scale 0-2 (0 = no mucositis, 1 = moderate, 2 = severe), at 9 weekly evaluation visits. Assessment used: day 28. Other reported outcomes: salivary lactoferrin, salivary albumin, amount of anaesthetic mouthwash, radiotherapy interrupted, toxicity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Visit at week 4 taken. Antifungal agents given to 29 patients during study. <BR/>Funding source: government.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 18:34:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Makkonen-2000">
<CHAR_METHODS MODIFIED="2010-10-18 18:34:12 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Finland. Clear information about withdrawals: none. Dentist involved in study. Drop outs: 0%. Duration: during therapy (9 weeks).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-09 12:54:07 +0100" MODIFIED_BY="Helen Worthington">
<P>Adults with head and neck cancer. 40 patients eligible, enrolled between November 1994 and August 1996, all were evaluated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, no treatment control versus GM-CSF (150 to 300 ug given subcutaneously daily until last day of irradiation. Dose depends on body weight).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis on scale 0-2 (0 = no mucositis, 1 = moderate, 2 = severe). Assessment used: day 28. Other reported outcomes: oral pain on scale 1-4, and patient VAS scale for pain. Evaluated weekly during treatment then 1 and 6 months after therapy, use of analgesic, weight loss, toxicity, survival.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>All patients used sucralfate suspension 1 g 6 times daily. <BR/>Funding source: pharmaceutical.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 18:34:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McAleese-2006">
<CHAR_METHODS MODIFIED="2010-10-18 18:34:04 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study single centre study conducted in the UK. Clear information about withdrawals: 2/29. Unclear if dentist involved in study. Drop outs: 7%. Duration: 10 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-09 12:37:26 +0100" MODIFIED_BY="Helen Worthington">
<P>Adults with head and neck cancer to be treated with radiotherapy. 29 patients eligible, enrolled between September 1997 and October 2000. 27 patients evaluated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-09 12:39:50 +0100" MODIFIED_BY="Helen Worthington">
<P>2 groups, GM-CSF at dose of 150 ug subcutaneous injection once daily for 14 days beginning at the end of second week of radiotherapy. Compared to no treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-09 12:40:30 +0100" MODIFIED_BY="Helen Worthington">
<P>RTOG rating for mucositis on 0-4 scale. </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-09 12:46:30 +0100" MODIFIED_BY="Helen Worthington">
<P>Maximum value of mucositis taken. Funding unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 12:04:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McGaw-1985">
<CHAR_METHODS MODIFIED="2010-10-18 18:10:22 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group single site study conducted in Canada. Dentist involved in study. Drop outs: 0%. Duration: 28 days. No enrolment dates.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 12:04:23 +0000" MODIFIED_BY="[Empty name]">
<P>16 patients with acute myeloblative leukaemia aged between 17 and 54 years old. All patients received conditioning with cytosine-arabinoside (200 mg/m<SUP>2 </SUP>daily for 5 days), adriamycin (40 mg/m<SUP>2 </SUP>on day 1 and 2) and amsacrine (100 mg/m<SUP>2</SUP> daily for 5 days) chemotherapy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 12:04:42 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, intervention group received 10 ml of 0.1% aqueous solution of chlorhexidine gluconate (corsodyl), placebo group received a identically coloured and flavoured solution. Both groups rinsed twice daily for 2 minutes.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 12:04:55 +0000" MODIFIED_BY="[Empty name]">
<P>Hickey instrument used (0-3 scale). Other outcome measures: dental plaque scores, gingivitis scores, numbers of patients developing candidiasis, number of patients requiring antibiotics, average number of febrile days, level of tooth staining and discolouration.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 12:04:57 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: not stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 12:06:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meropol-2003">
<CHAR_METHODS MODIFIED="2010-11-10 12:05:56 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group, multicentre study conducted in USA. Clear information about withdrawals: 0. Dentist not involved in study. Drop outs: 0% Duration: 28 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with solid cancer treated with 5-FU. Patients enrolled, 81 completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 12:06:26 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, KGF IV injection patient cohorts treated with escalating doses of KGF 1,10, 20, 40, 60 and 80 micrograms/kg per day versus placebo control.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 12:06:39 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis WHO grading evaluated by examination on day 1, 4, 8, 15 and 28. Other reported outcomes: nausea, vomiting, blood changes.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 18:33:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mills-1988">
<CHAR_METHODS MODIFIED="2010-10-18 18:33:39 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in South Africa. Clear information about withdrawals: 0. Dentist not involved in study. Drop outs: 0%. Duration: unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with head and neck cancer. 10 enrolled, 10 completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, beta carotene (250 mg/day for 21 days, 75 mg daily after this) versus no treatment control.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: pharmaceutical.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 12:09:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Motallebnejad-2008">
<CHAR_METHODS MODIFIED="2010-11-10 12:08:35 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Iran. Clear information about withdrawals. Unclear if dentist involved in study. Duration unclear (5-6 weeks?).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 12:09:04 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with head and neck cancer receiving radiotherapy (1.8 Gy to 2 Gy per day, total dose 50-60 Gy).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 12:09:24 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, saline (20 ml saline 0.09% before and after radiotherapy) versus honey (20 ml pure honey, 15 minutes before and 15 minutes after radiotherapy, and 6 hours after radiotherapy).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 12:09:30 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis assessed using the OMAS instrument weekly. Other reported outcomes: weight loss.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 12:09:35 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: university.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 12:15:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nemunaitis-1995">
<CHAR_METHODS MODIFIED="2010-11-10 12:10:38 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group, multicentre study conducted in USA and Canada. Clear information about withdrawals: none. Unclear if dentist involved in study. Drop outs: 0%. Duration: 1 year.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-09 13:23:00 +0100" MODIFIED_BY="Helen Worthington">
<P>Adults with mixed cancer receiving BMT, chemotherapy cyclosporine &amp; prednisolone. 109 patients enrolled between November 1990 and July 1993. 109 completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 12:14:35 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, placebo versus RhGM-CSF (human granulocyte macrophage colony-stimulating factor) 250 ug/m/day IV day 0-20.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 12:15:04 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis scored by nurse 3 grades (categorised according to WHO criteria for analysis). Assessment used: day 28. Other reported outcomes: infection, anorexia, diarrhoea, hypertension, stomatitis. Mucositis reported on all 109 patients.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: pharmaceutical.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 18:33:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nottage-2003">
<CHAR_METHODS MODIFIED="2010-10-18 18:33:04 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Canada. Clear information about withdrawals, 1 placebo. Dentists not involved in study. Drop outs: 1.2%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with solid cancer treated with 5-FU. 81 enrolled 80 completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus sucralfate mouthwash (10 ml mouthwash for 2 minutes then swallow 4 times per day).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis severity (patient daily diary scores). Other reported outcomes: pain eating/drinking difficulty, quality of life score, weight loss, nausea and vomiting.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 12:18:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oberbaum-2001">
<CHAR_METHODS MODIFIED="2010-10-18 18:32:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Israel. Clear information about withdrawals: 1/16 control, 1/16 test. Unclear if dentist involved in study. Drop outs: 6%. Duration: unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children and adults with mixed cancer receiving a BMT. 32 consecutive patients enrolled, 30 completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus traumeel (homeopathic) rinse vigorously 30 sec before swallowing 5/day for a minimum 14 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 12:18:12 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis WHO scale evaluated every 2 days. Assessment used: day 7. Other reported outcomes: subjective symptom score for dry mouth, oral pain and difficulty in eating.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 12:18:13 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;unsure of reference to pharmaceutical funding (AMG)&lt;/p&gt;" NOTES_MODIFIED="2010-11-10 12:18:13 +0000" NOTES_MODIFIED_BY="[Empty name]">
<P>All patients twice daily chlorhexidine, oral amphotericin B, gentle toothbrushing.<BR/>Funding source: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 12:24:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Okuno-1999">
<CHAR_METHODS MODIFIED="2010-11-10 12:23:47 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in USA. Clear information about withdrawals: none. Dentist not involved in study. Drop outs: 0%. Duration: up to 5 weeks after initial chemotherapy. Dentist involvement unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 12:24:01 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with cancer (type unclear) receiving chemotherapy with 5-FU, 134 eligible, enrolled and 134 evaluated by physician, but patient assessment only completed by 124 patients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-29 14:31:26 +0100" MODIFIED_BY="[Empty name]">
<P>2 groups, placebo versus glutamine (4 g twice a day, swish for 10 seconds, then swallow).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Maximum severity of mucositis over 14 days using 0-4 scale, both physician and patient assessment. Other reported outcomes: toxicity (no detail). Assessment used: day 14.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>All patients used ice chips 5 minutes before 5-FU for 30 minutes. <BR/>Funding source: government.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 12:25:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Panahi-2009">
<CHAR_METHODS MODIFIED="2010-11-10 12:25:09 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Iran. Clear information on withdrawals. Unclear if dentist involved in study. Duration: 3 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-22 01:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Adults with solid tumours (colon, breast, stomach, pancreas, rectum, esophagus and other) receiving chemotherapy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 12:25:24 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, placebo versus allopurinol (1 mg/ml), patients asked to swish 20 ml of mouthwash for 30 seconds at 1 hr, 2 hrs and 3 hrs after chemotherapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 12:25:29 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis assessed 3 times (day 1, day 3 and day 7) using the WHO scale. Other reported outcome measures: use of dentures and education (multiple logistic regression).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 12:25:30 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 12:30:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peterson-2009">
<CHAR_METHODS MODIFIED="2010-11-10 12:27:03 +0000" MODIFIED_BY="[Empty name]">
<P>Parallel groupstudy. Duration 14 days treatment from the beginning of cycle 2 of chemotherapy, final follow-up at day 21+/-2. Dentist involvement - unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 12:28:41 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: aged &gt; 18 years with colorectal cancer, undergoing chemotherapy &amp; having experienced grade 2 or greater OM in cycle 1.Patients had to have WHO grade 0 OM at study entry and ECOG performance status &lt;/= 2.</P>
<P>Exclusion: pregnancy, lactation, administration of other investigational drugs within 14 days of start of study or plans to use topical or systemic treatments for OM during study, radiotherapy to head &amp; neck, alcohol or drug abuse, active fungal or herpetic infection.</P>
<P>Number randomised 99; number completed 98.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 12:30:12 +0000" MODIFIED_BY="[Empty name]">
<P>3 groups: low dose (n = 33) 10 mg/ml recombinant human intestinal trefoil factor (rhITF) in aqueous solution dispensed as 3.5 ml spray vial. Patients (all outpatients) administered 3 puffs (approx 100 ul each) to oral mucosa 8 times daily for 14 days. High dose (n = 33) 80 mg/ml rhITF, administered as above. Placebo (n = 33) water packaged and administered as above.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 12:30:31 +0000" MODIFIED_BY="[Empty name]">
<P>Incidence of grade 2 or greater OM, duration of grade 2 or greater OM.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 12:30:50 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source:the GI company (private pharma).</P>
<P>All patients received analgesia as required but dose was low and comparable between groups.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 18:32:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pfeiffer-1990">
<CHAR_METHODS MODIFIED="2010-10-18 18:32:24 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, cross-over study conducted in Denmark. Unclear information about withdrawals. Dentist not involved in study. Drop outs: 43%. Duration: 14 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with head and neck cancer. 40 patients enrolled, 23 evaluable.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus sulcralfate (1 g 15 ml suspension, swish for 2 min then spit out or swallow).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Ulceration or not.<BR/>Assessment used: day 14. Other reported outcomes: pain, problems eating.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: pharmaceutical support for product.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 12:32:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pillsbury-1986">
<CHAR_METHODS MODIFIED="2010-10-18 18:32:14 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel study conducted in USA. Clear information about withdrawals, 2/10 control, 0/10 test. Dentist involved in study. Drop outs: 10%.<BR/>Duration: until treatment was completed.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with head and neck cancer. 20 enrolled, 18 completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus prostaglandin inhibitor (25 mg of indomethacin 4 times per day).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis grade at day 1, 2 and 3.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 12:32:39 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: none.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 12:34:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pitten-2003">
<CHAR_METHODS MODIFIED="2010-11-10 12:34:04 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Germany. Clear information about withdrawals: none. Dentist involved in study. Drop outs: 0%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-08 21:41:09 +0100" MODIFIED_BY="[Empty name]">
<P>Adults with mixed cancer treated with chemotherapy, 47 enrolled, 47 completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus chlorhexidine 100 ml 0.3% chlorhexidine, 10.4 g ethanol, 1.67 g hydrogen peroxide versus stannous fluoride.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 12:34:15 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis WHO grading. Other reported outcomes: systemic infection, febrile episodes, blood changes, microbial counts.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: external.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 12:35:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prada-1987">
<CHAR_METHODS MODIFIED="2010-11-10 12:35:27 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Italy. Unclear information about withdrawals. Dentist not involved in study. Drop outs: 10%. Duration: 10 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with head and neck cancer. 40 patients eligible and enrolled, 36 evaluated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus benzydamine (120 ml solution of 0.15% benzydamine, 15 ml mouthwash for 5 mins every 3 hours up to max of 6 times daily).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Physician evaluation of mucositis on 0 (absent) to 3 (intense or remarkable) scale every day for 10 days. Assessment used: day 10. Other reported outcomes: global clinical symptomatology, burning, chewing pain, dysphasia and odynophasia assessed.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: none.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 12:42:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Puataweepong-2009">
<CHAR_METHODS MODIFIED="2010-11-10 12:38:50 +0000" MODIFIED_BY="[Empty name]">
<P>Parallel group study. Duration 8 weeks (throughout 3-4 weeks of radiotherapy and until 8 week follow-up. Dentist involvement - unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 12:40:41 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: stage 2-4 histologically confirmed head and neck cancer planning to undergo adjuvant or definitive radiotherapy.Karnofsky performance status &gt; 70%.</P>
<P>Exclusions:prior RT, history of allergy to aloe vera, underlying diabetes mellitus, HIV positive.</P>
<P>Number randomised 61; completed 60; evaluated 61.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 12:41:52 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups:A (n = 30) 15 ml aloe vera solution 3 times daily beginning on day 1 of RT. B (n = 31) 15 ml of placebo (identical in taste and appearance) 3 times daily beginning on day 1 of RT.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 12:42:11 +0000" MODIFIED_BY="[Empty name]">
<P>Onset &amp; incidence of severe mucositis, weight loss, number of patients &amp; duration of radiotherapy interruption, adverse events, requirement for analgesics, antibiotics, antifungals.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 12:42:23 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: The Thailand Research Fund.</P>
<P>All patients received daily supportive care including rinsing mouth with water, saline or viscous lidocaine.Analgesic drugs and antibiotics were allowed and feeding tubes were used as required.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 12:44:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Qin-2007">
<CHAR_METHODS MODIFIED="2010-11-10 12:44:01 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in China. Withdrawals: 0. Unclear if dentist involved in study, duration: duration of therapy.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 12:44:06 +0000" MODIFIED_BY="[Empty name]">
<P>Adults and children aged 16 to 70 with nasogastric carcinoma receiving radiotherapy (total dose 50-78 Gy).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-22 18:11:46 +0100" MODIFIED_BY="[Empty name]">
<P>2 groups, no treatment control versus dental stent (worn by patients during radiotherapy). </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 12:44:15 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis assessed using a 0-4 scale. Other reported outcome measures: weight loss, taste disruption.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 12:44:20 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 12:44:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rahn-1997">
<CHAR_METHODS MODIFIED="2010-11-10 12:44:43 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Germany. Clear information about withdrawals: none. Dentist involvement unclear. Drop outs: 0%. Duration: until 1 week after end of radiotherapy.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with head and neck cancer. 40 patients eligible, enrolled. 2 died but all 40 were evaluated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-25 15:43:17 +0100" MODIFIED_BY="[Empty name]">
<P>2 groups, control (sterile water) versus povidone iodine rinse (rinsing for 3 mins with 100 ml solution 4 times daily).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>WHO assessment of mucositis on 0-4 scale. During therapy and at 2, 6 weeks after therapy. Assessment used: day 28.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>All patients received nystatin, dexpanthenol, ratoside and immunoglobin.<BR/>Funding source: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 12:46:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rashad-2008">
<CHAR_METHODS MODIFIED="2010-11-10 12:45:36 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised parallel group trial conducted in Egypt. Duration of follow-up 7 week.s</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 12:45:45 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with histologically confirmed SCCHN T1-4, N0-3, m0, KPS &#8805; 50%. 40 randomised and evaluated. Recruited April 2005 to July 2006.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 12:45:51 +0000" MODIFIED_BY="[Empty name]">
<P>Honey (from Trifolium Alexandrenum) versus no treatment. 15 min before, 15 min after and 6 hours after radiotherapy patients smeared mouth with honey, and then swallowed slowly to smear honey on mucosa.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 12:46:05 +0000" MODIFIED_BY="[Empty name]">
<P>WHO mucositis grade, weekly during therapy (7 weeks) 4-week data used.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 12:46:10 +0000" MODIFIED_BY="[Empty name]">
<P>All patients received chemoradiotherapy (60-66 Gy plus cisplatin 20 mg/m<SUP>2</SUP> weekly) for 6-7 weeks.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 12:46:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rocke-1993">
<CHAR_METHODS MODIFIED="2010-11-10 12:46:50 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised parallel group study conducted in USA. Clear explanation of withdrawals: 1 in 30 min arm. Drop outs: &lt; 1%. Duration: 5 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults receiving first course of 5-FU, cancer type unclear. 179 eligible, and randomised, 178 evaluated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, 30 versus 60 minute cryotherapy. Ice chips placed in mouth 5 min before 5-FU and then swished round during treatment and replenished as ice melted.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Physician and patient assessment of mucositis on 0-4 scale.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Some cross-over data were included in paper. We have not included this as only patients with mild mucositis crossed-over.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 12:48:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rosen-2006">
<CHAR_METHODS MODIFIED="2010-11-10 12:47:37 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group multisite study conducted in the USA and Australia. Clear information on withdrawals. Unclear if dentist involved in study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 12:48:02 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with tumours of the colon and rectum receiving chemotherapy or chemoradiotherapy. All patients received leucovorin 20 mg/m<SUP>2</SUP>/day and fluorouracil 425 mg/m<SUP>2</SUP>/day for 5 consecutive days.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 12:48:10 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, placebo versus palifermin (40 &#956;g/kg) for 3 days before chemotherapy administration.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-22 22:55:33 +0100" MODIFIED_BY="[Empty name]">
<P>Mucositis assessed on days 1, 4, 8, 12, and 15 and day 28 using the WHO score. Patients completed the oral mucositis daily questionnaire daily between days 1 and 27. Other reported outcomes: diarrhoea, patient reported mouth and throat soreness, safety, laboratory assessments, disease outcomes, antibody assessments. </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 12:48:15 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: pharmaceutical (Amgen).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 18:31:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saarilahti-2002">
<CHAR_METHODS MODIFIED="2010-10-18 18:31:01 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Finland. Clear information about withdrawals: none. Unclear if dentist involved in study. Drop outs: 0%. Duration: 10 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-09 10:39:31 +0100" MODIFIED_BY="Helen Worthington">
<P>Adults with head and neck cancer. 40 patients eligible, enrolled between October<BR/>1999 and April 2001, and evaluated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, GM-CSF mouthwash made by dissolving 150 mg of dried powder in 100 ml sterile water versus mouthwash of 4 g sucralfate with 100 ml sterile water. 4 doses x 25 ml per day after meals.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>RTOG rating for mucositis on 0-4 scale. Author provided data in right form for the review.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Maximum value of mucositis taken.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 12:51:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Scarantino-2006">
<CHAR_METHODS MODIFIED="2010-10-18 18:30:38 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in USA. Clear information on withdrawals: 1 in pilocarpine and 2 in placebo group refused protocol treatment. Dentist not involved in study. Drop outs: 1%. Duration: 13 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 12:50:57 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with head and neck cancer. Planned radiotherapy to include have 50% of the volume of the major salivary glands receive 50 Gy. 249 enrolled, 4 ineligible, 245 randomised, 242 completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus pilocarpine 5 mg 4 times per day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 12:51:17 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis graded 3 times per week according to the RTOG acute mucositis toxicity scale (0-4). Assessment used: unclear. We used the highest RTOG score recoded. Other reported outcomes: sialometry of unstimulated and stimulated whole saliva, eating, taste swallowing, pain, adverse events included nausea and vomiting.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: government. Pharmacological company provided drug and organised randomisation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-25 16:30:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Scherlacher-1990">
<CHAR_METHODS MODIFIED="2010-10-18 18:30:30 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Germany. Clear description of withdrawals: none. Unclear if dentist involved in study. Drop outs: 0%. Duration 6-7 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with head and neck cancer. 45 eligible.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-25 16:30:49 +0100" MODIFIED_BY="[Empty name]">
<P>2 groups: usual care control versus sucralfate suspension (1 g orally 4 times per day for 5 mins).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis scored on 1-5 scale and number with mucositis 3-5 given.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Both groups received standard oral hygiene, frequent tooth cleaning and disinfection of oral and pharyngeal mucosa. <BR/>Funding source: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 18:29:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schneider-1999">
<CHAR_METHODS MODIFIED="2010-10-18 18:29:34 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in USA. Clear information about withdrawals: none. Dentist involved in study. Drop outs: 0%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-01 11:21:46 +0100" MODIFIED_BY="[Empty name]">
<P>Adults with head and neck cancer. 14 patients enrolled and evaluated. Recruitment January 1995 to April 1996.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-29 17:00:08 +0100" MODIFIED_BY="[Empty name]">
<P>2 groups, placebo versus filgrastim (subcutaneous injections daily throughout treatment titrated to keep neutrophil count between 10x 10<SUP>9</SUP>/l and 30x 10<SUP>9</SUP>/l).<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>WHO mucositis 0-4 scale, and Hickey mucositis scores. Proportion of patients greater than WHO mucositis grade 3 presented. Assessment used: week 10.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-29 17:10:16 +0100" MODIFIED_BY="[Empty name]">
<P>All patients had oral hygiene instruction. Funding source: pharmaceutical. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 12:54:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schubert-2007">
<CHAR_METHODS MODIFIED="2010-11-10 12:54:02 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in the USA. Clear information about withdrawals. Duration: 7-13 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-22 23:05:09 +0100" MODIFIED_BY="[Empty name]">
<P>Adults (children over 12 could be recruited, however, youngest participant appears to have been 18) undergoing transplantation (both allogeneic and autologous). Conditioning: busulfan and cytoxan, TBI and cytoxan, fludarabine and busulfan, and other. </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 12:54:32 +0000" MODIFIED_BY="[Empty name]">
<P>3 groups, sham laser versus laser (650 nm, (40 mW)) laser, versus laser (780 nm (60 mW)). Laser therapy started on the first day of conditioning and continued for 3 days post-transplant.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 12:54:52 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis assessed using the oral mucositis index on days 0, 4, 7, 11, 14, 18, and 21. Other reported outcomes: oral pain, adverse events (death).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 12:54:53 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 18:29:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shenep-1988">
<CHAR_METHODS MODIFIED="2010-10-18 18:29:23 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in USA. Clear information about withdrawals: none. Dentist not involved in study. Drop outs: 0%. Duration: 50 days.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children with leukaemia. Chemotherapy- remission induction multiagent ANLL-83. 48 patients enrolled and evaluated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus sucralfate (0.75 mg/kg daily, suspension swished every 6 hours).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis (clinical and patients scales given, 0-4), gram-ve, gram+ve, fungal, all organisms. Assessment used: day 50. Other reported outcomes: gastroenteritis, gingival bleeding, nutrition, fever, infection, rash.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Clinician's mucositis score used. <BR/>Funding source: government.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 18:29:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shieh-1997">
<CHAR_METHODS MODIFIED="2010-10-18 18:29:12 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in China. Clear information about withdrawals: none. Dentist involved in study. Drop outs: 0%. Duration: 5 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-09 10:40:41 +0100" MODIFIED_BY="Helen Worthington">
<P>Adults with head and neck cancer. 30 patients were enrolled between June 1994 and May 1995 and all evaluated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-30 17:07:53 +0100" MODIFIED_BY="Helen Worthington">
<P>3 groups (oral care protocols), control given no instructions, E1 given protocol to follow 1 day before radiotherapy, E2 given protocol to follow 1 week before radiotherapy. Oral care protocol included instructions on how to brush teeth. Data from E1 and E2 combined as oral care intervention. </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Stomatitis free survival (graph). Also means and standard deviations of oral assessment guide (OAG) index, which includes multiple factors including voice and teeth. Assessment used: day 28.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: government.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 12:58:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sorensen-2008">
<CHAR_METHODS MODIFIED="2010-11-10 12:57:59 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Denmark. Clear information about withdrawals. Unclear if dentis involved in study. Drop outs: 8%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 12:58:03 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with gastric or colorectal cancer treated with 5-FU containing chemotherapy, 225 enrolled, 206 completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-08 23:05:15 +0100" MODIFIED_BY="[Empty name]">
<P>3 groups, placebo (saline mouthrinse 3 times/day) versus chlorhexidine mouthrinse (3 times/day) versus crushed ice.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 12:58:13 +0000" MODIFIED_BY="[Empty name]">
<P>CTC v2 grading of mucositis. Assessment used: day 28. Other reported outcomes: patient reporting of severity and duration of mucositis, compliance.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 12:58:20 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: government.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 13:00:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sornsuvit-2008">
<CHAR_METHODS MODIFIED="2010-11-10 12:59:37 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Thailand. No withdrawals, losses to follow-up described. Unclear if dentist involved in study. Duration: 5 days concurrently with each chemotherapy cycle. Recruitment period: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-29 14:20:48 +0100" MODIFIED_BY="[Empty name]">
<P>Adults with acute myeloid leukaemia. 16 patients eligible, and evaluated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 12:59:49 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, glutamine 30 g/day IV or and equivalent quantity of standard amino acid mixture (control) each day on days 1-5 of each chemotherapy cycle.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 12:59:59 +0000" MODIFIED_BY="[Empty name]">
<P>Grades for mucositis on 0-4 scale, blood changes, infection, weight loss, adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 13:00:14 +0000" MODIFIED_BY="[Empty name]">
<P>Any mucositis, &#8805; grade 2 mucositis, &#8805; grade 3 mucositis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 13:41:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spencer-2005">
<CHAR_METHODS MODIFIED="2010-10-18 18:28:11 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group, multicentre study conducted in Australia. Clear information on withdrawals: none. Unclear if dentist involved in study. Drop outs: 0%. Duration: up to 46 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 13:41:28 +0000" MODIFIED_BY="[Empty name]">
<P>Adults blood cancer - multiple myeloma undergoing BMT high dose melphalan conditioned autologous stem cell transplantation (ASCT). Between May 1999 and November 2000, 90 patients were randomised, with 82 evaluable at end of trial.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, no treatment control versus amifostine (patients undergoing ASCT were randomised to receive or not receive amifostine 910 mg/m prior to melphalan 200 mg/m).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis graded according to the adapted WHO toxicity scale. Assessment used: time unclear. Other reported outcomes: parenteral nutrition, analgesic use, complete remission, adverse events included: toxicity, nausea (grade 1), vomiting and hypotention.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: industry and charity. All participants received antibacterial prophylaxis and fluconazole. Pharmacological company provided drug and organised randomisation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 13:43:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spielberger-2004">
<CHAR_METHODS MODIFIED="2010-10-18 18:28:04 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group, multicentre study conducted in USA. Clear information on withdrawals: none. Dentist involved in study. Drop outs: 0%. Duration: 28 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with mixed cancer. BMT. Treated with fractionated total-body irradiation plus high-dose chemotherapy and auto-HSCT. 212 enrolled, randomised and completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus palifermin (recombinant human keratinocyte growth factor) 60 micrograms per kilogram of body weight per day iv for 3 consecutive days immediately before the initiation of conditioning therapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 13:43:06 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis assessed daily using 3 scales: the WHO oral-toxicity scale (0-4) (primary scale), RTOG (0-4) acute radiation morbidity scoring criteria for mucous membranes, and the 4-grade Western Consortium for Cancer Nursing Research (WCCNR) revised staging system for oral mucositis. Assessment used: -8 up to day 28. Other reported outcomes: soreness of the mouth and throat, swallowing limitations, opioid use, incidence of febrile neutropenia, incidence of infections, incidence of the use of total parenteral nutrition. Adverse events: included rash, purities, erythema, taste alteration.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: industry. Pharmacological company provided drug and organised randomisation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 13:45:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spijkervet-1989">
<CHAR_METHODS MODIFIED="2010-11-10 13:44:30 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in The Netherlands. Clear information about withdrawals: none. Dentist involved in study. Drop outs: 0%. Duration: 5 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-08 22:11:13 +0100" MODIFIED_BY="[Empty name]">
<P>Adults with head and neck cancer treated with radiotherapy. 30 patients eligible, enrolled and evaluated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus chlorhexidine spray/rinse (0.1% chlorhexidine 100 ml per day (spray 50 ml) rinsing 3 times with 15 ml).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 13:45:14 +0000" MODIFIED_BY="[Empty name]">
<P>Semiquantitative scoring of mucositis in "described elsewhere". Assessed thrice weekly until end of treatment (at least 50 Gy). Assessment used: day 35. Other reported outcomes: microflora.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Used data from text: 24 patients showed the most severe stage of pseudomembrane formation (12 in placebo and 12 in test). During radiotherapy daily cleaning of teeth by hygienist. <BR/>Funding source: government.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 13:46:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stokman-2003">
<CHAR_METHODS MODIFIED="2010-11-10 13:46:40 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in The Netherlands. Clear information on withdrawals: 2/32 placebo, 5/33 test. Unclear whether dentist involved in study. Drop outs: 10.7%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with head and neck cancer. 65 enrolled, 58 completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus active lozenges (containing polymyxin E 2 mg, tobramycin 1.8 mg and amphotericin B 10 mg (PTA)).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-29 14:00:25 +0100" MODIFIED_BY="[Empty name]">
<P>Percentage developing mucositis (WHO 3-4). Other reported outcomes: weight loss.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 13:47:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Su-2004">
<CHAR_METHODS MODIFIED="2010-11-10 13:47:41 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in USA. Clear information about withdrawals: 0. Unclear if dentist involved in study. Drop outs: 0%.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with head and neck cancer. 58 enrolled, 58 completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-05 11:47:50 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, placebo versus aloe vera solution (AV). 20 cc aloe vera a day during radiotherapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis RTOG grade 3-4. Other reported outcomes: mean overall health, mean soreness score.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-23 00:39:42 +0100" MODIFIED_BY="[Empty name]">
<P>Funding source: none.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 13:52:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Su-2006">
<CHAR_METHODS MODIFIED="2010-11-10 13:48:38 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised double blind placebo controlled parallel group study conducted in USA. Dentist involvement unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 13:48:58 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with stage 2-4 M0 SCCHN recruited January 92 to December 96. 19 in G-CSF and 22 in placebo, all but 1 patient in placebo group completed treatment and were evaluable.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 13:49:58 +0000" MODIFIED_BY="[Empty name]">
<P>G-CSF 3 &#956;g/kg daily SC, 7 times/week. Placebo equal volume 5% dextrose in water. Treatment started 3 days prior to radiotherapy and continued throughout. Planned dose reductions if white blood cell count exceeded set limits, assessed by investigator who communicated directly with pharmacist to maintain blinding.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 13:52:23 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: incidence of percutaneous endoscopic gastrostomy placement. Also mucositis grade, level of mucositis treatment required, overall survival, progression free survival, locoregional control.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 13:52:37 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: NCI grant. Median duration of follow-up 7.25 years.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 13:57:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Svanberg-2007">
<CHAR_METHODS MODIFIED="2010-11-10 13:54:18 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Sweden. Clear information about withdrawals: 0. Dentist involved in study. Duration: during chemotherapy administration. Recruitment between January 2002 and August 2004.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-03 12:15:56 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with a mix of testicular cancer and haematological malignancies undergoing myeloablative therapy prior to bone marrow or stem cell transplantation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-22 23:23:27 +0100" MODIFIED_BY="[Empty name]">
<P>2 groups, no treatment versus cryotherapy. </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 13:56:37 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis assessed daily using the OMAS instrument. Other reported outcome measures: blood counts, c-reactive protein, compliance, adverse events. Days of intravenous opioids.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 13:57:35 +0000" MODIFIED_BY="[Empty name]">
<P>45 staff members assessed mucositis using the OMAS instrument. Unclear if inter-rater reliability had been conducted before starting data collection. Probably not due to the number of staff involved.</P>
<P>Funding: government.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 18:18:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Symonds-1996">
<CHAR_METHODS MODIFIED="2010-10-18 18:18:55 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Scotland. Clear information about withdrawals: 30/139 control, 24/136 test. Unclear if dentist involved in study. Drop outs: 20%. Duration: until radiation reaction settled, 8 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with head and neck cancer. 275 patients enrolled and 221 evaluated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus antibiotic pastille (polymyxin E 2 mg, tobramycin 1.8 mg and amphotericin B 10 mg, 4 times daily from start of radiotherapy).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Physician assessment of mucositis (none, patchy confluent). Assessment used: day 56. Other reported outcomes: patients asked about pain on swallowing and dysphagia, weight loss and compliance.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: none.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 14:00:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trotti-2004">
<CHAR_METHODS MODIFIED="2010-10-18 18:18:32 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group, multicentre study conducted in USA, Canada, Germany, France and UK between July 2000 and December 2001. Clear information about withdrawals: 0. Dentist involvement unclear. Drop outs: 0%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 13:59:53 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with head and neck cancer receiving chemoradiotherapy. 545 enrolled, 511 results reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 14:00:27 +0000" MODIFIED_BY="[Empty name]">
<P>3 groups, placebo plus SOC, iseganan (9 mg as 0.3% aqueous solution) plus SOC, SOC alone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-10 10:12:47 +0100" MODIFIED_BY="Anne Littlewood">
<P>Percentage mucositis NCI CTC grade 2-4. Other reported outcomes: completion of radiotherapy and chemotherapy up to 28 days after radiotherapy.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 14:00:51 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: pharmaceutical.<BR/>Correspondence with Dr D Peterson: clinical trials with iseganan were discontinued approximately 6 years ago. Approval of the drug for oral mucositis was not obtained in the United States.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 14:03:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tu-1998">
<CHAR_METHODS MODIFIED="2010-11-10 14:03:12 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group multisite study conducted in China. Unclear if dentist involved in study. Drop outs: 0%. Duration: 4 to 6 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-18 18:09:12 +0100" MODIFIED_BY="[Empty name]">
<P>Data presented for 159 patients with mixed cancers receiving radiotherapy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 14:03:32 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, placebo group (intramuscular injection of lactose liquid) versus copper zinc super oxide dismutase (SOD) (40000 units by intramuscular injection). Both groups received 1 injection a day, 5 days per week.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 14:03:41 +0000" MODIFIED_BY="[Empty name]">
<P>Oral mucositis graded as slight, moderate and severe. Other outcome measures: skin pelvic visceral and systemic adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 14:03:45 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 14:04:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vacha-2003">
<CHAR_METHODS MODIFIED="2010-11-10 14:04:27 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Germany. Clear information on withdrawals. Unclear if dentist involved in study. Duration: during radiotherapy.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 14:04:31 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with cancers of the larynx, oropharynx and hypopharynx receiving radiotherapy (60 Gy /70 Gy) and chemotherapy (70 mg/m<SUP>2</SUP>).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 14:04:37 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, no treatment versus amifostine (250 mg). Amifostine given over short infusion (10-15 minutes).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-22 01:17:33 +0100" MODIFIED_BY="[Empty name]">
<P>Mucositis assessed weekly using the CTC criteria. Other reported outcome measures: xerostomia, skin toxicity, body weight, performance status.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 14:04:42 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 14:08:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vadhan_x002d_Raj-2010">
<CHAR_METHODS MODIFIED="2010-11-10 14:06:19 +0000" MODIFIED_BY="[Empty name]">
<P>Parallel group study, but 2 very different randomisation schedules used within this study. Duration: planned to be 6 cycles of chemotherapy but results reported based on 2 &#8220;blinded cycles&#8221; only. Dentist involvement: unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 14:07:59 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: patients with sarcoma who were planned to undergo multicycle chemotherapy aged 15-65 years with Karnofsky performance status &gt;/= 80% &amp; adequate bone marrow, hepatic and renal function.</P>
<P>Exclusion criteria: patients with history of pelvic radiation or clinically significant cardiac disease or those who had undergone surgery in previous 2 weeks were excluded.</P>
<P>Number randomised 48. Number completed (6 cycles) 25.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 14:08:41 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups: (n = 32) 180 Ug/kg palifermin IV 3 days prior to the start of each cycle of chemotherapy. (n = 16) placebo single dose IV 3 days prior to chemotherapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 14:08:51 +0000" MODIFIED_BY="[Empty name]">
<P>Moderate to severe, severe mucositis according to WHO grades, adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 14:08:57 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: Amgen provided the palifermin and placebo, provided a grant to partially fund the study, and the principal investigator is a member of the Amgen board.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 14:15:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-der-Lelie-2001">
<CHAR_METHODS MODIFIED="2010-11-10 14:15:05 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in The Netherlands. Clear information about withdrawals: none. Dentist involved in study. Drop outs: 0%. Duration: until neutrophil recovery.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-12 09:22:32 +0100" MODIFIED_BY="Helen Worthington">
<P>Adults with mixed cancer receiving BMT or cell stem. 39 patients eligible, 36 enrolled between May 1997 and August 1999, all evaluated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus GM-CSF (300 ug of GM-CSF daily dose in 2% methylocellulose gel, 5 ml gel twice daily, keep in oral cavity as long as possible then swallow).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>WHO mucositis scale 0-4. Assessment used: day 14. Other reported outcomes: VAS mucositis pain, OAS mucositis, required morphine or not, fever, infection treated with antibiotics, duration of netropenia, days in hospital.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>All rinsed with 0.9% saline and in case of inflamation 0.12% chlorhexidine 6 times daily. Funding source: university, pharmaceutical for intervention.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 14:17:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Veerasarn-2006">
<CHAR_METHODS MODIFIED="2010-10-18 18:18:00 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group, multicentre study conducted in Thailand. Clear information on withdrawals: none. Unclear if dentist involved in study. Drop outs: 7%. Duration: up to 90 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-09 10:36:02 +0100" MODIFIED_BY="Helen Worthington">
<P>Adults with head and neck cancer. 67 enrolled and randomised between February 1999 and September 2001. 62 completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 14:16:30 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, no amifostine control versus intravenous amifostine with radiotherapy (200 mg/m 50 ml infusion daily 30 minutes prior to radiation treatment) (radiotherapy: 66-70 Gy or postoperative 50-60 Gy both in 2 Gy fractions).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-10 14:17:14 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis graded with reference to RTOG criteria on a 0-4 scale. Assessed at 1-6 weeks during treatment, 4 week data used for mucositis <U>&gt; </U>2.</P>
<P>Other reported outcomes: xerostomia, dysphasia; treatment related adverse events: vomiting, nausea, allergic reaction, haematologic, hypotension, hot flushes, somnolence, sneezing, hiccup.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 14:17:19 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: pharmaceutical company.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 14:18:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Veness-2006">
<CHAR_METHODS MODIFIED="2010-10-22 18:20:34 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Australia. Clear information on withdrawals: 10 (4/42 misoprostol, 6/41 placebo). Dentist involved in study. Duration: until grade 1 or less mucositis was recorded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 14:18:15 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with head and neck cancer radiotherapy (n = 52) or concomitant chemotherapy and radiotherapy (n = 31). All patients had &gt; 50% of the oral /oropharyngeal mucosa in the radiation field and received &gt; 50 Gy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 14:18:20 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, placebo tablets versus misoprostol tablets (200 &#956;g) dissolved in 15 ml of water. Patients asked to swish liquid around the oral cavity for 2 minutes and gargled before being swallowed.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-22 18:30:51 +0100" MODIFIED_BY="[Empty name]">
<P>Mucositis assessed weekly using a 0-4 scale. Other reported outcomes: quality of life, weight loss, hospital admission, pain, </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 14:18:32 +0000" MODIFIED_BY="[Empty name]">
<P>Data used from table 3 (incidence of mucositis). Data treated as provided the wrong way round, as the text suggests that 42 patients were received into the misoprostol group and 41 into the placebo group, while the table provides data for 42 placebo patients and 41 misoprostol patients.</P>
<P>Funding source: government.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 14:19:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vokurka-2005">
<CHAR_METHODS MODIFIED="2010-10-18 18:17:47 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group, multicentre study conducted in Czech/Slovak Republics between January 2002 and June 2004. Unclear whether assessors blind. Unclear information on withdrawals: 3 refused after start, 2 lost. Unclear if dentist involved in study. Drop outs: 4%. Duration: 28 days, total in-patient stay.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults. Disease unclear. BMT. High dose chemotherapy followed by autologous peripheral stem cell transplantation. 137 enrolled and randomised, 132 completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 14:19:39 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, placebo (saline) versus povidone iodine (betadine 1 ml and 100 ml water freshly made every morning) (1:100 mouthwashes after high-dose chemotherapy comprising BEAM or HD-L-PAM), patients gargled 4 times a day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis assessed once daily using the WHO grading on a scale of 0-4. Assessment used: up to 28 days. Other reported outcomes: oral pain, tolerability of mouthwashes, occurrence of infections, fever and oral microbiology in patients with clinical suspicion of local infection.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-10 10:17:33 +0100" MODIFIED_BY="Anne Littlewood">
<P>Funding source: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-18 18:17:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wahlin-1989">
<CHAR_METHODS MODIFIED="2010-10-18 18:17:20 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Sweden. Clear information about withdrawals: 4/14 control, 3/14 test. Dentist involved in study. Drop outs: 0%. Duration: 21 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children and adults with acute leukaemia at start of chemotherapy. 28 patients enrolled, 14 patients completed (although mucositis data presented on 28).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-05 22:05:28 +0100" MODIFIED_BY="[Empty name]">
<P>2 groups: no treatment versus chlorhexidine (0.2% 10 ml twice daily).<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis scored at the level of ulceration. Assessment used: day 28. Other reported outcomes: candidiasis verified by detecting pseudohypae in smears, days fever, plaque, gingival bleeding, burning sensation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-13 15:56:28 +0100" MODIFIED_BY="[Empty name]">
<P>Funding source: government.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 14:21:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2002">
<CHAR_METHODS MODIFIED="2010-10-18 18:17:10 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in China. Unclear information about withdrawals, although there appeared to be none. Dentist not involved in study. Drop outs: 0%. Duration: 1 week after course of chemotherapy.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-12 12:05:26 +0100" MODIFIED_BY="Helen Worthington">
<P>Adults with solid cancer (breast, lung and lymphoma). CHOP for malignant lymphoma, CMF for breast cancer and CAP for lung cancer. 147 eligible and enrolled, and with data.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 14:21:52 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, Dobell's solution as control (30 ml for 3 min, gargling 5 times per day). Concoction of Chinese medicine including 5 herbs (corktree bark, Chinese gaul, European vebena herb, catechu, forsythia fruit) and borneol (sucked and gargled 5 times per day).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis scored on 4-point scale. Time of healing ulcers.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-12 12:22:46 +0100" MODIFIED_BY="Helen Worthington">
<P>Funding source: none. All information is from translation from Chinese.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 14:29:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Watanabe-2010">
<CHAR_METHODS MODIFIED="2010-10-23 00:43:50 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised parallel group study conducted in Japan. Open study. No blinding. Clear information about withdrawals: none.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 14:22:58 +0000" MODIFIED_BY="[Empty name]">
<P>31 adults with head and neck cancer. Recruitment ran from January 2009 until October 2009. 21 patients received chemoradiotherapy. Remaining 9 patients received radiotherapy only. Difference between arms non-significant.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 14:29:10 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups. Polaprezinc (zinc-L-carnosine) granules (0.5 g dissolved in 20 ml of 5% sodium alginate solution) compared to azulene oral rinse (7 drops of 4% liquid in 100 ml water). Patients rinsed with solution for 3 minutes 4 times daily. Polaprezinc solution swallowed.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-21 10:01:31 +0100" MODIFIED_BY="[Empty name]">
<P>Mucositis assessed weekly using Common Terminology Criteria for Adverse Events (CTCAE). Other reported outcomes: pain, xerostomia, taste disturbances, reduction in the use of analgesics, number of patients experiencing inability to intake orally, reduction in daily meals.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 14:29:31 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: no information (e-publication ahead of print).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 14:31:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wijers-2001">
<CHAR_METHODS MODIFIED="2010-11-10 14:31:12 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in The Netherlands. Unclear information about withdrawals. Dentist involvement unclear. Drop outs: 32%. Duration: 3 weeks after radiation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults with head and neck cancer. 114 patients enrolled, 37 refused to continue, 77 completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 groups, placebo versus PTA paste containing antibiotics, polymyxin E, tobramycin, amphotericin.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis scored weekly, 5 point scale, Van der Schneren system. Assessment used: day 28 min. Other reported outcomes: pain, microflora.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 14:34:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wu-2009">
<CHAR_METHODS MODIFIED="2010-11-10 14:32:55 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Korea between January 2007 and August 2007. Unclear if dentist involved in study. Withdrawal information included.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 14:33:26 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with head and neck cancer receiving radiotherapy. 116 patients were screened. 3 refused to participate, 113 were randomised. 13 patients dropped out before the 5th week of radiotherapy so the endpoint evaluation was only done on 100 patients, 6 because of interruption of radiotherapy for more than 2 consecutive days, 3 for receiving prohibitive drug treatments, 2 for refusal to participate, 1 because of adverse effects of radiotherapy, 1 for not being treated with the test drug.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 14:34:20 +0000" MODIFIED_BY="[Empty name]">
<P>Patients were randomised to 1 of 4 arms: placebo, epidermal growth factor 10 &#956;g/mL, 50 &#956;g/mL or 100 &#956;g/mL. Epidermal growth factor and placebo both administered as a spray over the entire oral mucosa, twice daily with patients swallowing the residual. Treatment from day 1 to day 5 of radiotherapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-10 10:27:51 +0100" MODIFIED_BY="Anne Littlewood">
<P>Mucositis scored weekly using RTOG scoring criteria. Assessment used: day 28. Other reported outcomes: WHO oral toxicity grade, patient weight, pain score, opioid analgesia use and time to develop mucositis. </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-10 14:34:25 +0000" MODIFIED_BY="[Empty name]">
<P>Funding source: grant from the National R&amp;D Program for Cancer Central, Ministry of Health, Welfare and Family Affairs, Republic of Korea.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 14:37:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-You-2009">
<CHAR_METHODS MODIFIED="2010-10-18 18:15:49 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Taiwan. Clear information about withdrawals. Unclear if dentist involved in study. Drop outs: 9%. Duration: 1 week after course of chemotherapy.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-10 14:36:42 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with head and neck cancer receiving radiotherapy. 22 patients randomised to 2 groups enrolled between October 2005 and May 2006. 2 patients in control withdrew due to refusal to give blood sample.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 14:37:00 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, saline and indigo wood root (IR) (Isatis indigotica called Ban-Lan-Gen in Chinese is a medicinal plant belonging to the Brassicacaee family). Patients gargled with 30-mL solution of either saline or IR for 3 minutes and then swallowed before meals daily.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-12 11:39:53 +0100" MODIFIED_BY="Helen Worthington">
<P>Mucositis scored on 4-point scale. Time of healing ulcers. Also reported difficulty swallowing, anorexia, rest from treatment, blood changes.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-12 11:15:30 +0100" MODIFIED_BY="Helen Worthington">
<P>Funding source: none.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 14:38:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yuen-2001">
<CHAR_METHODS MODIFIED="2010-10-18 18:16:17 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Hong Kong. Clear information on withdrawals: none. Unclear if dentist involved in study. Drop outs: 0%. Duration: 60 days after BMT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-09 10:38:21 +0100" MODIFIED_BY="Helen Worthington">
<P>Adults with mixed cancer receiving BMT, 70 enrolled between October 1996 to February 1998. 70 evaluated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 14:38:27 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups no treatment versus clarithromycin oral 500 mg twice daily or IV 500 mg 12 hourly. Start day -7.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mucositis scoring system not clear. Grade 2 data used. Assessment used: unclear. Other reported outcomes: toxicity (rash, diarrhoea, liver function), infection, duration of fever, neutropenic fever, use of antibiotics, parenteral nutrition, growth factors.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding source: none.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ASTC = autologous stem cell transplantation<BR/>BMT = bone marrow transplant<BR/>EORTC = European Organization for Research and Treatment of Oral Cancer<BR/>GI = glycaemic index<BR/>GM-CSF = granulocyte/macrophage colony-stimulating factor<BR/>GVHD = graft-versus-host disease<BR/>HSCT = haematopoietic stem cell transplant<BR/>HSV = herpes simplex virus<BR/>ITT = intention-to-treat analysis<BR/>IV = intravenous<BR/>KGF = keratinocyte growth factor<BR/>NCI CTC = National Cancer Institute Common Toxicity Criteria<BR/>OAG = oral assessment guide<BR/>OM = oral mucositis<BR/>OMAS = oral mucosa assessment scale<BR/>OMS = objective mucositis score<BR/>ROB = risk of bias<BR/>RT = radiotherapy<BR/>RTOG = Radiation Therapy Oncology Group<BR/>SD = standard deviation<BR/>SOC = standard oral care<BR/>TBI = total body irradiation<BR/>TPN = total parenteral nutrition<BR/>UOM = ulcerative oral mucositis<BR/>VAS = visual analogue scale<BR/>WBC - white blood count<BR/>WHO = World Health Organization<BR/>5-FU = 5-fluorouracil<BR/>(c) indicates from correspondence with authors.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-03-09 17:10:12 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-06-26 11:39:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abramoff-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-26 11:39:47 +0100" MODIFIED_BY="[Empty name]">
<P>Patients considered new case and re-randomised for each CT cycle (laser versus no treatment).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:32:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aisa-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:32:58 +0000" MODIFIED_BY="[Empty name]">
<P>Not RCT (cryotherapy).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Altmann-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT (amifostine).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Andersen-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cancer treatments comparing toxic effects.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-01 10:17:24 +0000" MODIFIED_BY="Helen V Worthington" STUDY_ID="STD-Anderson-1998b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-01 10:17:24 +0000" MODIFIED_BY="Helen V Worthington">
<P>Mucositis at baseline in some patients (glutamine versus placebo).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:33:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Antin-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:33:05 +0000" MODIFIED_BY="[Empty name]">
<P>Study stopped early due to adverse event triggering preset stopping rule - data only for 10 patients in rhIL group and 3 placebo (rhIL-11 versus placebo).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Antonadou-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract, insufficient information (radiotherapy with or without GM-CSF).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:33:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Apaydin-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:33:11 +0000" MODIFIED_BY="[Empty name]">
<P>Unclear whether allocation is randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-03 13:24:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aquino-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-03 13:24:08 +0100" MODIFIED_BY="[Empty name]">
<P>Composite score for mucositis including teeth with plaque (Walsh). Unable to use mucositis outcome outcomes (oral glutamine).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:33:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ardizzoni-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:33:16 +0000" MODIFIED_BY="[Empty name]">
<P>Cancer treatments comparing toxic effects and confounded by cancer (G-CSF).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:33:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arora-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:33:21 +0000" MODIFIED_BY="[Empty name]">
<P>Not RCT (laser).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Awada-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cancer treatment comparing toxic effects.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Awada-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT (temozolomide plus liposomal doxorubicin).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Awidi-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Episodes not patients. Type of cross-over study but some patients were included in more than 2 'courses' (pilocarpine versus placebo).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-15 15:13:45 +0100" MODIFIED_BY="Helen Worthington" STUDY_ID="STD-Awwad-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-15 15:13:45 +0100" MODIFIED_BY="Helen Worthington">
<P>Cancer treatments comparing toxic effects (conventional fractionation versus accelerated hyperfractionation radiotherapy).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-15 13:22:45 +0100" MODIFIED_BY="Helen Worthington" STUDY_ID="STD-Barasch-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-15 13:22:45 +0100" MODIFIED_BY="Helen Worthington">
<P>As patients had already received some chemotherapy before intervention started, some patients, but not all, have some mucositis. The trial is therefore a combination of prevention and treatment (He-Ne laser versus no treatment).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:33:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baydar-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:33:34 +0000" MODIFIED_BY="[Empty name]">
<P>Not RCT (cryotherapy).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bensadoun-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of different cancer treatment regimens, not primary outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bentzen-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparing different chemotherapy regimens.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bleehen-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Different chemotherapy regimens.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bourhis-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparing 2 radiotherapy regimens but looking at toxicity.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-09 17:06:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Braaksma-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-09 17:06:10 +0000" MODIFIED_BY="[Empty name]">
<P>Email sent to author requesting further information; no reply received by March 2011.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Buentzel-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract - insufficient information (amifostine).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:33:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Calais-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:33:49 +0000" MODIFIED_BY="[Empty name]">
<P>Trial of cancer treatments.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Calais-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT (chemotherapy).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cassidy-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cancer treatments comparing toxic effects.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-11 11:12:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Castro-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-11 11:12:18 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-09 17:06:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cella-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-09 17:06:35 +0000" MODIFIED_BY="[Empty name]">
<P>Emailed authors Nov 17 2010 requesting data to include this study in review. Authors replied stating that data held by pharma company and no longer available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cheng-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT (oral care protocol).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cheng-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT (oral care protocol).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-16 22:46:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cheng-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-16 22:46:43 +0100" MODIFIED_BY="[Empty name]">
<P>Grade 2 mucositis was an exclusion criteria. However, unclear how many patients had grade 1 mucositis at baseline. Email sent to authors. No reply.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:33:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clarke-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:33:57 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract, insufficient information (rHuKGF).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:34:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Colella-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:34:03 +0000" MODIFIED_BY="[Empty name]">
<P>Open non-randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Collova-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract - insufficient information.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Colombat-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract - insufficient information (fluconazole versus amphotericin B).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Costa-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract, not RCT (chlorhexidine versus no treatment).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Costa-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT (chlorhexidine versus control).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-15 13:36:03 +0100" MODIFIED_BY="Helen Worthington" STUDY_ID="STD-Cowen-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-15 13:36:03 +0100" MODIFIED_BY="Helen Worthington">
<P>Daily mucositis index used and summed across all categories (including voice, saliva). A cumulative oral mucositis score generated for both nursing and patient assessments was used and categorised into a 0-3 mucositis scale. Daily mucositis index ranging from 0-48 used, with means (SD) presented but excluded as composite scale (He-Ne laser versus no treatment).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cunningham-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Investigating new cancer treatment, tomudex, with oral mucositis as one of the minor side effects.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:34:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Damon-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:34:22 +0000" MODIFIED_BY="[Empty name]">
<P>Trial investigating 2 different methods of administering etoposide.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-De-Boer-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cancer treatments comparing toxic effects (conventional versus accelerated infusional chemotherapy).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Denham-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cancer treatments comparing toxic effects (conventional versus accelerated fractionation).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Djuric-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Some mucositis present at baseline.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dobrowsky-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Added to speed up radiotherapy, not radio-protection-toxic (mitomycin).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Doroshow-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cancer treatments comparing toxic effects.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:34:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dreicer-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:34:32 +0000" MODIFIED_BY="[Empty name]">
<P>Not RCT(edatrexate).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-15 13:53:22 +0100" MODIFIED_BY="Helen Worthington" STUDY_ID="STD-Dudjak-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-15 13:53:22 +0100" MODIFIED_BY="Helen Worthington">
<P>Uses Beck's OAG mucositis score (includes ability to swallow, saliva, diet and patient ability to self care) (2 oral care protocols).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Edelman-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT (cryotherapy).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eisen-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT (valacyclovir versus acyclovir).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-El_x002d_Sayed-2002a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT (antimicrobial lozenge).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:34:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Epstein-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:34:47 +0000" MODIFIED_BY="[Empty name]">
<P>Sum of composite self-reported scale including mouth pain and its effect on oral intake, and the absence or presence of stomatitis. Unable to use in review (3 groups: chlorhexidine rinse, nystatin suspension and saline solution).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-03 08:57:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Erkisi-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-03 08:57:44 +0000" MODIFIED_BY="[Empty name]">
<P>Patients randomised to different cancer treatments and where given G-CSF when clinically indicated, not randomly allocated (G-CSF versus no treatment).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:34:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Erlichman-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:34:53 +0000" MODIFIED_BY="[Empty name]">
<P>Comparing different chemotherapy regimens.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:35:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Etiz-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:35:09 +0000" MODIFIED_BY="[Empty name]">
<P>Multicomponent scale of mucositis including pain, dysphasia and use of systemic analgesics (sucralfate versus placebo).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ezzat-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparing 3 different radiotherapy regimens, survival not mucositis is primary outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fahlke-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT (amifostine).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Falcone-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparing different radiotherapy regimens.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fay-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT (GM-CSF).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:35:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feber-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:35:34 +0000" MODIFIED_BY="[Empty name]">
<P>Oral assessment guide not just mucositis but includes plaque and voice changes (hydrogen peroxide versus sodium chloride rinses).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:35:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feber-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:35:44 +0000" MODIFIED_BY="[Empty name]">
<P>Oral assessment guide not just mucositis but includes plaque and voice changes (2 oral care protocols).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-09 17:07:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ferreira-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-09 17:07:25 +0000" MODIFIED_BY="[Empty name]">
<P>Email sent to authors Nov 2010 requesting sufficient information to include study in this review. No reply received March 2011.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:35:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ferretti-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:35:53 +0000" MODIFIED_BY="[Empty name]">
<P>Patients had mucositis at baseline.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Foncuberta-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients assigned sequentially not RCT (GF-B3).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gabison-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract - insufficient information (zinc picolinate).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:35:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gandara-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:35:58 +0000" MODIFIED_BY="[Empty name]">
<P>Not RCT (edatrexate).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:36:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Genot_x002d_Klastersky-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:36:13 +0000" MODIFIED_BY="[Empty name]">
<P>Some patients had grade 1 mucositis in prevention trial (laser versus placebo).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-09 17:07:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ghoreishi-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-09 17:07:44 +0000" MODIFIED_BY="[Empty name]">
<P>Email sent to authors Nov 2010 requesting further information to enable this study to be included. No reply received by March 2011.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-03 08:59:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Giles-2003a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-03 08:59:07 +0000" MODIFIED_BY="[Empty name]">
<P>Comparing chemotherapy regimens not mucositis interventions.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Giles-2003b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cancer treatment toxicity (troxacitabine).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-04 15:32:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gladkov-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-04 15:32:46 +0100" MODIFIED_BY="[Empty name]">
<P>Comparing different radio-chemo regimes for oral cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Goldberg-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract - insufficient information (en3247).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:36:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gordon-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:36:19 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract, insufficient information (GM-CSF).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-22 12:32:23 +0100" MODIFIED_BY="Helen Worthington" STUDY_ID="STD-Grotz-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-22 12:32:23 +0100" MODIFIED_BY="Helen Worthington">
<P>Index not in suitable form. Total RTOG scores including salivary glands, mucosa, skin (comarin/troxerutine versus placebo).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gutierrez-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT (fluconazole).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Harris-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract, insufficient information (folinic acid mouthwash versus placebo).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-He-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract - insufficient information (amifostine).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hickey-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Problems with data. 21 patients in total, unclear how many patients per group, but data presented as 67 courses of chemotherapy (oral hygiene protocols).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:36:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Horsley-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:36:28 +0000" MODIFIED_BY="[Empty name]">
<P>Not RCT (keratinocyte).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Howell-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unclear if randomised. Cross-over study provided 59 paired course of treatment in 23 patients (allopurinol).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hu-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT (amifostine).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:36:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hunter-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:36:36 +0000" MODIFIED_BY="[Empty name]">
<P>Not RCT. This study combines patients who were in cohorts with increasing doses of mouthrinse to assess safety, with an RCT (ATL-104 mouthwash versus placebo).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-09 17:07:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hwang-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-09 17:07:59 +0000" MODIFIED_BY="[Empty name]">
<P>Email sent to authors Nov 2010 requesting further details concerning this study. No reply was received by March 2011.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:36:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Inagaki-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:36:41 +0000" MODIFIED_BY="[Empty name]">
<P>Not RCT (cryotherapy).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ito-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT (allopurinol spray).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-01 10:13:40 +0000" MODIFIED_BY="Helen V Worthington" STUDY_ID="STD-Jebb-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-01 10:13:40 +0000" MODIFIED_BY="Helen V Worthington">
<P>Index of mucositis had multiple components other than mucositis (glutamine versus placebo).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:36:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jham-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:36:53 +0000" MODIFIED_BY="[Empty name]">
<P>Study for prevention of xerostomia (bethanechol versus saliva supplement).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Johnson-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT (prostaglandin e1).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:36:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ju-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:36:59 +0000" MODIFIED_BY="[Empty name]">
<P>Quasi-randomised study. Patients alternatively allocated to intervention and placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kante-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract - insufficient information (oral care regimens).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:37:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karacetin-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:37:08 +0000" MODIFIED_BY="[Empty name]">
<P>Patients were 'randomised' to intervention or control according to file number (amifostine versus no treatment).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Karthaus-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Problems with the data. 8 patients, 32 chemo cycles and results presented assuming independent (G-CSF versus placebo).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-02 15:05:34 +0100" MODIFIED_BY="Helen Worthington" STUDY_ID="STD-Kenny-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-02 15:05:34 +0100" MODIFIED_BY="Helen Worthington">
<P>Oral assessment guide not only mucositis but includes plaque and voice changes (2 oral care protocols).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:37:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Khouri-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:37:15 +0000" MODIFIED_BY="[Empty name]">
<P>Quasi-randomised study. Patients allocated to intervention and placebo alternatively based on date of hospitalisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Klocke-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract - insufficient information.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-06 15:32:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuhn-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-06 15:32:58 +0100" MODIFIED_BY="[Empty name]">
<P>Children had mucositis grades 2+ on entry into trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:37:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuriakose-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:37:22 +0000" MODIFIED_BY="[Empty name]">
<P>Not RCT (edatrexate).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Labbate-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:37:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lanzos-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:37:30 +0000" MODIFIED_BY="[Empty name]">
<P>7 patients had mucositis at baseline (including 2 patients with grade 4 mucositis).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lavendag-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract, insufficient information (polyenes versus placebo).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:37:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Le-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:37:53 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract (keratinocyte growth factor).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:37:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lee-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:37:58 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention given as part of cancer treatment, not to prevent mucositis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Leong-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract, insufficient information (thymidine versus no treatment).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Levi-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of 2 cancer treatments where the primary outcome was maximum tumour response to therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-07-12 15:14:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Loo-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-12 15:14:58 +0100" MODIFIED_BY="[Empty name]">
<P>130 of the 139 patients recruited into the study had mucositis at baseline. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-08 14:00:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lopez-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-08 14:00:42 +0000" MODIFIED_BY="[Empty name]">
<P>Data presented as number of days patients suffered for each grade of mucositis. Cannot be used in meta-analysis unless we obtain further information from authors. Unable to contact authors.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-09 17:08:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lopez_x002d_Campo-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-09 17:08:38 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract only. Insufficient information to include in review. No subsequent publication identified (March 2011).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lorusso-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Episodes not patients considered in analysis (amifostine).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lozada-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract with insufficent information given (pilocarpine).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-07-12 19:00:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lugli_x00e9_-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-12 19:00:42 +0100" MODIFIED_BY="[Empty name]">
<P>Not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:38:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maddocks_x002d_Jennings-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:38:10 +0000" MODIFIED_BY="[Empty name]">
<P>Not RCT (alternate allocation and if patient could not gargle they were re-allocated to other groups) (essential oils).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Madero-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>No response to query whether patients were randomised to groups (rhGM-CFS).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mahmoud-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of 2 cancer treatments where the primary outcome was survival (folinic acid).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Malaker-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT (B-Carotene retinoic acid).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-01 10:22:00 +0000" MODIFIED_BY="Helen V Worthington" STUDY_ID="STD-Mantovani-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-01 10:22:00 +0000" MODIFIED_BY="Helen V Worthington">
<P>Not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Marcial-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract, insufficient information. It states it is an RCT but mentions historical control group (low energy laser versus no treatment).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:38:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martin-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:38:18 +0000" MODIFIED_BY="[Empty name]">
<P>Not RCT (G-CSF).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Masucci-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Treatment of mucositis not prevention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Matejka-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT (prostaglandin E2).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-02 13:11:02 +0100" MODIFIED_BY="Helen Worthington" STUDY_ID="STD-McIlroy-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-02 13:11:02 +0100" MODIFIED_BY="Helen Worthington">
<P>Scoring system incorporated visible signs of mucositis with pain dysphasia and weight loss. Qualitative assessment with no data given (polyenes versus placebo).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Merte-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract (German).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mills-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:38:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mori-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:38:27 +0000" MODIFIED_BY="[Empty name]">
<P>Not RCT (cryotherapy).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-13 20:27:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nicolatou_x002d_Galitis-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-13 20:27:41 +0000" MODIFIED_BY="[Empty name]">
<P>Not an RCT. Patients who received the intervention were compared to a control cohort. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-04 12:58:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Niibe-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-04 12:58:57 +0000" MODIFIED_BY="[Empty name]">
<P>Report in Japanese. Translator describes outcome as oral mucous symptoms, time of assessment unclear (based on radiation dose delivered) and reported as percentages per group with no denominators or estimate of precision. Insufficient information to include and study to old to be able to contact authors (amifostine versus placebo).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:38:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nikoletti-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:38:39 +0000" MODIFIED_BY="[Empty name]">
<P>Cross-over study, some doubt as to whether patients had any mucositis at baseline and outcomes used OAG assessment scale which is an exclusion criterion for this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:38:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Okuno-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:38:48 +0000" MODIFIED_BY="[Empty name]">
<P>Major change to protocol half way through study (antibiotic lozenge versus placebo). Data from blinded and unblinded patients combined. Chlorhexidine for first part included as study by Foote 1994. Data from first part comparing antibiotic lozenge with placebo mouthrinse have not been included as we feel this is an inappropriate control.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Okutomi-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT (Z-100 injections).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-04 15:28:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Papadeas-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-04 15:28:03 +0100" MODIFIED_BY="[Empty name]">
<P>CCT (cryotherapy).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Papas-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract (patient management system).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:39:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Papas-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:39:03 +0000" MODIFIED_BY="[Empty name]">
<P>The interventions were calcium phosphate rinses plus fluoride tray applications versus fluoride rinses + placebo tray applications. The individual interventions were confounded.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:39:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Penpattanagul-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:39:11 +0000" MODIFIED_BY="[Empty name]">
<P>Not RCT. "Patients were assigned to their treatment groups at the discretion of the investigator with an attempt to achieve equal distribution of patient demographics."</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Peters-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>CCT. Paper states "Randomisation procedure was done according to day of birth."</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Phillips-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT (amifostine).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-03 18:06:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Piccirillo-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-03 18:06:59 +0100" MODIFIED_BY="[Empty name]">
<P>Excluded as mucositis index inappropriate for review. Mucositis index included pain and difficulty in swallowing (response from authors).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pouli-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract, insufficient information (GM-CSF versus sodium bicarbonate mouthwash).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-01 10:14:30 +0000" MODIFIED_BY="Helen V Worthington" STUDY_ID="STD-Prada-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-01 10:14:30 +0000" MODIFIED_BY="Helen V Worthington">
<P>Mucositis present at baseline (benzydamine versus placebo mouthwash).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:39:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Putwatana-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:39:27 +0000" MODIFIED_BY="[Empty name]">
<P>Quasi-randomised trial. Patients allocated to the intervention (glycerin payayor) or control (benzydamine) by alternative allocation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-22 14:10:10 +0100" MODIFIED_BY="Helen Worthington" STUDY_ID="STD-Pyrhonen-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-22 14:10:10 +0100" MODIFIED_BY="Helen Worthington">
<P>Mucositis not primary outcome. Only presents data for test arm as adverse event (chemotherapy agents).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-22 14:26:00 +0100" MODIFIED_BY="Helen Worthington" STUDY_ID="STD-Pytlik-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-22 14:26:00 +0100" MODIFIED_BY="Helen Worthington">
<P>Inappropriate mucositis index includes voice quality and teeth (glutamine versus placebo).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:39:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rabinovitch-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:39:56 +0000" MODIFIED_BY="[Empty name]">
<P>Trial of radiotherapy for head and neck cancer looking at cancer treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-03 08:54:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rades-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-03 08:54:10 +0000" MODIFIED_BY="[Empty name]">
<P>Study halted when preset stopping rules were triggered due to adverse effects of amifostine. No mucositis outcomes reported (amifostine).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Radmard-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract - insufficient information (rhGM-CSF).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-09 17:09:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Raether-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-09 17:09:04 +0000" MODIFIED_BY="[Empty name]">
<P>Average mucosal rating presented without standard deviation. Cannot be used in meta-analysis unless we obtain further information from authors. Unable to contact authors.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Robustelli-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract - insufficient information (galenic preparation).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rocci-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not eligible since it is not dealing with prevention or treatment of mucositis, but uses mucositis to measure side effect of 2 different ways to deliver an antitumoural drug for the treatment of gastrointestinal tumours.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rojas-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Episodes not patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-20 21:11:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rothwell-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-20 21:11:43 +0100" MODIFIED_BY="[Empty name]">
<P>Mucositis scores presented as means. Oral screening tool includes moniliasis (candidiasis). </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-03 08:48:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rutkauskas-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-03 08:48:44 +0000" MODIFIED_BY="[Empty name]">
<P>No data for mucositis presented by randomised group, just line graph of all patients with no P values (chlorhexidine versus placebo).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:40:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ryu-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:40:02 +0000" MODIFIED_BY="[Empty name]">
<P>6% of patients had oral mucositis at baseline.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-09 17:09:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Samaranayake-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-09 17:09:24 +0000" MODIFIED_BY="[Empty name]">
<P>Average mucosal rating presented without standard deviation. Cannot be used in meta-analysis unless we obtain further information from authors. Unable to contact authors.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sato-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unsure if RCT and author has not responded to letter requesting further information.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:40:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sato-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:40:11 +0000" MODIFIED_BY="[Empty name]">
<P>Not RCT (cryotherapy).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:40:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schuster-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:40:14 +0000" MODIFIED_BY="[Empty name]">
<P>Not RCT (velafermin).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:40:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schwerkoske-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:40:19 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract, insufficient information (rhIL11).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:40:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shabanloei-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:40:26 +0000" MODIFIED_BY="[Empty name]">
<P>Quasi-randomised study. "Patients selected based on their ID code and by choosing from the box and were divided into three groups."</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:40:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharma-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:40:52 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:40:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shea-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:40:55 +0000" MODIFIED_BY="[Empty name]">
<P>Abstracts only, insufficient information (palifermin).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:41:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shidfar-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:41:04 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:41:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Simoes-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:41:08 +0000" MODIFIED_BY="[Empty name]">
<P>Not RCT (laser).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Spadaro-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract, insufficient information (vitamin E + vitamin A + fluconazole versus no treatment).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:41:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spielberger-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:41:14 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract, insufficient information (keratinocyte).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stokman-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT. This was a cross-over study but not randomised. All patients had control cycle first.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-03 14:57:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Teshima-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-03 14:57:22 +0000" MODIFIED_BY="[Empty name]">
<P>Japanese paper. Unclear information as to whether this was randomised. Written to authors but no reply.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thieblemont-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Throuvalas-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract, probably not RCT described as comparative study (GM-CSF).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:41:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tiemann-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:41:19 +0000" MODIFIED_BY="[Empty name]">
<P>Not RCT (herbs).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Toubai-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Probably not RCT, only 12 patients in total? (itraconazole).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Uchiyama-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:41:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Valcarcel-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:41:26 +0000" MODIFIED_BY="[Empty name]">
<P>Participants had mucositis at baseline.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Valc_x00e1_rcel-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract - insufficient information (thymostimulin).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:41:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-Zaanen-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:41:43 +0000" MODIFIED_BY="[Empty name]">
<P>Patients randomised per treatment cycle, 15 patients and 20 treatments cycles. Patients randomised up to 3 times, data treated as independent but not reported per patient (glutamine + TPN versus standard TPN).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-22 15:07:21 +0100" MODIFIED_BY="Helen Worthington" STUDY_ID="STD-Verdi-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-22 15:07:21 +0100" MODIFIED_BY="Helen Worthington">
<P>Mucositis measured by OAG which includes teeth. Only in 10 patients (pentoxifylline versus placebo).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vesole-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract insufficient information (IB-367).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:41:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Villar-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:41:57 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vitello-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract, insufficient information (lidocaine versus dyclone mouthrinses).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:42:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wagner-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:42:04 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract for treatment of mucositis review (GM-CSF).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wang-2002a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:42:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ward-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:42:15 +0000" MODIFIED_BY="[Empty name]">
<P>CCT (glutamine).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-09 17:10:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Warde-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-09 17:10:12 +0000" MODIFIED_BY="[Empty name]">
<P>Maximal toxicity during treatment presented as percentages. Cannot be used in meta-analysis unless we obtain further information from authors. Email sent 17 Nov 2010, no reply received by March 2011.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-08 14:05:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weisdorf-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-08 14:05:35 +0000" MODIFIED_BY="[Empty name]">
<P>Outcome data presented as graph with standard deviations. Cannot be used in meta-analysis unless we obtain further information from authors. Unable to contact authors.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:42:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weiss-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:42:20 +0000" MODIFIED_BY="[Empty name]">
<P>Not randomised. Cross-over trial and data in wrong form for review (allopurinol).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Whelan-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Whelan-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT (from author).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wollina-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT (dexpanthenol).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wymenga-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT (TGF-B3 mouthrinse versus no treatment).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yokomizo-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 11:42:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zanin-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 11:42:30 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis data presented as mean values. Unclear if randomised. Authors contacted - no reply.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>CCT = controlled clinical trial; CT = chemotherapy; RCT = randomised controlled trial; SD = standard deviation.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-01-17 14:24:47 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2010-11-09 11:43:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cheng-2003">
<CHAR_METHODS MODIFIED="2010-11-09 11:43:43 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised cross-over comparison of chlorhexidine versus benzydamine oral care protocols.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-09 11:43:44 +0000" MODIFIED_BY="[Empty name]">
<P>Children aged 6-17 undergoing chemotherapy recruited between April 2000 and April 2001.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-09 11:43:52 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, oral care protocol based on chlorhexidine mouthrinse twice daily during chemotherapy compared to an oral care protocol based on benzydamine twice daily.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-09 11:43:53 +0000" MODIFIED_BY="[Empty name]">
<P>WHO mucositis scores, oral symptoms (eating, chewing, swallowing, speaking, mouth dryness on VAS scale), pain, use of analgesics, concomitant medications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-03 16:31:03 +0000" MODIFIED_BY="[Empty name]">
<P>3 publications relating to the same study. Unclear whether any patients had oral mucositis at baseline. Email sent to authors requesting clarification. </P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-11-09 11:44:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-de-Koning-2007">
<CHAR_METHODS MODIFIED="2010-11-09 11:43:59 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, cross-over study conducted in The Netherlands.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-09 11:44:03 +0000" MODIFIED_BY="[Empty name]">
<P>Children with haematological malignancies receiving chemotherapy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-09 11:44:08 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, placebo feeds versus TGF-2 enriched feeds (dose dependant on patient weight).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-09 11:44:10 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis assessed daily using the WHO scale. Other reported outcomes: diarrhoea, pain, use of analgesics, administration of antibiotics, frequency of blood cultures.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-09 11:44:12 +0000" MODIFIED_BY="[Empty name]">
<P>Discrepancy between data presented in tables 2 &amp; 3 in the paper. Awaiting clarification of data from authors.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-11-09 11:44:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grzegorczyk-2006">
<CHAR_METHODS MODIFIED="2010-11-04 17:44:21 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in Poland.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-09 11:44:51 +0000" MODIFIED_BY="[Empty name]">
<P>Adults undergoing stem cell transplantation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-09 11:44:52 +0000" MODIFIED_BY="[Empty name]">
<P>2 groups, placebo (methylcellulose) versus G-CSF (300 g in 2% methylcellulose).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-09 11:44:56 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis assessed using the WHO score. Other reported outcomes: granulocytes, patient report of pain.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-09 11:44:59 +0000" MODIFIED_BY="[Empty name]">
<P>Translation provided insufficient information. Discrepancy between graph legends and descriptions. Awaiting more information from translators.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-11-09 11:45:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jellema-2006">
<CHAR_METHODS MODIFIED="2010-11-09 11:45:28 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in The Netherlands. Clear information about withdrawals: 0. Unclear if dentist involved in study. Recruitment took place between August 1999 and August 2003.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-04 17:28:40 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with head and neck cancer undergoing radiotherapy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-09 11:45:35 +0000" MODIFIED_BY="[Empty name]">
<P>3 groups, no treatment control versus amifostine (200 mg/m<SUP>2</SUP>) 5 times weekly versus amifostine(200 mg/m<SUP>2</SUP>) 3 times weekly. Amifostine administered 15-30 minutes before irradiation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-04 17:42:56 +0000" MODIFIED_BY="[Empty name]">
<P>Unclear how mucositis was assessed. Other reported outcomes: xerostomia, patient quality of life, sticky saliva, locoregional control and survival.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-09 11:45:39 +0000" MODIFIED_BY="[Empty name]">
<P>Discrepancy between legend for Figure 2 and the text in this paper. Email sent. Awaiting clarification from authors.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-11-18 10:03:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peterson-2007">
<CHAR_METHODS MODIFIED="2010-11-09 11:45:58 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, multicentre cross-overstudy conducted in Russia. Dentist involved in study. Duration: randomised to glutamine versus placebo in cycle 1 and then crossed over to alternative treatment in cycle 2.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-09 11:46:00 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with breast cancer receiving chemotherapy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-09 11:46:02 +0000" MODIFIED_BY="[Empty name]">
<P>Glutamine versus placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-03 16:14:54 +0000" MODIFIED_BY="[Empty name]">
<P>Mucositis on OMAS scale. Mean score calculated as mean ulceration score across all sites. Mean erythema score similarly calculated. Also WHO score assessed. Other outcomes: nausea, vomiting, dry mouth.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-18 10:03:37 +0000" MODIFIED_BY="[Empty name]">
<P>Eligible if experienced WHO mucositis <U>&gt;</U> 2 during screening cycle. Percentage of patients with WHO scores <U>&gt;</U> 2 presented 1 to 21 days in graph for each group during cycle 1. Significant carry-over effect from cycle 1 to cycle 2. Need to obtain further information from authors. </P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2011-03-09 17:12:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wu-2010">
<CHAR_METHODS MODIFIED="2010-11-05 09:33:46 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group study conducted in China. Recruited between February 2006 and May 2007.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-09 11:48:19 +0000" MODIFIED_BY="[Empty name]">
<P>Patients with nasopharyngeal carcinoma undergoing chemoradiotherapy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-09 11:48:28 +0000" MODIFIED_BY="[Empty name]">
<P>3 groups; actovegin from start of chemo, actovegin from time of grade 2 mucositis, versus no treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-09 11:48:33 +0000" MODIFIED_BY="[Empty name]">
<P>NCI-CTC mucositis scale, pain, weight loss, adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-09 17:12:17 +0000" MODIFIED_BY="[Empty name]">
<P>Full text paper published October 2010. To be included in next update.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Yasuda-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Zhe-2000">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES>
<P>BMT = bone marrow transplant; G-CSF = granulocyte colony-stimulating factor; NCI-CTC = National Cancer Institute - Common Toxicity Criteria; OMAS = oral mucosa assessment scale; RT = radiotherapy; RTOG = Radiation Therapy Oncology Group; VAS = visual analogue scale; WHO = World Health Organization.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-11-03 13:56:46 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-11-10 14:38:45 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-11-10 14:38:35 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:43:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abbasi_x002d_Nazari-2007">
<DESCRIPTION>
<P>Quote: "A dynamic randomization procedure was utilized to divide patients to receive allopurinol mouthwash (treatment group) or placebo mouthwashes (control group)".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:19:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ahmed-1993">
<DESCRIPTION>
<P>Quote: "patients were randomly assigned".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:21:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-1998">
<DESCRIPTION>
<P>Quote: "Patients were assigned randomly to two courses of glutamine and two courses of glycine".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:24:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Antonadou-2002">
<DESCRIPTION>
<P>Quote: "Eligible patients were randomized (1:1) to receive radiochemotherapy plus amifostine (study group) or radiochemotherapy".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:26:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Antunes-2007">
<DESCRIPTION>
<P>Quote: "Patients were randomised on the day of admission for the transplantation, between receiving laser therapy, or not receiving laser therapy".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:45:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arun-Maiya-2006">
<DESCRIPTION>
<P>Quote: "the patients were divided based on computer generated randomization into laser (study group) and control group with 25 patients in each group."</P>
<P>Comment: computer generated randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:32:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Attal-1993">
<DESCRIPTION>
<P>Quote: "patients were randomised to receive or not PTX. The treatment allocation for each patients was assigned by telephone by the biostatistics department, which had prepared before initiation of the trial a computer-generated sequence unknown to the physicians participating in the trial."</P>
<P>Comment: computer generated randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:35:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bensadoun-1999">
<DESCRIPTION>
<P>Quote: "patients were assigned to either laser treatment or sham-treatment by computer blocked randomisation, 15 in each arm&#8221;.</P>
<P>Comment: computer generated randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:37:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biswal-2003">
<DESCRIPTION>
<P>Quote: "twenty patients were allocated equally to one study arm and another 20 to the control arm by computer generated random numbers".</P>
<P>Comment: computer generated random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:47:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bjarnason-2009">
<DESCRIPTION>
<P>Quote: "A minimization procedure was used to randomize patients".</P>
<P>Quote: "patients were stratified by treatment centre, pretreatment smoking behaviour...tobacco use questionnaire, and planned total radiation dose".</P>
<P>Comment: minimization.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:49:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blazar-2006">
<DESCRIPTION>
<P>Quote: "Randomisation was structured to achieve balance between the placebo and palifermin groups within each study site in each cohort".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:53:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Borowski-1994">
<DESCRIPTION>
<P>Quote: "Patients fulfilling the enrolment criteria were randomly allocated by telephone".</P>
<P>Quote: "randomisation was balanced every 4 subjects and stratified on IOS."</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:55:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bourhis-2000">
<DESCRIPTION>
<P>Quote: "Patients were randomized to receive or not 150mg/m2 amifostine 15-30 min prior to each radiation session."</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:58:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brizel-2000">
<DESCRIPTION>
<P>Quote: "three hundred fifteen patients were enrolled and randomised from October 1995 to October 1997".</P>
<P>Quote: "Patients were randomized using a dynamic allocation process."</P>
<P>Comment: random component not described, however, authors make reference to two articles on randomisation. Probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:31:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brizel-2008">
<DESCRIPTION>
<P>Quote: "A multicentre, double blind, randomised, placebo controlled study was conducted at 22 centres".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:33:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bubley-1989">
<DESCRIPTION>
<P>Quote: "Randomization occurred on the basis of computer-generated random codes supplied by the sponsor of the study".</P>
<P>Comment: computer generated randomisation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:34:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Buentzel-2006">
<DESCRIPTION>
<P>Quote: "Patients were randomly assigned in a ratio of 1:1&#8221;.</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-04 10:46:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Buntzel-1998">
<DESCRIPTION>
<P>Quote: "eligible patients were randomised to receive RCTamifostine".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:36:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cartee-1995">
<DESCRIPTION>
<P>Quote: "patients were randomised by the Duke Centre Protocol office according to a block randomisation scheme and assigned a unique identifier number which designated the GM-CSF dose level to be received".</P>
<P>Comment: random component not explicit. However, setting makes adequate randomisation likely.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:37:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carter-1999">
<DESCRIPTION>
<P>Quote: "Patients were randomly assigned to receive either sucralfate or placebo".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:38:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cascinu-1994">
<DESCRIPTION>
<P>Quote: "randomised to a control arm or to receive chemotherapy".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:39:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Castagna-2001">
<DESCRIPTION>
<P>Quote: "patients fulfilling the enrolment criteria ... were randomly allocated to the sucralfate or the placebo group. Randomisation was stratified on TBI"</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:39:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cengiz-1999">
<DESCRIPTION>
<P>Quote: &#8220;patients were randomised&#8221;.</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:40:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cerchietti-2006">
<DESCRIPTION>
<P>Quote: "Patients were randomly assigned (in a 1:1 ratio in blocks of 6) to receive, in a double blind methodology, either intravenous L-alanyl-L-glutamine or placebo".</P>
<P>Comment:random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:42:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chi-1995">
<DESCRIPTION>
<P>Quote: "randomised".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:43:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Choi-2007">
<DESCRIPTION>
<P>Quote: "patients were randomised by the clinical trials office, using stage of therapy as the stratifying variable&#8221;.</P>
<P>Comment: computer generated randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:56:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chor-2010">
<DESCRIPTION>
<P>Quote: "randomised".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:57:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Crawford-1999">
<DESCRIPTION>
<P>Quote: "randomised within each study centre to receive chemotherapy with either filgrastim or the equivalent volume of placebo".</P>
<P>comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:02:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cruz-2007">
<DESCRIPTION>
<P>Quote: &#8220;patients were randomized to receive or not laser treatment according to group allocation&#8221;.</P>
<P>Comment: author contacted and replied that sequence was computer generated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:04:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dai-2009">
<DESCRIPTION>
<P>Quote: "They were randomised equally into the test group and control group&#8221;.</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:04:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dazzi-2003">
<DESCRIPTION>
<P>Quote: "were randomly allocated to the GM-CSF or the placebo group".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:06:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dickson-2000">
<DESCRIPTION>
<P>Quote: "the BMT or PBPCT patients were registered with the data managers and randomly assigned to receive glutamine".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:08:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dodd-1996">
<DESCRIPTION>
<P>Quote: "Researchers used a randomised, double-blind, placebo controlled trial design".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:10:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dorr-2007">
<DESCRIPTION>
<P>Quote: "randomisation was performed with the software 'Rancode plus' in randomly permuted blocks at a ratio of 1:1".</P>
<P>Comment: computer generated random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:11:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dozono-1989">
<DESCRIPTION>
<P>Quote: "the subject was randomised into allopurinol administration and control one by the envelope method".</P>
<P>Comment: unclear if envelopes were sequentially numbered or suffled. Random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:12:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Duenas-1996">
<DESCRIPTION>
<P>Quote: "...randomly assigned to receive misoprostol 250 mg three times a day by mouth, or identical tablets of placebo in the same schedule".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:14:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-El-Sayed-2002">
<DESCRIPTION>
<P>Quote: &#8220;enrolled patients were randomized&#8221;.</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:17:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Elad-2006">
<DESCRIPTION>
<P>Quote: "Patients were allocated at random to one of two treatment arms in a blocked randomisation schedule."</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:19:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Epstein-1989">
<DESCRIPTION>
<P>Quote: "the patients were selected randomly to receive drug (Bzd) or placebo rinse (carrier base only)&#8221;.</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:21:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Epstein-1994">
<DESCRIPTION>
<P>Quote: "following consent and randomisation&#8221;.</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:23:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Epstein-2001">
<DESCRIPTION>
<P>Quote: "randomised&#8221;.</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:24:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ertekin-2004">
<DESCRIPTION>
<P>Quote: randomly assigned to receive either zinc sulphate or placebo during RT&#8221;.</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:26:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Evensen-2001">
<DESCRIPTION>
<P>Quote: &#8220;The same patients were randomly allocated to receive either Na-SOS or placebo for the oral rinsing procedure&#8221;.</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:29:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferretti-1988">
<DESCRIPTION>
<P>Quote: "By prospective randomisation, patients were assigned in a double-blind fashion a mouthrinse containing 0.12% chlorhexidine digluconate or a control mouthrinse identical in composition but minus chlorhexidine".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-05 11:38:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fidler-1996">
<DESCRIPTION>
<P>Quote: "Randomised in a double-blind manner to receive a chamomile mouthwash or an identical-appearing placebo."</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:37:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Foote-1994">
<DESCRIPTION>
<P>Quote: "Following randomisation, they were randomized in a double-blind manner to receive a chlorhexidine mouthwash or a placebo mouthwash."</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:39:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Franzen-1995">
<DESCRIPTION>
<P>Quote: "granules of sucralfate or placebo similar in taste, colour, and consistency were dispensed randomly".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:43:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Freytes-2004">
<DESCRIPTION>
<P>Quote: &#8220;This study was a multicentre randomised, double-blinded, placebo controlled, phase I/II study.&#8221;</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:45:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gandemer-2007">
<DESCRIPTION>
<P>Quote: "Eligible patients were randomised by the study randomisation centre..."</P>
<P>Quote: "A minimization procedure was used..."</P>
<P>Comment: minimization.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:46:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giles-2004">
<DESCRIPTION>
<P>Quote: "A randomised, double blind, placebo controlled study".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-09 18:07:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gori-2007">
<DESCRIPTION>
<P>Quote: &#8220;After giving their informed consent, patients were included in a preformed randomization list that was updated by the co-ordinating centre. Randomization was performed at the ratio of 1 patient per arm with no further stratification.&#8221;</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:10:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goyal-2009">
<DESCRIPTION>
<P>Quote: &#8220;All patients were hospitalised during the course of treatment and were randomised to arm 1, receiving radiation in the morning and arm 2, receiving radiation in the evening.&#8221;</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:11:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gujral-2001">
<DESCRIPTION>
<P>Quote: "patient randomisation was carried out by the sealed envelope method."</P>
<P>Quote: "The patients were enrolled in chronological order. They were assigned consecutive patient numbers, and received either radiation therapy, or radiation therapy together with enzyme therapy&#8221;.</P>
<P>Comment: unclear if envelopes were shuffled. Random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:13:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Haddad-2009">
<DESCRIPTION>
<P>Quote: "the randomisation process was centralised and managed through the Dana-Farber Cancer Institute protocol office".</P>
<P>Comment: random component not explicit. However, setting makes adequate randomisation likely.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:14:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hanson-1995">
<DESCRIPTION>
<P>Quote: "randomized&#8221;.</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:17:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hartmann-2001">
<DESCRIPTION>
<P>Quote: "Patients had given informed consent for the treatment with HD-VIC and for the randomization to pre-treatment with or without amifostine."</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:18:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-He-2008">
<DESCRIPTION>
<P>Quote "randomization table".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:20:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2005">
<DESCRIPTION>
<P>Quote: "randomised".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:20:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2000">
<DESCRIPTION>
<P>Quote: "patients were sequentially randomised to two treatment arms".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:29:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2003">
<DESCRIPTION>
<P>Quote: "Randomisation were randomly assigned by random numbers generated from random number table".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:30:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ifrah-1999">
<DESCRIPTION>
<P>Quote: "At admission, patients were randomised to receive either rGM-CSF or a placebo 24 hours after induction treatment was completed."</P>
<P>Quote: "the randomisation sequences were generated by the co-ordinating centre and were balanced with each centre".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:33:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jebb-1994">
<DESCRIPTION>
<P>Quote: "Patients were randomised to receive either glutamine or placebo with the first cycle of treatment and the alternative supplement with cycle 2, such that each patient could act as his or her control".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:35:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Katano-1995">
<DESCRIPTION>
<P>Quote: "they were randomised into two groups of 7 patients each".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:36:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaul-1999">
<DESCRIPTION>
<P>Quote: "A prospective randomised phase III clinical trial".</P>
<P>Quote: "A randomisation of 50 patients fulfilling inclusion criteria".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:38:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kazemian-2009">
<DESCRIPTION>
<P>Quote: &#8220;one hundred patients were randomised into this study&#8221;.</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:39:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Koukourakis-2000">
<DESCRIPTION>
<P>Quote: &#8220;patients were randomly assigned to undergo radiotherapy or radiotherapy supported with subcutaneous administration of Amifostine, according to a table of random numbers (0 V 1)."</P>
<P>Comment: authors used random number table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:40:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Labar-1993">
<DESCRIPTION>
<P>Quote: &#8220;the patients were randomised to receive either prophylactic regimen A or B according to the Pocock and Simon method&#8221;.</P>
<P>Comment: minimization.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:41:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Leborgne-1997">
<DESCRIPTION>
<P>Quote: "69 patients were randomized".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:43:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2006">
<DESCRIPTION>
<P>Quote: "Eligible study patients were randomly assigned to a placebo (n = 30) or a glutamine group (n = 30)."</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:45:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lievens-1998">
<DESCRIPTION>
<P>Quote: "Randomised&#8221;.</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:49:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lilleby-2006">
<DESCRIPTION>
<P>Quote: "Patients were randomised to receive either ice-chips or room temperature normal saline rinses."</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:52:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2006">
<DESCRIPTION>
<P>Quote: "Blocked randomisation was used for all subjects to achieve balanced assignment. We adapted the RV.Uniform (0,1) function in SPSS for windows to generate random numbers and to assign distinct random permuted blocks to subjects&#8221;.</P>
<P>Comment: computer generated randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:54:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lockhart-2005">
<DESCRIPTION>
<P>Quote: &#8220;Subjects were stratified according to initial diagnosis and randomized by computer generated numbering scheme to receive either pilocarpine or an identical-appearing placebo&#8221;.</P>
<P>Comment: computer generated randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:55:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loprinzi-1990">
<DESCRIPTION>
<P>Quote: "a dynamic randomization procedure was utilized for assigning patients to initially receive either the allopurinol or the placebo mouthwash."</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:56:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Madan-2008">
<DESCRIPTION>
<P>Quote: "randomly assigned&#8221;.</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:59:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mahood-1991">
<DESCRIPTION>
<P>Quote: &#8220;prior to therapy, patients were stratified by age and whether or not they had denture. They were then randomised to a control arm or to receive cryotherapy&#8221;.</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:00:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Makkonen-1994">
<DESCRIPTION>
<P>Quote: &#8220;The sealed envelope method was used in randomization, and the envelopes were opened only after all clinical information for each patient had been collected.&#8221;</P>
<P>Comment: unclear if envelopes were shuffled. Random component not described. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-05 22:32:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Makkonen-2000">
<DESCRIPTION>
<P>Quote: "after obtaining an oral informed consent, assignment to the treatment groups were carried out via a phone call to the randomisation centre at the Finnish Cancer registry, Helsinki."</P>
<P>Comment: random component not explicit. However, setting makes adequate randomisation likely.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:03:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McAleese-2006">
<DESCRIPTION>
<P>Quote: "29 patients agreed to enter and were randomly assigned to the active or control arms."</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:05:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McGaw-1985">
<DESCRIPTION>
<P>Quote: "patients randomised into two experimental groups&#8221;.</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:06:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meropol-2003">
<DESCRIPTION>
<P>Quote: &#8220;This study was a multicentre, randomized, double blinded, placebo controlled, phase I study&#8221;.</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-05 11:34:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mills-1988">
<DESCRIPTION>
<P>Quote: "...randomised to receive standard diet with supplemental beta carotene (study patients) or standard diet only with no placebo (control patients)."</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:09:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Motallebnejad-2008">
<DESCRIPTION>
<P>Quote: "randomised&#8221;.</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:15:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nemunaitis-1995">
<DESCRIPTION>
<P>Quote: "Assignment to treatment was made via a randomisation schema prepared by Almedica Corporation (Waldwick, NJ)".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:16:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nottage-2003">
<DESCRIPTION>
<P>Quote: "permuted block randomisation was used to allocate patients to the treatment with sucralfate suspension or placebo with identical appearance".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-11 21:28:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oberbaum-2001">
<DESCRIPTION>
<P>Quote: "The randomisation code was prepared by the manufacturer (HEEL) and was revealed only on completion of the study."</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:24:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Okuno-1999">
<DESCRIPTION>
<P>Quote: "patients were subsequently randomised to receive 4 g of glutamine or an identical appearing placebo twice daily for 14 days".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:25:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Panahi-2009">
<DESCRIPTION>
<P>Quote: "patients were divided randomly into two groups and received allopurinol mouthwash (1 mg/ml) or placebo in a double blind fashion&#8221;.</P>
<P>Comment:random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:31:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peterson-2009">
<DESCRIPTION>
<P>Quote: &#8220;eligible patients who had developed WHO grade &gt; 2 OM in the first cycle of chemotherapy were randomised in a 1:1:1 ratio to receive one of two doses of rhITF or a matched placebo oral spray during the second cycle of chemotherapy&#8221;.</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:32:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pfeiffer-1990">
<DESCRIPTION>
<P>Quote: "The patients were randomly assigned to receive either sucralfate-placebo or placebo-sucralfate".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:32:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pillsbury-1986">
<DESCRIPTION>
<P>Quote: &#8220;Ten patients received indomethacin, 25 mg four times a day, whereas the others received placebo during the entire course of treatment in a double-blind fashion&#8221;.</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:34:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pitten-2003">
<DESCRIPTION>
<P>Quote: "the patients were assigned to one of the two treatment groups by stratified block randomisation; the blocks were selected using a set of random sampling numbers".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:35:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prada-1987">
<DESCRIPTION>
<P>Quote:."...according to the randomization code".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:42:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Puataweepong-2009">
<DESCRIPTION>
<P>Quote: "double blind randomised placebo controlled trial&#8221;.</P>
<P>Quote: "Stratified block randomisation&#8221;.</P>
<P>Comment: insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:44:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Qin-2007">
<DESCRIPTION>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:45:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rahn-1997">
<DESCRIPTION>
<P>Quote: &#8220;40 patients were enrolled in the study and randomly assigned to a treatment or control group&#8221;.</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:46:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rashad-2008">
<DESCRIPTION>
<P>Quote: &#8220;enrolled patients were randomised to either the treatment group, to receive concomitant chemotherapy and radiotherapy plus topical application of pure natural honey, or the control group, to receive concomitant chemotherapy and radiotherapy without honey&#8221;.</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:47:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rocke-1993">
<DESCRIPTION>
<P>Quote: "Patients were randomised to receive cryotherapy for either 30 or 60 minutes".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:48:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rosen-2006">
<DESCRIPTION>
<P>Quote: "patients were randomly assigned (by centre and prior chemotherapy) in a 1:1 ratio to receive palifermin or placebo".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:49:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saarilahti-2002">
<DESCRIPTION>
<P>Quote: "Randomisation was done using computer generated digits".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:51:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Scarantino-2006">
<DESCRIPTION>
<P>Quote: "249 patients were randomised: 124 to receive 5 mg of pilocarpine four times daily and 125 to receive a placebo on the same schedule".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:52:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Scherlacher-1990">
<DESCRIPTION>
<P>Quote: "random allocation to test and control group&#8221;.</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:53:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schneider-1999">
<DESCRIPTION>
<P>Quote: "The patients were randomised equally between the two treatment groups to receive either subcutaneous injections of filgrastim or placebo starting concurrently with the first day of radiation and continuing daily".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:55:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schubert-2007">
<DESCRIPTION>
<P>Quote: "subjects who consented were randomised into one of two laser treatment arms or a placebo therapy group&#8221;.</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-11 21:11:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shenep-1988">
<DESCRIPTION>
<P>Quote: "randomisation of treatment for patients was performed by the hospital pharmacist according to a scheme obtained from Biostatics Division."</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:57:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shieh-1997">
<DESCRIPTION>
<P>Quote: &#8220;to achieve an equal number of study subjects in each group, every 3 consecutive entries of eligible patients over time were treated as a block wherein a simple randomisation was performed&#8221;.</P>
<P>Comment: random component not described. However, reference made to randomisation article.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:58:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sorensen-2008">
<DESCRIPTION>
<P>Quote: "randomised after informed consent to 1 of 3 prophylactic regimens".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 13:00:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sornsuvit-2008">
<DESCRIPTION>
<P>Quote: "randomised to receive intravenous supplementation with either 30 g/day Gln or an equivalent quantity of a standard amino acid mixture".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 13:42:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spencer-2005">
<DESCRIPTION>
<P>Quote: &#8220;patients were randomised to receive Mel200 with or without amifostine 910 mg/m2 pretreatment 15-30 mins prior to melphalan infusion."</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 13:43:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spielberger-2004">
<DESCRIPTION>
<P>Quote: "Patients were randomised in a 1:1 (stratified according to centre and type of hematologic cancer) to receive Palifermin or placebo".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 13:45:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spijkervet-1989">
<DESCRIPTION>
<P>Quote: "This study was a prospective, double-blind, randomised placebo controlled program."</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 13:47:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stokman-2003">
<DESCRIPTION>
<P>Quote: "Randomisation was performed by the hospital pharmacist according to a computer-generated, randomised allocation schedule".</P>
<P>Comment: computer generated randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 13:47:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Su-2004">
<DESCRIPTION>
<P>Quote: "the assignment procedure was termed "biased coin" randomization and ensures that the number of subjects assigned to aloe vera would be roughly equal to those receiving chemotherapy and those with the same primary care site."</P>
<P>Comment: biased coin randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 13:53:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Su-2006">
<DESCRIPTION>
<P>Quote: "Patients were randomised to either G-CSF or placebo by randomly permuted blocks, after stratification by primary disease site".</P>
<P>Comment: random component not explicit. However, setting makes adequate randomisation likely.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 13:57:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svanberg-2007">
<DESCRIPTION>
<P>Quote: "The study was a randomised controlled trial with a random assignment to experimental (EXP) or control (CTR) group&#8221;.</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 13:58:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Symonds-1996">
<DESCRIPTION>
<P>Quote: "Patients were randomised to receive either a placebo or active pastilles containing polymyxin E 2 mg, tobramycin 1.8 mg and amphotericin B 10 mg".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:01:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Trotti-2004">
<DESCRIPTION>
<P>Quote: "randomised double blind".</P>
<P>Quote: &#8220;patients were randomised to receive 9 mg doses of iseganan formulated as a 0.3% aqueous vehicle solution plus institute specific standard-of-care (SOC) management of oral hygiene, or placebo (vehicle solution) plus SOC, or SOC alone in a 3:2:1 distribution&#8221;.</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:03:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tu-1998">
<DESCRIPTION>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:04:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vacha-2003">
<DESCRIPTION>
<P>Quote: "randomised&#8221;.</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:10:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vadhan_x002d_Raj-2010">
<DESCRIPTION>
<P>Quote: "Two distinct computer-generated randomization lists were prepared by the Dept of Biostatistics, University of Texas MD Anderson Cancer Centre, one for the 20 patients who consented to pharmacokinetic sampling and the other for the 28 patients who did not. For the pharmacokinetics cohort the treatment allocation ratio was 4:1 palifermin:placebo in 4 blocks of 5; for the other cohort the ratio was 4:3 palifermin to placebo in 2 blocks of 14."</P>
<P>Comment: the clinical research team would have known that 4/5 of the pharmacokinetic group were receiving active treatment.</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:17:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Veerasarn-2006">
<DESCRIPTION>
<P>Quote: "...were randomised to receive radiotherapy or radiotherapy plus amifostine".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:18:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Veness-2006">
<DESCRIPTION>
<P>Quote: "randomisation was carried out using stratified minimization".</P>
<P>Comment: minimization. Authors give information about which factors used for stratification.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:20:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vokurka-2005">
<DESCRIPTION>
<P>Quote: "prospective, randomised, multicentre study".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:21:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wahlin-1989">
<DESCRIPTION>
<P>Quote: "28 patients were randomly divided into 2 groups".</P>
<P>Quote: "randomisation was performed by means of the closed envelope method in blocks of 6".</P>
<P>Comment: unclear if envelopes were shuffled. Random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:22:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2002">
<DESCRIPTION>
<P>Quote: "randomised".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:29:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Watanabe-2010">
<DESCRIPTION>
<P>Quote: "randomly assigned".</P>
<P>Comment:random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:31:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wijers-2001">
<DESCRIPTION>
<P>Quote: "Patients were randomised to PTA or placebo paste".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:34:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wu-2009">
<DESCRIPTION>
<P>Quote: "We randomised patients to institution and concurrent use of chemotherapy".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:37:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-You-2009">
<DESCRIPTION>
<P>Quote: "Patients were sequentially randomised into two treatment arms: (I) indigowood root group: 0.5g IR powder in 30mL double distilled water; (II) Control group: placebo with 30mL normal saline".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:38:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yuen-2001">
<DESCRIPTION>
<P>Quote: "The 70 patients were randomly divided into 2 subgroups by computer".</P>
<P>Comment: computer generated randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:15:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-der-Lelie-2001">
<DESCRIPTION>
<P>Quote: "After giving their informed consent, the patients were randomised to receive GM-CSF or placebo".</P>
<P>Comment: random component not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-11-10 14:38:39 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:17:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abbasi_x002d_Nazari-2007">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-11 18:40:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ahmed-1993">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:21:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-1998">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:24:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Antonadou-2002">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-23 00:11:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Antunes-2007">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-09 19:31:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Arun-Maiya-2006">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:33:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Attal-1993">
<DESCRIPTION>
<P>Quote: "The treatment allocation for each patient was assigned by telephone by the biostatistics department."</P>
<P>Comment: central method of allocation. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:35:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bensadoun-1999">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-09 17:30:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Biswal-2003">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:47:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bjarnason-2009">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:49:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blazar-2006">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:53:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borowski-1994">
<DESCRIPTION>
<P>Quote: "Patients fulfilling the enrolment criteria were randomly allocated by telephone".</P>
<P>Comment: central allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:56:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bourhis-2000">
<DESCRIPTION>
<P>Quote: "The randomisation procedure was done by telephone".</P>
<P>Comment: central allocation. Probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:59:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brizel-2000">
<DESCRIPTION>
<P>Quote: "treatment assignment was determined by a phone call from the enrolling institution to the protocol sponsor".</P>
<P>Comment: central allocation. Probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:31:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brizel-2008">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:33:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bubley-1989">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:34:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Buentzel-2006">
<DESCRIPTION>
<P>Insufficient information to determine "yes" or "no".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-04 10:46:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Buntzel-1998">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:36:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cartee-1995">
<DESCRIPTION>
<P>Quote: "The patient supply of mouthwash was labelled to correspond with the assigned identifier number and dispensed by pharmacy. The patient assignment information was maintained by the pharmacy to perverse the study double blind".</P>
<P>Comment: pharmacy controlled randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-11 19:29:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carter-1999">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:38:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cascinu-1994">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-11 19:31:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Castagna-2001">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-11 19:33:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cengiz-1999">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-06 11:25:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cerchietti-2006">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:42:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chi-1995">
<DESCRIPTION>
<P>Insufficent information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:43:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Choi-2007">
<DESCRIPTION>
<P>Quote: "Packages containing anonymous treatment supplies for each patient were provided by the clinical trials office&#8221;.</P>
<P>Comment: unclear if packages were sequentially numbered.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:56:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chor-2010">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:57:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Crawford-1999">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:03:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cruz-2007">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:04:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dai-2009">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:05:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dazzi-2003">
<DESCRIPTION>
<P>Quote: "Study suspensions were prepared by the pharmacy unit and provided to the bone marrow transplant patients."</P>
<P>Comment: pharmacy controlled randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:06:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dickson-2000">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:08:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dodd-1996">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-09 17:34:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dorr-2007">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-01 21:11:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dozono-1989">
<DESCRIPTION>
<P>Envelope method of randomisation. Unclear if envelopes were opaque and sequentially numbered. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:12:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Duenas-1996">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:14:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-El-Sayed-2002">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:17:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Elad-2006">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:19:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Epstein-1989">
<DESCRIPTION>
<P>Quote: "Drugs were dispensed in a double blind manner".</P>
<P>Comment: insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:21:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Epstein-1994">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:23:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Epstein-2001">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:24:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ertekin-2004">
<DESCRIPTION>
<P>Quote: "the placebos were empty capsules bought from the same medical firm to be identical to the zinc sulphate capsules".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:26:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Evensen-2001">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:29:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferretti-1988">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-05 11:38:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fidler-1996">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:37:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Foote-1994">
<DESCRIPTION>
<P>Quote: "only a coded bottle was communicated to the treatment centre".</P>
<P>Comment: central allocation. Probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-11 19:39:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Franzen-1995">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:43:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Freytes-2004">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:45:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gandemer-2007">
<DESCRIPTION>
<P>Quote: "the study centres and the randomisation centres communicated by fax".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:46:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giles-2004">
<DESCRIPTION>
<P>Quote: "all study drugs were packaged in identical white opaque plastic bottles, each containing a 5 day supply."</P>
<P>Comment: authors do not state whether drugs were sequentially numbered. Insufficient information to determine &#8216;yes&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:08:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gori-2007">
<DESCRIPTION>
<P>Co-ordinating centre described in text, however, unclear who held the schedules.Therefore, there is insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-11 19:28:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goyal-2009">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-09 17:38:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gujral-2001">
<DESCRIPTION>
<P>Quote: "sealed envelope method."</P>
<P>Comment: unclear whether envelopes were sequentially numbered and opaque.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:13:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Haddad-2009">
<DESCRIPTION>
<P>Quote: "central method of allocation".</P>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:14:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hanson-1995">
<DESCRIPTION>
<P>Quote: 35 tablets containing 200 g each of MP of 35 placebo tablets containing the vehicle alone were supplied by Searle in coded bottles&#8221;.</P>
<P>Comment: unclear if bottles were sequentially numbered.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-04 10:41:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hartmann-2001">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:18:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-He-2008">
<DESCRIPTION>
<P>Quote &#8220;randomization table&#8221;.</P>
<P>Comment: method of concealment unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:20:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2005">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:20:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2000">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:29:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2003">
<DESCRIPTION>
<P>Comment: random number table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:30:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ifrah-1999">
<DESCRIPTION>
<P>Quote: "the randomisation sequences were generated by the co-ordinating centre and were balanced with each centre".</P>
<P>Comment: unclear if allocation remained with the co-ordinating centre. Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:33:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jebb-1994">
<DESCRIPTION>
<P>Quote: "Patients and investigator were unaware of the randomisation order for each subject".</P>
<P>Comment: insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:35:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Katano-1995">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-09 17:40:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaul-1999">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:38:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kazemian-2009">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:39:59 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Koukourakis-2000">
<DESCRIPTION>
<P>Comment: open random table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-11 19:23:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Labar-1993">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:41:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Leborgne-1997">
<DESCRIPTION>
<P>Quote: "The codes were broken after the mucosal reactions in the last patient were scored."</P>
<P>Comment: insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:43:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2006">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:45:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lievens-1998">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:49:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lilleby-2006">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:52:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lin-2006">
<DESCRIPTION>
<P>Quote: "The drug contents were not revealed, even to the principal investigator until the end of the experiment&#8221;.</P>
<P>Comment: insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:54:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lockhart-2005">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:55:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loprinzi-1990">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:56:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Madan-2008">
<DESCRIPTION>
<P>Quote: "the mouthwashes were numbered randomly from 1 to 80 by the mouthwash manufacturer. The coding was done by the manufacturer and was known only to him. It was revealed to the investigator only at the end of the study. Mouthwashes were dispensed in identical 500 ml coded glass bottles&#8221;.</P>
<P>Comment: sequentially numbered drugs containers of identical appearance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:59:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mahood-1991">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:01:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Makkonen-1994">
<DESCRIPTION>
<P>Quote: &#8220;All drugs prepared by the manufacturer, 1 g sucralfate or identically looking placebo granules were sealed in coded paper bags&#8221;.</P>
<P>Sealed envelope method of randomisation. However, authors do not state whether envelopes or bags were sequentially numbered.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-05 22:32:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Makkonen-2000">
<DESCRIPTION>
<P>Quote: "after obtaining an oral informed consent, assignment to the treatment groups were carried out via a phone call to the randomisation centre at the Finnish Cancer registry, Helsinki."</P>
<P>Comment: central method of allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:03:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McAleese-2006">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:05:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McGaw-1985">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:06:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meropol-2003">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:07:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mills-1988">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:09:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Motallebnejad-2008">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:15:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nemunaitis-1995">
<DESCRIPTION>
<P>Quote: "Blinded numbered vials containing placebo or rhGM-CSF were provided to each participating centre".</P>
<P>Comment: unclear whether these vials were sequentially numbered.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-11 21:01:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nottage-2003">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:22:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oberbaum-2001">
<DESCRIPTION>
<P>Quote: "packages of Traumeel S and placebo were prepared by the HEEL company and were identified by serial number only&#8221;.</P>
<P>Comment: adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:24:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Okuno-1999">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:25:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Panahi-2009">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:31:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peterson-2009">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-11 21:06:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pfeiffer-1990">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:32:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pillsbury-1986">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:34:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pitten-2003">
<DESCRIPTION>
<P>Quote: "the rinses were filled into brown glass bottles by the pharmacy of the University of Greifswald, which was responsible for randomisation&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:36:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prada-1987">
<DESCRIPTION>
<P>Quote: "8 anonymous and indistinguishable bottles... "</P>
<P>Comment: unclear if bottles were sequentially numbered.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:43:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Puataweepong-2009">
<DESCRIPTION>
<P>Quote: "The allocation was concealed&#8221;.</P>
<P>Comment:insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:44:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Qin-2007">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-09 19:50:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rahn-1997">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-09 17:33:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rashad-2008">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:47:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rocke-1993">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:48:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rosen-2006">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:49:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saarilahti-2002">
<DESCRIPTION>
<P>Quote: "After patients provided written consent, they were assigned to a treatment group by way of a telephone call to the randomisation office".</P>
<P>Quote: &#8220;The drug vials were marked with a study code that prevented identification of the allocation group&#8221;.</P>
<P>Comment: centralmethod of randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:51:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Scarantino-2006">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:52:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Scherlacher-1990">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:53:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schneider-1999">
<DESCRIPTION>
<P>Quote: &#8220;Amgen Inc. prepared and packaged all drug and placebo in identical containers, with the only designator being the randomisation number. The study material and randomisation list were held by the UCLA pharmacy for the duration of the study&#8221;.</P>
<P>Comment: pharmacy controlled randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:55:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schubert-2007">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:56:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shenep-1988">
<DESCRIPTION>
<P>Pharmacy controlled randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-09 19:41:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shieh-1997">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:58:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sorensen-2008">
<DESCRIPTION>
<P>Quote: "identical 500 mL bottles labelled x and y".</P>
<P>Comment: unclear if bottles were sequentially numbered.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 13:00:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sornsuvit-2008">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 13:42:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spencer-2005">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-09 19:25:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spielberger-2004">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 13:45:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spijkervet-1989">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-04 14:31:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stokman-2003">
<DESCRIPTION>
<P>Pharmacy controlled randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-01 21:47:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Su-2004">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 13:53:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Su-2006">
<DESCRIPTION>
<P>Quote: "a randomization list was prepared by the Memorial Sloan-Kettering Cancer centre biostatics service and held by the pharmacy. Investigators did not have access to this list".</P>
<P>Comment: pharmacy controlled randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 13:57:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svanberg-2007">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 13:58:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Symonds-1996">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:01:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Trotti-2004">
<DESCRIPTION>
<P>Quote: "all study drugs were packaged in identical multidose, white, opaque plastic bottles".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:03:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tu-1998">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:04:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vacha-2003">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:10:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vadhan_x002d_Raj-2010">
<DESCRIPTION>
<P>Both randomisation lists were held by the pharmacy who assigned the patient to the next sequential slot and treatment on the basis of whether or not there was consent for pharmacokinetic sampling.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:17:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Veerasarn-2006">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-22 18:17:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Veness-2006">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-11 18:26:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vokurka-2005">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:21:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wahlin-1989">
<DESCRIPTION>
<P>Quote: "Closed envelope method".</P>
<P>Comment: unclear if envelopes were sequentially numbered.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:22:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2002">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:29:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Watanabe-2010">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:31:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wijers-2001">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:34:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wu-2009">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:37:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-You-2009">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:38:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yuen-2001">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:15:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-der-Lelie-2001">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-11-10 14:38:45 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Carers</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Patients</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.03" NO="3">
<NAME>Outcome assessors</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-09 16:17:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abbasi_x002d_Nazari-2007">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-09 16:17:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abbasi_x002d_Nazari-2007">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-09 16:17:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abbasi_x002d_Nazari-2007">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-11 18:40:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ahmed-1993">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-09 16:19:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ahmed-1993">
<DESCRIPTION>
<P>Quote: "Trial drugs were administered blind".</P>
<P>Comment: unclear who was blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-09 16:19:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ahmed-1993">
<DESCRIPTION>
<P>Quote: "Assessment of mucositis severity was performed by two independent observers".</P>
<P>Comment: unclear if they were blinded to allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-09 16:22:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1998">
<DESCRIPTION>
<P>Quote: "In addition to the patients, the nurses and oncologists involved in the care of these patients also were blinded".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-09 16:22:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1998">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-09 16:22:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1998">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-09 16:24:43 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Antonadou-2002">
<DESCRIPTION>
<P>Comment: amifostine versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-09 16:24:44 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Antonadou-2002">
<DESCRIPTION>
<P>Comment: amifostine versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-09 16:24:45 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Antonadou-2002">
<DESCRIPTION>
<P>Comment: amifostine versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-09 16:45:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Antunes-2007">
<DESCRIPTION>
<P>Quote: "the dentists were the only members of the team who knew which group the patient was randomized to".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-09 16:45:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Antunes-2007">
<DESCRIPTION>
<P>Quote: "the dentists were the only members of the team who knew which group the patient was randomized to".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-09 16:27:16 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Antunes-2007">
<DESCRIPTION>
<P>Quote: "one dentist and 3 nurses (blinded for the study) performed daily oral evaluation of the patients".</P>
<P>Comment: one outcome assessor was not blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-23 00:11:47 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Arun-Maiya-2006">
<DESCRIPTION>
<P>Neon laser versus oral analgesics, local application of anaesthetics, 0.9% saline and povidine wash. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-23 00:11:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Arun-Maiya-2006">
<DESCRIPTION>
<P>Neon laser versus oral analgesics, local application of anaesthetics, 0.9% saline and povidine wash. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-09 16:30:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arun-Maiya-2006">
<DESCRIPTION>
<P>Quote: "Physician blinded to the type of treatment using WHO scale for mucositis and visual analogue scale for pain evaluation recorded the objective assessment of the degree of mucositis weekly".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-23 00:12:12 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Attal-1993">
<DESCRIPTION>
<P>PTX versus no treatment. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-23 00:12:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Attal-1993">
<DESCRIPTION>
<P>PTX versus no treatment. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-01-09 19:44:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Attal-1993">
<DESCRIPTION>
<P>The authors state that the physicians participating in the trial were unaware of the randomisation sequence. However, it is unclear who was doing the outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-09 16:35:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bensadoun-1999">
<DESCRIPTION>
<P>Quote: "this operator was the only person to know whether or not the patients was being sham treated, and did not participate in the evaluation and scoring of mucositis".</P>
<P>Comment: unlikely that nursing staff would know of allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-09 16:35:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bensadoun-1999">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-09 16:35:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bensadoun-1999">
<DESCRIPTION>
<P>Quote: "Objective assessment of degree of mucositis was recorded weekly by a physician blinded to the type of treatment the patient received".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-23 00:12:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Biswal-2003">
<DESCRIPTION>
<P>Honey versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-23 00:12:45 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Biswal-2003">
<DESCRIPTION>
<P>Honey versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-23 00:12:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Biswal-2003">
<DESCRIPTION>
<P>Honey versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-23 00:13:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bjarnason-2009">
<DESCRIPTION>
<P>Morning versus evening radiation. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-23 00:13:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bjarnason-2009">
<DESCRIPTION>
<P>Morning versus evening radiation. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-09 16:48:04 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bjarnason-2009">
<DESCRIPTION>
<P>Quote: "the oncologists performing the evaluations were aware of the treatment arm for each patient".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-09 16:49:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blazar-2006">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-09 16:51:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blazar-2006">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-09 16:51:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blazar-2006">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-23 00:13:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Borowski-1994">
<DESCRIPTION>
<P>Intensive oral hygiene versus limited oral hygiene. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-23 00:13:47 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Borowski-1994">
<DESCRIPTION>
<P>Intensive oral hygiene versus limited oral hygiene. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-09 16:53:42 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Borowski-1994">
<DESCRIPTION>
<P>Quote: "these evaluations could not be performed blindly because of dental plaque."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-09 16:56:27 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bourhis-2000">
<DESCRIPTION>
<P>Comment: amifostine versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-09 16:56:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bourhis-2000">
<DESCRIPTION>
<P>Comment: amifostine versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-09 16:56:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bourhis-2000">
<DESCRIPTION>
<P>Comment: amifostine versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-09 16:59:08 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Brizel-2000">
<DESCRIPTION>
<P>Quote: "open label".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-09 16:59:09 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Brizel-2000">
<DESCRIPTION>
<P>Quote: "open label".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-09 16:59:10 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Brizel-2000">
<DESCRIPTION>
<P>Quote: "open label".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 09:31:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brizel-2008">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 09:31:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brizel-2008">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 09:32:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brizel-2008">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 09:33:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bubley-1989">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 09:33:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bubley-1989">
<DESCRIPTION>
<P>Quote: "double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 09:33:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bubley-1989">
<DESCRIPTION>
<P>Quote: "double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 09:34:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Buentzel-2006">
<DESCRIPTION>
<P>Insufficient information to determine "yes" or "no".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 09:34:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Buentzel-2006">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 09:34:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Buentzel-2006">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-23 00:16:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Buntzel-1998">
<DESCRIPTION>
<P>Amifostine versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-23 00:16:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Buntzel-1998">
<DESCRIPTION>
<P>Amifostine versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-23 00:16:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Buntzel-1998">
<DESCRIPTION>
<P>Amifostine versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-05 21:40:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cartee-1995">
<DESCRIPTION>
<P>Adequate allocation concealment. Unlikely that carers would know of allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 09:36:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cartee-1995">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 09:36:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cartee-1995">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-11 19:30:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carter-1999">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 09:37:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carter-1999">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;.</P>
<P>Quote: &#8220;Both radiation oncology staff and patients were blinded to assigned treatment&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 09:37:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carter-1999">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;.</P>
<P>Quote: &#8220;Both radiation oncology staff and patients were blinded to assigned treatment&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 09:38:30 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cascinu-1994">
<DESCRIPTION>
<P>Ice chips versus no intervention. Blinding impossible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 09:38:30 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cascinu-1994">
<DESCRIPTION>
<P>Ice chips versus no intervention. Blinding impossible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 09:38:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cascinu-1994">
<DESCRIPTION>
<P>Ice chips versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-11 19:31:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Castagna-2001">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 09:39:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Castagna-2001">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 09:39:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Castagna-2001">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-11 19:33:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cengiz-1999">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 09:39:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cengiz-1999">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 09:39:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cengiz-1999">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-06 11:25:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cerchietti-2006">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 09:40:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cerchietti-2006">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 09:40:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cerchietti-2006">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 09:42:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chi-1995">
<DESCRIPTION>
<P>Insufficent information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-23 00:17:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chi-1995">
<DESCRIPTION>
<P>GM-CSF versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-23 00:17:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chi-1995">
<DESCRIPTION>
<P>GM-CSF versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 09:43:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Choi-2007">
<DESCRIPTION>
<P>Quote: "open label trial".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 09:43:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Choi-2007">
<DESCRIPTION>
<P>Quote: "open label trial".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 09:43:39 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Choi-2007">
<DESCRIPTION>
<P>Quote: "open label trial".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 09:56:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chor-2010">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 09:56:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chor-2010">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 09:56:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chor-2010">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 09:57:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Crawford-1999">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 09:58:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Crawford-1999">
<DESCRIPTION>
<P>Quote: "patients remained on blinded study drug until the primary endpoint of the study, FN, was reached."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 09:58:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Crawford-1999">
<DESCRIPTION>
<P>Quote: "A blinded chart review confirmed the exclusion of dental and oral problems related to mucositis".</P>
<P>Comment: outcome assessors presumed to be blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-23 00:18:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cruz-2007">
<DESCRIPTION>
<P>Laser versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-23 00:18:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cruz-2007">
<DESCRIPTION>
<P>Laser versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 10:03:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cruz-2007">
<DESCRIPTION>
<P>Quote: &#8220;oral mucositis was scored by the same investigator...who was blind to the randomisation allocation using the CTC NCI.&#8221;</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-23 00:19:12 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dai-2009">
<DESCRIPTION>
<P>Yangyin Humo Decoction (YHD) versus no treatment. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-23 00:19:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dai-2009">
<DESCRIPTION>
<P>Yangyin Humo Decoction (YHD) versus no treatment. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-23 00:19:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dai-2009">
<DESCRIPTION>
<P>Yangyin Humo Decoction (YHD) versus no treatment. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 10:05:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dazzi-2003">
<DESCRIPTION>
<P>Comment: intervention and control were dispatched from pharmacy, unlikely that carers would have knowledge of allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 10:05:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dazzi-2003">
<DESCRIPTION>
<P>Quote: &#8220;double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 10:05:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dazzi-2003">
<DESCRIPTION>
<P>Quote: &#8220;double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 10:06:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dickson-2000">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 10:07:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dickson-2000">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 10:07:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dickson-2000">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 10:09:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dodd-1996">
<DESCRIPTION>
<P>Quote:"physicians and intervention nurses performed blinded assessments".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 10:09:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dodd-1996">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 10:09:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dodd-1996">
<DESCRIPTION>
<P>Quote:"physicians and intervention nurses performed blinded assessments."</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 10:11:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dorr-2007">
<DESCRIPTION>
<P>Quote: "triple blind".</P>
<P>Comment: unclear who the third blind party was. Nurse or statistician?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 10:11:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dorr-2007">
<DESCRIPTION>
<P>Quote: "triple blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 10:11:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dorr-2007">
<DESCRIPTION>
<P>Quote: "triple blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-23 00:21:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dozono-1989">
<DESCRIPTION>
<P>Allopurinol mouthwash versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-23 00:21:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dozono-1989">
<DESCRIPTION>
<P>Allopurinol mouthwash versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-23 00:21:10 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dozono-1989">
<DESCRIPTION>
<P>Allopurinol mouthwash versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 10:12:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Duenas-1996">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 10:12:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Duenas-1996">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 10:13:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Duenas-1996">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 10:14:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-El-Sayed-2002">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 10:15:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El-Sayed-2002">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 10:15:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El-Sayed-2002">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 10:17:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elad-2006">
<DESCRIPTION>
<P>Quote: &#8220;Patient, investigator and staff were blinded to the treatment assignment.&#8221;</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 10:17:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elad-2006">
<DESCRIPTION>
<P>Quote: &#8220;Patient, investigator and staff were blinded to the treatment assignment.&#8221;</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 10:17:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elad-2006">
<DESCRIPTION>
<P>Quote: &#8220;Patient, investigator and staff were blinded to the treatment assignment.&#8221;</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 10:19:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Epstein-1989">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 10:19:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Epstein-1989">
<DESCRIPTION>
<P>Quote: "double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 10:19:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Epstein-1989">
<DESCRIPTION>
<P>Quote: "double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 10:21:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Epstein-1994">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 10:22:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Epstein-1994">
<DESCRIPTION>
<P>Quote: "double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 10:22:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Epstein-1994">
<DESCRIPTION>
<P>Quote: "double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 10:23:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Epstein-2001">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-07-21 16:59:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Epstein-2001">
<DESCRIPTION>
<P>Placebo controlled study, however no blinding information is given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-07-21 16:59:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Epstein-2001">
<DESCRIPTION>
<P>Placebo controlled study, however no blinding information is given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 10:24:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ertekin-2004">
<DESCRIPTION>
<P>Zinc versus placebo.</P>
<P>Reference made to the need for a "well-designed double-blind randomized study to evaluate the reliability and effectiveness" of zinc. However, no information on blinding provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-11 21:44:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ertekin-2004">
<DESCRIPTION>
<P>Reference made to the need for a "well-designed double-blind randomized study to evaluate the reliability and effectiveness" of zinc. However, no information on blinding provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-23 00:22:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ertekin-2004">
<DESCRIPTION>
<P>Reference made to the need for a "well-designed double-blind randomized study to evaluate the reliability and effectiveness" of zinc. However, no information on blinding provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 10:26:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Evensen-2001">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 10:26:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Evensen-2001">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 10:26:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Evensen-2001">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 10:29:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferretti-1988">
<DESCRIPTION>
<P>Quote: "Mouthrinse use was supervised by transplant unit nursing staff for the duration of hospitalization".</P>
<P>Comment: insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 10:29:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferretti-1988">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Quote: "mouthrinse identical in composition but without chlorhexidine".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 10:30:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferretti-1988">
<DESCRIPTION>
<P>Quote: "double Blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-05 11:38:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fidler-1996">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 10:36:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fidler-1996">
<DESCRIPTION>
<P>Quote: "double-blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 10:36:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fidler-1996">
<DESCRIPTION>
<P>Quote: "double-blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-05 15:38:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Foote-1994">
<DESCRIPTION>
<P>Adequate allocation concealment. Unlikely that carers would know allocations. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 10:38:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Foote-1994">
<DESCRIPTION>
<P>Quote: "double Blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 10:38:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Foote-1994">
<DESCRIPTION>
<P>Quote: "double Blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-11 19:39:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Franzen-1995">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 10:39:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Franzen-1995">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 10:39:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Franzen-1995">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 10:43:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Freytes-2004">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 10:43:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Freytes-2004">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 10:43:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Freytes-2004">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 10:45:40 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gandemer-2007">
<DESCRIPTION>
<P>Chewing gum versus no intervention. Blinding impossible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 10:45:40 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gandemer-2007">
<DESCRIPTION>
<P>Chewing gum versus no intervention. Blinding impossible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-23 00:25:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gandemer-2007">
<DESCRIPTION>
<P>Chewing gum versus no intervention. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 10:47:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giles-2004">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 10:47:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giles-2004">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Quote: "Patients, study personnel, and the sponsor were blinded to whether an individual patient received iseganan or placebo".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 10:48:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giles-2004">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Quote: "Patients, study personnel, and the sponsor were blinded to whether an individual patient received iseganan or placebo".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 11:09:03 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gori-2007">
<DESCRIPTION>
<P>Ice chips versus no intervention. Blinding impossible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 11:09:03 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gori-2007">
<DESCRIPTION>
<P>Ice chips versus no intervention. Blinding impossible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-23 00:24:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gori-2007">
<DESCRIPTION>
<P>Ice chips versus no intervention. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 11:10:22 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Goyal-2009">
<DESCRIPTION>
<P>Morning versus evening radiation. Blinding impossible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 11:10:23 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Goyal-2009">
<DESCRIPTION>
<P>Morning versus evening radiation. Blinding impossible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 11:10:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goyal-2009">
<DESCRIPTION>
<P>Quote: &#8220;Radiation reactions were assessed weekly by a blinded observer according by RTOG criteria&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 11:11:26 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gujral-2001">
<DESCRIPTION>
<P>Quote: &#8220;randomised, open trial&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 11:11:27 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gujral-2001">
<DESCRIPTION>
<P>Quote: &#8220;randomised, open trial&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 11:11:28 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gujral-2001">
<DESCRIPTION>
<P>Quote: &#8220;randomised, open trial&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 11:13:25 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Haddad-2009">
<DESCRIPTION>
<P>Radiotherapy with or without subcutaneous amifostine. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 11:13:25 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Haddad-2009">
<DESCRIPTION>
<P>Radiotherapy with or without subcutaneous amifostine. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 11:13:26 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Haddad-2009">
<DESCRIPTION>
<P>Radiotherapy with or without subcutaneous amifostine. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 11:15:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hanson-1995">
<DESCRIPTION>
<P>Quote: "each patient was assigned a bottle of tablets without knowledge of the content (MP or placebo), nor did the attending physician, nursing or administrative staff knew the content or coding&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 11:15:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hanson-1995">
<DESCRIPTION>
<P>Quote: "each patient was assigned a bottle of tablets without knowledge of the content (MP or placebo), nor did the attending physician, nursing or administrative staff knew the content or coding&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 11:15:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hanson-1995">
<DESCRIPTION>
<P>Quote: "each patient was assigned a bottle of tablets without knowledge of the content (MP or placebo), nor did the attending physician, nursing or administrative staff knew the content or coding&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 11:17:35 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hartmann-2001">
<DESCRIPTION>
<P>Amifostine versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 11:17:36 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hartmann-2001">
<DESCRIPTION>
<P>Amifostine versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 11:17:36 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hartmann-2001">
<DESCRIPTION>
<P>Amifostine versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 11:18:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-He-2008">
<DESCRIPTION>
<P>Parenteral amino acid solution with or without glutamine. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 11:18:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-He-2008">
<DESCRIPTION>
<P>Parenteral amino acid solution with or without glutamine. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 11:18:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-He-2008">
<DESCRIPTION>
<P>Parenteral amino acid solution with or without glutamine. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 11:20:28 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hu-2005">
<DESCRIPTION>
<P>Shenqi Fanghou recipe versus no treatment. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 11:20:28 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hu-2005">
<DESCRIPTION>
<P>Shenqi Fanghou recipe versus no treatment. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 11:20:29 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hu-2005">
<DESCRIPTION>
<P>Shenqi Fanghou recipe versus no treatment. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 11:20:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2000">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 11:21:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2000">
<DESCRIPTION>
<P>Quote: "single blind randomised study".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 11:21:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Huang-2000">
<DESCRIPTION>
<P>Quote: "due to manpower problems, not all physicians who evaluated patients were blind to test solutions".</P>
<P>Comment: assessors not blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-05 12:34:14 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Huang-2003">
<DESCRIPTION>
<P>Difference between intervention and control in the mode of application (gargle versus suck and swallow). Blinding impossible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-05 12:34:22 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Huang-2003">
<DESCRIPTION>
<P>Difference between intervention and control in the mode of application (gargle versus suck and swallow). Blinding impossible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 11:29:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2003">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 11:30:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ifrah-1999">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 11:30:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ifrah-1999">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 11:30:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ifrah-1999">
<DESCRIPTION>
<P>Quote: &#8220;double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 11:34:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jebb-1994">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 11:34:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jebb-1994">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 11:34:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jebb-1994">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 11:35:44 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Katano-1995">
<DESCRIPTION>
<P>G-CSF versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 11:35:45 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Katano-1995">
<DESCRIPTION>
<P>G-CSF versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 11:35:45 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Katano-1995">
<DESCRIPTION>
<P>G-CSF versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 11:36:23 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kaul-1999">
<DESCRIPTION>
<P>No intervention versus 9 tablets. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 11:36:25 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kaul-1999">
<DESCRIPTION>
<P>No intervention versus 9 tablets. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 11:36:25 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kaul-1999">
<DESCRIPTION>
<P>No intervention versus 9 tablets. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 11:38:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kazemian-2009">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 11:38:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kazemian-2009">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 11:38:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kazemian-2009">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 11:40:01 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Koukourakis-2000">
<DESCRIPTION>
<P>Amifostine versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 11:40:01 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Koukourakis-2000">
<DESCRIPTION>
<P>Amifostine versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 11:40:02 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Koukourakis-2000">
<DESCRIPTION>
<P>Amifostine versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-11 19:24:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Labar-1993">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 11:41:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Labar-1993">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 11:41:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Labar-1993">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-21 19:04:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Leborgne-1997">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 11:41:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leborgne-1997">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 11:41:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leborgne-1997">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 11:43:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2006">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 11:44:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2006">
<DESCRIPTION>
<P>Glutamine versus placebo (glycerine).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 11:44:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2006">
<DESCRIPTION>
<P>Glutamine versus placebo (glycerine).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 11:45:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lievens-1998">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 11:45:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lievens-1998">
<DESCRIPTION>
<P>Quote: "double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 11:45:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lievens-1998">
<DESCRIPTION>
<P>Quote: "double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 11:49:55 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lilleby-2006">
<DESCRIPTION>
<P>Ice chips versus saline. Blinding impossible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 11:49:56 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lilleby-2006">
<DESCRIPTION>
<P>Ice chips versus saline. Blinding impossible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 11:49:56 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lilleby-2006">
<DESCRIPTION>
<P>Ice chips versus saline. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 11:52:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lin-2006">
<DESCRIPTION>
<P>Comment: authors state that serum zinc levels were checked biweekly, staff who checked these levels would presumably have knowledge of allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 11:52:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2006">
<DESCRIPTION>
<P>Quote: "double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 11:53:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lin-2006">
<DESCRIPTION>
<P>Comment: authors state that serum zinc levels were checked biweekly, staff who checked these levels would presumably have knowledge of allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 11:54:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lockhart-2005">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 11:54:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lockhart-2005">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 11:54:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lockhart-2005">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 11:55:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loprinzi-1990">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 11:55:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loprinzi-1990">
<DESCRIPTION>
<P>Quote: "double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 11:55:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loprinzi-1990">
<DESCRIPTION>
<P>Quote: "double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-21 22:33:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Madan-2008">
<DESCRIPTION>
<P>Double blind study with adequate allocation concealment. Unlikely that carers would have knowledge of allocations.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 11:56:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Madan-2008">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 11:56:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Madan-2008">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 11:59:30 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mahood-1991">
<DESCRIPTION>
<P>Ice chips versus saline. Blinding impossible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 11:59:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mahood-1991">
<DESCRIPTION>
<P>Ice chips versus saline. Blinding impossible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:00:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mahood-1991">
<DESCRIPTION>
<P>Quote: &#8220;the attending physician who judged the mucositis grade was frequently not aware of whether the patient had received cryotherapy or not&#8221;.</P>
<P>Comment: insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-11 19:41:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Makkonen-1994">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:01:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Makkonen-1994">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:01:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Makkonen-1994">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 12:02:37 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Makkonen-2000">
<DESCRIPTION>
<P>Quote: "open, prospective, randomised study".</P>
<P>Comment: no blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:02:39 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Makkonen-2000">
<DESCRIPTION>
<P>Quote: "open, prospective, randomised study".</P>
<P>Comment: no blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:02:41 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Makkonen-2000">
<DESCRIPTION>
<P>Quote: "open, prospective, randomised study".</P>
<P>Comment: no blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 12:03:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McAleese-2006">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:03:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McAleese-2006">
<DESCRIPTION>
<P>Quote: &#8220;A placebo injection was not used because it was not considered ethically justifiable&#8221;.</P>
<P>Comment: GM-CSF versus no intervention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-01-05 22:43:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McAleese-2006">
<DESCRIPTION>
<P>Quote: &#8220;At each visit one of two independent observers, blinded to group allocation, scored mucositis by the RTOG system?&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 12:05:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McGaw-1985">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:05:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McGaw-1985">
<DESCRIPTION>
<P>Quote: "double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:05:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McGaw-1985">
<DESCRIPTION>
<P>Quote: "double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 12:07:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meropol-2003">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:07:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meropol-2003">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:07:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meropol-2003">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 12:08:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mills-1988">
<DESCRIPTION>
<P>Beta-carotene versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:08:08 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mills-1988">
<DESCRIPTION>
<P>Beta-carotene versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:08:10 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mills-1988">
<DESCRIPTION>
<P>Beta-carotene versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 12:09:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Motallebnejad-2008">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-07-21 22:46:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Motallebnejad-2008">
<DESCRIPTION>
<P>Honey versus saline. Single blind study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:10:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Motallebnejad-2008">
<DESCRIPTION>
<P>Quote: "evaluator was blinded to the group assignments of the patients&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 12:15:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nemunaitis-1995">
<DESCRIPTION>
<P>Quote: &#8220;The pharmacists, principal investigators, patients, support care personnel and sponsoring company were blinded to the study medication for the entire course of the study&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:15:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nemunaitis-1995">
<DESCRIPTION>
<P>Quote: &#8220;The pharmacists, principal investigators, patients, support care personnel and sponsoring company were blinded to the study medication for the entire course of the study&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:15:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nemunaitis-1995">
<DESCRIPTION>
<P>Quote: &#8220;The pharmacists, principal investigators, patients, support care personnel and sponsoring company were blinded to the study medication for the entire course of the study&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 12:16:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nottage-2003">
<DESCRIPTION>
<P>Quote: "the study nurse, in accordance with usual clinical practice estimated the severity of mucositis retrospectively. This person was blinded to treatment allocation".</P>
<P>Comment: no information given about other support staff.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:17:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nottage-2003">
<DESCRIPTION>
<P>Quote: "Investigators, treating physicians, and study subjects were all blinded to study allocation&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:17:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nottage-2003">
<DESCRIPTION>
<P>Quote: "Investigators, treating physicians, and study subjects were all blinded to study allocation&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-23 00:34:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oberbaum-2001">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:22:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oberbaum-2001">
<DESCRIPTION>
<P>Quote: "double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:22:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oberbaum-2001">
<DESCRIPTION>
<P>Quote: "all evaluations were performed blind by the same observer (the study nurse)".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 12:24:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Okuno-1999">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:24:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Okuno-1999">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:24:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Okuno-1999">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 12:25:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Panahi-2009">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:25:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Panahi-2009">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Quote: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:25:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Panahi-2009">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Quote: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 12:31:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peterson-2009">
<DESCRIPTION>
<P>Quote: "The placebo oral sprays were manufactured by the GI company."</P>
<P>Intervention was manufactured in the US and conducted in Russia. Therefore, carers likely to be blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:31:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peterson-2009">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:31:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peterson-2009">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-11 21:07:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pfeiffer-1990">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:32:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pfeiffer-1990">
<DESCRIPTION>
<P>Quote: "double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:32:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pfeiffer-1990">
<DESCRIPTION>
<P>Quote: "double blind.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 12:32:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pillsbury-1986">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:32:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pillsbury-1986">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:32:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pillsbury-1986">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 12:34:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pitten-2003">
<DESCRIPTION>
<P>Quote: "Neither the patient, nor the dentist knew whether the patient received the chlorhexidine based product or the control medication. In addition, none of the nurses, physicians, or oncologists knew the specific drug used for oral rinsing&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:35:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pitten-2003">
<DESCRIPTION>
<P>Quote: "Neither the patient, nor the dentist knew whether the patient received the chlorhexidine based product or the control medication. In addition, none of the nurses, physicians, or oncologists knew the specific drug used for oral rinsing&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:35:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pitten-2003">
<DESCRIPTION>
<P>Quote: "Neither the patient, nor the dentist knew whether the patient received the chlorhexidine based product or the control medication. In addition, none of the nurses, physicians, or oncologists knew the specific drug used for oral rinsing&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 12:36:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prada-1987">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:36:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prada-1987">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:36:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prada-1987">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 12:43:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Puataweepong-2009">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:43:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Puataweepong-2009">
<DESCRIPTION>
<P>Quote: "The allocation was concealed and blinded to physician, patients and personnel involved in the study&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:43:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Puataweepong-2009">
<DESCRIPTION>
<P>Quote: "The allocation was concealed and blinded to physician, patients and personnel involved in the study&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 12:44:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Qin-2007">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:44:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Qin-2007">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:44:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Qin-2007">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 12:45:06 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rahn-1997">
<DESCRIPTION>
<P>Quote: "Open, placebo controlled and randomised clinical trial".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:45:07 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rahn-1997">
<DESCRIPTION>
<P>Quote: "Open, placebo controlled and randomised clinical trial".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:45:08 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rahn-1997">
<DESCRIPTION>
<P>Quote: "Open, placebo controlled and randomised clinical trial".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 12:46:18 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rashad-2008">
<DESCRIPTION>
<P>Honey versus no intervention. Blinding impossible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:46:19 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rashad-2008">
<DESCRIPTION>
<P>Honey versus no intervention. Blinding impossible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:46:20 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rashad-2008">
<DESCRIPTION>
<P>Honey versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 12:47:06 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rocke-1993">
<DESCRIPTION>
<P>30 minutes versus 60 minutes of cryotherapy. Blinding impossible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:47:06 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rocke-1993">
<DESCRIPTION>
<P>30 minutes versus 60 minutes of cryotherapy. Blinding impossible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:47:06 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rocke-1993">
<DESCRIPTION>
<P>30 minutes versus 60 minutes of cryotherapy. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 12:48:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rosen-2006">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:49:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rosen-2006">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:49:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rosen-2006">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-05 22:54:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saarilahti-2002">
<DESCRIPTION>
<P>Comment: double blind study with adequate allocation concealment, drugs prepared by pharmacy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:50:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saarilahti-2002">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:50:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saarilahti-2002">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 12:51:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Scarantino-2006">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:51:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Scarantino-2006">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:52:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Scarantino-2006">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-11 21:24:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Scherlacher-1990">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-11 21:25:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Scherlacher-1990">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-01-11 21:25:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Scherlacher-1990">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-05 21:27:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schneider-1999">
<DESCRIPTION>
<P>Pharmacy controlled randomisation. Unlikely that carers would know allocations.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:53:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schneider-1999">
<DESCRIPTION>
<P>Quote: "double Blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:53:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schneider-1999">
<DESCRIPTION>
<P>Quote: "double Blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 12:55:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schubert-2007">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:55:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schubert-2007">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Quote: "by having subjects wear both laser safety goggles and a soft cloth blindfold, it was physically impossible for them to see the tip of the laser emitting device or the control panel of the unit, thus ensuring that subjects were blinded as to whether they were receiving actual laser".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:55:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schubert-2007">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Quote: "mucositis examinations were carried out by trained and calibrated oral medicine personnel who were blind to the subjects treatment arm assignment".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-11 21:11:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shenep-1988">
<DESCRIPTION>
<P>Double blind study with adequate allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:56:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shenep-1988">
<DESCRIPTION>
<P>Quote: "double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:56:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shenep-1988">
<DESCRIPTION>
<P>Quote: "double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 12:57:30 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shieh-1997">
<DESCRIPTION>
<P>2 different methods of oral care (E1/ E2) versus control. Blinding impossible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:57:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shieh-1997">
<DESCRIPTION>
<P>2 different methods of oral care (E1/ E2) versus control. Blinding impossible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:57:32 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shieh-1997">
<DESCRIPTION>
<P>2 different methods of oral care (E1/ E2) versus control. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 12:58:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sorensen-2008">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 12:58:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sorensen-2008">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 12:58:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sorensen-2008">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 13:00:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sornsuvit-2008">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-23 00:38:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sornsuvit-2008">
<DESCRIPTION>
<P>Glutamine versus standard amino acids. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-01-09 17:27:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sornsuvit-2008">
<DESCRIPTION>
<P>Glutamine versus standard amino acids.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 13:42:26 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Spencer-2005">
<DESCRIPTION>
<P>Quote: &#8220;open label&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 13:42:27 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Spencer-2005">
<DESCRIPTION>
<P>Quote: &#8220;open label&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 13:42:28 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Spencer-2005">
<DESCRIPTION>
<P>Quote: &#8220;open label&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-09 19:25:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spielberger-2004">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 13:43:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spielberger-2004">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 13:43:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spielberger-2004">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 13:45:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spijkervet-1989">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 13:45:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spijkervet-1989">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 13:45:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spijkervet-1989">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-17 09:03:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stokman-2003">
<DESCRIPTION>
<P>Adequate allocation concealment. Unlikely that carers would know of allocations. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-04 14:32:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stokman-2003">
<DESCRIPTION>
<P>Quote: &#8220;Patients, clinicians, dental hygienists and microbiologists were blind for who was taking antibiotics&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-01-04 14:32:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stokman-2003">
<DESCRIPTION>
<P>Quote: &#8220;Patients, clinicians, dental hygienists and microbiologists were blind for who was taking antibiotics&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 13:48:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Su-2004">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 13:48:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Su-2004">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Quote: "To minimize biases, both study physicians and patients were unaware of the results of randomisation".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 13:48:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Su-2004">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Quote: "To minimize biases, both study physicians and patients were unaware of the results of randomisation".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 13:53:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Su-2006">
<DESCRIPTION>
<P>Adequate allocation concealment. Unlikely that carers would know of allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 13:53:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Su-2006">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 13:53:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Su-2006">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 13:57:50 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Svanberg-2007">
<DESCRIPTION>
<P>Cryotherapy versus standard treatment. Blinding impossible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 13:57:53 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Svanberg-2007">
<DESCRIPTION>
<P>Cryotherapy versus standard treatment. Blinding impossible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 13:57:54 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Svanberg-2007">
<DESCRIPTION>
<P>Cryotherapy versus standard treatment. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 13:58:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Symonds-1996">
<DESCRIPTION>
<P>Quote: &#8220;The active and placebo pastilles were identical and neither the patients, clinicians, nurses nor microbiologists were aware who were taking antibiotics&#8221;.</P>
<P>Quote: &#8220;double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 13:59:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Symonds-1996">
<DESCRIPTION>
<P>Quote: &#8220;The active and placebo pastilles were identical and neither the patients, clinicians, nurses nor microbiologists were aware who were taking antibiotics&#8221;.</P>
<P>Quote: &#8220;double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 13:59:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Symonds-1996">
<DESCRIPTION>
<P>Quote: &#8220;The active and placebo pastilles were identical and neither the patients, clinicians, nurses nor microbiologists were aware who were taking antibiotics&#8221;.</P>
<P>Quote: &#8220;double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 14:01:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Trotti-2004">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 14:02:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trotti-2004">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Quote: &#8220;Patients, study personnel, and the sponsor were blinded as to whether an individual received iseganan or placebo&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 14:02:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trotti-2004">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Quote: &#8220;Patients, study personnel, and the sponsor were blinded as to whether an individual received iseganan or placebo&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 14:03:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tu-1998">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 14:04:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tu-1998">
<DESCRIPTION>
<P>Quote: "double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 14:04:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tu-1998">
<DESCRIPTION>
<P>Quote: "double blind&#8221;.</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 14:05:02 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vacha-2003">
<DESCRIPTION>
<P>Chemotherapy and radiotherapy with or without amifostine. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 14:05:06 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vacha-2003">
<DESCRIPTION>
<P>Chemotherapy and radiotherapy with or without amifostine. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 14:05:11 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vacha-2003">
<DESCRIPTION>
<P>Chemotherapy and radiotherapy with or without amifostine. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 14:11:19 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vadhan_x002d_Raj-2010">
<DESCRIPTION>
<P>Quote: "the patient and the clinical research team (who assessed outcomes) were blinded to the study treatment".</P>
<P>Comment:however paper states that "blinding might not have been maintained due to the adverse effects of palifermin (pronounced leukoedema of buccal mucosa &amp; gingival)", and describes cycles 1&amp; 2 as 'blinded cycles'.Pre- and post-administration biopsies in '8 consenting patients' would have also revealed who was allocated to active treatment.Those patients consenting to the pharmacokinetic study had a 4/5 chance of receiving active treatment.</P>
<P>Comment: we consider it likely that none of the treatment cycles were truly blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 14:12:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vadhan_x002d_Raj-2010">
<DESCRIPTION>
<P>Quote: "the patient and the clinical research team (who assessed outcomes) were blinded to the study treatment".</P>
<P>Comment:however paper states that "blinding might not have been maintained due to the adverse effects of palifermin (pronounced leukoedema of buccal mucosa &amp; gingival)", and describes cycles 1&amp; 2 as 'blinded cycles'.Pre- and post-administration biopsies in '8 consenting patients' would have also revealed who was allocated to active treatment.Those patients consenting to the pharmacokinetic study had a 4/5 chance of receiving active treatment.</P>
<P>Comment: we consider it likely that none of the treatment cycles were truly blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 14:13:20 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vadhan_x002d_Raj-2010">
<DESCRIPTION>
<P>Quote: "the patient and the clinical research team (who assessed outcomes) were blinded to the study treatment".</P>
<P>Comment:however paper states that "blinding might not have been maintained due to the adverse effects of palifermin (pronounced leukoedema of buccal mucosa &amp; gingival)", and describes cycles 1&amp; 2 as 'blinded cycles'.Pre- and post-administration biopsies in '8 consenting patients' would have also revealed who was allocated to active treatment.Those patients consenting to the pharmacokinetic study had a 4/5 chance of receiving active treatment.</P>
<P>Comment: we consider it likely that none of the treatment cycles were truly blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 14:17:32 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Veerasarn-2006">
<DESCRIPTION>
<P>Quote: "open label".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 14:17:33 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Veerasarn-2006">
<DESCRIPTION>
<P>Quote: "open label".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 14:17:33 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Veerasarn-2006">
<DESCRIPTION>
<P>Quote: "open label".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-22 18:17:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Veness-2006">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 14:18:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Veness-2006">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 14:19:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Veness-2006">
<DESCRIPTION>
<P>Quote: "the patient's mucositis grade was scored by an experienced head and neck clinic nurse on a weekly basis. She had no prior knowledge of patient randomisation".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 14:20:16 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vokurka-2005">
<DESCRIPTION>
<P>Only patients were blinded to the treatment allocation. Authors give no information on who made up the solutions each morning.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-11 18:28:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vokurka-2005">
<DESCRIPTION>
<P>Quote: &#8220;their composition was blinded to the patients.&#8221;</P>
<P>Comment: normal saline versus povidone-iodine. Likely that patients would be able to tell the difference between the treatments. Presumably iodine solution would be orange.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 14:20:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vokurka-2005">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 14:21:22 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wahlin-1989">
<DESCRIPTION>
<P>Chlorhexidine versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 14:21:22 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wahlin-1989">
<DESCRIPTION>
<P>Chlorhexidine versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 14:21:28 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wahlin-1989">
<DESCRIPTION>
<P>Chlorhexidine versus no intervention. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-05 14:27:55 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2002">
<DESCRIPTION>
<P>Intervention and control were different in terms of colour, smell, and style of packaging.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 14:22:18 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2002">
<DESCRIPTION>
<P>Intervention and control were different in terms of colour, smell, and style of packaging.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 14:22:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2002">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 14:30:07 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Watanabe-2010">
<DESCRIPTION>
<P>Quote: "open trial&#8221;.</P>
<P>Comment:polaprezinc compared to azulene control.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 14:30:27 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Watanabe-2010">
<DESCRIPTION>
<P>Quote: "open trial&#8221;.</P>
<P>Comment:polaprezinc compared to azulene control.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 14:30:43 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Watanabe-2010">
<DESCRIPTION>
<P>Quote: "open trial&#8221;.</P>
<P>Comment:polaprezinc compared to azulene control.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 14:31:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wijers-2001">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 14:31:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wijers-2001">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 14:32:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wijers-2001">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 14:34:54 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wu-2009">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;.</P>
<P>Comment: possible patient knowledge of allocation. Therefore all blinding deemed inadequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 14:35:09 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wu-2009">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;.</P>
<P>Comment: authors state that 1 patient dropped out because they were not randomised to the test drug. Patient knowledge of allocation. Therefore blinding judged to be inadequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 14:35:40 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wu-2009">
<DESCRIPTION>
<P>Quote: &#8220;double blind&#8221;.</P>
<P>Comment: possible patient knowledge of allocation. Therefore all blinding deemed inadequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 14:37:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-You-2009">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 14:37:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-You-2009">
<DESCRIPTION>
<P>Indigo wood root or placebo. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 14:38:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-You-2009">
<DESCRIPTION>
<P>Indigo wood root or placebo. No apparent blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 14:38:42 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yuen-2001">
<DESCRIPTION>
<P>Quote: "open-label".</P>
<P>Comment: no blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 14:38:43 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yuen-2001">
<DESCRIPTION>
<P>Quote: "open-label".</P>
<P>Comment: no blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 14:38:45 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yuen-2001">
<DESCRIPTION>
<P>Quote: "open-label".</P>
<P>Comment: no blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 14:15:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-der-Lelie-2001">
<DESCRIPTION>
<P>Insufficient information to determine &#8216;yes&#8217; or &#8216;no&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-10 14:15:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Lelie-2001">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-11-10 14:15:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Lelie-2001">
<DESCRIPTION>
<P>Quote: "double blind".</P>
<P>Comment: probably done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-11-10 14:35:49 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-23 00:10:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abbasi_x002d_Nazari-2007">
<DESCRIPTION>
<P>Quote: "Patients who experienced hypersensitivity reaction or serious side effects were excluded from the study. Also patients who complained about pain or other signs attributed to severe mucositis were excluded from the study."</P>
<P>Comment: 24 patients included in analysis. However, it is unclear how many patients were recruited.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-09 16:19:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ahmed-1993">
<DESCRIPTION>
<P>12 patients randomised. Authors do not give information about drop outs. Unclear how many patients in each arm. Unclear how many patients included in results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-09 16:23:39 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Anderson-1998">
<DESCRIPTION>
<P>24 patients randomised. Paired outcome data available for 13 patients. Authors give full reasons for attrition/exclusion. Potential for overall estimate to be reversed if excluded patients were included.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-09 16:24:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Antonadou-2002">
<DESCRIPTION>
<P>50 patients randomised. Assessable data from 45 patients. 2/24 in the amifostine group and 3/26 in the control group. Authors give full reasons for attrition and exclusion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-11 08:11:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Antunes-2007">
<DESCRIPTION>
<P>38 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-19 10:17:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arun-Maiya-2006">
<DESCRIPTION>
<P>50 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-19 13:56:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Attal-1993">
<DESCRIPTION>
<P>140 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-20 22:42:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bensadoun-1999">
<DESCRIPTION>
<P>30 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-07 21:27:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biswal-2003">
<DESCRIPTION>
<P>40 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-14 21:50:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bjarnason-2009">
<DESCRIPTION>
<P>216 patients recruited. 7 patients deemed ineligible (4/108 arm A, 3/108 arm B), 3 patients in arm A did not receive radiotherapy (3/108 arm A), 1 patient in arm B did not have mucositis assessment. 205 patients included in final analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-09 16:51:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blazar-2006">
<DESCRIPTION>
<P>100 patients randomised. 17 patients discontinued and replaced (1/31 placebo group). 3 patients suffered SAE and were not replaced (1/31 placebo group). Full reasons given for attrition/exclusion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-09 16:53:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borowski-1994">
<DESCRIPTION>
<P>166 patients randomised. 16 patients excluded from analysis: 9/ 84 intensive oral hygiene group, 7/82 limited oral hygiene group. Authors give complete reasons for exclusion/attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-09 16:56:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bourhis-2000">
<DESCRIPTION>
<P>26 patients randomised. 2 patients not included in mucositis assessment. Full reasons for drop outs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-09 16:59:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brizel-2000">
<DESCRIPTION>
<P>315 patients randomised. 12 patients never received intervention. 22 patients discontinued but included in efficacy analysis. 2/150 patients in amifostine group missing from mucositis analysis. Observed event risk not sufficient to have clinically relevant impact.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 09:32:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brizel-2008">
<DESCRIPTION>
<P>Quote: "Ninety-nine of 100 patients who were randomly assigned (67 palifermin, 32 placebo received at least 1 dose of study treatment and were evaluated".</P>
<P>Comment: 101 patients stated as randomised in figure 1. Table 1 gives baseline data for 99 patients.</P>
<P>Comment: 21 patients discontinued. 17/67 in palifermin group, 4/32 in placebo group. Authors give incomplete reasons for attrition/exclusion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-01 21:02:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bubley-1989">
<DESCRIPTION>
<P>57 patients recruited. All patients included analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 09:35:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Buentzel-2006">
<DESCRIPTION>
<P>132 patients randomised. 20/67 missing from treatment group, 9/65 missing from placebo group. 1 patient from each group not treated. Authors give full reasons for exclusions and withdrawals. ITT analysis. Mucositis data presented for 129 patients.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 09:35:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Buntzel-1998">
<DESCRIPTION>
<P>28 patients initially randomised. After positive results suggested an additional 11 patients were recruited to the amifostine arm. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 13:25:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cartee-1995">
<DESCRIPTION>
<P>50 patients randomised. 5 patients withdrew. Authors give full reasons for withdrawals and exclusions, but do not state which arm patients were randomised to.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 09:37:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carter-1999">
<DESCRIPTION>
<P>102 patients randomised. 16 patients withdrew. 7/50 placebo, 9/52 sucralfate. Authors give reasons for attrition/exclusion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-09 21:28:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cascinu-1994">
<DESCRIPTION>
<P>84 patients randomised. No patients discontinued over first cycle (data used in meta-analysis).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-22 17:55:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Castagna-2001">
<DESCRIPTION>
<P>105 patients randomised. 3 patients withdrawn due to disease recurrence (2/53 Sucralfate, 1/52 placebo).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-22 17:59:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cengiz-1999">
<DESCRIPTION>
<P>Data presented for 28 patients (18 sucralfate, 10 placebo). All randomised patients included in analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 18:50:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cerchietti-2006">
<DESCRIPTION>
<P>29 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-20 22:13:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chi-1995">
<DESCRIPTION>
<P>20 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 09:43:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Choi-2007">
<DESCRIPTION>
<P>51 patients recruited. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-20 22:08:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chor-2010">
<DESCRIPTION>
<P>34 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 09:58:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Crawford-1999">
<DESCRIPTION>
<P>211 patients randomised. 12 patients excluded (6/110 placebo, 6/101 intervention). 199 patients received at least one cycle of chemotherapy and were included in the efficacy analysis. Authors provide reasons for exclusions in linked paper.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-11 08:51:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cruz-2007">
<DESCRIPTION>
<P>62 patients randomised. 2 patients excluded. Authors do not provide allocation information. 56 patients evaluated at 2<SUP>nd</SUP> assessment. 59 patients evaluated at assessment 3. Authors give no reasons for omissions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 10:04:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dai-2009">
<DESCRIPTION>
<P>42 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 13:30:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dazzi-2003">
<DESCRIPTION>
<P>90 patients randomised. ITT analysis used. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 20:53:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dickson-2000">
<DESCRIPTION>
<P>58 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 10:09:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dodd-1996">
<DESCRIPTION>
<P>227 patients randomised. 5 patients were ineligible. Final sample of 222 patients.89 patients (40%) did not finish 3 cycles of chemotherapy. ITT analysis conducted.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 10:11:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dorr-2007">
<DESCRIPTION>
<P>69 patients randomised. 8 patients withdrew/excluded (4/36 wobe mugos; 4/33 placebo).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-01 21:13:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dozono-1989">
<DESCRIPTION>
<P>15 patients randomised into cross-over study. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-22 13:24:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Duenas-1996">
<DESCRIPTION>
<P>15 patients randomised to receive 16 courses of chemotherapy. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-04 14:12:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El-Sayed-2002">
<DESCRIPTION>
<P>138 patients randomised. 1 patient (1/68 placebo) deemed ineligible. 4 patients removed from primary analysis due to missing data (1/69 BCoG, 3/68 placebo). 137 patients included in extent of severe mucositis analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 10:17:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Elad-2006">
<DESCRIPTION>
<P>45 patients randomised. 39 patients matched inclusion criteria for efficacy analysis. No information given about 6 withdrawals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-20 22:59:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Epstein-1989">
<DESCRIPTION>
<P>49 patients recruited. 43 included in analysis. 6 patients (all placebo) withdrawn due to non-compliance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 10:22:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Epstein-1994">
<DESCRIPTION>
<P>33 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 10:23:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Epstein-2001">
<DESCRIPTION>
<P>173 patients randomised. 172 patients treated. 165 patients (who had received at least 1 on-radiation evaluation) included in ITT analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-23 16:50:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ertekin-2004">
<DESCRIPTION>
<P>30 patients randomised. 3 patients withdrew (3/15 placebo). Authors give no information about which arm patients were randomised to. 27 patients included in analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-22 18:14:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Evensen-2001">
<DESCRIPTION>
<P>60 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 10:30:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferretti-1988">
<DESCRIPTION>
<P>56 patients randomised. 5 patients excluded. Authors give reasons for attrition/exclusion but variable numbers are evaluated at each time point and reasons for missing data are not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-17 10:44:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fidler-1996">
<DESCRIPTION>
<P>165 patients randomised. 1 patient removed due to a major protocol violation. 164 patients had evaluable physician judged mucositis scores. Patient judged mucositis scores evaluable in 135 patients.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-20 19:28:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Foote-1994">
<DESCRIPTION>
<P>52 patients randomised. No incomplete outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 10:39:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Franzen-1995">
<DESCRIPTION>
<P>50 patients randomised. 2 patients excluded from analysis. Authors give full reasons for attrition/exclusion. Numbers of patients reported in outcome assessments not reported information only given in percentages.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-10 11:40:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Freytes-2004">
<DESCRIPTION>
<P>42 patients recruited. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 10:45:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gandemer-2007">
<DESCRIPTION>
<P>145 patients randomised. Primary end point (WHO score) was evaluable in 140 patients. Excluded patients equally distributed (3/73 intervention, 2/72 control). Authors do not give reasons for withdrawals/exclusions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 10:48:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giles-2004">
<DESCRIPTION>
<P>502 patients randomised. 56% of Iseganan group and 66% of placebo group completed study. Authors give incomplete reasons for exclusion/attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 11:09:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gori-2007">
<DESCRIPTION>
<P>130 patients were randomised. 8 patients were excluded. Authors give complete reasons for exclusions/withdrawals but do not state which arm patients were randomised to.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 11:10:44 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Goyal-2009">
<DESCRIPTION>
<P>212 patients randomised. 35 patients excluded. Authors give incomplete reasons for drop outs/exclusions and no information about which arms these patients were allocated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 11:11:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gujral-2001">
<DESCRIPTION>
<P>100 patients randomised. Outcome data given for 99 patients. 53: intervention, 46: control. 2 patients died during study 2/53 intervention. Missing patient from control group. No information given. Observed event risk not sufficient to have clinically relevant impact on result.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 11:13:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Haddad-2009">
<DESCRIPTION>
<P>58 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-21 17:04:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hanson-1995">
<DESCRIPTION>
<P>69 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-04 10:45:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hartmann-2001">
<DESCRIPTION>
<P>40 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 11:18:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-He-2008">
<DESCRIPTION>
<P>48 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 11:20:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hu-2005">
<DESCRIPTION>
<P>140 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 20:59:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2000">
<DESCRIPTION>
<P>17 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 11:29:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2003">
<DESCRIPTION>
<P>101 patients randomised. No withdrawals/exclusions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 11:30:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ifrah-1999">
<DESCRIPTION>
<P>67 patients randomised. 3 patients withdrew (1 patient was ineligible, 2 patients withdrawn due to major dose errors). Authors give full reasons for attrition/exclusion but do not state which arms patients were randomised too.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 11:34:32 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jebb-1994">
<DESCRIPTION>
<P>28 patients randomised. Paired outcome data available for 17 patients who completed 2 courses of treatment. Authors give full reasons for attrition/exclusion. However, there is the potential for the overall estimate to be reversed if excluded patients included.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 12:13:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Katano-1995">
<DESCRIPTION>
<P>14 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 11:36:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kaul-1999">
<DESCRIPTION>
<P>50 patients randomised. 1 patient died during study. 69.4% of patients completed the study without a treatment gap. However, authors presented data for 25 patients (50%) at week 11 of the study. Authors do not give full reasons for attrition/exclusion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 11:38:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kazemian-2009">
<DESCRIPTION>
<P>100 patients randomised. 81 patients included in the analysis. 19 cases excluded. Exclusions equally distributed.17/19 stopped due to side effects. Authors provide full reasons for withdrawals/drop outs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 11:40:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koukourakis-2000">
<DESCRIPTION>
<P>140 patients randomised. Interruption of treatment in 10 patients. 10/70 amifostine. Mucositis data presented for 130 patients.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-22 14:44:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Labar-1993">
<DESCRIPTION>
<P>60 patients randomised. Authors give outcome data in percentages making it difficult to assess the possibility of incomplete outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-21 19:08:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leborgne-1997">
<DESCRIPTION>
<P>69 patients randomised. 3 patients were excluded due to major protocol violations. Authors give full reasons for exclusions but do not state which arms patients were randomised to.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 22:02:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-2006">
<DESCRIPTION>
<P>60 patients randomised. 1 patient (1/30 glutamine) excluded from analysis due to lack of toxicity data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 11:49:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lievens-1998">
<DESCRIPTION>
<P>102 patients randomised. 19 patients withdrew (12 sucralfate, 7 placebo).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-09 21:37:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lilleby-2006">
<DESCRIPTION>
<P>41 patients randomised. 1 patient withdrew: 1/20 saline group. Authors give reasons for attrition/ exclusion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 11:53:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2006">
<DESCRIPTION>
<P>100 patients randomised. 3 patients dropped out (1/50 intervention, 2/50 placebo group). Authors give reasons for withdrawals/drop outs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 11:54:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lockhart-2005">
<DESCRIPTION>
<P>36 patients randomised.No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-01 21:18:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loprinzi-1990">
<DESCRIPTION>
<P>77 patients recruited. Data from all patients included in analysis. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 11:56:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Madan-2008">
<DESCRIPTION>
<P>80 patients randomised. 4 patients dropped out (1/20 chlorhexidine group, 1/20 povidone, 2/20 salt and bicarbonate). Authors give reasons for withdrawals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 12:00:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mahood-1991">
<DESCRIPTION>
<P>95 patients randomised. 2 patients not included in final analysis due to lack of data. Authors do not state which arms missing were randomised. Patient judged mucositis scores collected from 85 patients. Authors do not state to which arms missing were randomised.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-23 14:38:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Makkonen-1994">
<DESCRIPTION>
<P>40 patients recruited. Authors give mucositis data for 40 patients after 3 weeks of treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 14:09:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Makkonen-2000">
<DESCRIPTION>
<P>40 patients recruited. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 14:25:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McAleese-2006">
<DESCRIPTION>
<P>29 patients recruited. 2 patients withdrew (2/15 intervention group). Authors give full reasons for exclusions and withdrawals. ITT analysis performed. Mucositis data given for 29 patients.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-21 22:38:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McGaw-1985">
<DESCRIPTION>
<P>16 patients randomised. No incomplete outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-10 14:02:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meropol-2003">
<DESCRIPTION>
<P>81 patients recruited. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-17 10:18:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mills-1988">
<DESCRIPTION>
<P>20 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-21 22:47:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Motallebnejad-2008">
<DESCRIPTION>
<P>40 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 12:15:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nemunaitis-1995">
<DESCRIPTION>
<P>109 patients recruited. 21 patients withdrew (13/53 intervention, 8/56 placebo). Authors provide full reasons for drop outs/withdrawals. All patients included in efficacy and toxicity analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-23 15:33:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nottage-2003">
<DESCRIPTION>
<P>81 patients randomised. 1 patient was excluded from the placebo group 1/40. Remaining randomised patients included in outcome assessment. 89 missing data days (14%) in sucralfate group and 63 (11%) in placebo. Method of assigning values for missing data to give conservative outcome estimate clearly described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-23 16:27:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oberbaum-2001">
<DESCRIPTION>
<P>32 patients randomised. 2 patients (1/15 placebo and 1/15 traumeel S), received a single dose of study drug and then refused further treatment. Patients not included in analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-07 21:04:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Okuno-1999">
<DESCRIPTION>
<P>134 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 12:26:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Panahi-2009">
<DESCRIPTION>
<P>33 patients recruited. 3 patients excluded due to inappropriate use of the mouthwash. Authors do not state which arm excluded patients were randomised to.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 12:31:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peterson-2009">
<DESCRIPTION>
<P>99 patients randomised. 1 patient (1/33 low dose rhITF) lost to follow-up on day 21. Patient included in overall incidence of OM incidence data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 12:32:18 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pfeiffer-1990">
<DESCRIPTION>
<P>40 patients randomised. Only 23 patients (58%) included in the outcome assessment.5 due to change to chemotherapy regimen, 2 died, 10 not evaluable due to 'swishing' (7 had increased nausea and 3 excluded due to poor compliance). Authors give no information about which arms excluded patients were allocated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-22 16:50:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pillsbury-1986">
<DESCRIPTION>
<P>20 patients recruited. 1 patient withdrew from control group. Authors give complete reasons for withdrawal. In addition, 1 patient in control group was excluded because they had not yet completed treatment. Mucositis data presented for 18 patients.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-26 21:53:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pitten-2003">
<DESCRIPTION>
<P>47 patients randomised. No incomplete outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 12:36:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prada-1987">
<DESCRIPTION>
<P>40 patients randomised. 4 patients withdrew (1/20 benzydamine, 3/20 control). Authors give no reasons for withdrawal.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-15 11:19:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Puataweepong-2009">
<DESCRIPTION>
<P>61 patients recruited. 1 patient (1/31 placebo group) discontinued but was included in mucositis data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 12:44:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Qin-2007">
<DESCRIPTION>
<P>43 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 12:45:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rahn-1997">
<DESCRIPTION>
<P>40 patients recruited. 37 patients completed the study. Authors give incomplete reasons for attrition/exclusion. Mucositis data presented for 40 patients.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 12:46:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rashad-2008">
<DESCRIPTION>
<P>40 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 12:47:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rocke-1993">
<DESCRIPTION>
<P>179 patients recruited. 1 patient withdrawn. 1/90 30-minute cryotherapy. Authors give reason for attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 12:49:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rosen-2006">
<DESCRIPTION>
<P>65 patients recruited. 64 patients received study drugs. No patients discontinued during 1<SUP>st</SUP> cycle (data used in meta-analysis). 10 patients withdrew during 2<SUP>nd</SUP> cycle of chemotherapy. 8/28 palifermin and 2/36 placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 14:52:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saarilahti-2002">
<DESCRIPTION>
<P>40 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 12:52:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Scarantino-2006">
<DESCRIPTION>
<P>249 patients randomised. 4 patients were later deemed ineligible. A further 3 patients withdrew (1/121 pilocarpine, 2/124 placebo). Authors give full reasons for exclusions/withdrawals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-23 16:19:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Scherlacher-1990">
<DESCRIPTION>
<P>45 patients recruited. Outcomes given in percentages.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 12:26:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schneider-1999">
<DESCRIPTION>
<P>14 patients randomised. 1 patient withdrew, however, results were included in analysis. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 12:55:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schubert-2007">
<DESCRIPTION>
<P>70 patients randomised. 2 patients died during study. 67% had scores for all time points and a similar number in each group had missing data. Self assessment of pain was only completed by 17/70 patients.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-23 16:15:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shenep-1988">
<DESCRIPTION>
<P>48 patients recruited. No missing outcome data. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-19 13:43:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shieh-1997">
<DESCRIPTION>
<P>30 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-23 17:20:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sorensen-2008">
<DESCRIPTION>
<P>150 patients randomised to double blind arms. 11 patients withdrew (2/75 chlorhexidine, 9/75 placebo). 139 patients included in final analysis.</P>
<P>75 patients randomised to cryotherapy arm. 8 patients did not return questionnaire on side effects and compliance and were removed from final analysis. 67 patients included in final analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 13:00:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sornsuvit-2008">
<DESCRIPTION>
<P>16 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-04 13:35:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spencer-2005">
<DESCRIPTION>
<P>90 patients randomised. 82 patients were evaluable at the end of the trial. Authors do not denote which group withdrawals were from. ITT analysis performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 13:44:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spielberger-2004">
<DESCRIPTION>
<P>214 patients randomised. 212 patients received at least 1 dose of palifermin. 7 patients did not complete the study: 2/106 palifermin, 4/106 placebo. Authors give no reasons for non-completion. Mucositis data given for 212 patients.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-24 14:58:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spijkervet-1989">
<DESCRIPTION>
<P>30 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 13:47:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stokman-2003">
<DESCRIPTION>
<P>65 patients randomised. 7 patients withdrew (5/33 PTA, 2/32 placebo). ITT analysis performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-01 21:52:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Su-2004">
<DESCRIPTION>
<P>58 patients recruited. All patients included in analysis. Mucositis data (table 2) presented in percentages.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 13:53:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Su-2006">
<DESCRIPTION>
<P>41 patients recruited. 1 patient (1/22 placebo) withdrew. Authors do not give reason for withdrawal.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-21 23:18:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Svanberg-2007">
<DESCRIPTION>
<P>78 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 13:59:23 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Symonds-1996">
<DESCRIPTION>
<P>275 patients randomised. 54 patients were unevaluable (24 pastilles, 30 placebo). Authors do not give full reasons for withdrawal/drop out.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 14:02:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trotti-2004">
<DESCRIPTION>
<P>545 patients randomised. 27 patients were potentially affected by randomisation error and were subsequently excluded from the efficacy analysis. 7 patients additionally excluded because they did not receive the study drug/baseline assessment. Authors do not state which arms patients were randomised to.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-21 23:22:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tu-1998">
<DESCRIPTION>
<P>159 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 14:05:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vacha-2003">
<DESCRIPTION>
<P>56 patients randomised. 6 patients excluded. Authors do not state which arm these patients were randomised to but do give full reasons for exclusion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 14:13:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vadhan_x002d_Raj-2010">
<DESCRIPTION>
<P>12/32 (38%) and 12/16 (75%) patients in the palifermin and placebo groups respectively discontinued treatment.Some reasons are given.The reported rates of disease progression, chemotoxicity &amp; surgery are similar in each group, but the rate of switching to open label treatment is much higher in placebo group and there is some mismatch between information in figures 1 &amp; 3.</P>
<P>Outcomes are reported as percentages only, and for the 'blinded cycles' 1 &amp; 2 the numbers evaluated in each group are unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 14:17:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Veerasarn-2006">
<DESCRIPTION>
<P>67 patients randomised. 5 patients (5/35 patients control group) excluded because they were missing baseline data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-19 10:26:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Veness-2006">
<DESCRIPTION>
<P>83 patients randomised. 10 patients withdrew (4/42 misoprostol, 6/41 placebo). Mucositis data presented for 83 patients.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-21 18:55:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vokurka-2005">
<DESCRIPTION>
<P>132 patients recruited. 5 patients excluded. Authors give reasons for attrition/ exclusion, but do not state which arms patients were allocated to.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-02 18:09:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wahlin-1989">
<DESCRIPTION>
<P>28 patients randomised. Data from 7 patients excluded. 3/14 chlorhexidine, 4/14 control group. Authors give reasons for withdrawals and exclusions. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-20 18:26:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2002">
<DESCRIPTION>
<P>147 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 14:30:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Watanabe-2010">
<DESCRIPTION>
<P>31 patients recruited. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-17 09:51:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wijers-2001">
<DESCRIPTION>
<P>114 patients randomised. 37 patients withdrew during the first 4 weeks of the trial (32.5%). Authors give incomplete randomisation and withdrawal information. 77 patients included in efficacy analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-10 14:35:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wu-2009">
<DESCRIPTION>
<P>70 patients randomised (1/28 control group, 3/29 10 g/mL arm, 3/29 50 g/mL arm, 5/27 100 g/mL arm). No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-20 18:35:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-You-2009">
<DESCRIPTION>
<P>22 patients were randomised. 2 patients withdrew from the placebo group. 20 patients included in analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-02 20:59:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yuen-2001">
<DESCRIPTION>
<P>70 patients randomised. No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 18:34:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Lelie-2001">
<DESCRIPTION>
<P>36 patients randomised. 8 patients withdrew. 4/18 GM-CSF, 4/18 placebo. Authors give full reasons for attrition/ exclusion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-11-10 14:36:00 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-01 21:32:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abbasi_x002d_Nazari-2007">
<DESCRIPTION>
<P>Data presented for 24 patients for grade of mucositis by grade of mucositis by week for each arm of the study (figures 1 and 2). However, it is unclear how many patients were initially recruited. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-22 13:13:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ahmed-1993">
<DESCRIPTION>
<P>Brief mucositis data presented in text (enough for use in mucositis absent versus present dichotomy).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:23:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-1998">
<DESCRIPTION>
<P>Data presented for total days of mucositis compared to patient age and days of mucositis &gt; grade 2 by chemotherapy regime.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-03 13:01:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Antonadou-2002">
<DESCRIPTION>
<P>Data presented for 45 patients by mucositis grade (table 4).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:58:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Antunes-2007">
<DESCRIPTION>
<P>Data presented for all patients by mucositis grade (fig 1).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-19 10:17:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arun-Maiya-2006">
<DESCRIPTION>
<P>Data presented for all patients by arm and grade of mucositis in text (page 401).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:33:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Attal-1993">
<DESCRIPTION>
<P>Data presented in the text for the number of patients with mucositis grade 2 or higher in each study arm.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:58:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bensadoun-1999">
<DESCRIPTION>
<P>Data presented for mean grade of mucositis by arm by week of treatment (table 3/ fig 3) and distribution of mucositis grades, in number of weeks, for both treatment weeks.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 14:16:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biswal-2003">
<DESCRIPTION>
<P>Data presented for number of patients with mucositis, number of patients with grade 3/4 mucositis, mean grade, mean onset and mean total duration (all table 2).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-14 21:50:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bjarnason-2009">
<DESCRIPTION>
<P>Data presented for number of patients with grade 3 or greater mucositis, median interval to mucositis and median grade of mucositis (all RTOG). Data collected using OMAS instrument also presented (table 3).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:51:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blazar-2006">
<DESCRIPTION>
<P>Data presented for all patients by mucositis grade. Palifermin doses combined (table 4).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:58:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Borowski-1994">
<DESCRIPTION>
<P>Data presented in the text for proportions of patients with moderate/severe mucositis according to treatment allocation. Percentage of patients with moderate or severe mucositis presented over time for both arms of the study (fig 2) and patients receiving TBI/no TBI (fig 1).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:56:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bourhis-2000">
<DESCRIPTION>
<P>Data presented WHO grades 2 to 4 and mean duration of &gt; grade 3 mucositis (days) (table 1).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-03 14:26:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brizel-2000">
<DESCRIPTION>
<P>Data presented for 301 patients by grade of mucositis. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:33:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brizel-2008">
<DESCRIPTION>
<P>Data only presented for mucositis scores &gt; 2 and &gt; 3 (fig 2).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-01 21:03:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bubley-1989">
<DESCRIPTION>
<P>Data presented for absent versus present dichtomy. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-04 10:34:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Buentzel-2006">
<DESCRIPTION>
<P>Data presented for 129 patients by mucositis grade (table 2).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-04 10:51:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Buntzel-1998">
<DESCRIPTION>
<P>Data presented for all patients by mucositis grade (see table 2).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-03 13:25:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cartee-1995">
<DESCRIPTION>
<P>Data presented for grade 3 mucositis by dose (table 1).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:37:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carter-1999">
<DESCRIPTION>
<P>Data presented for grade 3 mucositis (table 3), time to healing of mucositis (figure 3) and cumulative fraction of patients with &gt; grade 3 mucositis during treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 21:28:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cascinu-1994">
<DESCRIPTION>
<P>Data presented for all patients by mucositis grade for first cycle (see table 3).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-26 09:57:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Castagna-2001">
<DESCRIPTION>
<P>Data presented in percentages for grades 3 and 4 mucositis, but stated that 51 patients in each group were evaluated (text).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-22 17:59:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cengiz-1999">
<DESCRIPTION>
<P>Data presented for 28 patients by treatment allocation and grades of mucositis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-03 18:53:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cerchietti-2006">
<DESCRIPTION>
<P>Data presented for intensity of objective mucositis developed (mean 3 highest OMS), patients with severe objective mucositis, and patients with mucositis WHO grade 4 (table 2).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:42:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chi-1995">
<DESCRIPTION>
<P>Data provided in text for percentage reduction in incidence of severe mucositis, the mean duration of severe mucositis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-15 11:08:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Choi-2007">
<DESCRIPTION>
<P>Data presented for 51 patients by grade of mucositis and treatment arm.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-20 22:09:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chor-2010">
<DESCRIPTION>
<P>Data presented in the text for the number of patients experiencing mucositis in each arm. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-03 12:09:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Crawford-1999">
<DESCRIPTION>
<P>Data presented for incidence of mucositis in percentages (present versus absent) for both treatment arms and time to first episode of mucositis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:58:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cruz-2007">
<DESCRIPTION>
<P>Data presented for 59 patients in text and fig 1.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:04:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dai-2009">
<DESCRIPTION>
<P>Data presented for 42 patients by arm and grade of mucositis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:05:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dazzi-2003">
<DESCRIPTION>
<P>Data presented for incidence of stomatitis, incidence and duration of severe stomatitis, and patients judged maximum mucositis score (table 3).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:07:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dickson-2000">
<DESCRIPTION>
<P>Data presented for median mucositis duration (days), median mucositis grade and mucositis grades 2-4 (in percentages).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-20 18:42:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dodd-1996">
<DESCRIPTION>
<P>Data presented for 222 patients for mucositis incidence, time to onset of mucositis and severity of mucositis (table 3).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 21:01:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dorr-2007">
<DESCRIPTION>
<P>Data presented for frequency distribution of oral mucositis by grade (fig 1, percentages, not clear if all participants included), mean values of maximum scores (fig 2), and average mucositis score (fig 3).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:11:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dozono-1989">
<DESCRIPTION>
<P>Data presented for grade of stomatitis for control and treatment arms by treatment regimen.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-22 13:24:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Duenas-1996">
<DESCRIPTION>
<P>Data presented for severity of mucositis in a graph (figure 1).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-04 14:19:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El-Sayed-2002">
<DESCRIPTION>
<P>Data presented for severity of mucositis by grade of mucositis for all randomised patients (table 4).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-07 21:20:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Elad-2006">
<DESCRIPTION>
<P>Data presented for maximum intensity, average intensity, and duration of mucositis. Incidence of mucositis &gt; grade 2 (table 3).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:20:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Epstein-1989">
<DESCRIPTION>
<P>Data presented for maximum size of ulcerations, total area of ulcerations, average ulceration size and area of reaction x severity of inflammation/surfaces involved.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:22:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Epstein-1994">
<DESCRIPTION>
<P>Data presented for total mucositis score and total ulceration by arm.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:23:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Epstein-2001">
<DESCRIPTION>
<P>Data presented for mean AUCs by radiotherapy interval.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-23 16:49:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ertekin-2004">
<DESCRIPTION>
<P>Data presented in the text for grade of mucositis by treatment arm. Data also presented for start of mucositis (week), severity of mucositis, dose of radiotherapy at which mucositis developed (table 2), and mucositis levels 6 weeks after radiotherapy (table 3).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-22 18:13:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Evensen-2001">
<DESCRIPTION>
<P>Data presented for 60 patients by treatment allocation and grade of mucositis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:30:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferretti-1988">
<DESCRIPTION>
<P>Data presented for percentage of patients with mucositis and mean mucositis score in the form of graphs (figure 1 and figure 2). Different numbers of patients re-evaluated at each time point.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-17 10:45:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fidler-1996">
<DESCRIPTION>
<P>Data presented for maximum severity of mucositis by grade for physician and patients judged mucositis scores (table 2).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-20 19:30:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Foote-1994">
<DESCRIPTION>
<P>Data presented for 52 patients for maximum mucositis severity score by grade of mucositis and intervention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-22 18:18:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Franzen-1995">
<DESCRIPTION>
<P>Data presented in a graph for mucosal reaction over time (figure 1).Figures given in percentages. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-10 11:39:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Freytes-2004">
<DESCRIPTION>
<P>Data only presented in percentages for mucositis grades between 2 and 4 (figure 1).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-24 15:04:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gandemer-2007">
<DESCRIPTION>
<P>Data presented in percentages for 140 patients for mucositis grades 1 and 2 combined and mucositis grades 3 and 4 combined (fig 2A).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-23 17:17:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giles-2004">
<DESCRIPTION>
<P>Data presented for percentage without mucositis, peak mucositis grade, mean mucositis grade, and incidence (percentage) of ulcerative mucositis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 21:33:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gori-2007">
<DESCRIPTION>
<P>Data presented for 122 patients by mucositis grade and arm.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-22 17:03:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goyal-2009">
<DESCRIPTION>
<P>Data presented for grade of mucositis by arm and week of treatment (table 3). Data also presented for grades I and II and grades III and IV in percentages (table 2).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:11:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gujral-2001">
<DESCRIPTION>
<P>Data presented for 99 patients by mucositis grade (table 3). AUC data presented for 93 patients with complete data (table 4). Minimum and maximum, mean (SD) grades given for 99 patients (table 2). Data presented for time to mucositis grade 2 (table 5).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:13:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Haddad-2009">
<DESCRIPTION>
<P>Data presented in percentages for number of patients experiencing grade 3 and 4 mucositis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 17:05:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hanson-1995">
<DESCRIPTION>
<P>Data presented for mean mucositis score over time for both hospital sites.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:17:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hartmann-2001">
<DESCRIPTION>
<P>Data presented for median WHO grade and for percentage of patients with mucositis grades &gt; 3 and 4.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-15 22:46:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-He-2008">
<DESCRIPTION>
<P>Data presented for number of patients with grades 0-2 mucositis and grades 3-4 mucositis for both arms.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:20:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hu-2005">
<DESCRIPTION>
<P>Data presented for 140 patients by grade and treatment arm.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-03 21:00:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2000">
<DESCRIPTION>
<P>Maximum grade of mucositis by grade and treatment arm (table 2).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-20 11:46:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2003">
<DESCRIPTION>
<P>Data presented for 101 patients for mucositis incidence by grade and treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:31:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ifrah-1999">
<DESCRIPTION>
<P>Data presented for mucositis grade &gt; 3 (WHO score) (table 2) and duration of mucositis grade &gt; 2 (median values in days) (table 4) for patients receiving autologous transplantation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:34:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jebb-1994">
<DESCRIPTION>
<P>Data presented for maximum WHO mucositis grade for 17 patients (34 scores) (figure 1a and figure 1b).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-03 12:13:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Katano-1995">
<DESCRIPTION>
<P>Data presented for incidence and duration (days) of mucositis. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 21:21:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaul-1999">
<DESCRIPTION>
<P>Data presented for oral mucositis by grade for radiotherapy and radiotherapy plus wobe-mugos for 11 weeks of treatment. Data only presented for 50% of sample at week 11.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:39:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kazemian-2009">
<DESCRIPTION>
<P>Data presented for grade &gt; 3 mucositis (in text).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:40:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koukourakis-2000">
<DESCRIPTION>
<P>Data presented for 130 patients for grades 0/1, grade 2, and grade 3/4 (table 4).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-22 14:45:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Labar-1993">
<DESCRIPTION>
<P>Data presented in percentages in a piechart for grades I and II vs grades III and IV (figure 1) and severity of OM over time (figure 2).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-21 19:09:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leborgne-1997">
<DESCRIPTION>
<P>Mucositis data for all grades of severity obtained after writing to authors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:44:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2006">
<DESCRIPTION>
<P>Data presented in a graph for grade of stomatitis (grade 0, grade 1-2, grade 3-4) by arm in percentages.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 21:42:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lievens-1998">
<DESCRIPTION>
<P>Data presented for mean peak mucositis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 21:38:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lilleby-2006">
<DESCRIPTION>
<P>Data presented for all patients by arm and mucositis grade (table 3).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:53:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lin-2006">
<DESCRIPTION>
<P>Data presented for time to grade 2 and 3 mucositis in text. Mean scores for mucositis plotted over time by treatment arm in fig 3.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:54:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lockhart-2005">
<DESCRIPTION>
<P>Data presented for incidence and duration of oral mucositis, gingival mucositis and oropharyngeal mucositis (days) (Table 3);highest grade of mucositis by treatment arms, average mucositis score between days 4 and 8 by treatment arm and average mucositis score between days 6 and 8 (separated into oral, gingival and oropharyngeal) (fig 1).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-01 21:24:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loprinzi-1990">
<DESCRIPTION>
<P>Data presented for 77 patients for physician judged mucositis (table 2) and 71 patients for patient judged mucositis grade (table 3).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:57:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Madan-2008">
<DESCRIPTION>
<P>Data presented for mean mucositis scores by arm by week of treatment (fig 2 and table 2).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 21:45:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mahood-1991">
<DESCRIPTION>
<P>Physician judged mucositis scales presented for 93 patients (table 2). Patient judged mucositis scales presented for 82 patients (table 3).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:58:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Makkonen-1994">
<DESCRIPTION>
<P>Data presented for grade of mucositis at week 3 for all patients (text), and for percentage of patients with radiation mucositis in each group at each evaluation visit (fig 1).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:03:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Makkonen-2000">
<DESCRIPTION>
<P>Data presented in graphs showing percentages of patients with mucositis (fig 1) and mucosal pain (fig 2). Figures given in the text for percentage of patients with mucositis at weeks 1 and 3.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:03:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McAleese-2006">
<DESCRIPTION>
<P>Maximum mucositis grades given for 29 patients by arm in text. Data also presented for the proportion of patients with each grade by arm in graphs (fig 1 and fig 2).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 22:38:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McGaw-1985">
<DESCRIPTION>
<P>Data presented for mean mucositis score by week for both study arms.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-10 14:03:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meropol-2003">
<DESCRIPTION>
<P>Data only presented in graphical form for incidence of grade 2 to 4 mucositis (as percentage), duration of mucositis (days) and patient reports of mucositis. Full data not presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:08:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mills-1988">
<DESCRIPTION>
<P>Data presented by mucositis grade by weeks of treatment (table 2).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:10:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Motallebnejad-2008">
<DESCRIPTION>
<P>Data presented for mean rank of OMAS (table 1), end of week OMAS score (fig 1) and change in OMAS score (fig 2) for both arms of the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:15:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nemunaitis-1995">
<DESCRIPTION>
<P>Data given in the text for percentage of patients with &gt; grade 2 mucositis and grade 3/4 mucositis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-23 15:41:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nottage-2003">
<DESCRIPTION>
<P>81 patients randomised. 1 patient was excluded from the placebo group 1/40. Remaining randomised patients included in outcome assessment. 89 missing data days (14%) in sucralfate group and 63 (11%) in placebo. Method of assigning values for missing data to give conservative outcome estimate clearly described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-23 16:29:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oberbaum-2001">
<DESCRIPTION>
<P>Data presented for individual AUC scores (table 3), and mean AUC scores for each group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:24:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Okuno-1999">
<DESCRIPTION>
<P>Physician judged mucositis scales presented for 134 patients by grade(table 3). Patient judged scores presented for 124 patients (table 4).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-15 10:59:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Panahi-2009">
<DESCRIPTION>
<P>Data presented in the text (and in figure 1) for the distribution of mucositis grades by arm.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:31:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peterson-2009">
<DESCRIPTION>
<P>Data presented for all patients by grade and treatment arm (fig 2).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-23 16:09:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pfeiffer-1990">
<DESCRIPTION>
<P>Data presented for numbers of patients in each treatment arm experiencing erythema, edema, erosion and ulceration (table 2).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:33:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pillsbury-1986">
<DESCRIPTION>
<P>Data presented for mucositis grade at days 1-3 for 18 patients (table 1).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-26 21:53:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pitten-2003">
<DESCRIPTION>
<P>Data presented for 47 patients by mucositis grades 0-1 and 2-4 (table 4). </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:36:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prada-1987">
<DESCRIPTION>
<P>Data presented for onset of mucositis (probability analysis) (fig 1) and the number of patients with mucositis in each arm (text). </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:43:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Puataweepong-2009">
<DESCRIPTION>
<P>Data presented in percentages for mucositis incidence by grade and arm. Data also presented for the incidence of severe mucositis by arm.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:44:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Qin-2007">
<DESCRIPTION>
<P>Data presented for all patients by grade of mucositis and arm.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-21 18:46:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rahn-1997">
<DESCRIPTION>
<P>Data presented for grades of mucositis for 40 patients (figure 3).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:46:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rashad-2008">
<DESCRIPTION>
<P>Data presented for grade of mucositis by arm for 40 patients.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:47:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rocke-1993">
<DESCRIPTION>
<P>Physician judged mucositis scores presented for 178 patients (table 2). Patient judged scores presented for 163 patients (table 3).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-10 20:26:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rosen-2006">
<DESCRIPTION>
<P>Data presented in percentages for all patients by mucositis grade (figure 2a).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:50:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saarilahti-2002">
<DESCRIPTION>
<P>Data presented for mean mucositis score over time (fig 1) and mean mucosal pain scores (fig 2).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-21 18:40:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Scarantino-2006">
<DESCRIPTION>
<P>Data presented for 242 patients by grade of mucositis for grades 0, 1 and 2+.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-23 16:19:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Scherlacher-1990">
<DESCRIPTION>
<P>Data presented for number of patients with mucositis grades 3-5.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:53:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schneider-1999">
<DESCRIPTION>
<P>Data presented for mean worst Hickey mucositis score by week (fig 1) and mean worst WHO mucositis by week (fig 2) and the proportion of patients whose scores remained below 3 by week (fig 3 and fig 4).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:56:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schubert-2007">
<DESCRIPTION>
<P>Data presented for mean mucositis scores over time (fig 1) and mean mucositis scores by arm (table 2).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:56:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shenep-1988">
<DESCRIPTION>
<P>Data presented for observed mucositis and patient reports of mucositis at grades 0, 1 and &gt; 2 (table 3).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:57:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shieh-1997">
<DESCRIPTION>
<P>Data presented in the text for the percentage of patients with mucositis at week 2. Data also presented for onset time of stomatitis (figure 1), percentage incidence of stomatitis by treatment day (figure 2), mean OAG scores compared to days of treatment (figure 3), and increases in mean OAG score by treatment day (figure 4).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:59:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sorensen-2008">
<DESCRIPTION>
<P>Data presented for mucositis by grade and treatment arm.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 13:00:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sornsuvit-2008">
<DESCRIPTION>
<P>Data presented for mean severity grade, number of patients with mucositis &gt; 2 and number of patients with mucositis &gt; 3 (table 2).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-04 13:36:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spencer-2005">
<DESCRIPTION>
<P>Data presented for percentage of patients with grade 0, grades 1/2 and 3/4 mucositis (figure 1), median mucositis grade, median duration (table 5) and percentage of patients with no mucositis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-11 08:03:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spielberger-2004">
<DESCRIPTION>
<P>Data presented in percentages for 212 patients by mucositis grade (figure 2).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-24 14:58:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spijkervet-1989">
<DESCRIPTION>
<P>Data presented for number of patients with severe mucositis (pseudomembrane formation) in text. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 13:47:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stokman-2003">
<DESCRIPTION>
<P>Data presented for mean mucositis score by weeks of radiation in a graph (fig 1) and a table (table 2). Percentages of patients with grades 3 and 4 mucositis presented in the text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-01 21:55:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Su-2004">
<DESCRIPTION>
<P>Data presented for grade 2-3 mucositis in percentages (table 2) and maximum toxicity grade (table 3).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-03 12:43:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Su-2006">
<DESCRIPTION>
<P>Data presented for 40 patients by grade of mucositis and arm.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 23:18:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svanberg-2007">
<DESCRIPTION>
<P>Data presented in the text for mucositis scores on day 10 (autologous patients), day 16 (allogeneic patients), days of mucositis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 13:59:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Symonds-1996">
<DESCRIPTION>
<P>Data presented for erythema of mucosa for 220 patients (nil/slight/moderate/severe), mucositis distribution for 221 patients (none/patchy/confluent) and mucositis area (median/IQ range/range).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-10 11:22:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Trotti-2004">
<DESCRIPTION>
<P>Data presented for mucositis grades 0/1, 2 and 3/4 in percentages, mean peak severity of OM, and average OM.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:04:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tu-1998">
<DESCRIPTION>
<P>Data presented for mild and moderate to severe mucositis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 23:26:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vacha-2003">
<DESCRIPTION>
<P>Data presented for mean mucositis scores by week of treatment for both arms of the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:14:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vadhan_x002d_Raj-2010">
<DESCRIPTION>
<P>Reported outcomes of moderate/severe &amp; severe mucositis.However all reported outcomes are expressed as percentages together with a statement that "all patients were evaluable for toxicity and response to palifermin".</P>
<P>Planned outcomes also included duration of oral mucositis, patient reported outcomes, use of narcotic analgesics, weight loss &amp; dose reductions/delays in chemotherapy.These outcomes are not reported in the paper.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:17:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Veerasarn-2006">
<DESCRIPTION>
<P>Data presented in percentages for number of patients with mucositis (&gt; grade 2).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:19:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Veness-2006">
<DESCRIPTION>
<P>Data presented for incidence of mucositis by grade and arm (table 3) for 83 patients.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:20:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vokurka-2005">
<DESCRIPTION>
<P>Data presented in percentages for grades of mucositis for both arms of the study (fig 1), and for incidence of maximum mucositis severity (fig 2/3).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-02 18:25:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wahlin-1989">
<DESCRIPTION>
<P>Ulceration data presented for 17 patients (table 4).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-20 18:30:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2002">
<DESCRIPTION>
<P>Data presented for 147 patients by grade and arm. However, it is unclear over what time interval.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-14 21:43:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Watanabe-2010">
<DESCRIPTION>
<P>Data presented for 31 patients by treatment arm and grade of mucositis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:32:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wijers-2001">
<DESCRIPTION>
<P>Data presented for mucositis grade at week 4 (77 patients) by grade for both groups (table 2). Authors also present data for max mucositis grade and moment of max mucositis grade (table 2).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:36:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wu-2009">
<DESCRIPTION>
<P>Data presented in text for percentage of patients with oral mucositis &gt; RTOG grade 3. Data also presented for average grade of mucositis by week for patient treated with 50 mg/mL compared with placebo (fig 4).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-20 18:36:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-You-2009">
<DESCRIPTION>
<P>Data presented for 20 patients for mucositis incidence by arm and treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-02 20:34:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yuen-2001">
<DESCRIPTION>
<P>Data presented for grade 0-1 and grade 2 mucositis (table 2).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-03 18:35:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-der-Lelie-2001">
<DESCRIPTION>
<P>Data presented for average WHO score, OAS and pains scores by days for both intervention and placebo group. Number of patients with grade 3 and grade 4 mucositis presented in text. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-11-10 14:38:09 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:18:10 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Abbasi_x002d_Nazari-2007">
<DESCRIPTION>
<P>Significant gender imbalance between the arms of the study (P = 0.028).</P>
<P>Authors state that they used to WHO instrument. However, this is not the instrument presented in table 1.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-10 18:11:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ahmed-1993">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-10 18:11:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1998">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-10 18:12:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Antonadou-2002">
<DESCRIPTION>
<P>Study appears to be free from other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:28:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Antunes-2007">
<DESCRIPTION>
<P>Study appears to be free from other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-19 10:17:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Arun-Maiya-2006">
<DESCRIPTION>
<P>No information given on characteristics of patients in each group at baseline. Amount of analgesics used in each group not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:33:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Attal-1993">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-20 22:40:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bensadoun-1999">
<DESCRIPTION>
<P>Possible imbalance of groups at baseline laser group older (mean 62.7 vs 58.1). Also 12/15 of laser group vs. 6/15 of placebo group received laser treatment to skin of neck ("possible distant laser effect&#8221;). Different power of laser used at one study site (Relms).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-10 18:10:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biswal-2003">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:48:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bjarnason-2009">
<DESCRIPTION>
<P>Study appears to be free from other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-10 18:13:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blazar-2006">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-10 18:13:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borowski-1994">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 23:33:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bourhis-2000">
<DESCRIPTION>
<P>Study stopped early due to problems with the tolerance of amifostine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-09 16:59:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brizel-2000">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-10 11:36:03 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Brizel-2008">
<DESCRIPTION>
<P>Authors used NCI CTC tool to assess patients for first 12 weeks and then the RTOG late onset tool at weeks 14/16/18/20. This prevented direct comparisons between the groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:34:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bubley-1989">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-11 09:19:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Buentzel-2006">
<DESCRIPTION>
<P>Study appears to be free from other sources of bias. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 23:35:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Buntzel-1998">
<DESCRIPTION>
<P>Quote: &#8220;In view of these positive results, an additional 11 patients were subsequently accrued to the amifostine arm.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:36:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cartee-1995">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:37:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carter-1999">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-11 09:22:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cascinu-1994">
<DESCRIPTION>
<P>Study appears to be free from other sources of bias. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:39:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Castagna-2001">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-11 09:23:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cengiz-1999">
<DESCRIPTION>
<P>Study appears to be free from other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:40:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cerchietti-2006">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-20 22:28:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chi-1995">
<DESCRIPTION>
<P>Study appears to be free from other sources of bias. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-23 00:18:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Choi-2007">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:56:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chor-2010">
<DESCRIPTION>
<P>Study appears to be free of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 09:58:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Crawford-1999">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:03:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cruz-2007">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:04:19 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dai-2009">
<DESCRIPTION>
<P>Patients in the intervention group received a higher dose of radiation than those in the control group (P &lt; 0.05).</P>
<P>All Chinese medicine RCTs are now a cause for concern in light of the findings of Taixiang et al, 2007.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-11 09:26:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dazzi-2003">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 23:37:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dickson-2000">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 23:38:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dodd-1996">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 23:38:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dorr-2007">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-03 14:30:18 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dozono-1989">
<DESCRIPTION>
<P>Risk of bias assessed from translation. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-22 13:25:06 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Duenas-1996">
<DESCRIPTION>
<P>15 patients received 16 courses of radiotherapy. Data presented for 16 patients. </P>
<P>Study ended prematurely: interim analysis demonstrated a significant difference favouring placebo in the incidence and severity of mucositis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-04 14:19:30 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-El-Sayed-2002">
<DESCRIPTION>
<P>Variation in radiation protocols and standard care between sites.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 23:39:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elad-2006">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 23:39:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Epstein-1989">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-20 23:27:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Epstein-1994">
<DESCRIPTION>
<P>Study appears to be free from other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 17:00:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Epstein-2001">
<DESCRIPTION>
<P>Study appears to be free from other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 23:40:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ertekin-2004">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:27:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Evensen-2001">
<DESCRIPTION>
<P>Difference between groups at baseline regarding tumour stage (23% sucralfate group T3/4, 53% placebo group). No P value presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 23:40:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferretti-1988">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 23:41:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fidler-1996">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:38:37 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Foote-1994">
<DESCRIPTION>
<P>Quote: &#8220;Due to the significantly higher toxicity rates and the lack of evidence of efficacy associated with chlorhexidine, the double-blinded portion of the trial was permanently closed&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 23:42:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Franzen-1995">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 10:43:56 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Freytes-2004">
<DESCRIPTION>
<P>Authors highlight possible bias because of the multiplicity of conditioning regimens used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 23:43:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gandemer-2007">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 23:44:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giles-2004">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 23:44:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gori-2007">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 17:01:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goyal-2009">
<DESCRIPTION>
<P>Study appears to be free from other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 17:01:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gujral-2001">
<DESCRIPTION>
<P>Study appears to be free from other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-25 16:03:29 +0000" MODIFIED_BY="Helen Worthington" RESULT="NO" STUDY_ID="STD-Haddad-2009">
<DESCRIPTION>
<P>The study was stopped before the completion of planned accrual because IMRT was becoming the de facto standard technique in treating head and neck cancer.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:15:35 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hanson-1995">
<DESCRIPTION>
<P>Significant difference seen between the 2 investigative sites in this study (1 showed an effect , the other did not). Authors have no definitive explanation but there is a suggestion that there may have been differences in the compliance with study protocol and/or the time between administration of prostagladin and the start of RT.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 23:45:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hartmann-2001">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 23:45:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-He-2008">
<DESCRIPTION>
<P>ROB assessed from a translation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:20:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hu-2005">
<DESCRIPTION>
<P>Risk of bias assessed from translation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 23:46:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2000">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:29:35 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Huang-2003">
<DESCRIPTION>
<P>Risk of bias assessed from a translation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:32:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ifrah-1999">
<DESCRIPTION>
<P>Patients randomised to the rGM-CSF arm were older (median age 36 years versus 28 years, P = 0.04).</P>
<P>More patients randomised to the rGM-CSF arm had Philadelphia chromosome, P = 0.026.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 23:47:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jebb-1994">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 23:47:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Katano-1995">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 23:47:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaul-1999">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 23:48:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kazemian-2009">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 23:48:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Koukourakis-2000">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 23:49:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Labar-1993">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 11:42:09 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Leborgne-1997">
<DESCRIPTION>
<P>Baseline differences: significantly more patients in the treatment arm had stage 3 disease compared to placebo (P = 0.02).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 23:49:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-2006">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 21:42:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lievens-1998">
<DESCRIPTION>
<P>Study appears to be free from other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:25:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lilleby-2006">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 22:30:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2006">
<DESCRIPTION>
<P>Study appears to be free from other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:25:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lockhart-2005">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-01 21:25:56 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Loprinzi-1990">
<DESCRIPTION>
<P>Study aimed to recruit 120 patients but was terminated early after 77 patients were recruited after the power calculation was re-run and the results found to favour the intervention. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 22:34:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Madan-2008">
<DESCRIPTION>
<P>Study appears to be free from other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:28:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mahood-1991">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:02:00 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Makkonen-1994">
<DESCRIPTION>
<P>Significant differences between the group for sex (P = 0.05) and age (P = 0.04) of patients at randomisation. Both have been suggested as independent variables for mucositis severity.</P>
<P>3 patients had a buccal mucosa resection as part of their treatment. Authors provide no information about allocation of these patients.</P>
<P>Dentate patients (10 sucralfate &amp; 6 placebo) also received weekly fluoride treatments.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:28:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Makkonen-2000">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:29:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McAleese-2006">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 22:38:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McGaw-1985">
<DESCRIPTION>
<P>Study appears to be free from other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:30:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meropol-2003">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:30:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mills-1988">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 22:48:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Motallebnejad-2008">
<DESCRIPTION>
<P>Study appears to be free from other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:16:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nemunaitis-1995">
<DESCRIPTION>
<P>5 patients in placebo arm also received cytokines off study during the first 42 days post-transplant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-23 15:41:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nottage-2003">
<DESCRIPTION>
<P>Authors suggest underreporting of mucositis by study staff due to the retrospective method of assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:23:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oberbaum-2001">
<DESCRIPTION>
<P>No other sources of bias identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:24:46 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Okuno-1999">
<DESCRIPTION>
<P>Statistically significant age difference between placebo and intervention group (P = 0.01).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:31:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Panahi-2009">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:31:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peterson-2009">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-23 16:09:43 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pfeiffer-1990">
<DESCRIPTION>
<P>Mode of application changed after 18 patients (next 22 patients were asked to swish and expectorate the solution rather than swallowing).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:32:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pillsbury-1986">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-26 21:54:18 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pitten-2003">
<DESCRIPTION>
<P>Data from unplanned interim analysis. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-17 10:14:14 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Prada-1987">
<DESCRIPTION>
<P>Not all patients had an oral mucositis score of 0 when entering the study. Double blind study. However, placebo patients also received paracetamol for pain control. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:43:53 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Puataweepong-2009">
<DESCRIPTION>
<P>Significant baseline imbalances between the study arms: gender (P = 0.03), previous smoking (P = 0.056), previous surgery (P = 0.04).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 22:53:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Qin-2007">
<DESCRIPTION>
<P>ROB assessed from translation. </P>
<P>Baseline imbalance: control group experienced more taste dysfunction at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:32:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rahn-1997">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-07 21:33:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rashad-2008">
<DESCRIPTION>
<P>Insufficient information to determine 'yes' or 'no'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:33:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rocke-1993">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:33:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rosen-2006">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:33:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saarilahti-2002">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:52:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Scarantino-2006">
<DESCRIPTION>
<P>Baseline imbalance: more patients with a KPS of 90-100 were in the pilocarpine group (P+0.03). However, it is unclear how this would affect mucositis development.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:33:47 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Scherlacher-1990">
<DESCRIPTION>
<P>Risk of bias assessed from translation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-29 17:10:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schneider-1999">
<DESCRIPTION>
<P>Study was stopped after an interim analysis. Authors state that "owing to administrative obstacles completion of the trial is not possible". Authors do not meet either of their previously stated early stopping rules.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:56:24 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schubert-2007">
<DESCRIPTION>
<P>Patients in the 650 nm laser arm were significantly more likely to have received a conditioning regimen which included TBI.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:34:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shenep-1988">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 12:57:52 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shieh-1997">
<DESCRIPTION>
<P>Baseline OAG score was 1.5 point higher for the E1 group due to random allocation of 3 patients with history of betel nut chewing to this group. Authors state that conclusions regarding the mean onset of mucositis did not change after these patients were excluded from the analysis. However, mean OAG scores are not provided for comparison.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:34:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sorensen-2008">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:35:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sornsuvit-2008">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:35:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spencer-2005">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:35:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spielberger-2004">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:35:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spijkervet-1989">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:35:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stokman-2003">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:36:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Su-2004">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:36:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Su-2006">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 23:18:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Svanberg-2007">
<DESCRIPTION>
<P>Study appears to be free from other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:36:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Symonds-1996">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:36:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trotti-2004">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:04:18 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tu-1998">
<DESCRIPTION>
<P>ROB assessed from translation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-21 23:27:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vacha-2003">
<DESCRIPTION>
<P>Study appears to be free from other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:14:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vadhan_x002d_Raj-2010">
<DESCRIPTION>
<P>Use of granulocyte macrophage colony-stimulating factor is listed as not permitted, but patients received Pegfilgrastim which is a pegylated form of human granulocyte colony-stimulating factor.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:37:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Veerasarn-2006">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-22 18:31:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Veness-2006">
<DESCRIPTION>
<P>Study appears to be free from other sources of bias. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:20:41 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vokurka-2005">
<DESCRIPTION>
<P>Patients in the povidone group received significantly more cycles of chemotherapy in the year prior to ASCT than the normal saline group (P = 0.01).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-05 20:56:41 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wahlin-1989">
<DESCRIPTION>
<P>Blocked randomisation in an unblinded study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:22:23 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2002">
<DESCRIPTION>
<P>Risk of bias assessed from translation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:30:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Watanabe-2010">
<DESCRIPTION>
<P>Baseline imbalance: mean serum creatinine values lower in the control arm compared to the polaprezinc arm (P = 0.006).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:38:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wijers-2001">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:40:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wu-2009">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-10 14:38:09 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-You-2009">
<DESCRIPTION>
<P>All Chinese medicine RCTs are now a cause for concern in light of the findings of Taixiang et al 2007.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:40:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yuen-2001">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 00:37:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Lelie-2001">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-01-31 15:24:12 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-01-31 15:24:12 +0000" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2011-03-07 16:52:01 +0000" MODIFIED_BY="Grade Profiler">Cryotherapy versus no treatment for preventing oral mucositis for patients with cancer receiving treatment</TITLE>
<TABLE COLS="7" ROWS="4">
<TR>
<TD COLSPAN="7">
<P>
<B>Cryotherapy versus no treatment for preventing oral mucositis for patients with cancer receiving treatment</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> preventing oral mucositis for patients with cancer receiving treatment<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> Cryotherapy versus no treatment<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Cryotherapy versus no treatment</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Mucositis (any)</B>
<BR/>0-4 scale<BR/>Follow-up: median 28 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population<SUP>1</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.74 </B>
<BR/>(0.57 to 0.95)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>472<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>600 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>444 per 1000</B>
<BR/>(342 to 570)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population<SUP>1</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>950 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>703 per 1000</B>
<BR/>(541 to 902)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Mucositis (severe)</B>
<BR/>0-4 scale<BR/>Follow-up: median 28 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population<SUP>4</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.36 </B>
<BR/>(0.17 to 0.77)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>472<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>300 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>108 per 1000</B>
<BR/>(51 to 231)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population<SUP>4</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>650 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>234 per 1000</B>
<BR/>(111 to 501)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Based on the range of absolute risk of developing any mucositis of patients (with different cancer types and treatments) in the control groups of the included studies.<BR/>
<SUP>2</SUP> 3 studies at high risk of bias and 2 unclear<BR/>
<SUP>3</SUP> Substantial heterogeneity Chi squared = 14.77, df=4, P=0.005, I squared =73%, <BR/>
<SUP>4</SUP> Based on the range of absolute risk of developing severe mucositis of patients (with different cancer types and treatments) in the control groups of the included studies.<BR/>
<SUP>5</SUP> Substantial heterogeneity Chi squared=14.31, df=4, P=0.006, I squared =72%.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2011-03-07 16:52:14 +0000" MODIFIED_BY="Grade Profiler" NO="2" READONLY="YES">
<TITLE MODIFIED="2011-03-07 16:52:14 +0000" MODIFIED_BY="Grade Profiler">Amifostine versus placebo/no treatment for preventing oral mucositis for patients with cancer receiving treatment</TITLE>
<TABLE COLS="7" ROWS="4">
<TR>
<TD COLSPAN="7">
<P>
<B>Amifostine versus placebo/no treatment for preventing oral mucositis for patients with cancer receiving treatment</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> preventing oral mucositis for patients with cancer receiving treatment<BR/>
<B>Settings:</B> <BR/>
<B>Intervention:</B> Amifostine versus placebo/no treatment<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Amifostine versus placebo/no treatment</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Mucositis (any)</B>
<BR/>0-4 scale<BR/>Follow-up: median 28 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population<SUP>1</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.95 </B>
<BR/>(0.91 to 0.99)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>430<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>600 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>570 per 1000</B>
<BR/>(546 to 594)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population<SUP>1</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>950 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>902 per 1000</B>
<BR/>(865 to 941)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Mucositis (severe)</B>
<BR/>0-4 scale<BR/>Follow-up: median 28 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population<SUP>3</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.68 </B>
<BR/>(0.45 to 1.03)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>845<BR/>(9 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>4,5,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>300 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>204 per 1000</B>
<BR/>(135 to 309)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population<SUP>3</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>650 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>442 per 1000</B>
<BR/>(292 to 669)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Based on the range of absolute risk of developing any mucositis of patients (with different cancer types and treatments) in the control groups of the included studies.<BR/>
<SUP>2</SUP> Two trials at high risk of bias and one unclear.<BR/>
<SUP>3</SUP> Based on the range of absolute risk of developing severe mucositis of patients (with different cancer types and treatments) in the control groups of included studies.<BR/>
<SUP>4</SUP> Six trials at high risk of bias and three unclear.<BR/>
<SUP>5</SUP> Substantial heterogeneity, Chi squared 40.39, df=8, P&lt;0..0001, I squared =80% with inconsistency (one trial favouring control)<BR/>
<SUP>6</SUP> Wide confidence intervals, small studies and/or low event rates</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2011-03-07 16:52:59 +0000" MODIFIED_BY="Grade Profiler" NO="3" READONLY="YES">
<TITLE MODIFIED="2011-03-07 16:52:59 +0000" MODIFIED_BY="Grade Profiler">Keratinocyte GF versus placebo for preventing oral mucositis for patients with cancer receiving treatment</TITLE>
<TABLE COLS="7" ROWS="4">
<TR>
<TD COLSPAN="7">
<P>
<B>Keratinocyte GF versus placebo for preventing oral mucositis for patients with cancer receiving treatment</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with preventing oral mucositis for patients with cancer receiving treatment<BR/>
<B>Settings:</B> <BR/>
<B>Intervention:</B> Keratinocyte GF versus placebo<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Keratinocyte GF versus placebo</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Mucositis (any)</B>
<BR/>0-4 scale<BR/>Follow-up: median 28 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population<SUP>1</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.82 </B>
<BR/>(0.71 to 0.94)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>160<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>600 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>492 per 1000</B>
<BR/>(426 to 564)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population<SUP>1</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>950 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>779 per 1000</B>
<BR/>(674 to 893)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Mucositis (severe)</B>
<BR/>0-4 scale<BR/>Follow-up: median 28 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population<SUP>4</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.72 </B>
<BR/>(0.58 to 0.9)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>559<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>5,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>300 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>216 per 1000</B>
<BR/>(174 to 270)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population<SUP>4</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>650 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>468 per 1000</B>
<BR/>(377 to 585)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Based on the range of absolute risk of developing any mucositis of patients (with different cancer types and treatments) in the control groups of the included studies.<BR/>
<SUP>2</SUP> Two studies at unclear risk of bias<BR/>
<SUP>3</SUP> Substantial heterogeneity Chi squared =10.11 df=1, P=0.001, I squared =90%.<BR/>
<SUP>4</SUP> Based on the range of absolute risk of developing severe mucositis of patients (with different cancer types and treatments) in the control groups of the included studies.<BR/>
<SUP>5</SUP> One study at high risk of bias and five at unclear risk of bias.<BR/>
<SUP>6</SUP> Moderate heterogeneity Chi squared 10.37, df=5,P=0.07, I squared =52%</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2011-03-07 14:30:07 +0000" MODIFIED_BY="Grade Profiler" NO="4" READONLY="YES">
<TITLE MODIFIED="2011-03-07 14:30:07 +0000" MODIFIED_BY="Grade Profiler">Sucralfate versus placebo/usual care for preventing oral mucositis for patients with cancer receiving treatment</TITLE>
<TABLE COLS="7" ROWS="4">
<TR>
<TD COLSPAN="7">
<P>
<B>Sucralfate versus placebo/usual care for preventing oral mucositis for patients with cancer receiving treatment</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> preventing oral mucositis for patients with cancer receiving treatment<BR/>
<B>Settings:</B> <BR/>
<B>Intervention:</B> Sucralfate versus placebo/usual care<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Sucralfate versus placebo/usual care</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Mucositis (any)</B>
<BR/>0-4 scale<BR/>Follow-up: median 28 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population<SUP>1</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.98 </B>
<BR/>(0.88 to 1.1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>222<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>600 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>588 per 1000</B>
<BR/>(528 to 660)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population<SUP>1</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>950 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>931 per 1000</B>
<BR/>(836 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Mucositis (severe)</B>
<BR/>0-4 scale<BR/>Follow-up: median 28 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population<SUP>3</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.67 </B>
<BR/>(0.48 to 0.92)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>428<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>300 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>201 per 1000</B>
<BR/>(144 to 276)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population<SUP>3</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>650 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>435 per 1000</B>
<BR/>(312 to 598)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Based on the range of absolute risk of developing any mucositis of patients (with different cancer types and treatments) in the control groups of the included studies.<BR/>
<SUP>2</SUP> All studies at unclear risk of bias<BR/>
<SUP>3</SUP> Based on the range of absolute risk of developing severe mucositis of patients (with different cancer types and treatments) in the control groups of the included studies.<BR/>
<SUP>4</SUP> One study at low risk of bias and six at unclear risk of bias</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-05" MODIFIED="2011-03-07 16:53:34 +0000" MODIFIED_BY="Grade Profiler" NO="5" READONLY="YES">
<TITLE MODIFIED="2011-03-07 16:53:34 +0000" MODIFIED_BY="Grade Profiler">Chlorhexidine versus placebo/no treatment for preventing oral mucositis for patients with cancer receiving treatment</TITLE>
<TABLE COLS="7" ROWS="4">
<TR>
<TD COLSPAN="7">
<P>
<B>Chlorhexidine versus placebo/no treatment for preventing oral mucositis for patients with cancer receiving treatment</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> preventing oral mucositis for patients with cancer receiving treatment<BR/>
<B>Settings:</B> <BR/>
<B>Intervention:</B> Chlorhexidine versus placebo/no treatment<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Chlorhexidine versus placebo/no treatment</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Mucositis (any)</B>
<BR/>0-4 scale<BR/>Follow-up: median 28 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population<SUP>1</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.76 </B>
<BR/>(0.47 to 1.24)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>454<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>600 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>456 per 1000</B>
<BR/>(282 to 744)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population<SUP>1</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>950 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>722 per 1000</B>
<BR/>(446 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Mucositis (severe)</B>
<BR/>0-4 scale<BR/>Follow-up: median 28 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population<SUP>4</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.82 </B>
<BR/>(0.54 to 1.23)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>244<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>5,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>300 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>246 per 1000</B>
<BR/>(162 to 369)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High risk population<SUP>4</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>650 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>533 per 1000</B>
<BR/>(351 to 800)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Based on the range of absolute risk of developing any mucositis of patients (with different cancer types and treatments) in the control groups of the included studies.<BR/>
<SUP>2</SUP> One study at low risk of bias and three unclear.<BR/>
<SUP>3</SUP> Substantial heterogeneity Chi squared 30.49, df=3, P&lt;0.0001, I squared = 90%.<BR/>
<SUP>4</SUP> Based on the range of absolute risk of developing severe mucositis of patients (with different cancer types and treatments) in the control groups of the included studies.<BR/>
<SUP>5</SUP> One high risk of bias, two unclear and one low<BR/>
<SUP>6</SUP> Moderate heterogeneity Chi squared 7.44,df=3, P=0.06, I squared = 60%, with some inconsistency (only one study, at unclear risk of bias, showing benefit)</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2011-02-24 14:02:44 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2011-02-24 13:56:50 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-11-04 14:28:47 +0000" MODIFIED_BY="[Empty name]">Outcome categories where only one study provided data - active versus placebo/no treatment</TITLE>
<TABLE COLS="8" ROWS="52">
<TR>
<TD ROWSPAN="2">
<P></P>
</TD>
<TD>
<P></P>
</TD>
<TD COLSPAN="2">
<P>
<B>Experimental</B>
</P>
</TD>
<TD COLSPAN="2">
<P>
<B>Control</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>RR (95%CI)</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>P value</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Mucositis category</B>
</P>
</TD>
<TD>
<P>
<B>Events/ Mean (SD) </B>
</P>
</TD>
<TD>
<P>
<B>Total</B>
</P>
</TD>
<TD>
<P>
<B>Events/ Mean (SD) </B>
</P>
</TD>
<TD>
<P>
<B>Total</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Aciclovir versus placebo</P>
<P>
<LINK REF="STD-Bubley-1989" TYPE="STUDY">Bubley 1989</LINK>
</P>
</TD>
<TD>
<P>Any</P>
<P></P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>1.33 (0.85, 2.08)</P>
</TD>
<TD>
<P>0.21</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Aloe vera versus placebo</P>
<P></P>
</TD>
<TD>
<P>Any</P>
<P>
<LINK REF="STD-Puataweepong-2009" TYPE="STUDY">Puataweepong 2009</LINK>
</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>0.97 (0.88, 1.06)</P>
</TD>
<TD>
<P>0.46</P>
</TD>
</TR>
<TR>
<TD>
<P>Severe</P>
<P>
<LINK REF="STD-Su-2004" TYPE="STUDY">Su 2004</LINK>
</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>0.13 (0.02, 0.97)</P>
</TD>
<TD>
<P>0.05</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>BCoG antibiotic pastilles <LINK REF="STD-El-Sayed-2002" TYPE="STUDY">El Sayed 2002</LINK>
</P>
</TD>
<TD>
<P>Any</P>
</TD>
<TD>
<P>62</P>
</TD>
<TD>
<P>69</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>68</P>
</TD>
<TD>
<P>1.02 (0.91, 1.15)</P>
</TD>
<TD>
<P>0.76</P>
</TD>
</TR>
<TR>
<TD>
<P>Moderate plus severe</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>69</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>68</P>
</TD>
<TD>
<P>0.93 (0.77, 1.13)</P>
</TD>
<TD>
<P>0.46</P>
</TD>
</TR>
<TR>
<TD>
<P>Severe</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>69</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>68</P>
</TD>
<TD>
<P>0.90 (0.63, 1.28)</P>
</TD>
<TD>
<P>0.55</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Benzydamine versus placebo</P>
</TD>
<TD>
<P>Any</P>
<P><LINK REF="STD-Prada-1987" TYPE="STUDY">Prada 1987</LINK>
</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>0.67 (0.47, 0.97)</P>
</TD>
<TD>
<P>0.03</P>
</TD>
</TR>
<TR>
<TD>
<P>Severe</P>
<P>
<LINK REF="STD-Kazemian-2009" TYPE="STUDY">Kazemian 2009</LINK>
</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>42</P>
</TD>
<TD>
<P>0.55 (0.38, 0.82)</P>
</TD>
<TD>
<P>0.003</P>
</TD>
</TR>
<TR>
<TD>
<P>Beta carotene versus no treatment control</P>
<P/>
</TD>
<TD>
<P>Severe</P>
<P><LINK REF="STD-Mills-1988" TYPE="STUDY">Mills 1988</LINK>
</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>0.38 (0.14, 1.02)</P>
</TD>
<TD>
<P>0.05</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>Camomile versus placebo</P>
<P>
<LINK REF="STD-Fidler-1996" TYPE="STUDY">Fidler 1996</LINK>
</P>
</TD>
<TD>
<P>Any</P>
<P></P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>82</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>82</P>
</TD>
<TD>
<P>0.89 (0.62, 1.27)</P>
</TD>
<TD>
<P>0.53</P>
</TD>
</TR>
<TR>
<TD>
<P>Moderate plus severe</P>
<P></P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>82</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>82</P>
</TD>
<TD>
<P>0.63 (0.33, 1.22)</P>
</TD>
<TD>
<P>0.17</P>
</TD>
</TR>
<TR>
<TD>
<P>Severe</P>
<P></P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>82</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>82</P>
</TD>
<TD>
<P>1.14 (0.43, 3.01)</P>
</TD>
<TD>
<P>0.79</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Chewing gum versus no chewing gum</P>
<P>
<LINK REF="STD-Gandemer-2007" TYPE="STUDY">Gandemer 2007</LINK>
</P>
</TD>
<TD>
<P>Any</P>
<P></P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>0.87 (0.71, 1.07)</P>
</TD>
<TD>
<P>0.18</P>
</TD>
</TR>
<TR>
<TD>
<P>Severe</P>
<P></P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>1.16 (0.82, 1.64)</P>
</TD>
<TD>
<P>0.40</P>
</TD>
</TR>
<TR>
<TD>
<P>Clarithromycin (systemic antibiotic) versus no treatment</P>
<P>
<LINK REF="STD-Yuen-2001" TYPE="STUDY">Yuen 2001</LINK>
</P>
<P></P>
</TD>
<TD>
<P>Moderate plus severe</P>
<P></P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>0.69 (0.48, 1.01)</P>
</TD>
<TD>
<P>0.06</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Dental stent versus no treatment control <LINK REF="STD-Qin-2007" TYPE="STUDY">Qin 2007</LINK>
</P>
</TD>
<TD>
<P>Moderate plus severe</P>
<P></P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>0.84 (0.62, 1.15)</P>
</TD>
<TD>
<P>0.27</P>
</TD>
</TR>
<TR>
<TD>
<P>Severe</P>
<P></P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>0.70 (0.28, 1.75)</P>
</TD>
<TD>
<P>0.45</P>
</TD>
</TR>
<TR>
<TD>
<P>Epidermal growth factor versus placebo <LINK REF="STD-Wu-2009" TYPE="STUDY">Wu 2009</LINK>
</P>
<P></P>
</TD>
<TD>
<P>Moderate plus severe</P>
<P></P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>76</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>0.67 (0.45, 0.99)</P>
</TD>
<TD>
<P>0.04</P>
</TD>
</TR>
<TR>
<TD>
<P>G-CSF versus placebo <LINK REF="STD-Su-2006" TYPE="STUDY">Su 2006</LINK>
</P>
<P></P>
</TD>
<TD>
<P>Moderate plus severe</P>
<P></P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>0.81 (0.51, 1.30)</P>
</TD>
<TD>
<P>0.38</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Histamine gel versus placebo <LINK REF="STD-Elad-2006" TYPE="STUDY">Elad 2006</LINK>
</P>
<P></P>
</TD>
<TD>
<P>Any</P>
<P></P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>1.35 (0.91, 1.99)</P>
</TD>
<TD>
<P>0.14</P>
</TD>
</TR>
<TR>
<TD>
<P>Severe</P>
<P></P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>0.95 (0.15, 6.08)</P>
</TD>
<TD>
<P>0.96</P>
</TD>
</TR>
<TR>
<TD>
<P>Hydrolytic enzymes (papain, trypsin, chymotrypsin, pancreatin, bromelain) versus no treatment <LINK REF="STD-Kaul-1999" TYPE="STUDY">Kaul 1999</LINK>
</P>
</TD>
<TD>
<P>Severe</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>0.20 (0.01, 3.97)</P>
</TD>
<TD>
<P>0.29</P>
</TD>
</TR>
<TR>
<TD>
<P>Indomethacin versus placebo <LINK REF="STD-Pillsbury-1986" TYPE="STUDY">Pillsbury 1986</LINK>
</P>
<P></P>
</TD>
<TD>
<P>Moderate plus severe</P>
<P></P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>1.00 (0.82, 1.23)</P>
</TD>
<TD>
<P>1.00</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Indigo wood root versus saline (placebo) <LINK REF="STD-You-2009" TYPE="STUDY">You 2009</LINK>
</P>
</TD>
<TD>
<P>Moderate to severe</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>0.75 (0.50, 1.10)</P>
</TD>
<TD>
<P>0.14</P>
</TD>
</TR>
<TR>
<TD>
<P>Severe</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>0.14 (0.02, 0.93)</P>
</TD>
<TD>
<P>0.04</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>Intestinal trefoil factor versus placebo <LINK REF="STD-Peterson-2009" TYPE="STUDY">Peterson 2009</LINK>
</P>
<P></P>
</TD>
<TD>
<P>Any</P>
<P></P>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>0.52 (0.35, 0.79)</P>
</TD>
<TD>
<P>0.002</P>
</TD>
</TR>
<TR>
<TD>
<P>Moderate plus severe</P>
<P></P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>0.22 (0.10, 0.48)</P>
</TD>
<TD>
<P>0.0001</P>
</TD>
</TR>
<TR>
<TD>
<P>Severe</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>1.52 (0.06, 36.39)</P>
</TD>
<TD>
<P>0.80</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>Oral care protocol versus none</P>
<P></P>
</TD>
<TD>
<P>Any</P>
<P>
<LINK REF="STD-Shieh-1997" TYPE="STUDY">Shieh 1997</LINK>
</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>0.62 (0.43, 0.91)</P>
</TD>
<TD>
<P>0.01</P>
</TD>
</TR>
<TR>
<TD>
<P>Moderate plus severe <LINK REF="STD-Borowski-1994" TYPE="STUDY">Borowski 1994</LINK>
</P>
<P></P>
</TD>
<TD>
<P>64</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>0.91 (0.82, 1.02)</P>
</TD>
<TD>
<P>0.12</P>
</TD>
</TR>
<TR>
<TD>
<P>Severe</P>
<P>
<LINK REF="STD-Borowski-1994" TYPE="STUDY">Borowski 1994</LINK>
</P>
</TD>
<TD>
<P>49</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>58</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>0.84 (0.69, 1.04)</P>
</TD>
<TD>
<P>0.11</P>
</TD>
</TR>
<TR>
<TD>
<P>Pentoxifylline versus no treatment <LINK REF="STD-Attal-1993" TYPE="STUDY">Attal 1993</LINK>
</P>
<P></P>
</TD>
<TD>
<P>Moderate plus severe</P>
<P></P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>1.00 (0.68, 1.47)</P>
</TD>
<TD>
<P>1.00</P>
</TD>
</TR>
<TR>
<TD>
<P>Pilocarpine versus placebo <LINK REF="STD-Lockhart-2005" TYPE="STUDY">Lockhart 2005</LINK>
</P>
<P/>
<P></P>
<P></P>
</TD>
<TD>
<P>Severe</P>
<P/>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>0.89 (0.58, 1.37)</P>
</TD>
<TD>
<P>0.59</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>Prednisone versus placebo <LINK REF="STD-Leborgne-1997" TYPE="STUDY">Leborgne 1997</LINK>
</P>
<P></P>
</TD>
<TD>
<P>Any</P>
<P></P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>1.03 (0.85, 1.24)</P>
</TD>
<TD>
<P>0.79</P>
</TD>
</TR>
<TR>
<TD>
<P>Moderate plus severe</P>
<P></P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>0.71 (0.47, 1.07)</P>
</TD>
<TD>
<P>0.10</P>
</TD>
</TR>
<TR>
<TD>
<P>Severe</P>
<P></P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>0.64 (0.17, 2.45)</P>
</TD>
<TD>
<P>0.51</P>
</TD>
</TR>
<TR>
<TD>
<P>Prostaglandin versus placebo (<LINK REF="STD-Veness-2006" TYPE="STUDY">Veness 2006</LINK>)</P>
</TD>
<TD>
<P>Moderate plus severe</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>42</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>41</P>
</TD>
<TD>
<P>0.95 (0.81, 1.11)</P>
</TD>
<TD>
<P>0.53</P>
</TD>
</TR>
<TR>
<TD>
<P>Propantheline versus placebo <LINK REF="STD-Ahmed-1993" TYPE="STUDY">Ahmed 1993</LINK>
</P>
<P></P>
</TD>
<TD>
<P>Any</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>0.40 (0.12, 1.31)</P>
</TD>
<TD>
<P>0.13</P>
</TD>
</TR>
<TR>
<TD>
<P>PTA antibiotic paste (<LINK REF="STD-Wijers-2001" TYPE="STUDY">Wijers 2001</LINK>)</P>
</TD>
<TD>
<P>Moderate plus severe</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>0.90 (0.68, 1.21)</P>
</TD>
<TD>
<P>0.5</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>Shenqi-fanghou versus no treatment <LINK REF="STD-Hu-2005" TYPE="STUDY">Hu 2005</LINK>
</P>
</TD>
<TD>
<P>Any</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>67</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>0.90 (0.80, 1.00)</P>
</TD>
<TD>
<P>0.04</P>
</TD>
</TR>
<TR>
<TD>
<P>Moderate plus severe</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>59</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>0.51 (0.38, 0.68)</P>
</TD>
<TD>
<P>0.00001</P>
</TD>
</TR>
<TR>
<TD>
<P>Severe</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>0.20 (0.11, 0.36)</P>
</TD>
<TD>
<P>0.00001</P>
</TD>
</TR>
<TR>
<TD>
<P>Superoxide dismutase versus placebo <LINK REF="STD-Tu-1998" TYPE="STUDY">Tu 1998</LINK>
</P>
</TD>
<TD>
<P>Any</P>
</TD>
<TD>
<P>59</P>
</TD>
<TD>
<P>119</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>1.17 (0.78, 1.75)</P>
</TD>
<TD>
<P>0.45</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>Sucralfate mouthwash plus gel on skin versus placebo mouthwash plus gel on skin (<LINK REF="STD-Evensen-2001" TYPE="STUDY">Evensen 2001</LINK>)</P>
</TD>
<TD>
<P>Any</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>1.07 (0.96, 1.20)</P>
</TD>
<TD>
<P>0.24</P>
</TD>
</TR>
<TR>
<TD>
<P>Moderate plus severe</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>1.21 (1.00, 1.46)</P>
</TD>
<TD>
<P>0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>Severe</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>1.13 (0.89, 1.44)</P>
</TD>
<TD>
<P>0.32</P>
</TD>
</TR>
<TR>
<TD>
<P>Traumeel versus placebo <LINK REF="STD-Oberbaum-2001" TYPE="STUDY">Oberbaum 2001</LINK>
</P>
<P></P>
</TD>
<TD>
<P>Any</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>0.71 (0.49, 1.05)</P>
</TD>
<TD>
<P>0.08</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>Zinc sulphate versus placebo <LINK REF="STD-Ertekin-2004" TYPE="STUDY">Ertekin 2004</LINK>
</P>
</TD>
<TD>
<P>Any</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>0.88 (0.69, 1.11)</P>
</TD>
<TD>
<P>0.28</P>
</TD>
</TR>
<TR>
<TD>
<P>Moderate plus severe</P>
<P></P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>0.36 (0.18, 0.71)</P>
</TD>
<TD>
<P>0.003</P>
</TD>
</TR>
<TR>
<TD>
<P>Severe</P>
<P></P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>0.05 (0.00, 0.75)</P>
</TD>
<TD>
<P>0.03</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>CI = confidence interval; RR = risk ratio; SD = standard deviation.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2011-02-24 14:02:44 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-11-09 11:54:28 +0000" MODIFIED_BY="[Empty name]">Outcome categories where only one study provided data - two active interventions</TITLE>
<TABLE COLS="8" ROWS="25">
<TR>
<TD>
<P/>
</TD>
<TD>
<P></P>
</TD>
<TD COLSPAN="2">
<P>
<B>Experimental</B>
</P>
</TD>
<TD COLSPAN="2">
<P>
<B>RR (95%CI)</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>RR (95%CI)</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>
<B>P value</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>
<B>Mucositis category</B>
</P>
</TD>
<TD>
<P>
<B>Events/ Mean (SD) </B>
</P>
</TD>
<TD>
<P>
<B>Total</B>
</P>
</TD>
<TD>
<P>
<B>Events/ Mean (SD) </B>
</P>
</TD>
<TD>
<P>
<B>Total</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Chinese herbs (coastal glenhnia, dwarf lilyturf tuber root, rehmannia dried root, figwort root, spreading hedyotis herb, belamcaude rhizome, platycodom root, shinyleaf pricklyoash root, honeysuckle flower, licorice root, lalang grass rhizome) versus Dobell's solution <LINK REF="STD-Huang-2003" TYPE="STUDY">Huang 2003</LINK>
</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>49</P>
</TD>
<TD>
<P>0.46 (0.34, 0.63)</P>
</TD>
<TD>
<P>0.00001</P>
</TD>
</TR>
<TR>
<TD>
<P>Severe</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>49</P>
</TD>
<TD>
<P>0.16 (0.07, 0.37)</P>
</TD>
<TD>
<P>0.0001</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>Chinese herbs (corktree bark, Chinese gall, European vebena herb, catechu, weeping forsythia fruit and burneol) versus Dobell's solution <LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK>
</P>
</TD>
<TD>
<P>Any</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>76</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>71</P>
</TD>
<TD>
<P>0.44 (0.20, 0.95)</P>
</TD>
<TD>
<P>0.04</P>
</TD>
</TR>
<TR>
<TD>
<P>Moderate plus severe</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>76</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>71</P>
</TD>
<TD>
<P>0.27 (0.09, 0.77)</P>
</TD>
<TD>
<P>0.01</P>
</TD>
</TR>
<TR>
<TD>
<P>Severe</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>76</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>71</P>
</TD>
<TD>
<P>0.09 (0.00, 1.51)</P>
</TD>
<TD>
<P>0.09</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>Chlorhexidine versus cryotherapy <LINK REF="STD-Sorensen-2008" TYPE="STUDY">Sorensen 2008</LINK>
</P>
<P></P>
</TD>
<TD>
<P>Any</P>
<P></P>
</TD>
<TD>
<P>39</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>63</P>
</TD>
<TD>
<P>1.03 (0.76, 1.41)</P>
</TD>
<TD>
<P>0.84</P>
</TD>
</TR>
<TR>
<TD>
<P>Moderate plus severe</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>63</P>
</TD>
<TD>
<P>1.13 (0.64, 1.97)</P>
</TD>
<TD>
<P>0.68</P>
</TD>
</TR>
<TR>
<TD>
<P>Severe</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>63</P>
</TD>
<TD>
<P>1.16 (0.46, 2.92)</P>
</TD>
<TD>
<P>0.76</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>Cryotherapy 30 versus 60 minutes <LINK REF="STD-Rocke-1993" TYPE="STUDY">Rocke 1993</LINK>
</P>
<P></P>
</TD>
<TD>
<P>Any</P>
<P></P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>89</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>89</P>
</TD>
<TD>
<P>0.89 (0.62, 1.29)</P>
</TD>
<TD>
<P>0.54</P>
</TD>
</TR>
<TR>
<TD>
<P>Moderate plus severe</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>89</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>89</P>
</TD>
<TD>
<P>0.68 (0.36, 1.30)</P>
</TD>
<TD>
<P>0.25</P>
</TD>
</TR>
<TR>
<TD>
<P>Severe</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>89</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>89</P>
</TD>
<TD>
<P>0.60 (0.23, 1.58)</P>
</TD>
<TD>
<P>0.30</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>GM-CSF versus sucralfate</P>
<P>
<LINK REF="STD-Saarilahti-2002" TYPE="STUDY">Saarilahti 2002</LINK>
</P>
</TD>
<TD>
<P>Moderate plus severe</P>
<P></P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>0.96 (0.80, 1.14)</P>
</TD>
<TD>
<P>0.61</P>
</TD>
</TR>
<TR>
<TD>
<P>Severe</P>
<P></P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>0.54 (0.24, 1.21)</P>
</TD>
<TD>
<P>0.13</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Keratinocyte 50 versus 25 mg <LINK REF="STD-Freytes-2004" TYPE="STUDY">Freytes 2004</LINK>
</P>
</TD>
<TD>
<P>Moderate plus severe</P>
<P></P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>0.78 (0.40, 1.49)</P>
</TD>
<TD>
<P>0.45</P>
</TD>
</TR>
<TR>
<TD>
<P>Severe</P>
<P></P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>0.33 (0.04, 2.83)</P>
</TD>
<TD>
<P>0.31</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Laser versus povidone <LINK REF="STD-Arun-Maiya-2006" TYPE="STUDY">Arun Maiya 2006</LINK>
</P>
</TD>
<TD>
<P>Moderate plus severe</P>
<P></P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>0.29 ( 0.16, 0.54)</P>
</TD>
<TD>
<P>&lt; 0.0001</P>
</TD>
</TR>
<TR>
<TD>
<P>Severe</P>
<P></P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>0.02 (0.00, 0.31)</P>
</TD>
<TD>
<P>0.005</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>Polaprezinc versus azulene oral rinse <LINK REF="STD-Watanabe-2010" TYPE="STUDY">Watanabe 2010</LINK>
</P>
</TD>
<TD>
<P>Any</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>0.82 (0.63, 1.06)</P>
</TD>
<TD>
<P>0.13</P>
</TD>
</TR>
<TR>
<TD>
<P>Moderate plus severe</P>
<P></P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>0.43 (0.22, 0.84)</P>
</TD>
<TD>
<P>0.01</P>
</TD>
</TR>
<TR>
<TD>
<P>Severe</P>
<P></P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>0.09 (0.01, 0.65)</P>
</TD>
<TD>
<P>0.02</P>
</TD>
</TR>
<TR>
<TD>
<P>Radiotherapy morning versus afternoon <LINK REF="STD-Goyal-2009" TYPE="STUDY">Goyal 2009</LINK>
</P>
<P></P>
</TD>
<TD>
<P>Moderate plus severe</P>
<P></P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>88</P>
</TD>
<TD>
<P>42</P>
</TD>
<TD>
<P>89</P>
</TD>
<TD>
<P>0.70 (0.48, 1.01)</P>
</TD>
<TD>
<P>0.06</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Yangyin humo decoctalion versus 'traditional Western medicine' (lidocaine (iv), dexamethasone, gentamycin, vitamin B12, bicarbonate) <LINK REF="STD-Dai-2009" TYPE="STUDY">Dai 2009</LINK>
</P>
</TD>
<TD>
<P>Moderate</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>0.65 (0.41, 1.02)</P>
</TD>
<TD>
<P>0.06</P>
</TD>
</TR>
<TR>
<TD>
<P>Severe</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>0.57 (0.20, 1.66)</P>
</TD>
<TD>
<P>0.30</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>CI = confidence interval; RR = risk ratio; SD = standard deviation.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2011-02-16 16:06:32 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-07-25 15:09:47 +0100" MODIFIED_BY="[Empty name]">Text only inclusions</TITLE>
<TABLE COLS="3" ROWS="14">
<TR>
<TD>
<P>
<B>Intervention</B>
</P>
</TD>
<TD>
<P>
<B>Study</B>
</P>
</TD>
<TD>
<P>
<B>Text</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Amifostine versus no treatment</P>
</TD>
<TD>
<P>
<LINK REF="STD-Vacha-2003" TYPE="STUDY">Vacha 2003</LINK>
</P>
</TD>
<TD>
<P>CTC mucositis index used. Results presented as weekly means for both arms with standard deviations. Text indicated statistically significant difference in favour of amifostine at 2 weeks but does not mention overall result.</P>
</TD>
</TR>
<TR>
<TD>
<P>Benzydamine versus placebo</P>
</TD>
<TD>
<P>
<LINK REF="STD-Epstein-1989" TYPE="STUDY">Epstein 1989</LINK>
</P>
</TD>
<TD>
<P>Signs of mucositis were recorded by area of involvement, severity of inflammation, severity of ulceration and maximum size of ulceration for each region of the oral cavity. Results in Table 3 indicate borderline statistically significant differences in favour of benzydamine. Maximum size of ulcerations (P = 0.04); total area of ulcerations (P = 0.05); average area of mucositis (P = 0.050).</P>
</TD>
</TR>
<TR>
<TD>
<P>Benzydamine versus placebo</P>
</TD>
<TD>
<P>
<LINK REF="STD-Epstein-2001" TYPE="STUDY">Epstein 2001</LINK>
</P>
</TD>
<TD>
<P>Area under the curve of mean mucositis cores presented for different radiotherapy intervals.Overall there was a statistically significant difference in favour of benzydamine (P = 0.006), Table 4.</P>
</TD>
</TR>
<TR>
<TD>
<P>Chlorhexidine versus placebo</P>
</TD>
<TD>
<P>
<LINK REF="STD-McGaw-1985" TYPE="STUDY">McGaw 1985</LINK>
</P>
</TD>
<TD>
<P>Hickey (0-3 scale) index for mucositis used over 4-week period. During the third and fourth weeks the average mucositis scores were significantly higher in the control group.</P>
</TD>
</TR>
<TR>
<TD>
<P>Chlorhexidine versus povidone-iodine, salt/soda versus water</P>
</TD>
<TD>
<P>
<LINK REF="STD-Madan-2008" TYPE="STUDY">Madan 2008</LINK>
</P>
</TD>
<TD>
<P>After 4 weeks there was a statistically significant decrease in mean mucositis scores in each of the active treatment groups compared to placebo.</P>
</TD>
</TR>
<TR>
<TD>
<P>Cryotherapy versus no treatment control</P>
</TD>
<TD>
<P>
<LINK REF="STD-Svanberg-2007" TYPE="STUDY">Svanberg 2007</LINK>
</P>
</TD>
<TD>
<P>"The results demonstrated that oral cryotherapy alleviated the development of mucositis and oral pain, which resulted in a reduction in the number of days of iv opioids for patients treated with autologous BMT."</P>
</TD>
</TR>
<TR>
<TD>
<P>GM-CSF versus no treatment control</P>
</TD>
<TD>
<P>
<LINK REF="STD-Chi-1995" TYPE="STUDY">Chi 1995</LINK>
</P>
</TD>
<TD>
<P>Cross-over study showing period effect but indicating GM-CSF significantly prevents mucositis (P &lt; 0.001).</P>
</TD>
</TR>
<TR>
<TD>
<P>Laser versus placebo light treatment</P>
</TD>
<TD>
<P>
<LINK REF="STD-Bensadoun-1999" TYPE="STUDY">Bensadoun 1999</LINK>
</P>
</TD>
<TD>
<P>Parallel group study mucositis measured on 0-4 scale. Mean calculated for each patient over 7 weeks.Quote "the mean grade of mucositis during radiotherapy was 2.1 +/ 0.26 for the group without laser and 1.7 +/- 0.26 for the group with laser (P = 0.01)."</P>
</TD>
</TR>
<TR>
<TD>
<P>Laser versus sham laser treatment</P>
<P/>
</TD>
<TD>
<P>
<LINK REF="STD-Schubert-2007" TYPE="STUDY">Schubert 2007</LINK>
</P>
</TD>
<TD>
<P>OMI appropriate index (Schubert 1992).</P>
<P>Quote: "Figure 1 shows the mean OMI over time by treatment group. The placebo patient scores are higher on average than the laser patient scores at nearly every time point, signifying more severe mucositis over the course of the study.." The authors then present day 11 data and statistical test for that day (P = 0.06).</P>
<P>"The peak severity of mucositis that generally occurs during the second week of transplant was reduced in the 650 nm laser group."</P>
<P>The results of the overall burden over time in Table 2 showed the differences in the unadjusted model to be non-significant. Only one difference comparing low-level laser with placebo was significant in the adjusted model (P = 0.03).</P>
</TD>
</TR>
<TR>
<TD>
<P>Prostaglandin versus placebo</P>
<P/>
</TD>
<TD>
<P>
<LINK REF="STD-Hanson-1995" TYPE="STUDY">Hanson 1995</LINK>
</P>
</TD>
<TD>
<P>Data from 2 centres reported separately.Overall ANOVA for 1 centre showed no significant difference.The other centre found statistically significant differences for weeks 4 and 5 with less mucositis in the intervention group (P &lt; 0.05).</P>
</TD>
</TR>
<TR>
<TD>
<P>Sucralfate versus placebo</P>
</TD>
<TD>
<P>
<LINK REF="STD-Epstein-1994" TYPE="STUDY">Epstein 1994</LINK>
</P>
</TD>
<TD>
<P>Signs of mucositis were recorded by area of involvement, severity of inflammation, severity of ulceration and maximum size of ulceration for each region of the oral cavity. No statistically significant difference was seen in mucositis ulceration or the composite mucositis score (Table 3).</P>
<P>Total mucositis score:<BR/>Placebo (n = 17) mean = 18.7 +/- 21.3<BR/>Sucralfate (n = 16) mean = 22.3 +/- 31.2</P>
<P>Total mucosal ulceration:<BR/>Placebo (n = 17) mean = 15.3 +/- 17.6<BR/>Sucralfate (n = 16) mean = 19.4 +/- 19.8.</P>
</TD>
</TR>
<TR>
<TD>
<P>Sucralfate versus placebo</P>
</TD>
<TD>
<P>
<LINK REF="STD-Lievens-1998" TYPE="STUDY">Lievens 1998</LINK>
</P>
</TD>
<TD>
<P>Mucositis scores on 0-6 ECOG scale. Graph (fig 1) displays mean mucositis scores for each week 1-7. Quote: "Comparing the time course of the mean scores for . . .mucositis . . . no statistically significant differences between the two treatment arms were observed."</P>
<P>Quote: "At 5 week when the mucosal reaction tends to be most severe a clear but not statistically significant advantage is seen for sucralfate as opposed to placebo."</P>
</TD>
</TR>
<TR>
<TD>
<P>Zinc versus placebo</P>
</TD>
<TD>
<P>
<LINK REF="STD-Lin-2006" TYPE="STUDY">Lin 2006</LINK>
</P>
</TD>
<TD>
<P>RTOG mucositis index used. Results presented as graphs. Quote: "This study no significant difference was found in the improvement of radiation mucositis and dermatitis during the 2 weeks between the patients with zinc supplement and those without."</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>ANOVA = analysis of variance; BMT = bone marrow transplant; CTC = Common Toxicity Criteria; ECOG = Eastern Cooperative Oncology Group; GM-CSF = granulocyte/macrophage colony-stimulating factor; OMI = oral mucositis index; RTOG = Radiation Therapy Oncology Group.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-02-24 14:16:37 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2011-02-22 16:57:40 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Allopurinol versus placebo/no treatment</NAME>
<IV_OUTCOME CHI2="8.511456783860222" CI_END="1.1922956814202432" CI_START="0.498360589634289" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="0.7708392691158181" ESTIMABLE="YES" I2="64.75338974065257" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.07638397091188046" LOG_CI_START="-0.3024563090075854" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.11303616904785249" MODIFIED="2011-02-22 16:57:12 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.03654357751996795" P_Q="1.0" P_Z="0.24215981997871505" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.11450731473488879" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="1.1696054090724917">
<NAME>Mucositis (any)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours allopurinol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.7086902894647766" CI_START="0.11541010949041666" EFFECT_SIZE="0.2859895520852553" ESTIMABLE="YES" ESTIMATE="-1.2518" LOG_CI_END="-0.14954351793801235" LOG_CI_START="-0.9377561469549689" LOG_EFFECT_SIZE="-0.5436498324464906" MODIFIED="2010-01-04 14:30:13 +0000" MODIFIED_BY="[Empty name]" ORDER="631" SE="0.463" STUDY_ID="STD-Dozono-1989" TOTAL_1="0" TOTAL_2="0" WEIGHT="15.057570472713799"/>
<IV_DATA CI_END="1.766133363905434" CI_START="0.7907348177186024" EFFECT_SIZE="1.1817542653083615" ESTIMABLE="YES" ESTIMATE="0.167" LOG_CI_END="0.2470234948368885" LOG_CI_START="-0.10196913788120238" LOG_EFFECT_SIZE="0.07252717847784303" MODIFIED="2009-08-07 17:05:47 +0100" MODIFIED_BY="[Empty name]" ORDER="632" SE="0.205" STUDY_ID="STD-Loprinzi-1990" TOTAL_1="0" TOTAL_2="0" WEIGHT="31.63614039895908"/>
<IV_DATA CI_END="1.121643833760689" CI_START="0.6738179435460414" EFFECT_SIZE="0.8693582353988059" ESTIMABLE="YES" ESTIMATE="-0.14" LOG_CI_END="0.04985497315147598" LOG_CI_START="-0.1714574280843865" LOG_EFFECT_SIZE="-0.060801227466455235" MODIFIED="2010-05-11 09:08:24 +0100" MODIFIED_BY="[Empty name]" ORDER="633" SE="0.13" STUDY_ID="STD-Abbasi_x002d_Nazari-2007" TOTAL_1="0" TOTAL_2="0" WEIGHT="37.684951525854515"/>
<IV_DATA CI_END="1.5249838091360148" CI_START="0.2613267358623935" EFFECT_SIZE="0.631283645506926" ESTIMABLE="YES" ESTIMATE="-0.46" LOG_CI_END="0.1832652327711893" LOG_CI_START="-0.5828161561221811" LOG_EFFECT_SIZE="-0.19977546167549584" MODIFIED="2010-03-09 14:09:37 +0000" MODIFIED_BY="[Empty name]" ORDER="443" SE="0.45" STUDY_ID="STD-Panahi-2009" TOTAL_1="0" TOTAL_2="0" WEIGHT="15.621337602472623"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="8.240364271621575" CI_END="0.8619605658558956" CI_START="0.5013577252206328" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6573816155988859" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" I2="87.86461414765569" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.06451260241534475" LOG_CI_START="-0.29985228880108034" LOG_EFFECT_SIZE="-0.18218244560821253" METHOD="MH" MODIFIED="2011-02-22 16:57:29 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.004096927650651949" P_Q="1.0" P_Z="0.0024092190720601714" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="25" WEIGHT="100.0" Z="3.034516086014184">
<NAME>Mucositis (moderate plus severe)</NAME>
<GROUP_LABEL_1>Allopurinol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours allopurinol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7563115847557464" CI_START="0.1950962313794853" EFFECT_SIZE="0.38412698412698415" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="-0.12129924727417835" LOG_CI_START="-0.7097511196721225" LOG_EFFECT_SIZE="-0.41552518347315043" MODIFIED="2010-05-11 09:08:34 +0100" MODIFIED_BY="[Empty name]" ORDER="419" O_E="0.0" SE="0.34565954273029914" STUDY_ID="STD-Abbasi_x002d_Nazari-2007" TOTAL_1="14" TOTAL_2="10" VAR="0.11948051948051949" WEIGHT="43.871866295264624"/>
<DICH_DATA CI_END="1.0945424640227575" CI_START="0.6930611030879321" EFFECT_SIZE="0.8709677419354839" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.03923261518035183" LOG_CI_START="-0.15922847453092262" LOG_EFFECT_SIZE="-0.05999792967528537" MODIFIED="2010-03-09 11:50:38 +0000" MODIFIED_BY="[Empty name]" ORDER="432" O_E="0.0" SE="0.11657702649464058" STUDY_ID="STD-Panahi-2009" TOTAL_1="15" TOTAL_2="15" VAR="0.013590203106332133" WEIGHT="56.12813370473538"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.142144044368136" CI_END="1.0351689725766318" CI_START="0.6336802395649989" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8099173553719007" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" I2="92.39089149666918" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.015011246283763371" LOG_CI_START="-0.1981298355316739" LOG_EFFECT_SIZE="-0.0915592946239553" METHOD="MH" MODIFIED="2011-02-22 16:57:40 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="2.8873136194107474E-4" P_Q="1.0" P_Z="0.09220319812622542" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="25" WEIGHT="99.99999999999999" Z="1.6838886092192753">
<NAME>Mucositis (severe)</NAME>
<GROUP_LABEL_1>Allopurinol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours allopurinol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.367166229387423" CI_START="0.02332397803325536" EFFECT_SIZE="0.17857142857142858" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.13582132226107876" LOG_CI_START="-1.6321973762734796" LOG_EFFECT_SIZE="-0.7481880270062005" MODIFIED="2009-07-29 14:31:16 +0100" MODIFIED_BY="[Empty name]" ORDER="421" O_E="0.0" SE="1.0385429353529052" STUDY_ID="STD-Abbasi_x002d_Nazari-2007" TOTAL_1="14" TOTAL_2="10" VAR="1.0785714285714285" WEIGHT="23.140495867768593"/>
<DICH_DATA CI_END="1.1325342689505136" CI_START="0.8829754890566542" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.054051352045522444" LOG_CI_START="-0.054051352045522395" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-09 11:53:27 +0000" MODIFIED_BY="[Empty name]" ORDER="433" O_E="0.0" SE="0.06350006350009522" STUDY_ID="STD-Panahi-2009" TOTAL_1="15" TOTAL_2="15" VAR="0.0040322580645161255" WEIGHT="76.8595041322314"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2011-02-22 16:57:54 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Aloe vera versus placebo</NAME>
<DICH_OUTCOME CHI2="2.4154286052263765" CI_END="0.9606989048724839" CI_START="0.5774728738688043" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7448339127076091" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="48" I2="58.59948011560959" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.017412704362466055" LOG_CI_START="-0.2384684114458311" LOG_EFFECT_SIZE="-0.12794055790414857" METHOD="MH" MODIFIED="2011-02-22 16:57:54 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.12014528574905892" P_Q="1.0" P_Z="0.023284183869269483" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="61" WEIGHT="100.0" Z="2.268739305242418">
<NAME>Mucositis (moderate plus severe)</NAME>
<GROUP_LABEL_1>Aloe vera</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours aloe vera</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3190554956071203" CI_START="0.639395830374199" EFFECT_SIZE="0.9183673469387755" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="21" LOG_CI_END="0.12026306766837781" LOG_CI_START="-0.19423020017471776" LOG_EFFECT_SIZE="-0.03698356625316997" MODIFIED="2008-12-18 11:20:55 +0000" MODIFIED_BY="Philip Riley" ORDER="204" O_E="0.0" SE="0.18473490229781736" STUDY_ID="STD-Su-2004" TOTAL_1="28" TOTAL_2="30" VAR="0.034126984126984124" WEIGHT="43.29374275782155"/>
<DICH_DATA CI_END="0.878668271099845" CI_START="0.42674493086650034" EFFECT_SIZE="0.6123456790123457" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="27" LOG_CI_END="-0.05617505578269803" LOG_CI_START="-0.36983162899420646" LOG_EFFECT_SIZE="-0.21300334238845228" MODIFIED="2010-02-11 15:42:22 +0000" MODIFIED_BY="[Empty name]" ORDER="444" O_E="0.0" SE="0.1842434237295179" STUDY_ID="STD-Puataweepong-2009" TOTAL_1="30" TOTAL_2="31" VAR="0.03394563918757468" WEIGHT="56.706257242178445"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2011-02-24 14:04:56 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Amifostine versus placebo/no treatment</NAME>
<DICH_OUTCOME CHI2="0.9378861375928185" CI_END="0.9851837311012129" CI_START="0.9123120071295302" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9480479666727348" ESTIMABLE="YES" EVENTS_1="197" EVENTS_2="208" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-0.006482768525289044" LOG_CI_START="-0.03985660925789465" LOG_EFFECT_SIZE="-0.02316968889159185" METHOD="MH" MODIFIED="2011-02-22 16:58:06 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6256632401744857" P_Q="1.0" P_Z="0.00650063953012352" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="YEAR" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="216" TOTAL_2="214" WEIGHT="100.0" Z="2.721398242675217">
<NAME>Mucositis (any)</NAME>
<GROUP_LABEL_1>Amifostine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours amifostine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0936122212933046" CI_START="0.799414805554219" EFFECT_SIZE="0.9350132625994695" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="14" LOG_CI_END="0.03886335489790314" LOG_CI_START="-0.0972278126546538" LOG_EFFECT_SIZE="-0.029182228878375353" MODIFIED="2010-04-12 13:03:18 +0100" MODIFIED_BY="Helen Worthington" ORDER="876" O_E="0.0" SE="0.07994062548251601" STUDY_ID="STD-Buntzel-1998" TOTAL_1="25" TOTAL_2="14" VAR="0.006390503602535888" WEIGHT="6.013848706757427"/>
<DICH_DATA CI_END="0.9916229588896678" CI_START="0.9142853331964016" EFFECT_SIZE="0.9521692745376956" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="152" LOG_CI_END="-0.0036534266363007937" LOG_CI_START="-0.0389182470514854" LOG_EFFECT_SIZE="-0.02128583684389309" MODIFIED="2008-12-18 11:30:34 +0000" MODIFIED_BY="Philip Riley" ORDER="205" O_E="0.0" SE="0.020714730075555802" STUDY_ID="STD-Brizel-2000" TOTAL_1="148" TOTAL_2="153" VAR="4.2910004210313605E-4" WEIGHT="89.56308099452936"/>
<DICH_DATA CI_END="1.062192088025935" CI_START="0.7370806257094044" EFFECT_SIZE="0.884828349944629" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="42" LOG_CI_END="0.02620306215610395" LOG_CI_START="-0.13248500415513273" LOG_EFFECT_SIZE="-0.05314097099951441" MODIFIED="2010-04-12 13:03:19 +0100" MODIFIED_BY="Helen Worthington" ORDER="209" O_E="0.0" SE="0.09321415566981733" STUDY_ID="STD-Spencer-2005" TOTAL_1="43" TOTAL_2="47" VAR="0.008688878817236938" WEIGHT="4.423070298713218"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="25.85820474758875" CI_END="0.9559219268896243" CI_START="0.5844380026701306" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.74744705609157" ESTIMABLE="YES" EVENTS_1="217" EVENTS_2="282" I2="80.66377751739999" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-0.019577576453624887" LOG_CI_START="-0.23326155212629013" LOG_EFFECT_SIZE="-0.12641956428995751" METHOD="MH" MODIFIED="2011-02-24 14:04:39 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="9.506754860988398E-5" P_Q="1.0" P_Z="0.02038934132003444" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.06147393028058417" TOTALS="YES" TOTAL_1="370" TOTAL_2="387" WEIGHT="100.0" Z="2.3191050444430563">
<NAME>Mucositis (moderate plus severe)</NAME>
<GROUP_LABEL_1>Amifostine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours amifostine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0273631836944186" CI_START="0.8282562205065682" EFFECT_SIZE="0.9224532224532225" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="130" LOG_CI_END="0.011723998409103408" LOG_CI_START="-0.08183529372365717" LOG_EFFECT_SIZE="-0.03505564765727687" MODIFIED="2011-02-23 10:41:47 +0000" MODIFIED_BY="[Empty name]" ORDER="210" O_E="0.0" SE="0.054957191324748834" STUDY_ID="STD-Brizel-2000" TOTAL_1="148" TOTAL_2="153" VAR="0.0030202928783050484" WEIGHT="24.42858426857407"/>
<DICH_DATA CI_END="0.6384567658098825" CI_START="0.21259712370653938" EFFECT_SIZE="0.3684210526315789" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="38" LOG_CI_END="-0.1948685063973086" LOG_CI_START="-0.6724426154798357" LOG_EFFECT_SIZE="-0.43365556093857216" MODIFIED="2011-02-23 10:41:52 +0000" MODIFIED_BY="[Empty name]" ORDER="212" O_E="0.0" SE="0.280529395705043" STUDY_ID="STD-Koukourakis-2000" TOTAL_1="60" TOTAL_2="70" VAR="0.07869674185463658" WEIGHT="11.239887354990215"/>
<DICH_DATA CI_END="1.0394431609194046" CI_START="0.7212728144113106" EFFECT_SIZE="0.8658649398704903" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.01680074612159137" LOG_CI_START="-0.14190043655200157" LOG_EFFECT_SIZE="-0.06254984521520511" MODIFIED="2011-02-23 10:41:52 +0000" MODIFIED_BY="[Empty name]" ORDER="215" O_E="0.0" SE="0.09322186028599244" STUDY_ID="STD-Antonadou-2002" TOTAL_1="22" TOTAL_2="23" VAR="0.008690315235181094" WEIGHT="22.45449307823236"/>
<DICH_DATA CI_END="0.9573763244602618" CI_START="0.43992978519369763" EFFECT_SIZE="0.6489825581395349" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="32" LOG_CI_END="-0.018917316652900598" LOG_CI_START="-0.35661663336899163" LOG_EFFECT_SIZE="-0.18776697501094608" MODIFIED="2011-02-23 10:41:58 +0000" MODIFIED_BY="[Empty name]" ORDER="217" O_E="0.0" SE="0.19836625027760946" STUDY_ID="STD-Spencer-2005" TOTAL_1="43" TOTAL_2="47" VAR="0.03934916924919919" WEIGHT="15.626404788396137"/>
<DICH_DATA CI_END="0.7232548136112138" CI_START="0.09920079013557695" EFFECT_SIZE="0.26785714285714285" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="14" LOG_CI_END="-0.1407086672301607" LOG_CI_START="-1.0034848686708777" LOG_EFFECT_SIZE="-0.5720967679505191" MODIFIED="2010-07-16 01:48:46 +0100" MODIFIED_BY="[Empty name]" ORDER="384" O_E="0.0" SE="0.506799011537353" STUDY_ID="STD-Veerasarn-2006" TOTAL_1="32" TOTAL_2="30" VAR="0.25684523809523807" WEIGHT="4.949442954729752"/>
<DICH_DATA CI_END="1.2802007458134128" CI_START="0.826087112874372" EFFECT_SIZE="1.0283760683760683" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="45" LOG_CI_END="0.10727807586911028" LOG_CI_START="-0.08297415286629957" LOG_EFFECT_SIZE="0.01215196150140536" MODIFIED="2011-02-23 10:41:58 +0000" MODIFIED_BY="[Empty name]" ORDER="381" O_E="0.0" SE="0.11175510092290056" STUDY_ID="STD-Buentzel-2006" TOTAL_1="65" TOTAL_2="64" VAR="0.012489202582287688" WEIGHT="21.301187555077462"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="40.39354267298438" CI_END="1.0346615372819452" CI_START="0.45213577095481217" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6839645398968162" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="175" I2="80.19485424993316" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.014798304835880832" LOG_CI_START="-0.34473113217442886" LOG_EFFECT_SIZE="-0.16496641366927403" METHOD="MH" MODIFIED="2011-02-24 14:04:56 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="2.705794849844345E-6" P_Q="1.0" P_Z="0.07207897748017186" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.24456706141453835" TOTALS="YES" TOTAL_1="413" TOTAL_2="432" WEIGHT="100.0" Z="1.7986189511444182">
<NAME>Mucositis (severe)</NAME>
<GROUP_LABEL_1>Amifostine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours amifostine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6161435324990371" CI_START="0.00259679752461331" EFFECT_SIZE="0.04" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="12" LOG_CI_END="-0.21031810583697877" LOG_CI_START="-2.5855619115070967" LOG_EFFECT_SIZE="-1.3979400086720375" MODIFIED="2010-07-23 00:12:50 +0100" MODIFIED_BY="[Empty name]" ORDER="222" O_E="0.0" SE="1.39522996909709" STUDY_ID="STD-Buntzel-1998" TOTAL_1="14" TOTAL_2="14" VAR="1.9466666666666665" WEIGHT="2.035426429024698"/>
<DICH_DATA CI_END="1.272845428419082" CI_START="0.785641349430806" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.10477566707822558" LOG_CI_START="-0.1047756670782256" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-23 00:12:53 +0100" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="0.1230914909793328" STUDY_ID="STD-Bourhis-2000" TOTAL_1="12" TOTAL_2="12" VAR="0.015151515151515166" WEIGHT="17.172799501973554"/>
<DICH_DATA CI_END="1.2029812370182171" CI_START="0.6672748612826618" EFFECT_SIZE="0.8959459459459459" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="60" LOG_CI_END="0.08025885367151588" LOG_CI_START="-0.1756952363239221" LOG_EFFECT_SIZE="-0.04771819132620308" MODIFIED="2010-07-23 00:12:52 +0100" MODIFIED_BY="[Empty name]" ORDER="220" O_E="0.0" SE="0.15034869945649956" STUDY_ID="STD-Brizel-2000" TOTAL_1="148" TOTAL_2="153" VAR="0.022604731428260836" WEIGHT="16.69373474965253"/>
<DICH_DATA CI_END="0.5716415096865914" CI_START="0.010582476278473937" EFFECT_SIZE="0.07777777777777778" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="15" LOG_CI_END="-0.2428762424890336" LOG_CI_START="-1.9754126963611025" LOG_EFFECT_SIZE="-1.109144469425068" MODIFIED="2010-07-23 00:12:49 +0100" MODIFIED_BY="[Empty name]" ORDER="226" O_E="0.0" SE="1.0177004891982149" STUDY_ID="STD-Koukourakis-2000" TOTAL_1="60" TOTAL_2="70" VAR="1.0357142857142858" WEIGHT="3.4836835296468798"/>
<DICH_DATA CI_END="1.2012652304020692" CI_START="0.2081139066318633" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.07963890697224746" LOG_CI_START="-0.6816988983002099" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2010-07-23 00:12:50 +0100" MODIFIED_BY="[Empty name]" ORDER="223" O_E="0.0" SE="0.44721359549995804" STUDY_ID="STD-Hartmann-2001" TOTAL_1="20" TOTAL_2="20" VAR="0.20000000000000007" WEIGHT="10.032446011891938"/>
<DICH_DATA CI_END="0.6463361427992651" CI_START="0.1304808768974932" EFFECT_SIZE="0.2904040404040404" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="18" LOG_CI_END="-0.18954155786442362" LOG_CI_START="-0.8844531332793779" LOG_EFFECT_SIZE="-0.5369973455719006" MODIFIED="2010-07-23 00:12:54 +0100" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="0.4081944992665198" STUDY_ID="STD-Antonadou-2002" TOTAL_1="22" TOTAL_2="23" VAR="0.16662274923144485" WEIGHT="10.84680341494832"/>
<DICH_DATA CI_END="0.9176751620815213" CI_START="0.1446529577149974" EFFECT_SIZE="0.3643410852713178" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" LOG_CI_END="-0.03731102280902571" LOG_CI_START="-0.8396726819180373" LOG_EFFECT_SIZE="-0.4384918523635315" MODIFIED="2010-07-23 00:12:49 +0100" MODIFIED_BY="[Empty name]" ORDER="227" O_E="0.0" SE="0.47131121031490164" STUDY_ID="STD-Spencer-2005" TOTAL_1="43" TOTAL_2="47" VAR="0.22213425696849745" WEIGHT="9.556636903790082"/>
<DICH_DATA CI_END="3.065238942988014" CI_START="1.008539346499213" EFFECT_SIZE="1.7582417582417582" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="14" LOG_CI_END="0.48646433450743576" LOG_CI_START="0.003692846162226607" LOG_EFFECT_SIZE="0.24507859033483118" MODIFIED="2010-05-12 08:24:10 +0100" MODIFIED_BY="[Empty name]" ORDER="221" O_E="0.0" SE="0.2835823620113847" STUDY_ID="STD-Buentzel-2006" TOTAL_1="65" TOTAL_2="64" VAR="0.08041895604395605" WEIGHT="13.723959809675273"/>
<DICH_DATA CI_END="1.5133158096681454" CI_START="0.7995687299832945" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="20" LOG_CI_END="0.17992956918910002" LOG_CI_START="-0.09714419887264991" LOG_EFFECT_SIZE="0.04139268515822507" MODIFIED="2010-07-23 00:12:51 +0100" MODIFIED_BY="[Empty name]" ORDER="424" O_E="0.0" SE="0.16275450289674367" STUDY_ID="STD-Haddad-2009" TOTAL_1="29" TOTAL_2="29" VAR="0.02648902821316615" WEIGHT="16.454509649396712"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2011-02-24 14:05:44 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Chlorhexidine versus placebo/no treatment</NAME>
<DICH_OUTCOME CHI2="30.492175673605754" CI_END="1.2378272486598534" CI_START="0.4678142290694577" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7609685933420494" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="116" I2="90.16141048079812" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.09266003871578743" LOG_CI_START="-0.3299265727954261" LOG_EFFECT_SIZE="-0.11863326703981932" METHOD="MH" MODIFIED="2011-02-22 16:59:40 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0872929731009506E-6" P_Q="1.0" P_Z="0.2711377440078593" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.19276642498455426" TOTALS="YES" TOTAL_1="230" TOTAL_2="224" WEIGHT="100.0" Z="1.1004462727054412">
<NAME>Mucositis (any)</NAME>
<GROUP_LABEL_1>Chlorhexidine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chlorhexidine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8036916801610163" CI_START="0.11779959722122563" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.09491052747760731" LOG_CI_START="-0.9288561944801411" LOG_EFFECT_SIZE="-0.5118833609788743" MODIFIED="2010-07-16 02:17:07 +0100" MODIFIED_BY="[Empty name]" ORDER="267" O_E="0.0" SE="0.4898638128949172" STUDY_ID="STD-Ferretti-1988" TOTAL_1="23" TOTAL_2="23" VAR="0.23996655518394647" WEIGHT="14.23923558614161"/>
<DICH_DATA CI_END="1.1490119851547482" CI_START="0.9346164506107608" EFFECT_SIZE="1.0362844702467344" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" LOG_CI_END="0.06032455876611383" LOG_CI_START="-0.029366579029016657" LOG_EFFECT_SIZE="0.015478989868548586" MODIFIED="2010-05-13 15:43:36 +0100" MODIFIED_BY="[Empty name]" ORDER="269" O_E="0.0" SE="0.0526850183191521" STUDY_ID="STD-Foote-1994" TOTAL_1="25" TOTAL_2="27" VAR="0.0027757111552893926" WEIGHT="31.511299672546137"/>
<DICH_DATA CI_END="1.4511156152694817" CI_START="0.5731627301831277" EFFECT_SIZE="0.9119897959183674" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="28" LOG_CI_END="0.1617020155206193" LOG_CI_START="-0.24172205728733498" LOG_EFFECT_SIZE="-0.04001002088335782" MODIFIED="2010-07-16 02:17:07 +0100" MODIFIED_BY="[Empty name]" ORDER="266" O_E="0.0" SE="0.23697329734875966" STUDY_ID="STD-Dodd-1996" TOTAL_1="112" TOTAL_2="110" VAR="0.05615634365634366" WEIGHT="24.75380972241062"/>
<DICH_DATA CI_END="0.9334365526606976" CI_START="0.5673043561850055" EFFECT_SIZE="0.7276967930029155" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="49" LOG_CI_END="-0.029915196478485746" LOG_CI_START="-0.24618388158628243" LOG_EFFECT_SIZE="-0.1380495390323841" MODIFIED="2010-07-16 02:17:08 +0100" MODIFIED_BY="[Empty name]" ORDER="406" O_E="0.0" SE="0.12703729617957665" STUDY_ID="STD-Sorensen-2008" TOTAL_1="70" TOTAL_2="64" VAR="0.01613847462061748" WEIGHT="29.49565501890164"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.841512137470268" CI_END="1.2066667116944279" CI_START="0.7156346821904439" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.929264520324127" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="54" I2="81.55238886753047" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.08158733201955949" LOG_CI_START="-0.14530862014639406" LOG_EFFECT_SIZE="-0.03186064406341729" METHOD="MH" MODIFIED="2011-02-22 17:00:15 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0044238175300778115" P_Q="1.0" P_Z="0.5820211825148056" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="119" TOTAL_2="114" WEIGHT="100.0" Z="0.5504348076062149">
<NAME>Mucositis (moderate plus severe)</NAME>
<GROUP_LABEL_1>Chlorhexidine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chlorhexidine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4501719327757776" CI_START="0.882744027319986" EFFECT_SIZE="1.1314285714285715" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="21" LOG_CI_END="0.16141949535855293" LOG_CI_START="-0.05416521220807959" LOG_EFFECT_SIZE="0.053627141575236674" MODIFIED="2008-12-23 13:56:17 +0000" MODIFIED_BY="Philip Riley" ORDER="270" O_E="0.0" SE="0.12663552438615333" STUDY_ID="STD-Foote-1994" TOTAL_1="25" TOTAL_2="27" VAR="0.016036556036556036" WEIGHT="36.966730222304605"/>
<DICH_DATA CI_END="17.866952437820103" CI_START="1.0408969472954528" EFFECT_SIZE="4.3125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.2520504813075757" LOG_CI_START="0.017407734855085264" LOG_EFFECT_SIZE="0.6347291080813305" MODIFIED="2008-12-23 13:56:50 +0000" MODIFIED_BY="Philip Riley" ORDER="271" O_E="0.0" SE="0.7252352608463541" STUDY_ID="STD-Pitten-2003" TOTAL_1="24" TOTAL_2="23" VAR="0.5259661835748793" WEIGHT="3.7393701574416327"/>
<DICH_DATA CI_END="0.9236368714785079" CI_START="0.37670311376291465" EFFECT_SIZE="0.5898617511520737" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="31" LOG_CI_END="-0.034498738422649056" LOG_CI_START="-0.42400078997867324" LOG_EFFECT_SIZE="-0.22924976420066115" MODIFIED="2010-07-16 02:21:51 +0100" MODIFIED_BY="[Empty name]" ORDER="407" O_E="0.0" SE="0.22879543315025924" STUDY_ID="STD-Sorensen-2008" TOTAL_1="70" TOTAL_2="64" VAR="0.052347350230414744" WEIGHT="59.293899620253754"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.442609417982061" CI_END="1.2297951581398348" CI_START="0.544673432976362" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8184355506951857" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="57" I2="59.69155666355793" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.08983277883930818" LOG_CI_START="-0.26386380738364956" LOG_EFFECT_SIZE="-0.08701551427217064" METHOD="MH" MODIFIED="2011-02-24 14:05:44 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.05905158213381545" P_Q="1.0" P_Z="0.33486022675886895" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.10062150563471811" TOTALS="YES" TOTAL_1="124" TOTAL_2="120" WEIGHT="99.99999999999999" Z="0.9643704842668663">
<NAME>Mucositis (severe)</NAME>
<GROUP_LABEL_1>Chlorhexidine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours chlorhexidine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6172727052180043" CI_START="0.48855301535780066" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.20878325700323286" LOG_CI_START="-0.31108830189799547" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2011-02-23 10:43:16 +0000" MODIFIED_BY="[Empty name]" ORDER="273" O_E="0.0" SE="0.3053751271043014" STUDY_ID="STD-Wahlin-1989" TOTAL_1="14" TOTAL_2="14" VAR="0.09325396825396826" WEIGHT="22.264557492681227"/>
<DICH_DATA CI_END="1.4302350891163809" CI_START="0.6991857545725675" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.15540742873399502" LOG_CI_START="-0.155407428733995" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-23 10:43:12 +0000" MODIFIED_BY="[Empty name]" ORDER="272" O_E="0.0" SE="0.18257418583505536" STUDY_ID="STD-Spijkervet-1989" TOTAL_1="15" TOTAL_2="15" VAR="0.033333333333333326" WEIGHT="32.223932095838535"/>
<DICH_DATA CI_END="1.6360330530940477" CI_START="0.6210534671524093" EFFECT_SIZE="1.008" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.21379207355984425" LOG_CI_START="-0.2068710093408313" LOG_EFFECT_SIZE="0.0034605321095064895" MODIFIED="2011-02-23 10:43:16 +0000" MODIFIED_BY="[Empty name]" ORDER="274" O_E="0.0" SE="0.24709957721170034" STUDY_ID="STD-Foote-1994" TOTAL_1="25" TOTAL_2="27" VAR="0.06105820105820106" WEIGHT="26.698165917717617"/>
<DICH_DATA CI_END="0.7917963925976402" CI_START="0.19390846951430998" EFFECT_SIZE="0.39183673469387753" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="21" LOG_CI_END="-0.1013864812128969" LOG_CI_START="-0.7124032214370313" LOG_EFFECT_SIZE="-0.40689485132496406" MODIFIED="2010-11-03 11:12:16 +0000" MODIFIED_BY="[Empty name]" ORDER="408" O_E="0.0" SE="0.3589142577893005" STUDY_ID="STD-Sorensen-2008" TOTAL_1="70" TOTAL_2="64" VAR="0.12881944444444443" WEIGHT="18.813344493762614"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2011-02-24 14:06:10 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Cryotherapy versus no treatment</NAME>
<IV_OUTCOME CHI2="14.769406352120189" CI_END="0.9533784701637662" CI_START="0.5749825625345026" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_SIZE="0.7403890840902412" ESTIMABLE="YES" I2="72.91698864101068" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-0.020734659829418495" LOG_CI_START="-0.24034532593624017" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.1305399928828293" MODIFIED="2011-02-22 17:00:35 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0052041960116346875" P_Q="1.0" P_Z="0.019802657591209267" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="YEAR" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.053258128503445266" TOTALS="YES" TOTAL_1="92" TOTAL_2="86" WEIGHT="100.00000000000001" Z="2.3300661040571655">
<NAME>Mucositis (any)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.0487412505052134" CI_START="0.37848053429258083" EFFECT_SIZE="0.6300223399419123" ESTIMABLE="YES" ESTIMATE="-0.462" LOG_CI_END="0.020668350596560216" LOG_CI_START="-0.4219564518751649" LOG_EFFECT_SIZE="-0.20064405063930238" ORDER="505" SE="0.26" STUDY_ID="STD-Mahood-1991" TOTAL_1="27" TOTAL_2="27" WEIGHT="13.769120402142034"/>
<IV_DATA CI_END="1.0817176990892106" CI_START="0.37390622817473207" EFFECT_SIZE="0.6359724717440972" ESTIMABLE="YES" ESTIMATE="-0.4526" LOG_CI_END="0.03411393570181418" LOG_CI_START="-0.4272373007206377" LOG_EFFECT_SIZE="-0.19656168250941178" ORDER="502" SE="0.271" STUDY_ID="STD-Cascinu-1994" TOTAL_1="44" TOTAL_2="40" WEIGHT="13.134345457603054"/>
<IV_DATA CI_END="0.8986458438378906" CI_START="0.4543289729553987" EFFECT_SIZE="0.6389685776949493" ESTIMABLE="YES" ESTIMATE="-0.4479" LOG_CI_END="-0.04641142992508154" LOG_CI_START="-0.3426295669638515" LOG_EFFECT_SIZE="-0.19452049844446648" ORDER="503" SE="0.174" STUDY_ID="STD-Lilleby-2006" TOTAL_1="21" TOTAL_2="19" WEIGHT="19.921320216716662"/>
<IV_DATA CI_END="1.0601374392424767" CI_START="0.9062876223283437" EFFECT_SIZE="0.9801986733067553" ESTIMABLE="YES" ESTIMATE="-0.02" LOG_CI_END="0.02536217209052918" LOG_CI_START="-0.04273395136665928" LOG_EFFECT_SIZE="-0.008685889638065058" MODIFIED="2009-10-23 10:27:30 +0100" MODIFIED_BY="Helen Worthington" ORDER="692" SE="0.04" STUDY_ID="STD-Gori-2007" TOTAL_1="0" TOTAL_2="0" WEIGHT="30.334795742019903"/>
<IV_DATA CI_END="0.9179567138296412" CI_START="0.5302562186503116" EFFECT_SIZE="0.697676326071031" ESTIMABLE="YES" ESTIMATE="-0.36" LOG_CI_END="-0.03717779743509081" LOG_CI_START="-0.27551422953525045" LOG_EFFECT_SIZE="-0.15634601348517066" MODIFIED="2009-10-23 10:27:53 +0100" MODIFIED_BY="Helen Worthington" ORDER="695" SE="0.14" STUDY_ID="STD-Sorensen-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="22.840418181518356"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="19.020921015550748" CI_END="0.9099739380781671" CI_START="0.30564808751806427" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_SIZE="0.5273820189055304" ESTIMABLE="YES" I2="78.97052410485402" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-0.04097104582277626" LOG_CI_START="-0.5147783173057401" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.2778746815642582" MODIFIED="2011-02-22 17:00:49 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="7.785427798208122E-4" P_Q="1.0" P_Z="0.02150903614722957" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="YEAR" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.2722083639381109" TOTALS="YES" TOTAL_1="92" TOTAL_2="86" WEIGHT="100.0" Z="2.2989278589029194">
<NAME>Mucositis (moderate plus severe)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9205163385568371" CI_START="0.0985511603538052" EFFECT_SIZE="0.3011942119122021" ESTIMABLE="YES" ESTIMATE="-1.2" LOG_CI_END="-0.03596849865143433" LOG_CI_START="-1.00633825791637" LOG_EFFECT_SIZE="-0.5211533782839022" ORDER="498" SE="0.57" STUDY_ID="STD-Mahood-1991" TOTAL_1="27" TOTAL_2="27" WEIGHT="12.972554159223833"/>
<IV_DATA CI_END="1.0744257299300533" CI_START="0.24224968848754366" EFFECT_SIZE="0.5101757524408203" ESTIMABLE="YES" ESTIMATE="-0.673" LOG_CI_END="0.03117640010075678" LOG_CI_START="-0.6157367727425338" LOG_EFFECT_SIZE="-0.2922801863208885" ORDER="496" SE="0.38" STUDY_ID="STD-Cascinu-1994" TOTAL_1="44" TOTAL_2="40" WEIGHT="18.593051077734447"/>
<IV_DATA CI_END="0.6721090369147551" CI_START="0.13578733834914097" EFFECT_SIZE="0.3020991512782834" ESTIMABLE="YES" ESTIMATE="-1.197" LOG_CI_END="-0.17256026520653128" LOG_CI_START="-0.8671407244698537" LOG_EFFECT_SIZE="-0.5198504948381925" ORDER="497" SE="0.408" STUDY_ID="STD-Lilleby-2006" TOTAL_1="21" TOTAL_2="19" WEIGHT="17.657872314029586"/>
<IV_DATA CI_END="1.204900220088875" CI_START="0.8467102279651875" EFFECT_SIZE="1.010050167084168" ESTIMABLE="YES" ESTIMATE="0.01" LOG_CI_END="0.08095108370836958" LOG_CI_START="-0.07226519407030449" LOG_EFFECT_SIZE="0.004342944819032472" MODIFIED="2009-10-23 10:29:58 +0100" MODIFIED_BY="Helen Worthington" ORDER="697" SE="0.09" STUDY_ID="STD-Gori-2007" TOTAL_1="0" TOTAL_2="0" WEIGHT="27.63392601379143"/>
<IV_DATA CI_END="0.8521361164131278" CI_START="0.3198219014365602" EFFECT_SIZE="0.522045776761016" ESTIMABLE="YES" ESTIMATE="-0.65" LOG_CI_END="-0.06949102743339972" LOG_CI_START="-0.4950917990408278" LOG_EFFECT_SIZE="-0.2822914132371137" MODIFIED="2009-10-23 10:30:04 +0100" MODIFIED_BY="Helen Worthington" ORDER="700" SE="0.25" STUDY_ID="STD-Sorensen-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="23.1425964352207"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="14.311440367734994" CI_END="0.7678169771324562" CI_START="0.17326915204429366" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_SIZE="0.36474511176019003" ESTIMABLE="YES" I2="72.05033248073366" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-0.1147422894660338" LOG_CI_START="-0.7612787499776346" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.43801051972183414" MODIFIED="2011-02-24 14:06:10 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.006364632117934921" P_Q="1.0" P_Z="0.00791574872536464" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="YEAR" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.4691219832641636" TOTALS="YES" TOTAL_1="92" TOTAL_2="86" WEIGHT="100.0" Z="2.6556424762963924">
<NAME>Mucositis (severe)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cryotherapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.7587883350628223" CI_START="0.022282189737808048" EFFECT_SIZE="0.1300287108784259" ESTIMABLE="YES" ESTIMATE="-2.04" LOG_CI_END="-0.11987935418926336" LOG_CI_START="-1.6520421319760041" LOG_EFFECT_SIZE="-0.8859607430826337" ORDER="501" SE="0.9" STUDY_ID="STD-Mahood-1991" TOTAL_1="27" TOTAL_2="27" WEIGHT="11.275849841528725"/>
<IV_DATA CI_END="1.0575767345172389" CI_START="0.12245885395552931" EFFECT_SIZE="0.3598744710020595" ESTIMABLE="YES" ESTIMATE="-1.022" LOG_CI_END="0.024311888263047456" LOG_CI_START="-0.9120098092732943" LOG_EFFECT_SIZE="-0.4438489605051234" MODIFIED="2010-02-09 21:24:45 +0000" MODIFIED_BY="[Empty name]" ORDER="499" SE="0.55" STUDY_ID="STD-Cascinu-1994" TOTAL_1="44" TOTAL_2="40" WEIGHT="18.692037973401504"/>
<IV_DATA CI_END="0.572352693533379" CI_START="0.06575627866588887" EFFECT_SIZE="0.19399944126505356" ESTIMABLE="YES" ESTIMATE="-1.6399" LOG_CI_END="-0.24233626901854213" LOG_CI_START="-1.182062772727743" LOG_EFFECT_SIZE="-0.7121995208731426" ORDER="500" SE="0.552" STUDY_ID="STD-Lilleby-2006" TOTAL_1="21" TOTAL_2="19" WEIGHT="18.63879958055303"/>
<IV_DATA CI_END="1.249562533947234" CI_START="0.6170572219126137" EFFECT_SIZE="0.8780954309205613" ESTIMABLE="YES" ESTIMATE="-0.13" LOG_CI_END="0.09675799513125131" LOG_CI_START="-0.2096745604260968" LOG_EFFECT_SIZE="-0.05645828264742275" MODIFIED="2011-02-07 11:57:31 +0000" MODIFIED_BY="[Empty name]" ORDER="702" SE="0.18" STUDY_ID="STD-Gori-2007" TOTAL_1="0" TOTAL_2="0" WEIGHT="28.758833896794687"/>
<IV_DATA CI_END="0.7584982659609786" CI_START="0.15204401409138552" EFFECT_SIZE="0.3395955256449391" ESTIMABLE="YES" ESTIMATE="-1.08" LOG_CI_END="-0.12004540773742109" LOG_CI_START="-0.8180306731736029" LOG_EFFECT_SIZE="-0.469038040455512" MODIFIED="2009-10-23 10:31:36 +0100" MODIFIED_BY="Helen Worthington" ORDER="705" SE="0.41" STUDY_ID="STD-Sorensen-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="22.634478707722053"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2011-02-24 14:06:40 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Glutamine versus placebo</NAME>
<IV_OUTCOME CHI2="13.28264460575583" CI_END="1.0507907724143466" CI_START="0.5561053263139537" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_SIZE="0.764428116555881" ESTIMABLE="YES" I2="62.356893913781846" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.021516250346306633" LOG_CI_START="-0.254842945279724" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.11666334746670869" MODIFIED="2011-02-22 17:01:26 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.02086927886357348" P_Q="0.42184610949096146" P_Z="0.09797041807520346" Q="0.6451671967903628" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="YEAR" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.07898289616076962" TOTALS="SUB" TOTAL_1="96" TOTAL_2="98" WEIGHT="200.0" Z="1.6547736639098378">
<NAME>Mucositis (any)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glutamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="12.387552822153996" CI_END="1.0763205309569237" CI_START="0.5653058269430338" DF="4" EFFECT_SIZE="0.7800322222885212" ESTIMABLE="YES" I2="67.70952215157162" ID="CMP-006.01.01" LOG_CI_END="0.031941624579478065" LOG_CI_START="-0.24771653798554974" LOG_EFFECT_SIZE="-0.10788745670303583" MODIFIED="2010-07-27 13:39:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.014690457702563608" P_Z="0.1304720917659048" STUDIES="5" TAU2="0.08089180293932302" TOTAL_1="96" TOTAL_2="98" WEIGHT="99.99999999999999" Z="1.5122428580814673">
<NAME>Oral suspension/supplementation</NAME>
<IV_DATA CI_END="1.722516519232376" CI_START="0.3883740667918075" EFFECT_SIZE="0.8179124315538594" ESTIMABLE="YES" ESTIMATE="-0.201" LOG_CI_END="0.23616339555909163" LOG_CI_START="-0.410749777284199" LOG_EFFECT_SIZE="-0.08729319086255362" MODIFIED="2010-07-27 13:39:39 +0100" MODIFIED_BY="[Empty name]" ORDER="449" SE="0.38" STUDY_ID="STD-Jebb-1994" TOTAL_1="17" TOTAL_2="17" WEIGHT="11.978013914206498">
<FOOTNOTE>15g/day</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.9542706730535699" CI_START="0.4028495641810401" EFFECT_SIZE="0.620022196981994" ESTIMABLE="YES" ESTIMATE="-0.478" LOG_CI_END="-0.02032842284248608" LOG_CI_START="-0.3948571018570227" LOG_EFFECT_SIZE="-0.20759276234975432" MODIFIED="2010-07-27 13:39:39 +0100" MODIFIED_BY="[Empty name]" ORDER="452" SE="0.22" STUDY_ID="STD-Anderson-1998" TOTAL_1="13" TOTAL_2="13" WEIGHT="20.87176672468799"/>
<IV_DATA CI_END="1.3664220458020249" CI_START="0.8536827185730634" EFFECT_SIZE="1.0800420763926004" ESTIMABLE="YES" ESTIMATE="0.077" LOG_CI_END="0.13558486029233313" LOG_CI_START="-0.06870351007923231" LOG_EFFECT_SIZE="0.03344067510655043" MODIFIED="2010-07-27 13:39:39 +0100" MODIFIED_BY="[Empty name]" ORDER="450" SE="0.12" STUDY_ID="STD-Okuno-1999" TOTAL_1="66" TOTAL_2="68" WEIGHT="28.31878784035787"/>
<IV_DATA CI_END="1.2515652373215773" CI_START="0.722964645432598" EFFECT_SIZE="0.951229424500714" ESTIMABLE="YES" ESTIMATE="-0.05" LOG_CI_END="0.09745349195491723" LOG_CI_START="-0.14088294014524244" LOG_EFFECT_SIZE="-0.021714724095162587" MODIFIED="2010-07-27 13:39:39 +0100" MODIFIED_BY="[Empty name]" ORDER="453" SE="0.14" STUDY_ID="STD-Li-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="26.853417606541136"/>
<IV_DATA CI_END="0.6940483267073215" CI_START="0.15648637803107646" EFFECT_SIZE="0.329558961075189" ESTIMABLE="YES" ESTIMATE="-1.11" LOG_CI_END="-0.15861028849096426" LOG_CI_START="-0.8055234613342548" LOG_EFFECT_SIZE="-0.4820668749126096" MODIFIED="2010-07-27 13:39:39 +0100" MODIFIED_BY="[Empty name]" ORDER="451" SE="0.38" STUDY_ID="STD-Choi-2007" TOTAL_1="0" TOTAL_2="0" WEIGHT="11.978013914206498">
<FOOTNOTE>control = 'best supportive care'</FOOTNOTE>
</IV_DATA>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="2.6315205199927076" CI_START="0.04127237769943702" DF="0" EFFECT_SIZE="0.329558961075189" ESTIMABLE="YES" I2="0.0" ID="CMP-006.01.02" LOG_CI_END="0.42020676089513775" LOG_CI_START="-1.384340510720357" LOG_EFFECT_SIZE="-0.4820668749126096" MODIFIED="2010-07-27 15:09:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.2950212811905394" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="1.0471698113207548">
<NAME>IV supplementation</NAME>
<IV_DATA CI_END="2.6315205199927076" CI_START="0.04127237769943702" EFFECT_SIZE="0.329558961075189" ESTIMABLE="YES" ESTIMATE="-1.11" LOG_CI_END="0.42020676089513775" LOG_CI_START="-1.384340510720357" LOG_EFFECT_SIZE="-0.4820668749126096" MODIFIED="2010-07-27 13:39:39 +0100" MODIFIED_BY="[Empty name]" ORDER="454" SE="1.06" STUDY_ID="STD-Sornsuvit-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="6.387826555495531" CI_END="1.1071701349735104" CI_START="0.681444538632453" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_SIZE="0.8686052278306035" ESTIMABLE="YES" I2="21.72611518860927" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.04421436252531322" LOG_CI_START="-0.16656948472444463" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.0611775610995657" MODIFIED="2011-02-22 17:01:43 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2702890399318282" P_Q="0.35727058226396546" P_Z="0.2552401449827981" Q="0.8474648716625053" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="YEAR" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.018946010263257932" TOTALS="SUB" TOTAL_1="120" TOTAL_2="123" WEIGHT="199.99999999999997" Z="1.1377135200978752">
<NAME>Mucositis (moderate plus severe)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glutamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="5.515953633142011" CI_END="1.1239908694872252" CI_START="0.6894870231928836" DF="4" EFFECT_SIZE="0.8803278472811864" ESTIMABLE="YES" I2="27.483074259971435" ID="CMP-006.02.01" LOG_CI_END="0.05076278334387787" LOG_CI_START="-0.16147390324992728" LOG_EFFECT_SIZE="-0.05535555995302468" MODIFIED="2010-07-27 13:39:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.23833093496362245" P_Z="0.3065938208018899" STUDIES="5" TAU2="0.021012707924421826" TOTAL_1="120" TOTAL_2="123" WEIGHT="99.99999999999997" Z="1.0223953793589142">
<NAME>Oral suspension/supplementation</NAME>
<IV_DATA CI_END="1.0359229794444218" CI_START="0.47298443552046443" EFFECT_SIZE="0.699982460976843" ESTIMABLE="YES" ESTIMATE="-0.3567" LOG_CI_END="0.015327466948081254" LOG_CI_START="-0.32515315033786113" LOG_EFFECT_SIZE="-0.15491284169488992" MODIFIED="2010-07-27 13:39:39 +0100" MODIFIED_BY="[Empty name]" ORDER="456" SE="0.2" STUDY_ID="STD-Jebb-1994" TOTAL_1="17" TOTAL_2="17" WEIGHT="25.473922142496036">
<FOOTNOTE>15g/day</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.663610558801553" CI_START="0.5773016978934273" EFFECT_SIZE="0.9800026531747605" ESTIMABLE="YES" ESTIMATE="-0.0202" LOG_CI_END="0.22105166813356542" LOG_CI_START="-0.2385971652024568" LOG_EFFECT_SIZE="-0.008772748534445691" MODIFIED="2010-07-27 13:39:39 +0100" MODIFIED_BY="[Empty name]" ORDER="457" SE="0.27" STUDY_ID="STD-Okuno-1999" TOTAL_1="66" TOTAL_2="68" WEIGHT="16.549762068626254"/>
<IV_DATA CI_END="1.5683008888339145" CI_START="0.7160589400470472" EFFECT_SIZE="1.0597149957102876" ESTIMABLE="YES" ESTIMATE="0.058" LOG_CI_END="0.1954293885933598" LOG_CI_START="-0.14505122869258255" LOG_EFFECT_SIZE="0.025189079950388632" MODIFIED="2010-07-27 13:39:39 +0100" MODIFIED_BY="[Empty name]" ORDER="459" SE="0.2" STUDY_ID="STD-Dickson-2000" TOTAL_1="29" TOTAL_2="29" WEIGHT="25.473922142496036"/>
<IV_DATA CI_END="1.3948592543123164" CI_START="0.688807445039324" EFFECT_SIZE="0.9801986733067553" ESTIMABLE="YES" ESTIMATE="-0.02" LOG_CI_END="0.14453038814060906" LOG_CI_START="-0.16190216741673907" LOG_EFFECT_SIZE="-0.008685889638065058" MODIFIED="2010-07-27 13:39:39 +0100" MODIFIED_BY="[Empty name]" ORDER="458" SE="0.18" STUDY_ID="STD-Huang-2000" TOTAL_1="8" TOTAL_2="9" WEIGHT="29.098561592660477">
<FOOTNOTE>swish &amp; expectorate oral suspension</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="1.0550374139895682" CI_START="0.07937465011361575" EFFECT_SIZE="0.28938421793905067" ESTIMABLE="YES" ESTIMATE="-1.24" LOG_CI_END="0.023267860961772687" LOG_CI_START="-1.1003181760818372" LOG_EFFECT_SIZE="-0.5385251575600323" MODIFIED="2010-07-27 13:39:39 +0100" MODIFIED_BY="[Empty name]" ORDER="455" SE="0.66" STUDY_ID="STD-Choi-2007" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.403832053721177">
<FOOTNOTE>control = 'best supportive care'</FOOTNOTE>
</IV_DATA>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="2.6315205199927076" CI_START="0.04127237769943702" DF="0" EFFECT_SIZE="0.329558961075189" ESTIMABLE="YES" I2="0.0" ID="CMP-006.02.02" LOG_CI_END="0.42020676089513775" LOG_CI_START="-1.384340510720357" LOG_EFFECT_SIZE="-0.4820668749126096" MODIFIED="2010-07-27 15:09:31 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.2950212811905394" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="1.0471698113207548">
<NAME>IV supplementation</NAME>
<IV_DATA CI_END="2.6315205199927076" CI_START="0.04127237769943702" EFFECT_SIZE="0.329558961075189" ESTIMABLE="YES" ESTIMATE="-1.11" LOG_CI_END="0.42020676089513775" LOG_CI_START="-1.384340510720357" LOG_EFFECT_SIZE="-0.4820668749126096" MODIFIED="2010-07-27 13:39:39 +0100" MODIFIED_BY="[Empty name]" ORDER="460" SE="1.06" STUDY_ID="STD-Sornsuvit-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="15.892542726542764" CI_END="0.8226221131726361" CI_START="0.2941900553335504" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_SIZE="0.4919423187659911" ESTIMABLE="YES" I2="55.954184799459284" I2_Q="69.01753784245979" ID="CMP-006.03" LOG_CI_END="-0.0847996202586782" LOG_CI_START="-0.5313720120529479" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.30808581615581304" MODIFIED="2011-02-24 14:06:40 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.026116492559359217" P_Q="0.07240534795913922" P_Z="0.006844454499048635" Q="3.227632442235162" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="YEAR" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.33687391928273724" TOTALS="SUB" TOTAL_1="110" TOTAL_2="113" WEIGHT="200.00000000000006" Z="2.7043190081092257">
<NAME>Mucositis (severe)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours glutamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="9.236547967541224" CI_END="1.2875454019625203" CI_START="0.36567171589425784" DF="4" EFFECT_SIZE="0.6861624708677942" ESTIMABLE="YES" I2="56.693777653115966" ID="CMP-006.03.01" LOG_CI_END="0.10976255225624769" LOG_CI_START="-0.4369086303266985" LOG_EFFECT_SIZE="-0.16357303903522546" MODIFIED="2011-02-23 10:39:59 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.05545143609199288" P_Z="0.2408330684461374" STUDIES="5" TAU2="0.2595894396439069" TOTAL_1="96" TOTAL_2="98" WEIGHT="100.00000000000003" Z="1.1729071352765599">
<NAME>Oral suspension/supplementation</NAME>
<IV_DATA CI_END="1.9618574762775018" CI_START="0.7963697296883399" EFFECT_SIZE="1.2499455620426687" ESTIMABLE="YES" ESTIMATE="0.2231" LOG_CI_END="0.29266745385203236" LOG_CI_START="-0.09888525602680143" LOG_EFFECT_SIZE="0.09689109891261549" MODIFIED="2011-02-23 10:39:59 +0000" MODIFIED_BY="[Empty name]" ORDER="461" SE="0.23" STUDY_ID="STD-Jebb-1994" TOTAL_1="17" TOTAL_2="17" WEIGHT="32.99834969967102">
<FOOTNOTE>15g/day crossover design</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="0.8126810432714293" CI_START="0.1339105240693585" EFFECT_SIZE="0.329888684870685" ESTIMABLE="YES" ESTIMATE="-1.109" LOG_CI_END="-0.09007987055187251" LOG_CI_START="-0.8731852903095401" LOG_EFFECT_SIZE="-0.4816325804307063" MODIFIED="2011-02-23 10:39:59 +0000" MODIFIED_BY="[Empty name]" ORDER="462" SE="0.46" STUDY_ID="STD-Anderson-1998" TOTAL_1="13" TOTAL_2="13" WEIGHT="21.88426764109297"/>
<IV_DATA CI_END="2.9328556998199478" CI_START="0.22947146563627505" EFFECT_SIZE="0.820369853137831" ESTIMABLE="YES" ESTIMATE="-0.198" LOG_CI_END="0.46729069567281256" LOG_CI_START="-0.6392713105065002" LOG_EFFECT_SIZE="-0.0859903074168439" MODIFIED="2010-07-27 13:39:39 +0100" MODIFIED_BY="[Empty name]" ORDER="463" SE="0.65" STUDY_ID="STD-Okuno-1999" TOTAL_1="66" TOTAL_2="68" WEIGHT="15.11771801100922"/>
<IV_DATA CI_END="1.6920678809246237" CI_START="0.008514783600312402" EFFECT_SIZE="0.12003162851145673" ESTIMABLE="YES" ESTIMATE="-2.12" LOG_CI_END="0.2284177817051618" LOG_CI_START="-2.0698263849749496" LOG_EFFECT_SIZE="-0.9207043016348939" MODIFIED="2010-07-27 13:39:39 +0100" MODIFIED_BY="[Empty name]" ORDER="464" SE="1.35" STUDY_ID="STD-Huang-2000" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.952542196548216"/>
<IV_DATA CI_END="1.607027105843499" CI_START="0.3484062991405" EFFECT_SIZE="0.7482635675785652" ESTIMABLE="YES" ESTIMATE="-0.29" LOG_CI_END="0.20602320210185077" LOG_CI_START="-0.4579140016057368" LOG_EFFECT_SIZE="-0.12594539975194308" MODIFIED="2010-07-27 13:39:39 +0100" MODIFIED_BY="[Empty name]" ORDER="465" SE="0.39" STUDY_ID="STD-Li-2006" TOTAL_1="0" TOTAL_2="0" WEIGHT="25.047122451678593"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.1784592573922485" CI_END="0.6154076637413506" CI_START="0.10349577827799342" DF="2" EFFECT_SIZE="0.2523729286535161" ESTIMABLE="YES" I2="0.0" ID="CMP-006.03.02" LOG_CI_END="-0.2108370997365044" LOG_CI_START="-0.9850773652598737" LOG_EFFECT_SIZE="-0.5979572324981891" MODIFIED="2010-07-27 15:09:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9146355666588197" P_Z="0.0024665224033526855" STUDIES="3" TAU2="0.0" TOTAL_1="14" TOTAL_2="15" WEIGHT="100.00000000000001" Z="3.027418469896978">
<NAME>IV supplementation</NAME>
<IV_DATA CI_END="0.8112131055549118" CI_START="0.056428805813542655" EFFECT_SIZE="0.21395276770062824" ESTIMABLE="YES" ESTIMATE="-1.542" LOG_CI_END="-0.09086504170871221" LOG_CI_START="-1.2484991404809165" LOG_EFFECT_SIZE="-0.6696820910948144" MODIFIED="2010-07-27 13:39:39 +0100" MODIFIED_BY="[Empty name]" ORDER="466" SE="0.68" STUDY_ID="STD-Cerchietti-2006" TOTAL_1="14" TOTAL_2="15" WEIGHT="44.73102870723849"/>
<IV_DATA CI_END="3.7808391290611616" CI_START="0.010567775273362483" EFFECT_SIZE="0.1998876140751445" ESTIMABLE="YES" ESTIMATE="-1.61" LOG_CI_END="0.5775881989580485" LOG_CI_START="-1.9760164306865196" LOG_EFFECT_SIZE="-0.6992141158642354" MODIFIED="2010-07-27 13:39:39 +0100" MODIFIED_BY="[Empty name]" ORDER="468" SE="1.5" STUDY_ID="STD-Sornsuvit-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.19272341076759"/>
<IV_DATA CI_END="1.1539327255565586" CI_START="0.08347768990088465" EFFECT_SIZE="0.31036694126548503" ESTIMABLE="YES" ESTIMATE="-1.17" LOG_CI_END="0.062180490127148956" LOG_CI_START="-1.0784295777807582" LOG_EFFECT_SIZE="-0.5081245438268046" MODIFIED="2010-07-27 13:39:39 +0100" MODIFIED_BY="[Empty name]" ORDER="467" SE="0.67" STUDY_ID="STD-He-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="46.076247881993936"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2011-02-22 17:02:16 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>G-CSF versus placebo or no treatment</NAME>
<DICH_OUTCOME CHI2="20.484777888584283" CI_END="1.2269805785828414" CI_START="0.4793484119426336" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7669101589026832" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="79" I2="85.35497911514172" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.0888376884963143" LOG_CI_START="-0.3193487070862571" LOG_EFFECT_SIZE="-0.11525550929497139" METHOD="MH" MODIFIED="2011-02-22 17:02:09 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.3467107531539568E-4" P_Q="1.0" P_Z="0.26836708584005" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.17436035160372534" TOTALS="YES" TOTAL_1="127" TOTAL_2="136" WEIGHT="100.00000000000001" Z="1.1068308482724485">
<NAME>Mucositis (any)</NAME>
<GROUP_LABEL_1>G-CSF</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours G-CSF</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9461617036823344" CI_START="0.11743353242757715" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="-0.02403463419490035" LOG_CI_START="-0.9302078752444247" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2010-03-30 11:42:46 +0100" MODIFIED_BY="[Empty name]" ORDER="307" O_E="0.0" SE="0.5322906474223771" STUDY_ID="STD-Katano-1995" TOTAL_1="7" TOTAL_2="7" VAR="0.2833333333333333" WEIGHT="12.560801020432816"/>
<DICH_DATA CI_END="0.8737418647744396" CI_START="0.40393875488523046" EFFECT_SIZE="0.5940860215053764" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="48" LOG_CI_END="-0.05861685485143272" LOG_CI_START="-0.39368447754214086" LOG_EFFECT_SIZE="-0.2261506661967868" MODIFIED="2008-12-23 15:52:20 +0000" MODIFIED_BY="Philip Riley" ORDER="305" O_E="0.0" SE="0.19682038018000403" STUDY_ID="STD-Crawford-1999" TOTAL_1="93" TOTAL_2="102" VAR="0.038738262054201326" WEIGHT="26.97811687330616"/>
<DICH_DATA CI_END="1.296234718466769" CI_START="0.7714652182614229" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.11268364945520531" LOG_CI_START="-0.11268364945520531" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-30 10:23:32 +0100" MODIFIED_BY="[Empty name]" ORDER="435" O_E="0.0" SE="0.13238186696609675" STUDY_ID="STD-Schneider-1999" TOTAL_1="8" TOTAL_2="6" VAR="0.01752495870142934" WEIGHT="29.960601442916317"/>
<DICH_DATA CI_END="1.3177063611599462" CI_START="0.8269239636269208" EFFECT_SIZE="1.043859649122807" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.11981864247663675" LOG_CI_START="-0.08253442236452053" LOG_EFFECT_SIZE="0.01864211005605813" MODIFIED="2009-06-17 12:13:40 +0100" MODIFIED_BY="[Empty name]" ORDER="397" O_E="0.0" SE="0.11886319195152141" STUDY_ID="STD-Su-2006" TOTAL_1="19" TOTAL_2="21" VAR="0.014128458400904223" WEIGHT="30.500480663344725"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.17619203453043" CI_END="0.8641342903923829" CI_START="0.15365251567045868" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3643849716932578" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="-0.06341876094190434" LOG_CI_START="-0.8134603248781227" LOG_EFFECT_SIZE="-0.4384395429100136" METHOD="MH" MODIFIED="2011-02-22 17:02:16 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6746663834798003" P_Q="1.0" P_Z="0.021939812904122096" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="2.2914082494097756">
<NAME>Mucositis (severe)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours G-CSF</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8479658692495935" CI_START="0.03382097096056189" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.2666939458162049" LOG_CI_START="-1.4708139284721296" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2008-12-23 16:30:17 +0000" MODIFIED_BY="Philip Riley" ORDER="315" O_E="0.0" SE="1.0206207261596574" STUDY_ID="STD-Schneider-1999" TOTAL_1="8" TOTAL_2="6" VAR="1.0416666666666665" WEIGHT="24.704065877509006"/>
<DICH_DATA CI_END="1.0512512892972783" CI_START="0.15365951513481965" EFFECT_SIZE="0.4019138755980861" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.021706541442686907" LOG_CI_START="-0.8134405415410317" LOG_EFFECT_SIZE="-0.39586700004917236" MODIFIED="2009-06-17 12:14:45 +0100" MODIFIED_BY="[Empty name]" ORDER="398" O_E="0.0" SE="0.4905695305893701" STUDY_ID="STD-Su-2006" TOTAL_1="19" TOTAL_2="21" VAR="0.2406584643426749" WEIGHT="75.29593412249099"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2011-02-22 17:03:02 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>GM-CSF versus no treatment/placebo</NAME>
<DICH_OUTCOME CHI2="0.6705188048477575" CI_END="1.0408036568073502" CI_START="0.8371355906411326" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9334311886705264" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="55" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.017368809426381176" LOG_CI_START="-0.07720419374140287" LOG_EFFECT_SIZE="-0.02991769215751082" METHOD="MH" MODIFIED="2011-02-22 17:02:42 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.41287111538015864" P_Q="1.0" P_Z="0.2149571371993425" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="61" TOTAL_2="58" WEIGHT="100.0" Z="1.2400494256325427">
<NAME>Mucositis (any)</NAME>
<GROUP_LABEL_1>GM-CSF</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GM-CSF</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0365773946372296" CI_START="0.800588519178907" EFFECT_SIZE="0.9109730848861284" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="42" LOG_CI_END="0.015601733645554571" LOG_CI_START="-0.096590642176204" LOG_EFFECT_SIZE="-0.040494454265324706" ORDER="385" O_E="0.0" SE="0.0659023569189181" STUDY_ID="STD-Dazzi-2003" TOTAL_1="46" TOTAL_2="44" VAR="0.004343120647468474" WEIGHT="76.14776155916171"/>
<DICH_DATA CI_END="1.2258179913435978" CI_START="0.8241702405076415" EFFECT_SIZE="1.005128205128205" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.08842599120756338" LOG_CI_START="-0.08398307121964735" LOG_EFFECT_SIZE="0.0022214599939580325" MODIFIED="2009-06-17 12:23:24 +0100" MODIFIED_BY="[Empty name]" ORDER="400" O_E="0.0" SE="0.1012739367083667" STUDY_ID="STD-McAleese-2006" TOTAL_1="15" TOTAL_2="14" VAR="0.010256410256410262" WEIGHT="23.852238440838295"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5983880827308306" CI_END="1.0505249299368182" CI_START="0.7586931623514683" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8927631719682546" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="60" I2="37.43697098319767" I2_Q="100.0" ID="CMP-008.02" LOG_CI_END="0.02140636307755131" LOG_CI_START="-0.11993382995518659" LOG_EFFECT_SIZE="-0.04926373343881763" METHOD="MH" MODIFIED="2011-02-22 17:02:53 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.20613184359814096" P_Q="0.0" P_Z="0.17185107904337057" Q="2.7940483772348544E-32" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="68" TOTAL_2="70" WEIGHT="100.0" Z="1.3662800539928444">
<NAME>Mucositis (moderate plus severe)</NAME>
<GROUP_LABEL_1>GM-CSF</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GM-CSF</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.129526510167655" CI_START="0.7892793698771953" EFFECT_SIZE="0.944199116820554" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="47" LOG_CI_END="0.05289642833687523" LOG_CI_START="-0.1027692486016865" LOG_EFFECT_SIZE="-0.024936410132405617" ORDER="389" O_E="0.0" SE="0.0914387891912394" STUDY_ID="STD-Nemunaitis-1995" TOTAL_1="53" TOTAL_2="56" VAR="0.00836105216875992" WEIGHT="77.26592080775237"/>
<DICH_DATA CI_END="1.0563815875979703" CI_START="0.48793955484992224" EFFECT_SIZE="0.717948717948718" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.023820822983308336" LOG_CI_START="-0.3116339743518683" LOG_EFFECT_SIZE="-0.14390657568427997" MODIFIED="2009-06-17 12:24:07 +0100" MODIFIED_BY="[Empty name]" ORDER="401" O_E="0.0" SE="0.19704780848271022" STUDY_ID="STD-McAleese-2006" TOTAL_1="15" TOTAL_2="14" VAR="0.03882783882783884" WEIGHT="22.73407919224763"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.777013177206545" CI_END="1.3983032144168237" CI_START="0.3855895558483034" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7342827217007343" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="50" I2="57.5444136406581" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="0.1456013560087413" LOG_CI_START="-0.41387473799244" LOG_EFFECT_SIZE="-0.13413669099184938" METHOD="MH" MODIFIED="2011-02-22 17:03:02 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.03797435176054642" P_Q="1.0" P_Z="0.347310510967916" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="YEAR" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.3221141336900649" TOTALS="YES" TOTAL_1="203" TOTAL_2="170" WEIGHT="100.0" Z="0.9398188275363484">
<NAME>Mucositis (severe)</NAME>
<GROUP_LABEL_1>GM-CSF</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GM-CSF</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.739357538547456" CI_START="0.0943734489191765" EFFECT_SIZE="0.2641509433962264" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" LOG_CI_END="-0.13114549466641756" LOG_CI_START="-1.0251501731786845" LOG_EFFECT_SIZE="-0.578147833922551" ORDER="391" O_E="0.0" SE="0.5251427735526362" STUDY_ID="STD-Nemunaitis-1995" TOTAL_1="53" TOTAL_2="56" VAR="0.27577493261455527" WEIGHT="18.06415540921227"/>
<DICH_DATA CI_END="6.756585591731205" CI_START="0.5203256811106584" EFFECT_SIZE="1.875" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="2" LOG_CI_END="0.8297272827338283" LOG_CI_START="-0.28372473860635306" LOG_EFFECT_SIZE="0.27300127206373764" ORDER="393" O_E="0.0" SE="0.6540472290116194" STUDY_ID="STD-Cartee-1995" TOTAL_1="36" TOTAL_2="9" VAR="0.42777777777777776" WEIGHT="14.402557016590283"/>
<DICH_DATA CI_END="1.2662762775177754" CI_START="0.06024054978574862" EFFECT_SIZE="0.2761904761904762" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.10252847085604105" LOG_CI_START="-1.2201110731980052" LOG_EFFECT_SIZE="-0.558791301170982" ORDER="396" O_E="0.0" SE="0.7769250153486812" STUDY_ID="STD-Ifrah-1999" TOTAL_1="35" TOTAL_2="29" VAR="0.6036124794745484" WEIGHT="11.666901283386725"/>
<DICH_DATA CI_END="2.593331616143913" CI_START="0.7290332590828532" EFFECT_SIZE="1.375" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.4138580546995368" LOG_CI_START="-0.13725265836697398" LOG_EFFECT_SIZE="0.13830269816628143" ORDER="395" O_E="0.0" SE="0.3237251608972954" STUDY_ID="STD-van-der-Lelie-2001" TOTAL_1="18" TOTAL_2="18" VAR="0.1047979797979798" WEIGHT="25.298792585087728"/>
<DICH_DATA CI_END="1.4744463211353542" CI_START="0.4831093009977853" EFFECT_SIZE="0.8439897698209718" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.1686289662000834" LOG_CI_START="-0.3159546012360421" LOG_EFFECT_SIZE="-0.07366281751797933" ORDER="392" O_E="0.0" SE="0.2846467862393251" STUDY_ID="STD-Dazzi-2003" TOTAL_1="46" TOTAL_2="44" VAR="0.08102379291637604" WEIGHT="26.79073413437285"/>
<DICH_DATA CI_END="7.092090538223847" CI_START="0.013769741019755389" EFFECT_SIZE="0.3125" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8507742712041246" LOG_CI_START="-1.8610742278439367" LOG_EFFECT_SIZE="-0.505149978319906" MODIFIED="2009-06-17 12:24:38 +0100" MODIFIED_BY="[Empty name]" ORDER="402" O_E="0.0" SE="1.592953232207399" STUDY_ID="STD-McAleese-2006" TOTAL_1="15" TOTAL_2="14" VAR="2.5374999999999996" WEIGHT="3.776859571350146"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2011-02-24 14:12:28 +0000" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Honey versus control</NAME>
<DICH_OUTCOME CHI2="10.710688892733536" CI_END="0.8784921628437716" CI_START="0.5636918842887557" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7037037037037037" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="53" I2="81.32706476651691" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="-0.056262108555579685" LOG_CI_START="-0.24895821785673697" LOG_EFFECT_SIZE="-0.15261016320615833" METHOD="MH" MODIFIED="2011-02-22 17:03:18 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.004722856006771137" P_Q="1.0" P_Z="0.0019061505244774852" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="60" WEIGHT="100.0" Z="3.1044780783963004">
<NAME>Mucositis (any)</NAME>
<GROUP_LABEL_1>Honey</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours honey</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5758663963747823" CI_START="0.6345715615869848" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.19751939476726493" LOG_CI_START="-0.19751939476726496" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-30 13:20:24 +0100" MODIFIED_BY="[Empty name]" ORDER="321" O_E="0.0" SE="0.23204774044612855" STUDY_ID="STD-Biswal-2003" TOTAL_1="20" TOTAL_2="20" VAR="0.05384615384615385" WEIGHT="24.074074074074073"/>
<DICH_DATA CI_END="1.0453758184710666" CI_START="0.6971013526512311" EFFECT_SIZE="0.8536585365853658" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="20" LOG_CI_END="0.019272449821380405" LOG_CI_START="-0.15670407456030017" LOG_EFFECT_SIZE="-0.06871581236945987" MODIFIED="2009-07-29 14:49:56 +0100" MODIFIED_BY="[Empty name]" ORDER="423" O_E="0.0" SE="0.10336948151964373" STUDY_ID="STD-Rashad-2008" TOTAL_1="20" TOTAL_2="20" VAR="0.010685249709639966" WEIGHT="37.96296296296296"/>
<DICH_DATA CI_END="0.6519231529986157" CI_START="0.2053139221224876" EFFECT_SIZE="0.36585365853658536" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" LOG_CI_END="-0.18580359475214153" LOG_CI_START="-0.6875816005759671" LOG_EFFECT_SIZE="-0.4366925976640542" MODIFIED="2010-06-30 16:16:02 +0100" MODIFIED_BY="[Empty name]" ORDER="236" O_E="0.0" SE="0.2947468844621028" STUDY_ID="STD-Motallebnejad-2008" TOTAL_1="20" TOTAL_2="20" VAR="0.08687572590011616" WEIGHT="37.96296296296296"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.9484064054555597" CI_END="0.7439648042773985" CI_START="0.3147072443177269" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4838709677419355" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="31" I2="74.67332646866625" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="-0.12844760970905117" LOG_CI_START="-0.5020932598481318" LOG_EFFECT_SIZE="-0.3152704347785914" METHOD="MH" MODIFIED="2011-02-22 17:03:35 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.046915844754110037" P_Q="1.0" P_Z="9.412874773647833E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="3.3075117953404134">
<NAME>Mucositis (moderate plus severe)</NAME>
<GROUP_LABEL_1>Honey</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours honey</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6640205011606787" CI_START="0.10709174037068436" EFFECT_SIZE="0.26666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="15" LOG_CI_END="-0.17781851189175857" LOG_CI_START="-0.9702440235636791" LOG_EFFECT_SIZE="-0.5740312677277188" MODIFIED="2010-03-30 13:22:04 +0100" MODIFIED_BY="[Empty name]" ORDER="1510" O_E="0.0" SE="0.4654746681256314" STUDY_ID="STD-Biswal-2003" TOTAL_1="20" TOTAL_2="20" VAR="0.21666666666666667" WEIGHT="48.387096774193544"/>
<DICH_DATA CI_END="1.0814061697989674" CI_START="0.4370755995296998" EFFECT_SIZE="0.6875" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.03398884304800442" LOG_CI_START="-0.35944343804340384" LOG_EFFECT_SIZE="-0.16272729749769974" MODIFIED="2009-07-29 14:50:33 +0100" MODIFIED_BY="[Empty name]" ORDER="424" O_E="0.0" SE="0.23110406943429385" STUDY_ID="STD-Rashad-2008" TOTAL_1="20" TOTAL_2="20" VAR="0.053409090909090906" WEIGHT="51.61290322580645"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.007839410508192823" CI_END="0.5242950708492006" CI_START="0.12820140270018388" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.25925925925925924" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="-0.2804242252789441" LOG_CI_START="-0.8921072230105169" LOG_EFFECT_SIZE="-0.5862657241447304" METHOD="MH" MODIFIED="2011-02-24 14:12:28 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9294471399258495" P_Q="1.0" P_Z="1.719328672177351E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="3.757043138211314">
<NAME>Mucositis (severe)</NAME>
<GROUP_LABEL_1>Honey</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours honey</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6640205011606787" CI_START="0.10709174037068436" EFFECT_SIZE="0.26666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="15" LOG_CI_END="-0.17781851189175857" LOG_CI_START="-0.9702440235636791" LOG_EFFECT_SIZE="-0.5740312677277188" MODIFIED="2009-01-05 14:12:15 +0000" MODIFIED_BY="Philip Riley" ORDER="322" O_E="0.0" SE="0.4654746681256314" STUDY_ID="STD-Biswal-2003" TOTAL_1="20" TOTAL_2="20" VAR="0.21666666666666667" WEIGHT="55.55555555555556"/>
<DICH_DATA CI_END="0.7532478029295167" CI_START="0.08297402230305383" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.12306212640134118" LOG_CI_START="-1.0810578562545836" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2009-07-29 14:50:59 +0100" MODIFIED_BY="[Empty name]" ORDER="425" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Rashad-2008" TOTAL_1="20" TOTAL_2="20" VAR="0.31666666666666665" WEIGHT="44.44444444444444"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2011-02-23 10:38:17 +0000" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Hydrolytic enzymes versus no treatment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="62" EVENTS_2="71" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-02-23 10:38:02 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="78" TOTAL_2="71" WEIGHT="0.0" Z="0.0">
<NAME>Mucositis (any)</NAME>
<GROUP_LABEL_1>Hydrolytic enz</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours hydrolytic enzyme</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6967188212533293" CI_START="0.29191591773578174" EFFECT_SIZE="0.45098039215686275" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="25" LOG_CI_END="-0.15694245721904612" LOG_CI_START="-0.5347422229416409" LOG_EFFECT_SIZE="-0.3458423400803435" MODIFIED="2010-10-29 11:45:11 +0100" MODIFIED_BY="[Empty name]" ORDER="170" O_E="0.0" SE="0.22192145252445358" STUDY_ID="STD-Kaul-1999" TOTAL_1="25" TOTAL_2="25" VAR="0.04924913109056331" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.0295400857866375" CI_START="0.902554607731087" EFFECT_SIZE="0.9639585822381521" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="46" LOG_CI_END="0.01264326081030968" LOG_CI_START="-0.04452651228233763" LOG_EFFECT_SIZE="-0.015941625736013963" MODIFIED="2010-10-29 11:45:01 +0100" MODIFIED_BY="[Empty name]" ORDER="327" O_E="0.0" SE="0.033581807709561935" STUDY_ID="STD-Gujral-2001" TOTAL_1="53" TOTAL_2="46" VAR="0.0011277378090419933" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="49" EVENTS_2="79" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-02-23 10:38:17 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="109" TOTAL_2="101" WEIGHT="0.0" Z="0.0">
<NAME>Mucositis (moderate plus severe)</NAME>
<GROUP_LABEL_1>Hydrolytic enz</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours hydrolytic enzyme</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0625075319530595" CI_START="0.05882311242077971" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.026332017380285656" LOG_CI_START="-1.2304520000362105" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2010-10-29 11:44:07 +0100" MODIFIED_BY="[Empty name]" ORDER="172" O_E="0.0" SE="0.7382411530116699" STUDY_ID="STD-Kaul-1999" TOTAL_1="25" TOTAL_2="25" VAR="0.5449999999999999" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.5027171205389681" CI_START="0.21746112620512353" EFFECT_SIZE="0.3306379155435759" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="42" LOG_CI_END="-0.29867632418312356" LOG_CI_START="-0.6626183671392577" LOG_EFFECT_SIZE="-0.4806473456611907" MODIFIED="2010-10-29 11:44:07 +0100" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="0.2137813575746008" STUDY_ID="STD-Gujral-2001" TOTAL_1="53" TOTAL_2="46" VAR="0.04570246884643932" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.132511551684015" CI_START="0.9448391192674069" EFFECT_SIZE="1.0344279661016949" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="29" LOG_CI_END="0.05404264053655894" LOG_CI_START="-0.024642133884950575" LOG_EFFECT_SIZE="0.014700253325804193" MODIFIED="2010-10-29 11:44:07 +0100" MODIFIED_BY="[Empty name]" ORDER="173" O_E="0.0" SE="0.0462198259911098" STUDY_ID="STD-Dorr-2007" TOTAL_1="31" TOTAL_2="30" VAR="0.0021362723146484686" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2011-02-24 14:14:16 +0000" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Iseganan versus placebo</NAME>
<DICH_OUTCOME CHI2="2.4631989664026035" CI_END="1.0261382451735432" CI_START="0.8879105437660768" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9545255194342416" ESTIMABLE="YES" EVENTS_1="373" EVENTS_2="314" I2="59.402386342323894" I2_Q="100.0" ID="CMP-011.01" LOG_CI_END="0.01120587449070105" LOG_CI_START="-0.05163078681798547" LOG_EFFECT_SIZE="-0.02021245616364219" METHOD="MH" MODIFIED="2011-02-22 17:05:15 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.11654146203924631" P_Q="0.0" P_Z="0.20734131332019712" Q="3.5341020579499824E-32" RANDOM="NO" SCALE="2.0" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="504" TOTAL_2="422" WEIGHT="100.0" Z="1.260909962266148">
<NAME>Mucositis (moderate plus severe)</NAME>
<GROUP_LABEL_1>Iseganan</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours iseganan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0588118811044347" CI_START="0.93786180176585" EFFECT_SIZE="0.9965034965034965" ESTIMABLE="YES" EVENTS_1="230" EVENTS_2="156" LOG_CI_END="0.024818805947354392" LOG_CI_START="-0.02786115218842" LOG_EFFECT_SIZE="-0.0015211731205328225" MODIFIED="2010-03-26 12:25:05 +0000" MODIFIED_BY="Helen Worthington" ORDER="332" O_E="0.0" SE="0.030944468178952276" STUDY_ID="STD-Trotti-2004" TOTAL_1="253" TOTAL_2="171" VAR="9.5756011087819E-4" WEIGHT="54.09242914313908"/>
<DICH_DATA CI_END="1.0446293125463262" CI_START="0.7841437638496933" EFFECT_SIZE="0.9050632911392406" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="158" LOG_CI_END="0.01896220807814411" LOG_CI_START="-0.10560430705686562" LOG_EFFECT_SIZE="-0.04332104948936079" MODIFIED="2009-01-05 14:18:15 +0000" MODIFIED_BY="Philip Riley" ORDER="331" O_E="0.0" SE="0.07317098760449926" STUDY_ID="STD-Giles-2004" TOTAL_1="251" TOTAL_2="251" VAR="0.005353993427017785" WEIGHT="45.907570856860914"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.2472072441332522" CI_END="1.0989397023628005" CI_START="0.8888728840735679" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9883408838362252" ESTIMABLE="YES" EVENTS_1="305" EVENTS_2="256" I2="69.2043061986048" I2_Q="99.99999999999999" ID="CMP-011.02" LOG_CI_END="0.04097386380700398" LOG_CI_START="-0.051160342171130205" LOG_EFFECT_SIZE="-0.0050932391820631044" METHOD="MH" MODIFIED="2011-02-24 14:14:16 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.07154531989670487" P_Q="0.0" P_Z="0.8284451233130681" Q="1.0274093478399318E-33" RANDOM="NO" SCALE="2.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="504" TOTAL_2="422" WEIGHT="100.0" Z="0.21669618260694717">
<NAME>Mucositis (severe)</NAME>
<GROUP_LABEL_1>Iseganan</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours iseganan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0473516570838193" CI_START="0.7767527276416234" EFFECT_SIZE="0.9019607843137255" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="153" LOG_CI_END="0.020092524170902893" LOG_CI_START="-0.10971721300362747" LOG_EFFECT_SIZE="-0.04481234441636228" MODIFIED="2009-01-05 14:18:34 +0000" MODIFIED_BY="Philip Riley" ORDER="333" O_E="0.0" SE="0.0762508821848814" STUDY_ID="STD-Giles-2004" TOTAL_1="251" TOTAL_2="251" VAR="0.005814197033972663" WEIGHT="55.45089323873835"/>
<DICH_DATA CI_END="1.2738433573424388" CI_START="0.9427437124422183" EFFECT_SIZE="1.0958593959860317" ESTIMABLE="YES" EVENTS_1="167" EVENTS_2="103" LOG_CI_END="0.10511602672432846" LOG_CI_START="-0.025606355406834536" LOG_EFFECT_SIZE="0.039754835658746976" MODIFIED="2009-01-05 14:20:10 +0000" MODIFIED_BY="Philip Riley" ORDER="334" O_E="0.0" SE="0.0767869743500728" STUDY_ID="STD-Trotti-2004" TOTAL_1="253" TOTAL_2="171" VAR="0.005896239429838737" WEIGHT="44.54910676126165"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2011-02-24 14:15:32 +0000" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Keratinocyte GF versus placebo</NAME>
<DICH_OUTCOME CHI2="10.108689693258556" CI_END="0.9428778522858947" CI_START="0.7148787258352451" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8210014114850308" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="61" I2="90.10752105026138" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="-0.025544565496175883" LOG_CI_START="-0.1457676269649834" LOG_EFFECT_SIZE="-0.08565609623057965" METHOD="MH" MODIFIED="2011-02-23 10:34:29 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.001475728748132843" P_Q="1.0" P_Z="0.00522449051153769" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="93" TOTAL_2="67" WEIGHT="100.0" Z="2.7928562393462473">
<NAME>Mucositis (any)</NAME>
<GROUP_LABEL_1>KGF</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours keratinocyte GF</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0136631465338515" CI_START="0.8554764725839026" EFFECT_SIZE="0.9312169312169312" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="31" LOG_CI_END="0.005893657259150742" LOG_CI_START="-0.06779192997733938" LOG_EFFECT_SIZE="-0.030949136359094343" MODIFIED="2008-12-01 15:42:35 +0000" MODIFIED_BY="[Empty name]" ORDER="188" O_E="0.0" SE="0.04328327869225371" STUDY_ID="STD-Blazar-2006" TOTAL_1="65" TOTAL_2="31" VAR="0.0018734422143513035" WEIGHT="61.77847113884555"/>
<DICH_DATA CI_END="0.9348759324981419" CI_START="0.44205363701912437" EFFECT_SIZE="0.6428571428571429" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="30" LOG_CI_END="-0.029246020578406952" LOG_CI_START="-0.35452503189941925" LOG_EFFECT_SIZE="-0.1918855262389131" MODIFIED="2009-01-15 11:42:20 +0000" MODIFIED_BY="[Empty name]" ORDER="189" O_E="0.0" SE="0.19107050140703696" STUDY_ID="STD-Rosen-2006" TOTAL_1="28" TOTAL_2="36" VAR="0.03650793650793652" WEIGHT="38.22152886115444"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="50.74861015124775" CI_END="0.8941273252865471" CI_START="0.6191088995136528" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7440175968236504" ESTIMABLE="YES" EVENTS_1="271" EVENTS_2="236" I2="88.1770161150857" I2_Q="0.0" ID="CMP-012.02" LOG_CI_END="-0.048600632510574136" LOG_CI_START="-0.2082329530830542" LOG_EFFECT_SIZE="-0.12841679279681417" METHOD="MH" MODIFIED="2011-02-23 10:35:27 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="3.3268963139931884E-9" P_Q="1.0" P_Z="0.0016138044660494667" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="USER" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.04049461501426082" TOTALS="YES" TOTAL_1="378" TOTAL_2="262" WEIGHT="100.0" Z="3.1534001133262874">
<NAME>Mucositis (moderate plus severe)</NAME>
<GROUP_LABEL_1>KGF</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours keratinocyte GF</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9614199423392249" CI_START="0.42455850390677474" EFFECT_SIZE="0.6388888888888888" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="18" LOG_CI_END="-0.017086873721770937" LOG_CI_START="-0.3720624557776179" LOG_EFFECT_SIZE="-0.1945746647496944" MODIFIED="2011-02-23 10:35:03 +0000" MODIFIED_BY="[Empty name]" ORDER="190" O_E="0.0" SE="0.20851441405707477" STUDY_ID="STD-Meropol-2003" TOTAL_1="54" TOTAL_2="27" VAR="0.043478260869565216" WEIGHT="10.470750977218232"/>
<DICH_DATA CI_END="0.8190533138497922" CI_START="0.4229667560864433" EFFECT_SIZE="0.5885850178359097" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="-0.08668782820638275" LOG_CI_START="-0.37369376552230404" LOG_EFFECT_SIZE="-0.2301907968643434" MODIFIED="2011-02-23 10:35:10 +0000" MODIFIED_BY="[Empty name]" ORDER="191" O_E="0.0" SE="0.16858870828167466" STUDY_ID="STD-Freytes-2004" TOTAL_1="28" TOTAL_2="14" VAR="0.028422152560083597" WEIGHT="12.758274991233304"/>
<DICH_DATA CI_END="0.9792837625049238" CI_START="0.8735035853526578" EFFECT_SIZE="0.9248826291079812" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="106" LOG_CI_END="-0.009091446467033667" LOG_CI_START="-0.05873530808725591" LOG_EFFECT_SIZE="-0.03391337727714479" MODIFIED="2011-02-23 10:35:19 +0000" MODIFIED_BY="[Empty name]" ORDER="192" O_E="0.0" SE="0.029161050056796825" STUDY_ID="STD-Spielberger-2004" TOTAL_1="106" TOTAL_2="106" VAR="8.503668404150101E-4" WEIGHT="21.26640363057648"/>
<DICH_DATA CI_END="0.9326665541161182" CI_START="0.7270631588595367" EFFECT_SIZE="0.8234728234728235" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="31" LOG_CI_END="-0.03027359697280831" LOG_CI_START="-0.1384278610078612" LOG_EFFECT_SIZE="-0.08435072899033476" MODIFIED="2011-02-23 10:35:19 +0000" MODIFIED_BY="[Empty name]" ORDER="193" O_E="0.0" SE="0.06353035006643143" STUDY_ID="STD-Blazar-2006" TOTAL_1="65" TOTAL_2="31" VAR="0.004036105379563323" WEIGHT="19.744999956082882"/>
<DICH_DATA CI_END="0.8875610895956279" CI_START="0.24627781767290596" EFFECT_SIZE="0.4675324675324675" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="22" LOG_CI_END="-0.051801745358817215" LOG_CI_START="-0.608574703451572" LOG_EFFECT_SIZE="-0.33018822440519463" MODIFIED="2011-02-23 10:35:27 +0000" MODIFIED_BY="[Empty name]" ORDER="194" O_E="0.0" SE="0.32705119165427604" STUDY_ID="STD-Rosen-2006" TOTAL_1="28" TOTAL_2="36" VAR="0.106962481962482" WEIGHT="5.962812846906074"/>
<DICH_DATA CI_END="1.0465513914696745" CI_START="0.86754457224973" EFFECT_SIZE="0.9528535980148883" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="31" LOG_CI_END="0.019760559462754505" LOG_CI_START="-0.06170820300991176" LOG_EFFECT_SIZE="-0.020973821773578646" MODIFIED="2011-02-23 10:35:27 +0000" MODIFIED_BY="[Empty name]" ORDER="195" O_E="0.0" SE="0.04785515435332237" STUDY_ID="STD-Brizel-2008" TOTAL_1="65" TOTAL_2="32" VAR="0.002290115798180309" WEIGHT="20.55076789135067"/>
<DICH_DATA CI_END="0.7339822342912986" CI_START="0.29368725075196467" EFFECT_SIZE="0.4642857142857143" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="-0.1343144518586312" LOG_CI_START="-0.5321149062121338" LOG_EFFECT_SIZE="-0.33321467903538243" MODIFIED="2010-10-18 17:55:55 +0100" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="0.23366995603125437" STUDY_ID="STD-Vadhan_x002d_Raj-2010" TOTAL_1="32" TOTAL_2="16" VAR="0.05460164835164835" WEIGHT="9.245989706632365"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.36516408580661" CI_END="0.9017158374183277" CI_START="0.5755240564539966" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7203881984873215" ESTIMABLE="YES" EVENTS_1="162" EVENTS_2="167" I2="51.761496888923546" I2_Q="0.0" ID="CMP-012.03" LOG_CI_END="-0.044930302463168266" LOG_CI_START="-0.23993651848619385" LOG_EFFECT_SIZE="-0.14243341047468105" METHOD="MH" MODIFIED="2011-02-24 14:15:32 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.06552553825223884" P_Q="1.0" P_Z="0.00419474600648173" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.030022672323631355" TOTALS="YES" TOTAL_1="324" TOTAL_2="235" WEIGHT="100.0" Z="2.863132882826897">
<NAME>Mucositis (severe)</NAME>
<GROUP_LABEL_1>KGF</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours keratinocyte GF</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.25558943732622" CI_START="0.2460692068670957" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2110027218934796" LOG_CI_START="-0.608942730565517" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2011-02-24 14:15:20 +0000" MODIFIED_BY="[Empty name]" ORDER="196" O_E="0.0" SE="1.0690449676496976" STUDY_ID="STD-Freytes-2004" TOTAL_1="28" TOTAL_2="14" VAR="1.1428571428571428" WEIGHT="1.118712786785344"/>
<DICH_DATA CI_END="0.7467108169274683" CI_START="0.5558152829919202" EFFECT_SIZE="0.6442307692307693" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="104" LOG_CI_END="-0.12684755739293815" LOG_CI_START="-0.2550695158029696" LOG_EFFECT_SIZE="-0.1909585365979539" MODIFIED="2011-02-24 14:15:32 +0000" MODIFIED_BY="[Empty name]" ORDER="197" O_E="0.0" SE="0.07531821307898302" STUDY_ID="STD-Spielberger-2004" TOTAL_1="106" TOTAL_2="106" VAR="0.0056728332214110895" WEIGHT="36.75856740422033"/>
<DICH_DATA CI_END="1.105600571554345" CI_START="0.6604087938209474" EFFECT_SIZE="0.8544871794871794" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="24" LOG_CI_END="0.04359825454426394" LOG_CI_START="-0.18018715242546882" LOG_EFFECT_SIZE="-0.06829444894060241" MODIFIED="2011-02-24 14:15:32 +0000" MODIFIED_BY="[Empty name]" ORDER="198" O_E="0.0" SE="0.1314526558096512" STUDY_ID="STD-Blazar-2006" TOTAL_1="65" TOTAL_2="31" VAR="0.017279800719410626" WEIGHT="27.73883820854839"/>
<DICH_DATA CI_END="2.718143091559291" CI_START="0.0380098924340822" EFFECT_SIZE="0.32142857142857145" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.43427231561901203" LOG_CI_START="-1.4201033594248005" LOG_EFFECT_SIZE="-0.49291552190289434" MODIFIED="2011-02-24 14:15:30 +0000" MODIFIED_BY="[Empty name]" ORDER="199" O_E="0.0" SE="1.089269450828369" STUDY_ID="STD-Rosen-2006" TOTAL_1="28" TOTAL_2="36" VAR="1.1865079365079365" WEIGHT="1.0785718313042703"/>
<DICH_DATA CI_END="1.035784288026235" CI_START="0.6400208757416499" EFFECT_SIZE="0.8142011834319527" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="26" LOG_CI_END="0.01526931885096189" LOG_CI_START="-0.193805860279324" LOG_EFFECT_SIZE="-0.08926827071418102" MODIFIED="2011-02-24 14:15:27 +0000" MODIFIED_BY="[Empty name]" ORDER="200" O_E="0.0" SE="0.12281179515995787" STUDY_ID="STD-Brizel-2008" TOTAL_1="65" TOTAL_2="32" VAR="0.01508273703041145" WEIGHT="29.08998422575136"/>
<DICH_DATA CI_END="0.7068996981167204" CI_START="0.08841424061505292" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="-0.1506422038052034" LOG_CI_START="-1.0534777788507215" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2010-10-18 17:55:22 +0100" MODIFIED_BY="[Empty name]" ORDER="337" O_E="0.0" SE="0.5303300858899106" STUDY_ID="STD-Vadhan_x002d_Raj-2010" TOTAL_1="32" TOTAL_2="16" VAR="0.28125" WEIGHT="4.2153255433903025"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2011-02-24 14:16:37 +0000" MODIFIED_BY="[Empty name]" NO="13">
<NAME>Laser versus no treatment</NAME>
<DICH_OUTCOME CHI2="2.8317860437150832" CI_END="1.1724051951462806" CI_START="0.7061407135638602" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.909880783996767" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="42" I2="29.373195251144207" I2_Q="100.0" ID="CMP-013.01" LOG_CI_END="0.06907773421058373" LOG_CI_START="-0.15110874790703055" LOG_EFFECT_SIZE="-0.041015506848223436" METHOD="MH" MODIFIED="2011-02-24 14:16:37 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.24270908806064106" P_Q="0.0" P_Z="0.4652744342950311" Q="1.1512879943973178E-32" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="67" WEIGHT="100.00000000000001" Z="0.7301893872597822">
<NAME>Mucositis (any)</NAME>
<GROUP_LABEL_1>Laser</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours laser</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4307436446842656" CI_START="0.7043191558274555" EFFECT_SIZE="1.3084415584415585" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.3857391589380878" LOG_CI_START="-0.15223049965675733" LOG_EFFECT_SIZE="0.11675432964066522" MODIFIED="2009-06-26 11:29:52 +0100" MODIFIED_BY="[Empty name]" ORDER="409" O_E="0.0" SE="0.3160060404513703" STUDY_ID="STD-Cruz-2007" TOTAL_1="28" TOTAL_2="31" VAR="0.09985981760175308" WEIGHT="24.893917963224897"/>
<DICH_DATA CI_END="1.0477509564225747" CI_START="0.6833459105640578" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.020258065944781457" LOG_CI_START="-0.16535940024200493" LOG_EFFECT_SIZE="-0.07255066714861173" MODIFIED="2009-06-26 11:02:16 +0100" MODIFIED_BY="[Empty name]" ORDER="400" O_E="0.0" SE="0.10903261845939445" STUDY_ID="STD-Antunes-2007" TOTAL_1="19" TOTAL_2="19" VAR="0.011888111888111882" WEIGHT="46.49424126086078"/>
<DICH_DATA CI_END="1.2029316496305333" CI_START="0.3694677453876539" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.08024095150309936" LOG_CI_START="-0.4324234696144619" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2010-06-14 21:34:27 +0100" MODIFIED_BY="[Empty name]" ORDER="234" O_E="0.0" SE="0.301141618694268" STUDY_ID="STD-Chor-2010" TOTAL_1="17" TOTAL_2="17" VAR="0.09068627450980389" WEIGHT="28.611840775914327"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.623432254425038" CI_END="1.0810418529505343" CI_START="0.3786235994638413" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6397718011409943" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="21" I2="78.37104676849302" I2_Q="0.0" ID="CMP-013.02" LOG_CI_END="0.03384250815646363" LOG_CI_START="-0.42179232011996703" LOG_EFFECT_SIZE="-0.19397490598175168" METHOD="MH" MODIFIED="2011-02-23 10:15:05 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.031538136187193366" P_Q="1.0" P_Z="0.09515517015488198" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="47" TOTAL_2="50" WEIGHT="100.00000000000001" Z="1.6688093448296333">
<NAME>Mucositis (moderate plus severe)</NAME>
<GROUP_LABEL_1>Laser</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours laser</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7567582336674237" CI_START="0.22404800564732757" EFFECT_SIZE="0.4117647058823529" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="17" LOG_CI_END="-0.1210428451426151" LOG_CI_START="-0.6496589175854193" LOG_EFFECT_SIZE="-0.38535088136401713" MODIFIED="2009-06-26 11:02:37 +0100" MODIFIED_BY="[Empty name]" ORDER="401" O_E="0.0" SE="0.3105116976446632" STUDY_ID="STD-Antunes-2007" TOTAL_1="19" TOTAL_2="19" VAR="0.09641751437417073" WEIGHT="81.74409127954361"/>
<DICH_DATA CI_END="5.283629589711974" CI_START="0.5219843465457342" EFFECT_SIZE="1.6607142857142858" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.722932363677006" LOG_CI_START="-0.2823425205815365" LOG_EFFECT_SIZE="0.22029492154773472" MODIFIED="2009-06-26 11:30:15 +0100" MODIFIED_BY="[Empty name]" ORDER="410" O_E="0.0" SE="0.5905034432043998" STUDY_ID="STD-Cruz-2007" TOTAL_1="28" TOTAL_2="31" VAR="0.3486943164362519" WEIGHT="18.2559087204564"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.1996794200873966" CI_END="0.6242145285526315" CI_START="0.06136844021695625" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.19572192513368986" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="16" I2="68.7468690231259" I2_Q="100.0" ID="CMP-013.03" LOG_CI_END="-0.20466612737717643" LOG_CI_START="-1.2120549149070001" LOG_EFFECT_SIZE="-0.7083605211420883" METHOD="MH" MODIFIED="2011-02-22 17:06:43 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.07365275365194512" P_Q="0.0" P_Z="0.005844932674499194" Q="1.4080271251375771E-31" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="47" TOTAL_2="50" WEIGHT="100.0" Z="2.756356089515071">
<NAME>Mucositis (severe)</NAME>
<GROUP_LABEL_1>Laser</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours laser</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.531018854307751" CI_START="0.011143031392034777" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="13" LOG_CI_END="-0.2748900586239025" LOG_CI_START="-1.952996645989771" LOG_EFFECT_SIZE="-1.1139433523068367" MODIFIED="2009-06-26 11:03:05 +0100" MODIFIED_BY="[Empty name]" ORDER="402" O_E="0.0" SE="0.9857281161802884" STUDY_ID="STD-Antunes-2007" TOTAL_1="19" TOTAL_2="19" VAR="0.9716599190283401" WEIGHT="82.03208556149733"/>
<DICH_DATA CI_END="4.100013857928528" CI_START="0.1328738388152938" EFFECT_SIZE="0.7380952380952381" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6127853246250329" LOG_CI_START="-0.8765605177522886" LOG_EFFECT_SIZE="-0.13188759656362778" MODIFIED="2009-06-26 11:30:23 +0100" MODIFIED_BY="[Empty name]" ORDER="411" O_E="0.0" SE="0.8748491201932586" STUDY_ID="STD-Cruz-2007" TOTAL_1="28" TOTAL_2="31" VAR="0.7653609831029186" WEIGHT="17.967914438502675"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2011-02-22 17:18:29 +0000" MODIFIED_BY="[Empty name]" NO="14">
<NAME>Pilocarpine versus placebo</NAME>
<DICH_OUTCOME CHI2="1.8275722222609598" CI_END="1.0974207086823384" CI_START="0.9974986729866712" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.046267509109752" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="130" I2="45.28260017199969" I2_Q="100.00000000000001" ID="CMP-014.01" LOG_CI_END="0.040373151214179184" LOG_CI_START="-0.0010876734005620032" LOG_EFFECT_SIZE="0.01964273890680861" METHOD="MH" MODIFIED="2011-02-22 17:18:16 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.17641473627889115" P_Q="0.0" P_Z="0.06329272817572204" Q="8.117633118486787E-32" RANDOM="NO" SCALE="2.0" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="138" TOTAL_2="138" WEIGHT="100.00000000000001" Z="1.8571295275868873">
<NAME>Mucositis (any)</NAME>
<GROUP_LABEL_1>Pilocarpine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours pilocarpine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1086086177462167" CI_START="0.8123077552580407" EFFECT_SIZE="0.94896331738437" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.04477825024875856" LOG_CI_START="-0.09027940045309234" LOG_EFFECT_SIZE="-0.022750575102166878" MODIFIED="2009-01-05 14:52:18 +0000" MODIFIED_BY="Philip Riley" ORDER="346" O_E="0.0" SE="0.07933353256842039" STUDY_ID="STD-Lockhart-2005" TOTAL_1="18" TOTAL_2="16" VAR="0.006293809389784619" WEIGHT="13.348711262661721"/>
<DICH_DATA CI_END="1.1154304500241121" CI_START="1.009715198181981" EFFECT_SIZE="1.0612573099415206" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="114" LOG_CI_END="0.047442496078923924" LOG_CI_START="0.004198893287439268" LOG_EFFECT_SIZE="0.025820694683181607" MODIFIED="2009-01-05 14:53:47 +0000" MODIFIED_BY="Philip Riley" ORDER="347" O_E="0.0" SE="0.02540150633900424" STUDY_ID="STD-Scarantino-2006" TOTAL_1="120" TOTAL_2="122" VAR="6.452365242904726E-4" WEIGHT="86.65128873733829"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.1540978162858666" CI_END="1.1597912228408134" CI_START="0.9417692619082179" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0451103883812571" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="113" I2="53.576852804009725" I2_Q="0.0" ID="CMP-014.02" LOG_CI_END="0.06437981773671347" LOG_CI_START="-0.02605548845423907" LOG_EFFECT_SIZE="0.019162164641237173" METHOD="MH" MODIFIED="2011-02-22 17:18:29 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.14219000947020577" P_Q="1.0" P_Z="0.40620751746896844" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="138" TOTAL_2="138" WEIGHT="100.0" Z="0.8305860652110912">
<NAME>Mucositis (moderate plus severe)</NAME>
<GROUP_LABEL_1>Pilocarpine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours pilocarpine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1609700097351434" CI_START="0.5868195678289575" EFFECT_SIZE="0.8253968253968254" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.06482100115566006" LOG_CI_START="-0.23149541279322516" LOG_EFFECT_SIZE="-0.08333720581878257" MODIFIED="2009-01-05 14:52:41 +0000" MODIFIED_BY="Philip Riley" ORDER="348" O_E="0.0" SE="0.17405772834348035" STUDY_ID="STD-Lockhart-2005" TOTAL_1="18" TOTAL_2="16" VAR="0.0302960927960928" WEIGHT="13.1175468483816"/>
<DICH_DATA CI_END="1.2025012923659146" CI_START="0.9668961398636184" EFFECT_SIZE="1.0782828282828283" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="99" LOG_CI_END="0.08008555179604294" LOG_CI_START="-0.014620173597019837" LOG_EFFECT_SIZE="0.03273268909951156" MODIFIED="2009-01-05 14:54:53 +0000" MODIFIED_BY="Philip Riley" ORDER="349" O_E="0.0" SE="0.05563061189678651" STUDY_ID="STD-Scarantino-2006" TOTAL_1="120" TOTAL_2="122" VAR="0.003094764980010885" WEIGHT="86.88245315161839"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2011-02-22 17:19:07 +0000" MODIFIED_BY="[Empty name]" NO="15">
<NAME>Povidone versus water</NAME>
<DICH_OUTCOME CHI2="3.347546815745173" CI_END="1.082184629345484" CI_START="0.756194020925016" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9046223224351749" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="66" I2="70.12737819538464" I2_Q="0.0" ID="CMP-015.01" LOG_CI_END="0.03430136120084514" LOG_CI_START="-0.12136676083957436" LOG_EFFECT_SIZE="-0.0435326998193646" METHOD="MH" MODIFIED="2011-02-22 17:18:43 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06730532684590118" P_Q="1.0" P_Z="0.2729866330702767" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="87" TOTAL_2="85" WEIGHT="100.0" Z="1.096210613674569">
<NAME>Mucositis (any)</NAME>
<GROUP_LABEL_1>Povidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours povidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9491105775238242" CI_START="0.527122396321889" EFFECT_SIZE="0.7073170731707317" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="20" LOG_CI_END="-0.022683186507582494" LOG_CI_START="-0.27808853113397636" LOG_EFFECT_SIZE="-0.15038585882077943" MODIFIED="2009-01-05 14:55:34 +0000" MODIFIED_BY="Philip Riley" ORDER="351" O_E="0.0" SE="0.15002636371038966" STUDY_ID="STD-Rahn-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.022507909808162127" WEIGHT="30.507328072153328"/>
<DICH_DATA CI_END="1.2363054644155937" CI_START="0.7947515280244669" EFFECT_SIZE="0.991239454899416" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="46" LOG_CI_END="0.09212578881093722" LOG_CI_START="-0.09976862841859215" LOG_EFFECT_SIZE="-0.0038214198038274516" MODIFIED="2009-01-05 14:57:19 +0000" MODIFIED_BY="Philip Riley" ORDER="352" O_E="0.0" SE="0.11271973057331053" STUDY_ID="STD-Vokurka-2005" TOTAL_1="67" TOTAL_2="65" VAR="0.012705737660519717" WEIGHT="69.49267192784667"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.5515066580103" CI_END="1.0957384338589484" CI_START="0.6155951794906459" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8212985436893204" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="49" I2="86.75760950380354" I2_Q="0.0" ID="CMP-015.02" LOG_CI_END="0.03970689512545252" LOG_CI_START="-0.210704789634596" LOG_EFFECT_SIZE="-0.08549894725457174" METHOD="MH" MODIFIED="2011-02-22 17:18:56 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.005996040394496194" P_Q="1.0" P_Z="0.1807677497963951" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="87" TOTAL_2="85" WEIGHT="100.0" Z="1.3383948715941534">
<NAME>Mucositis (moderate plus severe)</NAME>
<GROUP_LABEL_1>Povidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours povidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7453922804485456" CI_START="0.2881075224065349" EFFECT_SIZE="0.4634146341463415" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="20" LOG_CI_END="-0.1276151092692727" LOG_CI_START="-0.5404454022645404" LOG_EFFECT_SIZE="-0.33403025576690654" MODIFIED="2009-01-05 14:55:46 +0000" MODIFIED_BY="Philip Riley" ORDER="353" O_E="0.0" SE="0.24249855764832837" STUDY_ID="STD-Rahn-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.05880555046151964" WEIGHT="41.0497572815534"/>
<DICH_DATA CI_END="1.5480844476908417" CI_START="0.7402636445505731" EFFECT_SIZE="1.0705095213587237" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="29" LOG_CI_END="0.18979464766845805" LOG_CI_START="-0.13061357894249997" LOG_EFFECT_SIZE="0.02959053436297905" MODIFIED="2010-05-10 10:15:17 +0100" MODIFIED_BY="Anne Littlewood" ORDER="354" O_E="0.0" SE="0.1882093783575779" STUDY_ID="STD-Vokurka-2005" TOTAL_1="67" TOTAL_2="65" VAR="0.03542277010174591" WEIGHT="58.950242718446596"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.7301220246794364" CI_END="1.0601577572197582" CI_START="0.4021874898315721" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6529794692038057" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="30" I2="73.19122555820573" I2_Q="0.0" ID="CMP-015.03" LOG_CI_END="0.025370495446099473" LOG_CI_START="-0.39557144239570186" LOG_EFFECT_SIZE="-0.18510047347480119" METHOD="MH" MODIFIED="2011-02-22 17:19:07 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.053439743303275944" P_Q="1.0" P_Z="0.08476076863022362" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="87" TOTAL_2="85" WEIGHT="100.0" Z="1.7237069007282713">
<NAME>Mucositis (severe)</NAME>
<GROUP_LABEL_1>Povidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours povidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7827062162591947" CI_START="0.12095797151771454" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.1064012169960797" LOG_CI_START="-0.9173655049616689" LOG_EFFECT_SIZE="-0.5118833609788743" MODIFIED="2009-01-05 14:55:58 +0000" MODIFIED_BY="Philip Riley" ORDER="355" O_E="0.0" SE="0.476364437088955" STUDY_ID="STD-Rahn-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.22692307692307695" WEIGHT="42.96444667000501"/>
<DICH_DATA CI_END="1.6493162272136932" CI_START="0.505493177628725" EFFECT_SIZE="0.913081650570676" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" LOG_CI_END="0.2173039319133145" LOG_CI_START="-0.2962847014739546" LOG_EFFECT_SIZE="-0.039490384780320006" MODIFIED="2009-01-05 14:57:59 +0000" MODIFIED_BY="Philip Riley" ORDER="356" O_E="0.0" SE="0.3016845055564189" STUDY_ID="STD-Vokurka-2005" TOTAL_1="67" TOTAL_2="65" VAR="0.09101354089282096" WEIGHT="57.03555332999499"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" MODIFIED="2011-02-22 17:19:26 +0000" MODIFIED_BY="[Empty name]" NO="16">
<NAME>Prostaglandin versus placebo</NAME>
<DICH_OUTCOME CHI2="7.868383378047305" CI_END="1.1151993854896909" CI_START="0.9421713563628679" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0250409346176663" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="72" I2="74.5818180951887" I2_Q="0.0" ID="CMP-016.01" LOG_CI_END="0.04735252144393613" LOG_CI_START="-0.025870103199718386" LOG_EFFECT_SIZE="0.01074120912210889" METHOD="MH" MODIFIED="2011-02-22 17:19:18 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.019561544759086114" P_Q="1.0" P_Z="0.5652750726557382" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="82" TOTAL_2="77" WEIGHT="100.0" Z="0.5750239938051969">
<NAME>Mucositis (any)</NAME>
<GROUP_LABEL_1>Prostaglandin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prostaglandin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0476646580906932" CI_START="0.8389194416482032" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="29" LOG_CI_END="0.020222293672116146" LOG_CI_START="-0.0762797408726032" LOG_EFFECT_SIZE="-0.02802872360024354" MODIFIED="2009-01-06 11:18:59 +0000" MODIFIED_BY="Philip Riley" ORDER="362" O_E="0.0" SE="0.05668577278434327" STUDY_ID="STD-Labar-1993" TOTAL_1="31" TOTAL_2="29" VAR="0.0032132768361581923" WEIGHT="40.770752168042165"/>
<DICH_DATA CI_END="10.266031680982246" CI_START="0.9428192554294685" EFFECT_SIZE="3.111111111111111" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.0114026001599417" LOG_CI_START="-0.025571556354152845" LOG_EFFECT_SIZE="0.49291552190289434" MODIFIED="2009-01-06 11:18:27 +0000" MODIFIED_BY="Philip Riley" ORDER="361" O_E="0.0" SE="0.6091237526412395" STUDY_ID="STD-Duenas-1996" TOTAL_1="9" TOTAL_2="7" VAR="0.371031746031746" WEIGHT="3.0124575886874374"/>
<DICH_DATA CI_END="1.04318626939461" CI_START="0.9145338976991254" EFFECT_SIZE="0.9767441860465116" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="41" LOG_CI_END="0.018361862163345545" LOG_CI_START="-0.0388001925267177" LOG_EFFECT_SIZE="-0.010219165181686082" MODIFIED="2009-07-20 16:10:47 +0100" MODIFIED_BY="[Empty name]" ORDER="431" O_E="0.0" SE="0.03357727388167735" STUDY_ID="STD-Veness-2006" TOTAL_1="42" TOTAL_2="41" VAR="0.001127433321325172" WEIGHT="56.216790243270395"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.056536847132001876" CI_END="1.4301341341361289" CI_START="0.7201104120665376" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0148174617354535" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-016.02" LOG_CI_END="0.15537677241836562" LOG_CI_START="-0.14260090957576407" LOG_EFFECT_SIZE="0.00638793142130076" METHOD="MH" MODIFIED="2011-02-22 17:19:26 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.812055780553126" P_Q="1.0" P_Z="0.933029467277393" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="70" WEIGHT="100.0" Z="0.08403391447086901">
<NAME>Mucositis (severe)</NAME>
<GROUP_LABEL_1>Prostaglandin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours prostaglandin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.704945473115214" CI_START="0.6592914424253006" EFFECT_SIZE="1.060215053763441" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.2317104941180487" LOG_CI_START="-0.18092256134349644" LOG_EFFECT_SIZE="0.025393966387276125" MODIFIED="2010-10-29 16:22:41 +0100" MODIFIED_BY="[Empty name]" ORDER="363" O_E="0.0" SE="0.24238269934467824" STUDY_ID="STD-Labar-1993" TOTAL_1="31" TOTAL_2="29" VAR="0.058749372941612685" WEIGHT="45.97105592281579"/>
<DICH_DATA CI_END="1.596004369308024" CI_START="0.5970834818066043" EFFECT_SIZE="0.9761904761904762" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" LOG_CI_END="0.20303407596443934" LOG_CI_START="-0.22396494332076938" LOG_EFFECT_SIZE="-0.01046543367816498" MODIFIED="2010-10-29 16:22:42 +0100" MODIFIED_BY="[Empty name]" ORDER="435" O_E="0.0" SE="0.250821337607366" STUDY_ID="STD-Veness-2006" TOTAL_1="42" TOTAL_2="41" VAR="0.06291134339914828" WEIGHT="54.02894407718421"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" MODIFIED="2011-02-22 17:19:52 +0000" MODIFIED_BY="[Empty name]" NO="17">
<NAME>PTA antibiotic pastille or paste versus placebo/no treatment</NAME>
<DICH_OUTCOME CHI2="0.4201586005988479" CI_END="0.963673532761512" CI_START="0.7844917421477398" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8694791133648614" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="131" I2="0.0" I2_Q="0.0" ID="CMP-017.01" LOG_CI_END="-0.01607006872543425" LOG_CI_START="-0.10541162359845242" LOG_EFFECT_SIZE="-0.06074084616194335" METHOD="MH" MODIFIED="2011-02-22 17:19:42 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.516857933820143" P_Q="1.0" P_Z="0.007697679757861058" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="151" TOTAL_2="147" WEIGHT="100.0" Z="2.6650503461038575">
<NAME>Mucositis (any)</NAME>
<GROUP_LABEL_1>PTA antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PTA antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9649294350115449" CI_START="0.7537299606467457" EFFECT_SIZE="0.8528166421207658" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="97" LOG_CI_END="-0.015504445314901685" LOG_CI_START="-0.12278422124811855" LOG_EFFECT_SIZE="-0.06914433328151011" MODIFIED="2008-12-23 13:25:47 +0000" MODIFIED_BY="Philip Riley" ORDER="246" O_E="0.0" SE="0.06301667142662702" STUDY_ID="STD-Symonds-1996" TOTAL_1="112" TOTAL_2="109" VAR="0.00397110087769147" WEIGHT="74.05694536170273"/>
<DICH_DATA CI_END="1.1010509771670178" CI_START="0.7637877260580578" EFFECT_SIZE="0.9170437405731523" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="34" LOG_CI_END="0.04180742668276521" LOG_CI_START="-0.11702732494684163" LOG_EFFECT_SIZE="-0.03760994913203822" MODIFIED="2008-12-23 13:26:25 +0000" MODIFIED_BY="Philip Riley" ORDER="247" O_E="0.0" SE="0.09330031935193203" STUDY_ID="STD-Wijers-2001" TOTAL_1="39" TOTAL_2="38" VAR="0.008704949591172503" WEIGHT="25.943054638297266"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.09011029938583225" CI_END="1.0880510065752356" CI_START="0.6607377653718852" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8478893740902474" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-017.02" LOG_CI_END="0.03664925506338383" LOG_CI_START="-0.17997086978637156" LOG_EFFECT_SIZE="-0.07166080736149386" METHOD="MH" MODIFIED="2011-02-22 17:19:52 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.764036995723427" P_Q="1.0" P_Z="0.19471236359676883" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="68" WEIGHT="100.0" Z="1.2967641084041166">
<NAME>Mucositis (severe)</NAME>
<GROUP_LABEL_1>PTA antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PTA antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.365120657535483" CI_START="0.4829525332885556" EFFECT_SIZE="0.811965811965812" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" LOG_CI_END="0.13517103861929455" LOG_CI_START="-0.3160955515339223" LOG_EFFECT_SIZE="-0.09046225645731387" MODIFIED="2010-10-22 16:50:29 +0100" MODIFIED_BY="[Empty name]" ORDER="252" O_E="0.0" SE="0.2650762288616472" STUDY_ID="STD-Wijers-2001" TOTAL_1="39" TOTAL_2="38" VAR="0.07026540710751236" WEIGHT="41.15720524017467"/>
<DICH_DATA CI_END="1.095764805549069" CI_START="0.695547722173613" EFFECT_SIZE="0.873015873015873" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="27" LOG_CI_END="0.0397173473842422" LOG_CI_START="-0.15767306730291789" LOG_EFFECT_SIZE="-0.05897785995933785" MODIFIED="2008-12-23 13:29:18 +0000" MODIFIED_BY="Philip Riley" ORDER="251" O_E="0.0" SE="0.11594810668554897" STUDY_ID="STD-Stokman-2003" TOTAL_1="28" TOTAL_2="30" VAR="0.013443963443963446" WEIGHT="58.84279475982533"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-018" MODIFIED="2010-11-05 11:16:04 +0000" MODIFIED_BY="[Empty name]" NO="18">
<NAME>Radiotherapy: am versus pm</NAME>
<DICH_OUTCOME CHI2="2.372430919066646" CI_END="1.357394148837378" CI_START="0.8483551058260458" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.073104028873524" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="67" I2="57.849141487608975" I2_Q="0.0" ID="CMP-018.01" LOG_CI_END="0.13270597279627866" LOG_CI_START="-0.07142232201297014" LOG_EFFECT_SIZE="0.03064182539165428" METHOD="MH" MODIFIED="2010-11-05 11:16:04 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.12349478459514496" P_Q="1.0" P_Z="0.5562485223452587" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="189" TOTAL_2="193" WEIGHT="100.0" Z="0.5884228273628456">
<NAME>Mucositis (severe)</NAME>
<GROUP_LABEL_1>AM</GROUP_LABEL_1>
<GROUP_LABEL_2>PM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours AM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PM</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4939081820688493" CI_START="0.9312273980637922" EFFECT_SIZE="1.1794779477947794" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="55" LOG_CI_END="0.174323905882168" LOG_CI_START="-0.030944254931216747" LOG_EFFECT_SIZE="0.07168982547547563" MODIFIED="2010-10-22 16:48:32 +0100" MODIFIED_BY="[Empty name]" ORDER="439" O_E="0.0" SE="0.12057553375556558" STUDY_ID="STD-Bjarnason-2009" TOTAL_1="101" TOTAL_2="104" VAR="0.014538459340439534" WEIGHT="81.95571448218952"/>
<DICH_DATA CI_END="1.4285491054601684" CI_START="0.24364252032693617" EFFECT_SIZE="0.5899621212121212" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.1548951735698927" LOG_CI_START="-0.6132469166471405" LOG_EFFECT_SIZE="-0.22917587153862384" MODIFIED="2010-03-09 13:10:52 +0000" MODIFIED_BY="[Empty name]" ORDER="491" O_E="0.0" SE="0.4512104661581556" STUDY_ID="STD-Goyal-2009" TOTAL_1="88" TOTAL_2="89" VAR="0.20359088477066004" WEIGHT="18.04428551781048"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-019" MODIFIED="2011-02-22 17:20:39 +0000" MODIFIED_BY="[Empty name]" NO="19">
<NAME>Sucralfate versus placebo/usual care</NAME>
<DICH_OUTCOME CHI2="1.0510020464844538" CI_END="1.0952307546362792" CI_START="0.8834200930795089" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9836406128278369" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="95" I2="0.0" I2_Q="0.0" ID="CMP-019.01" LOG_CI_END="0.03950563050695769" LOG_CI_START="-0.05383272708994833" LOG_EFFECT_SIZE="-0.0071635482914953145" METHOD="MH" MODIFIED="2011-02-22 17:20:13 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5912591461490533" P_Q="1.0" P_Z="0.7635309348931816" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="YEAR" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="112" TOTAL_2="110" WEIGHT="100.00000000000001" Z="0.30084730467358595">
<NAME>Mucositis (any)</NAME>
<GROUP_LABEL_1>Sucralfate</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sucralfate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2045981471474054" CI_START="0.917479371826193" EFFECT_SIZE="1.0512820512820513" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="19" LOG_CI_END="0.08084219082503445" LOG_CI_START="-0.03740369143856187" LOG_EFFECT_SIZE="0.021719249693236305" MODIFIED="2011-02-16 12:19:37 +0000" MODIFIED_BY="[Empty name]" ORDER="429" O_E="0.0" SE="0.0694582165681937" STUDY_ID="STD-Makkonen-1994" TOTAL_1="20" TOTAL_2="20" VAR="0.004824443848834098" WEIGHT="20.254479356011426"/>
<DICH_DATA CI_END="1.1158756093571336" CI_START="0.8182690006811102" EFFECT_SIZE="0.9555555555555556" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="45" LOG_CI_END="0.047615784941427694" LOG_CI_START="-0.08710390133294192" LOG_EFFECT_SIZE="-0.01974405819575713" MODIFIED="2011-02-16 12:19:36 +0000" MODIFIED_BY="[Empty name]" ORDER="427" O_E="0.0" SE="0.07913501059076694" STUDY_ID="STD-Castagna-2001" TOTAL_1="51" TOTAL_2="51" VAR="0.006262349901200795" WEIGHT="46.74110620618021"/>
<DICH_DATA CI_END="1.2327774467948027" CI_START="0.7820839782915855" EFFECT_SIZE="0.981904012588513" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="31" LOG_CI_END="0.0908846805269095" LOG_CI_START="-0.10674661094211546" LOG_EFFECT_SIZE="-0.00793096520760298" MODIFIED="2011-02-16 12:19:38 +0000" MODIFIED_BY="[Empty name]" ORDER="430" O_E="0.0" SE="0.1160895988995757" STUDY_ID="STD-Nottage-2003" TOTAL_1="41" TOTAL_2="39" VAR="0.013476794972664366" WEIGHT="33.004414437808364"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.159547657075704" CI_END="1.0384164480487417" CI_START="0.5394620959959266" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7484559529999206" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="57" I2="51.29512478803883" I2_Q="0.0" ID="CMP-019.02" LOG_CI_END="0.01637155853972331" LOG_CI_START="-0.2680390645642241" LOG_EFFECT_SIZE="-0.12583375301225042" METHOD="MH" MODIFIED="2011-02-22 17:20:22 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.10410077855365718" P_Q="1.0" P_Z="0.08286118607013399" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.05578903800270392" TOTALS="YES" TOTAL_1="86" TOTAL_2="78" WEIGHT="100.0" Z="1.734320759554612">
<NAME>Mucositis (moderate plus severe)</NAME>
<GROUP_LABEL_1>Sucralfate</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sucralfate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3340019532379148" CI_START="0.6686461788732437" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.12515646547245463" LOG_CI_START="-0.17480363292251888" LOG_EFFECT_SIZE="-0.024823583725032152" MODIFIED="2011-02-16 12:30:25 +0000" MODIFIED_BY="[Empty name]" ORDER="437" O_E="0.0" SE="0.17619804662364144" STUDY_ID="STD-Shenep-1988" TOTAL_1="24" TOTAL_2="24" VAR="0.031045751633986922" WEIGHT="32.14201320329361"/>
<DICH_DATA CI_END="1.3682778805245681" CI_START="0.636647806348478" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.13617430624601318" LOG_CI_START="-0.19610075300089963" LOG_EFFECT_SIZE="-0.02996322337744321" MODIFIED="2011-02-16 12:30:25 +0000" MODIFIED_BY="[Empty name]" ORDER="434" O_E="0.0" SE="0.19518001458970666" STUDY_ID="STD-Makkonen-1994" TOTAL_1="20" TOTAL_2="20" VAR="0.0380952380952381" WEIGHT="29.728566603592533"/>
<DICH_DATA CI_END="0.9362280507022956" CI_START="0.2326118915305042" EFFECT_SIZE="0.4666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="-0.0286183509433344" LOG_CI_START="-0.6333680871395144" LOG_EFFECT_SIZE="-0.3309932190414244" MODIFIED="2011-02-16 12:30:24 +0000" MODIFIED_BY="[Empty name]" ORDER="433" O_E="0.0" SE="0.3552329886011098" STUDY_ID="STD-Franzen-1995" TOTAL_1="24" TOTAL_2="24" VAR="0.1261904761904762" WEIGHT="15.337138179437659"/>
<DICH_DATA CI_END="0.9215242926477607" CI_START="0.3349254900506632" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="-0.035493211694160046" LOG_CI_START="-0.47505179851245205" LOG_EFFECT_SIZE="-0.255272505103306" MODIFIED="2011-02-16 12:30:24 +0000" MODIFIED_BY="[Empty name]" ORDER="431" O_E="0.0" SE="0.2581988897471611" STUDY_ID="STD-Cengiz-1999" TOTAL_1="18" TOTAL_2="10" VAR="0.06666666666666665" WEIGHT="22.792282013676203"/>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="9.125430132714873" CI_END="0.9164731318386917" CI_START="0.48383941265106045" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_SIZE="0.6659022614613277" ESTIMABLE="YES" I2="34.24967467023977" I2_Q="0.0" ID="CMP-019.03" LOG_CI_END="-0.03788026268784028" LOG_CI_START="-0.3152987577192677" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.176589510203554" MODIFIED="2011-02-22 17:20:39 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.1666459676298272" P_Q="1.0" P_Z="0.012588163750483859" Q="0.0" RANDOM="YES" SCALE="50.0" SHOW_PARTICIPANTS="NO" SORT_BY="YEAR" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.057350703231803364" TOTALS="YES" TOTAL_1="215" TOTAL_2="208" WEIGHT="100.0" Z="2.495212729110402">
<NAME>Mucositis (severe)</NAME>
<GROUP_LABEL_1>Sucralfate</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sucralfate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.0682036338094743" CI_START="0.1016745360036189" EFFECT_SIZE="0.329558961075189" ESTIMABLE="YES" ESTIMATE="-1.11" LOG_CI_END="0.028654051016303937" LOG_CI_START="-0.9927878008415232" LOG_EFFECT_SIZE="-0.4820668749126096" MODIFIED="2010-05-11 13:31:43 +0100" MODIFIED_BY="Helen Worthington" ORDER="528" SE="0.6" STUDY_ID="STD-Shenep-1988" TOTAL_1="24" TOTAL_2="24" WEIGHT="6.362750257519315"/>
<IV_DATA CI_END="0.671930342488378" CI_START="0.07137558612313263" EFFECT_SIZE="0.21899639729690817" ESTIMABLE="YES" ESTIMATE="-1.5187" LOG_CI_END="-0.17267574694757096" LOG_CI_START="-1.1464503123853662" LOG_EFFECT_SIZE="-0.6595630296664685" MODIFIED="2010-10-22 16:56:28 +0100" MODIFIED_BY="[Empty name]" ORDER="527" SE="0.572" STUDY_ID="STD-Scherlacher-1990" TOTAL_1="24" TOTAL_2="21" WEIGHT="6.905744194596788"/>
<IV_DATA CI_END="1.242583645330193" CI_START="0.5673421052872727" EFFECT_SIZE="0.839624928963621" ESTIMABLE="YES" ESTIMATE="-0.1748" LOG_CI_END="0.09432563320628275" LOG_CI_START="-0.2461549840796596" LOG_EFFECT_SIZE="-0.07591467543668841" MODIFIED="2010-05-11 11:48:15 +0100" MODIFIED_BY="[Empty name]" ORDER="526" SE="0.2" STUDY_ID="STD-Pfeiffer-1990" TOTAL_1="23" TOTAL_2="23" WEIGHT="27.27764881308534"/>
<IV_DATA CI_END="2.1831017728531505" CI_START="0.006599596968987253" EFFECT_SIZE="0.12003162851145673" ESTIMABLE="YES" ESTIMATE="-2.12" LOG_CI_END="0.33907398232309294" LOG_CI_START="-2.180482585592881" LOG_EFFECT_SIZE="-0.9207043016348939" MODIFIED="2010-05-11 12:48:19 +0100" MODIFIED_BY="Helen Worthington" ORDER="533" SE="1.48" STUDY_ID="STD-Cengiz-1999" TOTAL_1="0" TOTAL_2="0" WEIGHT="1.1814024974593327"/>
<IV_DATA CI_END="1.308252237539346" CI_START="0.5522844394297028" EFFECT_SIZE="0.8500160902253981" ESTIMABLE="YES" ESTIMATE="-0.1625" LOG_CI_END="0.11669148619798986" LOG_CI_START="-0.2578371928165467" LOG_EFFECT_SIZE="-0.07057285330927841" ORDER="523" SE="0.22" STUDY_ID="STD-Carter-1999" TOTAL_1="52" TOTAL_2="50" WEIGHT="25.11092799679286"/>
<IV_DATA CI_END="1.0465201610482184" CI_START="0.3732635546813159" EFFECT_SIZE="0.6250022682827008" ESTIMABLE="YES" ESTIMATE="-0.47" LOG_CI_END="0.019747599370978804" LOG_CI_START="-0.42798441236003537" LOG_EFFECT_SIZE="-0.20411840649452836" ORDER="524" SE="0.263" STUDY_ID="STD-Castagna-2001" TOTAL_1="51" TOTAL_2="51" WEIGHT="20.988812229497146"/>
<IV_DATA CI_END="1.8784473497053074" CI_START="0.3900635681826703" EFFECT_SIZE="0.8559870769289292" ESTIMABLE="YES" ESTIMATE="-0.1555" LOG_CI_END="0.2737990268932016" LOG_CI_START="-0.40886461076511293" LOG_EFFECT_SIZE="-0.06753279193595564" MODIFIED="2010-05-11 12:42:19 +0100" MODIFIED_BY="Helen Worthington" ORDER="525" SE="0.401" STUDY_ID="STD-Nottage-2003" TOTAL_1="41" TOTAL_2="39" WEIGHT="12.172714011049218"/>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-11-10 14:38:46 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-11-10 14:38:46 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias assessment graph: review authors' judgements about each risk of bias domain presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAApoAAAEZCAMAAAAAHnUmAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-11-10 14:38:46 +0000" MODIFIED_BY="[Empty name]" NO="2" NOTES="&lt;p&gt; Makkonen TA, Minn H, Jekunen A, Vilja P, Tuominen J, Joeensuu H. Granulocyte Macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: A prospective randomized study. International Journal of Radiation Oncology, Biology and Physics 2000;46(3):525-34. McAleese 2006 McAleese JJ, Bishop KM, A'Hern R, Henk JM. Randomized phase II study of GM-CSF to reduce mucositis caused by accelerated radiotherapy of laryngeal cancer. British Journal of Radiology 2006;79(943):608-13. Meropol 2003 Meropol NJ, Somer RA, Gutheil J, Pelley RJ, Modiano MR, Rowinsky EK et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. Journal of Clinical Oncology 2003;21(8):1452-8.Meropol NJ, Somer RA, Gutheil J, Pelley RJ, Modiano MR, Rowinsky EK, et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant.+AFs-comment+AF0-. Journal of Clinical Oncology 2003+ADs- 21(8):1452-8. Mills 1988 Mills EE. The modifying effect of beta-carotene on radiation and chemotherapy induced oral mucositis. British Journal of Cancer 1988;57(4):416-7. Motallebnejad 2008 Motallebnejad M, Akram S, Moghadamnia A, Moulana Z, Omidi S. The effect of topical application of pure honey on radiation-induced mucositis: a randomized clinical trial. Journal of Contemporary Dental Practice [Electronic Resource] 2008;9(3):40-7. Naidu 2005 Naidu MU, Ramana GV, Ratnam SV, Sudhavani T, Naidu KJ, Roy P et al. A randomised, double-blind, parallel, placebo-controlled study to evaluate the efficacy of MF 5232 (Mucotrol), a concentrated oral gel wafer, in the treatment of oral mucositis. Drugs in R&amp;amp;D 2005;6(5):291-8. Nemunaitis 1995 Nemunaitis J, Rosenfeld CS, Ash R, Freedman MH, Deeg HJ, Appelbaum F et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplantation 1995;15(6):949-54. Niibe 1985 Niibe H, Takahashi I, Mitsuhashi N, Miyaishi K, Itoh J, Maehara Y et al. An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study.1. Head and neck tumors. Nippon-gan-chiryo-gakkai-shi 1985;20(5):984-93. Nottage 2003 Nottage M, McLachlan SA, Brittain MA, Oza A, Hedley D, Feld R, et al. Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial. Supportive Care in Cancer 2003;11(1):41-7.Nottage M, McLachlan SA, Brittain MA, Oza A, Hedley D, Feld R, et al. Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial. Supportive Care in Cancer 2003+ADs- 11(1):41-7. Oberbaum 2001 Oberbaum M, Yaniv I, Ben-Gal Y, Stein J, Ben-Zvi N, Freedman LS et al. A randomized, controlled clinical trial of the homeopathic medication TRAUMEEL S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation. American Cancer Society 2001;92(3):684-90. Oberbaum M, Yaniv I, Ben-Gal Y, Stein J, Ben-Zvi N, Freedman LS et al. A randomized, controlled clinical trial of the homoeopathic medication Traumeel S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation. Biologische Medizin 2002;31(1):25-31.Oberbaum MYIB-GYSJZNFLBD. A randomized, controlled clinical trial of the homoeopathic medication Traumeel S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation. Biologische Medizin 2002+ADs- Vol 31(1): 25-31. Oberbaum MY. Randomized, controlled study to prove the effectiveness of traumeel (R)s in the management of chemotherapy-induced stomatitis in children and young adults undergoing bone-marrow transplantation. Biol Medizin 2002;31(1):26-31. Okuno 1999 Okuno SH, Woodhouse CO, Loprinzi CL, Sloan JA, LaVasseur BI, Clemens-Schutjer D et al. Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy. American Journal of Clinical Oncology 1999;22(3):258-61. Papas 2003Reconsider inclusion as patients received active mouthwash + active Fl plate versus placebo (Fl) mouthwash and placebo plate. Papas AS, Clark RE, Martuscelli G, O'Loughlin KT, Johansen E, Miller KB. A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplantation 2003;31(8):705-12.Papas AS, Clark RE, Martuscelli G, O'Loughlin KT, Johansen E, Miller KB. A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplantation 2003+ADs- 31(8):705-12. Peterson 2007 Peterson DE, Jones JB, Petit RG. Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer 2007;109(2):322-31. Pfeiffer 1990 Pfeiffer P, Madsen EL, Hansen O, May O. Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy. Acta Oncologica 1990;29(2):171-3. Pillsbury 1986 Pillsbury HC 3rd, Webster WP, Rosenman J. Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers. Archives of Otolaryngology - Head &amp;amp; Neck Surgery 1986;112(5):552-3.Pillsbury HC 3rd WW, Rosenman J. Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers. Archives of Otolaryngology -- Head &amp;amp; Neck Surgery 1986;112(5):552-3. Pitten 2003 Pitten FA, Kiefer T, Buth C, Doelken G, Kramer A. Do cancer patients with chemotherapy-induced leukopenia benefit from an antiseptic chlorhexidine-based oral rinse? A double-blind, block-randomized, controlled study. Journal of Hospital Infection 2003;53(4):283-91.Pitten FA, Kiefer T, Buth C, Doelken G, Kramer A. Do cancer patients with chemotherapy-induced leukopenia benefit from an antiseptic chlorhexidine-based oral rinse? A double-blind, block-randomized, controlled study. Journal of Hospital Infection 2003+ADs- 53(4):283-91. Prada 1987 Prada A, Chiesa F. Effects of benzydamine on the oral mucositis during antineoplastic radiotherapy and/or intra-arterial chemotherapy. International Journal of Tissue Reaction 1987;9(2):115-9. Rahn 1997 Adamietz IA, Rahn R, Bottcher HD, Schafer V, Reimer K, Fleischer W. Prophylaxis of radiochemotherapy-induced mucositis. Efficacy of prophylactic oral rinsing with povidone iodine solution [Pophylaxe der radiochemotherapeutisch bedingten mukositis]. Stranhlentherapie und Onkologie 1998;174(3):149-55. Adamietz IA, Rhan R, Bottcher HD, Schafer V, Reimer K, Fleischer W. Prophylaxis with povidone-iodine against induction of oral mucositis by radiochemotherapy. Supportive Care in Cancer 1998;6(4):373-7. Rahn R AI, Bottcher HD, Reimer K, and Fleischer W. PVP-iodine solution as a mucositis prophylaxis by radiotherapy. Deutsche Zeitschrift fur Mund-, Kiefer- und Gesichtschirurgie 1996;20(3):137-9. Rahn R, Adamietz IA, Boettcher HD, Schaefer V, Reimer K, Fleischer W. Povidone-iodine to prevent mucositis in patients during antineoplastic radiochemotherapy. Dermatology 1997;195(Suppl 2):57-61. Rashad 2008 Rashad UM, Al-Gezawy SM, El-Gezawy E, Azzaz AN. Honey as topical prophylaxis against radiochemotherapy-induced mucositis in head and neck cancer. Journal of Laryngology &amp;amp; Otology 2009;123(2):223-8. Rocke 1993 Rocke LK, Loprinzi CL, Lee JK, Kunselman SJ, Iverson RK, Finck G et al. A randomized clinical trial of two different durations or oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. Cancer 1993;72(7):2234-8. Rosen 2006 Rosen LS, Abdi E, Davis ID, Gutheil J, Schnell FM, Zalcberg J, et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.[see comment]. Journal of Clinical Oncology 2006;24(33):5194-200. Rothwell 1990 Rothwell BR. Palliation of radiation-related mucositis. Special Care in Dentistry 1990:21-25. Saarilahti 2002 Saarilahti K, Kajanti M, Joensuu T, Kouri M, Joensuu H. Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized phase III study. International Journal of Radiation Oncology Biology and Physics 2002;54(2):479-85.Saarilahti K KM, Joensuu T, Kouri M, Joensuu H. Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized phase III study. International Journal of Radiation Oncology, Biology, Physics 2002+ADs-54(2):479-85. Scarantino 2006 Scarantino C, LeVeque F, Swann RS, White R, Schulsinger A, Hodson DI et al. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients. The Journal of Supportive Oncology 2006;4(5):252-8.Scarantino C, LeVeque F, Swann RS, White R, Schulsinger A, Hodson DI, et al. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients. The Journal of Supportive Oncology. 2006;4(5):252-8. Scherlacher 1990 Scherlacher A, Beaufort-Spontin F. [Radiotherapy of head-neck neoplasms: prevention of inflammation of the mucosa by sucralfate treatment]. [German]. HNO 1990;38(1):24-8.Scherlacher A B-SF. [Radiotherapy of head-neck neoplasms: prevention of inflammation of the mucosa by sucralfate treatment]. [German]. HNO 1990;38(1):24-8. Schneider 1999 Schneider SB, Nishimura RD, Zimmerman RP, Tran L, Shiplacoff J, Tormey M et al. Filgrastim (r-metHuG-CSF) and its potential use in the reduction of radiation-induced oropharyngeal mucositis: An interim look at a randomized, double blind, placebo-controlled trial. Cytokines, Cellular and Molecular Therapy 1999;5(3):175-80. Schubert 2007 Schubert MM, Eduardo FP, Guthrie KA, Franquin JC, Bensadoun RJ, Migliorati CA, et al. A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Supportive Care in Cancer 2007;15(10):1145-54. Shenep 1988 Shenep JL, Kalwinsky DK, Hutson PR, George SL, Dodge RK, Blankenship KR et al. Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositis. Journal of Pediatrics 1988;113(4):758-63.Shenep JL, Kalwinsky DK, Hutson PR, George SL, Dodge RK, Blankenship KR et al. Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositis. J Pediatr 1988;113:758-63.[published erratum appears in J Paediatr 1989 May; 114(5):900] Shieh 1997 Shieh SH, Wang ST, Tsai ST, Tseng CC. Mouth care for nasopharyngeal cancer patients undergoing radiotherapy. Oral Oncology 1997;33(1):36-41. Sorensen 2008 Sorensen J, Skovsgaard T, Bork E, Damstrup L, Ingeberg S. Double blind, placebo-controlled randomized study of chlorhexidine prophylaxis for chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) [abstract] 2001. Journal of Clinical Oncology : ASCO annual meeting proceedings 2006;24(18S Part I):470. Sorensen JB, Skovsgaard T, Bork E, Damstrup L, Ingeberg S. Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies. Cancer 2008;112(7):1600-6. Sornsuvit 2008 Sornsuvit C, Komindr S, Chuncharunee S, Wanikiat P, Archararit N, Santanirand P. Pilot Study: effects of parenteral glutamine dipeptide supplementation on neutrophil functions and prevention of chemotherapy-induced side-effects in acute myeloid leukaemia patients. Journal of International Medical Research 2008;36(6):1383-91. Spencer 2005 Spencer A, Horvath N, Gibson J, Prince HM, Herrmann R, Bashford J et al. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplantation 2005;35(10):971-7.Spencer A, Horvath N, Gibson J, Prince HM, Herrmann R, Bashford J, et al. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplantation. 2005;35(10):971-7. Spielberger 2004 Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. The New England Journal of Medicine 2004;351(25):2590-8. Spijkervet 1989 Spijkervet FKL, van Saene HK, Panders AK, Vermey A, van Saene JJ, Mehta DM et al. Effects of chlorhexidine rinsing on the oropharyngeal ecology in patients with head and neck cancer who have irradiation mucositis. Oral Surgery, Oral Medicine, Oral Pathology 1989;67(2):154-61. Stokman 2003 Stokman MA, Spijkervet FK, Burlage FR, Dijkstra PU, Manson WL, de Vries EG et al. Oral mucositis and selective elimination of oral flora in head and neck cancer patients receiving radiotherapy: a double-blind randomised clinical trial. British Journal of Cancer 2003;88(7):1012-6. Su 2003 Su C, Mehta V, Ravikumar L, Shah R, Pinto H, Halpern J et al. Phase II double-blind randomized study comparing oral aloe vera (AV) versus placebo to prevent radiation (RT)-related mucositis in patients with head and neck (HN) neoplasms. International Journal of Radiation, Oncology, Biology and Physics 2004;60(1 Sept):171-7.Su C, Mehta, V, Ravikumar, L, Shah, R, Pinto, H, Halpern, J, Koong, A, Goffinet, D, and Le, Q-T. Phase II double-blind randomized study comparing oral aloe vera (AV) versus placebo to prevent radiation (RT)-related mucositis in patients with head and neck (HN) neoplasms. Proceedings of ASCO 2003. Su 2006 Su YB, Vickers AJ, Zelefsky MJ, Kraus DH, Shaha AR, Shah JP, et al. Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor during postoperative radiotherapy for squamous head and neck cancer.[see comment]. Cancer Journal 2006;12(3):182-8. Symonds 1996 Symonds RP, McIlroy P, Khorrami J, Pyper E, Alcock SR, McCallum I et al. The reduction of radiation mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial. British Journal of Cancer 1996;74(2):312-7. Trotti 2004 Trotti A, Garden A, Warde P, Symonds P, Langer C, Redman R et al. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. International Journal of Radiation Oncology, Biology and Physics 2004;58(3):674-81.Trotti A, Garden A, Warde P, Symonds P, Langer C, Redman R, et al. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. International Journal of Radiation Oncology, Biology, Physics 2004; 58(3):674-81. Trotti A, Garden AS, Warde P, Symonds P, Langer C, Fleming T et al. Phase III trial of iseganan HCL oral solution (iseganan) for reducing oral mucositis severity in patients receiving radiotherapy for head and neck malignancies (PROMPT-RT). In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 2002:(Abs No 908). van der Lelie 2001 van der Lelie H, Thomas BL, van Oers RH, Ek-Post M, Sjamsoedin SA, van Dijk-Overtoom ML et al. Effect of locally applied GM-CSF on oral mucositis after stem cell transplantation: a prospective placebo-controlled double-blind study. Annals of Hematology 2001;80(3):150-4. Veerasarn 2006 Veerasarn V, Phromratanapongse P, Suntornpong N, Lorvidhaya V, Sukthomya V, Chitapanarux I, et al. Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand 2006;89(12):2056-67. Veness 2006 Veness MJ, Foroudi F, Gebski V, Timms I, Sathiyaseelan Y, Cakir B, et al. Use of topical misoprostol to reduce radiation-induced mucositis: results of a randomized, double-blind, placebo-controlled trial. Australasian Radiology 2006;50(5):468-74. Vokurka 2005 Vokurka S, Bystricka E, Koza V, Scudlova J, Pavlicova V, Valentova D, et al. The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT--results of a randomized multicentre study. Supportive Care in Cancer 2005;13(7):554-8.Vokurka S, Bystricka E, Koza V, Scudlova J, Pavlicova V, Valentova D, et al. The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT--results of a randomized multicentre study. Supportive Care in Cancer. 2005;13(7):554-8. Wahlin 1989 Wahlin YB. Effects of chlorhexidine mouthrinse on the oral health in patients with acute leukemia. Oral Surgery, Oral Medicine, Oral Pathology 1989;68(3):279-87.Wahlin YD. Effects of chlorhexidine mouth rinse on the oral health in patients with acute leukemia. Oral Surg Oral Med Oral Path 1989;68:279-87. Wang 2002a Wang J. Effect on Chinese herbs decoction gargling to treat and to prevent chemotherapy caused stomatitis. Chinese Nursing Research 2002;16(10):578-9. Wijers 2001 Wijers OB, Levendag PC, Harms ER, Gan-Teng AM, Schmitz PI, Hendriks WD et al. Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: A placebo-controlled double-blind randomized study. International Journal of Radiation Oncology, Biology and Physics 2001;50(2):343-52. Wu 2009 Wu PA, Kim YH, Lavori PW, Hoppe RT, Stockerl-Goldstein KE. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome. Biology of Blood &amp;amp; Marrow Transplantation 2009;15(8):982-90. You 2009 You WC, Hsieh CC, Huang JT. Effect of extracts from indigowood root (Isatis indigotica Fort.) on immune responses in radiation-induced mucositis. Journal of Alternative &amp;amp; Complementary Medicine 2009;15(7):771-8. Yuen 2001 Yuen KY, Woo PCY, Tai JW, Lie AK, Luk J, Liang R. Effects of clarithromycin on oral mucositis in bone marrow transplant recipients. Haematologica 2001;86(5):554-5. Excluded studies Abramoff 2008 Abramoff MM, Lopes NN, Lopes LA, Dib LL, Guilherme A, Caran EM, et al. Low-level laser therapy in the prevention and treatment of chemotherapy-induced oral mucositis in young patients. Photomed Laser Surg 2008;26(4):393-400. Adamietz 1997 Adamietz IA, Rahn R, Bottcher HD, Reimer K, Fleischer W. Prophylaxis of radiation induced oral mucositis with povidone iodine. Supportive Care in Cancer 1997;5 Suppl:165 (Abs No 48).Adamietz IA, Rahn R, Bottcher HD, Reimer K, Fleischer W. Prophylaxis of radiation induced oral mucositis with povidone iodine. Supportive Care in Cancer. 1997;5 Suppl(Abstr 48):165. Ahn 2008 Ahn YWH, Song S, Kim Y, Oh Y, Lee C, and, et al. The therapeutic effect of recombinant human epidermal growth factor (rhEGF) on mucositis in patients with head and neck cancer undergoing radiotherapy with or without chemotherapy: a double-blind placebo-controlled prospective phase II multi-institutional study. J Clin Oncol 2008;26(suppl):Abstract no: 6021. Aisa 2005 Aisa Y, Mori T, Kudo M, Yashima T, Kondo S, Yokoyama A et al. Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients.. Supportive Care in Cancer 2005;13(4):266-9. Altmann 1999 Altmann S Hoffmanns H. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors]. [German]. Strahlentherapie und Onkologie 1999;175(Suppl 4):30-3.Altmann S HH. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors]. [German]. Strahlentherapie und Onkologie 1999;175(Suppl 4):30-3. Andersen 1987 Andersen E, Pedersen H. Oral ftorafur versus intravenous 5-fluorouracil. A comparative study in patients with colorectal cancer. Acta Oncologica 1987;26(6):433-6.Andersen E PH. Oral ftorafur versus intravenous 5-fluorouracil. A comparative study in patients with colorectal cancer. Acta Oncologica 1987;26(6):433-6. Anderson 1998b Anderson PM, Ramsay NKC, Shu XO, Rydholm N, Rogosheske J, Nicklow R et al. Effect of low dose oral glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplantation 1998;22(4):339-44. Antin 2002 Antin JH, Lee SJ, Neuberg D, Alyea E, Soiffer RJ, Sonis S, et al. A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplantation 2002;29(5):373-7.Antin JH, Lee SJ, Neuberg D, Alyea E, Soiffer RJ, Sonis S, et al. A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplantation 2002; 29(5):373-7. Antonadou 1998 Antonadou D, Athanassiou E, Synodinou M, Koliarakis N, Panoussaki K, Karageorgis P et al. Evaluation of the efficacy of granulocyte macrophage colony stimulating factor (GM-CSF) in the prevention of radiation induced mucositis [abstract]. Radiotherapy Oncology 1998;48(S1):S39. Apaydin 1996 Apaydin A, Karadeniz AN, Aysigi G, Blige N. The effect and therapeutical use of benzydamine HCL on radiation-induced oral cavity and oropharyngeal mucositis. Medical Bulletin Istanbul 1996;29:1:59-63. Aquino 2005 Aquino VM, Harvey AR, Garvin JH, Godder KT, Nieder ML, Adams RH et al. A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplantation 2005;36(7):611-6.Aquino VM, Harvey AR, Garvin JH, Godder KT, Nieder ML, Adams RH, et al. A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplantation. 2005;36(7):611-6. Ardizzoni 2002 Ardizzoni A, Tjan-Heijnen VC, Postmus PE, Buchholz E, Biesma B, Karnicka-Mlodkowska H, et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. Journal of Clinical Oncology 2002;20(19):3947-55.Ardizzoni A, Tjan-Heijnen VC, Postmus PE, Buchholz E, Biesma B, Karnicka-Mlodkowska H, et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.+AFs-comment+AF0-. Arora 2008 Arora H, Pai KM, Maiya A, Vidyasagar MS, Rajeev A. Efficacy of He-Ne Laser in the prevention and treatment of radiotherapy-induced oral mucositis in oral cancer patients. Oral Surgery Oral Medicine Oral Pathology Oral Radiology &amp;amp; Endodontics 2008;186.e1, 105(2):180-6. Awada 2002 Awada A, Biganzoli L, Cufer T, Beex L, Lohrisch C, Batter V, et al. An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes. European Journal of Cancer 2002;38(6):773-8.Awada A, Biganzoli L, Cufer T, Beex L, Lohrisch C, Batter V, et al. An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes.2002+ADs- 38(6):773-8. Awada 2004 Awada A, Gil T, Sales F, Dubuisson M, Vereecken P, Klastersky J et al. Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers. Anti-Cancer Drugs 2004;15(5):499-502.Awada A, Gil T, Sales F, Dubuisson M, Vereecken P, Klastersky J, et al. Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers. Anti-Cancer Drugs. 2004;15(5):499-502. Awidi 2001 Awidi A, Homsi U, Kakail RI, Mubarak A, Hassan A, Kelta M, Martinez P et al. Double-blind, placebo-controlled cross-over study of oral pilocarpine for the prevention of chemotherapy-induced oral mucositis in adult patients with cancer. European Journal of Cancer 2001;37(16):2010-4.Awidi A HU, Kakail RI, Mubarak A, Hassan A, Kelta M, Martinez P, Sulaiti S, Al Qady A, Jamhoury A, Daniel M, Charles C, Ambrose A, El-Aloosy AS. Double-blind, placebo-controlled cross-over study of oral pilocarpine for the prevention of chemotherapy-induced oral mucositis in adult patients with cancer. +AFs-see comments.+AF0-. Awwad 2002 Awwad HK, Lotayef M, Shouman T, Begg AC, Wilson G, Bentzen SM et al. Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cnacer: influence of proliferation. British Journal of Cancer 2002;86(4):517-23. Barasch 1995 Barasch A, Peterson DE, Tanzer JM, D'Ambrososio JA, Nuki K, Schubert MM et al. Helium-Neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer 1995;76(12):2550-6. Baydar 2005 Baydar M, Dikilitas M, Sevinc A, Aydogdu I. Prevention of oral mucositis due to 5-fluorouracil treatment with oral cryotherapy. Journal of the National Medical Association 2005;97(8):1161-4. Bensadoun 1995 Bensadoun R, Cowen D, Nguyen TD, Ciais G, Franquin JC, Dassonville O et al. Low energy laser in the prevention of radiation-induced mucositis: A phase III randomized multicentric study in patients with head and neck cancer. In: Fifth International Congress on Anti-Cancer Chemotherapy. 1995.Bensadoun R, Cowen, D, Nguyen, TD, Ciais, G, Franquin, JC, Dassonville, O, Laudoyer, Y, Chauvel, P, Demard, F, and Zattara, H. Low energy laser in the prevention of radiation-induced mucositis: A phase III randomized multicentric study in patients with head and neck cancer. Fifth International Congress on Anti-Cancer Chemotherapy. 1995 1995. Bensadoun 1999 Bensadoun R, Franquin J, Benezery K, Ciais G, Tardieu C, Dejou J et al. Low energy He/Ne laser in the prevention of radiation induced mucositis: A multicenter phase III double blind study for patients with head and neck cancer. In: Proceedings of ASCO. 1999. Bensadoun RJ, Ciais G, Darcourt V, Franquin JC, Cheynet C, Cowen D et al. Low energy laser in the prevention of radiation induced mucositis: a phase II randomized multicentre study for patients with head and neck cancer. Supportive Care in Cancer 1999;7:SO-13. Bensadoun RJ, Franquin JC, Ciais G, Darcourt V, Schubert MM, Viot M et al. Low-energy He/Ne laser in the prevention of radiation-induced mucositis. A multicentre phase III randomized study in patients with head and neck cancer. Supportive Care in Cancer 1999;7(4):244-52. Bensadoun 2006 Bensadoun RJ, Benezery K, Dassonville O, Magne N, Poissonnet G, Ramaioli A et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). International Journal of Radiation Oncology, Biology, Physics 2006;64(4):983-94.Bensadoun RJ, Benezery K, Dassonville O, Magne N, Poissonnet G, Ramaioli A, et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). International Journal of Radiation Oncology, Biology, Physics. 2006;64(4):983-94. Bentzen 2001 Bentzen SM, Saunders MI, Dische S, Bond SJ. Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial. Radiotherapy Oncology 2001;60(2):123-35. Bergmann 1995 Bergmann OJ, Ellermann-Eriksen S, Mogensen SC, Ellegaard J. Acyclovir given as prophylaxis against oral ulcers in acute myeloid leukaemia: randomised, double blind, placebo controlled trial. BMJ 1995;6(310):116-72. Bleehen 1996 Bleehen NM, Girling DJ, Hopwood P, Lallemand G, Machin D, Stephens RJ et al. Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. British Journal of Cancer 1996;73:406-13.Bleehen NM, Girling DJ, Hopwood P, Lallemand G, Machin D, Stephens RJ, Bailey AJ. Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. British Journal of Cancer 1996 73 406-413. Bolwell 2004 Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplantation 2004;34(7):621-5.Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplantation. 2004;34(7):621-5. Bourhis 2006 Bourhis J, Lapeyre M, Tortochaux J, Rives M, Aghili M, Bourdin S et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. Journal of Clinical Oncology 2006;24(18):2873-8.Bourhis J, Lapeyre M, Tortochaux J, Rives M, Aghili M, Bourdin S, et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. Journal of Clinical Oncology. 2006;24(18):2873-8. Braaksma 2002 Braaksma M, Levendag P. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation. Seminars in Oncology 2002;29(6 Supp 19):63-70.Braaksma M, Levendag P. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation. Seminars in Oncology 2002+ADs- 29(6 Suppl 19):63-70. Buentzel 1999 Buentzel J, Glatzel M, Weinaug R, Schuth J, Kuettner K, Froehlich D. Amifostine in combined radio- and chemomodalities for head and neck cancer. European Journal of Cancer 1999;35(Suppl 4):363 (Abs No 1472).Buentzel J, Glatzel M, Weinaug R, Schuth J, Kuettner K, Froehlich D. Amifostine in combined radio- and chemomodalities for head and neck cancer. European Journal of Cancer. 1999;35(Suppl 4):363 Abstract #1472. Calais 1998 Calais GM, Alfonsi E, Bardet C, Sire H, Bourgeois C, Bergerot B et al. Randomized study comparing radiation alone (RT) versus RT with concomitant chemotherapy (CT) in stages III andf IV oropharynx carcinoma (ARCORO). Preliminary results of the 94.01 study from the French Group of radiation oncology for head and neck cancer (GORTEC). In: Proceedings of Annual Meeting of the American Society of Clinical Oncology. 1998:(Abs No 1484).Calais GM, Alfonsi E, Bardet C, Sire H, Bourgeois C, Bergerot B, et al. Randomized study comparing radiation alone (RT) versus RT with concomitant chemotherapy (CT) in stages III andf IV oropharynx carcinoma (ARCORO). Preliminary results of the 94.01 study from the French Group of radiation oncology for head and neck cancer (GORTEC). Proc-Annu-Meet-Am-Soc-Clin-Oncol. 1998:Abstract # 1484. Calais 2000 Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P et al. [Stage III and IV cancers of the oropharynx: results of a randomized study of Gortec comparing radiotherapy alone with concomitant chemotherapy]. Bulletin du Cancer 2000;87 Spec No:48-53.Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, et al. [Stage III and IV cancers of the oropharynx: results of a randomized study of Gortec comparing radiotherapy alone with concomitant chemotherapy]. [French]. Bulletin du Cancer. 2000;87 Spec No:48-53. Calais 2004 Calais G, Bardet E, Sire C, Alfonsi M, Bourhis J, Rhein B et al. Radiotherapy with concomitant weekly docetaxel for stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC phase II trial. International Journal of Radiation, Oncology, Biology and Physics 2004;58(1 Jan):161-6. Cassidy 2002 Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Annals of Oncology 2002;13(4):566-75.Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. 2002+ADs- 13(4):566-75. Cella 2003 Cella D, Pulliam J, Fuchs H, Miller C, Hurd D, Wingard JR et al. Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cancer 2003;98(2):406-12. Cheng 2001 Cheng KK Molassiotis A, Chang AM, Wai WC, Cheung SS. Evaluation of an oral care protocol intervention in the prevention of chemotherapy-induced oral mucositis in paediatric cancer patients. European Journal of Cancer 2001;37(16):2056-63.Cheng KK MA, Chang AM, Wai WC, Cheung SS. Evaluation of an oral care protocol intervention in the prevention of chemotherapy-induced oral mucositis in paediatric cancer patients. 2001+ADs-37(16):2056-63. Cheng 2002 Cheng KKF, Malassiotis A, Chang AM. An oral care protocol intervention to prevent chemotherapy-induced oral mucositis in paediatric cancer patients: a pilot study. European Journal of Oncology Nursing 2002;6(2):66-74.Cheng KKF MA, Chang AM. An oral care protocol intervention to prevent chemotherapy-induced oral mucositis in paediatric cancer patients: a pilot study... including commentary by Parr M. European Journal of Oncology Nursing: EUR J ONCOL NURS 2002+ADs- 6. 6(2. 2):66-74. Cheng 2003 Cheng KK, Chang AM. Palliation of oral mucositis symptoms in pediatric patients treated with cancer chemotherapy. Cancer Nursing 2003;26(6):476-84.Cheng KK, Chang AM. Palliation of oral mucositis symptoms in pediatric patients treated with cancer chemotherapy. Cancer Nursing 2003; 26(6):476-84. Cheng 2004a Cheng KK. Children's acceptance and tolerance of chlorhexidine and benzydamine oral rinses in the treatment of chemotherapy-induced oropharyngeal mucositis. European Journal of Oncology Nursing 2004;8(4):341-9.Cheng KK. Children's acceptance and tolerance of chlorhexidine and benzydamine oral rinses in the treatment of chemotherapy-induced oropharyngeal mucositis. European Journal of Oncology Nursing. 2004;8(4):341-9. Cheng 2004b Cheng KK, Chang AM, Yuen MP. Prevention of oral mucositis in paediatric patients treated with chemotherapy; a randomised crossover trial comparing two protocols of oral care. European Journal of Cancer 2004;40(8):1208-16.Cheng KK, Chang AM, Yuen MP. Prevention of oral mucositis in paediatric patients treated with chemotherapy; a randomised crossover trial comparing two protocols of oral care. Eur J Cancer 2004;40(8):1208-16. Chi 1994 Chi KH, Chen SY, Chan WK, Yen SH, Liang MJ, Chou KC, et al. Effect of granulocyte macrophage colony stimulating factor (GM-CSF) on oral mucositis in head and neck cancer patients after cisplatin, 5- FU and leucovorin chemotherapy [abstract]. Proceedings of the American Society of Clinical Oncology 1994;13:428, Abstract 1469. Chi 1995 Chi KH, Chen CH, Chan WK, Yen SH, Liang MJ, Chou KC et al. Effect of granulocyte-macrophage colony-stimulating factor (GH-CFS) on oral mucositis in head and neck cancer patients after cisplatin, 5-FU and leucovorin chemotherapy. In: Proceedings of Annual Meeting American Society of Clinical Oncology. Vol. 13. 1994:A1469. Chi KH, Chen SY, Chan WK, Yen SH, Liang MJ, Chou KC et al. Effect of granulocyte-macrophage colony-stimulating factor (GH-CFS) on oral mucositis in head and neck cancer patients after cisplatin, 5-FU and leucovorin chemotherapy. Journal of Clinical Oncology 1995;13(10):2620-8. Chiara 2000 Chiara S, Nobile MT, Vincenti M, Gozza A, Heouaine A, Marceca F, et al. Sucralfate in the treatment of chemotherapy-induced stomatitis: a double-blind, placebo-controlled pilot study [abstract]. Proceedings of the American Society of Clinical Oncology 2000;19:630a, Abstract 2485. Clarke 2001 Clarke SJ, Abdi E, Davis ID, Schnell FM, Zalcberg JR, Gutheil J, et al. Recombinant human keratinocyte growth factor (rHuKGF) prevents chemotherapy-induced mucositis in patients with advanced colorectal cancer: a randomized phase II trial [abstract]. Proceedings of the American Society of Clinical Oncology 2001;20 (Pt 1):383a, Abstract 1529. Collova 2004 Collova E, Castagna L, Nozza A, Perfetti V, Patrone F, Danova M et al. New approaches for reduction of oral mucositis in patients undergoing high-dose chemotherapy with hematopoietic stem cell support. Bone Marrow Transplantation 2004;33(Suppl 1):S323-S4.Collova E, Castagna L, Nozza A, Perfetti V, Patrone F, Danova M, et al. New approaches for reduction of oral mucositis in patients undergoing high-dose chemotherapy with hematopoietic stem cell support [abstract]. Bone Marrow Transplantation. 2004;33(Suppl 1):S323-S4. Colombat 1995 Colombat P, Colin B. Comparison of fluconazole and amphotericin B in the prevention of mucositis in patients with long term aplasia. Bone Marrow Transplantation 1995;15:178.Colombat P, Colin B, et al. Comparison of fluconazole and amphotericin B in the prevention of mucositis in patients with long term aplasia [abstract]. Bone-Marrow-Transplant. 1995;15:178. Costa 1999 Costa EMMB, Pinto LP, Fernandes MZ, Costa ALL. Preventing oral complications in leukemic children submitted to chemotherapy. Journal of Dental Research 1999;78:1021 (Abs No B-220). Costa 2003 Costa EM, Fernandes MZ, Quinder LB, de Souza LB, Pinto LP. Evaluation of an oral preventive protocol in children with acute lymphoblastic leukemia. Pesquisa Odontologica Brasileira 2003;17(2):147-50.Costa EM, Fernandes MZ, Quinder LB, de Souza LB, Pinto LP. Evaluation of an oral preventive protocol in children with acute lymphoblastic leukemia. Pesqui Odontol Bras. 2003 Apr-Jun;17(2):147-50. Cowen 1997 Cowen D, Tardieu C, Resbeut M, Hannoun-Levi JM, Alzieu C, Schubert M et al. Low energy helium-neon laser presents oral mucositis after high-dose chemo-radiotherapy: results of a double-blind randomized trial. International Journal of Radiation Oncology, Biology and Physics 1996;36(1S):264 (A1041). Cowen D, Tardieu C, Schubert M, Peterson D, Resbeut M, Faucher C et al. Low energy Helium-neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: Results of a double blind randomized trial. International Journal of Radiation Oncology, Biology and Physics 1997;38(4):697-703. Crawford 1994 Crawford J, Glaspy J, Vincent M, Tomita D, Mazanet R. Effect of filgrastim (r-metHug-CSF) on oral mucositis in patients with small cell lung cancer (SCLC) receiving chemotherapy (cyclophosphamide, doxorubicin and etoposide, CAE). In: Proceedings of Annual Meeting of American Society Clinical Oncology. Vol. 13. 1994:(Abs No A1523).Crawford J, Glaspy J, Vincent M, Tomita D, Mazanet R. Effect of filgrastim (r-metHug-CSF) on oral mucositis in patients with small cell lung cancer (SCLC) receiving chemotherapy (cyclophosphamide, doxorubicin and etoposide, CAE). Proc-Annu-Meet-Am-Soc-Clin-Oncol. 1994;13:Abs. A1523. Crispino 1997 Crispino SP, Olmi C, Fallai F, Rossi S, Marsoni A, Tinazzi M, et al. Conventional radiotherapy (RT) versus accelerated hyperfractionated RT versus conventional RT and concomitant chemotherapy in locally advanced oropharyngeal carcinoma (ORO-93/01). In: Proceedings of the American Society of Clinical Oncology. 1997.Crispino SP, Olmi C, Fallai F, Rossi S, Marsoni A, Tinazzi M, et al. Conventional radiotherapy (RT) versus accelerated hyperfractionated RT versus conventional RT and concomitant chemotherapy in locally advanced oropharyngeal carcinoma (ORO-93/01). Proc Am Soc Clin Oncol. 1997. Cruz 1997 Cruz J, Fonseca E, Rodriguez CA, Gomez-Bernal A, Martin G, Sanchez P et al. Randomized trial of cisplatin (P) plus 5-fluorouracil (F) with or without folinic acid in locally advanced head and neck cancer (LAHNC). In: Proceedings of the European Cancer Conference. 1997:(Abs No 854).Cruz J, Fonseca E, Rodriguez CA, Gomez-Bernal A, Martin G, Sanchez P, et al. Randomized trial of cisplatin (P) plus 5-fluorouracil (F) with or without folinic acid in locally advanced head and neck cancer (LAHNC). Proc-Eur-Cancer-Conf (ECCO). 1997:Abstract #854. Cunningham 1995 Cunningham D, Zalcberg JR, Rath U, Olver I, van Cutsem EV, Sevensson C et al. 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. European Journal of Cancer 1995;31A(12):1945-54. De Boer 2002 De Boer RH, Eisen TG, Ellis PA, Johnston SR, Walsh G, Ashley S et al. A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer. Annals of Oncology 2002;13(6):889-94. Decker-Baummann 1999 Decker-Baumann C, Buhl K, Frohmuller S, von Herbay A, Dueck M, Schlag PM. Reduction of chemotherapy-induced side-effects by parenteral glutamine supplementation in patients with metastatic colorectal cancer. European Journal of Cancer 1999;35(2):202-7. Denham 1999 Denham JW, Peters LJ, Johansen J, Poulsen M, Lamb DS, Hindley A et al. Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer? Radiotherapy Oncology 1999;52(2):157-64. Djuric 2006 Djuric M, Hillier-Kolarov V, Belic A, Jankovic L. Mucositis prevention by improved dental care in acute leukemia patients. Supportive Care in Cancer 2006;14(2):137-46.Djuric M, Hillier-Kolarov V, Belic A, Jankovic L. Mucositis prevention by improved dental care in acute leukemia patients. Supportive Care in Cancer. 2006;14(2):137-46. Dobrowsky 1998 Dobrowsky W, Naude J, Widder J, Dobrowsky E, Millesi W, Pavelka R et al. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer. International Journal of Radiation Oncology, Biology and Physics 1998;42(4):803-6.Dobrowsky W NJ, Widder J, Dobrowsky E, Millesi W, Pavelka R, Grasl C, Reichel M. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer. International Journal of Radiation Oncology, Biology, Physics 1998;42(4):803-6. Doroshow 1987 Doroshow JH, Berthtand M, Newman E, Multhauf P, Leong L, Blayney D et al. Preliminary analysis of a randomized comparison of 5-fluorouracil versus 5-fluorouracil and high-dose continuous-infusion folinic acid in disseminated colorectal cancer. NCI Monographs 1987;5:171-4.Doroshow JH BM, Newman E, Multhauf P, Leong L, Blayney D, Goldberg D, Margolin K, Carr B, Akman S, et al. Preliminary analysis of a randomized comparison of 5-fluorouracil versus 5-fluorouracil and high-dose continuous-infusion folinic acid in disseminated colorectal cancer. NCI Monographs 1987(5):171-4. Dose 1989 Dose AM, Loprinzi CL, Cianflone S, Etzell P, Burnham N, Therneau T, et al. A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis. A North Central Cancer Treatment Group and Mayo clinic study [abstract]. Proceedings of the American Society of Clinical Oncology 1989;8:341, Abstract 1328. Dose 1990 Dose AM, Mahood D, Loprinzi CL, Gainey D, Sorensen JM, Therneau T, et al. A controlled trial of oral cryotherapy for preventing stomatitis in patients receiving 5- fluorouracil (5FU) plus leucovorin (LV). A North Central Cancer Treatment Group and Mayo Clinic study [abstract]. Proceedings of the American Society of Clinical Oncology 1990;9:321, Abstract 1242. Dreicer 1997 Dreicer R, Propert KJ, Kuzel T, Kirkwood JM, O'Dwyer PJ, Loehrer PJ. A phase II trial of edatrexate in patients with advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study. American Journal of Clinical Oncology 1997;20(3):251-3. Dudjak 1987 Dudjak LA. Mouth care for mucositis due to radiation therapy. Cancer Nursing 1987;10(3):131-40. Edelman 1998 Edelman MJ, Gandara Dr, Perez EA, Lau D, Lauder I, Turrell C et al. Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy. Investigational New Drugs 1998;16(1):69-75. Eisen 2003 Eisen D, Essel J, Broun ER, Sigmund D, DeVoe M,. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. Bone Marrow Transplantation 2003;31(1):51-5. El-Sayed 2000 El-Sayed S, Nabid A, MacKenzie R, Gelinas M, Hay J, Shelley et al. Prophylaxis of radiation associated mucositis (RAM) in head and neck cancer, results of a double blind phase III trail evaluating the clinical efficacy of an antimicrobial lozenge utilizing a new validated mucositis scoring system. In: Proceedings of the 42nd Annual Meeting of the American Society of Therapeutic Oncology. Vol. 321. 2000:(Abs No 2115).El-Sayed S, Nabid, A, MacKenzie, R, Gelinas, M, Hay, J, Shelley, W, Berthelet, E, Lau, H, Duncan, G, and Epstein, J. Prophylaxis of radiation associated mucositis (RAM) in head and neck cancer, results of a double blind phase III trail evaluating the clinical efficacy of an antimicrobial lozenge utilizing a new validated mucositis scoring system. El-Sayed 2002b El-Sayed S, Epstein J, Minish E, Burns P, Hay J, Laukkanen E. A pilot study evaluating the safety and microbiologic efficacy of an economically viable antimicrobial lozenge in patients with head and neck cancer receiving radiation therapy. Head &amp;amp; Neck 2002;24(1):6-15.El-Sayed S, Epstein J, Minish E, Burns P, Hay J, Laukkanen E.A pilot study evaluating the safety and microbiologic efficacy of an economically viable antimicrobial lozenge in patients with head and neck cancer receiving radiation therapy. Head Neck. 2002 Jan;24(1):6-15. Epstein 1986 Epstein JB, Stephenson-Moore P. Benzydamine hydrochloride in prevention and management of pain in oral mucositis associated with radiation therapy. Oral Surgery, Oral Medicine, Oral Pathology 1986;62(2):145-8. Epstein 1989 Epstein JB, Stevenson-Moore P, Jackson S, Mohamed JH, Spinelli JJ. Prevention of oral mucositis in radiation therapy: A controlled study with benzydamine hydrochloride rinse. International Journal of Radiation Oncology, Biology and Physics 1989;16(6):1571-5. Epstein 1992 Epstein JB, Vickars L, Spinalli J, Reece D. Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. Oral Surgery, Oral Medicine, Oral Pathology 1992;73(6):682-9. Epstein 1994 Epstein JB, Wong FLW. The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy. International Journal of Radiation Oncology, Biology and Physics 1994;28(3):693-8. Epstein 1999 Epstein J, Silverman S Jr, Pagerino D, Lockhart P, Schubert M, Crockett R. Benzydamine HCL for prophylaxis of irradiation induced oral mucositis: a randomized double-blind, multicenter study. Supportive Care in Cancer 1999;7 Suppl:169 (Abs No O-18).Epstein J, Silverman S, Jr Pagerino D, Lockhart P, Schubert M, Crockett R. Benzydamine HCL fro prophilaxis of irradiation oral mucositis: a randomized double-blind, multicenter study. Supportive Care in Cancer. 1999;7 Suppl.(Abstr O-18):169. Epstein 2001 Epstein JB, Silverman S, Paggiarino DA, Crockett S, Schubert MM, Senzer NN et al. Benzydamine HCI for prophylaxis of radiation-induced oral mucositis. Cancer 2001;92(4):875-85. Erkisi 1996 Erkisi M, Erkurt E, Ozbarlas S, Burgut R, Doran F, Seyrek E. The use of recombinant human granulocyte colony-stimulating factor in combination with single or fractionated doses of ifosfamide and doxorubicin in patients with advanced soft tissue sarcoma. Journal of Chemotherapy 1996;8(3):224-8. Etiz 1998 Etiz M, Erkal HS, Serin M, Kucuk B, Hepari A, Tulunay O et al. Clinicohistopathological evaluation of effectiveness of sucralfate in prevention of severe radiation-induced mucositis in patients with head and neck malignancies. Radiotherapy Oncology 1998;48(S1):S68. Etiz 2000 Etiz D, Erkal HS, Serin M, Kucuk B, Hepari A, Elhan AH et al. Clinical and histopathological evaluation of sucralfate in prevention of oral mucositis induced by radiation therapy in patients with head and neck malignancies. Oral Oncology 2000;36(1):116-20. Evans 1990 Evans G, Mahendra P, Brightwell M, Jestivfe K, Marcus R. A double blind randomised trial of oral GMCFS mouthwash versus placebo in the treatment of mucositis following PBSC/bone marrow transplantation. Bone Marrow Transplantation 1998;21(S1):S88. Evans WK, Wierzbicki R, Shepherd FA, Rusthoven J, Stewart DJ, Aitken SE et al. 5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung. Cancer Investigation 1990;8(3-4):345-9. Ezzat 2005 Ezzat M, Shouman T, Zaza K, Safwat A, El-Khoudary A, El-Senosi M et al. A randomized study of accelerated fractionation radiotherapy with and without mitomycin C in the treatment of locally advanced head and neck cancer. Journal of the Egyptian National Cancer Institute 2005;17(2):85-92.Ezzat M, Shouman T, Zaza K, Safwat A, El-Khoudary A, El-Senosi M, et al. A randomized study of accelerated fractionation radiotherapy with and without mitomycin C in the treatment of locally advanced head and neck cancer. Journal of Egyptian National Cancer Institute. 2005;17(2):85-92. Fahlke 1999 Fahlke J, Ridwelski K, Lippert H. High-dose therapy with combined 5-fluorouracil and folinic acid with and without amifostine in the treatment of patients with metastatic colorectal carcinoma. International Journal of Colorectal Disease 1999;14(2):128-30. Falcone 2001 Falcone A, Allergrini G, Masi G, Lencioni M, Panner E, Brunetti I. 5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer. Oncology 2001;61(1):28-35. Fay 1994 Fay JW, Lazarus H, Herzig R, Saez R, Stevens DA, Collins RH Jr et al. Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study. Blood 1994;84(7):2151-7.Fay JW LH, Herzig R, Saez R, Stevens DA, Collins RH Jr, Pineiro LA, Cooper BW, DiCesare J, Campion M, et al. Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study. Blood 1994;84(7):2151-7. Feber 1995 Feber T. Mouth care for patients receiving oral irradiation. Professional Nurse 1995;10(10):666-70. Feber 1996 Feber T. Management of mucositis in oral irradiation. Clinical Oncology 1996;8(2):106-11. Ferreira 2002 Ferreira PR, Fleck J, Filho AB, Barletta D, Barletta A, Diehl A et al. Protective effect of vitamin E (VE) in head and neck cancer radiation induced mucositis: a double-blind randomized trial. In: Proceedings of American Society of Clinical Oncology Meeting. 2002:(Abs No 909).Ferreira P FJ, Filho A, Barletta D, Barletta A, Diehl A, de Azambuja E. Protective effect of vitamin E (VE ) in head and neck cancer radiation induced mucositis: a double-blind randomized trial. Proceedings of ASCO 2002. Ferreira 2002a Ferreira RR, Fleck JF, Filho AB, Barletta D, Barletta A, Diehl A, et al. Positive effect of vitamin E (VE) in head and neck cancer radiation induced mucositis: a double-blind randomized trial [abstract]. Proceedings of the American Society of Clinical Oncology 2002;21 (Pt 1):228a, Abstract 909. Ferreira 2004 Ferreira PR, Fleck JF, Diehl A, Barletta D, Braga-Filho A, Barletta A et al. Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial. Head &amp;amp; Neck 2004;26(4):313-21.Ferreira PR, Fleck JF, Diehl A, Barletta D, Braga-Filho A, Barletta A, et al. Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial. Head Neck 2004;26(4):313-21. Ferretti 1985 Ferretti G, Largent B, Brown A, Lillich T, Ash R. The effect of chlorhexidine mouthrinse on mucositis, plaque, gingivitis and stain in bone marrow transplant patients. Journal of Dental Research 1985;64(Special Issue):235 (Abs No 546). Fidler 1995 Fidler P, Loprinzi CL, O'Fallon JR, Michalak J, Novotny P, Hayes D, et al. A controlled evaluation of chamomile for preventing stomatitis in patients receiving 5-fluorouracil based chemotherapy: A North Central Cancer Treatment Group trial [abstract]. Proceedings of the American Society of Clinical Oncology 1995;14:534, Abstract 1765. Foncuberta 2001 Foncuberta MC, Cagnoni PJ, Brandts CH, Mandanas R, Fields K, Derigs HG et al. Topical transforming growth factor-beta3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors. Journal of Immunotherapy 2001;24(4):384-8.Foncuberta M, PJ C, CH B, R M, K F, HG D, et al. Topical transforming growth factor-beta3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors. Journal of Immunotherapy 2001;24(4):384-388. Gabison 1995 Gabison R. Can zinc picolinate in patients receiving chemotherapy for metastatic colorectal carcinoma prevent stomatitis? European Journal of Cancer 1995;31A(Suppl 5):S258 (Abs No 1234). Gandara 1997 Gandara DR, Edelman MJ, Crowley JJ, Lau DH, Livingston RB. Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study.. Cancer Chemotherapy and Pharmacology 1997;41:75-78. Genot-Klastersky 2008 Genot-Klastersky MT, Klastersky J, Awada F, Awada A, Crombez P, Martinez MD, et al. The use of low-energy laser (LEL) for the prevention of chemotherapy- and/or radiotherapy-induced oral mucositis in cancer patients: results from two prospective studies. Support Care Cancer 2008. Giles 2003b Giles FJ, Faderl S, Thomas DA, Cortes JE, Garcia-Manero G, Douer D et al. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. Journal of Clinical Oncology 2003;21(6):1050-6.Giles FJ FS, Thomas DA, Cortes JE, Garcia-Manero G, Douer D, Levine AM, Koller CA, Jeha SS, O'Brien SM, Estey EH, Kantarjian HM. Randomized Phase I/II Study of Troxacitabine Combined With Cytarabine, Idarubicin, or Topotecan in Patients With Refractory Myeloid Leukemias. Journal of Clinical Oncology 2003+ADs-21(6):1050-1056. Gladkov 2007 Gladkov OA, Vazhenin AV, Sharabura TM, Kandakova E, Galiatova Iu V, Sychev VI, et al. [Effectiveness of different regimes of combined treatment (cisplatin+ radiotherapy) for intraoral and oropharyngeal cancer]. [Russian]. Voprosy Onkologii 2007;53(5):575-7. Goldberg 2003 Goldberg S. Safety and tolerability of en3247 in the prevention of oral mucositis associated with chemotherapy with or without total body irradiation: results of a randomized, double-blind, placebo-controlled trial. In: Proceedings of the American Society of Clinical Oncology. 2003:770.Goldberg S. Safety and tolerability of en3247 in the prevention of oral mucositis associated with chemotherapy with or without total body irradiation: results of a randomized, double-blind, placebo-controlled trial [abstract]. Proceedings of the American Society of Clinical Oncology. 2003:770. Gordon 1993 Gordon B, Spadinger A, Hodges E, Coccia P. Effect of granulocyte macrophage colony stimulating factor (GMCSF) on oral mucositis after autologous bone marrow transplantation [abstract]. Proceedings of the American Society of Clinical Oncology 1993;12:432, Abstract 1489. Grotz 2001 Grotz KA, Henneicke-Von Zepelin H-H, Kohnen R, Kutzner J. Belz GG. Prophylaxis of mucositis and dry mouth after head and neck radiotherapy. A new treatment. Krankenhauspharmazie 2002;23(5):193-8. Grotz KA, Wustenberg P, Kohnen R, Al-Nawas B, Henneicke-von Zepelin H, Bockisch A et al. Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutine in patients with head and neck cancer- a prospective, randomized, placebo-controlled, double-blind study. British Journal of Oral and Maxillofacial Surgery 2001;39(1):34-9. Gujral 1999 Gujral MS, Patnaik PM, Kaul R, Daftary GV, Parikh HK, Tamhankar CP et al. Oral enzymes preventing side effects of radiation therapy in patients with head and neck cancers. European Journal of Cancer 1999;35(Suppl 4):168 (Abs No 634).Gujral MS PPKRDGPHTCSW. Oral enzymes preventing side effects of radiation therapy in patients with head and neck cancers. European Journal of Cancer 1999+ADs-35(Suppl. 4):Page 168 Abstract +ACM-634. Gutierrez 1996 Gutierrez AR, Boizas EC, Carreras PS, Rodriguez CS, Rodriguez OA, Chicote MJV et al. Fluconazol as prophylaxis of radioinduced oral mucositis. Preliminary study [Fluconazol en la profilaxis de la mucositis oral radioinducida. Estudio preliminar]. Oncologia 1996;19(6):56-9.Gutierrez AR BE, Carreras PS, Rodriguez CS, Rodriguez OA, Chicote MJV, Palacios AN, Solbes RS, Ripoll JJS. Fluconazol as prophylaxis of radioinduced oral mucositis. Preliminary study. Oncologia 1996;19(6):56-59. Hanson 1995 Hanson WR, Marks JE, Reddy SP, Simon S, Mihalo WE, Tova Y. Protection from radiation-induced oral mucositis by a mouth rinse containing the prostaglandin E1 analog, misoprostol: A placebo controlled double blind clinical trial. Advances in Experimental Medicine and Biology 1997;400B:811-8. Hanson WR, Marks JE, Reddy SP, Simon S, Mihalo WE, Tova Y. Protection from radiation-induced oral mucositis by misoprostol, a prostaglandin E(1) analog: a placebo-controlled, double-blind clinical trial. American Journal of Therapeutics 1995;2(11):850-7. Harris 1995 Harris JR, Russell NH, Hunter AE. Folinic acid mouthwashes do not reduce the degree of mucositis in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplantation 1995;15(S2):S164. Hartmann 1999 Hartmann J, von Vangerow A, Knop S, Brugger W, Fels L, Stolte H et al. A randomized trial comparing the toxicity and the treatment costs of HD-VIC plus PBSC transplantation with or without amifostine (AMI) in patients with solid tumors. European Journal of Cancer 1999;35(Suppl 4):361 (Abs No 1464).Hartmann J, von Vangerow A, Knop S, Brugger W, Fels L, Stolte H, et al. A randomized trial comparing the toxicity and the treatment costs of HD-VIC plus PBSC transplantation with or without amifostine (AMI) in patients with solid tumors. European Journal of Cancer. 1999;35(Suppl 4):361, Abstr #1464. He 2004 He XY, Hu CS, Wu YR. Radioprotective effect of amifostine in nasopharyngeal carcinoma. Acta Academiae Medicinae Shanghai 2004;31(1).He XY, Hu CS, Wu YR. Radioprotective effect of amifostine in nasopharyngeal carcinoma. Acta Academiae Medicinae Shanghai. 2004;31(1). Hickey 1982 Hickey AJ, Toth BB, Lindquist SB. Effect of intravenous hyperalimentation and oral care on the development of oral stomatitis during cancer chemotherapy. The Journal of Prosthetic Dentistry 1982;47(2):188-93. Horsley 2007 Horsley P, Bauer JD, Mazkowiack R, Gardner R, Bashford J. Palifermin improves severe mucositis, swallowing problems, nutrition impact symptoms, and length of stay in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer 2007;15(1):105-9. Howell 1983 Howell SB, Pfeifle CE, Wung WE. Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection. Cancer 1983;51(2):220-5.Howell SB PC, Wung WE. Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection. Cancer 1983;51(2):220-5. Hu 2003 Hu K, Ship JA, Harrison LB. Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/IV head and neck cancer. Seminars in Oncology 2003;30(6 Suppl 18):40-8.Hu K, Ship JA, Harrison LB. Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/IV head and neck cancer. [Review] [36 refs]. Seminars in Oncology 2003; 30(6 Suppl 18):40-8. Inagaki 2006 Inagaki N. [Report on the treatment of infections complicating hematological diseases. Case 2. Two cases of deep-seated mycosis developing during chemotherapy of leukemia]. [Japanese]. Japanese Journal of Antibiotics 2007;60(5):317-8. Ito 2002 Ito A, Hanawa T, Fujii E. The preventive effect of allopurinol spray on stomatitis induced by anti-cancer drugs. Gan To Kagaku Ryoho 2002;29(4):563-7. Jebb 1995 Jebb SA, Marcus R, Elia M. A pilot study of oral glutamine supplementation in patients receiving bone marrow transplants. Clinical Nutrition 1995;14:162-5. Johnson 2002 Johnson DJ, Scott CB, Marks JE, Seay TE, Atkins JN, Berk LB et al. Assessment of quality of life and oral function of patients participating in a phase II study of radioprotection of oral and pharyngeal mucosa by the prostaglandin E(1) analog misoprostol (RTOG 96-07). International Journal or Radiation Oncology Biology and Physics 2002;54(5):1455-9.Johnson DJ, Scott CB, Marks JE, Seay TE, Atkins JN, Berk LB, Meoz RT, Wheeler JA.Assessment of quality of life and oral function of patients participating in a phase II study of radioprotection of oral and pharyngeal mucosa by the prostaglandin E(1) analog misoprostol (RTOG 96-07). Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1455-9. Kante 1995 Kante V. Comparative study of two prophylactic regimes for the prevention of mucositis in autologous bone marrow transplants. Bone Marrow Transplantation 1995;15:253.Kante V, et al. Comparative study of two prophylactic regimes for the prevention of mucositis in autologous bone marrow transplants [abstract]. Bone-Marrow-Transplant. 1995;15:253. Karthaus 1998 Karthaus M, Rosenthal C, Huebner G, Paul H, Elser C, Hertenstein B et al. Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial. Bone Marrow Transplantation 1998;22(8):781-5.Karthaus M, Rosenthal C, Huebner G, Paul H, Elser C, Hertenstein B et al. Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial. Bone Marrow Transplant 1998;22:781-5. Kasten-Sportes 2003 Kasten-Sportes C. Randomized study of acupuncture for mucositis-related pain secondary to high-dose chemotherapy in patients undergoing hematopoietic stem cell transplantation. PDQ (NCI-03-C-0125) 2003.Kasten-Sportes C. Randomized Study of Acupuncture for Mucositis-Related Pain Secondary to High-Dose Chemotherapy in Patients Undergoing Hematopoietic Stem Cell Transplantation. PDQ, NCI-03-C-0125. 2003 2003. Kenny 1990 Kenny SA. Effect of two oral care protocols on the incidence of stomatitis in hematology patients. Cancer Nursing 1990;13(6):345-53. Klocke 2006 Klocke J, Cannon M, Gissinger D, Bayer R, Devoe C, John V. Prevention of mucositis in auto BMT/stem cell transplant patients. Oncology Nursing Forum 2006;33(2):454.Klocke J, Cannon M, Gissinger D, Bayer R, Devoe C, John V. Prevention of mucositis in auto BMT/stem cell transplant patients. Oncology Nursing Forum. 2006;33(2):454. Kokkonen 2002 Kokkonen J, Mottonen M, Karttunen TJ, Lanning M. Mucosal pathology of the upper gastrointestinal tract associated with intensive chemotherapy in children: Vitamin a supplements do not prevent lesions. Pediatric Hematology and Oncology 2002;19(3):181-92.Kokkonen JMMKTLM. Mucosal pathology of the upper gastrointestinal tract associated with intensive chemotherapy in children: Vitamin a supplements do not prevent lesions. Pediatric Hematology +ACY- Oncology 2002+ADs- Vol 19(3): 181-192. Kuhn 2009 Kuhn A, Porto FA, Miraglia P, Brunetto AL. Low-level infrared laser therapy in chemotherapy-induced oral mucositis: a randomized placebo-controlled trial in children. Journal of Pediatric Hematology/Oncology 2009;31(1):33-7. Kuriakose 2002 Kuriakose P, Gandara DR, Perez EA. Phase I trial of edatrexate in advanced breast and other cancers.[comment]. Cancer Investigation 2002;20(4):473-9. Labar 1990 Labar B, Pavletic Z, Bogdanic V, Nemet D, Aurer I, Jakie J. Prostaglandin E2 for prevention of oral mucositis in patients with leukaemia undergoing bone marrow transplantation: a radomized double-blind clinical trial. Experimental Hematology 1990;18:700. Labbate 2003 Labbate R, Lehn CN, Denardin OVP. Effects of chlorhexidine mouthwash on radiation induced mucosistis in head and neck cancer. Revista Brasileira de Otorrinolaringologia 2003;69(3):349-54.Labbate R, Lehn CN, Denardin OVP. Effects of chlorhexidine mouthwash on radiation induced mucosistis in head and neck cancer. Revista Brasileira de Otorrinolaringologia. 2003;69(3):349-54. Leong 1995 Leong L, Sakurai C, Sebastian W, Shaw N, Grant E, Grant M et al. Phase III trial assessing the use of oral thymidine (THY) for prevention of fluorouracil (5-FU)-induced mucositis. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology. Vol. 14. 1995:A334. Levendag 1998 Lavendag PC, Wijers OB, Harms RE, Schmitz PIM, Wilms BE, Visch LL. Mucositis prevention by selective elimination of oral flora in irradiated cancers of the head and neck: a prospective randomized study. Radiotherapy Oncology 1998;48:S10. Levi 1997 Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997;350(9079):681-6.Levi F ZR, Misset J-L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997+ADs-350(9079):681-686. Lievens 1998 Lievens Y, Haustermans K, van den Weyngaert D, van den Bogaert W, Scalliet P, Hutsebaut L et al. Does sucralfate reduce the acute side-effects in head and neck cancer treated with radiotherapy? A double-blind randomized trial. Radiotherapy Oncology 1998;47(2):149-53. Lin 2006 Lin J, Wang X, Fan Z. A study on quantizing evaluation on stomatitis of malignant tumor patients undergoing large dose of chemotherapy [Chinese]. Chinese Nursing Research 2008;22(2A):328-9. Lin LC, Que J, Lin LK, Lin FC. Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study. International Journal of Radiation Oncology, Biology, Physics 2006;65(3):745-50.Lin LC, Que J, Lin LK, Lin FC. Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study. International Journal of Radiation Oncology, Biology, Physics. 2006;65(3):745-50. Lopez 1994 Lopez I, Goudou C, Ribrag V, Sauvage C, Hazebroucq G, Dreyfus F. Traitement des mucites par la vitamine E lors de l'administration d'anti-neoplasiques neutropeniants. Annuals Medicine Interne 1994;145(6):405-8. Loprinzi 1997 Loprinzi CL, Ghosh C, Camoriano J, Sloan J, Steen PD, Michalak JC et al. Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy. Journal of Clinical Oncology 1997;15(3):1235-8. Lorusso 2003 Lorusso D, Ferrandina G, Greggi S, Gadducci A, Pignata S, Tateo S. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Annals of Oncology 2003;14(7):1086-93.Lorusso D FG, Greggi S, Gadducci A, Pignata S, Tateo S, Biamonte R, Manzione L, Di Vagno G, Ferrau' F, Scambia G, Multicenter Italian Trials in Ovarian Cancer invesitgators. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Annals of Oncology 2003;14(7):1086-93. Lozada 1998 Lozada-Nur F, Schoelch M, Fu K, Muscoplat C, Trivedi M, Smith C et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. In: Proceedings of the Annual Meeting of the Society of Clinical Oncology. 1998:1541. Maddocks-Jennings 2009 Maddocks-Jennings W, Wilkinson JM, Cavanagh HM, Shillington D. Evaluating the effects of the essential oils Leptospermum scoparium (manuka) and Kunzea ericoides (kanuka) on radiotherapy induced mucositis: a randomized, placebo controlled feasibility study. European Journal of Oncology Nursing 2009;13(2):87-93. Madero 1999 Madero L, Diaz MA, Ortega JJ, Olive T, Martinez A, Badell I et al. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates engraftment kinetics after allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia. Haematologica 1999;84(2):133-7.Madero L DM, Ortega JJ, Olive T, Martinez A, Badell I, Munoz A, Gomez P. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates engraftment kinetics after allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia. Haematologica 1999;84(2):133-7. Mahmoud 1996 Mahmoud HK SE, Kamel M, El HMA, Nassar A. Influence of folinic acid rescue on methotrexate-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation. Tumor Diagnostik Und Therapie 1996;17(1):18-21.Mahmoud HK SE, Kamel M, El HMA, Nassar A. Influence of folinic acid rescue on methotrexate-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation. Tumor Diagnostik Und Therapie. 1996+ADs-17(1):18-21. Malaker 1991 Malaker K, Anderson BJ, Beecroft WA, Hodson DI. Management of oral mucosal dysplasia with beta-carotene retinoic acid: a pilot cross-over study. Cancer Detection and Prevention 1991;15(5):335-40.Malaker K, Anderson BJ, Beecroft WA, Hodson DI. Management of oral mucosal dysplasia with beta-carotene retinoic acid: a pilot cross-over study. Cancer Detection +ACY- Prevention 1991+ADs-15(5):335-40. Mantovani 2003 Mantovani G, Massa E, Astara G, Murgia V, Gramignano G, Lusso MR et al. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs. Oncology Reports 2003;10(1):197-206.Mantovani G, Massa E, Astara G, Murgia V, Gramignano G, Lusso MR, et al. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs. Oncology Reports 2003+ADs- 10(1):197-206. Marcial 1994 Marcial F, Schubert M, Niccoli-Filho WD, Lloid ME, Kelly J, Franquin JC et al. A phase I/II nonblinded randomized trial to determine the efficacy of low-energy laser to prevent oral mucositis resulting from conditioning regimens for bone marrow transplantation. Oral Surgery, Oral Medicine, Oral Pathology 1994;78(6):738. Martin 2006 Martin M, Lluch A, Segui MA, Ruiz A, Ramos M, Adrover E, et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.[see comment]. Annals of Oncology 2006;17(8):1205-12. Masucci 2005 Masucci G, Broman P, Kelly C, Lindahl S, Malmberg L, Reizenstein J et al. Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy: a multicenter open randomized phase III study. Medical Oncology 2005;22(3):247-56.Masucci G, Broman P, Kelly C, Lindahl S, Malmberg L, Reizenstein J, et al. Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy: a multicenter open randomized phase III study. Medical Oncology. 2005;22(3):247-56. Matejka 1990 Matejka M, Nell A, Kment G, Schein A, Leukauf M, Porteder H et al. Local benefit of prostaglandin E2 in radiochemotherapy-induced oral mucositis. British Journal of Oral Maxillofacial Surgery 1990;28(2):89-91.Matejka M, Nell A, Kment G, Schein A, Leukauf M, Porteder H, Mailath G, Sinzinger H.Local benefit of prostaglandin E2 in radiochemotherapy-induced oral mucositis. Br J Oral Maxillofac Surg. 1990 Apr;28(2):89-91. McGaw 1985 McGaw WT, Belch A. Oral complications of acute leukemia: prophylactic impact of a chlorhexidine mouthrinse regimen. Oral Surgery, Oral Medicine, Oral Pathology 1985;60(3):275-80.McGaw WT, Belch A. Oral complications of acute leukemia: prophylactic impact of a chlorhexidine mouthrinse regimen. Oral Surg Oral Med Oral Pathol 1985;60:275-80. McIlroy 1996 McIlroy P. Radiation mucositis: a new approach to prevention and treatment. European Journal of Cancer Care 1996;5(3):153-8. Merte 1999 Merte H, Wied R, Engenhart-Cabillic R. Der effekt von immunglobulinen in der behandlung der radiogenen dermatitis und mukositis bei patienten mit hals-nasen und rachentumoren. Strahlentherapy und Onkologie 1999;175(1):135. Mills 1995 Mills W, Strang J, Goldstone AH, Linch DC. Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma. Leukemia &amp;amp; Lymphoma 1995;17(3-4):263-70. Minn 1999 Minn HR, Makkonen TA, Jekunen A, Vilja P, Tuominen J, Joensuu H. Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study. International Journal of Radiation Oncology Biology Physics 1999;45(3 Suppl):239.Minn HR, Makkonen TA, Jekunen A, Vilja P, Tuominen J, Joensuu H. Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study [abstract]. International Journal of Radiation Oncology Biology Physics. 1999;45(3 Suppl):239. Mohanta 1992 Mohanta PK, Singhal RM, Jindel R, Sharma RL, Julka PK. Hydroxyurea as a radiation sensitizer in malignancies of the head anc neck. Indian Journal of Radiology and Imaging 1992;2(2):143-6. Mok 2007 Mok TSK, Yeo W, Johnson PJ, Hui P, Ho WM, Lam KC, et al. A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. Annals of Oncology 2007;18(4):768-74. Mori 2006 Mori T, Yamazaki R, Aisa Y, Nakazato T, Kudo M, Yashima T, et al. Brief oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. Supportive Care in Cancer 2006;14(4):392-5. Nicholl 1995 Nicholl TA, Nimmo CR, Shepherd JD, Phillips P, Jewweson PJ. Amphotericin B infusion-related toxicity: comparison of two- and four-hour infusions. Annals of Pharmacotherapy 1995;29(11):1081-7. Niibe 1985b Niibe H, Takahashi I, Mitsuhashi N, Miyaishi K, Itoh J, Maehara Y et al. An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study.2 Abdominal and pelvic tumours. Nippon Gan Chiryo Gakkai Shi 1985;20(5):994-1001. Nikoletti 2005 Nikoletti S, Hyde S, Shaw T, Myers H, Kristjanson LJ. Comparison of plain ice and flavoured ice for preventing oral mucositis associated with the use of 5 fluorouracil. Journal of Clinical Nursing 2005;14(6):750-3. Ohnmacht 2001 Ohnmacht GA, Phan GQ, Mavroukakis SA, Steinberg SM, Shea YR, Witebsky FG et al. A prospective, randomized, double-blind, placebo-controlled trial evaluating the effect of nystatin on the development of oral irritation in patients receiving high-dose intravenous interleukin-2. Journal of Immunotherapy 2001;24(2):188-92.Ohnmacht GA PG, Mavroukakis SA, Steinberg SM, Shea YR, Witebsky FG, McIntyre LS, Goodwin RS, Muehlbauer PM, Morton KE, Rogers-Freezer LJ, Seipp CA, Rosenberg SA, Marincola FM. A prospective, randomized, double-blind, placebo-controlled trial evaluating the effect of nystatin on the development of oral irritation in patients receiving high-dose intravenous interleukin-2. Journal of Immunotherapy 2001;24(2):188-92. Okuno 1997 Okuno SH, Foote RL, Loprinzi CL, Gulavita S, Sloan JA, Earle J et al. A randomized trial of a nonabsorbable antibiotic lozenge given to alleviate radiation-induced mucositis. Cancer 1997;79(1):2193-9. Okuno 1998 Okuno SH, Swan L, Ebbert C. Phase III placebo-controlled clinical trial evaluation of glutamine for decreasing mucositis in patients receiving 5 FU (Fluorouracil)-based chemotherapy. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1998:256. Okutomi 2000 Okutomi T, Kato Y, Ichihara H, Hyodo I, Fujitsuka H, Yasuda S et al. [Clinical effects of adjuvant therapy using Z-100 (Ancer 20 injection) for oral cancer--prevention of stomatitis and hematopoietic impairment]. Gan To Kagaku Ryoho 2000;27(1):65-71.Okutomi T, Kato Y, Ichihara H, Hyodo I, Fujitsuka H, Yasuda S, Tatematsu N. [Clinical effects of adjuvant therapy using Z-100 (Ancer 20 injection) for oral cancer--prevention of stomatitis and hematopoietic impairment] Gan To Kagaku Ryoho. 2000 Jan;27(1):65-71. Papadeas 2007 Papadeas E, Naxakis S, Riga M, Kalofonos Ch. Prevention of 5-fluorouracil-related stomatitis by oral cryotherapy: a randomized controlled study. European Journal Oncology Nursing 2007;1:60-5. Papas 1984 Papas A, Johansen E. Prevention of mucositis in oncology patients undegoing radiation therapy. Journal of Dental Research 1984;63(Special Issue March):311 (Abs No 1267).Papas A, E J. Prevention of Mucositis in Oncology Patients Undegoing Radiation Therapy (JDR Abstract). J-Dent-Res 1984;63(Special Issue March):311 (Abs 1267). Peters 1993 Peters E, Antczak-Bouckoms A, Burdick E. Meta-analysis of chlorhexidine in the prevention of mucositis from chemotherapy. Journal of Dental Research 1993;Special Issue(259):1249.Peters E A-BA, Burdick E. Meta-Analysis of Chlorhexidine in the Prevention of Mucositis from Chemotherapy (IADR Abstract). Journal of Dental Research 1993+ADs-72:259 (Abs No 1249). Peterson 2003 Peterson DE, Petit RG. Phase III study: AES-14 in chemotherapy patients at risk for mucositis. In: Proceedings of the American Society of Clinical Oncology. 2003:725.Peterson DE, Petit RG. Phase III study: AES-14 in chemotherapy patients at risk for mucositis [abstract]. Proceedings of the American Society of Clinical Oncology. 2003:725. Petit 2001 Petit RG, II, French C. Phase III clinical trial design considerations for oral treatments of chemotherapy - induced mucositis: AES-14 (uptake-facilitated L-glutamine) pivotal studies [abstract]. Proceedings of the American Society of Clinical Oncology 2001;20 (Pt 2):301b, Abstract 2954. Pfeiffer 1989 Pfeiffer P, May O. Sucralfate prophylaxis of chemotherapy-induced stomatitis. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1989. Pfeiffer 1989a Pfeiffer P, Hansen SO, Madsen EL, May O. Sucralfate prophylaxis of chemotherapy-induced stomatitis [abstract]. Proceedings of the American Society of Clinical Oncology 1989;8:171, Abstract 665. Phillips 2002 Phillips II, GL. The potential of amifostine in high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Seminars in Oncology 2002;29(6 Supp 19):53-6. Piccirillo 2003 Piccirillo N, De Matteis S, Laurenti L, Chiusolo P, Sora F, Pittiruti M et al. Glutamine-enriched parenteral nutrition after autologous peripheral blood stem cell transplantation: effects on immune reconstitution and mucositis. Haematologica 2003;88(2):192-200. Porta 1994 Porta C, Moroni M, Nastasi G, Montecucco CM, Caporali R, Notario A. Allopurinol mouthwashes can reduce oral mucositis in chemotherapy-treated patients. Annals of Oncology 1994;5(Suppl 8):208.Porta C, Moroni M, Nastasi G, Montecucco CM, Caporali R, Notario A. Allopurinol mouthwashes can reduce oral mucositis in chemotherapy-treated patients. Annals of Oncology. 1994;5(Suppl 8):208. Pouli 1999 Pouli A, Nikiforakis E. A prospective randomized trial of GM-CFS mouthwash versus sodium bicarbonate mouthwash in the treatment of stomatitis following allogeneic bone marrow transplantation. Bone Marrow Transplantation 1999;23:S166. Prada 1985 Prada A, Lozza L, Moglia D, Sala L, Chiesa F. Effects of benzydamine on radio-polychemotherapeutic mucositis of the oral cavity. International Journal of Tissue Reaction 1985;7(3):237-9. Pyrhonen 1995 Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. British Journal of Cancer 1995;71(3):587-91.Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. British Journal of Cancer. 1996;71(3):587-91. Pytlik 2002 Pytlik R, Benes P, Patorkova M, Chocenska E, Gregora E, Prochazka B et al. Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo controlled study. Bone Marrow Transplantation 2002;30(12):953-61.Pytlik R, Benes P, Patorkova M, Chocenska E, Gregora E, Prochazka B, et al. Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo controlled study. Bone Marrow Transplantation 2002+ADs- 30(12):953-61. Rabinovitch 2006 Rabinovitch R, Grant B, Berkey BA, Raben D, Ang KK, Fu KK et al. Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: a secondary analysis of RTOG trial 90-03. Head &amp;amp; Neck 2006;28(4):287-96.Rabinovitch R, Grant B, Berkey BA, Raben D, Ang KK, Fu KK, et al. Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: a secondary analysis of RTOG trial 90-03. Head &amp;amp; Neck. 2006;28(4):287-96. Rades 2004 Rades D, Fehlauer F, Bajrovic A, Mahlmann B, Richter E, Alberti W. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiotherapy and Oncology 2004;70(3):261-4.Rades D, Fehlauer F, Bajrovic A, Mahlmann B, Richter E, Alberti W. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.[see comment]. Radiotherapy &amp;amp; Oncology. 2004;70(3):261-4. Radmard 2002 Radmard A, Niewohner-Desbordes U, Wagner W. [rhGM-CSF in the treatment of radiogenic mucositis: prospective randomised phase-II study on the effectivity and tolerance of rhGM-CSF in the treatment of oral mucositis under radiotherapy of head and neck tumors]. Strahlentherapie und Onkologie 2002;178(Suppl 1):24.Radmard A, Niewohner-Desbordes U, Wagner W. [ rhGM-CSF in the treatment of radiogenic mucositis: prospective randomised phase-II study on the effectivity and tolerance of rhGM-CSF in the treatment of oral mucositis under radiotherapy of head and neck tumors. ]. Strahlentherapie und Onkologie. 2002;178(Sondernr 1):24. Raether 1989 Raether D, Walker PO, Bostrum B, Weisdorf D. Effectiveness of oral chlorhexidine for reducing stomatitis in a pediatric bone marrow transplant population. Pediatric Dentistry 1989;11(1):37-42.Raether D, Walker PO, Bostrum B, Weisdorf D. Effectiveness of oral chlorhexidine for reducing stomatitis in a pediatric bone marrow transplant population. Pediatric Dentistry 1989;11:37-42. Robustelli 1999 Robustelli della Cuna FS, Ucci G, Cuomo AM, Goglio AM. Galenic preparation for the prophylaxsis of oral mucositis induced by 5-fluororacil continous infusion. Supportive Care in Cancer 1999;7 Suppl:132 (Abs No P-67).Robustelli della Cuna FS, Ucci G, Cuomo AM, Goglio AM. Galenic preparation for the prophylaxsis of oral mucositis induced by 5-fluororacil continous infusion. Supportive Care in Cancer. 1999;7 Suppl.(Abstr P-67):132. Rocci 2005 Rocci L, Vincenzi B, Santini D, Tonini G. [Timing of 5-fluorouracile infusion: a randomized clinical trial]. International Nursing Perspectives 2005;5(2):53-60.Rocci L, Vincenzi B, Santini D, Tonini G. Timing of 5-fluorouracile infusion: a randomized clinical trial [Italian]. International Nursing Perspectives. 2005;5(2):53-60. (32 ref). Rojas 2001 Rojas de Morales T, Zambrano O, Rivera L, Navas R, Chaparro N, Bernardonni C et al. Oral-disease prevention in children with cancer: testing preventive protocol effectiveness. Medicina Oral 2001;6(5):326-34.Rojas de Morales T ZO, Rivera L, Navas R, Chaparro N, Bernardonni C, Rivera F, Fonseca N, Tirado DM. Oral-disease prevention in children with cancer: testing preventive protocol effectiveness. Medicina Oral 2001+ADs-6(5):326-34. Rutkauskas 1993 Rutkauskas JS, Davis JW. Effects of chlorhexidine during immunosuppressive chemotherapy: A preliminary report. Oral Surgery, Oral Medicine, Oral Pathology 1993;76(4):441-8.Rutkausas JS, Davis JW. Effects of chlorhexidine during immunosuppressive chemotherapy: A preliminary report. Oral Surg Oral Med Oral Path 1993;76:441-8. Ryu 2007 Ryu JK, Swann S, LeVeque F, Scarantino CW, Johnson D, Chen A, et al. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901. International Journal of Radiation Oncology, Biology, Physics 2007;67(3):643-50. Samaranayake 1988 Samaranayake LP, Robertson AG, MacFarlane TW, Hunter IP, MacFarlane G, Soutar DS et al. The effect of chlorhexidine and benzydamine mouthwashes on mucositis induced by therapeutic irradiation. Clinical Radiology 1988;39(3):291-4. Sato 1997 Sato A, Kumagai S, Sakaki K, Morikawa H, Song ST, Mori S. [Inhibition of 5-fluorouracil-cisplatin-induced stomatitis by oral cryotherapy: use of an ice-bar containing fibrinolysin and deoxyribonuclease comiben (Elase)]. Gan to Kagaku Ryoho [Japanese Journal of Cancer &amp;amp; Chemotherapy] 1997;24(9):1135-9. Sato 2006 Sato A, Saisho-Hattori T, Koizumi Y, Minegishi M, Iinuma K, Imaizumi M. Prophylaxis of mucosal toxicity by oral propantheline and cryotherapy in children with malignancies undergoing myeloablative chemo-radiotherapy. Tohoku Journal of Experimental Medicine 2006;210(4):315-20. Scarantino 2001a Scarantino CW, LeVeque FG, Scott CB, White RL, Rotman M, Hodson DI et al. A phase III study of concomitant oral pilocarpine to reduce hypo-salivation and mucositis assocated with curative radiation therapy (RT) in head and neck (H&amp;amp;N) cancer patients. RTOG 9709. In: Proceedings of the American Society of Clinical Oncology. 2001:(Abs No 897).Scarantino C LF, Scott C, White R, Rotman M, Hodson D, Meredith R, Foote R, Brachman D. A Phase III Study of Concomitant Oral Pilocarpine to Reduce Hypo-Salivation and Mucositis Assocated with Curative Radiation Therapy (RT) in Head and Neck (H&amp;amp;N) Cancer Patients. RTOG 9709. Proceedings of ASCO 2001. Scarantino 2001b Sadar CM, Heard R, Prathikanti R, Lau D, Danilenko D, Hunt T et al. Safety, pharmacokinetics and biological activity of rHuKGF in normal volunteers.. Growth Factors and Cytokines;Abstract 761:172. Scarantino CW, Leveque F, Scott C, White RL, Rotman M, Hodson DI et al. A Phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97-09. International Journal of Radiation Oncology, Biology, Physics 2001;51(3 Suppl 1):85-6.Scarantino CW, Leveque F, Scott C, White RL, Rotman M, Hodson DI, et al. A Phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97-09 [abstract]. International Journal of Radiation Oncology Biology Physics. 2001;51(3 Suppl 1):85-6. Schuster 2008 Schuster MW, Anaissie E, Hurd D, Bensinger W, Mason J, McCarty J, et al. Final analysis of the phase II, randomized, double-blind, placebo-controlled trial of single-dose velafermin (CG53135-05) for the prevention of oral mucositis. Journal of Supportive Oncology 2007;5(4 SUPPL. 2):58-9. Schuster MW, Shore TB, Harpel JG, Greenberg J, Jalilizeinali B, Possley S, et al. Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant. Supportive Care in Cancer 2008;16(5):477-83. Schwerkkoske 1999 Schwerkkoske J, Schwartzberg L, Weaver CH, Schwertschlag US, Goodfellow J, Berdosian CL. A phase I double-masked, placebo-controlled study to evaluate tolerability of Neumega (rhIL-11; Oprelvekin) to reduce mucositis in patients with solid tumors or lymphoma receiving high-dose chemotherapy (CT) with autologous peripheral blood stem cell reinfusion (PBSCT). In: Proceedings of the American Society of Clinical Oncology. Vol. 18. 1999:584a.Schwerkkoske J, Schwartzberg L, Weaver CH, Schwertschlag US, Goodfellow J, Berdosian CL. A phase I double-masked, placebo-controlled study to evaluate tolerability of Neumega (rhIL-11; Oprelvekin) to reduce mucositis in patients with solid tumors or lymphoma receiving high-dose chemotherapy (CT) with autologous peripheral blood stem cell reinfusion (PBSCT) [abstract]. Proceedings of the American Society of Clinical Oncology. 1999;18:584a. Schwerkoske 1999 Schwerkoske J, Schwartzberg L, Weaver CH, Schwertschlag US, Goodfellow J, Bedrosian CL. A phase 1 double-masked, placebo-controlled study to evaluate tolerability of Neumega&amp;#174; (rhIL-11; oprelvekin) to reduce mucositis in patients with solid tumors or lymphoma receiving high-dose chemotherapy (CT) with autologous peripheral blood stem cell reinfusion (PBSCT) [abstract]. Proceedings of the American Society of Clinical Oncology 1999;18:584a, Abstract 2256. Shea 2007 Shea TC, Kewalramani T, Mun Y, Jayne G, Dreiling LK. Evaluation of Single-Dose Palifermin To Reduce Oral Mucositis (OM) in Fractionated Total Body Irradiation (fTBI) and High Dose (HD) Chemotherapy with Autologous Peripheral Blood Progenitor Cell (PBPC) Transplantation [abstract]. Blood 2006;108(11 Part 1):875-6. Shea TC, Kewalramani T, Mun Y, Jayne G, Dreiling LK. Evaluation of single-dose palifermin to reduce oral mucositis in fractionated total-body irradiation and high-dose chemotherapy with autologous peripheral blood progenitor cell transplantation. Journal of Supportive Oncology 2007;5(4 SUPPL. 2):60-2. Simoes 2009 Simoes A, Eduardo FP, Luiz AC, Campos L, Sa PH, Cristofaro M, et al. Laser phototherapy as topical prophylaxis against head and neck cancer radiotherapy-induced oral mucositis: comparison between low and high/low power lasers. Lasers in Surgery &amp;amp; Medicine 2009;41(4):264-70. Spadaro 1991 Spadaro P, Buemi B, Ferraro G, Marabello G, Russi E, Pergolizzi S. Prophylaxis of chemotherapy-radiotherapy induced mucositis or oral fungal infection with vitamin E + vitamin A and Fluconazolo. European Journal of Cancer 1991;27(Suppl 2):S288. Spielberger 2001 Spielberger RT, Stiff P, Emmanouilides C, Yanovich S, Bensinger W, Hedrick E, et al. Efficacy of recombinant human keratinocyte growth factor (rHuKGF) in reducing mucositis in patients with hematologic malignancies undergoing autologous peripheral blood progenitor cell transplantation (auto-PBPCT) after radiation-based conditioning - results of a phase 2 trial [abstract]. Proceedings of the American Society of Clinical Oncology 2001;20 (Pt 1):7a, Abstract 25. Staar 2001 Staar S. Benefits and toxicities of accelerated radiochemo- versus accelerated radiotherapy in advanced head and neck cancer - Results of a German randomized study. European Journal of Cancer 2001;37(Suppl 6):38 (Abs No 126).Staar S EHRVDAFMSMVPSPSHMR. Benefits and toxicities of accelerated radiochemo- versus accelerated radiotherapy in advanced head and neck cancer - Results of a German randomized study. European Journal of Cancer. 2001 2001;37(Suppl 6):38 Abs. 126. Stokman 2004 Stokman MA, Wachters FM, Koopmans P, Burgerhof JG, Groen HJ, Spijkervet FK et al. Outcome of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis. A phase II study. Anticancer Research 2004;24(5B):3263-7.Stokman MA, Wachters FM, Koopmans P, Burgerhof JG, Groen HJ, Spijkervet FK, et al. Outcome of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis. A phase II study. Anticancer Research. 2004;24(5B):3263-7. Su 2004a Su C, Mehta V, Ravikumar L, Shah R, Pinto H, Halpern J et al. Phase II double-blind randomized study comparing oral aloe vera (AV) versus placebo to prevent radiation (RT)-related mucositis in patients with head and neck (HN) neoplasms. In: Proceedings of the Amercian Society of Clinical Oncology. 2004.Su C, Mehta, V, Ravikumar, L, Shah, R, Pinto, H, Halpern, J, Koong, A, Goffinet, D, and Le, Q-T. Phase II double-blind randomized study comparing oral aloe vera (AV) versus placebo to prevent radiation (RT)-related mucositis in patients with head and neck (HN) neoplasms. Proceedings of ASCO. 2003 2003. Su 2004b Su YB. Double-blind, randomized trial of granulocyte-colony stimulating factor (GCSF) versus (v.) placebo during postoperative radiation (RT) for advanced resectable squamous cell head and neck cancer (SCCHN): impact on mucositis. Journal of Clinical Oncology 2004;22(Suppl):14S. Suc 1999 Suc A, Gandemer V, Le Deley MC, Schmitt C, Pichard-Leandri E, French Group. Gum98: Preventing mucositis with chewing gum in children receiving chemotherapy, a multicentric trial. Supportive Care in Cancer 1999;7S:180 (Abs No P-60). Svanberg 2004 Svanberg A, &amp;#214;hrn K. Cryotherapy during chemotherapy - could it delay or alleviate the development of mucositis? Bone Marrow Transplantation 2004;33(Suppl 1):S292.Svanberg A, &amp;#214;hrn K. Cryotherapy during chemotherapy - could it delay or alleviate the development of mucositis? [abstract]. Bone Marrow Transplantation. 2004;33(Suppl 1):S292. Svanberg 2007 Svanberg A, Birgegard G, Ohrn K. Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy--a randomized controlled trial. Supportive Care in Cancer 2007;15(10):1155-61. Sykes 2004 Sykes AJ, Slevin NJ, MacDougall RH, Ironside JAD, Mais KL. Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck. Radiotherapy and Oncology 2004;71(1):81-4. Symonds 1995 Symonds RP, Thomas M, Alcock SR, Khorrami J, McEllroy P, McMuuuray A. The reduction of radiation mucositis by antibiotic pastilles: a placebo-controlled double-blind trial. European Journal Surgery Oncology 1995;21:447.Symonds RP TM, Alcock SR, and et al. The reduction of radiation mucositis by antibiotic pastilles: a placebo-controlled double-blind trial [abstract]. Eur-J-Surg-Oncol 1995;21:447. Teshima 1986 Teshima T. [Clinical evaluation of kenalog ointment for radiation mucositis of patients with head and neck cancer]. Yakuri to Chiryo (Japanese Pharmacology and Therapeutics) 1986;14(11):7163-6.Teshima T, et al. [Clinical Evaluation of Kenalog Ointment for Radiation Mucositis of Patients with Head and Neck Cancer]. Yakuri to Chiryo (Japanese Pharmacology and Therapeutics). 1986;14(11):7163-6. Thieblemont 2002 Thieblemont C, Dumontet C, Saad H, Roch N, Bouafia F, Arnaud P et al. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplantation 2002;30(11):769-75.Thieblemont C, C D, H S, N R, F B, P A, et al. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplantation 2002;30(11):769-75. Throuvalas 1995 Throuvalas N, Antonadou D, Pulizzi M, Sarris G. Evaluation of the efficacy and safety of GM-CSF in the prophylaxis of mucositis in patients with head and neck cancer treated with RT. European Journal of Cancer 1995;31(Suppl 5):S93 (Abs No 431).Throuvalas Nao. Evaluation of the efficacy and safety of GM-CSF in the prophylaxis of mucositis in patients with head and neck cancer treated with RT. European Journal of Cancer 1995;31?(Suppl 5):S93 Abs. 431. Tiemann 2006 Tiemann P, Toelg M, Ramos FM. Administration of Ratanhia-based herbal oral care products for the prophylaxis of oral mucositis in cancer chemotherapy patients: a clinical trial. Evid Based Complement Alternat Med 2007;4(3):361-6. Toubai 2003 Toubai T, Tanaka J, Fujisawa F, Kondo Y, Imamura M, Ota S et al. Effect of prophylaxis against myocosis in patients with hematological malignancy disease: efficacy of dosage of itraconazole. Japanese Journal of Antibiotics 2003;56(1):61-5.Toubai T, Tanaka J, Fujisawa F, Kondo Y, Imamura M, Ota S, et al. Effect of prophylaxis against myocosis in patients with hematological malignancy disease: efficacy of dosage of itraconazole. +AFs-Japanese+AF0-. Japanese Journal of Antibiotics 2003+ADs- 56(1):61-5. Uchiyama 2005 Uchiyama Y, Murakami S, Kakimoto N, Nakatani A, Furukawa S. Effectiveness of Cepharanthin in decreasing interruptions during radiation therapy for oral cancer. Oral Radiology 2005;21(1):41-4.Uchiyama Y, Murakami S, Kakimoto N, Nakatani A, Furukawa S. Effectiveness of Cepharanthin in decreasing interruptions during radiation therapy for oral cancer. Oral Radiology. 2005;21(1):41-4. Vacha 1999 Vacha P, Marx M, Engel A, Richter E, Feyerabend T. Side effects of postoperative radiochemotherapy with amisfostine versus radiotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial [Nebenwirkungen einer posoperativen radiochemotherapie mit amifostin versus alleiniger radiochemotherapie bei kopf-hals-tumoren. Vorlaufige ergebnisse einer prospektiv randomisierten untersuchung]. Strahlentherapie und onkologie 1999;175(S4):18-22. Vacha 2003 Vacha P, Fehlauer F, Mahlmann B, Marx M, Hinke A, Sommer K et al. Randomized phase III trial of postoperative radiochemotherapy amifostine in head and neck cancer: Is there evidence for radioprotection? Strahlentherapie und Onkologie 2003;179(6):385-9.Vacha PFFMBMMHASKREFT. Randomized phase III trial of postoperative radiochemotherapy amifostine in head and neck cancer: Is there evidence for radioprotection? Strahlentherapie und Onkologie 2003+ADs- Vol 179(6): 385-389. Valcarcel 2002a Valcarcel D, Sanz M, Sureda A, Sala M, Munoz L, Subira M et al. Topically applied recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) for oropharyngeal mucositis (OM) in stem cell transplantation recipients: a randomized double-blind placebo-controlled study. Bone Marrow Transplantation 2002;Suppl 2:S20.Valcarcel D, Sanz M, Sureda A, Sala M, Munoz L, Subira M, et al. Topically applied recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) for oropharyngeal mucositis (OM) in stem cell transplantation recipients: a randomized double-blind placebo-controlled study [abstract]. Bone Marrow Transplantation. 2002(Suppl 2):S20. Valcarcel 2002b Valcarcel D, Sanz MA Jr, Sureda A, Sala M, Munoz L, Subira M et al. Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study. Bone Marrow Transplantation 2002;29(9):783-7.Valcarcel D, Sanz MAJ, Sureda A, Sala M, Munoz L, Subira M, et al. Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study. Bone Marrow Transplantation. 2002 2002; 29(9):783-7. Valc&amp;#225;rcel 1997 Valc&amp;#225;rcel F, De la Torre A, Arag&amp;#243;n G, Lanz&amp;#243;s E, Rodr&amp;#237;guez R, Veiras C. Double-blind randomized and pilot study on the potential of thymostimulin to reduce the incidence of mucositis in head and neck cancer patients with radical radiotherapy. In: Oncolog&amp;#237;a IX Congreso Nacional de la Asociaci&amp;#243;n Espa&amp;#241;ola de Radioterapia y Oncolog&amp;#237;a. Vol. 20. 1997:161.Valc&amp;#225;rcel F, De la Torre A, Arag&amp;#243;n G, Lanz&amp;#243;s E, Rodr&amp;#237;guez R, Veiras C. Double-blind randomized and pilot study on the potential of thymostimulin to reduce the incidence of mucositis in head and neck cancr patients with radical radiotherapy. Oncolog&amp;#237;a IX Congreso Nacional de la Asociaci&amp;#243;n Espa&amp;#241;ola de Radioterapia y Oncolog&amp;#237;a. 1997;20(10 - Congreso):161. van Zaanen 1994 van Zaanen HC, van der Lelie H, Timmer JG, Furst P, Sauerwein HP. Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapy-induced toxicity. Cancer 1994;74(10):2879-84.van Zaanen HC vdLH, Timmer JG, Furst P, Sauerwein HP. Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapy-induced toxicity. Cancer 1994;74(10):2879-84. Verdi 1995 Verdi CJ, Garewal HS, Koenig LM, Vaughn B, Burkhead T. A double-blind, randomized, placebo-controlled, crossover trial of pentoxiflline for the prevention of chemotherapy-induced oral mucositis. Osomopore 1995;80(1):36-42. Vesole 1999 Vesole D, Fuchs HJ. IB-367 reduces the number of days of severe oral mucositis complicating myeloablative chemotherapy. Blood 1999;94(10 Suppl 1):154 (Abs No 675).Vesole DHaF, H. J. IB-367 reduces the number of days of severe oral mucositis complicating myeloablative chemotherapy [abstract]. Blood 1999;94(10 Suppl 1):154a. Vitello 2000 Vitello M, Cianio SG. A comparison of two mouthrinse agents used during head/neck radiation. Journal of Dental Research 2000;79(Special Issue):215 (Abs No 576). Wagner 2002 Wagner W, Radmard A, Niewohner-Desbordes U, Haus U, Matt J. rhGM-CSF in the treatment of radiotherapy induced mucositis-prospective randomized, double-blind study to investigate the feasibility and effectiveness of rhGM-CSF in patients with head and neck cancer. In: Proceedings of the American Society for Therapeutic Radiology and Oncology Meeting. 2002:311 (Abs No 2175). Wang 2002b Wang HM, Wang CS, Chen JS, Chen IH, Liao CT, Chang TC. Cisplatin, tegafur, and leucovorin: a moderately effective and minimally toxic outpatient neoadjuvant chemotherapy for locally advanced squamous cell carcinoma of the head and neck. Cancer 2002;94(11):2989-95. Ward 2007 Ward E, Smith M, Henderson M, Reid U, Lewis I, Kinsey S, et al. The effect of high-dose enteral glutamine on the incidence and severity of mucositis in paediatric oncology patients. Eur J Clin Nutr 2007. Warde 2002 Warde P, O'Sullivan B, Aslanidis J, Kroll B, Lockwood G, Waldron J et al. A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. International Journal of Radiation Oncology Biology and Physics 2002;54(1):9-13.Warde P, O'Sullivan, B, Aslanidis, J, Kroll, B, Lockwood, G, Waldron, J, Payne, D, Bayley, A, Ringash, J, Kim, J, Liu, F, Maxymiw, W, Sprague, S, and Cummings, B. A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002+ADs-54(1):9-13. Weisdorf 1989 Weisdorf DJ, Bostrom B, Raether D, Mattingly M, Walker P, Pihlstrom B et al. Oropharyngeal mucositis complicating bone marrow transplantation: prognostic factors and the effect of chlorhexidine mouthrinse. Bone Marrow Transplantation 1989;4(1):89-95.Weisdorf DJ, Bostrom B, Raether D, Mattingly M, Walker P, Pihlstrom B et al. Oropharyngeal mucostitis complicating bone marrow transplantation: prognostic factors and the effect of chlorhexidine mouthrinse. Bone Marrow Transplant 1989;4:89-95. Weiss 1990 Weiss GR, Green S, Hannigan EV, Boutselis JG, Surwit EA, Wallace DL et al. A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial. Gynecologic Oncology 1990;37(3):354-8.Weiss GR GS, Hannigan EV, Boutselis JG, Surwit EA, Wallace DL, Alberts DS. A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial. Gynecologic Oncology 1990;37(3):354-8. Whelan 2002 Whelan HT, Connelly JF, Hodgson BD, Barbeau L, Post AC, Bullard G et al. NASA light-emitting diodes for the prevention of oral mucositis in pediatric bone marrow transplant patients. Journal of Clinical Laser Medicine &amp;amp; Surgery 2002;20(6):319-24. Whelan 2004 Whelan H. Phase II randomized study of NASA-developed light-emitting diode therapy for the prevention of oral mucositis in children receiving a myeloablative conditioning regimen comprising chemotherapy with or without radiotherapy followed by first allogeneic bone marrow transplantation. http://www.clinicaltrials.gov (accessed 2003).Whelan H. Phase II Randomized Study of NASA-Developed Light-Emitting Diode Therapy For the Prevention of Oral Mucositis in Children Receiving a Myeloablative Conditioning Regimen Comprising Chemotherapy With or Without Radiotherapy Followed By First Allogeneic Bone Marrow Transplantation. National Institutes of Health, ClinicalTrials.Gov [http://www.clinicaltrials.gov] 2003. Wollina 2002 Wollina U, Christen N, Kostler E, Schorcht J. On prophylaxis and treatment of radiation-induced dermatitis and mucositis. Zeitschrift fur Hautkrankheiten 2002;77(9):418-23. Wymenga 1999a Wymenga AN, van der Graaf WT, Hofstra LS, Timens W, Spijkervet FK, Hospers GAP et al. TGF-b3 mouthwashes aimed at prevention of chemotherapy induced mucositis, a phase-I study. Supportive Care in Cancer 1999;7:168. Wymenga 1999b Wymenga AN, van der Graaf WT, Hofstra LS, Spijkervet FK, Timens W, Timmer-Bosscha H et al. Phase I study of transforming growth factor-beta3 mouthwashes for prevention of chemotherapy-induced mucositis. Clinical Cancer Research 1999;5(6):1363-8.Wymenga AN, van der Graaf WT, Hofstra LS, Spijkervet FK, Timens W, Timmer-Bosscha H, Sluiter WJ, van Buuren AH, Mulder NH, de Vries EG.Phase I study of transforming growth factor-beta3 mouthwashes for prevention of chemotherapy-induced mucositis. Clin Cancer Res. 1999 Jun;5(6):1363-8. Yokomizo 2004 Yokomizo H, Yoshimatsu K, Hashimoto M, Ishibashi K, Umehara A, Yoshida K et al. Prophylactic efficacy of allopurinol ice ball for leucovorin/5-fluorouracil therapy-induced stomatitis. Anticancer Research 2004;24(2C):1131-4.Yokomizo H, Yoshimatsu K, Hashimoto M, Ishibashi K, Umehara A, Yoshida K, et al. Prophylactic efficacy of allopurinol ice ball for leucovorin/5-fluorouracil therapy-induced stomatitis. Anticancer Research. 2004;24(2C):1131-4. Zalcberg 1995 Zalcberg J, Cunningham D, Rath U, Olver I, Kerr D, van Cutsem E et al. 'Tomudex' (ZD1694) has a higher response rate, significantly less leucopenia and mucositis and a simpler dosing regimen than 5-Fluorouracil (5-FU) and leucovorin (LV) for advanced colorectal cancer (CRC): first results of a phase III study. European Journal of Cancer 1995;31f:S146 (Abs No 701). Studies awaiting classification Ongoing studies Haddad 2003 Haddad R, Wirth L, Costello R, Weeks L, Posner M. Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. Seminars in Oncology 2003;30(6 Suppl 18):84-8.Haddad R, Wirth L, Costello R, Weeks L, Posner M. Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. Seminars in Oncology 2003; 30(6 Suppl 18):84-8. National 2008 National Cancer I. Phase III comparison of oral capsaicin lozenge versus placebo lozenge for radiation-induced mucositis [completed]. ClinicalTrials.gov [accessed 31 Jul 2008] 2008:ClinicalTrials.gov ID: NCT00003610. National 2008a National Cancer I. A phase III study to test the efficacy and safety of GM-CSF to reduce the severity and duration of mucosal Injury and pain (mucositis) associated with curative radiation therapy in head and neck cancer patients [completed]. ClinicalTrials.gov [accessed 31 Jul 2008] 2008:ClinicalTrials.gov ID: NCT00008398. Other references Additional references Andreassen 2003 Barasch 2003 Begg 1996 Bellm 2002 Chang 2003 Clarkson 2004 Clarkson 2007a Clarkson 2007b De Pauw 1997 Denning 1992 Duncan 2003 Elbourne 2002 Gotzsche 2002 J Briggs Inst 1998 Kowanko 1998 Lortholary 1997 McGuire 2004 Meunier 1994 Moher 2001 Rubenstein 2004 Savarese 2003 Sonis 2004 Stevens 1995 Stokman 2006 Sunderland 2001 Symonds 1998 Verdi 1993 White 1993 Worthington 2004a Worthington 2004b Worthington 2007 Wright 2003 Other published versions of this review Clarkson 2000 Clarkson 2003a Worthington 2006 Classification pending references Data and analyses 1 Acyclovir versus placebo 1.1 Mucositis (absent versus present) 2 Allopurinol versus placebo/no treatment 2.1 Mucositis (absent versus present) 2.2 Mucositis (0-1 versus 2+) 2.3 Mucositis (0-2 versus 3+) 2.4 Mucositis (absent versus present) 2.5 Mucositis (0-1 versus 2+) 2.6 Mucositis (0-2 versus 3+) 3 Aloe vera versus placebo 3.1 Mucositis (0-1 versus 2+) 4 Amifostine versus placebo/no treatment 4.1 Mucositis (absent versus present) 4.2 Mucositis (0-1 versus 2+) 4.3 Mucositis (0-2 versus 3+) 4.4 Survival at 24 months 4.5 Recurrence at 18 months after cancer treatment 4.6 Incomplete response to radiotherapy 4.7 Delay to radiotherapy 4.8 Hypotension 4.9 Nausea 4.10 Vomiting 5 Antibiotic pastille or paste versus placebo/no treatment 5.1 Mucositis (absent versus present) 5.2 Mucositis (0-1 versus 2+) 5.3 Mucositis (0-2 versus 3+) 6 Benzydamine versus placebo 6.1 Mucositis (absent versus present) 6.3 Mucositis (0-2 versus 3+) 7 Beta carotene versus control 7.1 Mucositis (0-2 versus 3+) 8 Calcium phosphate versus placebo 8.1 Mucositis (absent versus present) 8.2 Mucositis (0-1 versus 2+) 8.3 Mucositis (0-2 versus 3+) 9 Chewing gum versus no chewing gum 9.1 Mucositis (absent versus present) 9.2 Mucositis (0-2 versus 3+) 10 Camomile versus placebo 10.1 Mucositis (absent versus present) 10.2 Mucositis (0-1 versus 2+) 10.3 Mucositis (0-2 versus 3+) 11 Chinese medicine versus control 11.1 Mucositis (absent versus present) 11.2 Mucositis (0-1 versus 2+) 11.3 Mucositis (0-2 versus 3+) 12 Chlorhexidine versus placebo/no treatment 12.1 Mucositis (absent versus present) 12.2 Mucositis (0-1 versus 2+) 12.3 Mucositis (0-2 versus 3+) 12.4 Mucositis (absent versus present) 12.5 Mucositis (0-1 versus 2+) 12.6 Mucositis (0-2 versus 3+) 13 Chlorhexidine versus cryotherapy 13.1 Mucositis (absent versus present) 13.2 Mucositis (0-1 versus 2+) 13.3 Mucositis (0-2 versus 3+) 14 Cryotherapy versus no treatment 14.1 Mucositis (absent versus present) 14.2 Mucositis (0-1 versus 2+) 14.3 Mucositis (0-2 versus 3+) 14.4 Mucositis (absent versus present) 14.5 Mucositis (0-1 versus 2+) 14.6 Mucositis (0-2 versus 3+) 15 Cryotherapy 30 min versus 60 min 15.1 Mucositis (absent versus present) 15.2 Mucositis (0-1 versus 2+) 15.3 Mucositis (0-2 versus 3+) 16 Etoposide: bolus versus continuous 16.1 Mucositis (absent versus present) 16.2 Mucositis (0-1 versus 2+) 16.3 Mucositis (0-2 versus 3+) 17 Folinic acid versus no treatment 17.1 Mucositis (absent versus present) 17.2 Mucositis (0-1 versus 2+) 17.3 Mucositis (0-2 versus 3+) 18 Glutamine versus placebo 18.1 Mucositis (absent versus present) 18.2 Mucositis (0-1 versus 2+) 18.3 Mucositis (0-2 versus 3+) 18.4 Mucositis (absent versus present) 18.5 Mucositis (0-1 versus 2+) 18.6 Mucositis (0-2 versus 3+) 19 G-CSF versus no treatment 19.1 Mucositis (absent versus present) 19.2 Mucositis (0-1 versus 2+) 19.3 Mucositis (0-2 versus 3+) 20 GM-CSF versus no treatment 20.1 Mucositis (absent versus present) 20.2 Mucositis (0-1 versus 2+) 20.3 Mucositis (0-2 versus 3+) 21 GM-CFS versus sucralfate 21.1 Mucositis (0-1 versus 2+) 21.2 Mucositis (0-2 versus 3+) 22 Histamine gel versus placebo 22.1 Mucositis (absent versus present) 22.2 Mucositis (0-2 versus 3+) 23 Honey versus control 23.1 Mucositis (absent versus present) 23.2 Mucositis (0-1 versus 2+) 23.3 Mucositis (0-2 versus 3+) 24 Hydrolytic enzymes versus no treatment 24.1 Mucositis (absent versus present) 24.2 Mucositis (0-1 versus 2+) 24.3 Mucositis (0-2 versus 3+) 25 Indomethacin versus placebo 25.1 Mucositis (0-1 versus 2+) 26 Iseganan versus placebo 26.1 Mucositis (absent versus present) 26.2 Mucositis (0-1 versus 2+) 26.3 Mucositis (0-2 versus 3+) 27 Keratinocyte GF versus placebo 27.1 Mucositis (absent versus present) 27.2 Mucositis (0-1 versus 2+) 27.3 Mucositis (0-2 versus 3+) 28 Keratinocyte: 50 mg versus 25 mg 28.1 Mucositis (0-1 versus 2+) 28.2 Mucositis (0-2 versus 3+) 29 Laser versus no treatment 29.2 Mucositis (absent versus present) 29.3 Mucositis (0-1 versus 2+) 29.4 Mucositis (0-2 versus 3+) 30 Laser versus povidine 30.1 Mucositis (0-1 versus 2+) 30.2 Mucositis (0-2 versus 3+) 31 Misonidazole versus control 31.1 Mucositis (absent versus present) 31.2 Mucositis (0-1 versus 2+) 31.3 Mucositis (0-2 versus 3+) 31.4 New Outcome 32 Oral care protocol versus none 32.1 Mucositis (absent versus present) 32.2 Mucositis (0-1 versus 2+) 32.3 Mucositis (0-2 versus 3+) 33 Pentoxifylline versus no treatment 33.1 Mucositis (0-1 versus 2+) 34 Pilocarpine versus placebo 34.1 Mucositis (absent versus present) 34.2 Mucositis (0-1 versus 2+) 34.3 Mucositis (0-2 versus 3+) 35 Povidone versus water 35.1 Mucositis (absent versus present) 35.2 Mucositis (0-1 versus 2+) 35.3 Mucositis (0-2 versus 3+) 36 Prednisone versus placebo 36.1 Mucositis (absent versus present) 36.2 Mucositis (0-1 versus 2+) 36.3 Mucositis (0-2 versus 3+) 37 Propantheline anticholinergic versus placebo 37.1 Mucositis (absent versus present) 38 Prostaglandin versus placebo 38.1 Mucositis (absent versus present) 38.2 Mucositis (0-1 versus 2+) 38.3 Mucositis (0-2 versus 3+) 39 Radiotherapy: am versus pm 39.3 Mucositis (0-2 versus 3+) 40 Sucralfate versus placebo 40.1 Mucositis (absent versus present) 40.2 Mucositis (0-1 versus 2+) 40.3 Mucositis (0-2 versus 3+) 40.4 Mucositis (absent versus present) 40.5 Mucositis (0-1 versus 2+) 40.6 Mucositis (0-2 versus 3+) 41 Systemic antibiotic clarithromycin versus no treatment 41.1 Mucositis (0-1 versus 2+) 42 Traumeel versus placebo 42.1 Mucositis (absent versus present) 43 Zinc sulphate versus placebo 43.1 Mucositis (absent versus present) 43.2 Mucositis (0-1 versus 2+) 43.3 Mucositis (0-2 versus 3+) 44 Active treatment versus placebo/no treatment 44.1 Mucositis (absent versus present) 44.1.1 Aclyclovir versus placebo 44.1.2 Allopurinol versus placebo/no treatment 44.1.3 Amifostine versus no treatment 44.1.4 Antibiotic (pastille or paste) versus placebo 44.1.5 Benzydamine versus placebo 44.1.6 Chinese medicine versus control (Dobell's solution) 44.1.7 Calcium phosphate versus placebo 44.1.8 Camomile versus placebo 44.1.9 Chlorhexidine versus placebo or no treatment 44.1.10 Folinic acid versus no treatment 44.1.11 Glutamine versus placebo 44.1.12 GM-CSF versus no treatment 44.1.13 Histamine gel versus placebo 44.1.14 Honey versus control 44.1.15 Hydrolytic enzymes versus no treatment 44.1.16 Ice chips versus no treatment 44.1.17 Iseganan versus placebo 44.1.18 Misonidazole versus control 44.1.19 Oral care protocol versus none 44.1.20 Pilocarpine versus placebo 44.1.21 Povidone versus water 44.1.22 Prednisone versus placebo 44.1.23 Propantheline versus placebo 44.1.24 Prostaglandin versus placebo 44.1.25 Sucralfate versus placebo 44.1.26 Traumeel versus placebo 44.1.27 Zinc sulphate versus placebo 44.1.28 Palifermin versus placebo 44.2 Mucositis (0-1 versus 2+) 44.2.1 Aloe vera versus placebo 44.2.2 Amifostine versus placebo or no treatment 44.2.3 Antibiotic pastille or paste versus placebo or no treatment 44.2.4 Calcium phosphate versus placebo 44.2.5 Camomile versus placebo 44.2.6 Chinese medicine versus control (Dobell's solution) 44.2.7 Chlorhexidine versus placebo or no treatment 44.2.8 Folinic acid versus no treatment 44.2.9 Glutamine versus placebo 44.2.10 GM-CSF versus no treatment 44.2.11 Hydrolic enzymes versus no treatment 44.2.12 Ice chips versus no treatment 44.2.13 Indomethacin versus placebo 44.2.14 Iseganan versus placebo 44.2.15 Keratinocyte GF versus placebo 44.2.16 Misonidazole versus control 44.2.17 Oral care protocol versus none 44.2.18 Pentoxifylline versus no treatment 44.2.19 Pilocarpine versus placebo 44.2.20 Povidone versus water 44.2.21 Prednisone versus placebo 44.2.22 Sucralfate versus placebo 44.2.23 Systemic antibiotic clarithromycin versus no treatment 44.2.24 Zinc sulphate versus placebo 44.3 Mucositis (0-2 versus 3+) 44.3.1 Amifostine versus no treatment 44.3.2 Antibiotic pastille or paste versus placebo 44.3.3 Beta carotene versus control 44.3.4 Calcium phosphate versus placebo 44.3.5 Camomile versus placebo 44.3.6 Chinese medicine versus control (Dobell's solution) 44.3.7 Chlorhexidine versus placebo or no treatment 44.3.8 Folinic acid versus no treatment 44.3.9 Glutamine versus placebo 44.3.10 GM-CSF versus placebo 44.3.11 Histamine gel versus placebo 44.3.12 Honey versus control 44.3.13 Hydrolytic enzymes versus no treatment 44.3.14 Ice chips versus no treatment 44.3.15 Iseganan versus placebo 44.3.16 Keratinocyte GF versus placebo 44.3.17 Misonidazole versus control 44.3.18 Oral care protocol versus none 44.3.19 Pilocarpine versus placebo 44.3.20 Povidone versus water 44.3.21 Prednisone versus placebo 44.3.22 Prostaglandin versus placebo 44.3.23 Sucralfate versus placebo 44.3.24 Zinc sulphate 45 Comparisons between active interventions 45.1 Mucositis (absent versus present) 45.1.1 Cryotherapy: 30 min versus 60 min 45.1.2 Etoposide: bolus versus continuous 45.2 Mucositis (0-1 versus 2+) 45.2.1 Cryotherapy: 30 min versus 60 min 45.2.2 Etoposide: bolus versus continuous 45.2.3 GM-CFS versus sucralfate 45.2.4 Keratinocyte: 50 mg versus 25 mg 45.3 Mucositis (0-2 versus 3+) 45.3.1 Cryotherapy: 30 min versus 60 min 45.3.2 Etoposide: bolus versus continuous 45.3.3 GM-CSF versus sucralfate 45.3.4 Keratinocyte: 50 mg versus 25 mg 46 Side effects 46.1 Amifostine 46.1.1 Survival at 24 months 46.1.2 Recurrence at 18 months after cancer treatment 46.1.3 Incomplete response to radiotherapy 46.1.4 Delay to radiotherapy 46.1.5 Hypotension 46.1.6 Nausea 46.1.7 Vomiting 47 Epidermal GF 47.2 Mucositis (0-1 versus 2+) Figures Figure 1 (Analysis 26.1) Figure 2 (Analysis 27.1) Figure 3 (Analysis 27.2) Figure 4 (Analysis 27.3) Figure 5 (Analysis 1.1) Sources of support Internal sources The University of Manchester, UK Chief Scientists Office, Scottish Executive, UK NHS Education for Scotland, UK University of Dundee, UK External sources NIDCR grant ref 1 DE016950-01, USA Feedback Appendices 1 Cochrane Oral Health Group Trials Register search strategy Appendix title Appendix text 2 CENTRAL search strategy Appendix title Appendix text 3 MEDLINE via OVID search strategy Appendix title Appendix text 4 EMBASE SS via OVID search strategy Appendix title Appendix text 5 CANCERLIT search strategy Appendix title Appendix text 6 SIGLE search strategy Appendix title Appendix text 7 LILACS search strategy Appendix title Appendix text 8 CINAHL via EBSCO search strategy Appendix title Appendix text&lt;/p&gt;" NOTES_MODIFIED="2010-11-10 14:38:46 +0000" NOTES_MODIFIED_BY="[Empty name]" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias domain for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAXsAABDrCAIAAABgkz1lAACAAElEQVR42uy9v24jubZ4XcBNfkEH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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2010-07-25 21:51:07 +0100" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2011-02-17 10:49:42 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-06-16 16:35:08 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-06-16 16:34:45 +0100" MODIFIED_BY="[Empty name]">Cochrane Oral Health Group Trials Register search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-06-16 16:35:08 +0100" MODIFIED_BY="[Empty name]">
<P>((neoplasm* OR leukemia OR leukaemia OR leukaemia OR lymphoma* OR plasmacytoma OR "histiocytosis malignant" OR reticuloendotheliosis OR "sarcoma mast cell" OR "Letterer Siwe disease" OR "immunoproliferative small intestine disease" OR "Hodgkin disease" OR "histiocytosis malignant" OR "bone marrow transplant*" OR cancer* Or tumor* OR tumour* OR malignan* OR neutropeni* OR carcino* OR adenocarcinoma* OR radioth* OR radiat* OR radiochemo* OR irradiat* OR chemo*) AND (stomatitis OR "Stevens Johnson syndrome" OR "candidiasis oral" OR mucositis OR (oral AND (cand* OR mucos* OR fung*)) OR mycosis OR mycotic OR thrush))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2010-11-09 12:06:31 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-06-16 16:35:24 +0100" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-11-09 12:06:31 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Exp NEOPLASMS</LI>
<LI>Exp LEUKEMIA</LI>
<LI>Exp LYMPHOMA</LI>
<LI>Exp RADIOTHERAPY</LI>
<LI>Exp BONE MARROW TRANSPLANTATION</LI>
<LI>neoplasm* or cancer* or carcino* or malignan*</LI>
<LI>leukemi* or leukaemia*</LI>
<LI>tumour* or tumor*</LI>
<LI>neutropeni*</LI>
<LI>adenocarcinoma*</LI>
<LI>lymphoma*</LI>
<LI>(radioth* or radiat* or irradiat* or radiochemo*)</LI>
<LI>(bone next marrow next transplant*)</LI>
<LI>chemo* or radiochemo*</LI>
<LI>(#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14)</LI>
<LI>Exp STOMATITIS</LI>
<LI>MUCOSITIS</LI>
<LI>CANDIDIASIS ORAL</LI>
<LI>stomatitis</LI>
<LI>(stevens next johnson next syndrome)</LI>
<LI>mucositis</LI>
<LI>oral near cand*</LI>
<LI>mouth near cand*</LI>
<LI>oral and fung*</LI>
<LI>mouth and fung*</LI>
<LI>(mycosis or mycotic or thrush)</LI>
<LI>#16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26</LI>
<LI>#15 AND #27</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2010-11-09 12:07:53 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2009-08-05 14:54:13 +0100" MODIFIED_BY="[Empty name]">MEDLINE via OVID search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-11-09 12:07:53 +0000" MODIFIED_BY="[Empty name]">
<P>1. exp NEOPLASMS/<BR/>2. exp LEUKEMIA/<BR/>3. exp LYMPHOMA/<BR/>4. exp RADIOTHERAPY/<BR/>5. Bone Marrow Transplantation/<BR/>6. neoplasm$.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name, device trade name]<BR/>7. cancer$.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name, device trade name]<BR/>8. (leukaemi$ or leukemi$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name, device trade name]<BR/>9. (tumour$ or tumor$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name, device trade name]<BR/>10. malignan$.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name, device trade name]<BR/>11. neutropeni$.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name, device trade name]<BR/>12. carcino$.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name, device trade name]<BR/>13. adenocarcinoma$.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name, device trade name]<BR/>14. lymphoma$.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name, device trade name]<BR/>15. (radioth$ or radiat$ or irradiat$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name, device trade name]<BR/>16. (bone adj marrow adj5 transplant$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name, device trade name]<BR/>17. chemo$.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name, device trade name]<BR/>18. or/1-17<BR/>19. exp STOMATITIS/<BR/>20. Candidiasis, Oral/<BR/>21. stomatitis.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name, device trade name]<BR/>22. mucositis.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name, device trade name]<BR/>23. (oral and cand$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name, device trade name]<BR/>24. (oral adj6 mucos$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name, device trade name]<BR/>25. (oral and fung$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name, device trade name]<BR/>26. (mycosis or mycotic).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name, device trade name]<BR/>27. or/19-26<BR/>28. 18 and 27</P>
<SUBSECTION>
<HEADING LEVEL="3">Search filter for MEDLINE via OVID</HEADING>
<P>Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised trials in MEDLINE: sensitivity maximising version (September 2009 revision) as referenced in Chapter 6 and detailed in box 6.4.c of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> version 5.0.2 (updated September 2008):</P>
<P>1. randomized controlled trial.pt.<BR/>2. controlled clinical trial.pt.<BR/>3. randomized.ab.<BR/>4. placebo.ab.<BR/>5. drug therapy.fs.<BR/>6. randomly.ab.<BR/>7. trial.ab.<BR/>8. groups.ab.<BR/>9. or/1-8<BR/>10. animals.sh. not (humans.sh. and animals.sh.)<BR/>11. 9 not 10<BR/>
</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2010-11-09 12:08:21 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2010-11-09 12:07:59 +0000" MODIFIED_BY="[Empty name]">EMBASE via OVID search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-11-09 12:08:21 +0000" MODIFIED_BY="[Empty name]">
<P>1. exp NEOPLASM/<BR/>2. exp LEUKEMIA/<BR/>3. exp LYMPHOMA/<BR/>4. exp RADIOTHERAPY/<BR/>5. exp bone marrow transplantation/<BR/>6. (neoplasm$ or cancer$ or leukemi$ or leukaemi$ or tumour$ or tumor$ or malignan$ or neutropeni$ or carcino$ or adenocarcinoma$ or lymphoma$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>7. (radioth$ or radiat$ or irradiat$ or radiochemo$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>8. (bone marrow adj3 transplant$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>9. chemo$.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>10. or/1-9<BR/>11. exp Stomatitis/<BR/>12. Thrush/<BR/>13. (stomatitis or mucositis or (oral and candid$) or (oral adj4 mucositis) or (oral and fung$) or mycosis or mycotic or thrush).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>14. or/11-13<BR/>15. 10 and 14</P>
<SUBSECTION>
<HEADING LEVEL="3">Filter for EMBASE via OVID</HEADING>
<P>1. random$.ti,ab.<BR/>2. factorial$.ti,ab.<BR/>3. (crossover$ or cross over$ or cross-over$).ti,ab.<BR/>4. placebo$.ti,ab.<BR/>5. (doubl$ adj blind$).ti,ab.<BR/>6. (singl$ adj blind$).ti,ab.<BR/>7. assign$.ti,ab.<BR/>8. allocat$.ti,ab.<BR/>9. volunteer$.ti,ab.<BR/>10. CROSSOVER PROCEDURE.sh.<BR/>11. DOUBLE-BLIND PROCEDURE.sh.<BR/>12. RANDOMIZED CONTROLLED TRIAL.sh.<BR/>13. SINGLE BLIND PROCEDURE.sh.<BR/>14. or/1-13<BR/>15. ANIMAL/ or NONHUMAN/ or ANIMAL EXPERIMENT/<BR/>16. HUMAN/<BR/>17. 16 and 15<BR/>18. 15 not 17<BR/>19. 14 not 18</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2010-11-09 12:09:01 +0000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2010-11-09 12:08:39 +0000" MODIFIED_BY="[Empty name]">CANCERLIT (PubMed Cancer Subset) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-11-09 12:09:01 +0000" MODIFIED_BY="[Empty name]">
<P>((neoplasm* OR leukemia OR leukaemia OR leukaemia OR lymphoma* OR plasmacytoma OR "histiocytosis malignant" OR reticuloendotheliosis OR "sarcoma mast cell" OR "Letterer Siwe disease" OR "immunoproliferative small intestine disease" OR "Hodgkin disease" OR "histiocytosis malignant" OR "bone marrow transplant*" OR cancer* Or tumor* OR tumour* OR malignan* OR neutropeni* OR carcino* OR adenocarcinoma* OR radioth* OR radiat* OR radiochemo* OR irradiat* OR chemotherap*) AND (stomatitis OR "Stevens Johnson syndrome" OR "candidiasis oral" OR mucositis OR (oral AND (candid* OR mucos* OR fung*)) OR mycosis OR mycotic OR thrush))<BR/>AND<BR/>(randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh] OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR ("clinical trial" [tw] OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw] )) OR (placebos [mh] OR placebo* [tw] OR random* [tw] OR research design [mh:noexp]) NOT (animals [mh] NOT human [mh]))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2011-02-17 10:49:42 +0000" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2008-06-16 16:43:17 +0100" MODIFIED_BY="[Empty name]">SIGLE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-02-17 10:49:42 +0000" MODIFIED_BY="[Empty name]">
<P>((neoplasm* OR leukemia OR leukaemia OR leukaemia OR lymphoma* OR plasmacytoma OR histiocytosis malignant OR reticuloendotheliosis OR sarcoma mast cell OR Letterer Siwe disease OR immunoproliferative small intestine disease OR Hodgkin disease OR histiocytosis malignant OR bone marrow transplant* OR cancer* Or tumor* OR tumour* OR malignan* OR neutropeni* OR carcino* OR adenocarcinoma* OR radioth* OR radiat* OR radiochemo* OR irradiat* OR chemo*)<BR/>AND<BR/>(stomatitis OR Stevens Johnson syndrome OR candidiasis oral OR mucositis OR (oral AND (cand* OR mucos* OR fung*)) OR mycosis OR mycotic OR thrush)</P>
<P>Not updated after 2005</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2009-08-05 14:59:27 +0100" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2008-06-16 16:44:39 +0100" MODIFIED_BY="[Empty name]">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-08-05 14:59:27 +0100" MODIFIED_BY="[Empty name]">
<P>(<A HREF="http://www.bireme.org">www.bireme.org</A>)<BR/>
</P>
<P>((Pt randomized controlled trial OR Pt controlled clinical trial OR Mh randomized controlled trials OR Mh random allocation OR Mh double-blind method OR Mh single-blind method) AND NOT (Ct animals AND NOT (Ct human and Ct animal)) OR (Pt clinical trial OR Ex E05.318.760.535$ OR (Tw clin$ AND (Tw trial$ OR Tw ensa$ OR Tw estud$ OR Tw experim$ OR Tw investiga$)) OR ((Tw singl$ OR Tw simple$ OR Tw doubl$ OR Tw doble$ OR Tw duplo$ OR Tw trebl$ OR Tw trip$) AND (Tw blind$ OR Tw cego$ OR Tw ciego$ OR Tw mask$ OR Tw mascar$)) OR Mh placebos OR Tw placebo$ OR (Tw random$ OR Tw randon$ OR Tw casual$ OR Tw acaso$ OR Tw azar OR Tw aleator$) OR Mh research design) AND NOT (Ct animals AND NOT (Ct human and Ct animals)) OR (Ct comparative study OR Ex E05.337$ OR Mh follow-up studies OR Mh prospective studies OR Tw control$ OR Tw prospectiv$ OR Tw volunt$ OR Tw volunteer$) AND NOT (Ct animals AND NOT (Ct human and Ct animals)))</P>
<P>AND</P>
<P>Mh NEOPLASMS OR Tw neoplasm$ OR Tw cancer$ OR Tw carcinoma$ OR Tw tumour$ OR Tw tumor$ OR Tw malignan$ OR Tw carcino$ OR Tw nuetropeni$ OR Tw adenocarcinoma$ OR Mh leukemia OR Tw leukaemia$ OR Tw leukemi$ OR Tw lymphoma$ OR Tw "bone marrow transplantation" OR Tw "bone marrow transplant$" OR Tw radiotherapy OR Tw radioth$ OR Tw radiat$ OR Tw irradiat$ OR Tw radiochemo$ OR Tw chemo$</P>
<P>AND</P>
<P>Mh stomatitis OR Tw stomatitis OR Mh Candidiasis-Oral OR Tw "oral candidiasis" OR (Tw candida$ AND (Tw mouth OR Tw oral)) OR Tw mucositis OR ((Tw oral OR mouth) AND Tw fung$) OR (Tw oral AND Tw candidiasis$)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-08" MODIFIED="2010-11-09 12:14:16 +0000" MODIFIED_BY="[Empty name]" NO="8">
<TITLE MODIFIED="2009-08-05 15:02:08 +0100" MODIFIED_BY="[Empty name]">CINAHL via EBSCO search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-11-09 12:14:16 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f3&quot;&gt;&lt;span coll_flag=&quot;f3&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Title&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s0&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Review information&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Authors&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s51&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Worthington, Helen&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s53&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Clarkson, Jan&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s55&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Eden, Tim&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s57&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bryan, Gemma&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Contact person&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s6&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dates&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s10&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;What's new&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s59&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Amended, 16 June 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s11&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;History&lt;/h2&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s49&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Abstract&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f210&quot;&gt;&lt;span coll_flag=&quot;f210&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Background&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f212&quot;&gt;&lt;span coll_flag=&quot;f212&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Objectives&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f214&quot;&gt;&lt;span coll_flag=&quot;f214&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Search methods&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f216&quot;&gt;&lt;span coll_flag=&quot;f216&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Selection criteria&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f218&quot;&gt;&lt;span coll_flag=&quot;f218&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data collection and analysis&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f220&quot;&gt;&lt;span coll_flag=&quot;f220&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Results&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f222&quot;&gt;&lt;span coll_flag=&quot;f222&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Authors' conclusions&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s48&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Plain language summary&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f205&quot;&gt;&lt;span coll_flag=&quot;f205&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Plain language title&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f207&quot;&gt;&lt;span coll_flag=&quot;f207&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Summary text&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f235&quot;&gt;&lt;span coll_flag=&quot;f235&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Background&lt;/h1&gt;&lt;p&gt;Useful quote The incidence of radiation mucositis was estimated to be 40-80% in the literature (Berger Ann &amp;amp; Kilroy Thomas 2001 Oral complications. In Principles and Practice of Oncolgy 6th ed |DeVita V.T.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Incidence of mucositis is up to 80% in BMT patients (Meropol 2003 J Clin Oncol 21(8) 1452-8; Larson 2000 Oncol Nurs Forum 20: 81-87)&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f245&quot;&gt;&lt;span coll_flag=&quot;f245&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Objectives&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f247&quot;&gt;&lt;span coll_flag=&quot;f247&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Methods&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f249&quot;&gt;&lt;span coll_flag=&quot;f249&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Criteria for considering studies for this review&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f251&quot;&gt;&lt;span coll_flag=&quot;f251&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Types of studies&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f253&quot;&gt;&lt;span coll_flag=&quot;f253&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Types of participants&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f255&quot;&gt;&lt;span coll_flag=&quot;f255&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Types of interventions&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f257&quot;&gt;&lt;span coll_flag=&quot;f257&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Types of outcome measures&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f263&quot;&gt;&lt;span coll_flag=&quot;f263&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Search methods for identification of studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f269&quot;&gt;&lt;span coll_flag=&quot;f269&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data collection and analysis&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f293&quot;&gt;&lt;span coll_flag=&quot;f293&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Results&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f295&quot;&gt;&lt;span coll_flag=&quot;f295&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Description of studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f303&quot;&gt;&lt;span coll_flag=&quot;f303&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias in included studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f315&quot;&gt;&lt;span coll_flag=&quot;f315&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Effects of interventions&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f317&quot;&gt;&lt;span coll_flag=&quot;f317&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Discussion&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f329&quot;&gt;&lt;span coll_flag=&quot;f329&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Authors' conclusions&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f331&quot;&gt;&lt;span coll_flag=&quot;f331&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Implications for practice&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f333&quot;&gt;&lt;span coll_flag=&quot;f333&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Implications for research&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f224&quot;&gt;&lt;span coll_flag=&quot;f224&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Acknowledgements&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f228&quot;&gt;&lt;span coll_flag=&quot;f228&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Contributions of authors&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f226&quot;&gt;&lt;span coll_flag=&quot;f226&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Declarations of interest&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f230&quot;&gt;&lt;span coll_flag=&quot;f230&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Differences between protocol and review&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f232&quot;&gt;&lt;span coll_flag=&quot;f232&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Published notes&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s19&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of studies&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s20&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of included studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2097&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Abbasi-Nazari 2007&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2098&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Ahmed 1993&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2099&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Anderson 1998&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2100&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Antonadou 2002&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2101&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Antunes 2007&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2102&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Arun Maiya 2006&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2103&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Attal 1993&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2104&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Biswal 2003&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2105&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Blazar 2006&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2106&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Borowski 1994&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2107&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Bourhis 2000&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2108&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Brizel 2000&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2109&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Brizel 2008&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2110&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Bubley 1989&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2111&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Buentzel 2006&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2112&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Buntzel 1998&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2113&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Cartee 1995&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2114&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Carter 1999&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2115&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Cascinu 1994&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2116&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Castagna 2001&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2117&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Cengiz 1999&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2118&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Cerchietti 2006&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2119&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Crawford 1999&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2120&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Cruz 2007&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2121&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Damon 2004&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2122&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Dazzi 2003&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2123&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Dickson 2000&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2124&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Dodd 1996&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2125&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Dorr 2007&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2126&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Dozono 1989&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2127&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Duenas 1996&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2128&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;El Sayed 2002a&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2129&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Elad 2006&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2130&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Erlichman 1988&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2131&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Ertekin 2004&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2132&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Evensen 2001&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2133&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Ferretti 1988&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2134&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Ferretti 1990&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2135&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Fidler 1996&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2136&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Foote 1994&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2137&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Franzen 1995&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2138&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Freytes 2004&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2139&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Gandemer 2007&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2140&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Ghoreishi 2007&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2141&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Giles 2003a&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2142&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Giles 2004&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2143&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Gori 2007&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2144&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Goyal 2009&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2145&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Gujral 2001&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2146&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Hartmann 2001&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2147&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Hu 2005&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2148&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Huang 2000&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2149&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Huang 2003&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2150&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Hunter 2007&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2151&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hwang 2004&lt;/h3&gt;&lt;p&gt;Patients were additionally randomised to receive antifungals: itraconazole or amphotericin B. Exclude?&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f16351&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f16351&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f16353&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f16353&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f16355&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f16355&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f16357&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f16357&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f16359&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f16359&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s415&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table width=&quot;100%&quot; cols=&quot;3&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Item&lt;/th&gt;&lt;th readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s3407&quot; id=&quot;s3407&quot;&gt;&lt;td readonly=&quot;true&quot; tooltip_fld=&quot;f165&quot; class=&quot;fixedcell&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f21834&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f21834&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2152&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Ifrah 1999&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2153&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Jebb 1994&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2154&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Karacetin 2004&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2155&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Katano 1995&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2156&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Kaul 1999&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2157&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Kazemian 2009&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2158&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Koukourakis 2000&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2159&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Kuhn 2008&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2160&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Labar 1993&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2161&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Leborgne 1997&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2162&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Lee 1989&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2163&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Li 2006&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2164&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Lilleby 2006&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2165&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Lockhart 2005&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2166&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Loprinzi 1990&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2167&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Madan 2008&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2168&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Mahood 1991&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2169&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Makkonen 1994&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2170&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Makkonen 2000&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2171&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;McAleese 2006&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2172&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Meropol 2003&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2173&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Mills 1988&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2174&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Motallebnejad 2008&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2175&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Naidu 2005&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2176&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Nemunaitis 1995&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2177&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Niibe 1985&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2178&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Nottage 2003&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2179&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Oberbaum 2001&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2180&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Okuno 1999&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2181&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Papas 2003&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2182&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Peterson 2007&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2183&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Pfeiffer 1990&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2184&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Pillsbury 1986&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2185&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Pitten 2003&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2186&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Prada 1987&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2187&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Rahn 1997&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2188&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Rashad 2008&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2189&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Rocke 1993&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2190&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Rosen 2006&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2191&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Rothwell 1990&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2192&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Saarilahti 2002&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2193&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Scarantino 2006&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2194&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Scherlacher 1990&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2195&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Schneider 1999&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2196&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Schubert 2007&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2197&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Shenep 1988&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2198&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Shieh 1997&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2199&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Sorensen 2008&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2200&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Sornsuvit 2008&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2201&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Spencer 2005&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2202&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Spielberger 2004&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2203&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Spijkervet 1989&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2204&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Stokman 2003&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2205&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Su 2003&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2206&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Su 2006&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2207&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Symonds 1996&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2208&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Trotti 2004&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2209&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;van der Lelie 2001&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2210&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Veerasarn 2006&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2211&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Veness 2006&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2212&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Vokurka 2005&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2213&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Wahlin 1989&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2214&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Wang 2002a&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2215&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Wijers 2001&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2216&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Wu 2009&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2217&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;You 2009&lt;/h3&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2218&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Yuen 2001&lt;/h3&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s21&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Characteristics of excluded studies&lt;/h2&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s22&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of studies awaiting classification&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s23&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of ongoing studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2444&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Haddad 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Study name&lt;/th&gt;&lt;td doc_fld_id=&quot;f17774&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f17774&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f17776&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f17776&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f17778&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f17778&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f17780&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f17780&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f17782&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f17782&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Starting date&lt;/th&gt;&lt;td doc_fld_id=&quot;f17784&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f17784&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Contact information&lt;/th&gt;&lt;td doc_fld_id=&quot;f17786&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f17786&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f17788&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f17788&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2445&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;National 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Study name&lt;/th&gt;&lt;td doc_fld_id=&quot;f17791&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f17791&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f17793&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f17793&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f17795&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f17795&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f17797&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f17797&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f17799&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f17799&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Starting date&lt;/th&gt;&lt;td doc_fld_id=&quot;f17801&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f17801&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Contact information&lt;/th&gt;&lt;td doc_fld_id=&quot;f17803&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f17803&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f17805&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f17805&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2446&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;National 2008a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table width=&quot;100%&quot; cols=&quot;2&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Study name&lt;/th&gt;&lt;td doc_fld_id=&quot;f17808&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f17808&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f17810&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f17810&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f17812&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f17812&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f17814&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f17814&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f17816&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f17816&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Starting date&lt;/th&gt;&lt;td doc_fld_id=&quot;f17818&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f17818&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Contact information&lt;/th&gt;&lt;td doc_fld_id=&quot;f17820&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f17820&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; readonly=&quot;true&quot; class=&quot;fixedcell&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f17822&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f17822&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s31&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Summary of findings tables&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s32&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Additional tables&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2447&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1 Quality assessment of trials&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s34&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;References to studies&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s35&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Included studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s66&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Abbasi-Nazari 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s69&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Abbasi Nazari M, Sadrolhefazi B, Nikoofar A, Erfan M, Azizian H, Alamy M. Allopurinol mouthwash for prevention or alleviation radiotherapy induced oral mucositis: A randomized, placebo-controlled trial. Daru 2007;15(4):227-30.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s72&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ahmed 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s75&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ahmed T, Engelking C, Szalyga J, Helson L, Coombe N, Cook P et al. Propantheline prevention of mucositis from etoposide. Bone Marrow Transplantation 1993;12(2):131-2.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s78&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Anderson 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s81&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Anderson PM, Schroeder G, Skubitz KM. Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer 1998;83(7):1433-9.&lt;/h4&gt;&lt;p&gt;Anderson PM, Schroeder G, Skubitz KM. Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer 1998;83:1433-9.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s84&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Antonadou 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s87&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. International Journal of Radiation Oncology, Biology and Physics 2002;52(3):739-47.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s90&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Antunes 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s93&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Antunes HS, de Azevedo AM, da Silva Bouzas LF, Adao CA, Pinheiro CT, Mayhe R, et al. Low-power laser in the prevention of induced oral mucositis in bone marrow transplantation patients: a randomized trial. Blood 2007;109(5):2250-5.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s96&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Arun Maiya 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s99&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Arun Maiya G, Sagar MS, Fernandes D. Effect of low level helium-neon (He-Ne) laser therapy in the prevention &amp;amp; treatment of radiation induced mucositis in head &amp;amp; neck cancer patients.[see comment]. Indian Journal of Medical Research 2006;124(4):399-402.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s102&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Attal 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s105&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Attal M, Huguet F, Rubie H, Charlet J-P, Schlaifer D, Huynh A et al. Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: A prospective, randomized trial. Blood 1993;82(3):732-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s108&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Biswal 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s111&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Biswal BM, Zakaria A, Ahmad NM. Topical application of honey in the management of radiation mucositis. A preliminary study. Supportive Care in Cancer 2003;11(4):242-8.&lt;/h4&gt;&lt;p&gt;Biswal BZAAN. Topical application of honey in the management of radiation mucositis. A preliminary study. Supportive Care in Cancer 2003+ADs- Vol 11(4): 242-248.&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s113&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Biswal BM, Zakaria A, Nik Min A. Topical application of honey in the management of radiation mucositis: A randomised study. International Journal of Cancer 2002;Supp 13:480 (Abs 1109).&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s116&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Blazar 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s119&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Blazar BR, Weisdorf DJ, Defor T, Goldman A, Braun T, Silver S, et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 2006;108(9):3216-22.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s122&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Borowski 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s125&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Borowski B, Benhamou E, Pico JL, Laplanche A, Margainaud JP, Hayat M. Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: a randomised controlled trial comparing two protocols of dental care. European Journal of Cancer Part B, Oral Oncology 1994;30B(2):93-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s128&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bourhis 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s131&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bourhis J, De Crevoisier R, Abdulkarim B, Deutsch E, Lusinchi A, Luboinski B et al. A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma. International Journal of Radiation Oncology, Biology and Physics 2000;46(5):1105-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s133&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bourhis J, Rosine D. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma. Seminars in Oncology 2002;29(6):Supp 19 61-2.&lt;/h4&gt;&lt;p&gt;Bourhis J, Rosine D. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma. +AFs-Review+AF0- +AFs-9 refs+AF0-. 2002+ADs- 29(6 Suppl 19):61-2.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s136&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Brizel 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s139&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Brizel DM, Wasserman TH, Henke H, Strnad V, Rudat V, Monnier A et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology 2000;18(19):3339-45.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s142&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Brizel 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s145&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Brizel DM, Murphy BA, Rosenthal DI, Pandya KJ, Gluck S, Brizel HE, et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology 2008;26(15):2489-96.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s148&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bubley 1989&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s151&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bubley GJ, Chapman B, Chapman SK, Crumpacker CS, Schnipper LE. Effect of acyclovir on radiation- and chemotherapy-induced mouth lesions. Antimicrobial Agents and Chemotherapy 1989;33(6):862-5.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s154&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Buentzel 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s157&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Buentzel J, Micke O, Adamietz IA, Monnier A, Glatzel M, de Vries A. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. International Journal of Radiation Oncology, Biology, Physics 2006;64(3):684-91.&lt;/h4&gt;&lt;p&gt;Buentzel J, Micke O, Adamietz IA, Monnier A, Glatzel M, de Vries A. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. International Journal of Radiation Oncology, Biology, Physics. 2006;64(3):684-91.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s160&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Buntzel 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s163&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bennett CL, Lane D, Stinson T, Glatzel M, Buntzel J. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: Preliminary results from a randomized phase II clinical trial from Germany. Cancer Investigation 2001;19(2):107-13.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s165&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bourhis J, Rosine D. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma. Seminars in Oncology 2002;29(6):Supp 19 61-2.&lt;/h4&gt;&lt;p&gt;Bourhis J, Rosine D. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma. +AFs-Review+AF0- +AFs-9 refs+AF0-. 2002+ADs- 29(6 Suppl 19):61-2.&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s167&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Buntzel J, Glatzel M, Kuttner K, Weinaug R, Frohlich D. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in Radiation Oncology 2002;12(1 (Supp 1)):4-13.&lt;/h4&gt;&lt;p&gt;Buntzel J, Glatzel M, Kuttner K, Weinaug R, Frohlich D. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. 2002+ADs- 12(1 Suppl 1):4-13.&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s169&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Buntzel J, Kuttner K, Frohlich D, Glatzel M. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Annals of Oncology 1998;9(5):505-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s171&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Buntzel J, Schuth J, Kuttner K, Glatzel M. Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Supportive Care in Cancer 1998;6(2):155-60.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s174&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cartee 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s177&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cartee L, Petros WP, Rosner GL, Gilbert C, Moore S, Affronti ML et al. Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study. Cytokine 1995;7(5):471-7.&lt;/h4&gt;&lt;p&gt;Cartee L, Petros WP, Rosner GL, Gilbert C, Moore S, Affronti ML et al. Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomised, double blind, dose-ranging study. Cytokine 1995;7: 471-7.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s180&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Carter 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s183&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Carter DL, Hebert ME, Smink K, Leopold KA, Clough RL, Brizel DM. Double blind randomized trial of sucralfate vs placebo radial radiotherapy for head and neck cancers. Head and Neck 1999;21(8):760-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s186&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cascinu 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s189&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cascinu S, Fedeli A, Fedeli SL, Catalano G. Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. European Journal of Cancer Part B, Oral Oncology 1994;30B:234-6.&lt;/h4&gt;&lt;p&gt;Cascinu S, Fedeli A, Fedeli SL, Catalano G. Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. Eur J Cancer B Oral Oncol 1994;30B:234-6.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s192&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Castagna 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s195&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Castagna L, Benhamou E, Pedraza E, Luboinski M, Forni M, Brandes I et al. Prevention of mucositis in bone marrow transplantation: a double blind randomised controlled trial of sucralfate. Annals of Oncology 2001;12(7):953-5.&lt;/h4&gt;&lt;p&gt;Castagna L BE, Pedraza E, Luboinski M, Forni M, Brandes I, Pico JL, Dietrich PY. Prevention of mucositis in bone marrow transplantation: a double blind randomised controlled trial of sucralfate. Annals of Oncology 2001+ADs-12(7):953-5.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s198&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cengiz 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s201&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cengiz M, Ozyar E, Ozturk D, Akyol F, Atahan IL, Hayran M. Sucralfate in the prevention of radiation-induced oral mucositis. Journal of Clinical Gastroenterology 1999;28(1):40-3.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s204&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cerchietti 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s207&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cerchietti LC, Navigante AH, Lutteral MA, Castro MA, Kirchuk R, Bonomi M et al. Double-blinded, placebo-controlled trial on intravenous L-alanyl-L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer. International Journal of Radiation Oncology, Biology, Physics 2006;65(5):1330-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s210&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Crawford 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s213&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Crawford J, Tomita DK, Mazanet R, Glaspy J, Ozer H. Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy. Cytokines, Cellular and Molecular Therapy 1999;5(4):187-93.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s216&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cruz 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s219&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cruz LB, Ribeiro AS, Rech A, Rosa LG, Castro CG, Jr., et al. Influence of low-energy laser in the prevention of oral mucositis in children with cancer receiving chemotherapy. Pediatric Blood &amp;amp; Cancer 2007;48(4):435-40.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s222&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Damon 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s225&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Damon LE, Johnston LJ, Ries CA, Rugo HS, Case D, Ault K et al. Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule. Cancer Chemotherapy and Pharmacology 2004;53(6):468-74.&lt;/h4&gt;&lt;p&gt;Damon LE, Johnston LJ, Ries CA, Rugo HS, Case D, Ault K, et al. Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule. Cancer Chemotherapy &amp;amp; Pharmacology. 2004;53(6):468-74.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s228&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dazzi 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s231&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dazzi C, Cariello A, Giovanis P, Monti M, Vertogen B, Leoni M, et al. Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double blind, randomized, placebo-controlled study. Annals of Oncology 2003;14(4):559-63.&lt;/h4&gt;&lt;p&gt;Dazzi C, Cariello A, Giovanis P, Monti M, Vertogen B, Leoni M, et al. Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double blind, randomized, placebo-controlled study. Annals of Oncology 2003+ADs- 14(4):559-63.&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s233&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dazzi C, Cariello A, Monti M, Giovanis P, Vertogen B, Nanni O et al. Prophylaxis with GM-CSF mouthwash does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high dose chemotherapy with autogous PBPC rescue: A double blind randomized placebo-controlled study. Annals of Oncology 2002;13 (Supp 5):167 (Abs 617).&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s236&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dickson 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s239&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Coghlin Dickson TM, Wong RM, Offrin RS, Shizuru JA, Johnston LJ, Hu WW et al. Effect of oral glutamine supplementation during bone marrow transplantation. Journal of Parenteral and Enteral Nutrition 2000;24(2):61-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s242&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dodd 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s245&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dodd MJ, Larson PJ, Dibble SL, Miaskowski C, Greenspan D, MacPhail L et al. Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncological Nursing Forum 1996;23(6):921-7.&lt;/h4&gt;&lt;p&gt;Dodd MJ, Larson PJ, Dibble SL, Miaskowski C, Greenspan D, MacPhail L, Hauck WW, Paul SM, Ignoffo R, Shiba G. Randomised clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncol Nurs Forum 1996;23: 921-7.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s248&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dorr 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s251&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dorr W, Herrmann T, Study G. Efficacy of Wobe-Mugos E for reduction of oral mucositis after radiotherapy : results of a prospective, randomized, placebo-controlled, triple-blind phase III multicenter study. Strahlentherapie und Onkologie 2007;183(3):121-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s254&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dozono 1989&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s257&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dozono H, Nakamura K, Motoya T, Nakamura S, Shinmura R, Miwa K et al. Prevention of stomatitis induced by anti-cancer drugs. Gan-to-kagaku-ryoho 1989;16(10):3449-51.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s260&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Duenas 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s263&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Duenas-Gonzalez A, Sobrevilla-Calvo P, Frias-Mendivil M, Gallardo-Rincon D, Lara-Medina F, Aguilar-Ponce L et al. Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study. Bone Marrow Transplantation 1996;17(5):809-12.&lt;/h4&gt;&lt;p&gt;Duenas Gonzalez A, Sobrevilla Calvo P, Frias Mendivil M, Gallardo Rincon D, Lara Medina F, Aguilar Ponce L, et al. Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomised double-blind study. Bone Marrow Transplant 1996;17: 809-12.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s266&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;El Sayed 2002a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s269&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Duncan GG, Epstein JB, Tu D, El Sayed S, Bezjak A, Ottaway J, et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head &amp;amp; Neck 2005;27(5):421-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s271&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;El-Sayed S, Nabid A, Shelley W, Hay J, Balogh J, Gelinas M et al. Prophylaxis of radiation-associated mucositis in conventionally treated patients with head and neck cancer: a double-blind, phase III, randomized, controlled trial evaluating the clinical efficacy of an antimicrobial lozenge using a validated mucositis scoring system. Journal of Clinical Oncology 2002;20(19):3956-63.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s274&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Elad 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s277&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Elad S, Ackerstein A, Bitan M, Shapira MY, Resnick I, Gesundheit B et al. A prospective, double-blind phase II study evaluating the safety and efficacy of a topical histamine gel for the prophylaxis of oral mucositis in patients post hematopoietic stem cell transplantation. Bone Marrow Transplantation 2006;37(8):757-62.&lt;/h4&gt;&lt;p&gt;Elad S, Ackerstein A, Bitan M, Shapira MY, Resnick I, Gesundheit B, et al. A prospective, double-blind phase II study evaluating the safety and efficacy of a topical histamine gel for the prophylaxis of oral mucositis in patients post hematopoietic stem cell transplantation. Bone Marrow Transplantation. 2006;37(8):757-62.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s280&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Erlichman 1988&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s283&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Erlichman C, Fine S, Wong A, Elhakim T. A randomized trial of fluorouracil and folonic acid in patients with metastatic colorectal carcinoma. Journal of Clinical Oncology 1988;6(3):469-75.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s285&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Erlichman C. Fluorouracil and leucovorin for metastatic colorectal cancer. Journal of Chemotherapy 1990;2(S1):38-40.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s288&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ertekin 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s291&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ertekin MV, Koc M, Karslioglu I, Sezen O. Zinc sulfate in the prevention of radiation-induced oropharyngeal mucositis: a prospective, placebo-controlled, randomized study. International Journal of Radiation Oncology, Biology, Physics 2004;58(1):167-74.&lt;/h4&gt;&lt;p&gt;Ertekin MV, Koc M, Karslioglu I, Sezen O. Zinc sulfate in the prevention of radiation-induced oropharyngeal mucositis: a prospective, placebo-controlled, randomized study. International Journal of Radiation Oncology, Biology, Physics 2004; 58(1):167-74.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s294&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Evensen 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s297&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Evensen JF, Bjordal K, Jacobsen AB, Lokkevik E, Tausjo JE. Effects of Na-sucrose octasulfate on skin and mucosa reactions during radiotherapy of head and neck cancers--a randomized prospective study. Acta Oncologica 2001;40(6):751-5.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s300&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ferretti 1988&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s303&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ferretti GA, Ash RC, Brown AT, Largent BM, Kaplan A, Lillich TT. Chlorhexidine for prophylaxis against oral infections and associated complications in patients receiving bone marrow transplants. Journal of American Dental Association 1987;114(4):461-7.&lt;/h4&gt;&lt;p&gt;Ferretti GA, Largent BM, Ash RC, Kaplan A, Brown AT, Lillich TL. Chlorhexidine for prophylaxis against oral infections and associated complications in patients receiving bone marrow transplants. JADA 1987;114;461-7.&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s305&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ferretti GA, Ash RC, Brown AT, Parr MD, Romond EH, Lillich TT. Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse. Bone Marrow Transplantation 1988;3(5):483-93.&lt;/h4&gt;&lt;p&gt;Ferretti GA, Ash RC, Brown AT, Parr MD, Romond EH, Lillich TT. Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse. Bone Marrow transplant 1988;3:483-93.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s308&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ferretti 1990&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s311&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ferretti GA, Raybould TP, Brown AT, Macdonal JS, Greenwood M, Maruyama Y et al. Chlorhexidine prophylaxis for chemotherapy- and radiotherapy- induced stomatitis: a randomised double-blind trial. Oral Surgery, Oral Medicine, Oral Pathology 1990;69(3):331-8.&lt;/h4&gt;&lt;p&gt;Ferretti GA, Raybould TP, Brown AT, Macdonal JS, Greenwood M, Maruyama Y et al. Oral Surg Oral Med Oral Pathol 1990;69:331-8.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s314&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Fidler 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s317&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Fidler P, Loprinzi CL, O'Fallon JR, Leitch JM, Lee JK, Hayes DL et al. Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis. Cancer 1996;77(3):522-5.&lt;/h4&gt;&lt;p&gt;Fidler P, Loprinzi CL, O'Fallon JR, Leitch JM, Lee JK, Hayes DL et al. Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis. Cancer 1996;77:522-5.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s320&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Foote 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s323&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Foote RL, Loprinzi CL, Frank AR, O'Fallon JR, Gulavita S, Tewfik HH et al. Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis. Journal of Clinical Oncology 1994;12(12):2630-3.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s326&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Franzen 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s329&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Franzen L, Henriksson R, Littbrand B, Zackrisson B. Effects of sucralfate on mucositis during and following radiotherapy of malignancies in the head and neck region. Acta Oncologica 1995;34(2):219-23.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s332&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Freytes 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s335&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Freytes CO, Ratanatharathorn V, Taylor C, Abboud C, Chesser N, Restrepo A et al. Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation. Clinical Cancer Research 2004;10(24):8318-24.&lt;/h4&gt;&lt;p&gt;Freytes CO, Ratanatharathorn V, Taylor C, Abboud C, Chesser N, Restrepo A, et al. Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation. Clinical Cancer Research. 2004;10(24):8318-24.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s338&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gandemer 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s341&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gandemer V, Le Deley MC, Dollfus C, Auvrignon A, Bonnaure-Mallet M, Duval M, et al. Multicenter randomized trial of chewing gum for preventing oral mucositis in children receiving chemotherapy. Journal of Pediatric Hematology/Oncology 2007;29(2):86-94.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s344&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ghoreishi 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s347&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ghoreishi Z, Shidfar F, Iravani M, Esfahani A, Ghavamzadeh A. Effect of vitamin E on chemotherapy-induced mucositis and neutropenia in leukemic patients undergoing bone marrow transplantation. Asia-Pacific Journal of Clinical Oncology 2007;3(3):113-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s350&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Giles 2003a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s353&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Giles FJ, Miller CB, Hurd DD, Wingard JR, Fleming TR, Sonis ST et al. A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial). Leukemia &amp;amp; Lymphoma 2003;44(7):1165-72.&lt;/h4&gt;&lt;p&gt;Giles FJ, Miller CB, Hurd DD, Wingard JR, Fleming TR, Sonis ST, et al. A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial). Leukemia &amp;amp; Lymphoma. 2003;44(7):1165-72.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s356&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Giles 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s359&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Giles FJ, Rodriguez R, Weisdorf D, Wingard JR, Martin PJ, Fleming TR et al. A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leukemia Research 2004;28(6):559-65.&lt;/h4&gt;&lt;p&gt;Giles FJ, Rodriguez R, Weisdorf D, Wingard JR, Martin PJ, Fleming TR, et al. A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leukemia Research. 2004;28(6):559-65.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s362&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gori 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s365&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gori E, Arpinati M, Bonifazi F, Errico A, Mega A, Alberani F, et al. Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group. Bone Marrow Transplantation 2007;39(6):347-52.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s368&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Goyal 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s371&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Goyal M, Shukla P, Gupta D, Bisht SS, Dhawan A, Gupta S, et al. Oral mucositis in morning vs. evening irradiated patients: a randomised prospective study. International Journal of Radiation Biology 2009;85(6):504-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s374&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gujral 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s377&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gujral MS, Patnaik PM, Kaul R, Parikh HK, Conradt C, Tamhankar CP et al. Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers. Cancer Chemotherapy Pharmacology 2001;47:S23-S28.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s380&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hartmann 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s383&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hartmann JT, von Vangerow A, Fels LM, Knop S, Stolte H, Kanz L et al. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation. British Journal of Cancer 2001;84(3):313-20.&lt;/h4&gt;&lt;p&gt;Hartmann JT vVA, Fels LM, Knop S, Stolte H, Kanz L, Bokemeyer C. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation. British Journal of Cancer 2001+ADs-84(3):313-20.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s386&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hu 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s389&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hu YR, Wu CQ, Liu YJ, Wang Y, Li X, Zhong H, et al. [Clinical observation on effect of shenqi fanghou recipe in preventing and treating radiation injury in patients with head and neck tumor]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban. 2005;25(7):623-5.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s392&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Huang 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s395&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Huang EY, Leung SW, Wang CJ, Chen HC, Sun LM, Fang FM et al. Oral glutamine to alleviate radiation-induced oral mucositis: A pilot randomized trial. International Journal of Radiation Oncology, Biology and Physics 2000;46(3):535-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s398&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Huang 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s401&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Huang GX, Zhao C, Han F, Zhang B, Qiu HJ, Xu BP et al. [Clinical study in prophylactic use of chinese medicine to prevent chemoradiotherapy induced mucositis in nasopharyngeal carcinoma]. Ai Zheng 2003;22(10):1084-7.&lt;/h4&gt;&lt;p&gt;Huang GX, Zhao C, Han F, Zhang B, Qiu HJ, Xu BP, et al. [Clinical study in prophylactic use of chinese medicine to prevent chemoradiotherapy induced mucositis in nasopharyngeal carcinoma]. Ai Zheng 2003;22(10):1084-7.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s404&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hunter 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s407&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hunter A, Mahendra P, Wilson K, Fields P, Cook G, Peniker A, et al. A randomized, double-blind, placebo-controlled, multicenter trial of ATL-104, a swallowable mMouthwash, in patients with oral mucositis following peripheral blood stem cell transplantation. Journal of Supportive Oncology 2007;5(4 Suppl 2):52-3.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s410&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hwang 2004&lt;/h3&gt;&lt;p&gt;Should be excluded as patients already been randomised to another clinical trial&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s413&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hwang WY, Koh LP, Ng HJ, Tan PH, Chuah CT, Fook SC, et al. A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation 2004;34(1):51-6.&lt;/h4&gt;&lt;p&gt;Hwang WY, Koh LP, Ng HJ, Tan PH, Chuah CT, Fook SC, et al. A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation. 2004;34(1):51-6.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s416&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ifrah 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s419&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ifrah N, Witz F, Jouet JP, Francois S, Lamy T, Linassier C et al. Intensive short term therapy with granulocyte-macrophage-colony stimulating factor support, similar to therapy for acute myeloblastic leukemia, does not improve overall results for adults with acute lymphoblastic leukemia. American Cancer Society 1999;86(8):1496-505.&lt;/h4&gt;&lt;p&gt;Ifrah N WF, Jouet J-P, Francois S, Lamy T, Linassier C, Pignon B, Berthou C, Guyotat D, Cahn J-Y, Harousseau J-L, Briere J, Tellier Z, Desablens B, Lioure B, Caillot D, Cassassus P, Audhuy B. Intensive short term therapy with granulocyte-macrophage-colony stimulating factor support, similar to therapy for acute myeloblastic leukemia, does not improve overall results for adults with acute lymphoblastic leukemia. Cancer 1999+ADs-86(8):1496-1505.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s422&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Jebb 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s425&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Jebb SA, Osborne RJ, Maughan TS, Mohideen N, Mack P, Mort D et al. 5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation. British Journal of Cancer 1994;70(4):732-5.&lt;/h4&gt;&lt;p&gt;Jebb SA, Osborne RJ, Maughan TS, Mohideen N, Mack P, Mort D et al. 5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation. Br J Cancer 1994;70:732-5.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s428&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Karacetin 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s431&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Karacetin D, Yucel B, Leblebicioglu B, Aksakal O, Maral O, Incekara O. A randomized trial of amifostine as radioprotector in the radiotherapy of head and neck cancer. Journal of B.U.ON. 2004;9(1):23-6.&lt;/h4&gt;&lt;p&gt;Karacetin D, Yuecel B, Leblebicioglu B, Aksakal OE, Maral O, Incekara O. A randomized trial of amifostine as radioprotector in the radiotherapy of head and neck cancer. Journal of Buon. 2004;9(1):23-6.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s434&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Katano 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s437&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Katano M, Nakamura M, Matsuo T, Iyama A, Hisatsugu T. Effect of granulocyte colony-stimulating factor (G-CSF) on chemotherapy-induced oral mucositis. Surgery Today 1995;25(3):202-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s440&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kaul 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s443&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kaul R, Mishra BK, Sutradar P, Choudhary V, Gujral MS. The role of Wobe-Mugos in reducing acute sequele of radiation in head and neck cancers - a clinical phase-III randomized trial. Indian Journal of Cancer 1999;36(2-4):141-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s445&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kaul RVC. To evaluate the effect of Wobe mugos hydrolytic enzyme therapy on inflammation induced by external radiotherapy in patients of head and neck cancers. Bahrain Medical Bulletin 2001;23(3):116-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s448&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kazemian 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s451&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kazemian A, Kamian S, Aghili M, Hashemi FA, Haddad P. Benzydamine for prophylaxis of radiation-induced oral mucositis in head and neck cancers: a double-blind placebo-controlled randomized clinical trial. European Journal of Cancer Care 2009;18(2):174-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s454&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Koukourakis 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s457&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Koukourakis MI, Kyria G, Kakolyris S, Kouroussis C, Frangiadaki C, Giatromonaolaki A et al. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. Journal of Clinical Oncology 2000;18(11 June):2226-33.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s460&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kuhn 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s463&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kuhn A, Heinzmann G, da Silva CA, Stobbe JC, Knack MA, Basualdo A, et al. Low-level infrared laser therapy to prevent radiotherapy-induced oral mucositis: a randomized placebo-controlled study. Journal of Oral Laser Applications 2008;8(4):219-24.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s467&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Labar 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s470&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Labar B, Mrsic M, Pavletic Z, Bogdanic V, Nemet D, Aurer I et al. Prostaglandin E2 for prophylaxis of oral mucositis following BMT. Bone Marrow Transplantation 1993;11(5):379-82.&lt;/h4&gt;&lt;p&gt;Labar B, Mrsic M, Pavletic Z, Bogdanic V, Nemet D, Aurer I et al. Prostaglandin E2 for prophylaxis of oral mucositis following BMT. Bone Marrow Transplant 1993;11:379-82.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s473&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Leborgne 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s476&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Leborgne JH, Leborgne F, Zubizarreta E, Ortega B, Mezzera J. Corticosteroids and radiation mucositis in head and neck cancer. A double-blind placebo-controlled randomized trial. Radiotherapy and Oncology 1997;47(2):145-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s479&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lee 1989&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s482&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lee DJ, Pajak TF, Stetz J, Order SE, Weissberg JB, Fischer JJ. A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04). International Journal of Radiation Oncology, Biology, Physics 1989;16(2):465-70.&lt;/h4&gt;&lt;p&gt;Lee DJ PT, Stetz J, Order SE, Weissberg JB, Fischer JJ. A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04). International Journal of Radiation Oncology, Biology, Physics 1989;16(2):465-70.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s485&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Li 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s488&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Li Y, Yu Z, Liu F, Tan L, Wu B, Li J. Oral glutamine ameliorates chemotherapy-induced changes of intestinal permeability and does not interfere with the antitumor effect of chemotherapy in patients with breast cancer: a prospective randomized trial. Tumori 2006;92(5):396-401.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s491&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lilleby 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s494&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lilleby K, Garcia P, Gooley T, McDonnnell P, Taber R, Holmberg L et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation 2006;37(11):1031-5.&lt;/h4&gt;&lt;p&gt;Lilleby K, Garcia P, Gooley T, McDonnnell P, Taber R, Holmberg L, et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation. 2006;37(11):1031-5.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s497&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lockhart 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s500&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lockhart PB, Brennan MT, Kent ML, Packman CH, Norton HJ, Fox PC et al. Randomized controlled trial of pilocarpine hydrochloride for the moderation of oral mucositis during autologous blood stem cell transplantation. Bone Marrow Transplantation 2005;35(7):713-20.&lt;/h4&gt;&lt;p&gt;Lockhart PB, Brennan MT, Kent ML, Packman CH, Norton HJ, Fox PC, et al. Randomized controlled trial of pilocarpine hydrochloride for the moderation of oral mucositis during autologous blood stem cell transplantation. Bone Marrow Transplantation. 2005;35(7):713-20.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s503&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Loprinzi 1990&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s506&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Loprinzi CL, Cainflone SG, Dose AM, Etzell PS, Burnham NL, Therneau TM et al. A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis. Cancer 1990;65(8):1879-82.&lt;/h4&gt;&lt;p&gt;Loprinzi CL, Cainflone SG, Dose AM, Etzell PS, Burnham NL, Therneau TM et al. A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouacil-induced stomatitis. Cancer 1990;65:1879-82.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s509&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Madan 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s512&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Madan PD, Sequeira PS, Shenoy K, Shetty J. The effect of three mouthwashes on radiation-induced oral mucositis in patients with head and neck malignancies: a randomized control trial. Journal of Cancer Research &amp;amp; Therapeutics 2008;4(1):3-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s515&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mahood 1991&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s518&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mahood DJ, Dose AM, Loprinzi CL, Veeder MH, Athmann LM, Thereau TM et al. Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. Journal of Clinical Oncology 1991;9(3):449-52.&lt;/h4&gt;&lt;p&gt;Mahood DJ, Dose AM, Loprinzi CL, Veeder MH, Athmann LM, Thereau TM et al. Inhibitation of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol 1991;9:449-52.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s521&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Makkonen 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s524&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Makkonen TA, Bostrom P, Vilja P, Joensuu H. Sucralfate mouth washing in the prevention of radiation-induced mucositis: A placebo-controlled double-blind randomized study. International Journal of Radiation Oncology, Biology and Physics 1994;30(1):177-82.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s527&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Makkonen 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s530&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Makkonen TA, Minn H, Jekunen A, Vilja P, Tuominen J, Joeensuu H. Granulocyte Macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: A prospective randomized study. International Journal of Radiation Oncology, Biology and Physics 2000;46(3):525-34.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s533&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;McAleese 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s536&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;McAleese JJ, Bishop KM, A'Hern R, Henk JM. Randomized phase II study of GM-CSF to reduce mucositis caused by accelerated radiotherapy of laryngeal cancer. British Journal of Radiology 2006;79(943):608-13.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s539&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Meropol 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s542&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Meropol NJ, Somer RA, Gutheil J, Pelley RJ, Modiano MR, Rowinsky EK et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. Journal of Clinical Oncology 2003;21(8):1452-8.&lt;/h4&gt;&lt;p&gt;Meropol NJ, Somer RA, Gutheil J, Pelley RJ, Modiano MR, Rowinsky EK, et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant.+AFs-comment+AF0-. Journal of Clinical Oncology 2003+ADs- 21(8):1452-8.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s545&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mills 1988&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s548&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mills EE. The modifying effect of beta-carotene on radiation and chemotherapy induced oral mucositis. British Journal of Cancer 1988;57(4):416-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s551&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Motallebnejad 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s554&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Motallebnejad M, Akram S, Moghadamnia A, Moulana Z, Omidi S. The effect of topical application of pure honey on radiation-induced mucositis: a randomized clinical trial. Journal of Contemporary Dental Practice [Electronic Resource] 2008;9(3):40-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s557&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Naidu 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s560&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Naidu MU, Ramana GV, Ratnam SV, Sudhavani T, Naidu KJ, Roy P et al. A randomised, double-blind, parallel, placebo-controlled study to evaluate the efficacy of MF 5232 (Mucotrol), a concentrated oral gel wafer, in the treatment of oral mucositis. Drugs in R&amp;amp;D 2005;6(5):291-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s563&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Nemunaitis 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s566&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Nemunaitis J, Rosenfeld CS, Ash R, Freedman MH, Deeg HJ, Appelbaum F et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplantation 1995;15(6):949-54.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s569&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Niibe 1985&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s572&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Niibe H, Takahashi I, Mitsuhashi N, Miyaishi K, Itoh J, Maehara Y et al. An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study.1. Head and neck tumors. Nippon-gan-chiryo-gakkai-shi 1985;20(5):984-93.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s575&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Nottage 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s578&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Nottage M, McLachlan SA, Brittain MA, Oza A, Hedley D, Feld R, et al. Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial. Supportive Care in Cancer 2003;11(1):41-7.&lt;/h4&gt;&lt;p&gt;Nottage M, McLachlan SA, Brittain MA, Oza A, Hedley D, Feld R, et al. Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial. Supportive Care in Cancer 2003+ADs- 11(1):41-7.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s581&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Oberbaum 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s584&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Oberbaum M, Yaniv I, Ben-Gal Y, Stein J, Ben-Zvi N, Freedman LS et al. A randomized, controlled clinical trial of the homeopathic medication TRAUMEEL S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation. American Cancer Society 2001;92(3):684-90.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s586&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Oberbaum M, Yaniv I, Ben-Gal Y, Stein J, Ben-Zvi N, Freedman LS et al. A randomized, controlled clinical trial of the homoeopathic medication Traumeel S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation. Biologische Medizin 2002;31(1):25-31.&lt;/h4&gt;&lt;p&gt;Oberbaum MYIB-GYSJZNFLBD. A randomized, controlled clinical trial of the homoeopathic medication Traumeel S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation. Biologische Medizin 2002+ADs- Vol 31(1): 25-31.&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s588&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Oberbaum MY. Randomized, controlled study to prove the effectiveness of traumeel (R)s in the management of chemotherapy-induced stomatitis in children and young adults undergoing bone-marrow transplantation. Biol Medizin 2002;31(1):26-31.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s591&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Okuno 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s594&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Okuno SH, Woodhouse CO, Loprinzi CL, Sloan JA, LaVasseur BI, Clemens-Schutjer D et al. Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy. American Journal of Clinical Oncology 1999;22(3):258-61.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s597&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Papas 2003&lt;/h3&gt;&lt;p&gt;Reconsider inclusion as patients received active mouthwash + active Fl plate versus placebo (Fl) mouthwash and placebo plate.&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s600&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Papas AS, Clark RE, Martuscelli G, O'Loughlin KT, Johansen E, Miller KB. A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplantation 2003;31(8):705-12.&lt;/h4&gt;&lt;p&gt;Papas AS, Clark RE, Martuscelli G, O'Loughlin KT, Johansen E, Miller KB. A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplantation 2003+ADs- 31(8):705-12.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s603&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Peterson 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s606&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Peterson DE, Jones JB, Petit RG. Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer 2007;109(2):322-31.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s609&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pfeiffer 1990&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s612&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pfeiffer P, Madsen EL, Hansen O, May O. Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy. Acta Oncologica 1990;29(2):171-3.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s615&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pillsbury 1986&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s618&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pillsbury HC 3rd, Webster WP, Rosenman J. Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers. Archives of Otolaryngology - Head &amp;amp; Neck Surgery 1986;112(5):552-3.&lt;/h4&gt;&lt;p&gt;Pillsbury HC 3rd WW, Rosenman J. Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers. Archives of Otolaryngology -- Head &amp;amp; Neck Surgery 1986;112(5):552-3.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s621&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pitten 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s624&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pitten FA, Kiefer T, Buth C, Doelken G, Kramer A. Do cancer patients with chemotherapy-induced leukopenia benefit from an antiseptic chlorhexidine-based oral rinse? A double-blind, block-randomized, controlled study. Journal of Hospital Infection 2003;53(4):283-91.&lt;/h4&gt;&lt;p&gt;Pitten FA, Kiefer T, Buth C, Doelken G, Kramer A. Do cancer patients with chemotherapy-induced leukopenia benefit from an antiseptic chlorhexidine-based oral rinse? A double-blind, block-randomized, controlled study. Journal of Hospital Infection 2003+ADs- 53(4):283-91.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s627&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Prada 1987&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s630&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Prada A, Chiesa F. Effects of benzydamine on the oral mucositis during antineoplastic radiotherapy and/or intra-arterial chemotherapy. International Journal of Tissue Reaction 1987;9(2):115-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s633&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rahn 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s636&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Adamietz IA, Rahn R, Bottcher HD, Schafer V, Reimer K, Fleischer W. Prophylaxis of radiochemotherapy-induced mucositis. Efficacy of prophylactic oral rinsing with povidone iodine solution [Pophylaxe der radiochemotherapeutisch bedingten mukositis]. Stranhlentherapie und Onkologie 1998;174(3):149-55.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s638&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Adamietz IA, Rhan R, Bottcher HD, Schafer V, Reimer K, Fleischer W. Prophylaxis with povidone-iodine against induction of oral mucositis by radiochemotherapy. Supportive Care in Cancer 1998;6(4):373-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s640&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rahn R AI, Bottcher HD, Reimer K, and Fleischer W. PVP-iodine solution as a mucositis prophylaxis by radiotherapy. Deutsche Zeitschrift fur Mund-, Kiefer- und Gesichtschirurgie 1996;20(3):137-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s642&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rahn R, Adamietz IA, Boettcher HD, Schaefer V, Reimer K, Fleischer W. Povidone-iodine to prevent mucositis in patients during antineoplastic radiochemotherapy. Dermatology 1997;195(Suppl 2):57-61.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s645&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rashad 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s648&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rashad UM, Al-Gezawy SM, El-Gezawy E, Azzaz AN. Honey as topical prophylaxis against radiochemotherapy-induced mucositis in head and neck cancer. Journal of Laryngology &amp;amp; Otology 2009;123(2):223-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s651&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rocke 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s654&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rocke LK, Loprinzi CL, Lee JK, Kunselman SJ, Iverson RK, Finck G et al. A randomized clinical trial of two different durations or oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. Cancer 1993;72(7):2234-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s657&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rosen 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s660&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rosen LS, Abdi E, Davis ID, Gutheil J, Schnell FM, Zalcberg J, et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.[see comment]. Journal of Clinical Oncology 2006;24(33):5194-200.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s663&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rothwell 1990&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s666&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rothwell BR. Palliation of radiation-related mucositis. Special Care in Dentistry 1990:21-25.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s670&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Saarilahti 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s673&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Saarilahti K, Kajanti M, Joensuu T, Kouri M, Joensuu H. Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized phase III study. International Journal of Radiation Oncology Biology and Physics 2002;54(2):479-85.&lt;/h4&gt;&lt;p&gt;Saarilahti K KM, Joensuu T, Kouri M, Joensuu H. Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized phase III study. International Journal of Radiation Oncology, Biology, Physics 2002+ADs-54(2):479-85.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s676&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Scarantino 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s679&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Scarantino C, LeVeque F, Swann RS, White R, Schulsinger A, Hodson DI et al. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients. The Journal of Supportive Oncology 2006;4(5):252-8.&lt;/h4&gt;&lt;p&gt;Scarantino C, LeVeque F, Swann RS, White R, Schulsinger A, Hodson DI, et al. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients. The Journal of Supportive Oncology. 2006;4(5):252-8.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s682&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Scherlacher 1990&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s685&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Scherlacher A, Beaufort-Spontin F. [Radiotherapy of head-neck neoplasms: prevention of inflammation of the mucosa by sucralfate treatment]. [German]. HNO 1990;38(1):24-8.&lt;/h4&gt;&lt;p&gt;Scherlacher A B-SF. [Radiotherapy of head-neck neoplasms: prevention of inflammation of the mucosa by sucralfate treatment]. [German]. HNO 1990;38(1):24-8.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s688&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Schneider 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s691&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Schneider SB, Nishimura RD, Zimmerman RP, Tran L, Shiplacoff J, Tormey M et al. Filgrastim (r-metHuG-CSF) and its potential use in the reduction of radiation-induced oropharyngeal mucositis: An interim look at a randomized, double blind, placebo-controlled trial. Cytokines, Cellular and Molecular Therapy 1999;5(3):175-80.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s694&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Schubert 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s697&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Schubert MM, Eduardo FP, Guthrie KA, Franquin JC, Bensadoun RJ, Migliorati CA, et al. A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Supportive Care in Cancer 2007;15(10):1145-54.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s700&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Shenep 1988&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s703&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Shenep JL, Kalwinsky DK, Hutson PR, George SL, Dodge RK, Blankenship KR et al. Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositis. Journal of Pediatrics 1988;113(4):758-63.&lt;/h4&gt;&lt;p&gt;Shenep JL, Kalwinsky DK, Hutson PR, George SL, Dodge RK, Blankenship KR et al. Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositis. J Pediatr 1988;113:758-63.&lt;/p&gt;&lt;p&gt;[published erratum appears in J Paediatr 1989 May; 114(5):900]&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s706&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Shieh 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s709&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Shieh SH, Wang ST, Tsai ST, Tseng CC. Mouth care for nasopharyngeal cancer patients undergoing radiotherapy. Oral Oncology 1997;33(1):36-41.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s712&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sorensen 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s715&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sorensen J, Skovsgaard T, Bork E, Damstrup L, Ingeberg S. Double blind, placebo-controlled randomized study of chlorhexidine prophylaxis for chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) [abstract] 2001. Journal of Clinical Oncology : ASCO annual meeting proceedings 2006;24(18S Part I):470.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s717&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sorensen JB, Skovsgaard T, Bork E, Damstrup L, Ingeberg S. Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies. Cancer 2008;112(7):1600-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s720&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sornsuvit 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s723&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sornsuvit C, Komindr S, Chuncharunee S, Wanikiat P, Archararit N, Santanirand P. Pilot Study: effects of parenteral glutamine dipeptide supplementation on neutrophil functions and prevention of chemotherapy-induced side-effects in acute myeloid leukaemia patients. Journal of International Medical Research 2008;36(6):1383-91.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s726&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Spencer 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s729&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Spencer A, Horvath N, Gibson J, Prince HM, Herrmann R, Bashford J et al. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplantation 2005;35(10):971-7.&lt;/h4&gt;&lt;p&gt;Spencer A, Horvath N, Gibson J, Prince HM, Herrmann R, Bashford J, et al. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplantation. 2005;35(10):971-7.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s732&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Spielberger 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s735&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. The New England Journal of Medicine 2004;351(25):2590-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s738&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Spijkervet 1989&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s741&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Spijkervet FKL, van Saene HK, Panders AK, Vermey A, van Saene JJ, Mehta DM et al. Effects of chlorhexidine rinsing on the oropharyngeal ecology in patients with head and neck cancer who have irradiation mucositis. Oral Surgery, Oral Medicine, Oral Pathology 1989;67(2):154-61.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s744&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Stokman 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s747&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Stokman MA, Spijkervet FK, Burlage FR, Dijkstra PU, Manson WL, de Vries EG et al. Oral mucositis and selective elimination of oral flora in head and neck cancer patients receiving radiotherapy: a double-blind randomised clinical trial. British Journal of Cancer 2003;88(7):1012-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s750&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Su 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s753&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Su C, Mehta V, Ravikumar L, Shah R, Pinto H, Halpern J et al. Phase II double-blind randomized study comparing oral aloe vera (AV) versus placebo to prevent radiation (RT)-related mucositis in patients with head and neck (HN) neoplasms. International Journal of Radiation, Oncology, Biology and Physics 2004;60(1 Sept):171-7.&lt;/h4&gt;&lt;p&gt;Su C, Mehta, V, Ravikumar, L, Shah, R, Pinto, H, Halpern, J, Koong, A, Goffinet, D, and Le, Q-T. Phase II double-blind randomized study comparing oral aloe vera (AV) versus placebo to prevent radiation (RT)-related mucositis in patients with head and neck (HN) neoplasms. Proceedings of ASCO 2003.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s756&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Su 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s759&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Su YB, Vickers AJ, Zelefsky MJ, Kraus DH, Shaha AR, Shah JP, et al. Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor during postoperative radiotherapy for squamous head and neck cancer.[see comment]. Cancer Journal 2006;12(3):182-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s762&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Symonds 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s765&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Symonds RP, McIlroy P, Khorrami J, Pyper E, Alcock SR, McCallum I et al. The reduction of radiation mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial. British Journal of Cancer 1996;74(2):312-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s768&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Trotti 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s771&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Trotti A, Garden A, Warde P, Symonds P, Langer C, Redman R et al. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. International Journal of Radiation Oncology, Biology and Physics 2004;58(3):674-81.&lt;/h4&gt;&lt;p&gt;Trotti A, Garden A, Warde P, Symonds P, Langer C, Redman R, et al. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. International Journal of Radiation Oncology, Biology, Physics 2004; 58(3):674-81.&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s773&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Trotti A, Garden AS, Warde P, Symonds P, Langer C, Fleming T et al. Phase III trial of iseganan HCL oral solution (iseganan) for reducing oral mucositis severity in patients receiving radiotherapy for head and neck malignancies (PROMPT-RT). In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 2002:(Abs No 908).&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s776&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;van der Lelie 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s779&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;van der Lelie H, Thomas BL, van Oers RH, Ek-Post M, Sjamsoedin SA, van Dijk-Overtoom ML et al. Effect of locally applied GM-CSF on oral mucositis after stem cell transplantation: a prospective placebo-controlled double-blind study. Annals of Hematology 2001;80(3):150-4.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s782&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Veerasarn 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s785&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Veerasarn V, Phromratanapongse P, Suntornpong N, Lorvidhaya V, Sukthomya V, Chitapanarux I, et al. Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand 2006;89(12):2056-67.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s788&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Veness 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s791&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Veness MJ, Foroudi F, Gebski V, Timms I, Sathiyaseelan Y, Cakir B, et al. Use of topical misoprostol to reduce radiation-induced mucositis: results of a randomized, double-blind, placebo-controlled trial. Australasian Radiology 2006;50(5):468-74.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s794&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Vokurka 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s797&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Vokurka S, Bystricka E, Koza V, Scudlova J, Pavlicova V, Valentova D, et al. The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT--results of a randomized multicentre study. Supportive Care in Cancer 2005;13(7):554-8.&lt;/h4&gt;&lt;p&gt;Vokurka S, Bystricka E, Koza V, Scudlova J, Pavlicova V, Valentova D, et al. The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT--results of a randomized multicentre study. Supportive Care in Cancer. 2005;13(7):554-8.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s800&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wahlin 1989&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s803&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wahlin YB. Effects of chlorhexidine mouthrinse on the oral health in patients with acute leukemia. Oral Surgery, Oral Medicine, Oral Pathology 1989;68(3):279-87.&lt;/h4&gt;&lt;p&gt;Wahlin YD. Effects of chlorhexidine mouth rinse on the oral health in patients with acute leukemia. Oral Surg Oral Med Oral Path 1989;68:279-87.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s806&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wang 2002a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s809&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wang J. Effect on Chinese herbs decoction gargling to treat and to prevent chemotherapy caused stomatitis. Chinese Nursing Research 2002;16(10):578-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s812&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wijers 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s815&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wijers OB, Levendag PC, Harms ER, Gan-Teng AM, Schmitz PI, Hendriks WD et al. Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: A placebo-controlled double-blind randomized study. International Journal of Radiation Oncology, Biology and Physics 2001;50(2):343-52.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s818&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wu 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s821&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wu PA, Kim YH, Lavori PW, Hoppe RT, Stockerl-Goldstein KE. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome. Biology of Blood &amp;amp; Marrow Transplantation 2009;15(8):982-90.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s824&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;You 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s827&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;You WC, Hsieh CC, Huang JT. Effect of extracts from indigowood root (Isatis indigotica Fort.) on immune responses in radiation-induced mucositis. Journal of Alternative &amp;amp; Complementary Medicine 2009;15(7):771-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s830&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Yuen 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s833&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Yuen KY, Woo PCY, Tai JW, Lie AK, Luk J, Liang R. Effects of clarithromycin on oral mucositis in bone marrow transplant recipients. Haematologica 2001;86(5):554-5.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s36&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Excluded studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s836&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Abramoff 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s839&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Abramoff MM, Lopes NN, Lopes LA, Dib LL, Guilherme A, Caran EM, et al. Low-level laser therapy in the prevention and treatment of chemotherapy-induced oral mucositis in young patients. Photomed Laser Surg 2008;26(4):393-400.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s842&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Adamietz 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s845&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Adamietz IA, Rahn R, Bottcher HD, Reimer K, Fleischer W. Prophylaxis of radiation induced oral mucositis with povidone iodine. Supportive Care in Cancer 1997;5 Suppl:165 (Abs No 48).&lt;/h4&gt;&lt;p&gt;Adamietz IA, Rahn R, Bottcher HD, Reimer K, Fleischer W. Prophylaxis of radiation induced oral mucositis with povidone iodine. Supportive Care in Cancer. 1997;5 Suppl(Abstr 48):165.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s847&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ahn 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s850&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ahn YWH, Song S, Kim Y, Oh Y, Lee C, and, et al. The therapeutic effect of recombinant human epidermal growth factor (rhEGF) on mucositis in patients with head and neck cancer undergoing radiotherapy with or without chemotherapy: a double-blind placebo-controlled prospective phase II multi-institutional study. J Clin Oncol 2008;26(suppl):Abstract no: 6021.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s852&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Aisa 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s855&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Aisa Y, Mori T, Kudo M, Yashima T, Kondo S, Yokoyama A et al. Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients.. Supportive Care in Cancer 2005;13(4):266-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s857&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Altmann 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s860&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Altmann S Hoffmanns H. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors]. [German]. Strahlentherapie und Onkologie 1999;175(Suppl 4):30-3.&lt;/h4&gt;&lt;p&gt;Altmann S HH. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors]. [German]. Strahlentherapie und Onkologie 1999;175(Suppl 4):30-3.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s862&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Andersen 1987&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s865&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Andersen E, Pedersen H. Oral ftorafur versus intravenous 5-fluorouracil. A comparative study in patients with colorectal cancer. Acta Oncologica 1987;26(6):433-6.&lt;/h4&gt;&lt;p&gt;Andersen E PH. Oral ftorafur versus intravenous 5-fluorouracil. A comparative study in patients with colorectal cancer. Acta Oncologica 1987;26(6):433-6.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s867&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Anderson 1998b&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s870&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Anderson PM, Ramsay NKC, Shu XO, Rydholm N, Rogosheske J, Nicklow R et al. Effect of low dose oral glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplantation 1998;22(4):339-44.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s872&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Antin 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s875&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Antin JH, Lee SJ, Neuberg D, Alyea E, Soiffer RJ, Sonis S, et al. A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplantation 2002;29(5):373-7.&lt;/h4&gt;&lt;p&gt;Antin JH, Lee SJ, Neuberg D, Alyea E, Soiffer RJ, Sonis S, et al. A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplantation 2002; 29(5):373-7.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s877&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Antonadou 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s880&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Antonadou D, Athanassiou E, Synodinou M, Koliarakis N, Panoussaki K, Karageorgis P et al. Evaluation of the efficacy of granulocyte macrophage colony stimulating factor (GM-CSF) in the prevention of radiation induced mucositis [abstract]. Radiotherapy Oncology 1998;48(S1):S39.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s882&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Apaydin 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s885&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Apaydin A, Karadeniz AN, Aysigi G, Blige N. The effect and therapeutical use of benzydamine HCL on radiation-induced oral cavity and oropharyngeal mucositis. Medical Bulletin Istanbul 1996;29:1:59-63.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s887&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Aquino 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s890&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Aquino VM, Harvey AR, Garvin JH, Godder KT, Nieder ML, Adams RH et al. A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplantation 2005;36(7):611-6.&lt;/h4&gt;&lt;p&gt;Aquino VM, Harvey AR, Garvin JH, Godder KT, Nieder ML, Adams RH, et al. A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplantation. 2005;36(7):611-6.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s892&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ardizzoni 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s895&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ardizzoni A, Tjan-Heijnen VC, Postmus PE, Buchholz E, Biesma B, Karnicka-Mlodkowska H, et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. Journal of Clinical Oncology 2002;20(19):3947-55.&lt;/h4&gt;&lt;p&gt;Ardizzoni A, Tjan-Heijnen VC, Postmus PE, Buchholz E, Biesma B, Karnicka-Mlodkowska H, et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.+AFs-comment+AF0-.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s897&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Arora 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s900&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Arora H, Pai KM, Maiya A, Vidyasagar MS, Rajeev A. Efficacy of He-Ne Laser in the prevention and treatment of radiotherapy-induced oral mucositis in oral cancer patients. Oral Surgery Oral Medicine Oral Pathology Oral Radiology &amp;amp; Endodontics 2008;186.e1, 105(2):180-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s902&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Awada 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s905&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Awada A, Biganzoli L, Cufer T, Beex L, Lohrisch C, Batter V, et al. An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes. European Journal of Cancer 2002;38(6):773-8.&lt;/h4&gt;&lt;p&gt;Awada A, Biganzoli L, Cufer T, Beex L, Lohrisch C, Batter V, et al. An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes.2002+ADs- 38(6):773-8.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s907&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Awada 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s910&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Awada A, Gil T, Sales F, Dubuisson M, Vereecken P, Klastersky J et al. Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers. Anti-Cancer Drugs 2004;15(5):499-502.&lt;/h4&gt;&lt;p&gt;Awada A, Gil T, Sales F, Dubuisson M, Vereecken P, Klastersky J, et al. Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers. Anti-Cancer Drugs. 2004;15(5):499-502.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s912&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Awidi 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s915&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Awidi A, Homsi U, Kakail RI, Mubarak A, Hassan A, Kelta M, Martinez P et al. Double-blind, placebo-controlled cross-over study of oral pilocarpine for the prevention of chemotherapy-induced oral mucositis in adult patients with cancer. European Journal of Cancer 2001;37(16):2010-4.&lt;/h4&gt;&lt;p&gt;Awidi A HU, Kakail RI, Mubarak A, Hassan A, Kelta M, Martinez P, Sulaiti S, Al Qady A, Jamhoury A, Daniel M, Charles C, Ambrose A, El-Aloosy AS. Double-blind, placebo-controlled cross-over study of oral pilocarpine for the prevention of chemotherapy-induced oral mucositis in adult patients with cancer. +AFs-see comments.+AF0-.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s917&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Awwad 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s920&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Awwad HK, Lotayef M, Shouman T, Begg AC, Wilson G, Bentzen SM et al. Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cnacer: influence of proliferation. British Journal of Cancer 2002;86(4):517-23.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s922&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Barasch 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s925&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Barasch A, Peterson DE, Tanzer JM, D'Ambrososio JA, Nuki K, Schubert MM et al. Helium-Neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer 1995;76(12):2550-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s927&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Baydar 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s930&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Baydar M, Dikilitas M, Sevinc A, Aydogdu I. Prevention of oral mucositis due to 5-fluorouracil treatment with oral cryotherapy. Journal of the National Medical Association 2005;97(8):1161-4.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s932&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bensadoun 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s935&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bensadoun R, Cowen D, Nguyen TD, Ciais G, Franquin JC, Dassonville O et al. Low energy laser in the prevention of radiation-induced mucositis: A phase III randomized multicentric study in patients with head and neck cancer. In: Fifth International Congress on Anti-Cancer Chemotherapy. 1995.&lt;/h4&gt;&lt;p&gt;Bensadoun R, Cowen, D, Nguyen, TD, Ciais, G, Franquin, JC, Dassonville, O, Laudoyer, Y, Chauvel, P, Demard, F, and Zattara, H. Low energy laser in the prevention of radiation-induced mucositis: A phase III randomized multicentric study in patients with head and neck cancer. Fifth International Congress on Anti-Cancer Chemotherapy. 1995 1995.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s937&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bensadoun 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s940&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bensadoun R, Franquin J, Benezery K, Ciais G, Tardieu C, Dejou J et al. Low energy He/Ne laser in the prevention of radiation induced mucositis: A multicenter phase III double blind study for patients with head and neck cancer. In: Proceedings of ASCO. 1999.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s942&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bensadoun RJ, Ciais G, Darcourt V, Franquin JC, Cheynet C, Cowen D et al. Low energy laser in the prevention of radiation induced mucositis: a phase II randomized multicentre study for patients with head and neck cancer. Supportive Care in Cancer 1999;7:SO-13.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s944&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bensadoun RJ, Franquin JC, Ciais G, Darcourt V, Schubert MM, Viot M et al. Low-energy He/Ne laser in the prevention of radiation-induced mucositis. A multicentre phase III randomized study in patients with head and neck cancer. Supportive Care in Cancer 1999;7(4):244-52.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s946&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bensadoun 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s949&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bensadoun RJ, Benezery K, Dassonville O, Magne N, Poissonnet G, Ramaioli A et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). International Journal of Radiation Oncology, Biology, Physics 2006;64(4):983-94.&lt;/h4&gt;&lt;p&gt;Bensadoun RJ, Benezery K, Dassonville O, Magne N, Poissonnet G, Ramaioli A, et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). International Journal of Radiation Oncology, Biology, Physics. 2006;64(4):983-94.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s951&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bentzen 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s954&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bentzen SM, Saunders MI, Dische S, Bond SJ. Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial. Radiotherapy Oncology 2001;60(2):123-35.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s956&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bergmann 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s959&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bergmann OJ, Ellermann-Eriksen S, Mogensen SC, Ellegaard J. Acyclovir given as prophylaxis against oral ulcers in acute myeloid leukaemia: randomised, double blind, placebo controlled trial. BMJ 1995;6(310):116-72.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s961&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bleehen 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s964&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bleehen NM, Girling DJ, Hopwood P, Lallemand G, Machin D, Stephens RJ et al. Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. British Journal of Cancer 1996;73:406-13.&lt;/h4&gt;&lt;p&gt;Bleehen NM, Girling DJ, Hopwood P, Lallemand G, Machin D, Stephens RJ, Bailey AJ. Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. British Journal of Cancer 1996 73 406-413.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s966&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bolwell 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s969&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplantation 2004;34(7):621-5.&lt;/h4&gt;&lt;p&gt;Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplantation. 2004;34(7):621-5.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s971&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bourhis 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s974&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bourhis J, Lapeyre M, Tortochaux J, Rives M, Aghili M, Bourdin S et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. Journal of Clinical Oncology 2006;24(18):2873-8.&lt;/h4&gt;&lt;p&gt;Bourhis J, Lapeyre M, Tortochaux J, Rives M, Aghili M, Bourdin S, et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. Journal of Clinical Oncology. 2006;24(18):2873-8.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s976&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Braaksma 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s979&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Braaksma M, Levendag P. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation. Seminars in Oncology 2002;29(6 Supp 19):63-70.&lt;/h4&gt;&lt;p&gt;Braaksma M, Levendag P. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation. Seminars in Oncology 2002+ADs- 29(6 Suppl 19):63-70.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s981&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Buentzel 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s984&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Buentzel J, Glatzel M, Weinaug R, Schuth J, Kuettner K, Froehlich D. Amifostine in combined radio- and chemomodalities for head and neck cancer. European Journal of Cancer 1999;35(Suppl 4):363 (Abs No 1472).&lt;/h4&gt;&lt;p&gt;Buentzel J, Glatzel M, Weinaug R, Schuth J, Kuettner K, Froehlich D. Amifostine in combined radio- and chemomodalities for head and neck cancer. European Journal of Cancer. 1999;35(Suppl 4):363 Abstract #1472.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s986&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Calais 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s989&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Calais GM, Alfonsi E, Bardet C, Sire H, Bourgeois C, Bergerot B et al. Randomized study comparing radiation alone (RT) versus RT with concomitant chemotherapy (CT) in stages III andf IV oropharynx carcinoma (ARCORO). Preliminary results of the 94.01 study from the French Group of radiation oncology for head and neck cancer (GORTEC). In: Proceedings of Annual Meeting of the American Society of Clinical Oncology. 1998:(Abs No 1484).&lt;/h4&gt;&lt;p&gt;Calais GM, Alfonsi E, Bardet C, Sire H, Bourgeois C, Bergerot B, et al. Randomized study comparing radiation alone (RT) versus RT with concomitant chemotherapy (CT) in stages III andf IV oropharynx carcinoma (ARCORO). Preliminary results of the 94.01 study from the French Group of radiation oncology for head and neck cancer (GORTEC). Proc-Annu-Meet-Am-Soc-Clin-Oncol. 1998:Abstract # 1484.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s991&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Calais 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s994&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P et al. [Stage III and IV cancers of the oropharynx: results of a randomized study of Gortec comparing radiotherapy alone with concomitant chemotherapy]. Bulletin du Cancer 2000;87 Spec No:48-53.&lt;/h4&gt;&lt;p&gt;Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, et al. [Stage III and IV cancers of the oropharynx: results of a randomized study of Gortec comparing radiotherapy alone with concomitant chemotherapy]. [French]. Bulletin du Cancer. 2000;87 Spec No:48-53.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s996&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Calais 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s999&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Calais G, Bardet E, Sire C, Alfonsi M, Bourhis J, Rhein B et al. Radiotherapy with concomitant weekly docetaxel for stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC phase II trial. International Journal of Radiation, Oncology, Biology and Physics 2004;58(1 Jan):161-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1001&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cassidy 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1004&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Annals of Oncology 2002;13(4):566-75.&lt;/h4&gt;&lt;p&gt;Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. 2002+ADs- 13(4):566-75.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1006&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cella 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1009&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cella D, Pulliam J, Fuchs H, Miller C, Hurd D, Wingard JR et al. Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cancer 2003;98(2):406-12.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1011&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cheng 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1014&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cheng KK Molassiotis A, Chang AM, Wai WC, Cheung SS. Evaluation of an oral care protocol intervention in the prevention of chemotherapy-induced oral mucositis in paediatric cancer patients. European Journal of Cancer 2001;37(16):2056-63.&lt;/h4&gt;&lt;p&gt;Cheng KK MA, Chang AM, Wai WC, Cheung SS. Evaluation of an oral care protocol intervention in the prevention of chemotherapy-induced oral mucositis in paediatric cancer patients. 2001+ADs-37(16):2056-63.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1016&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cheng 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1019&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cheng KKF, Malassiotis A, Chang AM. An oral care protocol intervention to prevent chemotherapy-induced oral mucositis in paediatric cancer patients: a pilot study. European Journal of Oncology Nursing 2002;6(2):66-74.&lt;/h4&gt;&lt;p&gt;Cheng KKF MA, Chang AM. An oral care protocol intervention to prevent chemotherapy-induced oral mucositis in paediatric cancer patients: a pilot study... including commentary by Parr M. European Journal of Oncology Nursing: EUR J ONCOL NURS 2002+ADs- 6. 6(2. 2):66-74.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1021&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cheng 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1024&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cheng KK, Chang AM. Palliation of oral mucositis symptoms in pediatric patients treated with cancer chemotherapy. Cancer Nursing 2003;26(6):476-84.&lt;/h4&gt;&lt;p&gt;Cheng KK, Chang AM. Palliation of oral mucositis symptoms in pediatric patients treated with cancer chemotherapy. Cancer Nursing 2003; 26(6):476-84.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1026&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cheng 2004a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1029&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cheng KK. Children's acceptance and tolerance of chlorhexidine and benzydamine oral rinses in the treatment of chemotherapy-induced oropharyngeal mucositis. European Journal of Oncology Nursing 2004;8(4):341-9.&lt;/h4&gt;&lt;p&gt;Cheng KK. Children's acceptance and tolerance of chlorhexidine and benzydamine oral rinses in the treatment of chemotherapy-induced oropharyngeal mucositis. European Journal of Oncology Nursing. 2004;8(4):341-9.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1031&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cheng 2004b&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1034&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cheng KK, Chang AM, Yuen MP. Prevention of oral mucositis in paediatric patients treated with chemotherapy; a randomised crossover trial comparing two protocols of oral care. European Journal of Cancer 2004;40(8):1208-16.&lt;/h4&gt;&lt;p&gt;Cheng KK, Chang AM, Yuen MP. Prevention of oral mucositis in paediatric patients treated with chemotherapy; a randomised crossover trial comparing two protocols of oral care. Eur J Cancer 2004;40(8):1208-16.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1036&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chi 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1039&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chi KH, Chen SY, Chan WK, Yen SH, Liang MJ, Chou KC, et al. Effect of granulocyte macrophage colony stimulating factor (GM-CSF) on oral mucositis in head and neck cancer patients after cisplatin, 5- FU and leucovorin chemotherapy [abstract]. Proceedings of the American Society of Clinical Oncology 1994;13:428, Abstract 1469.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1041&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chi 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1044&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chi KH, Chen CH, Chan WK, Yen SH, Liang MJ, Chou KC et al. Effect of granulocyte-macrophage colony-stimulating factor (GH-CFS) on oral mucositis in head and neck cancer patients after cisplatin, 5-FU and leucovorin chemotherapy. In: Proceedings of Annual Meeting American Society of Clinical Oncology. Vol. 13. 1994:A1469.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1046&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chi KH, Chen SY, Chan WK, Yen SH, Liang MJ, Chou KC et al. Effect of granulocyte-macrophage colony-stimulating factor (GH-CFS) on oral mucositis in head and neck cancer patients after cisplatin, 5-FU and leucovorin chemotherapy. Journal of Clinical Oncology 1995;13(10):2620-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1048&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chiara 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1051&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chiara S, Nobile MT, Vincenti M, Gozza A, Heouaine A, Marceca F, et al. Sucralfate in the treatment of chemotherapy-induced stomatitis: a double-blind, placebo-controlled pilot study [abstract]. Proceedings of the American Society of Clinical Oncology 2000;19:630a, Abstract 2485.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1053&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Clarke 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1056&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Clarke SJ, Abdi E, Davis ID, Schnell FM, Zalcberg JR, Gutheil J, et al. Recombinant human keratinocyte growth factor (rHuKGF) prevents chemotherapy-induced mucositis in patients with advanced colorectal cancer: a randomized phase II trial [abstract]. Proceedings of the American Society of Clinical Oncology 2001;20 (Pt 1):383a, Abstract 1529.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1058&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Collova 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1061&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Collova E, Castagna L, Nozza A, Perfetti V, Patrone F, Danova M et al. New approaches for reduction of oral mucositis in patients undergoing high-dose chemotherapy with hematopoietic stem cell support. Bone Marrow Transplantation 2004;33(Suppl 1):S323-S4.&lt;/h4&gt;&lt;p&gt;Collova E, Castagna L, Nozza A, Perfetti V, Patrone F, Danova M, et al. New approaches for reduction of oral mucositis in patients undergoing high-dose chemotherapy with hematopoietic stem cell support [abstract]. Bone Marrow Transplantation. 2004;33(Suppl 1):S323-S4.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1063&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Colombat 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1066&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Colombat P, Colin B. Comparison of fluconazole and amphotericin B in the prevention of mucositis in patients with long term aplasia. Bone Marrow Transplantation 1995;15:178.&lt;/h4&gt;&lt;p&gt;Colombat P, Colin B, et al. Comparison of fluconazole and amphotericin B in the prevention of mucositis in patients with long term aplasia [abstract]. Bone-Marrow-Transplant. 1995;15:178.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1068&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Costa 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1071&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Costa EMMB, Pinto LP, Fernandes MZ, Costa ALL. Preventing oral complications in leukemic children submitted to chemotherapy. Journal of Dental Research 1999;78:1021 (Abs No B-220).&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1073&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Costa 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1076&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Costa EM, Fernandes MZ, Quinder LB, de Souza LB, Pinto LP. Evaluation of an oral preventive protocol in children with acute lymphoblastic leukemia. Pesquisa Odontologica Brasileira 2003;17(2):147-50.&lt;/h4&gt;&lt;p&gt;Costa EM, Fernandes MZ, Quinder LB, de Souza LB, Pinto LP. Evaluation of an oral preventive protocol in children with acute lymphoblastic leukemia. Pesqui Odontol Bras. 2003 Apr-Jun;17(2):147-50.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1078&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cowen 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1081&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cowen D, Tardieu C, Resbeut M, Hannoun-Levi JM, Alzieu C, Schubert M et al. Low energy helium-neon laser presents oral mucositis after high-dose chemo-radiotherapy: results of a double-blind randomized trial. International Journal of Radiation Oncology, Biology and Physics 1996;36(1S):264 (A1041).&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1083&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cowen D, Tardieu C, Schubert M, Peterson D, Resbeut M, Faucher C et al. Low energy Helium-neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: Results of a double blind randomized trial. International Journal of Radiation Oncology, Biology and Physics 1997;38(4):697-703.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1085&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Crawford 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1088&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Crawford J, Glaspy J, Vincent M, Tomita D, Mazanet R. Effect of filgrastim (r-metHug-CSF) on oral mucositis in patients with small cell lung cancer (SCLC) receiving chemotherapy (cyclophosphamide, doxorubicin and etoposide, CAE). In: Proceedings of Annual Meeting of American Society Clinical Oncology. Vol. 13. 1994:(Abs No A1523).&lt;/h4&gt;&lt;p&gt;Crawford J, Glaspy J, Vincent M, Tomita D, Mazanet R. Effect of filgrastim (r-metHug-CSF) on oral mucositis in patients with small cell lung cancer (SCLC) receiving chemotherapy (cyclophosphamide, doxorubicin and etoposide, CAE). Proc-Annu-Meet-Am-Soc-Clin-Oncol. 1994;13:Abs. A1523.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1090&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Crispino 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1093&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Crispino SP, Olmi C, Fallai F, Rossi S, Marsoni A, Tinazzi M, et al. Conventional radiotherapy (RT) versus accelerated hyperfractionated RT versus conventional RT and concomitant chemotherapy in locally advanced oropharyngeal carcinoma (ORO-93/01). In: Proceedings of the American Society of Clinical Oncology. 1997.&lt;/h4&gt;&lt;p&gt;Crispino SP, Olmi C, Fallai F, Rossi S, Marsoni A, Tinazzi M, et al. Conventional radiotherapy (RT) versus accelerated hyperfractionated RT versus conventional RT and concomitant chemotherapy in locally advanced oropharyngeal carcinoma (ORO-93/01). Proc Am Soc Clin Oncol. 1997.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1095&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cruz 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1098&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cruz J, Fonseca E, Rodriguez CA, Gomez-Bernal A, Martin G, Sanchez P et al. Randomized trial of cisplatin (P) plus 5-fluorouracil (F) with or without folinic acid in locally advanced head and neck cancer (LAHNC). In: Proceedings of the European Cancer Conference. 1997:(Abs No 854).&lt;/h4&gt;&lt;p&gt;Cruz J, Fonseca E, Rodriguez CA, Gomez-Bernal A, Martin G, Sanchez P, et al. Randomized trial of cisplatin (P) plus 5-fluorouracil (F) with or without folinic acid in locally advanced head and neck cancer (LAHNC). Proc-Eur-Cancer-Conf (ECCO). 1997:Abstract #854.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1100&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cunningham 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1103&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Cunningham D, Zalcberg JR, Rath U, Olver I, van Cutsem EV, Sevensson C et al. 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. European Journal of Cancer 1995;31A(12):1945-54.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1105&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;De Boer 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1108&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;De Boer RH, Eisen TG, Ellis PA, Johnston SR, Walsh G, Ashley S et al. A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer. Annals of Oncology 2002;13(6):889-94.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1110&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Decker-Baummann 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1113&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Decker-Baumann C, Buhl K, Frohmuller S, von Herbay A, Dueck M, Schlag PM. Reduction of chemotherapy-induced side-effects by parenteral glutamine supplementation in patients with metastatic colorectal cancer. European Journal of Cancer 1999;35(2):202-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1115&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Denham 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1118&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Denham JW, Peters LJ, Johansen J, Poulsen M, Lamb DS, Hindley A et al. Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer? Radiotherapy Oncology 1999;52(2):157-64.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1120&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Djuric 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1123&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Djuric M, Hillier-Kolarov V, Belic A, Jankovic L. Mucositis prevention by improved dental care in acute leukemia patients. Supportive Care in Cancer 2006;14(2):137-46.&lt;/h4&gt;&lt;p&gt;Djuric M, Hillier-Kolarov V, Belic A, Jankovic L. Mucositis prevention by improved dental care in acute leukemia patients. Supportive Care in Cancer. 2006;14(2):137-46.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1125&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dobrowsky 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1128&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dobrowsky W, Naude J, Widder J, Dobrowsky E, Millesi W, Pavelka R et al. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer. International Journal of Radiation Oncology, Biology and Physics 1998;42(4):803-6.&lt;/h4&gt;&lt;p&gt;Dobrowsky W NJ, Widder J, Dobrowsky E, Millesi W, Pavelka R, Grasl C, Reichel M. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer. International Journal of Radiation Oncology, Biology, Physics 1998;42(4):803-6.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1130&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Doroshow 1987&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1133&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Doroshow JH, Berthtand M, Newman E, Multhauf P, Leong L, Blayney D et al. Preliminary analysis of a randomized comparison of 5-fluorouracil versus 5-fluorouracil and high-dose continuous-infusion folinic acid in disseminated colorectal cancer. NCI Monographs 1987;5:171-4.&lt;/h4&gt;&lt;p&gt;Doroshow JH BM, Newman E, Multhauf P, Leong L, Blayney D, Goldberg D, Margolin K, Carr B, Akman S, et al. Preliminary analysis of a randomized comparison of 5-fluorouracil versus 5-fluorouracil and high-dose continuous-infusion folinic acid in disseminated colorectal cancer. NCI Monographs 1987(5):171-4.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1135&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dose 1989&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1138&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dose AM, Loprinzi CL, Cianflone S, Etzell P, Burnham N, Therneau T, et al. A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis. A North Central Cancer Treatment Group and Mayo clinic study [abstract]. Proceedings of the American Society of Clinical Oncology 1989;8:341, Abstract 1328.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1140&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dose 1990&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1143&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dose AM, Mahood D, Loprinzi CL, Gainey D, Sorensen JM, Therneau T, et al. A controlled trial of oral cryotherapy for preventing stomatitis in patients receiving 5- fluorouracil (5FU) plus leucovorin (LV). A North Central Cancer Treatment Group and Mayo Clinic study [abstract]. Proceedings of the American Society of Clinical Oncology 1990;9:321, Abstract 1242.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1145&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dreicer 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1148&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dreicer R, Propert KJ, Kuzel T, Kirkwood JM, O'Dwyer PJ, Loehrer PJ. A phase II trial of edatrexate in patients with advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study. American Journal of Clinical Oncology 1997;20(3):251-3.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1150&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dudjak 1987&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1153&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dudjak LA. Mouth care for mucositis due to radiation therapy. Cancer Nursing 1987;10(3):131-40.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1155&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Edelman 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1158&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Edelman MJ, Gandara Dr, Perez EA, Lau D, Lauder I, Turrell C et al. Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy. Investigational New Drugs 1998;16(1):69-75.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1160&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Eisen 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1163&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Eisen D, Essel J, Broun ER, Sigmund D, DeVoe M,. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. Bone Marrow Transplantation 2003;31(1):51-5.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1165&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;El-Sayed 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1168&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;El-Sayed S, Nabid A, MacKenzie R, Gelinas M, Hay J, Shelley et al. Prophylaxis of radiation associated mucositis (RAM) in head and neck cancer, results of a double blind phase III trail evaluating the clinical efficacy of an antimicrobial lozenge utilizing a new validated mucositis scoring system. In: Proceedings of the 42nd Annual Meeting of the American Society of Therapeutic Oncology. Vol. 321. 2000:(Abs No 2115).&lt;/h4&gt;&lt;p&gt;El-Sayed S, Nabid, A, MacKenzie, R, Gelinas, M, Hay, J, Shelley, W, Berthelet, E, Lau, H, Duncan, G, and Epstein, J. Prophylaxis of radiation associated mucositis (RAM) in head and neck cancer, results of a double blind phase III trail evaluating the clinical efficacy of an antimicrobial lozenge utilizing a new validated mucositis scoring system.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1170&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;El-Sayed 2002b&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1173&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;El-Sayed S, Epstein J, Minish E, Burns P, Hay J, Laukkanen E. A pilot study evaluating the safety and microbiologic efficacy of an economically viable antimicrobial lozenge in patients with head and neck cancer receiving radiation therapy. Head &amp;amp; Neck 2002;24(1):6-15.&lt;/h4&gt;&lt;p&gt;El-Sayed S, Epstein J, Minish E, Burns P, Hay J, Laukkanen E.A pilot study evaluating the safety and microbiologic efficacy of an economically viable antimicrobial lozenge in patients with head and neck cancer receiving radiation therapy. Head Neck. 2002 Jan;24(1):6-15.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1175&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Epstein 1986&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1178&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Epstein JB, Stephenson-Moore P. Benzydamine hydrochloride in prevention and management of pain in oral mucositis associated with radiation therapy. Oral Surgery, Oral Medicine, Oral Pathology 1986;62(2):145-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1180&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Epstein 1989&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1183&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Epstein JB, Stevenson-Moore P, Jackson S, Mohamed JH, Spinelli JJ. Prevention of oral mucositis in radiation therapy: A controlled study with benzydamine hydrochloride rinse. International Journal of Radiation Oncology, Biology and Physics 1989;16(6):1571-5.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1185&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Epstein 1992&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1188&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Epstein JB, Vickars L, Spinalli J, Reece D. Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. Oral Surgery, Oral Medicine, Oral Pathology 1992;73(6):682-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1190&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Epstein 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1193&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Epstein JB, Wong FLW. The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy. International Journal of Radiation Oncology, Biology and Physics 1994;28(3):693-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1195&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Epstein 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1198&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Epstein J, Silverman S Jr, Pagerino D, Lockhart P, Schubert M, Crockett R. Benzydamine HCL for prophylaxis of irradiation induced oral mucositis: a randomized double-blind, multicenter study. Supportive Care in Cancer 1999;7 Suppl:169 (Abs No O-18).&lt;/h4&gt;&lt;p&gt;Epstein J, Silverman S, Jr Pagerino D, Lockhart P, Schubert M, Crockett R. Benzydamine HCL fro prophilaxis of irradiation oral mucositis: a randomized double-blind, multicenter study. Supportive Care in Cancer. 1999;7 Suppl.(Abstr O-18):169.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1200&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Epstein 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1203&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Epstein JB, Silverman S, Paggiarino DA, Crockett S, Schubert MM, Senzer NN et al. Benzydamine HCI for prophylaxis of radiation-induced oral mucositis. Cancer 2001;92(4):875-85.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1205&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Erkisi 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1208&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Erkisi M, Erkurt E, Ozbarlas S, Burgut R, Doran F, Seyrek E. The use of recombinant human granulocyte colony-stimulating factor in combination with single or fractionated doses of ifosfamide and doxorubicin in patients with advanced soft tissue sarcoma. Journal of Chemotherapy 1996;8(3):224-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1210&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Etiz 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1213&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Etiz M, Erkal HS, Serin M, Kucuk B, Hepari A, Tulunay O et al. Clinicohistopathological evaluation of effectiveness of sucralfate in prevention of severe radiation-induced mucositis in patients with head and neck malignancies. Radiotherapy Oncology 1998;48(S1):S68.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1215&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Etiz 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1218&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Etiz D, Erkal HS, Serin M, Kucuk B, Hepari A, Elhan AH et al. Clinical and histopathological evaluation of sucralfate in prevention of oral mucositis induced by radiation therapy in patients with head and neck malignancies. Oral Oncology 2000;36(1):116-20.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1220&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Evans 1990&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1223&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Evans G, Mahendra P, Brightwell M, Jestivfe K, Marcus R. A double blind randomised trial of oral GMCFS mouthwash versus placebo in the treatment of mucositis following PBSC/bone marrow transplantation. Bone Marrow Transplantation 1998;21(S1):S88.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1225&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Evans WK, Wierzbicki R, Shepherd FA, Rusthoven J, Stewart DJ, Aitken SE et al. 5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung. Cancer Investigation 1990;8(3-4):345-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1227&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ezzat 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1230&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ezzat M, Shouman T, Zaza K, Safwat A, El-Khoudary A, El-Senosi M et al. A randomized study of accelerated fractionation radiotherapy with and without mitomycin C in the treatment of locally advanced head and neck cancer. Journal of the Egyptian National Cancer Institute 2005;17(2):85-92.&lt;/h4&gt;&lt;p&gt;Ezzat M, Shouman T, Zaza K, Safwat A, El-Khoudary A, El-Senosi M, et al. A randomized study of accelerated fractionation radiotherapy with and without mitomycin C in the treatment of locally advanced head and neck cancer. Journal of Egyptian National Cancer Institute. 2005;17(2):85-92.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1232&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Fahlke 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1235&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Fahlke J, Ridwelski K, Lippert H. High-dose therapy with combined 5-fluorouracil and folinic acid with and without amifostine in the treatment of patients with metastatic colorectal carcinoma. International Journal of Colorectal Disease 1999;14(2):128-30.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1237&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Falcone 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1240&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Falcone A, Allergrini G, Masi G, Lencioni M, Panner E, Brunetti I. 5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer. Oncology 2001;61(1):28-35.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1242&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Fay 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1245&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Fay JW, Lazarus H, Herzig R, Saez R, Stevens DA, Collins RH Jr et al. Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study. Blood 1994;84(7):2151-7.&lt;/h4&gt;&lt;p&gt;Fay JW LH, Herzig R, Saez R, Stevens DA, Collins RH Jr, Pineiro LA, Cooper BW, DiCesare J, Campion M, et al. Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study. Blood 1994;84(7):2151-7.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1247&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Feber 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1250&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Feber T. Mouth care for patients receiving oral irradiation. Professional Nurse 1995;10(10):666-70.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1252&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Feber 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1255&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Feber T. Management of mucositis in oral irradiation. Clinical Oncology 1996;8(2):106-11.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1257&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ferreira 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1260&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ferreira PR, Fleck J, Filho AB, Barletta D, Barletta A, Diehl A et al. Protective effect of vitamin E (VE) in head and neck cancer radiation induced mucositis: a double-blind randomized trial. In: Proceedings of American Society of Clinical Oncology Meeting. 2002:(Abs No 909).&lt;/h4&gt;&lt;p&gt;Ferreira P FJ, Filho A, Barletta D, Barletta A, Diehl A, de Azambuja E. Protective effect of vitamin E (VE ) in head and neck cancer radiation induced mucositis: a double-blind randomized trial. Proceedings of ASCO 2002.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1262&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ferreira 2002a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1265&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ferreira RR, Fleck JF, Filho AB, Barletta D, Barletta A, Diehl A, et al. Positive effect of vitamin E (VE) in head and neck cancer radiation induced mucositis: a double-blind randomized trial [abstract]. Proceedings of the American Society of Clinical Oncology 2002;21 (Pt 1):228a, Abstract 909.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1267&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ferreira 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1270&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ferreira PR, Fleck JF, Diehl A, Barletta D, Braga-Filho A, Barletta A et al. Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial. Head &amp;amp; Neck 2004;26(4):313-21.&lt;/h4&gt;&lt;p&gt;Ferreira PR, Fleck JF, Diehl A, Barletta D, Braga-Filho A, Barletta A, et al. Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial. Head Neck 2004;26(4):313-21.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1272&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ferretti 1985&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1275&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ferretti G, Largent B, Brown A, Lillich T, Ash R. The effect of chlorhexidine mouthrinse on mucositis, plaque, gingivitis and stain in bone marrow transplant patients. Journal of Dental Research 1985;64(Special Issue):235 (Abs No 546).&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1277&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Fidler 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1280&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Fidler P, Loprinzi CL, O'Fallon JR, Michalak J, Novotny P, Hayes D, et al. A controlled evaluation of chamomile for preventing stomatitis in patients receiving 5-fluorouracil based chemotherapy: A North Central Cancer Treatment Group trial [abstract]. Proceedings of the American Society of Clinical Oncology 1995;14:534, Abstract 1765.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1282&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Foncuberta 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1285&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Foncuberta MC, Cagnoni PJ, Brandts CH, Mandanas R, Fields K, Derigs HG et al. Topical transforming growth factor-beta3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors. Journal of Immunotherapy 2001;24(4):384-8.&lt;/h4&gt;&lt;p&gt;Foncuberta M, PJ C, CH B, R M, K F, HG D, et al. Topical transforming growth factor-beta3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors. Journal of Immunotherapy 2001;24(4):384-388.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1287&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gabison 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1290&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gabison R. Can zinc picolinate in patients receiving chemotherapy for metastatic colorectal carcinoma prevent stomatitis? European Journal of Cancer 1995;31A(Suppl 5):S258 (Abs No 1234).&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1292&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gandara 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1295&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gandara DR, Edelman MJ, Crowley JJ, Lau DH, Livingston RB. Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study.. Cancer Chemotherapy and Pharmacology 1997;41:75-78.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1297&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Genot-Klastersky 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1300&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Genot-Klastersky MT, Klastersky J, Awada F, Awada A, Crombez P, Martinez MD, et al. The use of low-energy laser (LEL) for the prevention of chemotherapy- and/or radiotherapy-induced oral mucositis in cancer patients: results from two prospective studies. Support Care Cancer 2008.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1303&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Giles 2003b&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1306&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Giles FJ, Faderl S, Thomas DA, Cortes JE, Garcia-Manero G, Douer D et al. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. Journal of Clinical Oncology 2003;21(6):1050-6.&lt;/h4&gt;&lt;p&gt;Giles FJ FS, Thomas DA, Cortes JE, Garcia-Manero G, Douer D, Levine AM, Koller CA, Jeha SS, O'Brien SM, Estey EH, Kantarjian HM. Randomized Phase I/II Study of Troxacitabine Combined With Cytarabine, Idarubicin, or Topotecan in Patients With Refractory Myeloid Leukemias. Journal of Clinical Oncology 2003+ADs-21(6):1050-1056.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1308&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gladkov 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1311&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gladkov OA, Vazhenin AV, Sharabura TM, Kandakova E, Galiatova Iu V, Sychev VI, et al. [Effectiveness of different regimes of combined treatment (cisplatin+ radiotherapy) for intraoral and oropharyngeal cancer]. [Russian]. Voprosy Onkologii 2007;53(5):575-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1313&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Goldberg 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1316&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Goldberg S. Safety and tolerability of en3247 in the prevention of oral mucositis associated with chemotherapy with or without total body irradiation: results of a randomized, double-blind, placebo-controlled trial. In: Proceedings of the American Society of Clinical Oncology. 2003:770.&lt;/h4&gt;&lt;p&gt;Goldberg S. Safety and tolerability of en3247 in the prevention of oral mucositis associated with chemotherapy with or without total body irradiation: results of a randomized, double-blind, placebo-controlled trial [abstract]. Proceedings of the American Society of Clinical Oncology. 2003:770.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1318&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gordon 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1321&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gordon B, Spadinger A, Hodges E, Coccia P. Effect of granulocyte macrophage colony stimulating factor (GMCSF) on oral mucositis after autologous bone marrow transplantation [abstract]. Proceedings of the American Society of Clinical Oncology 1993;12:432, Abstract 1489.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1323&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Grotz 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1326&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Grotz KA, Henneicke-Von Zepelin H-H, Kohnen R, Kutzner J. Belz GG. Prophylaxis of mucositis and dry mouth after head and neck radiotherapy. A new treatment. Krankenhauspharmazie 2002;23(5):193-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1328&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Grotz KA, Wustenberg P, Kohnen R, Al-Nawas B, Henneicke-von Zepelin H, Bockisch A et al. Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutine in patients with head and neck cancer- a prospective, randomized, placebo-controlled, double-blind study. British Journal of Oral and Maxillofacial Surgery 2001;39(1):34-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1330&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gujral 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1333&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gujral MS, Patnaik PM, Kaul R, Daftary GV, Parikh HK, Tamhankar CP et al. Oral enzymes preventing side effects of radiation therapy in patients with head and neck cancers. European Journal of Cancer 1999;35(Suppl 4):168 (Abs No 634).&lt;/h4&gt;&lt;p&gt;Gujral MS PPKRDGPHTCSW. Oral enzymes preventing side effects of radiation therapy in patients with head and neck cancers. European Journal of Cancer 1999+ADs-35(Suppl. 4):Page 168 Abstract +ACM-634.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1335&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gutierrez 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1338&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gutierrez AR, Boizas EC, Carreras PS, Rodriguez CS, Rodriguez OA, Chicote MJV et al. Fluconazol as prophylaxis of radioinduced oral mucositis. Preliminary study [Fluconazol en la profilaxis de la mucositis oral radioinducida. Estudio preliminar]. Oncologia 1996;19(6):56-9.&lt;/h4&gt;&lt;p&gt;Gutierrez AR BE, Carreras PS, Rodriguez CS, Rodriguez OA, Chicote MJV, Palacios AN, Solbes RS, Ripoll JJS. Fluconazol as prophylaxis of radioinduced oral mucositis. Preliminary study. Oncologia 1996;19(6):56-59.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1340&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hanson 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1343&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hanson WR, Marks JE, Reddy SP, Simon S, Mihalo WE, Tova Y. Protection from radiation-induced oral mucositis by a mouth rinse containing the prostaglandin E1 analog, misoprostol: A placebo controlled double blind clinical trial. Advances in Experimental Medicine and Biology 1997;400B:811-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1345&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hanson WR, Marks JE, Reddy SP, Simon S, Mihalo WE, Tova Y. Protection from radiation-induced oral mucositis by misoprostol, a prostaglandin E(1) analog: a placebo-controlled, double-blind clinical trial. American Journal of Therapeutics 1995;2(11):850-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1347&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Harris 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1350&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Harris JR, Russell NH, Hunter AE. Folinic acid mouthwashes do not reduce the degree of mucositis in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplantation 1995;15(S2):S164.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1352&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hartmann 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1355&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hartmann J, von Vangerow A, Knop S, Brugger W, Fels L, Stolte H et al. A randomized trial comparing the toxicity and the treatment costs of HD-VIC plus PBSC transplantation with or without amifostine (AMI) in patients with solid tumors. European Journal of Cancer 1999;35(Suppl 4):361 (Abs No 1464).&lt;/h4&gt;&lt;p&gt;Hartmann J, von Vangerow A, Knop S, Brugger W, Fels L, Stolte H, et al. A randomized trial comparing the toxicity and the treatment costs of HD-VIC plus PBSC transplantation with or without amifostine (AMI) in patients with solid tumors. European Journal of Cancer. 1999;35(Suppl 4):361, Abstr #1464.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1357&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;He 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1360&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;He XY, Hu CS, Wu YR. Radioprotective effect of amifostine in nasopharyngeal carcinoma. Acta Academiae Medicinae Shanghai 2004;31(1).&lt;/h4&gt;&lt;p&gt;He XY, Hu CS, Wu YR. Radioprotective effect of amifostine in nasopharyngeal carcinoma. Acta Academiae Medicinae Shanghai. 2004;31(1).&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1362&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hickey 1982&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1365&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hickey AJ, Toth BB, Lindquist SB. Effect of intravenous hyperalimentation and oral care on the development of oral stomatitis during cancer chemotherapy. The Journal of Prosthetic Dentistry 1982;47(2):188-93.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1367&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Horsley 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1370&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Horsley P, Bauer JD, Mazkowiack R, Gardner R, Bashford J. Palifermin improves severe mucositis, swallowing problems, nutrition impact symptoms, and length of stay in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer 2007;15(1):105-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1372&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Howell 1983&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1375&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Howell SB, Pfeifle CE, Wung WE. Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection. Cancer 1983;51(2):220-5.&lt;/h4&gt;&lt;p&gt;Howell SB PC, Wung WE. Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection. Cancer 1983;51(2):220-5.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1377&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hu 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1380&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hu K, Ship JA, Harrison LB. Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/IV head and neck cancer. Seminars in Oncology 2003;30(6 Suppl 18):40-8.&lt;/h4&gt;&lt;p&gt;Hu K, Ship JA, Harrison LB. Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/IV head and neck cancer. [Review] [36 refs]. Seminars in Oncology 2003; 30(6 Suppl 18):40-8.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1382&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Inagaki 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1385&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Inagaki N. [Report on the treatment of infections complicating hematological diseases. Case 2. Two cases of deep-seated mycosis developing during chemotherapy of leukemia]. [Japanese]. Japanese Journal of Antibiotics 2007;60(5):317-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1387&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ito 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1390&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ito A, Hanawa T, Fujii E. The preventive effect of allopurinol spray on stomatitis induced by anti-cancer drugs. Gan To Kagaku Ryoho 2002;29(4):563-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1392&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Jebb 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1395&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Jebb SA, Marcus R, Elia M. A pilot study of oral glutamine supplementation in patients receiving bone marrow transplants. Clinical Nutrition 1995;14:162-5.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1397&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Johnson 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1400&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Johnson DJ, Scott CB, Marks JE, Seay TE, Atkins JN, Berk LB et al. Assessment of quality of life and oral function of patients participating in a phase II study of radioprotection of oral and pharyngeal mucosa by the prostaglandin E(1) analog misoprostol (RTOG 96-07). International Journal or Radiation Oncology Biology and Physics 2002;54(5):1455-9.&lt;/h4&gt;&lt;p&gt;Johnson DJ, Scott CB, Marks JE, Seay TE, Atkins JN, Berk LB, Meoz RT, Wheeler JA.Assessment of quality of life and oral function of patients participating in a phase II study of radioprotection of oral and pharyngeal mucosa by the prostaglandin E(1) analog misoprostol (RTOG 96-07). Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1455-9.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1402&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kante 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1405&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kante V. Comparative study of two prophylactic regimes for the prevention of mucositis in autologous bone marrow transplants. Bone Marrow Transplantation 1995;15:253.&lt;/h4&gt;&lt;p&gt;Kante V, et al. Comparative study of two prophylactic regimes for the prevention of mucositis in autologous bone marrow transplants [abstract]. Bone-Marrow-Transplant. 1995;15:253.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1407&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Karthaus 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1410&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Karthaus M, Rosenthal C, Huebner G, Paul H, Elser C, Hertenstein B et al. Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial. Bone Marrow Transplantation 1998;22(8):781-5.&lt;/h4&gt;&lt;p&gt;Karthaus M, Rosenthal C, Huebner G, Paul H, Elser C, Hertenstein B et al. Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial. Bone Marrow Transplant 1998;22:781-5.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1412&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kasten-Sportes 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1415&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kasten-Sportes C. Randomized study of acupuncture for mucositis-related pain secondary to high-dose chemotherapy in patients undergoing hematopoietic stem cell transplantation. PDQ (NCI-03-C-0125) 2003.&lt;/h4&gt;&lt;p&gt;Kasten-Sportes C. Randomized Study of Acupuncture for Mucositis-Related Pain Secondary to High-Dose Chemotherapy in Patients Undergoing Hematopoietic Stem Cell Transplantation. PDQ, NCI-03-C-0125. 2003 2003.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1417&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kenny 1990&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1420&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kenny SA. Effect of two oral care protocols on the incidence of stomatitis in hematology patients. Cancer Nursing 1990;13(6):345-53.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1422&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Klocke 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1425&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Klocke J, Cannon M, Gissinger D, Bayer R, Devoe C, John V. Prevention of mucositis in auto BMT/stem cell transplant patients. Oncology Nursing Forum 2006;33(2):454.&lt;/h4&gt;&lt;p&gt;Klocke J, Cannon M, Gissinger D, Bayer R, Devoe C, John V. Prevention of mucositis in auto BMT/stem cell transplant patients. Oncology Nursing Forum. 2006;33(2):454.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1427&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kokkonen 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1430&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kokkonen J, Mottonen M, Karttunen TJ, Lanning M. Mucosal pathology of the upper gastrointestinal tract associated with intensive chemotherapy in children: Vitamin a supplements do not prevent lesions. Pediatric Hematology and Oncology 2002;19(3):181-92.&lt;/h4&gt;&lt;p&gt;Kokkonen JMMKTLM. Mucosal pathology of the upper gastrointestinal tract associated with intensive chemotherapy in children: Vitamin a supplements do not prevent lesions. Pediatric Hematology +ACY- Oncology 2002+ADs- Vol 19(3): 181-192.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1432&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kuhn 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1435&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kuhn A, Porto FA, Miraglia P, Brunetto AL. Low-level infrared laser therapy in chemotherapy-induced oral mucositis: a randomized placebo-controlled trial in children. Journal of Pediatric Hematology/Oncology 2009;31(1):33-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1437&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kuriakose 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1440&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kuriakose P, Gandara DR, Perez EA. Phase I trial of edatrexate in advanced breast and other cancers.[comment]. Cancer Investigation 2002;20(4):473-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1444&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Labar 1990&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1447&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Labar B, Pavletic Z, Bogdanic V, Nemet D, Aurer I, Jakie J. Prostaglandin E2 for prevention of oral mucositis in patients with leukaemia undergoing bone marrow transplantation: a radomized double-blind clinical trial. Experimental Hematology 1990;18:700.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1449&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Labbate 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1452&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Labbate R, Lehn CN, Denardin OVP. Effects of chlorhexidine mouthwash on radiation induced mucosistis in head and neck cancer. Revista Brasileira de Otorrinolaringologia 2003;69(3):349-54.&lt;/h4&gt;&lt;p&gt;Labbate R, Lehn CN, Denardin OVP. Effects of chlorhexidine mouthwash on radiation induced mucosistis in head and neck cancer. Revista Brasileira de Otorrinolaringologia. 2003;69(3):349-54.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1454&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Leong 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1457&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Leong L, Sakurai C, Sebastian W, Shaw N, Grant E, Grant M et al. Phase III trial assessing the use of oral thymidine (THY) for prevention of fluorouracil (5-FU)-induced mucositis. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology. Vol. 14. 1995:A334.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1459&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Levendag 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1462&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lavendag PC, Wijers OB, Harms RE, Schmitz PIM, Wilms BE, Visch LL. Mucositis prevention by selective elimination of oral flora in irradiated cancers of the head and neck: a prospective randomized study. Radiotherapy Oncology 1998;48:S10.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1464&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Levi 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1467&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997;350(9079):681-6.&lt;/h4&gt;&lt;p&gt;Levi F ZR, Misset J-L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997+ADs-350(9079):681-686.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1469&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lievens 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1472&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lievens Y, Haustermans K, van den Weyngaert D, van den Bogaert W, Scalliet P, Hutsebaut L et al. Does sucralfate reduce the acute side-effects in head and neck cancer treated with radiotherapy? A double-blind randomized trial. Radiotherapy Oncology 1998;47(2):149-53.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1474&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lin 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1477&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lin J, Wang X, Fan Z. A study on quantizing evaluation on stomatitis of malignant tumor patients undergoing large dose of chemotherapy [Chinese]. Chinese Nursing Research 2008;22(2A):328-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1480&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lin LC, Que J, Lin LK, Lin FC. Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study. International Journal of Radiation Oncology, Biology, Physics 2006;65(3):745-50.&lt;/h4&gt;&lt;p&gt;Lin LC, Que J, Lin LK, Lin FC. Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study. International Journal of Radiation Oncology, Biology, Physics. 2006;65(3):745-50.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1482&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lopez 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1485&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lopez I, Goudou C, Ribrag V, Sauvage C, Hazebroucq G, Dreyfus F. Traitement des mucites par la vitamine E lors de l'administration d'anti-neoplasiques neutropeniants. Annuals Medicine Interne 1994;145(6):405-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1487&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Loprinzi 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1490&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Loprinzi CL, Ghosh C, Camoriano J, Sloan J, Steen PD, Michalak JC et al. Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy. Journal of Clinical Oncology 1997;15(3):1235-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1492&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lorusso 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1495&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lorusso D, Ferrandina G, Greggi S, Gadducci A, Pignata S, Tateo S. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Annals of Oncology 2003;14(7):1086-93.&lt;/h4&gt;&lt;p&gt;Lorusso D FG, Greggi S, Gadducci A, Pignata S, Tateo S, Biamonte R, Manzione L, Di Vagno G, Ferrau' F, Scambia G, Multicenter Italian Trials in Ovarian Cancer invesitgators. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Annals of Oncology 2003;14(7):1086-93.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1497&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lozada 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1500&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lozada-Nur F, Schoelch M, Fu K, Muscoplat C, Trivedi M, Smith C et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. In: Proceedings of the Annual Meeting of the Society of Clinical Oncology. 1998:1541.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1502&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Maddocks-Jennings 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1505&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Maddocks-Jennings W, Wilkinson JM, Cavanagh HM, Shillington D. Evaluating the effects of the essential oils Leptospermum scoparium (manuka) and Kunzea ericoides (kanuka) on radiotherapy induced mucositis: a randomized, placebo controlled feasibility study. European Journal of Oncology Nursing 2009;13(2):87-93.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1507&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Madero 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1510&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Madero L, Diaz MA, Ortega JJ, Olive T, Martinez A, Badell I et al. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates engraftment kinetics after allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia. Haematologica 1999;84(2):133-7.&lt;/h4&gt;&lt;p&gt;Madero L DM, Ortega JJ, Olive T, Martinez A, Badell I, Munoz A, Gomez P. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates engraftment kinetics after allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia. Haematologica 1999;84(2):133-7.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1512&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mahmoud 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1515&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mahmoud HK SE, Kamel M, El HMA, Nassar A. Influence of folinic acid rescue on methotrexate-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation. Tumor Diagnostik Und Therapie 1996;17(1):18-21.&lt;/h4&gt;&lt;p&gt;Mahmoud HK SE, Kamel M, El HMA, Nassar A. Influence of folinic acid rescue on methotrexate-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation. Tumor Diagnostik Und Therapie. 1996+ADs-17(1):18-21.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1517&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Malaker 1991&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1520&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Malaker K, Anderson BJ, Beecroft WA, Hodson DI. Management of oral mucosal dysplasia with beta-carotene retinoic acid: a pilot cross-over study. Cancer Detection and Prevention 1991;15(5):335-40.&lt;/h4&gt;&lt;p&gt;Malaker K, Anderson BJ, Beecroft WA, Hodson DI. Management of oral mucosal dysplasia with beta-carotene retinoic acid: a pilot cross-over study. Cancer Detection +ACY- Prevention 1991+ADs-15(5):335-40.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1522&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mantovani 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1525&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mantovani G, Massa E, Astara G, Murgia V, Gramignano G, Lusso MR et al. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs. Oncology Reports 2003;10(1):197-206.&lt;/h4&gt;&lt;p&gt;Mantovani G, Massa E, Astara G, Murgia V, Gramignano G, Lusso MR, et al. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs. Oncology Reports 2003+ADs- 10(1):197-206.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1527&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Marcial 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1530&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Marcial F, Schubert M, Niccoli-Filho WD, Lloid ME, Kelly J, Franquin JC et al. A phase I/II nonblinded randomized trial to determine the efficacy of low-energy laser to prevent oral mucositis resulting from conditioning regimens for bone marrow transplantation. Oral Surgery, Oral Medicine, Oral Pathology 1994;78(6):738.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1532&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Martin 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1535&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Martin M, Lluch A, Segui MA, Ruiz A, Ramos M, Adrover E, et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.[see comment]. Annals of Oncology 2006;17(8):1205-12.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1537&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Masucci 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1540&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Masucci G, Broman P, Kelly C, Lindahl S, Malmberg L, Reizenstein J et al. Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy: a multicenter open randomized phase III study. Medical Oncology 2005;22(3):247-56.&lt;/h4&gt;&lt;p&gt;Masucci G, Broman P, Kelly C, Lindahl S, Malmberg L, Reizenstein J, et al. Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy: a multicenter open randomized phase III study. Medical Oncology. 2005;22(3):247-56.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1542&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Matejka 1990&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1545&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Matejka M, Nell A, Kment G, Schein A, Leukauf M, Porteder H et al. Local benefit of prostaglandin E2 in radiochemotherapy-induced oral mucositis. British Journal of Oral Maxillofacial Surgery 1990;28(2):89-91.&lt;/h4&gt;&lt;p&gt;Matejka M, Nell A, Kment G, Schein A, Leukauf M, Porteder H, Mailath G, Sinzinger H.Local benefit of prostaglandin E2 in radiochemotherapy-induced oral mucositis. Br J Oral Maxillofac Surg. 1990 Apr;28(2):89-91.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1547&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;McGaw 1985&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1550&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;McGaw WT, Belch A. Oral complications of acute leukemia: prophylactic impact of a chlorhexidine mouthrinse regimen. Oral Surgery, Oral Medicine, Oral Pathology 1985;60(3):275-80.&lt;/h4&gt;&lt;p&gt;McGaw WT, Belch A. Oral complications of acute leukemia: prophylactic impact of a chlorhexidine mouthrinse regimen. Oral Surg Oral Med Oral Pathol 1985;60:275-80.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1552&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;McIlroy 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1555&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;McIlroy P. Radiation mucositis: a new approach to prevention and treatment. European Journal of Cancer Care 1996;5(3):153-8.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1557&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Merte 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1560&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Merte H, Wied R, Engenhart-Cabillic R. Der effekt von immunglobulinen in der behandlung der radiogenen dermatitis und mukositis bei patienten mit hals-nasen und rachentumoren. Strahlentherapy und Onkologie 1999;175(1):135.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1562&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mills 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1565&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mills W, Strang J, Goldstone AH, Linch DC. Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma. Leukemia &amp;amp; Lymphoma 1995;17(3-4):263-70.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1567&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Minn 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1570&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Minn HR, Makkonen TA, Jekunen A, Vilja P, Tuominen J, Joensuu H. Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study. International Journal of Radiation Oncology Biology Physics 1999;45(3 Suppl):239.&lt;/h4&gt;&lt;p&gt;Minn HR, Makkonen TA, Jekunen A, Vilja P, Tuominen J, Joensuu H. Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study [abstract]. International Journal of Radiation Oncology Biology Physics. 1999;45(3 Suppl):239.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1572&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mohanta 1992&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1575&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mohanta PK, Singhal RM, Jindel R, Sharma RL, Julka PK. Hydroxyurea as a radiation sensitizer in malignancies of the head anc neck. Indian Journal of Radiology and Imaging 1992;2(2):143-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1577&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mok 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1580&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mok TSK, Yeo W, Johnson PJ, Hui P, Ho WM, Lam KC, et al. A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. Annals of Oncology 2007;18(4):768-74.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1582&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mori 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1585&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mori T, Yamazaki R, Aisa Y, Nakazato T, Kudo M, Yashima T, et al. Brief oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. Supportive Care in Cancer 2006;14(4):392-5.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1587&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Nicholl 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1590&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Nicholl TA, Nimmo CR, Shepherd JD, Phillips P, Jewweson PJ. Amphotericin B infusion-related toxicity: comparison of two- and four-hour infusions. Annals of Pharmacotherapy 1995;29(11):1081-7.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1592&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Niibe 1985b&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1595&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Niibe H, Takahashi I, Mitsuhashi N, Miyaishi K, Itoh J, Maehara Y et al. An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study.2 Abdominal and pelvic tumours. Nippon Gan Chiryo Gakkai Shi 1985;20(5):994-1001.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1597&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Nikoletti 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1600&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Nikoletti S, Hyde S, Shaw T, Myers H, Kristjanson LJ. Comparison of plain ice and flavoured ice for preventing oral mucositis associated with the use of 5 fluorouracil. Journal of Clinical Nursing 2005;14(6):750-3.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1602&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ohnmacht 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1605&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ohnmacht GA, Phan GQ, Mavroukakis SA, Steinberg SM, Shea YR, Witebsky FG et al. A prospective, randomized, double-blind, placebo-controlled trial evaluating the effect of nystatin on the development of oral irritation in patients receiving high-dose intravenous interleukin-2. Journal of Immunotherapy 2001;24(2):188-92.&lt;/h4&gt;&lt;p&gt;Ohnmacht GA PG, Mavroukakis SA, Steinberg SM, Shea YR, Witebsky FG, McIntyre LS, Goodwin RS, Muehlbauer PM, Morton KE, Rogers-Freezer LJ, Seipp CA, Rosenberg SA, Marincola FM. A prospective, randomized, double-blind, placebo-controlled trial evaluating the effect of nystatin on the development of oral irritation in patients receiving high-dose intravenous interleukin-2. Journal of Immunotherapy 2001;24(2):188-92.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1607&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Okuno 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1610&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Okuno SH, Foote RL, Loprinzi CL, Gulavita S, Sloan JA, Earle J et al. A randomized trial of a nonabsorbable antibiotic lozenge given to alleviate radiation-induced mucositis. Cancer 1997;79(1):2193-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1612&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Okuno 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1615&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Okuno SH, Swan L, Ebbert C. Phase III placebo-controlled clinical trial evaluation of glutamine for decreasing mucositis in patients receiving 5 FU (Fluorouracil)-based chemotherapy. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1998:256.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1617&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Okutomi 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1620&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Okutomi T, Kato Y, Ichihara H, Hyodo I, Fujitsuka H, Yasuda S et al. [Clinical effects of adjuvant therapy using Z-100 (Ancer 20 injection) for oral cancer--prevention of stomatitis and hematopoietic impairment]. Gan To Kagaku Ryoho 2000;27(1):65-71.&lt;/h4&gt;&lt;p&gt;Okutomi T, Kato Y, Ichihara H, Hyodo I, Fujitsuka H, Yasuda S, Tatematsu N. [Clinical effects of adjuvant therapy using Z-100 (Ancer 20 injection) for oral cancer--prevention of stomatitis and hematopoietic impairment] Gan To Kagaku Ryoho. 2000 Jan;27(1):65-71.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1622&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Papadeas 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1625&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Papadeas E, Naxakis S, Riga M, Kalofonos Ch. Prevention of 5-fluorouracil-related stomatitis by oral cryotherapy: a randomized controlled study. European Journal Oncology Nursing 2007;1:60-5.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1627&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Papas 1984&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1630&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Papas A, Johansen E. Prevention of mucositis in oncology patients undegoing radiation therapy. Journal of Dental Research 1984;63(Special Issue March):311 (Abs No 1267).&lt;/h4&gt;&lt;p&gt;Papas A, E J. Prevention of Mucositis in Oncology Patients Undegoing Radiation Therapy (JDR Abstract). J-Dent-Res 1984;63(Special Issue March):311 (Abs 1267).&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1632&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Peters 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1635&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Peters E, Antczak-Bouckoms A, Burdick E. Meta-analysis of chlorhexidine in the prevention of mucositis from chemotherapy. Journal of Dental Research 1993;Special Issue(259):1249.&lt;/h4&gt;&lt;p&gt;Peters E A-BA, Burdick E. Meta-Analysis of Chlorhexidine in the Prevention of Mucositis from Chemotherapy (IADR Abstract). Journal of Dental Research 1993+ADs-72:259 (Abs No 1249).&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1637&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Peterson 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1640&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Peterson DE, Petit RG. Phase III study: AES-14 in chemotherapy patients at risk for mucositis. In: Proceedings of the American Society of Clinical Oncology. 2003:725.&lt;/h4&gt;&lt;p&gt;Peterson DE, Petit RG. Phase III study: AES-14 in chemotherapy patients at risk for mucositis [abstract]. Proceedings of the American Society of Clinical Oncology. 2003:725.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1642&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Petit 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1645&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Petit RG, II, French C. Phase III clinical trial design considerations for oral treatments of chemotherapy - induced mucositis: AES-14 (uptake-facilitated L-glutamine) pivotal studies [abstract]. Proceedings of the American Society of Clinical Oncology 2001;20 (Pt 2):301b, Abstract 2954.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1647&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pfeiffer 1989&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1650&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pfeiffer P, May O. Sucralfate prophylaxis of chemotherapy-induced stomatitis. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1989.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1652&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pfeiffer 1989a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1655&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pfeiffer P, Hansen SO, Madsen EL, May O. Sucralfate prophylaxis of chemotherapy-induced stomatitis [abstract]. Proceedings of the American Society of Clinical Oncology 1989;8:171, Abstract 665.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1657&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Phillips 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1660&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Phillips II, GL. The potential of amifostine in high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Seminars in Oncology 2002;29(6 Supp 19):53-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1662&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Piccirillo 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1665&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Piccirillo N, De Matteis S, Laurenti L, Chiusolo P, Sora F, Pittiruti M et al. Glutamine-enriched parenteral nutrition after autologous peripheral blood stem cell transplantation: effects on immune reconstitution and mucositis. Haematologica 2003;88(2):192-200.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1667&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Porta 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1670&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Porta C, Moroni M, Nastasi G, Montecucco CM, Caporali R, Notario A. Allopurinol mouthwashes can reduce oral mucositis in chemotherapy-treated patients. Annals of Oncology 1994;5(Suppl 8):208.&lt;/h4&gt;&lt;p&gt;Porta C, Moroni M, Nastasi G, Montecucco CM, Caporali R, Notario A. Allopurinol mouthwashes can reduce oral mucositis in chemotherapy-treated patients. Annals of Oncology. 1994;5(Suppl 8):208.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1672&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pouli 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1675&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pouli A, Nikiforakis E. A prospective randomized trial of GM-CFS mouthwash versus sodium bicarbonate mouthwash in the treatment of stomatitis following allogeneic bone marrow transplantation. Bone Marrow Transplantation 1999;23:S166.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1677&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Prada 1985&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1680&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Prada A, Lozza L, Moglia D, Sala L, Chiesa F. Effects of benzydamine on radio-polychemotherapeutic mucositis of the oral cavity. International Journal of Tissue Reaction 1985;7(3):237-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1682&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pyrhonen 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1685&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. British Journal of Cancer 1995;71(3):587-91.&lt;/h4&gt;&lt;p&gt;Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. British Journal of Cancer. 1996;71(3):587-91.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1687&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pytlik 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1690&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Pytlik R, Benes P, Patorkova M, Chocenska E, Gregora E, Prochazka B et al. Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo controlled study. Bone Marrow Transplantation 2002;30(12):953-61.&lt;/h4&gt;&lt;p&gt;Pytlik R, Benes P, Patorkova M, Chocenska E, Gregora E, Prochazka B, et al. Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo controlled study. Bone Marrow Transplantation 2002+ADs- 30(12):953-61.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1692&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rabinovitch 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1695&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rabinovitch R, Grant B, Berkey BA, Raben D, Ang KK, Fu KK et al. Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: a secondary analysis of RTOG trial 90-03. Head &amp;amp; Neck 2006;28(4):287-96.&lt;/h4&gt;&lt;p&gt;Rabinovitch R, Grant B, Berkey BA, Raben D, Ang KK, Fu KK, et al. Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: a secondary analysis of RTOG trial 90-03. Head &amp;amp; Neck. 2006;28(4):287-96.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1697&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rades 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1700&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rades D, Fehlauer F, Bajrovic A, Mahlmann B, Richter E, Alberti W. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiotherapy and Oncology 2004;70(3):261-4.&lt;/h4&gt;&lt;p&gt;Rades D, Fehlauer F, Bajrovic A, Mahlmann B, Richter E, Alberti W. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.[see comment]. Radiotherapy &amp;amp; Oncology. 2004;70(3):261-4.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1702&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Radmard 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1705&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Radmard A, Niewohner-Desbordes U, Wagner W. [rhGM-CSF in the treatment of radiogenic mucositis: prospective randomised phase-II study on the effectivity and tolerance of rhGM-CSF in the treatment of oral mucositis under radiotherapy of head and neck tumors]. Strahlentherapie und Onkologie 2002;178(Suppl 1):24.&lt;/h4&gt;&lt;p&gt;Radmard A, Niewohner-Desbordes U, Wagner W. [ rhGM-CSF in the treatment of radiogenic mucositis: prospective randomised phase-II study on the effectivity and tolerance of rhGM-CSF in the treatment of oral mucositis under radiotherapy of head and neck tumors. ]. Strahlentherapie und Onkologie. 2002;178(Sondernr 1):24.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1707&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Raether 1989&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1710&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Raether D, Walker PO, Bostrum B, Weisdorf D. Effectiveness of oral chlorhexidine for reducing stomatitis in a pediatric bone marrow transplant population. Pediatric Dentistry 1989;11(1):37-42.&lt;/h4&gt;&lt;p&gt;Raether D, Walker PO, Bostrum B, Weisdorf D. Effectiveness of oral chlorhexidine for reducing stomatitis in a pediatric bone marrow transplant population. Pediatric Dentistry 1989;11:37-42.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1712&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Robustelli 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1715&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Robustelli della Cuna FS, Ucci G, Cuomo AM, Goglio AM. Galenic preparation for the prophylaxsis of oral mucositis induced by 5-fluororacil continous infusion. Supportive Care in Cancer 1999;7 Suppl:132 (Abs No P-67).&lt;/h4&gt;&lt;p&gt;Robustelli della Cuna FS, Ucci G, Cuomo AM, Goglio AM. Galenic preparation for the prophylaxsis of oral mucositis induced by 5-fluororacil continous infusion. Supportive Care in Cancer. 1999;7 Suppl.(Abstr P-67):132.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1717&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rocci 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1720&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rocci L, Vincenzi B, Santini D, Tonini G. [Timing of 5-fluorouracile infusion: a randomized clinical trial]. International Nursing Perspectives 2005;5(2):53-60.&lt;/h4&gt;&lt;p&gt;Rocci L, Vincenzi B, Santini D, Tonini G. Timing of 5-fluorouracile infusion: a randomized clinical trial [Italian]. International Nursing Perspectives. 2005;5(2):53-60. (32 ref).&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1722&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rojas 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1725&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rojas de Morales T, Zambrano O, Rivera L, Navas R, Chaparro N, Bernardonni C et al. Oral-disease prevention in children with cancer: testing preventive protocol effectiveness. Medicina Oral 2001;6(5):326-34.&lt;/h4&gt;&lt;p&gt;Rojas de Morales T ZO, Rivera L, Navas R, Chaparro N, Bernardonni C, Rivera F, Fonseca N, Tirado DM. Oral-disease prevention in children with cancer: testing preventive protocol effectiveness. Medicina Oral 2001+ADs-6(5):326-34.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1727&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rutkauskas 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1730&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rutkauskas JS, Davis JW. Effects of chlorhexidine during immunosuppressive chemotherapy: A preliminary report. Oral Surgery, Oral Medicine, Oral Pathology 1993;76(4):441-8.&lt;/h4&gt;&lt;p&gt;Rutkausas JS, Davis JW. Effects of chlorhexidine during immunosuppressive chemotherapy: A preliminary report. Oral Surg Oral Med Oral Path 1993;76:441-8.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1732&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ryu 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1735&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ryu JK, Swann S, LeVeque F, Scarantino CW, Johnson D, Chen A, et al. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901. International Journal of Radiation Oncology, Biology, Physics 2007;67(3):643-50.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1737&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Samaranayake 1988&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1740&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Samaranayake LP, Robertson AG, MacFarlane TW, Hunter IP, MacFarlane G, Soutar DS et al. The effect of chlorhexidine and benzydamine mouthwashes on mucositis induced by therapeutic irradiation. Clinical Radiology 1988;39(3):291-4.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1742&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sato 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1745&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sato A, Kumagai S, Sakaki K, Morikawa H, Song ST, Mori S. [Inhibition of 5-fluorouracil-cisplatin-induced stomatitis by oral cryotherapy: use of an ice-bar containing fibrinolysin and deoxyribonuclease comiben (Elase)]. Gan to Kagaku Ryoho [Japanese Journal of Cancer &amp;amp; Chemotherapy] 1997;24(9):1135-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1747&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sato 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1750&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sato A, Saisho-Hattori T, Koizumi Y, Minegishi M, Iinuma K, Imaizumi M. Prophylaxis of mucosal toxicity by oral propantheline and cryotherapy in children with malignancies undergoing myeloablative chemo-radiotherapy. Tohoku Journal of Experimental Medicine 2006;210(4):315-20.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1752&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Scarantino 2001a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1755&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Scarantino CW, LeVeque FG, Scott CB, White RL, Rotman M, Hodson DI et al. A phase III study of concomitant oral pilocarpine to reduce hypo-salivation and mucositis assocated with curative radiation therapy (RT) in head and neck (H&amp;amp;N) cancer patients. RTOG 9709. In: Proceedings of the American Society of Clinical Oncology. 2001:(Abs No 897).&lt;/h4&gt;&lt;p&gt;Scarantino C LF, Scott C, White R, Rotman M, Hodson D, Meredith R, Foote R, Brachman D. A Phase III Study of Concomitant Oral Pilocarpine to Reduce Hypo-Salivation and Mucositis Assocated with Curative Radiation Therapy (RT) in Head and Neck (H&amp;amp;N) Cancer Patients. RTOG 9709. Proceedings of ASCO 2001.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1757&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Scarantino 2001b&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1760&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sadar CM, Heard R, Prathikanti R, Lau D, Danilenko D, Hunt T et al. Safety, pharmacokinetics and biological activity of rHuKGF in normal volunteers.. Growth Factors and Cytokines;Abstract 761:172.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1762&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Scarantino CW, Leveque F, Scott C, White RL, Rotman M, Hodson DI et al. A Phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97-09. International Journal of Radiation Oncology, Biology, Physics 2001;51(3 Suppl 1):85-6.&lt;/h4&gt;&lt;p&gt;Scarantino CW, Leveque F, Scott C, White RL, Rotman M, Hodson DI, et al. A Phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97-09 [abstract]. International Journal of Radiation Oncology Biology Physics. 2001;51(3 Suppl 1):85-6.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1764&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Schuster 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1767&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Schuster MW, Anaissie E, Hurd D, Bensinger W, Mason J, McCarty J, et al. Final analysis of the phase II, randomized, double-blind, placebo-controlled trial of single-dose velafermin (CG53135-05) for the prevention of oral mucositis. Journal of Supportive Oncology 2007;5(4 SUPPL. 2):58-9.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1769&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Schuster MW, Shore TB, Harpel JG, Greenberg J, Jalilizeinali B, Possley S, et al. Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant. Supportive Care in Cancer 2008;16(5):477-83.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1771&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Schwerkkoske 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1774&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Schwerkkoske J, Schwartzberg L, Weaver CH, Schwertschlag US, Goodfellow J, Berdosian CL. A phase I double-masked, placebo-controlled study to evaluate tolerability of Neumega (rhIL-11; Oprelvekin) to reduce mucositis in patients with solid tumors or lymphoma receiving high-dose chemotherapy (CT) with autologous peripheral blood stem cell reinfusion (PBSCT). In: Proceedings of the American Society of Clinical Oncology. Vol. 18. 1999:584a.&lt;/h4&gt;&lt;p&gt;Schwerkkoske J, Schwartzberg L, Weaver CH, Schwertschlag US, Goodfellow J, Berdosian CL. A phase I double-masked, placebo-controlled study to evaluate tolerability of Neumega (rhIL-11; Oprelvekin) to reduce mucositis in patients with solid tumors or lymphoma receiving high-dose chemotherapy (CT) with autologous peripheral blood stem cell reinfusion (PBSCT) [abstract]. Proceedings of the American Society of Clinical Oncology. 1999;18:584a.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1776&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Schwerkoske 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1779&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Schwerkoske J, Schwartzberg L, Weaver CH, Schwertschlag US, Goodfellow J, Bedrosian CL. A phase 1 double-masked, placebo-controlled study to evaluate tolerability of Neumega&amp;#174; (rhIL-11; oprelvekin) to reduce mucositis in patients with solid tumors or lymphoma receiving high-dose chemotherapy (CT) with autologous peripheral blood stem cell reinfusion (PBSCT) [abstract]. Proceedings of the American Society of Clinical Oncology 1999;18:584a, Abstract 2256.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1781&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Shea 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1784&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Shea TC, Kewalramani T, Mun Y, Jayne G, Dreiling LK. Evaluation of Single-Dose Palifermin To Reduce Oral Mucositis (OM) in Fractionated Total Body Irradiation (fTBI) and High Dose (HD) Chemotherapy with Autologous Peripheral Blood Progenitor Cell (PBPC) Transplantation [abstract]. Blood 2006;108(11 Part 1):875-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1786&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Shea TC, Kewalramani T, Mun Y, Jayne G, Dreiling LK. Evaluation of single-dose palifermin to reduce oral mucositis in fractionated total-body irradiation and high-dose chemotherapy with autologous peripheral blood progenitor cell transplantation. Journal of Supportive Oncology 2007;5(4 SUPPL. 2):60-2.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1788&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Simoes 2009&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1791&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Simoes A, Eduardo FP, Luiz AC, Campos L, Sa PH, Cristofaro M, et al. Laser phototherapy as topical prophylaxis against head and neck cancer radiotherapy-induced oral mucositis: comparison between low and high/low power lasers. Lasers in Surgery &amp;amp; Medicine 2009;41(4):264-70.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1793&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Spadaro 1991&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1796&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Spadaro P, Buemi B, Ferraro G, Marabello G, Russi E, Pergolizzi S. Prophylaxis of chemotherapy-radiotherapy induced mucositis or oral fungal infection with vitamin E + vitamin A and Fluconazolo. European Journal of Cancer 1991;27(Suppl 2):S288.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1798&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Spielberger 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1801&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Spielberger RT, Stiff P, Emmanouilides C, Yanovich S, Bensinger W, Hedrick E, et al. Efficacy of recombinant human keratinocyte growth factor (rHuKGF) in reducing mucositis in patients with hematologic malignancies undergoing autologous peripheral blood progenitor cell transplantation (auto-PBPCT) after radiation-based conditioning - results of a phase 2 trial [abstract]. Proceedings of the American Society of Clinical Oncology 2001;20 (Pt 1):7a, Abstract 25.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1803&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Staar 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1806&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Staar S. Benefits and toxicities of accelerated radiochemo- versus accelerated radiotherapy in advanced head and neck cancer - Results of a German randomized study. European Journal of Cancer 2001;37(Suppl 6):38 (Abs No 126).&lt;/h4&gt;&lt;p&gt;Staar S EHRVDAFMSMVPSPSHMR. Benefits and toxicities of accelerated radiochemo- versus accelerated radiotherapy in advanced head and neck cancer - Results of a German randomized study. European Journal of Cancer. 2001 2001;37(Suppl 6):38 Abs. 126.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1808&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Stokman 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1811&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Stokman MA, Wachters FM, Koopmans P, Burgerhof JG, Groen HJ, Spijkervet FK et al. Outcome of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis. A phase II study. Anticancer Research 2004;24(5B):3263-7.&lt;/h4&gt;&lt;p&gt;Stokman MA, Wachters FM, Koopmans P, Burgerhof JG, Groen HJ, Spijkervet FK, et al. Outcome of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis. A phase II study. Anticancer Research. 2004;24(5B):3263-7.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1813&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Su 2004a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1816&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Su C, Mehta V, Ravikumar L, Shah R, Pinto H, Halpern J et al. Phase II double-blind randomized study comparing oral aloe vera (AV) versus placebo to prevent radiation (RT)-related mucositis in patients with head and neck (HN) neoplasms. In: Proceedings of the Amercian Society of Clinical Oncology. 2004.&lt;/h4&gt;&lt;p&gt;Su C, Mehta, V, Ravikumar, L, Shah, R, Pinto, H, Halpern, J, Koong, A, Goffinet, D, and Le, Q-T. Phase II double-blind randomized study comparing oral aloe vera (AV) versus placebo to prevent radiation (RT)-related mucositis in patients with head and neck (HN) neoplasms. Proceedings of ASCO. 2003 2003.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1818&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Su 2004b&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1821&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Su YB. Double-blind, randomized trial of granulocyte-colony stimulating factor (GCSF) versus (v.) placebo during postoperative radiation (RT) for advanced resectable squamous cell head and neck cancer (SCCHN): impact on mucositis. Journal of Clinical Oncology 2004;22(Suppl):14S.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1823&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Suc 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1826&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Suc A, Gandemer V, Le Deley MC, Schmitt C, Pichard-Leandri E, French Group. Gum98: Preventing mucositis with chewing gum in children receiving chemotherapy, a multicentric trial. Supportive Care in Cancer 1999;7S:180 (Abs No P-60).&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1828&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Svanberg 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1831&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Svanberg A, &amp;#214;hrn K. Cryotherapy during chemotherapy - could it delay or alleviate the development of mucositis? Bone Marrow Transplantation 2004;33(Suppl 1):S292.&lt;/h4&gt;&lt;p&gt;Svanberg A, &amp;#214;hrn K. Cryotherapy during chemotherapy - could it delay or alleviate the development of mucositis? [abstract]. Bone Marrow Transplantation. 2004;33(Suppl 1):S292.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1833&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Svanberg 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1836&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Svanberg A, Birgegard G, Ohrn K. Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy--a randomized controlled trial. Supportive Care in Cancer 2007;15(10):1155-61.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1838&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sykes 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1841&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sykes AJ, Slevin NJ, MacDougall RH, Ironside JAD, Mais KL. Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck. Radiotherapy and Oncology 2004;71(1):81-4.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1843&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Symonds 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1846&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Symonds RP, Thomas M, Alcock SR, Khorrami J, McEllroy P, McMuuuray A. The reduction of radiation mucositis by antibiotic pastilles: a placebo-controlled double-blind trial. European Journal Surgery Oncology 1995;21:447.&lt;/h4&gt;&lt;p&gt;Symonds RP TM, Alcock SR, and et al. The reduction of radiation mucositis by antibiotic pastilles: a placebo-controlled double-blind trial [abstract]. Eur-J-Surg-Oncol 1995;21:447.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1848&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Teshima 1986&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1851&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Teshima T. [Clinical evaluation of kenalog ointment for radiation mucositis of patients with head and neck cancer]. Yakuri to Chiryo (Japanese Pharmacology and Therapeutics) 1986;14(11):7163-6.&lt;/h4&gt;&lt;p&gt;Teshima T, et al. [Clinical Evaluation of Kenalog Ointment for Radiation Mucositis of Patients with Head and Neck Cancer]. Yakuri to Chiryo (Japanese Pharmacology and Therapeutics). 1986;14(11):7163-6.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1853&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Thieblemont 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1856&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Thieblemont C, Dumontet C, Saad H, Roch N, Bouafia F, Arnaud P et al. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplantation 2002;30(11):769-75.&lt;/h4&gt;&lt;p&gt;Thieblemont C, C D, H S, N R, F B, P A, et al. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplantation 2002;30(11):769-75.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1858&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Throuvalas 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1861&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Throuvalas N, Antonadou D, Pulizzi M, Sarris G. Evaluation of the efficacy and safety of GM-CSF in the prophylaxis of mucositis in patients with head and neck cancer treated with RT. European Journal of Cancer 1995;31(Suppl 5):S93 (Abs No 431).&lt;/h4&gt;&lt;p&gt;Throuvalas Nao. Evaluation of the efficacy and safety of GM-CSF in the prophylaxis of mucositis in patients with head and neck cancer treated with RT. European Journal of Cancer 1995;31?(Suppl 5):S93 Abs. 431.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1863&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Tiemann 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1866&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Tiemann P, Toelg M, Ramos FM. Administration of Ratanhia-based herbal oral care products for the prophylaxis of oral mucositis in cancer chemotherapy patients: a clinical trial. Evid Based Complement Alternat Med 2007;4(3):361-6.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1869&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Toubai 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1872&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Toubai T, Tanaka J, Fujisawa F, Kondo Y, Imamura M, Ota S et al. Effect of prophylaxis against myocosis in patients with hematological malignancy disease: efficacy of dosage of itraconazole. Japanese Journal of Antibiotics 2003;56(1):61-5.&lt;/h4&gt;&lt;p&gt;Toubai T, Tanaka J, Fujisawa F, Kondo Y, Imamura M, Ota S, et al. Effect of prophylaxis against myocosis in patients with hematological malignancy disease: efficacy of dosage of itraconazole. +AFs-Japanese+AF0-. Japanese Journal of Antibiotics 2003+ADs- 56(1):61-5.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1874&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Uchiyama 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1877&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Uchiyama Y, Murakami S, Kakimoto N, Nakatani A, Furukawa S. Effectiveness of Cepharanthin in decreasing interruptions during radiation therapy for oral cancer. Oral Radiology 2005;21(1):41-4.&lt;/h4&gt;&lt;p&gt;Uchiyama Y, Murakami S, Kakimoto N, Nakatani A, Furukawa S. Effectiveness of Cepharanthin in decreasing interruptions during radiation therapy for oral cancer. Oral Radiology. 2005;21(1):41-4.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1879&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Vacha 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1882&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Vacha P, Marx M, Engel A, Richter E, Feyerabend T. Side effects of postoperative radiochemotherapy with amisfostine versus radiotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial [Nebenwirkungen einer posoperativen radiochemotherapie mit amifostin versus alleiniger radiochemotherapie bei kopf-hals-tumoren. Vorlaufige ergebnisse einer prospektiv randomisierten untersuchung]. Strahlentherapie und onkologie 1999;175(S4):18-22.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1884&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Vacha 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1887&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Vacha P, Fehlauer F, Mahlmann B, Marx M, Hinke A, Sommer K et al. Randomized phase III trial of postoperative radiochemotherapy amifostine in head and neck cancer: Is there evidence for radioprotection? Strahlentherapie und Onkologie 2003;179(6):385-9.&lt;/h4&gt;&lt;p&gt;Vacha PFFMBMMHASKREFT. Randomized phase III trial of postoperative radiochemotherapy amifostine in head and neck cancer: Is there evidence for radioprotection? Strahlentherapie und Onkologie 2003+ADs- Vol 179(6): 385-389.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1889&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Valcarcel 2002a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1892&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Valcarcel D, Sanz M, Sureda A, Sala M, Munoz L, Subira M et al. Topically applied recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) for oropharyngeal mucositis (OM) in stem cell transplantation recipients: a randomized double-blind placebo-controlled study. Bone Marrow Transplantation 2002;Suppl 2:S20.&lt;/h4&gt;&lt;p&gt;Valcarcel D, Sanz M, Sureda A, Sala M, Munoz L, Subira M, et al. Topically applied recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) for oropharyngeal mucositis (OM) in stem cell transplantation recipients: a randomized double-blind placebo-controlled study [abstract]. Bone Marrow Transplantation. 2002(Suppl 2):S20.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1894&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Valcarcel 2002b&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1897&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Valcarcel D, Sanz MA Jr, Sureda A, Sala M, Munoz L, Subira M et al. Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study. Bone Marrow Transplantation 2002;29(9):783-7.&lt;/h4&gt;&lt;p&gt;Valcarcel D, Sanz MAJ, Sureda A, Sala M, Munoz L, Subira M, et al. Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study. Bone Marrow Transplantation. 2002 2002; 29(9):783-7.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1899&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Valc&amp;#225;rcel 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1902&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Valc&amp;#225;rcel F, De la Torre A, Arag&amp;#243;n G, Lanz&amp;#243;s E, Rodr&amp;#237;guez R, Veiras C. Double-blind randomized and pilot study on the potential of thymostimulin to reduce the incidence of mucositis in head and neck cancer patients with radical radiotherapy. In: Oncolog&amp;#237;a IX Congreso Nacional de la Asociaci&amp;#243;n Espa&amp;#241;ola de Radioterapia y Oncolog&amp;#237;a. Vol. 20. 1997:161.&lt;/h4&gt;&lt;p&gt;Valc&amp;#225;rcel F, De la Torre A, Arag&amp;#243;n G, Lanz&amp;#243;s E, Rodr&amp;#237;guez R, Veiras C. Double-blind randomized and pilot study on the potential of thymostimulin to reduce the incidence of mucositis in head and neck cancr patients with radical radiotherapy. Oncolog&amp;#237;a IX Congreso Nacional de la Asociaci&amp;#243;n Espa&amp;#241;ola de Radioterapia y Oncolog&amp;#237;a. 1997;20(10 - Congreso):161.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1904&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;van Zaanen 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1907&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;van Zaanen HC, van der Lelie H, Timmer JG, Furst P, Sauerwein HP. Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapy-induced toxicity. Cancer 1994;74(10):2879-84.&lt;/h4&gt;&lt;p&gt;van Zaanen HC vdLH, Timmer JG, Furst P, Sauerwein HP. Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapy-induced toxicity. Cancer 1994;74(10):2879-84.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1909&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Verdi 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1912&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Verdi CJ, Garewal HS, Koenig LM, Vaughn B, Burkhead T. A double-blind, randomized, placebo-controlled, crossover trial of pentoxiflline for the prevention of chemotherapy-induced oral mucositis. Osomopore 1995;80(1):36-42.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1914&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Vesole 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1917&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Vesole D, Fuchs HJ. IB-367 reduces the number of days of severe oral mucositis complicating myeloablative chemotherapy. Blood 1999;94(10 Suppl 1):154 (Abs No 675).&lt;/h4&gt;&lt;p&gt;Vesole DHaF, H. J. IB-367 reduces the number of days of severe oral mucositis complicating myeloablative chemotherapy [abstract]. Blood 1999;94(10 Suppl 1):154a.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1919&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Vitello 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1922&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Vitello M, Cianio SG. A comparison of two mouthrinse agents used during head/neck radiation. Journal of Dental Research 2000;79(Special Issue):215 (Abs No 576).&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1924&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wagner 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1927&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wagner W, Radmard A, Niewohner-Desbordes U, Haus U, Matt J. rhGM-CSF in the treatment of radiotherapy induced mucositis-prospective randomized, double-blind study to investigate the feasibility and effectiveness of rhGM-CSF in patients with head and neck cancer. In: Proceedings of the American Society for Therapeutic Radiology and Oncology Meeting. 2002:311 (Abs No 2175).&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1929&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wang 2002b&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1932&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wang HM, Wang CS, Chen JS, Chen IH, Liao CT, Chang TC. Cisplatin, tegafur, and leucovorin: a moderately effective and minimally toxic outpatient neoadjuvant chemotherapy for locally advanced squamous cell carcinoma of the head and neck. Cancer 2002;94(11):2989-95.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1934&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ward 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1937&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ward E, Smith M, Henderson M, Reid U, Lewis I, Kinsey S, et al. The effect of high-dose enteral glutamine on the incidence and severity of mucositis in paediatric oncology patients. Eur J Clin Nutr 2007.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1940&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Warde 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1943&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Warde P, O'Sullivan B, Aslanidis J, Kroll B, Lockwood G, Waldron J et al. A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. International Journal of Radiation Oncology Biology and Physics 2002;54(1):9-13.&lt;/h4&gt;&lt;p&gt;Warde P, O'Sullivan, B, Aslanidis, J, Kroll, B, Lockwood, G, Waldron, J, Payne, D, Bayley, A, Ringash, J, Kim, J, Liu, F, Maxymiw, W, Sprague, S, and Cummings, B. A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002+ADs-54(1):9-13.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1945&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Weisdorf 1989&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1948&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Weisdorf DJ, Bostrom B, Raether D, Mattingly M, Walker P, Pihlstrom B et al. Oropharyngeal mucositis complicating bone marrow transplantation: prognostic factors and the effect of chlorhexidine mouthrinse. Bone Marrow Transplantation 1989;4(1):89-95.&lt;/h4&gt;&lt;p&gt;Weisdorf DJ, Bostrom B, Raether D, Mattingly M, Walker P, Pihlstrom B et al. Oropharyngeal mucostitis complicating bone marrow transplantation: prognostic factors and the effect of chlorhexidine mouthrinse. Bone Marrow Transplant 1989;4:89-95.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1950&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Weiss 1990&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1953&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Weiss GR, Green S, Hannigan EV, Boutselis JG, Surwit EA, Wallace DL et al. A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial. Gynecologic Oncology 1990;37(3):354-8.&lt;/h4&gt;&lt;p&gt;Weiss GR GS, Hannigan EV, Boutselis JG, Surwit EA, Wallace DL, Alberts DS. A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial. Gynecologic Oncology 1990;37(3):354-8.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1955&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Whelan 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1958&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Whelan HT, Connelly JF, Hodgson BD, Barbeau L, Post AC, Bullard G et al. NASA light-emitting diodes for the prevention of oral mucositis in pediatric bone marrow transplant patients. Journal of Clinical Laser Medicine &amp;amp; Surgery 2002;20(6):319-24.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1960&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Whelan 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1963&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Whelan H. Phase II randomized study of NASA-developed light-emitting diode therapy for the prevention of oral mucositis in children receiving a myeloablative conditioning regimen comprising chemotherapy with or without radiotherapy followed by first allogeneic bone marrow transplantation. http://www.clinicaltrials.gov (accessed 2003).&lt;/h4&gt;&lt;p&gt;Whelan H. Phase II Randomized Study of NASA-Developed Light-Emitting Diode Therapy For the Prevention of Oral Mucositis in Children Receiving a Myeloablative Conditioning Regimen Comprising Chemotherapy With or Without Radiotherapy Followed By First Allogeneic Bone Marrow Transplantation. National Institutes of Health, ClinicalTrials.Gov [http://www.clinicaltrials.gov] 2003.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1965&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wollina 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1968&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wollina U, Christen N, Kostler E, Schorcht J. On prophylaxis and treatment of radiation-induced dermatitis and mucositis. Zeitschrift fur Hautkrankheiten 2002;77(9):418-23.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1970&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wymenga 1999a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1973&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wymenga AN, van der Graaf WT, Hofstra LS, Timens W, Spijkervet FK, Hospers GAP et al. TGF-b3 mouthwashes aimed at prevention of chemotherapy induced mucositis, a phase-I study. Supportive Care in Cancer 1999;7:168.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1975&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wymenga 1999b&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1978&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wymenga AN, van der Graaf WT, Hofstra LS, Spijkervet FK, Timens W, Timmer-Bosscha H et al. Phase I study of transforming growth factor-beta3 mouthwashes for prevention of chemotherapy-induced mucositis. Clinical Cancer Research 1999;5(6):1363-8.&lt;/h4&gt;&lt;p&gt;Wymenga AN, van der Graaf WT, Hofstra LS, Spijkervet FK, Timens W, Timmer-Bosscha H, Sluiter WJ, van Buuren AH, Mulder NH, de Vries EG.Phase I study of transforming growth factor-beta3 mouthwashes for prevention of chemotherapy-induced mucositis. Clin Cancer Res. 1999 Jun;5(6):1363-8.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1980&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Yokomizo 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1983&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Yokomizo H, Yoshimatsu K, Hashimoto M, Ishibashi K, Umehara A, Yoshida K et al. Prophylactic efficacy of allopurinol ice ball for leucovorin/5-fluorouracil therapy-induced stomatitis. Anticancer Research 2004;24(2C):1131-4.&lt;/h4&gt;&lt;p&gt;Yokomizo H, Yoshimatsu K, Hashimoto M, Ishibashi K, Umehara A, Yoshida K, et al. Prophylactic efficacy of allopurinol ice ball for leucovorin/5-fluorouracil therapy-induced stomatitis. Anticancer Research. 2004;24(2C):1131-4.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1985&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zalcberg 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1988&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Zalcberg J, Cunningham D, Rath U, Olver I, Kerr D, van Cutsem E et al. 'Tomudex' (ZD1694) has a higher response rate, significantly less leucopenia and mucositis and a simpler dosing regimen than 5-Fluorouracil (5-FU) and leucovorin (LV) for advanced colorectal cancer (CRC): first results of a phase III study. European Journal of Cancer 1995;31f:S146 (Abs No 701).&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s37&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Studies awaiting classification&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s38&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ongoing studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1990&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Haddad 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1993&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Haddad R, Wirth L, Costello R, Weeks L, Posner M. Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. Seminars in Oncology 2003;30(6 Suppl 18):84-8.&lt;/h4&gt;&lt;p&gt;Haddad R, Wirth L, Costello R, Weeks L, Posner M. Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. Seminars in Oncology 2003; 30(6 Suppl 18):84-8.&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1995&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;National 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s1998&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;National Cancer I. Phase III comparison of oral capsaicin lozenge versus placebo lozenge for radiation-induced mucositis [completed]. ClinicalTrials.gov [accessed 31 Jul 2008] 2008:ClinicalTrials.gov ID: NCT00003610.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2000&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;National 2008a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2003&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;National Cancer I. A phase III study to test the efficacy and safety of GM-CSF to reduce the severity and duration of mucosal Injury and pain (mucositis) associated with curative radiation therapy in head and neck cancer patients [completed]. ClinicalTrials.gov [accessed 31 Jul 2008] 2008:ClinicalTrials.gov ID: NCT00008398.&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s39&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Other references&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s40&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Additional references&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2005&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Andreassen 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2007&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Barasch 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2009&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Begg 1996&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2011&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Bellm 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2013&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chang 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2015&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Clarkson 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2018&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Clarkson 2007a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2021&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Clarkson 2007b&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2024&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;De Pauw 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2026&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Denning 1992&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2028&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Duncan 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2030&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Elbourne 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2032&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gotzsche 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2035&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;J Briggs Inst 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2037&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Kowanko 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2039&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lortholary 1997&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2041&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;McGuire 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2043&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Meunier 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2045&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Moher 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2047&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Rubenstein 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2049&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Savarese 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2051&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sonis 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2053&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Stevens 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2055&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Stokman 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2057&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sunderland 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2059&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Symonds 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2061&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Verdi 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2063&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;White 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2065&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Worthington 2004a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2068&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Worthington 2004b&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2071&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Worthington 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2074&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wright 2003&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s41&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Other published versions of this review&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2076&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Clarkson 2000&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2078&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Clarkson 2003a&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2081&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Worthington 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s42&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;Classification pending references&lt;/h2&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s46&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data and analyses&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2448&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1 Acyclovir versus placebo&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2449&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2452&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2 Allopurinol versus placebo/no treatment&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2453&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2458&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2461&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2464&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.4 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2469&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.5 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2474&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2.6 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2479&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3 Aloe vera versus placebo&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2480&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3.1 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2483&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4 Amifostine versus placebo/no treatment&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2484&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2493&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2505&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2517&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.4 Survival at 24 months&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2520&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.5 Recurrence at 18 months after cancer treatment&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2524&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.6 Incomplete response to radiotherapy&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2528&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.7 Delay to radiotherapy&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2531&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.8 Hypotension&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2537&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.9 Nausea&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2543&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4.10 Vomiting&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2548&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5 Antibiotic pastille or paste versus placebo/no treatment&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2549&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2554&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2558&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2563&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;6 Benzydamine versus placebo&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2564&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;6.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2567&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;6.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2570&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7 Beta carotene versus control&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2571&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7.1 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2574&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;8 Calcium phosphate versus placebo&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2575&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;8.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2578&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;8.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2581&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;8.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2594&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;9 Chewing gum versus no chewing gum&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2595&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;9.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2598&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;9.2 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2584&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;10 Camomile versus placebo&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2585&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;10.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2588&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;10.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2591&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;10.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2601&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;11 Chinese medicine versus control&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2602&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;11.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2606&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;11.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2611&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;11.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2616&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;12 Chlorhexidine versus placebo/no treatment&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2617&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;12.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2624&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;12.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2629&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;12.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2635&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;12.4 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2642&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;12.5 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2647&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;12.6 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2653&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;13 Chlorhexidine versus cryotherapy&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2654&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;13.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2657&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;13.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2660&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;13.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2663&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;14 Cryotherapy versus no treatment&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2664&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;14.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2671&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;14.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2678&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;14.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2685&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;14.4 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2692&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;14.5 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2699&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;14.6 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2706&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;15 Cryotherapy 30 min versus 60 min&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2707&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;15.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2710&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;15.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2713&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;15.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2716&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;16 Etoposide: bolus versus continuous&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2717&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;16.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2720&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;16.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2723&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;16.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2726&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;17 Folinic acid versus no treatment&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2727&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;17.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2730&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;17.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2733&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;17.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2736&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;18 Glutamine versus placebo&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2737&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;18.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2743&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;18.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2750&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;18.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2759&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;18.4 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2765&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;18.5 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2772&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;18.6 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2781&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;19 G-CSF versus no treatment&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2782&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;19.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2787&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;19.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2790&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;19.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2794&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;20 GM-CSF versus no treatment&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2795&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;20.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2799&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;20.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2805&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;20.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2813&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;21 GM-CFS versus sucralfate&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2814&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;21.1 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2817&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;21.2 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2820&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;22 Histamine gel versus placebo&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2821&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;22.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2824&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;22.2 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2827&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;23 Honey versus control&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2828&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;23.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2832&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;23.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2835&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;23.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2839&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;24 Hydrolytic enzymes versus no treatment&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2840&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;24.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2844&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;24.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2848&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;24.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2853&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;25 Indomethacin versus placebo&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2854&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;25.1 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2857&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;26 Iseganan versus placebo&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2858&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;26.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2861&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;26.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2865&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;26.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2869&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;27 Keratinocyte GF versus placebo&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2870&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;27.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2874&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;27.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2882&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;27.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2889&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;28 Keratinocyte: 50 mg versus 25 mg&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2890&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;28.1 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2893&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;28.2 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2896&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;29 Laser versus no treatment&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2897&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;29.2 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2902&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;29.3 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2907&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;29.4 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2912&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;30 Laser versus povidine&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2913&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;30.1 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2916&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;30.2 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2919&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;31 Misonidazole versus control&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2920&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;31.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2923&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;31.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2926&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;31.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2929&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;31.4 New Outcome&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2931&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;32 Oral care protocol versus none&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2932&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;32.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2935&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;32.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2939&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;32.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2943&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;33 Pentoxifylline versus no treatment&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2944&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;33.1 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2947&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;34 Pilocarpine versus placebo&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2948&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;34.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2952&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;34.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2956&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;34.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2959&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;35 Povidone versus water&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2960&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;35.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2964&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;35.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2968&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;35.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2972&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;36 Prednisone versus placebo&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2973&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;36.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2976&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;36.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2979&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;36.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2982&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;37 Propantheline anticholinergic versus placebo&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2983&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;37.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2986&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;38 Prostaglandin versus placebo&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2987&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;38.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2992&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;38.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s2995&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;38.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3000&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;39 Radiotherapy: am versus pm&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3001&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;39.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3004&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;40 Sucralfate versus placebo&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3005&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;40.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3010&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;40.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3016&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;40.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3026&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;40.4 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3031&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;40.5 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3036&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;40.6 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3041&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;41 Systemic antibiotic clarithromycin versus no treatment&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3042&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;41.1 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3045&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;42 Traumeel versus placebo&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3046&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;42.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3049&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;43 Zinc sulphate versus placebo&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3050&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;43.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3053&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;43.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3056&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;43.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3059&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44 Active treatment versus placebo/no treatment&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3060&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3061&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1.1 Aclyclovir versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3063&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1.2 Allopurinol versus placebo/no treatment&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3066&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1.3 Amifostine versus no treatment&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3072&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1.4 Antibiotic (pastille or paste) versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3076&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1.5 Benzydamine versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3078&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1.6 Chinese medicine versus control (Dobell's solution)&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3080&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1.7 Calcium phosphate versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3082&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1.8 Camomile versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3084&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1.9 Chlorhexidine versus placebo or no treatment&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3089&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1.10 Folinic acid versus no treatment&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3091&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1.11 Glutamine versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3095&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1.12 GM-CSF versus no treatment&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3099&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1.13 Histamine gel versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3101&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1.14 Honey versus control&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3103&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1.15 Hydrolytic enzymes versus no treatment&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3106&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1.16 Ice chips versus no treatment&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3110&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1.17 Iseganan versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3112&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1.18 Misonidazole versus control&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3114&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1.19 Oral care protocol versus none&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3116&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1.20 Pilocarpine versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3119&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1.21 Povidone versus water&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3122&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1.22 Prednisone versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3124&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1.23 Propantheline versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3126&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1.24 Prostaglandin versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3129&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1.25 Sucralfate versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3132&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1.26 Traumeel versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3134&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1.27 Zinc sulphate versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3136&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.1.28 Palifermin versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3139&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3140&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.2.1 Aloe vera versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3142&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.2.2 Amifostine versus placebo or no treatment&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3151&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.2.3 Antibiotic pastille or paste versus placebo or no treatment&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3154&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.2.4 Calcium phosphate versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3156&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.2.5 Camomile versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3158&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.2.6 Chinese medicine versus control (Dobell's solution)&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3161&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.2.7 Chlorhexidine versus placebo or no treatment&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3164&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.2.8 Folinic acid versus no treatment&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3166&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.2.9 Glutamine versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3171&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.2.10 GM-CSF versus no treatment&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3175&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.2.11 Hydrolic enzymes versus no treatment&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3178&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.2.12 Ice chips versus no treatment&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3182&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.2.13 Indomethacin versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3184&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.2.14 Iseganan versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3187&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.2.15 Keratinocyte GF versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3191&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.2.16 Misonidazole versus control&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3193&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.2.17 Oral care protocol versus none&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3196&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.2.18 Pentoxifylline versus no treatment&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3198&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.2.19 Pilocarpine versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3201&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.2.20 Povidone versus water&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3204&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.2.21 Prednisone versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3206&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.2.22 Sucralfate versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3210&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.2.23 Systemic antibiotic clarithromycin versus no treatment&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3212&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.2.24 Zinc sulphate versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3214&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3215&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.3.1 Amifostine versus no treatment&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3226&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.3.2 Antibiotic pastille or paste versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3230&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.3.3 Beta carotene versus control&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3232&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.3.4 Calcium phosphate versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3234&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.3.5 Camomile versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3236&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.3.6 Chinese medicine versus control (Dobell's solution)&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3239&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.3.7 Chlorhexidine versus placebo or no treatment&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3243&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.3.8 Folinic acid versus no treatment&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3245&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.3.9 Glutamine versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3251&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.3.10 GM-CSF versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3258&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.3.11 Histamine gel versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3260&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.3.12 Honey versus control&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3262&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.3.13 Hydrolytic enzymes versus no treatment&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3265&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.3.14 Ice chips versus no treatment&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3269&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.3.15 Iseganan versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3272&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.3.16 Keratinocyte GF versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3275&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.3.17 Misonidazole versus control&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3277&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.3.18 Oral care protocol versus none&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3280&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.3.19 Pilocarpine versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3282&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.3.20 Povidone versus water&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3285&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.3.21 Prednisone versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3287&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.3.22 Prostaglandin versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3290&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.3.23 Sucralfate versus placebo&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3297&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;44.3.24 Zinc sulphate&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3299&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;45 Comparisons between active interventions&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3300&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;45.1 Mucositis (absent versus present)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3301&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;45.1.1 Cryotherapy: 30 min versus 60 min&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3303&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;45.1.2 Etoposide: bolus versus continuous&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3305&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;45.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3306&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;45.2.1 Cryotherapy: 30 min versus 60 min&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3308&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;45.2.2 Etoposide: bolus versus continuous&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3310&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;45.2.3 GM-CFS versus sucralfate&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3312&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;45.2.4 Keratinocyte: 50 mg versus 25 mg&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3314&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;45.3 Mucositis (0-2 versus 3+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3315&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;45.3.1 Cryotherapy: 30 min versus 60 min&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3317&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;45.3.2 Etoposide: bolus versus continuous&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3319&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;45.3.3 GM-CSF versus sucralfate&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3321&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;45.3.4 Keratinocyte: 50 mg versus 25 mg&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3323&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;46 Side effects&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3324&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;46.1 Amifostine&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3325&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;46.1.1 Survival at 24 months&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3327&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;46.1.2 Recurrence at 18 months after cancer treatment&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3330&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;46.1.3 Incomplete response to radiotherapy&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3333&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;46.1.4 Delay to radiotherapy&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3335&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;46.1.5 Hypotension&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3340&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;46.1.6 Nausea&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3345&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;46.1.7 Vomiting&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3349&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;47 Epidermal GF&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3350&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;47.2 Mucositis (0-1 versus 2+)&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s43&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Figures&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3475&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Figure 1 (Analysis 26.1)&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3476&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Figure 2 (Analysis 27.1)&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3477&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Figure 3 (Analysis 27.2)&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3478&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Figure 4 (Analysis 27.3)&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3479&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Figure 5 (Analysis 1.1)&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s12&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Sources of support&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s13&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Internal sources&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s61&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;The University of Manchester, UK&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s62&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chief Scientists Office, Scottish Executive, UK&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s63&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;NHS Education for Scotland, UK&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s64&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;University of Dundee, UK&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s14&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;External sources&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s65&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;NIDCR grant ref 1 DE016950-01, USA&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s44&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Feedback&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s17&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendices&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3480&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;1 Cochrane Oral Health Group Trials Register search strategy&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f22055&quot;&gt;&lt;span coll_flag=&quot;f22055&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix title&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f22057&quot;&gt;&lt;span coll_flag=&quot;f22057&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix text&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3481&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;2 CENTRAL search strategy&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f22060&quot;&gt;&lt;span coll_flag=&quot;f22060&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix title&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f22062&quot;&gt;&lt;span coll_flag=&quot;f22062&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix text&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3482&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;3 MEDLINE via OVID search strategy&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f22065&quot;&gt;&lt;span coll_flag=&quot;f22065&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix title&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f22067&quot;&gt;&lt;span coll_flag=&quot;f22067&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix text&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3483&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;4 EMBASE SS via OVID search strategy&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f22070&quot;&gt;&lt;span coll_flag=&quot;f22070&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix title&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f22072&quot;&gt;&lt;span coll_flag=&quot;f22072&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix text&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3484&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;5 CANCERLIT search strategy&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f22075&quot;&gt;&lt;span coll_flag=&quot;f22075&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix title&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f22077&quot;&gt;&lt;span coll_flag=&quot;f22077&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix text&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3485&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;6 SIGLE search strategy&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f22080&quot;&gt;&lt;span coll_flag=&quot;f22080&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix title&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f22082&quot;&gt;&lt;span coll_flag=&quot;f22082&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix text&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3486&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;7 LILACS search strategy&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f22085&quot;&gt;&lt;span coll_flag=&quot;f22085&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix title&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f22087&quot;&gt;&lt;span coll_flag=&quot;f22087&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix text&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 readonly=&quot;true&quot; class=&quot;fixedtext&quot;&gt;&lt;span coll_flag=&quot;s3487&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;8 CINAHL via EBSCO search strategy&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f22090&quot;&gt;&lt;span coll_flag=&quot;f22090&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix title&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 readonly=&quot;true&quot; class=&quot;fixedtext&quot; id=&quot;f22092&quot;&gt;&lt;span coll_flag=&quot;f22092&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Appendix text&lt;/h3&gt;&lt;p&gt;Makkonen TA, Minn H, Jekunen A, Vilja P, Tuominen J, Joeensuu H. Granulocyte Macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: A prospective randomized study. International Journal of Radiation Oncology, Biology and Physics 2000;46(3):525-34. McAleese 2006 McAleese JJ, Bishop KM, A'Hern R, Henk JM. Randomized phase II study of GM-CSF to reduce mucositis caused by accelerated radiotherapy of laryngeal cancer. British Journal of Radiology 2006;79(943):608-13. Meropol 2003 Meropol NJ, Somer RA, Gutheil J, Pelley RJ, Modiano MR, Rowinsky EK et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. Journal of Clinical Oncology 2003;21(8):1452-8.Meropol NJ, Somer RA, Gutheil J, Pelley RJ, Modiano MR, Rowinsky EK, et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant.+AFs-comment+AF0-. Journal of Clinical Oncology 2003+ADs- 21(8):1452-8. Mills 1988 Mills EE. The modifying effect of beta-carotene on radiation and chemotherapy induced oral mucositis. British Journal of Cancer 1988;57(4):416-7. Motallebnejad 2008 Motallebnejad M, Akram S, Moghadamnia A, Moulana Z, Omidi S. The effect of topical application of pure honey on radiation-induced mucositis: a randomized clinical trial. Journal of Contemporary Dental Practice [Electronic Resource] 2008;9(3):40-7. Naidu 2005 Naidu MU, Ramana GV, Ratnam SV, Sudhavani T, Naidu KJ, Roy P et al. A randomised, double-blind, parallel, placebo-controlled study to evaluate the efficacy of MF 5232 (Mucotrol), a concentrated oral gel wafer, in the treatment of oral mucositis. Drugs in R&amp;amp;D 2005;6(5):291-8. Nemunaitis 1995 Nemunaitis J, Rosenfeld CS, Ash R, Freedman MH, Deeg HJ, Appelbaum F et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplantation 1995;15(6):949-54. Niibe 1985 Niibe H, Takahashi I, Mitsuhashi N, Miyaishi K, Itoh J, Maehara Y et al. An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study.1. Head and neck tumors. Nippon-gan-chiryo-gakkai-shi 1985;20(5):984-93. Nottage 2003 Nottage M, McLachlan SA, Brittain MA, Oza A, Hedley D, Feld R, et al. Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial. Supportive Care in Cancer 2003;11(1):41-7.Nottage M, McLachlan SA, Brittain MA, Oza A, Hedley D, Feld R, et al. Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial. Supportive Care in Cancer 2003+ADs- 11(1):41-7. Oberbaum 2001 Oberbaum M, Yaniv I, Ben-Gal Y, Stein J, Ben-Zvi N, Freedman LS et al. A randomized, controlled clinical trial of the homeopathic medication TRAUMEEL S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation. American Cancer Society 2001;92(3):684-90. Oberbaum M, Yaniv I, Ben-Gal Y, Stein J, Ben-Zvi N, Freedman LS et al. A randomized, controlled clinical trial of the homoeopathic medication Traumeel S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation. Biologische Medizin 2002;31(1):25-31.Oberbaum MYIB-GYSJZNFLBD. A randomized, controlled clinical trial of the homoeopathic medication Traumeel S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation. Biologische Medizin 2002+ADs- Vol 31(1): 25-31. Oberbaum MY. Randomized, controlled study to prove the effectiveness of traumeel (R)s in the management of chemotherapy-induced stomatitis in children and young adults undergoing bone-marrow transplantation. Biol Medizin 2002;31(1):26-31. Okuno 1999 Okuno SH, Woodhouse CO, Loprinzi CL, Sloan JA, LaVasseur BI, Clemens-Schutjer D et al. Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy. American Journal of Clinical Oncology 1999;22(3):258-61. Papas 2003Reconsider inclusion as patients received active mouthwash + active Fl plate versus placebo (Fl) mouthwash and placebo plate. Papas AS, Clark RE, Martuscelli G, O'Loughlin KT, Johansen E, Miller KB. A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplantation 2003;31(8):705-12.Papas AS, Clark RE, Martuscelli G, O'Loughlin KT, Johansen E, Miller KB. A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplantation 2003+ADs- 31(8):705-12. Peterson 2007 Peterson DE, Jones JB, Petit RG. Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer 2007;109(2):322-31. Pfeiffer 1990 Pfeiffer P, Madsen EL, Hansen O, May O. Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy. Acta Oncologica 1990;29(2):171-3. Pillsbury 1986 Pillsbury HC 3rd, Webster WP, Rosenman J. Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers. Archives of Otolaryngology - Head &amp;amp; Neck Surgery 1986;112(5):552-3.Pillsbury HC 3rd WW, Rosenman J. Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers. Archives of Otolaryngology -- Head &amp;amp; Neck Surgery 1986;112(5):552-3. Pitten 2003 Pitten FA, Kiefer T, Buth C, Doelken G, Kramer A. Do cancer patients with chemotherapy-induced leukopenia benefit from an antiseptic chlorhexidine-based oral rinse? A double-blind, block-randomized, controlled study. Journal of Hospital Infection 2003;53(4):283-91.Pitten FA, Kiefer T, Buth C, Doelken G, Kramer A. Do cancer patients with chemotherapy-induced leukopenia benefit from an antiseptic chlorhexidine-based oral rinse? A double-blind, block-randomized, controlled study. Journal of Hospital Infection 2003+ADs- 53(4):283-91. Prada 1987 Prada A, Chiesa F. Effects of benzydamine on the oral mucositis during antineoplastic radiotherapy and/or intra-arterial chemotherapy. International Journal of Tissue Reaction 1987;9(2):115-9. Rahn 1997 Adamietz IA, Rahn R, Bottcher HD, Schafer V, Reimer K, Fleischer W. Prophylaxis of radiochemotherapy-induced mucositis. Efficacy of prophylactic oral rinsing with povidone iodine solution [Pophylaxe der radiochemotherapeutisch bedingten mukositis]. Stranhlentherapie und Onkologie 1998;174(3):149-55. Adamietz IA, Rhan R, Bottcher HD, Schafer V, Reimer K, Fleischer W. Prophylaxis with povidone-iodine against induction of oral mucositis by radiochemotherapy. Supportive Care in Cancer 1998;6(4):373-7. Rahn R AI, Bottcher HD, Reimer K, and Fleischer W. PVP-iodine solution as a mucositis prophylaxis by radiotherapy. Deutsche Zeitschrift fur Mund-, Kiefer- und Gesichtschirurgie 1996;20(3):137-9. Rahn R, Adamietz IA, Boettcher HD, Schaefer V, Reimer K, Fleischer W. Povidone-iodine to prevent mucositis in patients during antineoplastic radiochemotherapy. Dermatology 1997;195(Suppl 2):57-61. Rashad 2008 Rashad UM, Al-Gezawy SM, El-Gezawy E, Azzaz AN. Honey as topical prophylaxis against radiochemotherapy-induced mucositis in head and neck cancer. Journal of Laryngology &amp;amp; Otology 2009;123(2):223-8. Rocke 1993 Rocke LK, Loprinzi CL, Lee JK, Kunselman SJ, Iverson RK, Finck G et al. A randomized clinical trial of two different durations or oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. Cancer 1993;72(7):2234-8. Rosen 2006 Rosen LS, Abdi E, Davis ID, Gutheil J, Schnell FM, Zalcberg J, et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.[see comment]. Journal of Clinical Oncology 2006;24(33):5194-200. Rothwell 1990 Rothwell BR. Palliation of radiation-related mucositis. Special Care in Dentistry 1990:21-25. Saarilahti 2002 Saarilahti K, Kajanti M, Joensuu T, Kouri M, Joensuu H. Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized phase III study. International Journal of Radiation Oncology Biology and Physics 2002;54(2):479-85.Saarilahti K KM, Joensuu T, Kouri M, Joensuu H. Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized phase III study. International Journal of Radiation Oncology, Biology, Physics 2002+ADs-54(2):479-85. Scarantino 2006 Scarantino C, LeVeque F, Swann RS, White R, Schulsinger A, Hodson DI et al. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients. The Journal of Supportive Oncology 2006;4(5):252-8.Scarantino C, LeVeque F, Swann RS, White R, Schulsinger A, Hodson DI, et al. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients. The Journal of Supportive Oncology. 2006;4(5):252-8. Scherlacher 1990 Scherlacher A, Beaufort-Spontin F. [Radiotherapy of head-neck neoplasms: prevention of inflammation of the mucosa by sucralfate treatment]. [German]. HNO 1990;38(1):24-8.Scherlacher A B-SF. [Radiotherapy of head-neck neoplasms: prevention of inflammation of the mucosa by sucralfate treatment]. [German]. HNO 1990;38(1):24-8. Schneider 1999 Schneider SB, Nishimura RD, Zimmerman RP, Tran L, Shiplacoff J, Tormey M et al. Filgrastim (r-metHuG-CSF) and its potential use in the reduction of radiation-induced oropharyngeal mucositis: An interim look at a randomized, double blind, placebo-controlled trial. Cytokines, Cellular and Molecular Therapy 1999;5(3):175-80. Schubert 2007 Schubert MM, Eduardo FP, Guthrie KA, Franquin JC, Bensadoun RJ, Migliorati CA, et al. A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Supportive Care in Cancer 2007;15(10):1145-54. Shenep 1988 Shenep JL, Kalwinsky DK, Hutson PR, George SL, Dodge RK, Blankenship KR et al. Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositis. Journal of Pediatrics 1988;113(4):758-63.Shenep JL, Kalwinsky DK, Hutson PR, George SL, Dodge RK, Blankenship KR et al. Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositis. J Pediatr 1988;113:758-63.[published erratum appears in J Paediatr 1989 May; 114(5):900] Shieh 1997 Shieh SH, Wang ST, Tsai ST, Tseng CC. Mouth care for nasopharyngeal cancer patients undergoing radiotherapy. Oral Oncology 1997;33(1):36-41. Sorensen 2008 Sorensen J, Skovsgaard T, Bork E, Damstrup L, Ingeberg S. Double blind, placebo-controlled randomized study of chlorhexidine prophylaxis for chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) [abstract] 2001. Journal of Clinical Oncology : ASCO annual meeting proceedings 2006;24(18S Part I):470. Sorensen JB, Skovsgaard T, Bork E, Damstrup L, Ingeberg S. Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies. Cancer 2008;112(7):1600-6. Sornsuvit 2008 Sornsuvit C, Komindr S, Chuncharunee S, Wanikiat P, Archararit N, Santanirand P. Pilot Study: effects of parenteral glutamine dipeptide supplementation on neutrophil functions and prevention of chemotherapy-induced side-effects in acute myeloid leukaemia patients. Journal of International Medical Research 2008;36(6):1383-91. Spencer 2005 Spencer A, Horvath N, Gibson J, Prince HM, Herrmann R, Bashford J et al. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplantation 2005;35(10):971-7.Spencer A, Horvath N, Gibson J, Prince HM, Herrmann R, Bashford J, et al. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplantation. 2005;35(10):971-7. Spielberger 2004 Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. The New England Journal of Medicine 2004;351(25):2590-8. Spijkervet 1989 Spijkervet FKL, van Saene HK, Panders AK, Vermey A, van Saene JJ, Mehta DM et al. Effects of chlorhexidine rinsing on the oropharyngeal ecology in patients with head and neck cancer who have irradiation mucositis. Oral Surgery, Oral Medicine, Oral Pathology 1989;67(2):154-61. Stokman 2003 Stokman MA, Spijkervet FK, Burlage FR, Dijkstra PU, Manson WL, de Vries EG et al. Oral mucositis and selective elimination of oral flora in head and neck cancer patients receiving radiotherapy: a double-blind randomised clinical trial. British Journal of Cancer 2003;88(7):1012-6. Su 2003 Su C, Mehta V, Ravikumar L, Shah R, Pinto H, Halpern J et al. Phase II double-blind randomized study comparing oral aloe vera (AV) versus placebo to prevent radiation (RT)-related mucositis in patients with head and neck (HN) neoplasms. International Journal of Radiation, Oncology, Biology and Physics 2004;60(1 Sept):171-7.Su C, Mehta, V, Ravikumar, L, Shah, R, Pinto, H, Halpern, J, Koong, A, Goffinet, D, and Le, Q-T. Phase II double-blind randomized study comparing oral aloe vera (AV) versus placebo to prevent radiation (RT)-related mucositis in patients with head and neck (HN) neoplasms. Proceedings of ASCO 2003. Su 2006 Su YB, Vickers AJ, Zelefsky MJ, Kraus DH, Shaha AR, Shah JP, et al. Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor during postoperative radiotherapy for squamous head and neck cancer.[see comment]. Cancer Journal 2006;12(3):182-8. Symonds 1996 Symonds RP, McIlroy P, Khorrami J, Pyper E, Alcock SR, McCallum I et al. The reduction of radiation mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial. British Journal of Cancer 1996;74(2):312-7. Trotti 2004 Trotti A, Garden A, Warde P, Symonds P, Langer C, Redman R et al. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. International Journal of Radiation Oncology, Biology and Physics 2004;58(3):674-81.Trotti A, Garden A, Warde P, Symonds P, Langer C, Redman R, et al. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. International Journal of Radiation Oncology, Biology, Physics 2004; 58(3):674-81. Trotti A, Garden AS, Warde P, Symonds P, Langer C, Fleming T et al. Phase III trial of iseganan HCL oral solution (iseganan) for reducing oral mucositis severity in patients receiving radiotherapy for head and neck malignancies (PROMPT-RT). In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 2002:(Abs No 908). van der Lelie 2001 van der Lelie H, Thomas BL, van Oers RH, Ek-Post M, Sjamsoedin SA, van Dijk-Overtoom ML et al. Effect of locally applied GM-CSF on oral mucositis after stem cell transplantation: a prospective placebo-controlled double-blind study. Annals of Hematology 2001;80(3):150-4. Veerasarn 2006 Veerasarn V, Phromratanapongse P, Suntornpong N, Lorvidhaya V, Sukthomya V, Chitapanarux I, et al. Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand 2006;89(12):2056-67. Veness 2006 Veness MJ, Foroudi F, Gebski V, Timms I, Sathiyaseelan Y, Cakir B, et al. Use of topical misoprostol to reduce radiation-induced mucositis: results of a randomized, double-blind, placebo-controlled trial. Australasian Radiology 2006;50(5):468-74. Vokurka 2005 Vokurka S, Bystricka E, Koza V, Scudlova J, Pavlicova V, Valentova D, et al. The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT--results of a randomized multicentre study. Supportive Care in Cancer 2005;13(7):554-8.Vokurka S, Bystricka E, Koza V, Scudlova J, Pavlicova V, Valentova D, et al. The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT--results of a randomized multicentre study. Supportive Care in Cancer. 2005;13(7):554-8. Wahlin 1989 Wahlin YB. Effects of chlorhexidine mouthrinse on the oral health in patients with acute leukemia. Oral Surgery, Oral Medicine, Oral Pathology 1989;68(3):279-87.Wahlin YD. Effects of chlorhexidine mouth rinse on the oral health in patients with acute leukemia. Oral Surg Oral Med Oral Path 1989;68:279-87. Wang 2002a Wang J. Effect on Chinese herbs decoction gargling to treat and to prevent chemotherapy caused stomatitis. Chinese Nursing Research 2002;16(10):578-9. Wijers 2001 Wijers OB, Levendag PC, Harms ER, Gan-Teng AM, Schmitz PI, Hendriks WD et al. Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: A placebo-controlled double-blind randomized study. International Journal of Radiation Oncology, Biology and Physics 2001;50(2):343-52. Wu 2009 Wu PA, Kim YH, Lavori PW, Hoppe RT, Stockerl-Goldstein KE. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome. Biology of Blood &amp;amp; Marrow Transplantation 2009;15(8):982-90. You 2009 You WC, Hsieh CC, Huang JT. Effect of extracts from indigowood root (Isatis indigotica Fort.) on immune responses in radiation-induced mucositis. Journal of Alternative &amp;amp; Complementary Medicine 2009;15(7):771-8. Yuen 2001 Yuen KY, Woo PCY, Tai JW, Lie AK, Luk J, Liang R. Effects of clarithromycin on oral mucositis in bone marrow transplant recipients. Haematologica 2001;86(5):554-5. Excluded studies Abramoff 2008 Abramoff MM, Lopes NN, Lopes LA, Dib LL, Guilherme A, Caran EM, et al. Low-level laser therapy in the prevention and treatment of chemotherapy-induced oral mucositis in young patients. Photomed Laser Surg 2008;26(4):393-400. Adamietz 1997 Adamietz IA, Rahn R, Bottcher HD, Reimer K, Fleischer W. Prophylaxis of radiation induced oral mucositis with povidone iodine. Supportive Care in Cancer 1997;5 Suppl:165 (Abs No 48).Adamietz IA, Rahn R, Bottcher HD, Reimer K, Fleischer W. Prophylaxis of radiation induced oral mucositis with povidone iodine. Supportive Care in Cancer. 1997;5 Suppl(Abstr 48):165. Ahn 2008 Ahn YWH, Song S, Kim Y, Oh Y, Lee C, and, et al. The therapeutic effect of recombinant human epidermal growth factor (rhEGF) on mucositis in patients with head and neck cancer undergoing radiotherapy with or without chemotherapy: a double-blind placebo-controlled prospective phase II multi-institutional study. J Clin Oncol 2008;26(suppl):Abstract no: 6021. Aisa 2005 Aisa Y, Mori T, Kudo M, Yashima T, Kondo S, Yokoyama A et al. Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients.. Supportive Care in Cancer 2005;13(4):266-9. Altmann 1999 Altmann S Hoffmanns H. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors]. [German]. Strahlentherapie und Onkologie 1999;175(Suppl 4):30-3.Altmann S HH. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors]. [German]. Strahlentherapie und Onkologie 1999;175(Suppl 4):30-3. Andersen 1987 Andersen E, Pedersen H. Oral ftorafur versus intravenous 5-fluorouracil. A comparative study in patients with colorectal cancer. Acta Oncologica 1987;26(6):433-6.Andersen E PH. Oral ftorafur versus intravenous 5-fluorouracil. A comparative study in patients with colorectal cancer. Acta Oncologica 1987;26(6):433-6. Anderson 1998b Anderson PM, Ramsay NKC, Shu XO, Rydholm N, Rogosheske J, Nicklow R et al. Effect of low dose oral glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplantation 1998;22(4):339-44. Antin 2002 Antin JH, Lee SJ, Neuberg D, Alyea E, Soiffer RJ, Sonis S, et al. A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplantation 2002;29(5):373-7.Antin JH, Lee SJ, Neuberg D, Alyea E, Soiffer RJ, Sonis S, et al. A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplantation 2002; 29(5):373-7. Antonadou 1998 Antonadou D, Athanassiou E, Synodinou M, Koliarakis N, Panoussaki K, Karageorgis P et al. Evaluation of the efficacy of granulocyte macrophage colony stimulating factor (GM-CSF) in the prevention of radiation induced mucositis [abstract]. Radiotherapy Oncology 1998;48(S1):S39. Apaydin 1996 Apaydin A, Karadeniz AN, Aysigi G, Blige N. The effect and therapeutical use of benzydamine HCL on radiation-induced oral cavity and oropharyngeal mucositis. Medical Bulletin Istanbul 1996;29:1:59-63. Aquino 2005 Aquino VM, Harvey AR, Garvin JH, Godder KT, Nieder ML, Adams RH et al. A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplantation 2005;36(7):611-6.Aquino VM, Harvey AR, Garvin JH, Godder KT, Nieder ML, Adams RH, et al. A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplantation. 2005;36(7):611-6. Ardizzoni 2002 Ardizzoni A, Tjan-Heijnen VC, Postmus PE, Buchholz E, Biesma B, Karnicka-Mlodkowska H, et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. Journal of Clinical Oncology 2002;20(19):3947-55.Ardizzoni A, Tjan-Heijnen VC, Postmus PE, Buchholz E, Biesma B, Karnicka-Mlodkowska H, et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.+AFs-comment+AF0-. Arora 2008 Arora H, Pai KM, Maiya A, Vidyasagar MS, Rajeev A. Efficacy of He-Ne Laser in the prevention and treatment of radiotherapy-induced oral mucositis in oral cancer patients. Oral Surgery Oral Medicine Oral Pathology Oral Radiology &amp;amp; Endodontics 2008;186.e1, 105(2):180-6. Awada 2002 Awada A, Biganzoli L, Cufer T, Beex L, Lohrisch C, Batter V, et al. An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes. European Journal of Cancer 2002;38(6):773-8.Awada A, Biganzoli L, Cufer T, Beex L, Lohrisch C, Batter V, et al. An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes.2002+ADs- 38(6):773-8. Awada 2004 Awada A, Gil T, Sales F, Dubuisson M, Vereecken P, Klastersky J et al. Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers. Anti-Cancer Drugs 2004;15(5):499-502.Awada A, Gil T, Sales F, Dubuisson M, Vereecken P, Klastersky J, et al. Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers. Anti-Cancer Drugs. 2004;15(5):499-502. Awidi 2001 Awidi A, Homsi U, Kakail RI, Mubarak A, Hassan A, Kelta M, Martinez P et al. Double-blind, placebo-controlled cross-over study of oral pilocarpine for the prevention of chemotherapy-induced oral mucositis in adult patients with cancer. European Journal of Cancer 2001;37(16):2010-4.Awidi A HU, Kakail RI, Mubarak A, Hassan A, Kelta M, Martinez P, Sulaiti S, Al Qady A, Jamhoury A, Daniel M, Charles C, Ambrose A, El-Aloosy AS. Double-blind, placebo-controlled cross-over study of oral pilocarpine for the prevention of chemotherapy-induced oral mucositis in adult patients with cancer. +AFs-see comments.+AF0-. Awwad 2002 Awwad HK, Lotayef M, Shouman T, Begg AC, Wilson G, Bentzen SM et al. Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cnacer: influence of proliferation. British Journal of Cancer 2002;86(4):517-23. Barasch 1995 Barasch A, Peterson DE, Tanzer JM, D'Ambrososio JA, Nuki K, Schubert MM et al. Helium-Neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer 1995;76(12):2550-6. Baydar 2005 Baydar M, Dikilitas M, Sevinc A, Aydogdu I. Prevention of oral mucositis due to 5-fluorouracil treatment with oral cryotherapy. Journal of the National Medical Association 2005;97(8):1161-4. Bensadoun 1995 Bensadoun R, Cowen D, Nguyen TD, Ciais G, Franquin JC, Dassonville O et al. Low energy laser in the prevention of radiation-induced mucositis: A phase III randomized multicentric study in patients with head and neck cancer. In: Fifth International Congress on Anti-Cancer Chemotherapy. 1995.Bensadoun R, Cowen, D, Nguyen, TD, Ciais, G, Franquin, JC, Dassonville, O, Laudoyer, Y, Chauvel, P, Demard, F, and Zattara, H. Low energy laser in the prevention of radiation-induced mucositis: A phase III randomized multicentric study in patients with head and neck cancer. Fifth International Congress on Anti-Cancer Chemotherapy. 1995 1995. Bensadoun 1999 Bensadoun R, Franquin J, Benezery K, Ciais G, Tardieu C, Dejou J et al. Low energy He/Ne laser in the prevention of radiation induced mucositis: A multicenter phase III double blind study for patients with head and neck cancer. In: Proceedings of ASCO. 1999. Bensadoun RJ, Ciais G, Darcourt V, Franquin JC, Cheynet C, Cowen D et al. Low energy laser in the prevention of radiation induced mucositis: a phase II randomized multicentre study for patients with head and neck cancer. Supportive Care in Cancer 1999;7:SO-13. Bensadoun RJ, Franquin JC, Ciais G, Darcourt V, Schubert MM, Viot M et al. Low-energy He/Ne laser in the prevention of radiation-induced mucositis. A multicentre phase III randomized study in patients with head and neck cancer. Supportive Care in Cancer 1999;7(4):244-52. Bensadoun 2006 Bensadoun RJ, Benezery K, Dassonville O, Magne N, Poissonnet G, Ramaioli A et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). International Journal of Radiation Oncology, Biology, Physics 2006;64(4):983-94.Bensadoun RJ, Benezery K, Dassonville O, Magne N, Poissonnet G, Ramaioli A, et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). International Journal of Radiation Oncology, Biology, Physics. 2006;64(4):983-94. Bentzen 2001 Bentzen SM, Saunders MI, Dische S, Bond SJ. Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial. Radiotherapy Oncology 2001;60(2):123-35. Bergmann 1995 Bergmann OJ, Ellermann-Eriksen S, Mogensen SC, Ellegaard J. Acyclovir given as prophylaxis against oral ulcers in acute myeloid leukaemia: randomised, double blind, placebo controlled trial. BMJ 1995;6(310):116-72. Bleehen 1996 Bleehen NM, Girling DJ, Hopwood P, Lallemand G, Machin D, Stephens RJ et al. Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. British Journal of Cancer 1996;73:406-13.Bleehen NM, Girling DJ, Hopwood P, Lallemand G, Machin D, Stephens RJ, Bailey AJ. Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. British Journal of Cancer 1996 73 406-413. Bolwell 2004 Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplantation 2004;34(7):621-5.Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplantation. 2004;34(7):621-5. Bourhis 2006 Bourhis J, Lapeyre M, Tortochaux J, Rives M, Aghili M, Bourdin S et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. Journal of Clinical Oncology 2006;24(18):2873-8.Bourhis J, Lapeyre M, Tortochaux J, Rives M, Aghili M, Bourdin S, et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. Journal of Clinical Oncology. 2006;24(18):2873-8. Braaksma 2002 Braaksma M, Levendag P. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation. Seminars in Oncology 2002;29(6 Supp 19):63-70.Braaksma M, Levendag P. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation. Seminars in Oncology 2002+ADs- 29(6 Suppl 19):63-70. Buentzel 1999 Buentzel J, Glatzel M, Weinaug R, Schuth J, Kuettner K, Froehlich D. Amifostine in combined radio- and chemomodalities for head and neck cancer. European Journal of Cancer 1999;35(Suppl 4):363 (Abs No 1472).Buentzel J, Glatzel M, Weinaug R, Schuth J, Kuettner K, Froehlich D. Amifostine in combined radio- and chemomodalities for head and neck cancer. European Journal of Cancer. 1999;35(Suppl 4):363 Abstract #1472. Calais 1998 Calais GM, Alfonsi E, Bardet C, Sire H, Bourgeois C, Bergerot B et al. Randomized study comparing radiation alone (RT) versus RT with concomitant chemotherapy (CT) in stages III andf IV oropharynx carcinoma (ARCORO). Preliminary results of the 94.01 study from the French Group of radiation oncology for head and neck cancer (GORTEC). In: Proceedings of Annual Meeting of the American Society of Clinical Oncology. 1998:(Abs No 1484).Calais GM, Alfonsi E, Bardet C, Sire H, Bourgeois C, Bergerot B, et al. Randomized study comparing radiation alone (RT) versus RT with concomitant chemotherapy (CT) in stages III andf IV oropharynx carcinoma (ARCORO). Preliminary results of the 94.01 study from the French Group of radiation oncology for head and neck cancer (GORTEC). Proc-Annu-Meet-Am-Soc-Clin-Oncol. 1998:Abstract # 1484. Calais 2000 Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P et al. [Stage III and IV cancers of the oropharynx: results of a randomized study of Gortec comparing radiotherapy alone with concomitant chemotherapy]. Bulletin du Cancer 2000;87 Spec No:48-53.Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, et al. [Stage III and IV cancers of the oropharynx: results of a randomized study of Gortec comparing radiotherapy alone with concomitant chemotherapy]. [French]. Bulletin du Cancer. 2000;87 Spec No:48-53. Calais 2004 Calais G, Bardet E, Sire C, Alfonsi M, Bourhis J, Rhein B et al. Radiotherapy with concomitant weekly docetaxel for stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC phase II trial. International Journal of Radiation, Oncology, Biology and Physics 2004;58(1 Jan):161-6. Cassidy 2002 Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Annals of Oncology 2002;13(4):566-75.Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. 2002+ADs- 13(4):566-75. Cella 2003 Cella D, Pulliam J, Fuchs H, Miller C, Hurd D, Wingard JR et al. Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cancer 2003;98(2):406-12. Cheng 2001 Cheng KK Molassiotis A, Chang AM, Wai WC, Cheung SS. Evaluation of an oral care protocol intervention in the prevention of chemotherapy-induced oral mucositis in paediatric cancer patients. European Journal of Cancer 2001;37(16):2056-63.Cheng KK MA, Chang AM, Wai WC, Cheung SS. Evaluation of an oral care protocol intervention in the prevention of chemotherapy-induced oral mucositis in paediatric cancer patients. 2001+ADs-37(16):2056-63. Cheng 2002 Cheng KKF, Malassiotis A, Chang AM. An oral care protocol intervention to prevent chemotherapy-induced oral mucositis in paediatric cancer patients: a pilot study. European Journal of Oncology Nursing 2002;6(2):66-74.Cheng KKF MA, Chang AM. An oral care protocol intervention to prevent chemotherapy-induced oral mucositis in paediatric cancer patients: a pilot study... including commentary by Parr M. European Journal of Oncology Nursing: EUR J ONCOL NURS 2002+ADs- 6. 6(2. 2):66-74. Cheng 2003 Cheng KK, Chang AM. Palliation of oral mucositis symptoms in pediatric patients treated with cancer chemotherapy. Cancer Nursing 2003;26(6):476-84.Cheng KK, Chang AM. Palliation of oral mucositis symptoms in pediatric patients treated with cancer chemotherapy. Cancer Nursing 2003; 26(6):476-84. Cheng 2004a Cheng KK. Children's acceptance and tolerance of chlorhexidine and benzydamine oral rinses in the treatment of chemotherapy-induced oropharyngeal mucositis. European Journal of Oncology Nursing 2004;8(4):341-9.Cheng KK. Children's acceptance and tolerance of chlorhexidine and benzydamine oral rinses in the treatment of chemotherapy-induced oropharyngeal mucositis. European Journal of Oncology Nursing. 2004;8(4):341-9. Cheng 2004b Cheng KK, Chang AM, Yuen MP. Prevention of oral mucositis in paediatric patients treated with chemotherapy; a randomised crossover trial comparing two protocols of oral care. European Journal of Cancer 2004;40(8):1208-16.Cheng KK, Chang AM, Yuen MP. Prevention of oral mucositis in paediatric patients treated with chemotherapy; a randomised crossover trial comparing two protocols of oral care. Eur J Cancer 2004;40(8):1208-16. Chi 1994 Chi KH, Chen SY, Chan WK, Yen SH, Liang MJ, Chou KC, et al. Effect of granulocyte macrophage colony stimulating factor (GM-CSF) on oral mucositis in head and neck cancer patients after cisplatin, 5- FU and leucovorin chemotherapy [abstract]. Proceedings of the American Society of Clinical Oncology 1994;13:428, Abstract 1469. Chi 1995 Chi KH, Chen CH, Chan WK, Yen SH, Liang MJ, Chou KC et al. Effect of granulocyte-macrophage colony-stimulating factor (GH-CFS) on oral mucositis in head and neck cancer patients after cisplatin, 5-FU and leucovorin chemotherapy. In: Proceedings of Annual Meeting American Society of Clinical Oncology. Vol. 13. 1994:A1469. Chi KH, Chen SY, Chan WK, Yen SH, Liang MJ, Chou KC et al. Effect of granulocyte-macrophage colony-stimulating factor (GH-CFS) on oral mucositis in head and neck cancer patients after cisplatin, 5-FU and leucovorin chemotherapy. Journal of Clinical Oncology 1995;13(10):2620-8. Chiara 2000 Chiara S, Nobile MT, Vincenti M, Gozza A, Heouaine A, Marceca F, et al. Sucralfate in the treatment of chemotherapy-induced stomatitis: a double-blind, placebo-controlled pilot study [abstract]. Proceedings of the American Society of Clinical Oncology 2000;19:630a, Abstract 2485. Clarke 2001 Clarke SJ, Abdi E, Davis ID, Schnell FM, Zalcberg JR, Gutheil J, et al. Recombinant human keratinocyte growth factor (rHuKGF) prevents chemotherapy-induced mucositis in patients with advanced colorectal cancer: a randomized phase II trial [abstract]. Proceedings of the American Society of Clinical Oncology 2001;20 (Pt 1):383a, Abstract 1529. Collova 2004 Collova E, Castagna L, Nozza A, Perfetti V, Patrone F, Danova M et al. New approaches for reduction of oral mucositis in patients undergoing high-dose chemotherapy with hematopoietic stem cell support. Bone Marrow Transplantation 2004;33(Suppl 1):S323-S4.Collova E, Castagna L, Nozza A, Perfetti V, Patrone F, Danova M, et al. New approaches for reduction of oral mucositis in patients undergoing high-dose chemotherapy with hematopoietic stem cell support [abstract]. Bone Marrow Transplantation. 2004;33(Suppl 1):S323-S4. Colombat 1995 Colombat P, Colin B. Comparison of fluconazole and amphotericin B in the prevention of mucositis in patients with long term aplasia. Bone Marrow Transplantation 1995;15:178.Colombat P, Colin B, et al. Comparison of fluconazole and amphotericin B in the prevention of mucositis in patients with long term aplasia [abstract]. Bone-Marrow-Transplant. 1995;15:178. Costa 1999 Costa EMMB, Pinto LP, Fernandes MZ, Costa ALL. Preventing oral complications in leukemic children submitted to chemotherapy. Journal of Dental Research 1999;78:1021 (Abs No B-220). Costa 2003 Costa EM, Fernandes MZ, Quinder LB, de Souza LB, Pinto LP. Evaluation of an oral preventive protocol in children with acute lymphoblastic leukemia. Pesquisa Odontologica Brasileira 2003;17(2):147-50.Costa EM, Fernandes MZ, Quinder LB, de Souza LB, Pinto LP. Evaluation of an oral preventive protocol in children with acute lymphoblastic leukemia. Pesqui Odontol Bras. 2003 Apr-Jun;17(2):147-50. Cowen 1997 Cowen D, Tardieu C, Resbeut M, Hannoun-Levi JM, Alzieu C, Schubert M et al. Low energy helium-neon laser presents oral mucositis after high-dose chemo-radiotherapy: results of a double-blind randomized trial. International Journal of Radiation Oncology, Biology and Physics 1996;36(1S):264 (A1041). Cowen D, Tardieu C, Schubert M, Peterson D, Resbeut M, Faucher C et al. Low energy Helium-neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: Results of a double blind randomized trial. International Journal of Radiation Oncology, Biology and Physics 1997;38(4):697-703. Crawford 1994 Crawford J, Glaspy J, Vincent M, Tomita D, Mazanet R. Effect of filgrastim (r-metHug-CSF) on oral mucositis in patients with small cell lung cancer (SCLC) receiving chemotherapy (cyclophosphamide, doxorubicin and etoposide, CAE). In: Proceedings of Annual Meeting of American Society Clinical Oncology. Vol. 13. 1994:(Abs No A1523).Crawford J, Glaspy J, Vincent M, Tomita D, Mazanet R. Effect of filgrastim (r-metHug-CSF) on oral mucositis in patients with small cell lung cancer (SCLC) receiving chemotherapy (cyclophosphamide, doxorubicin and etoposide, CAE). Proc-Annu-Meet-Am-Soc-Clin-Oncol. 1994;13:Abs. A1523. Crispino 1997 Crispino SP, Olmi C, Fallai F, Rossi S, Marsoni A, Tinazzi M, et al. Conventional radiotherapy (RT) versus accelerated hyperfractionated RT versus conventional RT and concomitant chemotherapy in locally advanced oropharyngeal carcinoma (ORO-93/01). In: Proceedings of the American Society of Clinical Oncology. 1997.Crispino SP, Olmi C, Fallai F, Rossi S, Marsoni A, Tinazzi M, et al. Conventional radiotherapy (RT) versus accelerated hyperfractionated RT versus conventional RT and concomitant chemotherapy in locally advanced oropharyngeal carcinoma (ORO-93/01). Proc Am Soc Clin Oncol. 1997. Cruz 1997 Cruz J, Fonseca E, Rodriguez CA, Gomez-Bernal A, Martin G, Sanchez P et al. Randomized trial of cisplatin (P) plus 5-fluorouracil (F) with or without folinic acid in locally advanced head and neck cancer (LAHNC). In: Proceedings of the European Cancer Conference. 1997:(Abs No 854).Cruz J, Fonseca E, Rodriguez CA, Gomez-Bernal A, Martin G, Sanchez P, et al. Randomized trial of cisplatin (P) plus 5-fluorouracil (F) with or without folinic acid in locally advanced head and neck cancer (LAHNC). Proc-Eur-Cancer-Conf (ECCO). 1997:Abstract #854. Cunningham 1995 Cunningham D, Zalcberg JR, Rath U, Olver I, van Cutsem EV, Sevensson C et al. 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. European Journal of Cancer 1995;31A(12):1945-54. De Boer 2002 De Boer RH, Eisen TG, Ellis PA, Johnston SR, Walsh G, Ashley S et al. A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer. Annals of Oncology 2002;13(6):889-94. Decker-Baummann 1999 Decker-Baumann C, Buhl K, Frohmuller S, von Herbay A, Dueck M, Schlag PM. Reduction of chemotherapy-induced side-effects by parenteral glutamine supplementation in patients with metastatic colorectal cancer. European Journal of Cancer 1999;35(2):202-7. Denham 1999 Denham JW, Peters LJ, Johansen J, Poulsen M, Lamb DS, Hindley A et al. Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer? Radiotherapy Oncology 1999;52(2):157-64. Djuric 2006 Djuric M, Hillier-Kolarov V, Belic A, Jankovic L. Mucositis prevention by improved dental care in acute leukemia patients. Supportive Care in Cancer 2006;14(2):137-46.Djuric M, Hillier-Kolarov V, Belic A, Jankovic L. Mucositis prevention by improved dental care in acute leukemia patients. Supportive Care in Cancer. 2006;14(2):137-46. Dobrowsky 1998 Dobrowsky W, Naude J, Widder J, Dobrowsky E, Millesi W, Pavelka R et al. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer. International Journal of Radiation Oncology, Biology and Physics 1998;42(4):803-6.Dobrowsky W NJ, Widder J, Dobrowsky E, Millesi W, Pavelka R, Grasl C, Reichel M. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer. International Journal of Radiation Oncology, Biology, Physics 1998;42(4):803-6. Doroshow 1987 Doroshow JH, Berthtand M, Newman E, Multhauf P, Leong L, Blayney D et al. Preliminary analysis of a randomized comparison of 5-fluorouracil versus 5-fluorouracil and high-dose continuous-infusion folinic acid in disseminated colorectal cancer. NCI Monographs 1987;5:171-4.Doroshow JH BM, Newman E, Multhauf P, Leong L, Blayney D, Goldberg D, Margolin K, Carr B, Akman S, et al. Preliminary analysis of a randomized comparison of 5-fluorouracil versus 5-fluorouracil and high-dose continuous-infusion folinic acid in disseminated colorectal cancer. NCI Monographs 1987(5):171-4. Dose 1989 Dose AM, Loprinzi CL, Cianflone S, Etzell P, Burnham N, Therneau T, et al. A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis. A North Central Cancer Treatment Group and Mayo clinic study [abstract]. Proceedings of the American Society of Clinical Oncology 1989;8:341, Abstract 1328. Dose 1990 Dose AM, Mahood D, Loprinzi CL, Gainey D, Sorensen JM, Therneau T, et al. A controlled trial of oral cryotherapy for preventing stomatitis in patients receiving 5- fluorouracil (5FU) plus leucovorin (LV). A North Central Cancer Treatment Group and Mayo Clinic study [abstract]. Proceedings of the American Society of Clinical Oncology 1990;9:321, Abstract 1242. Dreicer 1997 Dreicer R, Propert KJ, Kuzel T, Kirkwood JM, O'Dwyer PJ, Loehrer PJ. A phase II trial of edatrexate in patients with advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study. American Journal of Clinical Oncology 1997;20(3):251-3. Dudjak 1987 Dudjak LA. Mouth care for mucositis due to radiation therapy. Cancer Nursing 1987;10(3):131-40. Edelman 1998 Edelman MJ, Gandara Dr, Perez EA, Lau D, Lauder I, Turrell C et al. Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy. Investigational New Drugs 1998;16(1):69-75. Eisen 2003 Eisen D, Essel J, Broun ER, Sigmund D, DeVoe M,. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. Bone Marrow Transplantation 2003;31(1):51-5. El-Sayed 2000 El-Sayed S, Nabid A, MacKenzie R, Gelinas M, Hay J, Shelley et al. Prophylaxis of radiation associated mucositis (RAM) in head and neck cancer, results of a double blind phase III trail evaluating the clinical efficacy of an antimicrobial lozenge utilizing a new validated mucositis scoring system. In: Proceedings of the 42nd Annual Meeting of the American Society of Therapeutic Oncology. Vol. 321. 2000:(Abs No 2115).El-Sayed S, Nabid, A, MacKenzie, R, Gelinas, M, Hay, J, Shelley, W, Berthelet, E, Lau, H, Duncan, G, and Epstein, J. Prophylaxis of radiation associated mucositis (RAM) in head and neck cancer, results of a double blind phase III trail evaluating the clinical efficacy of an antimicrobial lozenge utilizing a new validated mucositis scoring system. El-Sayed 2002b El-Sayed S, Epstein J, Minish E, Burns P, Hay J, Laukkanen E. A pilot study evaluating the safety and microbiologic efficacy of an economically viable antimicrobial lozenge in patients with head and neck cancer receiving radiation therapy. Head &amp;amp; Neck 2002;24(1):6-15.El-Sayed S, Epstein J, Minish E, Burns P, Hay J, Laukkanen E.A pilot study evaluating the safety and microbiologic efficacy of an economically viable antimicrobial lozenge in patients with head and neck cancer receiving radiation therapy. Head Neck. 2002 Jan;24(1):6-15. Epstein 1986 Epstein JB, Stephenson-Moore P. Benzydamine hydrochloride in prevention and management of pain in oral mucositis associated with radiation therapy. Oral Surgery, Oral Medicine, Oral Pathology 1986;62(2):145-8. Epstein 1989 Epstein JB, Stevenson-Moore P, Jackson S, Mohamed JH, Spinelli JJ. Prevention of oral mucositis in radiation therapy: A controlled study with benzydamine hydrochloride rinse. International Journal of Radiation Oncology, Biology and Physics 1989;16(6):1571-5. Epstein 1992 Epstein JB, Vickars L, Spinalli J, Reece D. Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. Oral Surgery, Oral Medicine, Oral Pathology 1992;73(6):682-9. Epstein 1994 Epstein JB, Wong FLW. The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy. International Journal of Radiation Oncology, Biology and Physics 1994;28(3):693-8. Epstein 1999 Epstein J, Silverman S Jr, Pagerino D, Lockhart P, Schubert M, Crockett R. Benzydamine HCL for prophylaxis of irradiation induced oral mucositis: a randomized double-blind, multicenter study. Supportive Care in Cancer 1999;7 Suppl:169 (Abs No O-18).Epstein J, Silverman S, Jr Pagerino D, Lockhart P, Schubert M, Crockett R. Benzydamine HCL fro prophilaxis of irradiation oral mucositis: a randomized double-blind, multicenter study. Supportive Care in Cancer. 1999;7 Suppl.(Abstr O-18):169. Epstein 2001 Epstein JB, Silverman S, Paggiarino DA, Crockett S, Schubert MM, Senzer NN et al. Benzydamine HCI for prophylaxis of radiation-induced oral mucositis. Cancer 2001;92(4):875-85. Erkisi 1996 Erkisi M, Erkurt E, Ozbarlas S, Burgut R, Doran F, Seyrek E. The use of recombinant human granulocyte colony-stimulating factor in combination with single or fractionated doses of ifosfamide and doxorubicin in patients with advanced soft tissue sarcoma. Journal of Chemotherapy 1996;8(3):224-8. Etiz 1998 Etiz M, Erkal HS, Serin M, Kucuk B, Hepari A, Tulunay O et al. Clinicohistopathological evaluation of effectiveness of sucralfate in prevention of severe radiation-induced mucositis in patients with head and neck malignancies. Radiotherapy Oncology 1998;48(S1):S68. Etiz 2000 Etiz D, Erkal HS, Serin M, Kucuk B, Hepari A, Elhan AH et al. Clinical and histopathological evaluation of sucralfate in prevention of oral mucositis induced by radiation therapy in patients with head and neck malignancies. Oral Oncology 2000;36(1):116-20. Evans 1990 Evans G, Mahendra P, Brightwell M, Jestivfe K, Marcus R. A double blind randomised trial of oral GMCFS mouthwash versus placebo in the treatment of mucositis following PBSC/bone marrow transplantation. Bone Marrow Transplantation 1998;21(S1):S88. Evans WK, Wierzbicki R, Shepherd FA, Rusthoven J, Stewart DJ, Aitken SE et al. 5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung. Cancer Investigation 1990;8(3-4):345-9. Ezzat 2005 Ezzat M, Shouman T, Zaza K, Safwat A, El-Khoudary A, El-Senosi M et al. A randomized study of accelerated fractionation radiotherapy with and without mitomycin C in the treatment of locally advanced head and neck cancer. Journal of the Egyptian National Cancer Institute 2005;17(2):85-92.Ezzat M, Shouman T, Zaza K, Safwat A, El-Khoudary A, El-Senosi M, et al. A randomized study of accelerated fractionation radiotherapy with and without mitomycin C in the treatment of locally advanced head and neck cancer. Journal of Egyptian National Cancer Institute. 2005;17(2):85-92. Fahlke 1999 Fahlke J, Ridwelski K, Lippert H. High-dose therapy with combined 5-fluorouracil and folinic acid with and without amifostine in the treatment of patients with metastatic colorectal carcinoma. International Journal of Colorectal Disease 1999;14(2):128-30. Falcone 2001 Falcone A, Allergrini G, Masi G, Lencioni M, Panner E, Brunetti I. 5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer. Oncology 2001;61(1):28-35. Fay 1994 Fay JW, Lazarus H, Herzig R, Saez R, Stevens DA, Collins RH Jr et al. Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study. Blood 1994;84(7):2151-7.Fay JW LH, Herzig R, Saez R, Stevens DA, Collins RH Jr, Pineiro LA, Cooper BW, DiCesare J, Campion M, et al. Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study. Blood 1994;84(7):2151-7. Feber 1995 Feber T. Mouth care for patients receiving oral irradiation. Professional Nurse 1995;10(10):666-70. Feber 1996 Feber T. Management of mucositis in oral irradiation. Clinical Oncology 1996;8(2):106-11. Ferreira 2002 Ferreira PR, Fleck J, Filho AB, Barletta D, Barletta A, Diehl A et al. Protective effect of vitamin E (VE) in head and neck cancer radiation induced mucositis: a double-blind randomized trial. In: Proceedings of American Society of Clinical Oncology Meeting. 2002:(Abs No 909).Ferreira P FJ, Filho A, Barletta D, Barletta A, Diehl A, de Azambuja E. Protective effect of vitamin E (VE ) in head and neck cancer radiation induced mucositis: a double-blind randomized trial. Proceedings of ASCO 2002. Ferreira 2002a Ferreira RR, Fleck JF, Filho AB, Barletta D, Barletta A, Diehl A, et al. Positive effect of vitamin E (VE) in head and neck cancer radiation induced mucositis: a double-blind randomized trial [abstract]. Proceedings of the American Society of Clinical Oncology 2002;21 (Pt 1):228a, Abstract 909. Ferreira 2004 Ferreira PR, Fleck JF, Diehl A, Barletta D, Braga-Filho A, Barletta A et al. Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial. Head &amp;amp; Neck 2004;26(4):313-21.Ferreira PR, Fleck JF, Diehl A, Barletta D, Braga-Filho A, Barletta A, et al. Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial. Head Neck 2004;26(4):313-21. Ferretti 1985 Ferretti G, Largent B, Brown A, Lillich T, Ash R. The effect of chlorhexidine mouthrinse on mucositis, plaque, gingivitis and stain in bone marrow transplant patients. Journal of Dental Research 1985;64(Special Issue):235 (Abs No 546). Fidler 1995 Fidler P, Loprinzi CL, O'Fallon JR, Michalak J, Novotny P, Hayes D, et al. A controlled evaluation of chamomile for preventing stomatitis in patients receiving 5-fluorouracil based chemotherapy: A North Central Cancer Treatment Group trial [abstract]. Proceedings of the American Society of Clinical Oncology 1995;14:534, Abstract 1765. Foncuberta 2001 Foncuberta MC, Cagnoni PJ, Brandts CH, Mandanas R, Fields K, Derigs HG et al. Topical transforming growth factor-beta3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors. Journal of Immunotherapy 2001;24(4):384-8.Foncuberta M, PJ C, CH B, R M, K F, HG D, et al. Topical transforming growth factor-beta3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors. Journal of Immunotherapy 2001;24(4):384-388. Gabison 1995 Gabison R. Can zinc picolinate in patients receiving chemotherapy for metastatic colorectal carcinoma prevent stomatitis? European Journal of Cancer 1995;31A(Suppl 5):S258 (Abs No 1234). Gandara 1997 Gandara DR, Edelman MJ, Crowley JJ, Lau DH, Livingston RB. Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study.. Cancer Chemotherapy and Pharmacology 1997;41:75-78. Genot-Klastersky 2008 Genot-Klastersky MT, Klastersky J, Awada F, Awada A, Crombez P, Martinez MD, et al. The use of low-energy laser (LEL) for the prevention of chemotherapy- and/or radiotherapy-induced oral mucositis in cancer patients: results from two prospective studies. Support Care Cancer 2008. Giles 2003b Giles FJ, Faderl S, Thomas DA, Cortes JE, Garcia-Manero G, Douer D et al. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. Journal of Clinical Oncology 2003;21(6):1050-6.Giles FJ FS, Thomas DA, Cortes JE, Garcia-Manero G, Douer D, Levine AM, Koller CA, Jeha SS, O'Brien SM, Estey EH, Kantarjian HM. Randomized Phase I/II Study of Troxacitabine Combined With Cytarabine, Idarubicin, or Topotecan in Patients With Refractory Myeloid Leukemias. Journal of Clinical Oncology 2003+ADs-21(6):1050-1056. Gladkov 2007 Gladkov OA, Vazhenin AV, Sharabura TM, Kandakova E, Galiatova Iu V, Sychev VI, et al. [Effectiveness of different regimes of combined treatment (cisplatin+ radiotherapy) for intraoral and oropharyngeal cancer]. [Russian]. Voprosy Onkologii 2007;53(5):575-7. Goldberg 2003 Goldberg S. Safety and tolerability of en3247 in the prevention of oral mucositis associated with chemotherapy with or without total body irradiation: results of a randomized, double-blind, placebo-controlled trial. In: Proceedings of the American Society of Clinical Oncology. 2003:770.Goldberg S. Safety and tolerability of en3247 in the prevention of oral mucositis associated with chemotherapy with or without total body irradiation: results of a randomized, double-blind, placebo-controlled trial [abstract]. Proceedings of the American Society of Clinical Oncology. 2003:770. Gordon 1993 Gordon B, Spadinger A, Hodges E, Coccia P. Effect of granulocyte macrophage colony stimulating factor (GMCSF) on oral mucositis after autologous bone marrow transplantation [abstract]. Proceedings of the American Society of Clinical Oncology 1993;12:432, Abstract 1489. Grotz 2001 Grotz KA, Henneicke-Von Zepelin H-H, Kohnen R, Kutzner J. Belz GG. Prophylaxis of mucositis and dry mouth after head and neck radiotherapy. A new treatment. Krankenhauspharmazie 2002;23(5):193-8. Grotz KA, Wustenberg P, Kohnen R, Al-Nawas B, Henneicke-von Zepelin H, Bockisch A et al. Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutine in patients with head and neck cancer- a prospective, randomized, placebo-controlled, double-blind study. British Journal of Oral and Maxillofacial Surgery 2001;39(1):34-9. Gujral 1999 Gujral MS, Patnaik PM, Kaul R, Daftary GV, Parikh HK, Tamhankar CP et al. Oral enzymes preventing side effects of radiation therapy in patients with head and neck cancers. European Journal of Cancer 1999;35(Suppl 4):168 (Abs No 634).Gujral MS PPKRDGPHTCSW. Oral enzymes preventing side effects of radiation therapy in patients with head and neck cancers. European Journal of Cancer 1999+ADs-35(Suppl. 4):Page 168 Abstract +ACM-634. Gutierrez 1996 Gutierrez AR, Boizas EC, Carreras PS, Rodriguez CS, Rodriguez OA, Chicote MJV et al. Fluconazol as prophylaxis of radioinduced oral mucositis. Preliminary study [Fluconazol en la profilaxis de la mucositis oral radioinducida. Estudio preliminar]. Oncologia 1996;19(6):56-9.Gutierrez AR BE, Carreras PS, Rodriguez CS, Rodriguez OA, Chicote MJV, Palacios AN, Solbes RS, Ripoll JJS. Fluconazol as prophylaxis of radioinduced oral mucositis. Preliminary study. Oncologia 1996;19(6):56-59. Hanson 1995 Hanson WR, Marks JE, Reddy SP, Simon S, Mihalo WE, Tova Y. Protection from radiation-induced oral mucositis by a mouth rinse containing the prostaglandin E1 analog, misoprostol: A placebo controlled double blind clinical trial. Advances in Experimental Medicine and Biology 1997;400B:811-8. Hanson WR, Marks JE, Reddy SP, Simon S, Mihalo WE, Tova Y. Protection from radiation-induced oral mucositis by misoprostol, a prostaglandin E(1) analog: a placebo-controlled, double-blind clinical trial. American Journal of Therapeutics 1995;2(11):850-7. Harris 1995 Harris JR, Russell NH, Hunter AE. Folinic acid mouthwashes do not reduce the degree of mucositis in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplantation 1995;15(S2):S164. Hartmann 1999 Hartmann J, von Vangerow A, Knop S, Brugger W, Fels L, Stolte H et al. A randomized trial comparing the toxicity and the treatment costs of HD-VIC plus PBSC transplantation with or without amifostine (AMI) in patients with solid tumors. European Journal of Cancer 1999;35(Suppl 4):361 (Abs No 1464).Hartmann J, von Vangerow A, Knop S, Brugger W, Fels L, Stolte H, et al. A randomized trial comparing the toxicity and the treatment costs of HD-VIC plus PBSC transplantation with or without amifostine (AMI) in patients with solid tumors. European Journal of Cancer. 1999;35(Suppl 4):361, Abstr #1464. He 2004 He XY, Hu CS, Wu YR. Radioprotective effect of amifostine in nasopharyngeal carcinoma. Acta Academiae Medicinae Shanghai 2004;31(1).He XY, Hu CS, Wu YR. Radioprotective effect of amifostine in nasopharyngeal carcinoma. Acta Academiae Medicinae Shanghai. 2004;31(1). Hickey 1982 Hickey AJ, Toth BB, Lindquist SB. Effect of intravenous hyperalimentation and oral care on the development of oral stomatitis during cancer chemotherapy. The Journal of Prosthetic Dentistry 1982;47(2):188-93. Horsley 2007 Horsley P, Bauer JD, Mazkowiack R, Gardner R, Bashford J. Palifermin improves severe mucositis, swallowing problems, nutrition impact symptoms, and length of stay in patients undergoing hematopoietic stem cell transplantation. Supportive Care in Cancer 2007;15(1):105-9. Howell 1983 Howell SB, Pfeifle CE, Wung WE. Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection. Cancer 1983;51(2):220-5.Howell SB PC, Wung WE. Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection. Cancer 1983;51(2):220-5. Hu 2003 Hu K, Ship JA, Harrison LB. Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/IV head and neck cancer. Seminars in Oncology 2003;30(6 Suppl 18):40-8.Hu K, Ship JA, Harrison LB. Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/IV head and neck cancer. [Review] [36 refs]. Seminars in Oncology 2003; 30(6 Suppl 18):40-8. Inagaki 2006 Inagaki N. [Report on the treatment of infections complicating hematological diseases. Case 2. Two cases of deep-seated mycosis developing during chemotherapy of leukemia]. [Japanese]. Japanese Journal of Antibiotics 2007;60(5):317-8. Ito 2002 Ito A, Hanawa T, Fujii E. The preventive effect of allopurinol spray on stomatitis induced by anti-cancer drugs. Gan To Kagaku Ryoho 2002;29(4):563-7. Jebb 1995 Jebb SA, Marcus R, Elia M. A pilot study of oral glutamine supplementation in patients receiving bone marrow transplants. Clinical Nutrition 1995;14:162-5. Johnson 2002 Johnson DJ, Scott CB, Marks JE, Seay TE, Atkins JN, Berk LB et al. Assessment of quality of life and oral function of patients participating in a phase II study of radioprotection of oral and pharyngeal mucosa by the prostaglandin E(1) analog misoprostol (RTOG 96-07). International Journal or Radiation Oncology Biology and Physics 2002;54(5):1455-9.Johnson DJ, Scott CB, Marks JE, Seay TE, Atkins JN, Berk LB, Meoz RT, Wheeler JA.Assessment of quality of life and oral function of patients participating in a phase II study of radioprotection of oral and pharyngeal mucosa by the prostaglandin E(1) analog misoprostol (RTOG 96-07). Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1455-9. Kante 1995 Kante V. Comparative study of two prophylactic regimes for the prevention of mucositis in autologous bone marrow transplants. Bone Marrow Transplantation 1995;15:253.Kante V, et al. Comparative study of two prophylactic regimes for the prevention of mucositis in autologous bone marrow transplants [abstract]. Bone-Marrow-Transplant. 1995;15:253. Karthaus 1998 Karthaus M, Rosenthal C, Huebner G, Paul H, Elser C, Hertenstein B et al. Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial. Bone Marrow Transplantation 1998;22(8):781-5.Karthaus M, Rosenthal C, Huebner G, Paul H, Elser C, Hertenstein B et al. Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial. Bone Marrow Transplant 1998;22:781-5. Kasten-Sportes 2003 Kasten-Sportes C. Randomized study of acupuncture for mucositis-related pain secondary to high-dose chemotherapy in patients undergoing hematopoietic stem cell transplantation. PDQ (NCI-03-C-0125) 2003.Kasten-Sportes C. Randomized Study of Acupuncture for Mucositis-Related Pain Secondary to High-Dose Chemotherapy in Patients Undergoing Hematopoietic Stem Cell Transplantation. PDQ, NCI-03-C-0125. 2003 2003. Kenny 1990 Kenny SA. Effect of two oral care protocols on the incidence of stomatitis in hematology patients. Cancer Nursing 1990;13(6):345-53. Klocke 2006 Klocke J, Cannon M, Gissinger D, Bayer R, Devoe C, John V. Prevention of mucositis in auto BMT/stem cell transplant patients. Oncology Nursing Forum 2006;33(2):454.Klocke J, Cannon M, Gissinger D, Bayer R, Devoe C, John V. Prevention of mucositis in auto BMT/stem cell transplant patients. Oncology Nursing Forum. 2006;33(2):454. Kokkonen 2002 Kokkonen J, Mottonen M, Karttunen TJ, Lanning M. Mucosal pathology of the upper gastrointestinal tract associated with intensive chemotherapy in children: Vitamin a supplements do not prevent lesions. Pediatric Hematology and Oncology 2002;19(3):181-92.Kokkonen JMMKTLM. Mucosal pathology of the upper gastrointestinal tract associated with intensive chemotherapy in children: Vitamin a supplements do not prevent lesions. Pediatric Hematology +ACY- Oncology 2002+ADs- Vol 19(3): 181-192. Kuhn 2009 Kuhn A, Porto FA, Miraglia P, Brunetto AL. Low-level infrared laser therapy in chemotherapy-induced oral mucositis: a randomized placebo-controlled trial in children. Journal of Pediatric Hematology/Oncology 2009;31(1):33-7. Kuriakose 2002 Kuriakose P, Gandara DR, Perez EA. Phase I trial of edatrexate in advanced breast and other cancers.[comment]. Cancer Investigation 2002;20(4):473-9. Labar 1990 Labar B, Pavletic Z, Bogdanic V, Nemet D, Aurer I, Jakie J. Prostaglandin E2 for prevention of oral mucositis in patients with leukaemia undergoing bone marrow transplantation: a radomized double-blind clinical trial. Experimental Hematology 1990;18:700. Labbate 2003 Labbate R, Lehn CN, Denardin OVP. Effects of chlorhexidine mouthwash on radiation induced mucosistis in head and neck cancer. Revista Brasileira de Otorrinolaringologia 2003;69(3):349-54.Labbate R, Lehn CN, Denardin OVP. Effects of chlorhexidine mouthwash on radiation induced mucosistis in head and neck cancer. Revista Brasileira de Otorrinolaringologia. 2003;69(3):349-54. Leong 1995 Leong L, Sakurai C, Sebastian W, Shaw N, Grant E, Grant M et al. Phase III trial assessing the use of oral thymidine (THY) for prevention of fluorouracil (5-FU)-induced mucositis. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology. Vol. 14. 1995:A334. Levendag 1998 Lavendag PC, Wijers OB, Harms RE, Schmitz PIM, Wilms BE, Visch LL. Mucositis prevention by selective elimination of oral flora in irradiated cancers of the head and neck: a prospective randomized study. Radiotherapy Oncology 1998;48:S10. Levi 1997 Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997;350(9079):681-6.Levi F ZR, Misset J-L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997+ADs-350(9079):681-686. Lievens 1998 Lievens Y, Haustermans K, van den Weyngaert D, van den Bogaert W, Scalliet P, Hutsebaut L et al. Does sucralfate reduce the acute side-effects in head and neck cancer treated with radiotherapy? A double-blind randomized trial. Radiotherapy Oncology 1998;47(2):149-53. Lin 2006 Lin J, Wang X, Fan Z. A study on quantizing evaluation on stomatitis of malignant tumor patients undergoing large dose of chemotherapy [Chinese]. Chinese Nursing Research 2008;22(2A):328-9. Lin LC, Que J, Lin LK, Lin FC. Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study. International Journal of Radiation Oncology, Biology, Physics 2006;65(3):745-50.Lin LC, Que J, Lin LK, Lin FC. Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study. International Journal of Radiation Oncology, Biology, Physics. 2006;65(3):745-50. Lopez 1994 Lopez I, Goudou C, Ribrag V, Sauvage C, Hazebroucq G, Dreyfus F. Traitement des mucites par la vitamine E lors de l'administration d'anti-neoplasiques neutropeniants. Annuals Medicine Interne 1994;145(6):405-8. Loprinzi 1997 Loprinzi CL, Ghosh C, Camoriano J, Sloan J, Steen PD, Michalak JC et al. Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy. Journal of Clinical Oncology 1997;15(3):1235-8. Lorusso 2003 Lorusso D, Ferrandina G, Greggi S, Gadducci A, Pignata S, Tateo S. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Annals of Oncology 2003;14(7):1086-93.Lorusso D FG, Greggi S, Gadducci A, Pignata S, Tateo S, Biamonte R, Manzione L, Di Vagno G, Ferrau' F, Scambia G, Multicenter Italian Trials in Ovarian Cancer invesitgators. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Annals of Oncology 2003;14(7):1086-93. Lozada 1998 Lozada-Nur F, Schoelch M, Fu K, Muscoplat C, Trivedi M, Smith C et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. In: Proceedings of the Annual Meeting of the Society of Clinical Oncology. 1998:1541. Maddocks-Jennings 2009 Maddocks-Jennings W, Wilkinson JM, Cavanagh HM, Shillington D. Evaluating the effects of the essential oils Leptospermum scoparium (manuka) and Kunzea ericoides (kanuka) on radiotherapy induced mucositis: a randomized, placebo controlled feasibility study. European Journal of Oncology Nursing 2009;13(2):87-93. Madero 1999 Madero L, Diaz MA, Ortega JJ, Olive T, Martinez A, Badell I et al. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates engraftment kinetics after allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia. Haematologica 1999;84(2):133-7.Madero L DM, Ortega JJ, Olive T, Martinez A, Badell I, Munoz A, Gomez P. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates engraftment kinetics after allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia. Haematologica 1999;84(2):133-7. Mahmoud 1996 Mahmoud HK SE, Kamel M, El HMA, Nassar A. Influence of folinic acid rescue on methotrexate-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation. Tumor Diagnostik Und Therapie 1996;17(1):18-21.Mahmoud HK SE, Kamel M, El HMA, Nassar A. Influence of folinic acid rescue on methotrexate-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation. Tumor Diagnostik Und Therapie. 1996+ADs-17(1):18-21. Malaker 1991 Malaker K, Anderson BJ, Beecroft WA, Hodson DI. Management of oral mucosal dysplasia with beta-carotene retinoic acid: a pilot cross-over study. Cancer Detection and Prevention 1991;15(5):335-40.Malaker K, Anderson BJ, Beecroft WA, Hodson DI. Management of oral mucosal dysplasia with beta-carotene retinoic acid: a pilot cross-over study. Cancer Detection +ACY- Prevention 1991+ADs-15(5):335-40. Mantovani 2003 Mantovani G, Massa E, Astara G, Murgia V, Gramignano G, Lusso MR et al. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs. Oncology Reports 2003;10(1):197-206.Mantovani G, Massa E, Astara G, Murgia V, Gramignano G, Lusso MR, et al. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs. Oncology Reports 2003+ADs- 10(1):197-206. Marcial 1994 Marcial F, Schubert M, Niccoli-Filho WD, Lloid ME, Kelly J, Franquin JC et al. A phase I/II nonblinded randomized trial to determine the efficacy of low-energy laser to prevent oral mucositis resulting from conditioning regimens for bone marrow transplantation. Oral Surgery, Oral Medicine, Oral Pathology 1994;78(6):738. Martin 2006 Martin M, Lluch A, Segui MA, Ruiz A, Ramos M, Adrover E, et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.[see comment]. Annals of Oncology 2006;17(8):1205-12. Masucci 2005 Masucci G, Broman P, Kelly C, Lindahl S, Malmberg L, Reizenstein J et al. Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy: a multicenter open randomized phase III study. Medical Oncology 2005;22(3):247-56.Masucci G, Broman P, Kelly C, Lindahl S, Malmberg L, Reizenstein J, et al. Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy: a multicenter open randomized phase III study. Medical Oncology. 2005;22(3):247-56. Matejka 1990 Matejka M, Nell A, Kment G, Schein A, Leukauf M, Porteder H et al. Local benefit of prostaglandin E2 in radiochemotherapy-induced oral mucositis. British Journal of Oral Maxillofacial Surgery 1990;28(2):89-91.Matejka M, Nell A, Kment G, Schein A, Leukauf M, Porteder H, Mailath G, Sinzinger H.Local benefit of prostaglandin E2 in radiochemotherapy-induced oral mucositis. Br J Oral Maxillofac Surg. 1990 Apr;28(2):89-91. McGaw 1985 McGaw WT, Belch A. Oral complications of acute leukemia: prophylactic impact of a chlorhexidine mouthrinse regimen. Oral Surgery, Oral Medicine, Oral Pathology 1985;60(3):275-80.McGaw WT, Belch A. Oral complications of acute leukemia: prophylactic impact of a chlorhexidine mouthrinse regimen. Oral Surg Oral Med Oral Pathol 1985;60:275-80. McIlroy 1996 McIlroy P. Radiation mucositis: a new approach to prevention and treatment. European Journal of Cancer Care 1996;5(3):153-8. Merte 1999 Merte H, Wied R, Engenhart-Cabillic R. Der effekt von immunglobulinen in der behandlung der radiogenen dermatitis und mukositis bei patienten mit hals-nasen und rachentumoren. Strahlentherapy und Onkologie 1999;175(1):135. Mills 1995 Mills W, Strang J, Goldstone AH, Linch DC. Dose intensification of etoposide in the BEAM ABMT protocol for malignant &lt;/p&gt;" NOTES_MODIFIED="2010-11-09 12:14:16 +0000" NOTES_MODIFIED_BY="[Empty name]">
<P>S1 (MH "Neoplasms+") <BR/>S2 (MH "Leukemia+")<BR/>S3 (MH "Lymphoma+")<BR/>S4(MH "Radiotherapy+")<BR/>S5 (MH "Bone Marrow Transplantation")<BR/>S6 neoplasm*<BR/>S7 cancer*<BR/>S8 (leukemi* or leukaemi*)<BR/>S9 (tumour* or tumor*)<BR/>S10 malignan*<BR/>S11neutropeni*<BR/>S12carcino*<BR/>S13adenocarcinoma*<BR/>S14lymphoma*<BR/>S15(radioth* or radiat* or irradiat*)<BR/>S16(bone N1 marrow N5 transplant*)<BR/>S17chemo*<BR/>S18S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 orS12 or S13 or S14 or S15 or S16 or S17<BR/>S19MH "Stomatitis+"<BR/>S20MH "Candidiasis, Oral"<BR/>S21stomatitis<BR/>S22mucositis<BR/>S23(oral and cand*)<BR/>S24(oral N6 mucos*)<BR/>S25(oral and fung*)<BR/>S26(mycosis or mycotic)<BR/>S27S19 or S20 or S21 or S22 or S23 or S24 or S25 or S26<BR/>S28S18 AND S27</P>
<SUBSECTION>
<HEADING LEVEL="3">Filter for CINAHL search</HEADING>
<P>S1 MH Random Assignment or MH Single-blind Studies or MH Double-blind Studies or MH Triple-blind Studies or MH Crossover design or MH Factorial Design<BR/>S2TI ("multicentre study" or "multicenter study" or "multi-centre study" or "multi-center study") or AB ("multicentre study" or "multicenter study" or "multi-centre study" or "multi-center study") or SU ("multicentre study" or "multicenter study" or "multi-centre study" or "multi-center study")<BR/>S3TI random* or AB random*<BR/>S4AB "latin square" or TI "latin square"<BR/>S5TI (crossover or cross-over) or AB (crossover or cross-over) or SU (crossover or cross-over)<BR/>S6 MH Placebos<BR/>S7 AB (singl* or doubl* or trebl* or tripl*) or TI (singl* or doubl* or trebl* or tripl*)<BR/>S8 TI blind* or AB mask* or AB blind* or TI mask*<BR/>S9 S7 and S8<BR/>S10 TI Placebo* or AB Placebo* or SU Placebo*<BR/>S11MH Clinical Trials<BR/>S12TI (Clinical AND Trial) or AB (Clinical AND Trial) or SU (Clinical AND Trial)<BR/>S13S1 or S2 or S3 or S4 or S5 or S6 or S9 or S10 or S11 or S12</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2008-12-05 12:05:03 +0000" MODIFIED_BY="[Empty name]"/>
</COCHRANE_REVIEW>